XXVI ISTH Congress and 63rd Annual SSC Meeting

TRANSCENDING SCIENTIFIC BOUNDARIES
BERLIN, GERMANY

JULY 8-13

FINAL PROGRAM

www.isth2017.org
A new open access journal from ISTH

Peer-Reviewed Open Access Journal
Now Open for Submissions

Research and Practice in Thrombosis and Haemostasis (RPTH) is an exciting new open access journal from the International Society on Thrombosis and Haemostasis (ISTH) for innovative science and discourse among researchers, clinicians and patients in the global thrombosis and haematology community. In an ever-changing environment, RPTH offers an exciting medium for rigorous yet rapid peer review and immediate dissemination of research. The journal will publish basic, translational, clinical, population and implementation research in thrombosis, haemostasis, vascular disease and related areas with an aim to advance the treatment of patients.

Paper types covered by RPTH: original science, review articles on recent advances, debates, synthesis articles on research translation to practice and compelling case reports.

The call for submissions to RPTH is now open.
Visit RPTH.ISTH.ORG to get started today!

Questions? Contact us at +1 919 929 3807

WIFI Username: ISTH2017 Password: sobibivv
Dear ISTH 2017 Congress participants,

We are pleased to welcome you to the XXVI International Society on Thrombosis and Haemostasis (ISTH) Congress and 63rd Annual Scientific and Standardization Committee (SSC) Meeting in Berlin, a city full of life with a distinctive culture and cosmopolitan blend of people and events.

Founded in the 13th century, Berlin has experienced an eventful history, with frequent and radical changes over the years that have continually transformed the city. Once divided by a wall for decades, Berlin is now seen as a global symbol for unity and a vibrant metropolis in the heart of Europe.

We are proud to host the congress for the first time in Berlin, Germany, after nearly 37 years following the inaugural ISTH congress, which was hosted in Montreux, Switzerland, in 1970. With the developments that have occurred in the field of thrombosis and hemostasis over the decades, this year’s congress motto truly hits the mark: “Transcending Scientific Boundaries.” Here at ISTH 2017, we are excited to welcome more than 8,000 scientists and clinicians from around the world focused in thrombosis and hemostasis who have the ambition and drive to push scientific boundaries in the field.

Saturday and the first half of Sunday are devoted to the 63rd Annual ISTH SSC Meeting. Work in progress, preliminary or final reports from the multitude of projects of the SSC, mixed with a wide variety of educational lectures focus on the critically important diagnostic and therapeutic standards, disease nomenclature, and classification that allow the field to work together toward real-time and patient-centric solutions.

The XXVI ISTH Congress kicks off with the opening ceremony on Sunday evening. We look forward to sharing a taste of history in medicine and science mixed with modern artists and music, which illustrates the river of knowledge. The opening ceremony will be followed by a networking reception in the exhibition halls.

The scientific part of the congress features 131 invited speakers, including eight plenary lectures by front-line scientists and 84 state-of-the-art lectures by leaders in their respective fields (accompanied by selected state-of-the-art papers in the Journal of Thrombosis and Haemostasis). The congress also offers 39 abstract symposia with an introductory review lecture, followed by oral presentations of top-scoring abstracts. A late-breaking session will be held on Tuesday highlighting important and timely results from clinical trials.

From Monday to Wednesday, poster sessions will be presented. For those who have reserved tickets, there are master classes covering 40 topics in the early mornings between Sunday to Wednesday, and career development sessions for small groups will be held from Monday to Wednesday at lunch time. Overall, more than 3,000 abstracts will be presented as oral or poster presentations.

During the lunch break, you have the opportunity to discuss poster presentations in the poster area and network with your colleagues followed by industry supported product theater presentations and supported symposia.

We are grateful to our industry partners for their generous support of the congress. We encourage you to visit the exhibition hall, attend product theater and supported symposia, learn about the latest diagnostic and therapeutic advances available to us and exchange ideas with representatives from the diagnostic and pharmaceutical industry.

On Wednesday evening, we invite you to attend the networking evening at the famous Tempodrom in downtown Berlin with live music and delicious catering by Sarah Wiener, a famous Austrian chef now living in Berlin. Make sure you purchase tickets to attend before it is sold out!

The congress closes on Thursday at noon with a session on the highlights of ISTH 2017, where you will hear a recap of selected, top-scoring presentations from both basic and clinical science.

Finally we are excited about the many new innovations that will be introduced at the congress. Be sure to download the ISTH 2017 mobile app and stay up to date and build your itinerary for the meeting.

We wish you an informative and memorable experience at ISTH 2017. We hope you will be inspired by the science, news, and innovation taking place at the congress, as well as by the culture of Berlin and its history.

Johannes Oldenburg, M.D.
ISTH XXVI Congress President

Ingrid Pabinger, M.D.
ISTH Council Chair

Walter Ageno, M.D.
ISTH SSC Chair
WELCOME MESSAGE

With this year’s Congress, the title of which is "Transcending Scientific Boundaries," you are once again sending out an important signal with regard to global and cross-border advances in the prevention and treatment of thrombosis, blood coagulation disorders and related secondary diseases. Over 9,000 experts from 90 countries will be coming together at this event to report both on the latest scientific findings and their experience. They will be providing insights into the current state of research and identifying possibilities for further improving the life of patients the world over. Furthermore, with your guidelines and the valuable recommendations on diagnosis and therapy that go with them, you are supporting family doctors and specialists in providing the best possible treatment for their patients.

I wish to express my sincere gratitude for your untiring efforts in the further development of the prevention, diagnosis and treatment of thrombosis and blood coagulation disorders, as well as the secondary diseases that might accompany them. For this year’s conference of the International Society of Thrombosis and Haemostasis, which is taking place in Germany for the first time this year, I wish you a successful outcome, with many new insights and an exciting exchange of know-how among the experts present.

Hermann Gröhe
Federal Minister of Health
Member of the German Bundestag

Dear Participants of the ISTH 2017 Congress,

Welcome to Berlin!

I am delighted that you are holding this prestigious congress in Germany for the first time and have chosen Berlin as your venue. Experts from all over the world will gather here to explore the latest findings on endemic cardiovascular diseases.

As one of the world’s leading trade show and congress venues, Berlin offers ideal conditions for professional meetings. At the same time, as a modern health care capital with a long history, our city boasts an excellent scientific landscape. Along with Charité-Universitätsmedizin Berlin, Berlin’s flagship of modern medical research and practice, you will find a broad spectrum of public and private hospitals, excellent colleges and universities, and a host of renowned non-university research institutes doing cutting-edge research.

And so I would like to wish you all a productive and successful congress that is a source of useful insights and fresh professional inspiration. And, of course, I hope you will enjoy an unforgettable stay in Berlin – both at the conference sessions organized by your renowned medical society and on forays through our exciting city.

Michael Müller
Governing Mayor of Berlin
The mission of the Journal of Thrombosis and Haemostasis (JTH) is to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. Editors invite both fundamental and clinical contributions.

Benefits of publishing in JTH

**Speed:** Submissions are quick and easy with our online system. Papers receive rapid peer review by JTH's international editorial board and are published online within days of acceptance through Accepted Articles.

**Impact:** Your research will be read widely around the world, including exposure to the membership of the International Society on Thrombosis and Haemostasis. Our author tools provide you with extensive opportunities to drive your impact through social and online activity.

**Reputation:** For more than 13 years, JTH has provided a home for high quality research in the field of thrombosis and hemostasis. In conjunction with its prominent editors-in-chief, editorial board and associate editors, JTH has published some of the best authors in the field.

Submit online at jth.isth.org
ISTH 2017 COMMITTEES

ISTH Organizing Committee

Local Organizing Committee
Johannes Oldenburg, Germany
Ingrid Pabinger, Austria
Anne Angelillo-Scherrer, Switzerland
Andreas Greinacher, Germany
Bettina Kemkes-Matthews, Germany
Christoph Male, Austria
Christine Mannhalter, Austria
Klaus T. Preisssner, Germany
Wolfram Ruf, Germany
Christian Weber, Germany

Scientific Program Committee Chairs
Christoph Binder, Austria
Bernd Engelmann, Germany
Karl Lackner, Germany
Johann Woita, Austria
Andreas Tiede, Germany
Stavros Konstantinides, Germany
Katrin Khair, United Kingdom
Sabine Eichinger, Austria
Christoph Male, Austria
Bernhard Nieswandt, Germany
Meinrad Gawaz, Germany
Erhard Seifried, Germany
Hellmut Augustin, Germany

Scientific Program Committee

Atherothrombosis and Stroke
Christoph Binder, Austria, Chair
Steffen Massberg, Germany, Co-Chair
Steen Dalby Kristensen, Denmark
Lina Badimon, Spain
Irene Lang, Austria
Andreas Zirlik, Germany

Coagulant and Anticoagulant Mechanisms
Bernd Isermann, Germany, Chair
Thomas Renné, Germany, Co-Chair
Rodney Camire, United States
Björn Dahlbäck, Sweden
Christophe Dubois, France
Tilman Hackeng, the Netherlands
Peter Lenting, France

Coagulation Signaling and Immunity
Bernd Engelmann, Germany, Chair
Triantafyllos Chavakis, Germany, Co-Chair
Tobias Fuchs, Germany
Heiko Herwald, Sweden
Craig Morrell, United States
Henri Versteeg, the Netherlands
Hartmut Weiler, United States

Diagnostics and OMICs
Karl Lackner, Germany, Chair
Pierre Morange, France, Co-Chair
Mihaela Delcea, Germany
Jens Mueller, Germany
Williem Oostveen, United Kingdom
Michael Spannagl, Austria
John Weisel, United States

Fibrinolysis and Proteolysis
Johann Woitä, Austria, Chair
Florian Langer, Germany, Co-Chair
Thomas Bugge, United States
Paul Declerck, Belgium
Marguerite Neerman Arbez, Switzerland
Maria Stopelli, Italy
Annetta Undas, Poland
Joost Meijers, the Netherlands

Hemorrhagic Disorders, Hemophilia
Andreas Tiede, Germany, Chair
Reinhard Schneppenheim, Germany, Co-Chair
David Lillicrap, Canada
Christoph Male, Austria
Flora Peyvandi, Italy
Alok Srivastava, Italy
Jerzy Windyga, Canada
Peter Lenting, France
Dan Hart, United Kingdom

Management of Thromboembolism
Stavros Konstantinides, Germany, Chair
Jan Beyer-Westendorf, Germany, Co-Chair
Harry Bülter, the Netherlands
Guy Meyer, France
Ulrike Nowak-Göttl, Germany
Marc Righini, Switzerland
Sebastian Schellong, Germany
Jeffrey Weitz, Canada

Pathogenesis of Thromboembolism
Sabine Eichinger, Austria, Chair
Bernd Pützsch, Germany, Co-Chair
Cihan Aý, Austria
Francesco Bernardi, Italy
Saska Middeldorp, the Netherlands
Pieter Reitsma, the Netherlands
Per Morten Sandset, Norway

Pediactrics
Christoph Male, Austria, Chair
Manuela Albusetti, Switzerland
Barbara Zieger, Germany
Karim Kurnik, Germany
Ulrike Nowak-Göttl, Germany

Platelets – Basic
Bernhard Nieswandt, Germany, Chair
Beate Kehrel, Germany, Co-Chair
Wolfgang Bergmeier, United States
Ken Clemetson, Switzerland
Christian Gachet, France
Johan Heemskerk, the Netherlands
Steve Watson, United Kingdom
XXVI ISTH Congress and 63rd Annual SSC Meeting

ISTH 2017 COMMITTEES

Platelets – Clinical

- Meinrad Gawaz, Germany, Chair
- Johanna Kremer Hovinga, Germany, Co-Chair
- Tamam Bakchouch, Germany
- Carlo Balduni, Italy
- Pierre Fontana, Switzerland
- Paul Knöbl, Austria
- Alan Michelson, United States

Transfusion and Biotherapeutics

- Erhard Seifried, Germany, Chair
- Peter Horn, Germany, Co-Chair
- Cedric Ghevaert, United Kingdom
- Behrouz Mansouri Taleghani, Germany
- Patrick Meybohm, Germany
- Simon Panzer, Austria
- Ulrich Sachs, Germany

Vascular Biology and Angiogenesis

- Hellmut Augustin, Germany, Chair
- Stefanie Dimmeler, Germany, Co-Chair
- Chantal Boulanger, France
- Jozef Dulak, Poland
- Gou Young Koh, Republic of Korea

Nurses and Allied Health

- Maura Malone, United States, Chair
- Bunis Packham, United Kingdom, Co-Chair
- Regina Butler, United States
- Jennifer Maahs, United States
- Jim Munn, United States
- Fiona Newell, Australia
- Anne O’Sullivan, Ireland

International Advisory Board

- Lorenzo Alberio, Switzerland
- Cihan Ay, Austria
- Lina Badimon, Spain
- Tamam Bakchouch, Germany
- Wolfgang Bergmeier, United States
- Francesco Bernardi, Italy
- Christoph Binder, Austria
- Vladimir Bogdanov, United States
- Paul Bray, United States
- Benjamin Brenner, Israel
- Thomas Bugge, United States
- Harry Büller, the Netherlands
- Rodney Camire, United States
- Peter Carmeliet, Belgium
- Marco Cattaneo, Italy
- Tran Chavakis, Germany
- Ken Clementson, Switzerland
- Barry Coller, United States
- Ed Conway, Canada
- Björn Dahlbäck, Sweden
- Philippe de Moerloose, France
- Paul Declerq, Belgium
- Elisabetta Dejana, Italy
- Mihaela Delcea, Germany
- Cecile Denis, France
- Francoise Dignat-George, France
- Donna DiMichele, United States
- Jing-Fei Dong, United States
- Christoph Dubois, France
- Charles Esmon, United States
- Anna Falanga, Italy
- Jane Freedman, United States
- Christian Gachet, France
- David Gailani, United States
- Ian Greer, United Kingdom
- John Griffin, United States
- Yves Gruel, France
- Tilman Hackeng, the Netherlands
- Katherine Hajjar, United States
- Paul Harrison, United Kingdom
- Johan Heemskerk, the Netherlands
- Philip Hogg, Australia
- Kurt Huber, Austria
- Shaun Jackson, Australia

ISTH 2017 COMMITTEES

- Nigel Key, United States
- Robert, Klamroth, Germany
- Ralf Knöfler, Germany
- Wolfgang Korte, Switzerland
- Johanna Kremer Hovinga, Switzerland
- Siriram Krishnaswamy, United States
- Steen Kristensen, Denmark
- Karin Kurnik, Germany
- Bernhard Lämmle, Switzerland
- David Lane, United Kingdom
- Florian Langer, Germany
- Dan Lawrence, United States
- Peter Lenting, France
- Marcel Levi, the Netherlands
- Klaus Ley, United States
- David Lillicrap, Canada
- Gregory Lip, United Kingdom
- Nigel Mackman, United States
- Jonny Mahlangu, South Africa
- Mike Makris, United Kingdom
- Robert Medcalf, Australia
- Diego Mezzano, Chile
- Alan Michelson, United States
- Toshiyuki Miyata, Japan
- Craig Morrell, United States
- James Morrisey, United States
- Laurent Mosnier, United States
- Michael Nagler, Switzerland
- Amit Nathwani, United Kingdom
- Marguerite Neerman Arbez, Switzerland
- Ute Nowak-Göttl, Germany
- Paquita Nurden, France
- Yukio Ozaki, Japan
- Rafal Pawlinski, United States
- Karlheinz Peter, Australia
- Flora Peyvandi, Italy
- Ed Plow, United States
- Michael Spannagl, Germany
- Maria Stoppelli, Italy
- Hugo Ten Cate, the Netherlands
- Anetta Undas, Poland
- Tetsumei Urano, Japan
- Marijke van den Berg, the Netherlands
- Karen Vanhoorebeke, Belgium
- Freek Verheugt, the Netherlands
- Henri Versteeg, the Netherlands
- Denis Wagner, United States
- Christopher Ward, Australia
- Steve Watson, United Kingdom
- Jeffrey Weitz, Canada
- Jerzy Windyga, Poland
- Sidney Whiteheart, United States
- Alisa Wolberg, United States
- Walter Wüllenwein, Switzerland
- Barbara Zieger, Germany
- Andreas Zirlik, Germany

Sam Schulman, Canada
Jean-François Schved, France
Michael Spannagl, Germany
Maria Stoppelli, Italy
Hugo Ten Cate, the Netherlands
Anetta Undas, Poland
Tetsuumei Urano, Japan
Marijke van den Berg, the Netherlands
Victor van Hinsbergh, the Netherlands
Karen Vanhoorebeke, Belgium
Freek Verheugt, the Netherlands
Henri Versteeg, the Netherlands
Denis Wagner, United States
Christopher Ward, Australia
Steve Watson, United Kingdom
Jeffrey Weitz, Canada
Jerzy Windyga, Poland
Sidney Whiteheart, United States
Alisa Wolberg, United States
Walter Wüllenwein, Switzerland
Barbara Zieger, Germany
Andreas Zirlik, Germany
## ISTH 2017 ABSTRACT REVIEWERS

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walter Ageno, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Josefín Ahnström, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Lorenzo Alberio, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Manuela Albisetti, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Marie-Christine Alessi, France</td>
<td>France</td>
</tr>
<tr>
<td>Robert Andrews, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Pantej Angchasikusri, Thailand</td>
<td>Thailand</td>
</tr>
<tr>
<td>Gemma Arderiu, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Robert Ariens, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Donald Arnold, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Alice Assinger, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>Jan Astarmerk, Sweden</td>
<td>Sweden</td>
</tr>
<tr>
<td>Hellmut Augustin, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Cihan Ay, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>Lina Badimon, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Juan Jose Badimon, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Tamam Bakchoul, Germany</td>
<td>United States</td>
</tr>
<tr>
<td>Ross Baker, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Alessandra Baldiuini, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Stefano Barco, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Angelika Batorova, Slovakia</td>
<td>Slovakia</td>
</tr>
<tr>
<td>Rupert Bauersachs, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Cecilia Becattini, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Markus Bender, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Frauke Bergmann, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Wolfgang Bergmeier, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Francesco Bernardi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Erik Berntorp, Sweden</td>
<td>Sweden</td>
</tr>
<tr>
<td>Laurent Bertoletti, France</td>
<td>France</td>
</tr>
<tr>
<td>Jan Beyer-Westendorf, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Christoph Binder, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>Tina Biss, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Jan Blatny, Czech Republic</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Marc Blondon, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Mark Blosten, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Christoph Bode, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Vladimir Bogdanov, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Eric Boillard, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Mariana Bonduel, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td>Maria Borrell, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Chantal Boulanger, France</td>
<td>France</td>
</tr>
<tr>
<td>Henri Bounameaux, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Vanessa Bousskill, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Leonardo Brandao, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Lawrence Brass, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Benjamín Brenner, Israel</td>
<td>Israel</td>
</tr>
<tr>
<td>Thomas Bugge, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Harry Büller, the Netherlands</td>
<td>United States</td>
</tr>
<tr>
<td>James Bussel, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Regina Butler, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Marina Camera, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Scott Cameron, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Rodney Camire, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Suzanne Cammi, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Ilaria Canobbio, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Madeline Cantini, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Manuel Carcao, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Marc Carrier, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Giancarlo Castaman, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Francis Castellino, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Elisabetta Castoldi, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Marco Cattaneo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Elizabeth Chalmers, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Anthony Chan, Canada</td>
<td>China</td>
</tr>
<tr>
<td>Meera Chittur, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Olivier Christophe, France</td>
<td>France</td>
</tr>
<tr>
<td>Kenneth Cleftson, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Ander Cohen, United Kingdom</td>
<td>United States</td>
</tr>
<tr>
<td>Barry Collier, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Peter Collins, United Kingdom</td>
<td>United States</td>
</tr>
<tr>
<td>Marco Colucci, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Ed Conway, Canada</td>
<td>United States</td>
</tr>
<tr>
<td>Michiel Coppens, the Netherlands</td>
<td>United States</td>
</tr>
<tr>
<td>Javier Corral, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Judith Cosmans, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Benilde Cosmi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Francis Couturaud, France</td>
<td>France</td>
</tr>
<tr>
<td>Jim Crawford, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Judit Cubedo, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Mary Cushman, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Björn Dahlbäck, Sweden</td>
<td>Sweden</td>
</tr>
<tr>
<td>Steen Dalby Kristensen, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td>Sven Danckwardt, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Armando D'Angelo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Philippe de Groot, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Bas de Laat, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Moniek de Maat, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Simon De Meyer, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>Philippe de Moerloose, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Hans Deckmyn, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>Paul Declerck, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>Raimondo DeCristofaro, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Ahmet Muzaffer Demir, Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>Cecile Denis, France</td>
<td>France</td>
</tr>
<tr>
<td>Francesco Dentali, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Katrien Devreeze, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>Scott Diamond, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Hans Christoph Diener, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Donna DiMichele, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Marcello DiNisio, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Reyhan Diz-Küçükayak, Turkey</td>
<td>France</td>
</tr>
<tr>
<td>Roseline D'Oiron, France</td>
<td>France</td>
</tr>
<tr>
<td>Gerry Dolan, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Jing-Fei Dong, United States</td>
<td>United States</td>
</tr>
<tr>
<td>James Douketis, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Christophe Dubois, France</td>
<td>France</td>
</tr>
<tr>
<td>Jozef Dulak, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>Sabine Eichinger, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>Jeroen Eikenboom, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Jonas Emsley, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Bernd Engelmann, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Carmen Escurioila, Germany</td>
<td>Italy</td>
</tr>
<tr>
<td>Koji Eto, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>Elena Faioni, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Anna Falanga, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Augusto Federici, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>Karin Fijnvandraat, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Kathelijn Fischer, the Netherlands</td>
<td>Germany</td>
</tr>
<tr>
<td>Robert Flaumenhaft, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Ingrid Fleming, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Matthew Flick, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Pierre Fontana, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Andrew L. Frelinger, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Tobias Freytag, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Janine Furmede, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>David Gailani, United States</td>
<td>United States</td>
</tr>
<tr>
<td>David Garcia, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Pablo Garcia de Frutos, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Elizabeth Gardiner, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Thomas Gary, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>Maragethe Geiger, Austria</td>
<td>Germany</td>
</tr>
<tr>
<td>Holger Gerhardt, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Grigoris Gerotziasfas, France</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Cedric Ghevaert, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Paul Giangrande, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Sam Goldhaber, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Jenny Goudemand, France</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Samantha Gow, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>Andreas Greinacher, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Paolo Gresele, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>John Griffin, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Jean-Christophe Gris, France</td>
<td>France</td>
</tr>
<tr>
<td>Peter Gross, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Erik Grove, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td>Yves Gruel, France</td>
<td>France</td>
</tr>
<tr>
<td>Chris Guelcher, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Mayer Günter, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Sylvia Haas, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Tilman Hackeng, the Netherlands</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>John-Bjarne Hansen, Norway</td>
<td>Norway</td>
</tr>
<tr>
<td>Paul Harrison, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Charles Hay, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Beatrice Hechler, France</td>
<td>France</td>
</tr>
<tr>
<td>Johan W.M. Heemskerk, the Netherlands</td>
<td>Heiko Herwald, Sweden</td>
</tr>
<tr>
<td>Anne-Mette Hvas, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td>Vera Ignjatovic, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Berend Isermann, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Shaun Jackson, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Shannon Jackson, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Paula James, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Martine Jandrot-Perrus, France</td>
<td>France</td>
</tr>
<tr>
<td>Davit Jangidze, Georgia</td>
<td>Georgia</td>
</tr>
<tr>
<td>Susan Kahn, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Walter Kahr, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>Sandip Kanse, Norway</td>
<td>Norway</td>
</tr>
<tr>
<td>Kaan Kavaklı, Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>Beate Kehrel, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Bettina Kemkes-Matthes, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Gili Kenet, Israel</td>
<td>Israel</td>
</tr>
<tr>
<td>Steven K. Kerrigan, Ireland</td>
<td>Ireland</td>
</tr>
<tr>
<td>Nigel Key, United States</td>
<td>United States</td>
</tr>
<tr>
<td>Kate Khair, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Benjamin Kile, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Paul Kim, Canada</td>
<td>Canada</td>
</tr>
</tbody>
</table>
XXVI ISTH Congress and 63rd Annual SSC Meeting

ISTH 2017 ABSTRACT REVIEWERS

Robert Klarmroth, Germany
Frederikus A. Kloq, the Netherlands
Cornelis (Kees) Kluit, the Netherlands
Paul Knöbl, Austria
Ralf Knöller, Germany
Rory Koenen, Germany
Christoph Koenigs, Germany
Gou Young Koh, Republic of Korea
Oliver Königsbrügge, Austria
Stavros Konstantinides, Germany
Wolfgang Korte, Switzerland
Johanna Kremer, Switzerland
Sririam Krishnaswamy, United States
Mariëke Kruijff, the Netherlands
Karin Kurnik, Germany
Karl Lackner, Germany
Bernhard Lämmlle, Germany
David Lane, United Kingdom
Florian Langer, Germany
Mareike Lankeit, Germany
Francois Lanza, France
Sanne Bejot Larsen, Denmark
Riitta Lassila, Finland
Mandy Lauw, the Netherlands
Dan Lawrence, United States
Grégoire le Gal, Canada
Thomas Lecompte, Switzerland
Agnes Lee, Canada
Christine Lee, United Kingdom
Frank Leebek, the Netherlands
Peter Lenting, France
Catherine Leon, France
Marcel Levi, the Netherlands
Renéul Li, United States
Ri Lissens, United Kingdom
W.M. Lifering, the Netherlands
Rigobert Lijnen, Belgium
David Lillicrap, Canada
Edegard Lindhoff-Last, Germany
Gregory Lip, United Kingdom
Tom Lismen, the Netherlands
Rustam Litvinov, United States
Rolf Ljung, Sweden
Colin Longstaff, United Kingdom
Marie Lordkipanidze, Canada
Jennifer Maahs, United States
Coen Maas, the Netherlands
Nigel Mackman, United States
Patricia Maguire, Ireland
Johnny Mahlagu, South Africa
Mike Makris, United Kingdom
Christoph Male, Austria
Maura Malone, United States
Maria Elisa Mancuso, Italy
Pierre Mangin, France
Christine Marvinhalter, Austria
Pier Mannuccio Mannucci, Italy
Karyn Martin, United States
Ida Martinelli, Italy
Steffen Massberg, Germany
Patti Massicotte, Canada
Alan Mast, United States
Manuel May, United Kingdom
Lucia Mazzolai, Switzerland
Owen McCarty, United States
Simon McRae, Australia
Rob Medcalf, Australia
Karina Meijer, the Netherlands
Joost Meijers, the Netherlands
Kelly Metcalfe Pate, United States
Patrick Meybohm, Germany
Guy Meyer, France
Diego Mezzano, Chile
Alan Michelson, United States
Saskia Middeldorp, the Netherlands
Lindsay Miles, United States
Lesley Mitchell, Canada
Toshiyuki Miyata, Japan
Shigeki Miyata, Japan
Paul Morley, United States
Pierre Morange, France
Craig Morrell, United States
James Morrissey, United States
John Morser, United States
Laurent Mosnier, United States
Jens Mueller, Germany
Greta Mulders, the Netherlands
Jim Murn, United States
Laszlo Muszbek, Hungary
Nicola Mutch, United Kingdom
Linda Myrin-Westesson, Sweden
Michael Nagler, Switzerland
Marguerite Neeman-Arbe, Switzerland
Claude Negrier, France
Fiona Newall, Australia
Heyu Ni, Canada
Tim Nicholas, United States
Gerry Nicolaes, the Netherlands
Marvin Nieman, United States
Bernhard Nieswander, Germany
Rienk Nieuwland, the Netherlands
Ulrike Nowak-Gott, Germany
Paquita Norden, France
Johannes Oldenburg, Germany
El-Maarri Osman, Lebanon
Yukio Otsuki, Japan
Margareth Ozelo, Brazil
Ingrid Pabinger, Austria
Bunis Packham, United Kingdom
Teresa Padro, Spain
John Pasi, United Kingdom
Carlo Patrono, Italy
Rafal Pawlinski, United States
Bernard Payastrre, France
Dirk Peetz, Germany
Karhinez Peter, Australia
Flora Peyvandi, Italy
Helen Philippou, United Kingdom
Victoria Ploplis, United States
Michael Ploug, Denmark
Ed Plow, United States
Alastair Poole, United Kingdom
Paolo Prandoni, Italy
Roger Preston, United States
Klaus T. Preissern, Germany
Patrick Provost, Canada
Leslie Raffini, United States
Margeret Ragni, United States
Jacob Rand, United States
Gary Raskob, United States
Pieter Reitzema, the Netherlands
Thomas Renné, Germany
Jean-Luc Reny, Switzerland
Shoshana Revel-Vilk, Israel
Alirea Rezaie, United States
Marc Righini, Switzerland
Dick Rijken, the Netherlands
Helia Robert-Ebadi, Switzerland
Bianca Rocca, Italy
Francesco Rodighiero, Italy
Marc Rodger, Canada
Matthew Rondina, United States
Frits Rosendaal, the Netherlands
Wolfram Ruf, Germany
Ulrich Sachs, Germany
Evan Sadler, United States
Olivier Sanchez, France
Per Morten Sandset, Norway
Kim Schafner, United States
Richard Schäfer, Germany
Sebastian Schellong, Germany
Peter Schlenke, Austria
Alvin Schmaier, United States
Reinhard Schneppenheim, Germany
Sam Schulman, Canada
Harald Schulze, Germany
Jean-François Schved, France
Erhard Seifried, Germany
John Semple, Sweden
Yotis Senis, United Kingdom
Melchior Seyfarth, Germany
Dirk Sibbing, Germany
Paolo Simioni, Italy
Michael Spannagl, Germany
Sherry Spinelli, United States
Henri Spronk, the Netherlands
Alessandro Squizzato, Italy
Alok Srivastava, India
Evi Stavrour, United States
Lucia Stefanini, Italy
Rosen Steffen, Sweden
Scott Steinberg, United States
Sophie Susen, France
Katsumi Suzuki-Inoue, Japan
Roman Szabo, United States
Jason Taylor, United States
Arina ten Cate, the Netherlands
Hugo Ten Cate, the Netherlands
Andreas Tiede, Germany
Torsten Tonn, Germany
Alberto Tosetto, Italy
Paula B. Tracy, United States
Elena Tremoli, Italy
Sotirios Tsimikas, United States
ISTH 2017 ABSTRACT REVIEWERS

Edward (Ted) Tuddenham, United Kingdom
Shirley Uitte de Willige, the Netherlands
Anetta Undas, Poland
Tetsuemi Urano, Japan
Rolf Urbanus, the Netherlands
William Vainchenker, France
Marijke van den Berg, the Netherlands
Nick Van Es, the Netherlands
Chris van Geet, Belgium
Victor van Hinsbergh, the Netherlands
Astrid Van Hylckama Vlieg, the Netherlands
Heleen van Ommen, the Netherlands
Karen Vanhoorelbeke, Belgium
David Varon, Israel
Peter Verhamme, Belgium
Henri Versteeg, the Netherlands
Gemma Vilahur, Spain
Denis Vivien, France
Jan Voorberg, the Netherlands
Denisa Wagner, United States
Christopher Ward, Australia
Theodore Warkentin, Canada
Steve Watson, United Kingdom
Christian Weber, Germany
Hartmut Weiler, United States
John Weisel, United States
Jeffrey Weitz, Canada
Jerzy Windyga, Poland
Johann Wöta, Austria
Alisa Wolberg, United States
Walter A. Wuillemin, Switzerland
Guy Young, United States
Laurent Yvan-Charvet, France
Rene Zahedi, Germany
Barbara Zieger, Germany

ISTH COUNCIL

Officers
Ingrid Pabinger, Austria
Chairman (2016 – 2018)
Claire McLintock, New Zealand
Secretary/Chairman-Elect (2016 – 2018)
Björn Dahlbäck, Sweden
Treasurer (2015 – 2018)

Class of 2018
Peter Lenting, France
Claire McLintock, New Zealand
James Morrissey, United States
Ingrid Pabinger, Austria
Jeffrey Weitz, Canada

Class of 2020
Anna Falanga, Italy
David Lillicrap, Canada
José López, United States
Suely Rezende, Brazil
Steve Watson, United Kingdom

Class of 2022
Pantep Angchaisuksiri, Thailand
Michael Makris, United Kingdom
Flora Peyvandi, Italy
Sam Schulman, Canada
Alisa Wolberg, United States

Ex-Officio Council Members
J. Evan Sadler, United States
Secretary General, ISTH
Johannes Oldenburg, Germany
President, XXVI ISTH Congress
Berlin, 2017
Sam Schulman, Canada
Past President, XXV ISTH Congress
Toronto, 2015
Nigel Key, United States
Immediate Past Chairman, ISTH Council
Pieter Reitsma, the Netherlands
Editor-in-Chief, Journal of Thrombosis and Haemostasis
Frits Rosendaal, the Netherlands
Editor-in-Chief, Journal of Thrombosis and Haemostasis
Walter Ageno, Italy
Chairman, Scientific and Standardization Committee (SSC)
You are invited to attend the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) Annual Meeting. Held in Dublin, Ireland, from July 18–21, 2018, the ISTH SSC 2018 meeting is both engaging and informative. It is an excellent and affordable scientific event in the field of thrombosis and hemostasis that brings together the world’s leading experts.

**SSC Executive Committee 2016-2018**
- Walter Ageno, Italy
- Nicola Mutch, United Kingdom
- Sabine Eichinger, Austria
- Dermot Cox, Ireland

**Standing Committee Chairmen**
- Anthony R. Hubbard, United Kingdom
- Peter Lenting, France

**Subcommittee Chairmen**
- Jose A. Diaz, United States
- Keith B. Neeves, United States
- Mark Crowther, Canada
- Jecko Thachil, United Kingdom
- Guy Young, United States
- Joost Meijers, the Netherlands
- Verena Schroeder, Switzerland
- Nicola Mutch, United Kingdom
- Willem H. Ouwehand, United Kingdom
- Bas de Laat, the Netherlands
- Christoph Maile, Austria
- Charles Marc Samama, France
- Richard A. Marlar, United States
- Donald M. Arnold, Canada
- Paolo Gresele, Italy
- Paul A. Kyrle, Austria
- Rezan A. Abdul-Kadir, United Kingdom

**SSC Chairman**
- SSC Chairman
- Secretary/Chairman-Elect
- Immediate Past SSC Chairman
- Ex-Officio: President, SSC 2018

**Coagulation Standards**
- WHO-ISTH Standards Liaison Group

**Subcommittee Chairmen**
- Animal, Cellular and Molecular Models of Thrombosis
- Biophysics
- Control of Anticoagulation
- Disseminated Intravascular Coagulation
- Factor VIII, Factor IX and Rare Coagulation Disorders
- Factor XI and the Contact System
- Factor XIII and Fibrinogen
- Fibrinolysis
- Genomics in Thrombosis and Hemostasis
- Hemostasis and Malignancy
- Lupus Anticoagulant/Antiphospholipid Antibodies
- Pediatric and Neonatal Thrombosis and Hemostasis
- Perioperative Thrombosis and Hemostasis
- Plasma Coagulation Inhibitors
- Platelet Immunology
- Platelet Physiology
- Predictive and Diagnostic Variables in Thrombotic Disease
- Vascular Biology
- Von Willebrand Factor
- Women’s Health Issues in Thrombosis and Hemostasis
Robert P. Grant Medal

The Robert P. Grant Medal is the highest award of the ISTH. It is presented during the biennial ISTH Congress in honor of research achievements, organizational activities, support of research activities, facilitation of institutional cooperation and communication, unusual teaching or educational initiatives and/or the development of concepts that result in a clearer understanding of research data.

This medal is named after Robert P. Grant, a renowned cardiologist who spent many years as a representative of the National Institutes of Health in Europe, traveling extensively and facilitating American-European collaboration in medical research and education.

The ISTH Grant Medal will be presented at the Opening Ceremony on Sunday, July 9.

Harold R. Roberts Medal

The ISTH Harold R. Roberts Award honors meritorious service to the Scientific and Standardization Committee of the ISTH, beyond expectations and over a significant period of time.

The Roberts Medal will be presented at the President’s Dinner on Monday, July 10.

Biennial Awards for Contributions to Hemostasis (BACH)

The ISTH’s Biennial Awards for Contributions to Hemostasis (BACH) are presented during the ISTH Congress to individuals who, in the opinion of their peers, have made significant contributions to research and education in blood coagulation.

The Investigator Recognition Awards recognize ISTH members whose accomplishments are internationally regarded as exemplary models of excellence in research and mentoring excellence. The Distinguished Career Awards recognize ISTH members whose career contributions have significantly advanced the scientific community’s understanding of the diseases and disorders affecting hemostasis.

The ISTH BACH will be presented at the President’s Dinner on Monday, July 10.
ISTH AND ISTH 2017 AWARDS

2017 Recipients of the Biennial Awards for Contributions to Hemostasis (BACH)
Distinguished Career
Peter Carmeliet, Belgium
James Huntington, United Kingdom
Yasuo Ikeda, Japan
Bernhard Lämmle, Germany
Paula Tracy, United States
Investigator Recognition
Rodney Carriere, United States
Douglas Cines, United States
Mark Crowther, Canada
Cécile Denis, France
Mortimer Poncz, United States

ISTH 2017 Travel Awards
Travel Award recipients can go to the specific “Travel Award” desk in the Registration Area on the main entrance level of the CityCube Berlin to receive their grant. Grants can be collected between 08:00 on Saturday, July 8, through 12:00 on Tuesday, July 11. See page 513 for more information about travel grants.

Young Investigator Travel Awards
The Young Investigator Travel Awards are provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of July 7, 2017) who submitted highly rated abstracts.

Recipients of an ISTH 2017 Young Investigator Travel Award
Sonia Aguila, Ireland
Mikel Allende, Sweden
Ana Belén Arroyo Rodriguez, Spain
Nathan Asquith, United Kingdom
Francis Ayomib, United States
Elena Barbon, France
Sarah Beck, Germany
Isabelle Becker, Germany
Roelof Hendrik Bekendam, France

ISTH 2017 AWARDS
Johana Hrdinová, the Netherlands
Jennifer Elizabeth Huffman, United States
Vaishali Inamdar, United States
Isuru Induruwa, United Kingdom
Ivan Ivanov, United States
Sjoert Bernardus Gerardus Jansen, the Netherlands
Ian Johnston, United States
Lining Ju, Australia
Sergei Kalabushev, Russian Federation
Elle Karampini, the Netherlands
Sravya Kattula, United States
Charlotte Kawecki, France
Oliver Königsbrügge, Austria
Anna Kopeć, United States
Kim Jürgen Krot, Germany
Jesse D. Lai, Canada
Eldicje Lariand, Belgium
Christine Lee, Australia
Robert H. Lee, United States
Marcus Lehmann, United States
Gabriela Lesyk, Canada
Laurens Liesenborghs, Belgium
Randolph Lyde, United States
Sai Ma, China
Kellie Machlus, United States
Annabel MacIachlan, United Kingdom
Jayakumar Manoharan, Germany
Mauritia C. Marijnen, the Netherlands
Sara Martinez de Lizarrondo, France
Lisa-Marie Mauracher, Austria
Helen McPherson, United Kingdom
Simone Merlin, Italy
Alison Michels, Canada
Annachiara Mitrugno, Canada
Amel Mohamadi, France
Bassem M. Mohammed, United States
Gael B. Morrow, the Netherlands
Vincent Muczynski, France
Patrick Münzer, Germany
Marion Müssbacher, Austria
Magdalena Nagy, the Netherlands
Zoltan Nagy, United Kingdom
Prajeeva M. Nair, United States
Clément Naudin, Sweden
Manuel Navarro-Oviedo, Spain
Miguel A.D. Neves, Canada

Giang N. Nguyen, United States
Georg Obermayer, Austria
Cristina Olgașă, Italy
Fergal O’Shaughnessy, Ireland
Olive Pagel, Germany
Verónica Palma-Barqueros, Spain
Vishal Patel, Canada
Akruti Patel, United States
Marie-Claude Pelland-Marcotte, Canada
Sameera Peraramelli, United States
Victoria Petermann, Germany
Anastasios Petri, United Kingdom
Ivan Peyron, the Netherlands
Silvia Pignani, Italy
Irina Portier, Belgium
Florian Posch, Austria
Anna D. Protopopova, United States
Malgorzata Przeradzka, the Netherlands
Cristina Puy, United States
Michael Quach, United States
Orla Rawley, Canada
José Miguel Rivera-Caravaca, Spain
Eilen Roosevelt, Belgium
Manuel Salzmann, Austria
Luuk J.J. Scheres, the Netherlands
Maaike Schilleman, the Netherlands
Maria Isabel Schmidgen, Germany
David Emanuel Schmidt, the Netherlands
Rogier Matijis Schoeman, United States
Mark Schreuder, the Netherlands
Waltraud Cornelia Schrottmair, Sweden
Lisette M. Schütte, the Netherlands
Fatemeh Shahneh, Germany
Shana A. Shaya, the Netherlands
Suzanne M. Silvis, the Netherlands
Satish Singh, United States
Hanne Skille, Norway
Nicoletta Sorvillo, United States
Markus Spindler, Germany
Benedicte Stavik, Norway
Rebecca Steubing, Germany
Michelle Storage, United States
Saravanan Subramaniam, Germany
Pierre Suchon, France
Ravi Talati, United States
Julie L. Tarrant, Canada
### ISTH 2017 AWARDS

#### Reach-the-World Travel Awards

The Reach-the-World Travel Awards are provided in the form of travel grants to clinicians and scientists from Reach-the-World countries to enable participation from all areas of the world in the ISTH 2017 Congress.

Recipients of an ISTH 2017 Reach-the-World Travel Award

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>Emilse Bermejo, Argentina</td>
</tr>
<tr>
<td>Belarus</td>
<td>Ashish Bhalla, India</td>
</tr>
<tr>
<td>Belarus</td>
<td>Volha D. Bichan, Belarus</td>
</tr>
<tr>
<td>Germany</td>
<td>Jelena Bodrozic, Serbia</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Munira Borhany, Pakistan</td>
</tr>
<tr>
<td>Brazil</td>
<td>Christina Castro Bommomschonkel, Brazil</td>
</tr>
<tr>
<td>Argentina</td>
<td>Carolina Cervio, Argentina</td>
</tr>
<tr>
<td>Canada</td>
<td>Charee Chai-Adisaksophia, Canada</td>
</tr>
<tr>
<td>China</td>
<td>Chia-Yau Chang, Taiwan</td>
</tr>
<tr>
<td>China</td>
<td>Xue Chen, China</td>
</tr>
<tr>
<td>Taiwan</td>
<td>Kowit-Yu Chong, Taiwan</td>
</tr>
<tr>
<td>South Africa</td>
<td>Heléne Toiné Cronjé,</td>
</tr>
<tr>
<td>China</td>
<td>Lan Dai, China</td>
</tr>
<tr>
<td>United States</td>
<td>Jing Dai, United States</td>
</tr>
<tr>
<td>Argentina</td>
<td>Lina Paola D’Atri, Argentina</td>
</tr>
<tr>
<td>Egypt</td>
<td>Zaida De Lange, South Africa</td>
</tr>
<tr>
<td>Argentina</td>
<td>Gabriela de Larrafa,</td>
</tr>
<tr>
<td>Argentina</td>
<td>Jean Gabriel de Souza,</td>
</tr>
<tr>
<td>Argentina</td>
<td>Célia Dos Santos, Argentina</td>
</tr>
<tr>
<td>Argentina</td>
<td>Anjalin Dsouza, India</td>
</tr>
<tr>
<td>Brazil</td>
<td>Bruno Kosa Lino Duarte,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Luci Dusse, Brazil</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Xuemei Fan, China</td>
</tr>
<tr>
<td>Lebanon</td>
<td>Roula Farah, Lebanon</td>
</tr>
<tr>
<td>Egypt</td>
<td>Botheina Farweez, Egypt</td>
</tr>
<tr>
<td>Brazil</td>
<td>Daria Fedorova, Russian Federation</td>
</tr>
<tr>
<td>Brazil</td>
<td>Roberto J. Fonseca, Brazil</td>
</tr>
<tr>
<td>India</td>
<td>Madankumar Ghatge, India</td>
</tr>
<tr>
<td>Brazil</td>
<td>Daniel Goncalves Chaves,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Yue Han, China</td>
</tr>
<tr>
<td>China</td>
<td>Yating Hao, China</td>
</tr>
<tr>
<td>China</td>
<td>Yang He, China</td>
</tr>
<tr>
<td>Russia</td>
<td>Bidossiwi Wilfried Hounkpe,</td>
</tr>
<tr>
<td>Nigeria</td>
<td>Khon Huynh, Vietnam</td>
</tr>
<tr>
<td>Russia</td>
<td>Anastasia Ignatova,</td>
</tr>
<tr>
<td>Russia</td>
<td>Asif Iqbal, Brazil</td>
</tr>
<tr>
<td>Vietnam</td>
<td>Shundong Ji, China</td>
</tr>
<tr>
<td>South Africa</td>
<td>Jaco Joubert, South Africa</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Sehar Khalqi, Pakistan</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Sumaira Khan, Pakistan</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Ruchika Kohli, United Kingdom</td>
</tr>
<tr>
<td>Thailand</td>
<td>Patcharee Komvilaisak,</td>
</tr>
<tr>
<td>Ukraine</td>
<td>Olekssii Korzh,</td>
</tr>
<tr>
<td>Russia</td>
<td>Ekaterina Kropacheva,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Ana Clara Ladeira Cruz,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Supakanya Lasom, Thailand</td>
</tr>
</tbody>
</table>

#### ISTH 2017 AWARDS

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td>Huiyuan Li, China</td>
</tr>
<tr>
<td>China</td>
<td>Yang Li, China</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Ruifang Li-Gao, the Netherlands</td>
</tr>
<tr>
<td>United States</td>
<td>Lin Lin, United States</td>
</tr>
<tr>
<td>China</td>
<td>Wenjie Liu, China</td>
</tr>
<tr>
<td>India</td>
<td>Susan Louw, South Africa</td>
</tr>
<tr>
<td>Nepal</td>
<td>Mingen Lyu, China</td>
</tr>
<tr>
<td>India</td>
<td>Pankaj Malhotra, India</td>
</tr>
<tr>
<td>Nepal</td>
<td>Ram Lala Mallick, Nepal</td>
</tr>
<tr>
<td>Venezuela</td>
<td>Rita Marchi, Venezuela</td>
</tr>
<tr>
<td>Argentina</td>
<td>Marta Martinuzzo, Argentina</td>
</tr>
<tr>
<td>Brazil</td>
<td>Samuel S. Medina, Brazil</td>
</tr>
<tr>
<td>Argentina</td>
<td>Hebe Agustina Mena, Argentina</td>
</tr>
<tr>
<td>Italy</td>
<td>Predrag Milijic, Serbia</td>
</tr>
<tr>
<td>India</td>
<td>Yanan Min, China</td>
</tr>
<tr>
<td>Brazil</td>
<td>Silmara A.L. Montalvo, Brazil</td>
</tr>
<tr>
<td>Brazil</td>
<td>Robson Queiroz Monteiro, Brazil</td>
</tr>
<tr>
<td>the Netherlands</td>
<td>Vania Mariis Morelli,</td>
</tr>
<tr>
<td>India</td>
<td>Jiny Nair, India</td>
</tr>
<tr>
<td>Thailand</td>
<td>R. Natesiriinkil, Thailand</td>
</tr>
<tr>
<td>Russia</td>
<td>Dmitry Nechipurenko,</td>
</tr>
<tr>
<td>Nepal</td>
<td>Bipin Nepal, Nepal</td>
</tr>
<tr>
<td>Nigeria</td>
<td>Sergei Obydenny, Russian Federation</td>
</tr>
<tr>
<td>Nigeria</td>
<td>Helen Chioma Okoyo, Nigeria</td>
</tr>
<tr>
<td>Nigeria</td>
<td>Dorothy Chioma Okpokam,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Fernanda Orsi, Brazil</td>
</tr>
<tr>
<td>Argentina</td>
<td>Juvenal Paiva, Argentina</td>
</tr>
<tr>
<td>Brazil</td>
<td>Mariana Sá Pereira, Brazil</td>
</tr>
<tr>
<td>Brazil</td>
<td>Silvia Perés, Argentina</td>
</tr>
<tr>
<td>Thailand</td>
<td>Sithakom Phusanti, Thailand</td>
</tr>
<tr>
<td>Thailand</td>
<td>Bunchoo Pongtanakul, Thailand</td>
</tr>
<tr>
<td>Brazil</td>
<td>Alessandra N.L. Prestozi,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Claudia Pamela Redic,</td>
</tr>
<tr>
<td>Argentina</td>
<td>Anna Virginia Calazans Romano, Brazil</td>
</tr>
<tr>
<td>Thailand</td>
<td>Theera Ruchutarakool,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Roberta Casagrande Saez,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Ana Maria Salazar,</td>
</tr>
<tr>
<td>Venezuela</td>
<td>Renu Saxena, India</td>
</tr>
<tr>
<td>Chile</td>
<td>Mirta Schattner, Argentina</td>
</tr>
<tr>
<td>India</td>
<td>Tanusree Sengupta, India</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Aneeta Shahn, Pakistan</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Khurram Shahzad, Pakistan</td>
</tr>
<tr>
<td>India</td>
<td>Ankit Sharma, India</td>
</tr>
<tr>
<td>China</td>
<td>Wenhong Shen, China</td>
</tr>
<tr>
<td>Brazil</td>
<td>Taisiya Shepel’yuk, Russian Federation</td>
</tr>
<tr>
<td>Brazil</td>
<td>Panlai Shi, China</td>
</tr>
<tr>
<td>India</td>
<td>Neeraj Sidharthan, India</td>
</tr>
<tr>
<td>Brazil</td>
<td>Sandra Martins Silva Soares,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Michelle Sugimoto, Brazil</td>
</tr>
<tr>
<td>Russia</td>
<td>Anastasia Sweshnikova,</td>
</tr>
<tr>
<td>Russia</td>
<td>Ning Tang, China</td>
</tr>
<tr>
<td>India</td>
<td>Lakshmi Narasimha Rao Thota,</td>
</tr>
<tr>
<td>India</td>
<td>Hui-Ju Tsai, Taiwan</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Ikradmind Ujian, Pakistan</td>
</tr>
<tr>
<td>Brazil</td>
<td>Maria Luzia Viela Oliva,</td>
</tr>
<tr>
<td>Brazil</td>
<td>Maximiliano Jesus Vilagra Iturre, Argentina</td>
</tr>
<tr>
<td>Brazil</td>
<td>Natalya Vorobyeva, Russian Federation</td>
</tr>
<tr>
<td>Brazil</td>
<td>Biljana Vuckovic, Serbia</td>
</tr>
<tr>
<td>United States</td>
<td>Yingchun Wang, United States</td>
</tr>
<tr>
<td>China</td>
<td>Jianbo Wu, China</td>
</tr>
<tr>
<td>China</td>
<td>Xiaodong Xi, China</td>
</tr>
<tr>
<td>Brazil</td>
<td>Gabriela Goes Yamaguti-Hayakawa, Brazil</td>
</tr>
<tr>
<td>China</td>
<td>Jialu Yao, China</td>
</tr>
<tr>
<td>India</td>
<td>Yuanjie Yu, the Netherlands</td>
</tr>
<tr>
<td>Brazil</td>
<td>Kiara Cristina Senger Zapponi, Brazil</td>
</tr>
<tr>
<td>China</td>
<td>Xian Zhang, China</td>
</tr>
<tr>
<td>China</td>
<td>Donglei Zhang, China</td>
</tr>
<tr>
<td>China</td>
<td>Lital Zhao, China</td>
</tr>
<tr>
<td>China</td>
<td>Yiming Zhao, China</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Xiaojuan Zhao, United Kingdom</td>
</tr>
<tr>
<td>China</td>
<td>Zeping Zhou, China</td>
</tr>
<tr>
<td>China</td>
<td>Mingqiang Zhu, China</td>
</tr>
</tbody>
</table>

### XXVI ISTH Congress and 63rd Annual SSC Meeting
ABOUT THE ISTH

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

At the ISTH, we initiate and promote education and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.

Through its mission of building community and advancing knowledge, the Society also offers a complete portfolio of publications. They include the new open-access journals: Journal of Thrombosis and Haemostasis (JTH) and Research and Practice in Thrombosis and Haemostasis (RTH).

A highly-regarded Society poised on the leading edge of science, the ISTH offers a comprehensive membership that includes the following benefits:

ISTH membership benefits:

- Subscription and exclusive discounts on open access article submissions to the official ISTH publications: Journal of Thrombosis and Haemostasis (JTH) and Research and Practice in Thrombosis and Haemostasis (RTH)
- Priority registration and discounted fees for ISTH meetings and congresses
- Full access to the online ISTH Academy webinars, webcasts and courses with Continuing Medical Education (CME) at academy.isth.org
- Access to ISTH member-only resources, including an increasing array of educational materials, communication and membership directory
- Eligibility to apply for travel grants, fellowships and awards
- Access to the ISTH Career Center and exclusive discounts to post job openings
- Opportunity to hold elected and/or appointed offices, nominate and vote on Society matters

For more information or to join the ISTH, please contact:

**ISTH Headquarters**  
610 Jones Ferry Road, Suite 205  
Carrboro, NC 27510  
USA  
T: +1 919-929-3807  
F: +1 919-929-3935  
E: membership@isth.org  
W: www.isth.org

Join the conversation online!

Use #ISTH2017

www.facebook.com/internationalsocietythrombosisandhaemostasis  
www.facebook.com/worldthrombosisday

www.twitter.com/isth  
www.twitter.com/jthjournal  
www.twitter.com/rpthjournal  
www.twitter.com/thrombosisday

www.youtube.com/user/IntlSocThrombHemo

www.linkedin.com/company/2253026/  
www.linkedin.com/groups/7025460

www.instagram.com/isthofficeteam/  
www.instagram.com/worldthrombosisday/
## Program Overview

### Friday, July 7, 2017
- Registration: 8:00–18:00
- SSC & Education Program 1: 9:00–13:15

### Saturday, July 8, 2017
- Registration: 8:00–17:30
- SSC & Education Program 2: 14:00–18:15
- Nurses Sessions: 8:00–17:30
- World Thrombosis Day Session: 12:15–14:00
- YIA/RW Reception: 12:15–13:00

### Sunday, July 9, 2017
- Master Classes (ticket needed): 7:00–7:45
- SSC & Education Program 3: 8:00–12:15
- Support Symposia: 14:15–15:45
- Supported Symposia: 16:15–17:45
- Special Sessions: 13:00–14:00
- Opening Ceremony: 18:15–19:15
- Welcome Reception in the Exhibition Halls: 19:15–20:45

### Monday, July 10, 2017
- Registration: 6:30–19:00
- Master Classes (ticket needed): 7:00–7:45
- State of the Art: 8:00–9:15
- Oral Communications: 9:30–10:45
- Plenary Session: 11:15–12:00
- Lunch, Poster Session & Industry Exhibits: 12:00–13:15
- Product Theater Presentations: 12:15–13:00
- Product Theater Presentations: 12:15–13:00
- Lunch, Poster Session & Industry Exhibits: 12:00–13:15
- Career Development: 13:15–14:15
- Abstract Symposia: 14:45–16:15
- Plenary Session: 16:45–17:30
- Oral Communications: 17:45–19:00

### Tuesday, July 11, 2017
- Registration: 6:30–19:00
- Master Classes (ticket needed): 7:00–7:45
- State of the Art: 8:00–9:15
- Oral Communications: 9:30–10:45
- Plenary Session: 11:15–12:00
- Lunch, Poster Session & Industry Exhibits: 12:00–13:15
- Product Theater Presentations: 12:15–13:00
- Product Theater Presentations: 12:15–13:00
- Lunch, Poster Session & Industry Exhibits: 12:00–13:15
- Career Development: 13:15–14:15
- Abstract Symposia: 14:45–16:15
- Plenary Session: 16:45–17:30
- Oral Communications: 17:45–19:00

### Thursday, July 6, 2017
- ISTH 2017 Charity Run & Walk: 20:00–21:00
- Victory Ceremony
Program Overview

**Wednesday, July 12, 2017**

- Master Classes (ticket needed)
  7:00–7:45
- State of the Art
  8:00–9:15
- Oral Communications
  9:30–10:45
- Plenary Session
  11:15–12:00
- Lunch, Poster Session & Industry Exhibits
  12:00–13:15
- Supported Symposia
  13:15–14:30
- Career Development
  13:15–14:15
- Abstract Symposia
  14:45–16:15
- Plenary Session
  16:45–17:30
- Registration
  6:30–19:00
- Exhibition
  10:30–17:00
- Networking Evening
  18:30–23:30

**Thursday, July 13, 2017**

- State of the Art
  8:00–9:15
- Oral Communications
  9:30–10:45
- Plenary Session
  11:15–12:30
- Highlights of ISTH
  12:30–13:30
- Closing Remarks
  13:30–13:45
- Registration
  7:30–15:00
- Exhibition
  10:30–17:00
- Networking Evening
  18:30–23:30
<table>
<thead>
<tr>
<th>Time</th>
<th>A1</th>
<th>A2</th>
<th>A3</th>
<th>A5</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Predictive and Diagnostic Variables in Thrombotic Disease</td>
<td>Lupus Anticoagulant/Antiphospholipid Antibodies</td>
<td>Platelet Immunology</td>
<td>Women’s Health Issues in Thrombosis and Hemostasis</td>
</tr>
<tr>
<td>09:30</td>
<td>Predictive and Diagnostic Variables in Thrombotic Disease</td>
<td>Lupus Anticoagulant/Antiphospholipid Antibodies</td>
<td>Platelet Immunology</td>
<td>Women’s Health Issues in Thrombosis and Hemostasis</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Predictive and Diagnostic Variables in Thrombotic Disease</td>
<td>Lupus Anticoagulant/Antiphospholipid Antibodies</td>
<td>Platelet Immunology</td>
<td>Women’s Health Issues in Thrombosis and Hemostasis</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Lunch</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Plasma Coagulation Inhibitors</td>
<td>Factor XIII and Fibrinogen</td>
<td>Von Willebrand Factor</td>
<td>Pediatric and Neonatal Thrombosis and Hemostasis</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Monday, July 10, 2017

#### Hall B

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>What Happens After Acute VTE?</td>
</tr>
<tr>
<td>07:30</td>
<td>Break</td>
</tr>
<tr>
<td>08:00</td>
<td>Coffee Break in Exhibition Halls</td>
</tr>
<tr>
<td>11:00</td>
<td>Marion I. Barnhart Memorial Lecture: Platelet Signaling</td>
</tr>
<tr>
<td>11:30</td>
<td>Lunch, Poster Session and Industry Exhibition in Exhibition Halls</td>
</tr>
<tr>
<td>14:30</td>
<td>Break</td>
</tr>
<tr>
<td>15:00</td>
<td>Clinical Research and Outcomes in Hemophilia</td>
</tr>
<tr>
<td>15:30</td>
<td>Coffee Break in Exhibition Halls</td>
</tr>
<tr>
<td>16:30</td>
<td>Kenneth M. Brinkhous Memorial Lecture: Hemo-philia Therapy - From Disease to Cure</td>
</tr>
<tr>
<td>17:30</td>
<td>Break</td>
</tr>
</tbody>
</table>

---

#### Berlin, Budapest, Helsinki 1, Helsinki 2, Paris

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Master Classes (ticket needed)</td>
</tr>
<tr>
<td>07:30</td>
<td>Break</td>
</tr>
<tr>
<td>08:00</td>
<td>Break</td>
</tr>
<tr>
<td>08:30</td>
<td>Poster Session</td>
</tr>
<tr>
<td>09:00</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>09:30</td>
<td>Break</td>
</tr>
<tr>
<td>10:00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>10:30</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>11:00</td>
<td>Break</td>
</tr>
<tr>
<td>11:30</td>
<td>Career Development</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch, Poster Session and Industry Exhibition in Exhibition Halls</td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch, Poster Session and Industry Exhibition in Exhibition Halls</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch, Poster Session and Industry Exhibition in Exhibition Halls</td>
</tr>
<tr>
<td>13:30</td>
<td>Poster Session</td>
</tr>
<tr>
<td>14:00</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>14:30</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>15:00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>15:30</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>16:00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>16:30</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>17:00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Theater</td>
</tr>
<tr>
<td>18:00</td>
<td>Long-Term VTE Outcomes and Complications of Treatment</td>
</tr>
<tr>
<td>18:30</td>
<td>Hemorrhagic Disorders: Pediatric Aspects</td>
</tr>
<tr>
<td>19:00</td>
<td>Hemophilia: Animal Models of Inhibitor Formation</td>
</tr>
<tr>
<td>Time</td>
<td>Hall B</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
</tr>
<tr>
<td>07:00</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Hall B</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>08:00</td>
<td>Megakaryopoiesis</td>
</tr>
<tr>
<td>09:00</td>
<td>Break</td>
</tr>
<tr>
<td>09:30</td>
<td>Proficiency Testing and Quality Control</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
</tbody>
</table>
NOTES

SSC and Educational Program
### SSC Program

#### Saturday, July 8, 2017

**SSC Session**

**Predictive and Diagnostic Variables in Thrombotic Disease**

**Chairman:** Paul A. Kyrle, Austria  
**Co-Chairmen:** Cecilia Becattini, Italy, Suzanne Cannegieter, the Netherlands, Geert-Jan Geersing, the Netherlands, John-Bjarne Hansen, Norway, Gregoire le Gal, France, Marc Righini, Switzerland

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:05</td>
<td>Welcome</td>
<td>Paul Kyrle, Austria</td>
</tr>
<tr>
<td>09:00 – 09:15</td>
<td>Diagnosis of VTE</td>
<td>Frederikus Klok, the Netherlands</td>
</tr>
<tr>
<td>09:15 – 09:30</td>
<td>Adjudication of Death from PE</td>
<td>Philippe Girard, France</td>
</tr>
<tr>
<td>09:30 – 09:45</td>
<td>Common Data Elements Project</td>
<td>Gregoire le Gal, France</td>
</tr>
<tr>
<td>09:45 – 11:00</td>
<td>Ongoing Clinical Studies</td>
<td></td>
</tr>
<tr>
<td>09:45 – 09:55</td>
<td>VALID</td>
<td>Lisbeth Eischer, Austria</td>
</tr>
<tr>
<td>09:55 – 10:05</td>
<td>VISTA</td>
<td>Geert-Jan Geersing, the Netherlands</td>
</tr>
<tr>
<td>10:05 – 10:15</td>
<td>L-TRIP</td>
<td>Suzanne Cannegieter, the Netherlands</td>
</tr>
<tr>
<td>10:15 – 10:25</td>
<td>Apidulcis</td>
<td>Paolo Prandoni, Italy</td>
</tr>
<tr>
<td>10:25 – 10:35</td>
<td>Hypercan</td>
<td>Marina Marchetti, Italy</td>
</tr>
</tbody>
</table>

**Lupus Anticoagulant/Antiphospholipid Antibodies**

**Chairman:** Bas de Laat, the Netherlands  
**Co-Chairmen:** Maria Laura Bertolaccini, United Kingdom, Katrien Devreese, Belgium, Doruk Erkan, United States, Masahiro Ieko, Japan, Rolf T. Urbanus, the Netherlands, Denis G. Wahl, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:15</td>
<td>Update of the Multicenter Study on Solid Phase Assays</td>
<td>Katrien Devreese, Belgium</td>
</tr>
<tr>
<td>09:15 – 09:30</td>
<td>Cut-Off Values for Solid Phase Assays</td>
<td>Katrien Devreese, Belgium</td>
</tr>
<tr>
<td>09:30 – 09:40</td>
<td>Hydroxychloroquine for Secondary Prevention of Relapses in Primary Antiphospholipid, Syndrome</td>
<td>Cristina Belizna, France</td>
</tr>
<tr>
<td>09:40 – 10:00</td>
<td>First Results out of the Multicenter Study on the Role of IgM in APS</td>
<td>Walid Chayoua, the Netherlands</td>
</tr>
<tr>
<td>10:00 – 10:10</td>
<td>New Subset for Antiphospholipid Antibodies for Diagnosis of Antiphospholipid Syndrome</td>
<td>Kenji Oku, Japan</td>
</tr>
<tr>
<td>10:10 – 10:20</td>
<td>APTT Mixing Test for Diagnosis of the Lupus Anticoagulant</td>
<td>Osamu Kumano, Japan</td>
</tr>
<tr>
<td>10:20 – 10:35</td>
<td>Even More on the Great Mixing Test Debate</td>
<td>Gary Moore, United Kingdom</td>
</tr>
</tbody>
</table>
SSC PROGRAM

10:35 – 10:55  Update on Treatment of APS Patients with DOACs
Vittorio Pengo, Italy

10:55 – 11:00  Trial on Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS)
Hannah Cohen, United Kingdom

09:00 – 11:00  SSC Session
Platelet Immunology
Chairman: Donald Arnold, Canada
Co-Chairmen: Tamam Bakchoul, Germany, Brian Curtis, United States, Shigeki Miyata, Japan, Francois Mullier, Belgium, Rachel Petermann, France, Christopher M. Ward, Australia

09:00 – 09:20  Welcome and Introduction
Donald Arnold, Canada

09:20 – 09:40  Clinical and Laboratory Evaluation of Patients With Suspected ITP: IS TH-SSC Consensus on a Diagnostic Algorithm
Donald Arnold, Canada

09:40 – 10:00  Platelet Counting: Current Issues and Solutions
Francois Mullier, Belgium

10:00 – 10:20  Unconventional Destruction Pathways in ITP: Do We Need New Diagnostic Tools?
Tamam Bakchoul, Germany

SSC PROGRAM

09:00 – 11:00  A5
SSC Session
Women’s Health Issues in Thrombosis and Hemostasis
Chairman: Rezan Kadir, United Kingdom
Co-Chairmen: Claudia Chi, Singapore, Hannah Cohen, United Kingdom, Ian A. Greer, United Kingdom, Susan Halimeh, Germany, Predrag Miljic, Serbia, Maha Othman, Canada

Welcome and Introduction
Moderator: Rezan Kadir, United Kingdom

09:00 – 09:05  Outline of the SSC and Overview of Activities
Rezan Kadir, United Kingdom

09:05 – 09:10  Report on the Women’s Health Issues in Thrombosis and Hemostasis Symposium 2017
Benjamin Brenner, Israel

Subcommittee Session I
Moderators: Hannah Cohen, United Kingdom, Susan Halimeh, Germany

09:10 – 09:30  The Use of IVC Filter in Pregnancy
Maeve P. Crowley, Ireland

09:30 – 09:50  Thrombolysis (Systemic or Catheter Directed) in Pregnancy
James Douketis, Canada

09:50 – 10:10  Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pregnancy
Morag Griffin, United Kingdom

10:10 – 10:30  Anti-Thrombin Deficiency in Pregnancy
Hannelore Rott, Germany

10:30 – 10:40  Ligneous Conjunctivitis in Women
Pratima Chowdary, United Kingdom

10:40 – 10:50  Pelvic Vein Thrombosis
Tejal Amin, United Kingdom

10:50 – 11:00  Risks of Thromboembolism Associated With Hormonal Contraceptives in Japanese Women Compared to Western Women
Takao Kobayashi, Japan
SSC Program

**XXVI ISTH Congress and 63rd Annual SSC Meeting**

**SSC PROGRAM**

09:00 – 11:00

**SSC Session**

**Vascular Biology**

**Chairman:** Rienk Nieuwland, *the Netherlands*


**Extracellular Vesicles**

**Moderators:** Chris Gardiner, *United Kingdom*, Pia Siljander, *Finland*

- **09:00 – 09:15**
  - **The Complex Relationship Between Low Density Lipoprotein and Extracellular Vesicles**
    - Pia Siljander, *Finland*

- **09:15 – 09:35**
  - **Measuring Extracellular Vesicle Concentrations: Standardize the Unknown**
    - Edwin van der Pol, *the Netherlands*

- **09:35 – 09:45**
  - **New Strategies for Detection of Leucocyte-Derived Microvesicles by Fluoro-Sensitive Flow Cytometry**
    - Romaric Lacroix, *France*

- **09:45 – 10:00**
  - **Standardization of Vesicle Detection by Flow Cytometry**
    - Rienk Nieuwland, *the Netherlands*

**Neutrophil Extracellular Traps**

**Moderator:** Alexander Brill, *United Kingdom*

- **10:00 – 10:20**
  - **Measuring NETs**
    - Arturo Zychlinsky, *Germany*

- **10:20 – 10:40**
  - **Histone Citrullination as a Marker of NETosis in Mice**
    - Kim Martinod, *Belgium*

- **10:40 – 11:00**
  - **A View on Challenges and Pitfalls When Studying Phagocyte Extracellular Traps**
    - Maren von Köckritz-Blickwede, *Germany*

**Factor VIII, IX and Rare Coagulation Disorders, Part 1**

**Chairman:** Guy Young, *United States*


- **09:00 – 09:10**
  - **Introduction**
    - Guy Young, *United States*

**Achieving Higher Factor Levels: The "New" Normal**

**Moderators:** Peter Collins, *United Kingdom*, Johnny Mahlangu, *South Africa*

- **09:10 – 09:40**
  - **FVIII: What Is an Achievable Trough With Current Products and at What Cost**
    - Alfonso Iorio, *Canada*

- **09:40 – 10:10**
  - **FIX: What Is an Achievable Trough With Current Products and at What Cost**
    - David Keeling, *United Kingdom*

- **10:10 – 10:50**
  - **Debate: Extended Half-Life Factor IX Versus Gene Therapy**
    - Manuel Carcao, *Canada*
    - K. John Pasi, *United Kingdom*

- **10:50 – 11:00**
  - **Discussion**

**Fibrinolysis**

**Chairman:** Nicola Mutch, *United Kingdom*


**Standardization of Fibrinolytic Proteins**

- **09:00 – 09:15**
  - **Standardization of D-dimer**
    - Colin Longstaff, *United Kingdom*

- **09:15 – 09:30**
  - **Development of Shiny App Tools to Simplify and Standardize the Analysis of Hemostasis Assay Data**
    - Colin Longstaff, *United Kingdom*
SSC PROGRAM

Defining Trauma Induced Coagulopathy (TIC) and Disseminated Intravascular Coagulation (DIC)

09:30 – 09:50 Coagulopathy of Traumatic Brain Injury: Pathophysiologic Origins Distinct From Disseminated Intravascular Coagulation
Mark Walsh, United States

09:50 – 10:10 Viscoelastic Technology to Define TIC
Klaus Görlinger, Germany

10:10 – 10:30 Shock Induced Endotheliopathy (SHINE) and TIC
Pär Ingeman Johansson, Denmark

10:30 – 11:00 Activation of the Hemostasis System in Gram- and Gram+ Sepsis
Francis Castellino, United States

11:15 – 13:15

A1 SSC Session
Predictive and Diagnostic Variables in Thrombotic Disease
Chairman: Paul A. Kyrle, Austria
Co-Chairmen: Cecilia Becattini, Italy, Suzanne Cannytieter, the Netherlands, Geert-Jan Geersing, the Netherlands, John-Bjarne Hansen, Norway, Gregoire le Gal, France, Marc Righini, Switzerland

Education Session
Moderators: John-Bjarne Hansen, Norway, Paul Kyrle, Austria

Geert-Jan Geersing, the Netherlands

11:45 – 12:15 Management of Pulmonary Embolism in Pregnancy
Cecilia Becattini, Italy

Prediction of VTE
Moderator: Cecilia Becattini, Italy

12:15 – 12:35 D-Dimer Measured at Diagnosis of First Venous Thromboembolism and Future Risk of Cancer and Recurrence
Esben Bjerre, Norway

12:35 – 12:55 Impact of Prothrombotic Genotypes on the Risk of Venous Thromboembolism in Cancer
Sigrid Braekkan, Norway

12:55 – 13:15 Discovery of Novel Biomarkers of Venous Thromboembolism by Plasma Proteomics
Jacob Odeberg, Sweden

A2 SSC Session
Lupus Anticoagulant/Antiphospholipid Antibodies
Chairman: Bas de Laat, the Netherlands
Co-Chairmen: Maria Laura Bertolaccini, United Kingdom, Katrien Devreese, Belgium, Doruk Erkan, United States, Masahiro Ieko, Japan, Rolf T. Urbanus, the Netherlands, Denis G. Wahl, France

Education Session

11:15 – 11:45 From Antibody-Antigen Structure to Diagnosis of APS Patients
Bas de Laat, the Netherlands

11:45 – 12:15 Clinical Challenges Facing an APS Patient
Doruk Erkan, United States

12:15 – 12:30 Thrombin Generation and APS: Standardization of Assays
Romy Kremers, the Netherlands

12:30 – 12:45 Thrombin Generation Characteristics in APS According to Antiphospholipid Antibody Profile
Denis Wahl, France

12:45 – 13:05 What Don’t We Know About APS?
Philip de Groot, the Netherlands

13:05 – 13:15 APS-Mediated Complement Activation
Jacob Rand, United States

A3 SSC Session
Platelet Immunology
Chairman: Donald Arnold, Canada
Co-Chairmen: Tamam Bakchoul, Germany, Brian Curtis, United States, Shigeki Miyata, Japan, Francois Mullier, Belgium, Rachel Petermann, France, Christopher M. Ward, Australia

Education Session

11:15 – 11:45 New Diagnostic Tools for Neonatal Alloimmune Thrombocytopenia
Ulrich J. Sachs, Germany

11:45 – 12:15 State of the Art Diagnostic Strategies for Heparin Induced Thrombocytopenia
Theodore Warkentin, Canada
**SSC PROGRAM**

**Heparin-Induced Thrombocytopenia**

*Moderators: Tamam Bakchoul, Germany, Chris Ward, Australia*

- **12:15 – 12:35** Nationwide Heparin-Induced Thrombocytopenia (HIT) Registry: Towards Appropriate Diagnosis and Treatment of HIT in Japan
  Shigeki Miyata, Japan

- **12:35 – 12:55** Cellular Response to PF4/Heparin Stimulation
  Ischac Nazy, Canada

  Chris Ward, Australia

- **13:10 – 13:15** Closing Remarks
  Donald Arnold, Canada

**SSC Session**

**Women’s Health Issues in Thrombosis and Hemostasis**

*Chairman: Rezan Kadir, United Kingdom*

*Co-Chairmen: Claudia Chi, Singapore, Hannah Cohen, United Kingdom, Ian A. Greer, United Kingdom, Susan Halimeh, Germany, Predrag Miljic, Serbia, Maha Othman, Canada*

**Educational Session Moderators**

*Maha Othman, United Kingdom, Ian Greer, United Kingdom*

- **11:15 – 11:45** Harnessing the Power of Next Generation Sequencing for the Diagnosis of Bleeding Disorders in Women
  Keith Gomez, United Kingdom

- **11:45 – 12:15** DOACs and Women - Overview
  Jan Beyer-Westendorf, Germany

**Subcommittee Session II - Registries and Projects**

*Moderators: Ida Martinelli, Italy, Predrag Miljic, Serbia*

- **12:15 – 12:25** The Use of Thrombo-Elastography in Pregnancy: Registry
  Maha Othman, Canada

- **12:25 – 12:45** PPH Core Outcome Set
  Beverley Hunt, United Kingdom

**SSC PROGRAM**

**SSC Session**

**Vascular Biology**

*Chairman: Rienk Nieuwland, the Netherlands*

*Co-Chairmen: Alexander Brill, United Kingdom, Chris Gardiner, United Kingdom, Emma C. Joseffson, Australia, Anna Randi, United Kingdom, Florence Sabatier, France, Pia Siljander, Finland*

**Educational Session: Angiogenesis**

*Moderator: Rienk Nieuwland, the Netherlands*

- **11:15 – 11:45** From Cells to Networks – Mechanisms in Vascular Patterning
  Holger Gerhardt, Germany

- **11:45 – 12:15** Crosstalk Between the Hemostatic System and Angiogenesis
  Anna Randi, United Kingdom

**Round Table Discussion on Standardization of Measuring Endothelial Progenitor Cells**

*Moderator: Chris Gardiner, United Kingdom*

- **12:15 – 12:45** Blood Outgrowth Endothelial Cells
  Anna Randi, United Kingdom
  Florence Sabatier, France
  David Smadja, France
  Juan Meiero-Martin, United States
  Jeroen Eikenboom, the Netherlands
  Ester Weijers, the Netherlands
SSC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

12:45 – 13:15
Endothelial Progenitor Cells
David Smadja, France
Florence Sabatier, France
Gian Paolo Fadini, Italy

11:15 – 13:15
SSC Session
Factor VIII, IX and Rare Coagulation Disorders, Part 1
Chairman: Guy Young, United States
Co-Chairmen: Manuel Carcao, Canada, Peter Collins, United Kingdom, Alfonso Iorio, Italy, Gili Kenet, Israel, Johnny Mahlangu, South Africa, Maria Elisa Mancuso, Italy

Education Session
Moderator: Maria Elisa Mancuso, Italy
11:15 – 11:45
Gene Therapy: Recent Advances and Future Perspectives
Thierry VandenDriessche, Belgium
11:45 – 12:15
The Current and Future Treatment of Rare Bleeding Disorders
Flora Peyvandi, Italy

Rare Bleeding Disorders
Moderator: Manuel Carcao, Canada
12:15 – 12:35
Factor XI Update
Ophira Salomon, Israel
12:35 – 12:55
Congenital Fibrinogen Disorders: Update on Diagnosis and Management
Alessandro Cassini, Switzerland

Working Groups Update
Moderator: Guy Young, United States
12:55 – 13:00
Establishment of a Standard for FVIII Inhibitors
Koen Mertens, the Netherlands
13:00 – 13:05
Prophylaxis in Inhibitor Patients
Carmen Escuriola-Ettingshausen, Germany
13:05 – 13:10
Working Group on Pharmacokinetics and Population Pharmacokinetics
Alfonso Iorio, Canada
13:10 – 13:15
Post-Registration Surveillance for New Products
Flora Peyvandi, Italy

11:15 – 13:15
A8
SSC Session
Fibrinolysis
Chairman: Nicola Mutch, United Kingdom
Co-Chairmen: Paul Kim, Canada, Krasimir Kolev, Hungary, Colin Longstaff, United Kingdom, Victoria Ploplis, United States, Guy Reed, United States, Tetsumei Urano, Japan

Educational Session: Clinical Manifestations of Trauma Induced Coagulopathy (TIC) and Disseminated Intravascular Coagulation (DIC)
11:15 – 11:45
TIC is Not DIC
Karim Brohi, United Kingdom
11:45 – 12:15
Disseminated Intravascular Coagulation in Trauma and Traumatic Shock
Satoshi Gando, Japan

Fibrinolysis in Trauma Induced Coagulopathy
12:15 – 12:35
Fibrinolysis Shutdown in Trauma
Hunter Moore, United States
12:35 – 12:55
Anti-Fibrinolytics in Trauma: Unresolved Issues and Effects Nobody Talks About
Dominik Draxler, Australia
12:55 – 13:15
Tranexamic Acid Use in Europe and the United States: A Trauma Surgeons View
Scott Thomas, United States

13:15 – 14:00
Lunch Break

14:00 – 16:00
A1
SSC Session
Plasma Coagulation Inhibitors
Chairman: Richard Marlar, United States
Co-Chairmen: Herm Jan Brinkman, the Netherlands, Cecilia Guillermo, Uruguay, Ian Jennings, United Kingdom, Jun Teruya, United States, Hiroko Tsuda, Japan

Education Session
Moderator: Richard Marlar, United States
14:00 – 14:30
Unique Non-Anticoagulant Functions of Protein C
Laurent Mosnier, United States
### SSC PROGRAM

#### 14:30 – 15:00
**TFPI: New Insights Into an Old Inhibitor**
Elisabetta Castoldi, the Netherlands

#### Working Session 1: Progress of Current Projects

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 – 15:15</td>
<td>Protein S Testing</td>
<td>Ian Jennings, United Kingdom</td>
</tr>
<tr>
<td>15:15 – 15:45</td>
<td>Racial Differences</td>
<td>Hiroko Tsuda, Japan</td>
</tr>
<tr>
<td>15:45 – 16:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

#### 14:00 – 16:00

**SSC Session**

**Factor XIII and Fibrinogen**

- **Chairman:** Verena Schroeder, Switzerland
- **Co-Chairmen:** Zsuzsa Bagoly, Hungary, Matthew J. Flick, United States, Martin Guthold, United States, Helen Philippou, United Kingdom, Marien Pieters, South Africa, Alisa Wolberg, United States

**Education Session**

- **14:00 – 14:30**
  **Current View of Fibrin Structure and Clot Structure**
  Martin Guthold, United States
- **14:30 – 15:00**
  **Fibrin Structure and Crosslinking in Disease**
  Alisa Wolberg, United States

**Standardization Topics**

- **Moderators:** Zsuzsa Bagoly, Hungary, Verena Schroeder, Switzerland
- **15:00 – 15:20**
  **WHO 1st International Standard Factor XIII Plasma, (02/206): Collaborative Study to Additionally Assign Value for Factor XIII B-Subunit (Both Total & Free)**
  Sanj Raut, United Kingdom
- **15:20 – 15:40**
  **Oligomeric State of Factor XIII Changes Upon Activation**
  Muriel Maurer, United States
- **15:40 – 16:00**
  **A Follow-Up on the Question of Novel Guidelines for FXIII Deficiency**
  Verena Schroeder, Switzerland

#### 16:00 – 17:00

**Educational Session**

**ADAMTS13 and TTP**

- **Moderators:** Simon De Meyer, Belgium, Koichi Kokame, Japan
- **15:00 – 15:15**
  **Immunoprofiling of ADAMTS13 Autoantibodies in TTP**
  Karen Vanhoorelbeke, Belgium
- **15:15 – 15:30**
  **A Proposal of VWF Large Multimer Index for Standardization of the Quantitative Description of VWF Multimers Among Laboratories**
  Hisanori Horiuchi, Japan
- **15:30 – 15:45**
  **VWF:GPIbM, VWF:Ab, and VWF:RCo in the Willebrand in the Netherlands (WiN) Cohort**
  Johan Boender, the Netherlands
- **15:45 – 16:00**
  **VWF:GPIbM, VWF:GPIbR, VWF:RCo in the Zimmerman Program**
  Sandra Haberichter, United States
SSC PROGRAM

14:00 – 16:00  A5

SSC Session

Pediatric and Neonatal Thrombosis and Hemostasis
Chairman: Christoph Male, Austria
Co-Chairmen: Manuela Albisetti Pedroni, Switzerland, Anthony Chan, Canada, Fiona Newall, Australia, Sarah O’Brien, United States, Shoshana Revel-Vilk, Israel, Heleen Van Ommen, the Netherlands

Education Session

14:00 – 14:30  Post-Thrombotic Syndrome in Children
Maria Laura Avila, Canada

14:30 – 15:00  Therapeutic Options for Post-Thrombotic Syndrome
Oliver Schlager, Austria

15:00 – 15:20  Primary Prevention of CVC-Related VTE
Sarah O’Brien, United States

15:20 – 15:40  Diagnostic Imaging of VTE in Vascular Abnormalities
Leonardo Brandão, Canada

15:40 – 16:00  Results of the DIC Survey
Ziad Solh, Canada

14:00 – 16:00  A6

SSC Session

Biorheology
Chairman: Keith Neeves, United States
Co-Chairmen: Judith Cosemans, the Netherlands, Wilbur Lam, United States, Pierre Mangin, France, Warwick Nesbitt, Australia, Erik Westein, Australia

Education Session: The Biomechanics of Thrombus Formation

14:00 – 14:30  Fibrin Biomechanics
John Weisel, United States

14:30 – 15:00  Platelet Biomechanics
Wilbur Lam, United States

SSC PROGRAM

14:00 – 16:00  A7

SSC Session

Hemostasis & Malignancy
Chairman: Marc Carrier, Canada
Co-Chairmen: Cihan Ay, Austria, Christophe Dubois, France, Nigel Mackman, United States, Guy Meyer, France, Simon Noble, United Kingdom, Casey O’Connell United States

Education Session

14:00 – 14:30  Intracranial Hemorrhage in Cancer Patients
Jeffrey Zwicker, United States

14:30 – 15:00  Mice Model of Thrombosis and Cancer
Christophe Dubois, France

Updates on SSC Projects

15:00 – 15:20  New Guidance: Occult Cancer Detection in Patients With VTE
Aurélien Delluc, France

15:20 – 15:40  Developing a Tool to Assess QoL in Patients With CAT
Simon Noble, United Kingdom

15:40 – 16:00  Guidance: D-Dimer Use in Cancer Patients
Cihan Ay, Austria
SSC PROGRAM

14:00 – 16:00

SSC Session Perioperative Thrombosis and Hemostasis
Chairman: Charles Marc Samama, France
Co-Chairmen: Pierre Albaladejo, France, James Douketis, Canada, Andreas Greinacher, Germany, Jerrold H. Levy, United States, Alex C. Spyropoulos, United States

Education Session: The Global Problem of Perioperative Venous Thromboembolism Prevention, and How to Deliver Care
14:00 – 14:30 In-Patients
Beverley Hunt, United Kingdom
14:30 – 15:00 Day Surgery and Fast-Track Surgery Patients
Charles Marc Samama, France

Hemostasis and Thrombosis in the Perioperative Setting, Part 1
Moderator: James Douketis, Canada
15:00 – 15:20 "Pharmacokinetic" Vs "Laboratory" Based Strategy on Management of OACs in Elective Procedures
Alex Spyropoulos, United States
15:20 – 15:40 Bridging for VKA and DOACs: New Data
James Douketis, Canada
15:40 – 16:00 Use of Antidotes for Surgical Patients
Pierre Albaladejo, France

16:15 – 18:15

SSC Session Plasma Coagulation Inhibitors
Chairman: Richard Marlar, United States
Co-Chairmen: Herm Jan Brinkman, the Netherlands, Cecilia Guillermo, Uruguay, Ian Jennings, United Kingdom, Jun Teruya, United States, Hiroko Tsuda, Japan

Working Session 2: Manuscript Progress for Clinical Testing for AT, PC, PS and APC-R
16:15 – 16:25 Protein C
Richard Marlar, United States
16:25 – 16:35 Protein S
Richard Marlar, United States

SSC PROGRAM

16:35 – 16:45 Antithrombin
Richard Marlar, United States
16:45 – 16:55 APC Resistance
Gary Moore, United Kingdom
16:55 – 17:15 Discussion

Working Session 3
17:15 – 17:35 Clinical Relevance of Other Potential Plasma Inhibitors
Jun Teruya, United States
17:35 – 17:50 PC & PS Def Type Distribution
Richard Marlar, United States
17:50 – 18:05 Conclusions

16:15 – 18:15

SSC Session Factor XIII and Fibrinogen
Chairman: Verena Schroeder, Switzerland
Co-Chairmen: Zsuzsa Bagoly, Hungary, Matthew J. Flick, United States, Martin Guthold, United States, Helen Philippou, United Kingdom, Marien Pieters, South Africa, Alisa Wolberg, United States

Scientific Topics
Moderators: Verena Schroeder, Switzerland, Alisa Wolberg, United States
16:15 – 16:35 Novel Methodological Approach to the Detection and Characterization of Anti-FXIII Antibodies
László Muszbek, Hungary
16:35 – 16:55 Effect of Factor XIII Levels and Polymorphisms on the Risk of Myocardial Infarction in Young Patients
Zsuzsanna Bereczky, Hungary, Éva Katona, Hungary
16:55 – 17:15 Factor XIII Levels and Polymorphisms in Patients With Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Zsuzsa Bagoly, Hungary
17:15 – 17:35 Structure of Fibrin in Thrombi Extracted With Interventional Treatment of Ischemic Coronary, Peripheral and Cerebral Artery Disease
Veronika Farkas, Hungary
### SSC PROGRAM

#### 17:35 – 17:55
**Role of Fibrinogen and FXIII in Obesity and Metabolic Inflammation**  
Matthew Flick, *United States*

#### 17:55 – 18:15
**Congenital Fibrinogen Disorders: An Update**  
Marguerite Neerman-Arbez, *Switzerland*

#### 16:15 – 18:15
**A3 SSC Session**  
**Von Willebrand Factor**  
Chairman: Sandra Haberichter, *United States*  

#### 16:15 – 16:25
**Assignment of Standard for VWF:GPIbM and VWF:GPIbR**  
Anthony Hubbard, *United Kingdom*

#### 16:25 – 16:35
**Discussion**

**Delineation Of "Low VWF" and Type 1 VWD – Results From Large Population Studies**  
Moderators: Veronica Flood, *United States*, Frank Leebeek, *the Netherlands*

#### 16:35 – 16:50
**Results From the Canadian Study**  
Paula James, *Canada*

#### 16:50 – 17:05
**Results From the WiN study**  
Frank Leebeek, *the Netherlands*

#### 17:05 – 17:20
**Results From the Zimmerman Study**  
Pamela Christopherson, *United States*

#### 17:20 – 17:35
**Results From the Irish Study**  
Michelle Lavin, *Ireland*

#### 17:35 – 17:45
**Results From the EU Study**  
Augusto B. Federici, *Italy*

#### 17:45 – 17:55
**Results From the 3Winters-Ips Study**  
Augusto B. Federici, *Italy*

#### 17:55 – 18:15
**Discussion of Definitions and Guidelines**  
Veronica Flood, *United States*
SSC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

SSC Session
Biorheology
Chairman: Keith Neeves, United States
Co-Chairmen: Judith Cosemans, the Netherlands, Wilbur Lam, United States, Pierre Mangin, France, Warwick Nesbitt, Australia, Erik Westein, Australia

Building Endothelial Cell Function Into Flow Chambers
Moderator: Warwick Nesbitt, Australia
16:15 – 16:40 Endothelial Cell Culture in Microfluidic Systems
Wilbur Lam, United States
16:40 – 17:05 Thrombosis-On-A-Chip
Abhishek Jain, United States

New Mechanisms in Blood Flow-Dependent Platelet Function
Moderator: Pierre Mangin, France
17:05 – 17:30 Modeling in Flow the Role of GPVI in the Initiation of Thrombus Formation, Growth, and Lysis
Martine Jandrot-Perrus, France
17:30 – 17:55 Selective Targeting of VWF in Shear Gradient Mediated Thrombus Formation
Erik Westein, Australia
17:55 – 18:15 Update on SSC Multicenter Study of Flow Chambers
Keith Neeves, United States

New Projects
16:15 – 18:15 A6

SSC Session
Hemostasis & Malignancy
Chairman: Marc Carrier, Canada
Co-Chairmen: Cihan Ay, Austria, Christophe Dubois, France, Nigel Mackman, United States, Guy Meyer, France, Simon Noble, United Kingdom, Casey O’Connell, United States

New Projects
16:15 – 16:35 Update of Guidance: New Insights on DOACs Use in CAT
Alok Khorana, United States

SSC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

SSC PROGRAM

16:15 – 18:15 A7

SSC Session
Perioperative Thrombosis and Hemostasis
Chairman: Charles Marc Samama, France
Co-Chairmen: Pierre Albaladejo, France, James Douketis, Canada, Andreas Greinacher, Germany, Jerrold H. Levy, United States, Alex C. Spyropoulos, United States

Hemostasis and Thrombosis in the Perioperative Setting, Part 2
Moderator: Charles Marc Samama, France
16:15 – 16:35 Platelet Transfusion in Patients With Acquired Platelet Defects
Andreas Greinacher, Germany
16:35 – 16:55 Use of Factor Concentrates for Managing Bleeding
Jerrold Levy, United States

16:35 – 16:55 A8

New Guidance: Anticoagulation for Atrial Fibrillation While Undergoing Chemotherapy
Simon Noble, United Kingdom

New Investigators Projects
16:55 – 17:15 IPDMA: Occult Cancer Detection in Patients With Unprovoked VTE
Nick van Es, the Netherlands
17:15 – 17:35 Pilot Trial: Management of Thrombocytopenia in CAT
Bethany Samuelson, United States
17:35 – 17:55 Cancer Detection in Patients With Von Willebrand Disease
Holleh Husseinzadeh, United States

Updates of Ongoing Studies
17:55 – 18:00 Multinational Registry: Management of Antiplatelet and Anticoagulant Drugs During Thrombocytopenia
Avi Leader, the Netherlands
18:00 – 18:10 External Validation of Thrombosis Lymphoma/ThroLy/Score
Darko Antic, Serbia
18:10 – 18:15 Updates of Ongoing CAT Studies
Marc Carrier, Canada

16:15 – 18:15 A8
SSC PROGRAM

Sunday, July 9, 2017

SSC Session
Factor XI & the Contact System
Chairman: Joost C.M. Meijers, the Netherlands
Co-Chairmen: Edward Feener, United States, Heiko Herwald, Sweden, Coen Maas, the Netherlands, Owen J. McCarty, United States, Stephanie Smith, United States, Evi X. Stavrou, United States

08:00 – 08:05 Opening
Joost C.M. Meijers, the Netherlands

Polyphosphates and the Contact System

08:05 – 08:15 Structural Models of Contact System Activation and Ligand Binding
Jonas Emsley, United Kingdom

08:15 – 08:25 Comparing and Inhibiting the Procoagulant Activities of Nucleic Acids versus Polyphosphate
James H. Morrissey, United States

08:25 – 08:35 Particles and Polymers
Coen Maas, the Netherlands

08:35 – 08:45 Targeting the Factor XII Activator Polyphosphate in Vivo
Thomas Renné, Sweden

08:45 – 09:15 Joint Discussion

09:15 – 09:30 The 1st International Standard for Blood Coagulation Factor XII, Plasma
Elaine Gray, United Kingdom

09:30 – 09:45 FXIa Contamination of IVIG
Mikhail Ovanesov, United States

09:45 – 10:00 Contact System in Diabetic Retinopathy
Edward Feener, United States

SSC Program
SSC PROGRAM

SSC Session
Genomics in Thrombosis and Hemostasis
Chairman: Willem H. Ouwehand, United Kingdom
Co-Chairmen: Daniel Bellissimo, United States, Paul F. Bray, United States, Kathleen Freson, Belgium, Anne Goodoe, United Kingdom, Michele P. Lambert, United States, Pieter Reitsma, the Netherlands

08:00 – 08:10 Welcome
Willem H. Ouwehand, United Kingdom

Updates on Diagnostic High Throughput Sequencing Tests

08:10 – 08:25 Molecular Diagnosis of Rare BPD Using NGS
Kate Downes, United Kingdom

08:25 – 08:40 Experiences from the ÖResund Region with Implementation of WES in Patients with IBD
Eva Leinoe, Denmark

08:40 – 08:55 Tier-1 Genes: New Genes and Modes of Inheritance
Kathleen Freson, Belgium

What Should I Tell My Patients?

08:55 – 09:10 From the Neonatal/Pediatric Perspective
Shoshana Revel-Vilk, Israel

09:10 – 09:25 Dealing with Variants of Uncertain Significance
Keith Gomez, United Kingdom

Challenges of Interpretation (Part. I)

09:25 – 09:40 New Control Datasets and Updates to Variant Catalogs
Karyn Megy, United Kingdom

09:40 – 10:00 Challenges in Interpreting Genetic Data in Females At-Risk for Bleeding Disorders
Jill Johnsen, United States

SSC PROGRAM

SSC Session
Platelet Physiology
Chairman: Paolo Gresele, Italy
Co-Chairmen: Hans Deckmyn, Belgium, Andrew L. Frelinger III, United States, Martine Jandrot-Perrus, France, Shinji Kunishima, Japan, Marie Lordkipanidzé, Canada, Jose Rivera, Spain

08:00 – 08:10 Overview of Platelet Physiology SSC and Projects
Paolo Gresele, Italy

08:10 – 08:20 Evaluation of the ISTH Bleeding Assessment Tool (BAT) for the Assessment of Inherited Platelet Disorders: Follow-Up Data
Paolo Gresele, Italy

08:20 – 08:40 Measurement of Platelet Dimensions: Methods and Clinical Use: Guidance from the SSC of the ISTH
Patrizia Noris, Italy

08:40 – 08:50 Use of PRP in Regenerative Medicine: Where are we?
Jeremy Magalon, France

08:50 – 09:00 Use of Platelets in Regenerative Medicine: Guidance from the SSC of the ISTH
Paul Harrison, United Kingdom

09:00 – 09:20 Measurement of Platelet Secretion: Guidance from the SSC of the ISTH
Diego Mezzano, Chile

09:20 – 09:40 Diagnosis of Inherited Platelet Disorders on a Blood Smear: Survey and Workshop
Shinji Kunishima, Japan

09:40 – 10:00 Methods for the Conservation and Shipment of Platelets for Platelet Studies
Marie Lordkipanidzé, Canada
08:00 – 10:00

SSC Session
Control of Anticoagulation
Chairman: Mark Crowther, Canada
Co-Chairmen: Chatree Chai-Adisaksopha, Canada, Benilde Cosmi, Italy, Adam Cuker, United States, Jonathan Douxfils, Belgium, Ismail Elalamy, France, Pieter W. Kamphuisen, the Netherlands

New and Ongoing projects

08:00 – 08:15 START SSC Event Registry: Overview
Walter Ageno, Italy

08:15 – 08:30 START Laboratory: DOAC Levels and Clinical Events?
Benilde Cosmi, Italy

08:30 – 08:45 Cerebral Vein Thrombosis Registry
Francesco Dentali, Italy

08:45 – 09:00 Classification of Major Bleeding
Karina Meijer, the Netherlands

09:00 – 09:15 Standard Method for Determination of the Plasma Prothrombin Time by Manual Tilt Tube Technique
Anton van den Besselaar, the Netherlands

09:15 – 09:30 Ad Hoc Working Party to Guide the Laboratory Measurements of the DOACs
Ismail Elalamy, France

09:30 – 09:45 Proposing for Establishment a WHO Reference Reagent for Human Factor Xa
Craig Thelwell, United Kingdom

09:45 – 10:00 Developing a Registry of the Outcomes of Stents in Patients with Venous Thrombosis
Andrea Cervi, Canada

08:00 – 10:00

SSC Session
Disseminated Intravascular Coagulation
Chairman: Jecko Thachil, United Kingdom
Co-Chairmen: Marcello Di Nisio, Italy, Toshiaki Iba, Japan, Takashi Ito, Japan, Bernd Jilma, Austria, Alessandro Squizzato, Italy, Sacha Zeerleder, the Netherlands

08:00 – 08:20 Platelet-Neutrophil Interactions in Sepsis
Dorith Claushuis, the Netherlands

08:20 – 08:40 Complement and Coagulation in Thromboinflammation
Bo Nilsson, Sweden

08:40 – 09:00 What’s New in Septic DIC?
Kazuma Yamakawa, Japan

09:00 – 09:20 What’s New in Trauma-Related DIC?
Satoshi Gando, Japan

09:20 – 09:40 Challenges in the Critical Care Management of Sepsis
Ruth Kleinpell, United States

09:40 – 10:00 Global Sepsis Alliance
Marvin Zick, Germany

08:00 – 10:00

SSC Session
Factor VIII, IX and Rare Coagulation Disorders, Part 2
Chairman: Guy Young, United States
Co-Chairmen: Manuel Carcao, Canada, Peter Collins, United Kingdom, Alfonso Iorio, Italy, Gili Kenet, Israel, Johnny Mahlangu, South Africa, Maria Elisa Mancuso, Italy

Old and New Challenges in Immune Tolerance Therapy
Moderators: Peter Collins, United Kingdom, Guy Young, United States

08:00 – 08:20 Definitions of Tolerance—What Is/Should Be Different with EHL
Charles Hay, United Kingdom

08:20 – 08:40 When to Start and When to Stop and What Are the Relevant Outcomes
Rolf Ljung, Sweden
SSC PROGRAM

08:40 – 09:00 Debate on FVIII Products for ITI: Recombinant Versus Plasma-Derived
Carmen Escuriola-Ettingshausen, Germany
Ri Liesner, United Kingdom

09:20 – 09:50 The Future of Inhibitor Eradication and Prevention in the Era of Non-Factor Products: A Theoretical Panel Discussion
Shannon Meeks, United States
Gili Kenet, Israel
Maria Elisa Mancuso, Italy
Julie Curtin, Australia

09:50 – 10:00 Discussion

08:00 – 10:00 A8
SSC Session
Animal, Cellular and Molecular Models of Thrombosis
Chairman: Jose Diaz, United States
Co-Chairmen: Brian Cooley, United States, Alexandra Kopic, Austria, Nobuo Nagai, Japan, Leslie Parise, United States, Denise E. Sabatino, United States

AAA Pre-Clinical Models

08:00 – 08:30 AAA MODEL–Elastase Model
Sean English, United States

08:30 – 09:00 AAA Peri-Adventitial Model
John Curci, United States

09:00 – 09:30 AAA Angiotensin II Model
Alan Daugherty, United States

09:30 – 10:00 Cremaster Arteriole Laser-Injury Model of Thrombosis
Steve Grover, United States

10:15 – 12:15 A1
SSC Session
Factor XI & the Contact System
Chairman: Joost C.M. Meijers, the Netherlands
Co-Chairmen: Edward Feener, United States, Heiko Herwald, Sweden, Coen Maas, the Netherlands, Owen J. Mccarty, United States, Stephanie Smith, United States, Evi X. Stavrou, United States

SSC PROGRAM

Education Session

10:15 – 10:45 Vascular Biology of Factor XII and the Kallikrein/Kinin System
Alvin Schmaier, United States

10:45 – 11:15 Microfluidics and the Contact System
Scott Diamond, United States

11:15 – 11:30 Clinical Experience with Factor XI Inhibitors
Jeffrey I. Weitz, Canada

11:30 – 11:45 Bradykinin and Stroke
Sara Martinez de Lizarrondo, France

11:45 – 12:10 Nomenclature Proposal
Alvin Schmaier, United States

12:10 – 12:15 Closure
Joost C.M. Meijers, the Netherlands

10:15 – 12:15 A2
SSC Session
Genomics in Thrombosis and Hemostasis
Chairman: Willem H. Ouwehand, United Kingdom
Co-Chairmen: Daniel Bellissimo, United States, Paul F. Bray, United States, Kathleen Freson, Belgium, Anne Goodeve, United Kingdom, Michele P. Lambert, United States, Pieter Reitsma, the Netherlands

Education Session: Challenges of Interpretation (Part. II)

Jonathan Berg, United States

10:45 – 11:15 Human Phenotype Ontology to Support Clinical Reporting and Genomic Diagnostics
Peter Robinson, United States

11:15 – 11:30 Break
SSC PROGRAM

What’s new?

11:30 – 11:40 Assessing the Relevance of Non-Coding DNA Variants
Dominik Seelow, Germany

11:40 – 11:50 New Platelet Population Studies for Genomic Discovery
Andrew Johnson, United States

11:50 – 12:00 A Fast Association Test for Identifying Exonic and Non-Exonic Pathogenic Variants Involved in Rare Diseases
Ernest Turro, United Kingdom

12:00 – 12:15 Discussion/Closing the Session
Michelle Lambert, United States

10:15 – 12:15 SSC Session
Platelet Physiology
Chairman: Paolo Gresele, Italy
Co-Chairmen: Hans Deckmyn, Belgium, Andrew L. Frelinger III, United States, Martine Jandrot-Perrus, France, Shinji Kunishima, Japan, Marie Lordkipanidzé, Canada, Jose Rivera, Spain

Education Session

10:15 – 10:45 Cytoskeletal Dynamics in Megakaryocytes and Platelets
Markus Bender, Germany

10:45 – 11:15 The Granule Secretion Mechanisms and Actin Dynamics
Robert Flaumenhaft, United States

11:15 – 11:30 Abnormal αIIbβ3 and Cytoskeletal Perturbation Causing Platelet Dysfunction
Loredana Bury, Italy

11:30 – 11:45 How to Reach Consensus on Using the SSC LTA Guidelines: the Netherlands Experience
Yvonne M.C. Henskens, the Netherlands

11:45 – 12:00 Standardization of Flow Cytometry for the Assessment of Platelets Disorders
Andrew L. Frelinger III, United States
José Rivera Pozo, Spain

12:00 – 12:15 Measurement of Soluble Markers of Platelet Activation: Methods and Use. A Project for Generation of Guidelines
Hans Deckmyn, Belgium
Martine Jandrot-Perrus, France

10:15 – 12:15 SSC Session
Control of Anticoagulation
Chairman: Mark Crowther, Canada
Co-Chairmen: Chatree Chai-Adisaksopha, Canada, Benilde Cosmi, Italy, Adam Cuker, United States, Jonathan Douxfils, Belgium, Ismail Elalamy, France, Pieter W. Kamphuisen, the Netherlands

Education Session: The Role of Oral Vitamin K Antagonists in 2017

10:15 – 10:45 Current State of the Art with Oral VKA’s: Efficacy and Safety in Very Well Managed Patients
Vittorio Pengo, Italy

10:45 – 11:15 Monitoring Oral VKA’s – Should the Standard Prothrombin Time Be Replaced?
Pál Torfi Öndundarson, Iceland

Update in Control of Anticoagulation

11:15 – 11:35 Determination of DOAC Levels Using Various Coagulometers in Comparison with LC-MS/MS
Jovan P. Antovic, Sweden

11:35 – 11:55 Point of Care vs Laboratory INR Determinations in Critically Ill Patients
Robin Zenlander, Sweden

11:55 – 12:15 Automated Thrombin Generation Assay in Bleeding Patients on Anticoagulant
Jonathan Douxfils, Belgium
SSC PROGRAM

**SSC Session**

**Disseminated Intravascular Coagulation**

Chairman: Jecko Thachil, *United Kingdom*


**Education Session**

10:15 – 10:45  
*Histones and Neutrophil Extracellular Traps in Disseminated Intravascular Coagulation*  
Cheng-Hock Toh, *United Kingdom*

10:45 – 11:15  
*Perturbations in Hemostasis in Viral Hemorrhagic Fevers*  
Daniel Bausch, *Switzerland*

11:15 – 11:30  
*Acute DIC, Shock Liver, and Symmetrical Peripheral Gangrene: An Update*  
Theodore Warkentin, *Canada*

11:30 – 11:45  
*The Issues in DIC Diagnosis and Management*  
Alessandro Squizzato, *Italy*

11:45 – 12:00  
*International Survey on Pediatric DIC*  
Ziad Solh, *Canada*

12:00 – 12:15  
*Update on Obstetrical DIC*  
Offer Erez, *Israel*

10:15 – 12:15  

**SSC Session**

**Factor VIII, IX and Rare Coagulation Disorders, Part 2**

Chairman: Guy Young, *United States*


**Laboratory Assays Update**

Moderators: Alfonso Iorio, *Italy*, Gili Kenet, *Israel*

10:15 – 10:30  
*Establishment of the 2nd International Standard for FIX (FIXa)*  
Elaine Gray, *United Kingdom*

10:30 – 10:45  
*U.S. National Inhibitor Surveillance Using a Central Laboratory: Testing Protocol and Results*  
Connie Miller, *United States*

10:45 – 11:05  
*Measuring Extended Half-Life Factors in the Laboratory*  
Guy Young, *United States*

11:05 – 11:25  
*Implementing the Chromogenic Factor Assays in the Clinical Coagulation Laboratory*  
Steven Pipe, *United States*

11:25 – 11:45  
*Is All Thrombin Generation the Same?*  
Claude Negrier, *France*

11:45 – 12:05  
*Discussion*

12:05 – 12:15  
*Closing*  
Guy Young, *United States*

10:15 – 12:15  

**SSC Session**

**Animal, Cellular and Molecular Models of Thrombosis**

Chairman: Jose Diaz, *United States*


**Education Session: Pre-Clinical Models of VT**

10:15 – 10:45  
*Murine IVC Thrombosis Model*  
Jose Diaz, *United States*

10:45 – 11:15  
*IVC Stenosis Model*  
Prakash Saha, *United Kingdom*

11:15 – 11:45  
*Directing Your Research: Unmet Needs from the Clinical Perspective*  
Fedor Lurie, *United States*

11:45 – 12:15  
*Benchside to Bedside to Community: The Role of Pre-Clinical Models*  
Alisa Wolberg, *United States*

13:15 - 14:30  
*Supported Symposia*  
See page 526
NOTES

Special Sessions
SPECIAL SESSIONS

Sunday, July 9, 2017

Special Sessions

12:00 – 13:00

Special Session

YIA/RtW Reception

12:15 – 14:00

Special Session

World Thrombosis Day: Building Awareness and Elevating Impact for the Global Burden of Thrombosis

12:15 – 12:25

Opening Remarks and Overview of World Thrombosis Day
Gary Raskob, United States

12:25 – 12:40

Presentation: The Global Burden of Thrombosis and the Case for a Systematic Approach to VTE Risk Assessment in the Hospital Setting
Gary Raskob, United States

12:40 – 13:10

Partner Panel: Engagement, Awareness and Achieving Outcomes Around the World
Moderator: Claire McLintock, New Zealand
Lai Heng Lee, Singapore
Alex Spyropoulos, United States
Aurora de la Peña Díaz, Mexico
Beverley Hunt, United Kingdom

13:10 – 13:30

Case Study: Governmental Partnership – The Centers for Disease Control and Prevention (CDC) (USA) Initiative on Health-Care Associated VTE
Craig Hooper, United States

13:30 – 13:50

Private – Public Partnership: Corporate Engagement, Social Responsibility and Partnership around World Thrombosis Day
Moderator: Jeffrey I. Weitz, Canada
Paul Field, Germany
Mark Gossett, United States
Charlene Herndon, United States

13:50 – 14:00

Audience Q&A and World Thrombosis Day in 2017 and Beyond
Gary Raskob, United States

13:00 – 14:00

A4

Special Session

Adopting New VTE and Cancer Guidelines: Is Clinical Practice Improving?
Chair: James Douketis, Canada

13:00 – 13:05

Introductory Remarks
James Douketis, Canada

13:05 – 13:25

VTE and Cancer – 2016 and Beyond
Dominique Farge-Bancel, France

13:25 – 13:40

Putting Guidelines Into Practice
Rupert Bauersachs, Germany

13:40 – 13:55

Looking to the Future
Panel Discussion

13:55 – 14:00

Concluding Remarks and Evaluation
James Douketis, Canada

13:00 – 14:00

M8

Special Session

Building Capacity Globally: The Impact and Future of the RtW and IHTC Programs

This session will focus on the ISTH Reach-the-World (RtW) programs, including fellowships and the new Regional Training Center (RTC) initiative, and the World Federation of Hemophilia (WFH) International Hemophilia Training Center (IHTC) fellowship program. Mentors from participating programs will share their experiences and provide guidance for those considering engaging with either the RtW or the IHTC programs. Future applicants will be able ask questions and connect with leaders from both programs.

Moderators: Dr. Miguel Escobar, United States, Prof. Flora Peyvandi, Italy
RtW Speakers: Dr. Suely Rezende, Brazil, Dr. Renu Saxena, India
IHTC Speakers: Dr. Magdy El Ekiaby, Egypt, Dr. Johnny Mahlangu, South Africa
NURSES FORUM

Sunday, July 9, 2017

08:55 – 17:15  M1

Nurses Session
Nurses Forum: Optimal Outcomes for Patients and Families: The Contribution of Nurses in 2017 and Beyond

Introduction: Optimal Outcomes for Patients and Families
Moderator: Maura Malone, United States

08:55 – 09:10  NUR 01.1
Welcome and Introduction
Maura Malone, United States

09:10 – 09:25  NUR 01.2
Nursing Practice in Germany: Hemostasis
Manuela Siebert, Germany

09:25 – 09:40  NUR 01.3
Nursing Practice in Germany: Thrombosis
Karin Andristschke, Germany

Improving Patient Outcomes through Transition of Care Programs
Moderators: Jennifer Maahs, United States, Brittany Savage, United States

09:40 – 10:00  NUR 02.1
Hemostasis Transition: Adolescent to Adulthood
Brittany Savage, United States

10:00 – 10:15  Break

10:15 – 10:25  NUR 02.2
Thrombosis Transition: Inpatient to Outpatient: A QI Project
Maura Malone, United States

10:25 – 10:35  NUR 02.3
Thrombosis Transition: Inpatient to Outpatient Infants and Children
Mary Lou MacDermott, United States

10:35 – 10:50  NUR 02.4
Hemostasis and Thrombosis Case Scenarios: The Legal Implications
James E. Munn, United States

10:50 – 11:00  Panel Question and Answer

11:00 – 11:35  NUR 03.1
Overview on Approach to Research
Fiona Newall, Australia

11:35 – 11:50  NUR 03.2
Nurse-Led Research: Cancer Associated Thrombosis
Karen French, United Kingdom

11:50 – 12:05  NUR 03.3
The Role of the Clinical Research Co-Ordinator in Clinical Trials
Margaret Nolan, Ireland

12:05 – 12:15  Panel Question and Answer

12:15 – 13:00  Lunch Break

13:00 – 13:15  NUR 03.4
Audit Service Evaluation
Bunis Packham, United Kingdom

13:15 – 13:30  NUR 03.5
Quality Improvement: An HTC Initiative
Regina Butler, United States

13:30 – 13:45  NUR 03.6
Improving Dental Care for Patients with Hemophilia in China
Kuixing Li, China

13:45 – 14:00  Panel Question and Answer

14:00 – 14:15  Break
NURSES FORUM

**Improving Patients' Outcomes Through Education of a Diverse Population**
*Moderators: Jim Munn, United States; Marilyn Blumenstein, United States*

14:15 – 14:35  NUR 04.1
Approach of a Resourced Community to Nursing Education to Low Resource Countries in Africa
Anne-Louise Cruickshank, South Africa

14:35 – 14:55  NUR 04.2
Development of Education in a Low Resource Environment: Both Teacher and Learner
Sulochana Badagabettu, India

14:55 – 15:10  NUR 04.3
Nursing Approach for Improving Outcomes in Religiously Diverse Communities: Amish
Jennifer Maahs, United States

15:10 – 15:25  NUR 04.4
Nursing Approach for Improving Outcomes in Religiously Diverse Communities: Muslim/Jewish
Dalia Bashari, Israel

15:25 – 15:35  NUR 04.5
Knowledge and Awareness of Pharmacists about Venous Thromboembolism and Anti Coagulation in Pakistan
S. Khan, S. Ahsan, A. Zehra, D.B. Moiz, S.S. Raza (Pakistan)

15:35 – 15:45  Panel Question and Answer

15:45 – 16:15  Coffee Break

16:15 – 17:15  Nurse Networking Reception

---

**Monday, July 10, 2017**

**Nurses Forum**

08:00 – 17:30  M1

**Nurses Session**

*Nurses Forum: Optimal Outcomes for Patients and Families: The Contribution of Nurses in 2017 and Beyond*

**Peer-Reviewed Abstracts From Nurses and Allied Health Professionals**
*Moderators: Regina Butler, United States; Manuela Siebert, Germany*

08:00 – 08:10  NUR 05.1
Delays in the Presentation of Chemotherapy Induced Venous Thromboembolism: Scope of the Problem and Potential Solutions
S. Noble, N. Pease (United Kingdom)

08:10 – 08:20  NUR 05.2
Significant Reduction in Hospital Acquired Thrombosis: Impact of a National Risk Assessment Target & Local Real-time Reporting
H. Rowswell, T. Nokes (United Kingdom)

08:20 – 08:30  NUR 05.3
Impact of a Thrombosis Pharmacist in Optimizing Anticoagulation Management in Paediatric Patients
E. Chung, C. Chan, M. Ho, J. Fung, L. Brandão, W. Seto (Canada)

08:30 – 08:40  NUR 05.4
St. Joseph's Healthcare Hamilton Perioperative Anticoagulation Clinic Quality Improvement Project
L. Sardo, J. Bayadinova (Canada)

08:40 – 08:50  NUR 05.5
National Quality Improvement for Transition from Pediatric to Adult Care: Evaluation of a Pilot Program

08:50 – 09:00  NUR 05.6
Nurse as Change Agent for Improved Nurse Safety and Patient Satisfaction
M. Blumenstein, C. Law, J. Whittle (United States)

09:00 – 09:15  Question and Answer

09:15 – 09:30  Break
NURSES FORUM

Peer-Reviewed Abstracts From Nurses and Allied Health Professionals
Moderators: Jennifer Meldau, United States; Bunis Packham, United Kingdom

11:15 – 11:25  NUR 05.13  Implementation of the Nurse Practitioner Role in the Thrombosis Service at St. Joseph’s Healthcare, Hamilton
L. Sardo, J. Bayadinova (Canada)

11:25 – 11:35  NUR 05.14  Nurse Practitioner-led Quality Improvement Project on Inferior Vena Cava Filter Placement and Retrieval: A Patient Focused Approach
L. Sardo, J. Bayadinova, W. Lim (Canada)

11:35 – 11:45  NUR 05.16  Living with the Unpredictability of an Inhibitor as an Adolescent - Results of the SO-HEROIC Study
K. Khair, L. Wollard, M. Holland (United Kingdom)

11:45 – 11:55  NUR 05.15  Providing Leadership in Thrombosis - A National Network for Nurses, Midwives and AHPs
E. Gee, L. Bonner, on behalf of the VTE National Nursing and Midwifery Network (United Kingdom)

11:55 – 12:00  Question and Answer

12:00 – 13:15  Lunch in Exhibition Halls

Patient Reported Outcomes
Moderators: Anne-Louise Cruickshank, South Africa, Ann O’Sullivan, Ireland

13:15 – 13:35  NUR 06.1  Doing My Treatment: Who Says I am Adherent?
Kate Khair, United Kingdom

13:35 – 13:55  NUR 06.2  Management of Health Anxiety in Thrombotic Patients: What Helps?
Patricia Byrne, Ireland

13:55 – 14:15  NUR 06.3  Anticoagulation Management Service: An NP Model
Jennifer Meldau, United States

14:15 – 14:30  Panel Question and Answer

14:30 – 14:45  Break in Exhibition Halls

10:00 – 10:10  NUR 05.9  Prevention of Hospital-acquired Venous Thromboembolism: The Project of Effective Quality Improvement
G. Saharov, Y.N. Nadir, I. Tzoran, A. Jabareen, G. Heims, B. Brenner, Orit Gur (Israel)

10:10 – 10:20  NUR 05.10  A Unique National Plan for Prevention of Severe Familial Hemophilia
D. Bashari, V. Shemer, R. Dardik, B. Feldman, T. Brutman Barazani, D. Eli, G. Kenet (Israel)

10:20 – 10:30  NUR 05.12  Effect of Comprehensive Hemophilia Education Programme (CHEP) for Children and Youth on Knowledge and Quality of Life - A Pilot Project
A. Dsouza, D. Nayak, A. Kurien (India)

10:30 – 10:45  Question and Answer

10:45 – 11:15  Coffee Break in Exhibition Halls
NURSES FORUM

Future Direction of Nursing Practice
Moderator: Maura Malone, United States

14:45 – 15:00  NUR 07.1
Highlights: WFH, Net Hemophilia, Open Access Journal and GHNA Initiative
Kate Khair, United Kingdom

15:00 – 15:15  NUR 07.2
Identifying the Principles Guiding the Development and Delivery of Patient Education in Thrombosis and Hemostasis Disorders: A Literature Review
J. Hew-Girard¹, C. Guelcher², J. Meldau², E. McDonald¹, F. Newell³ (¹Canada, ²United States, ³Australia)

15:15 – 15:30  NUR 07.3
Preliminary ISTH Survey Results: Nurses Needs Assessment in Thrombosis and Hemostasis
James E. Munn, United States

15:30 – 16:45  Panel Question and Answer

16:45 – 17:00  Wrap-up

These are ticketed events. Please be sure to arrive on-time as to not disrupt the session. If you have not arrived to the session by 10 minutes after the start, your seat may be given up to a participant on the waiting list.
## MASTER CLASSES

### Sunday, July 9, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 07:45</td>
<td>R2</td>
<td>Coagulation and the Complement System</td>
<td>Edward M. Conway</td>
<td>Canada</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R3</td>
<td>Personalized Treatment in Patients With VTE: Duration of Anticoagulation Based on Prediction Models</td>
<td>Sabine Eichinger</td>
<td>Austria</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R4</td>
<td>Perinterventional Management of Patients Receiving Antiplatelet Therapy</td>
<td>Anne Godier</td>
<td>France</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R5</td>
<td>Tests of Global Hemostasis: What Do They Mean and Why Would We Use Them?</td>
<td>Edelgard Lindhoff-Last</td>
<td>Germany</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R6</td>
<td>Management Issues in Pediatric Thrombosis</td>
<td>Paul Monagle</td>
<td>Australia</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R7</td>
<td>Laboratory Investigations for Suspected Bleeding Disorders</td>
<td>Reinhard Schneppenheim</td>
<td>Germany</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R8</td>
<td>Bleeding Scores</td>
<td>Alberto Tosetto</td>
<td>Italy</td>
</tr>
</tbody>
</table>

### Maintaining Vascular Flow: From Liquid to Solid to Liquid Again: The Dynamics of Clot Formation and Lysis

Alisa Wolberg, United States

### ITP: Clinical Aspects and Laboratory Testing

Donald Arnold, Canada

### Prophylaxis, Treatment (Including Use and Monitoring of Long-Acting Formulations), and Inhibitors

Alok Srivastava, India
## MASTER CLASSES

### Monday, July 10, 2017

### Master Classes

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 07:45</td>
<td>R2</td>
<td>Methodology for Clinical Studies</td>
<td>Suzanne Cannegieter, the Netherlands</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R3</td>
<td>Antiphospholipid Antibodies: Testing, Treatment, Prognosis</td>
<td>Mark Crowther, Canada</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R4</td>
<td>Platelet Function Testing and Diagnosis of Platelet Function Disorders</td>
<td>Paolo Gresele, Italy</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R5</td>
<td>VWD: Biology, Diagnosis, Therapy</td>
<td>David Lillicrap, Canada</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R6</td>
<td>Platelet MicroRNAs: From Molecules to Patients</td>
<td>Manuel Mayr, United Kingdom</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R7</td>
<td>Rare Bleeding Disorders</td>
<td>Flora Peyvandi, Italy</td>
</tr>
<tr>
<td>07:00 – 07:45</td>
<td>R8</td>
<td>Perioperative Anticoagulant Management</td>
<td>Charles Marc Samama, France</td>
</tr>
</tbody>
</table>
MASTER CLASSES

Tuesday, July 11, 2017

Master Classes

07:00 – 07:45

R2

**Immune Mechanisms in Atherosclerosis**

Christoph Binder, Austria

07:00 – 07:45

R3

**Biophysics in Thrombosis and Hemostasis**

Mihaela Delcea, Germany

07:00 – 07:45

R4

**Platelets and Immunity**

Meinhard Gawaz, Germany

07:00 – 07:45

R5

**Coagulopathy in the Emergency Room**

Wolfgang Korte, Switzerland

07:00 – 07:45

R6

**Atrial Fibrillation: Anticoagulant Choice and Monitoring**

Gregory Y.H. Lip, United Kingdom

07:00 – 07:45

R7

**Targeting Platelet Receptors by Antibodies**

Bernhard Nieswandt, Germany

07:00 – 07:45

R8

**Polyphosphate**

Thomas Renné, Sweden

07:00 – 07:45

R9

**The Ups and Downs of Thrombin Generation**

Armando Tripodi, Italy

07:00 – 07:45

R10

**HIT: Delayed Onset, and Autoimmune HIT**

Theodore Warkentin, Canada

07:00 – 07:45

R11

**Glycans in Platelet Biology**

Karin M. Hoffmeister, United States
Wednesday, July 12, 2017

Master Classes

07:00 – 07:45
Treatment of Acute Deep Vein Thrombosis or Pulmonary Embolism
Harry Büller, the Netherlands

07:00 – 07:45
Coagulation System: Mechanisms and Unanswered Questions
Björn Dahlbäck, Sweden

07:00 – 07:45
Platelets and Coagulation
Johan W. M. Heemskerk, the Netherlands

07:00 – 07:45
TTP Clinical
Johanna Kremer Hovinga, Switzerland

07:00 – 07:45
Hormone Therapy, Pregnancy, and Thrombosis
Saskia Middeldorp, the Netherlands

07:00 – 07:45
Genomics in Large Populations and Rare Inherited Bleeding and Platelet Diseases: Are They Coming Together?
Willem H. Ouwehand, United Kingdom

07:00 – 07:45
Post-Thrombotic Syndrome
Arina ten Cate-Hoek, the Netherlands

07:00 – 07:45
Platelet Disorders in Children and Newborns
Chris Van Geet, Belgium

07:00 – 07:45
Laboratory Measurements and the Direct Oral Anticoagulants
Jeffrey I. Weitz, Canada

07:00 – 07:45
Platelet Thrombus Formation
Lawrence Brass, United States
## CAREER DEVELOPMENT SESSIONS

### Monday, July 10, 2017

**Career Development Sessions**

13:15 – 14:15  
**R5**  
**Women at the Top: Building a Research Career as an Investigator**  
Karin M. Hoffmeister, *United States*

13:15 – 14:15  
**R6**  
**How to Nurture a Mentor/Mentee Relationship**  
Ingrid Pabinger, *Austria*

13:15 – 14:15  
**R7**  
**Tips for Preparing Successful Grant Applications**  
Wolfram Ruf, *Germany*

13:15 – 14:15  
**R8**  
**Combining a Clinical and Research Career European View**  
Andreas Greinacher, *Germany*

### Tuesday, July 11, 2017

**Career Development Sessions**

13:15 – 14:15  
**R5**  
**How to Establish a Career in Thrombosis and Hemostasis in Reach-the-World Countries**  
Pantep Angchaisuksiri, *Thailand*

13:15 – 14:15  
**R6**  
**Transitioning to Independence in a Research Career**  
Wolfgang Bergmeier, *United States*

13:15 – 14:15  
**R7**  
**How to Set up Animal Studies**  
Bernhard Nieswandt, *Germany*

13:15 – 14:15  
**R8**  
**How to Get Your Paper Published**  
Frits Rosendaal, *the Netherlands*
CAREER DEVELOPMENT SESSIONS

Wednesday, July 12, 2017

13:15 – 14:15

Combining a Clinical and Research Career: North American View
Mark Crowther, Canada

13:15 – 14:15

ISTH Leadership: My Journey
Claire McLintock, New Zealand

13:15 – 14:15

What Makes an Effective Journal Reviewer?
Klaus T. Preissner, Germany

13:15 – 14:15

Keys to Convincing Scientific Presentations
Denisa Wagner, United States
Sunday, July 9, 2017

Scientific Program

18:15 – 21:00 Hall B

Opening Ceremony

---

Monday, July 10, 2017

Hall B and A rooms are in the CityCube.
Hall 7 rooms (city names) are in the Messe Berlin.

Legend

- Plenary Sessions
- State-of-the-Art Sessions
- Oral Communication Sessions
- Abstract Symposia Sessions
- Supported Symposia
- Product Theater Presentations
State of the Art Symposia

**What Happens After Acute VTE?**
Chairs: Frederikus Klok, the Netherlands
        Heinrike Wilkens, Germany

08:00 – 08:25  SOA 01.1  
Prediction of Recurrence  
Sabine Eichinger, Austria

08:25 – 08:50  SOA 01.2  
Prevention and Treatment of the Post-Thrombotic Syndrome  
Arina ten Cate-Hoek, the Netherlands

08:50 – 09:15  SOA 01.3  
Chronic Thromboembolic Pulmonary Hypertension  
Irene Lang, Austria

**Regulation of Extracellular Proteolysis**
Chairs: Johann Wojta, Austria  
        Silvio Antoniak, United States

08:00 – 08:25  SOA 02.1  
Novel Plasminogen Receptors in Cancer and Inflammation  
Lindsey Miles, United States

08:25 – 08:50  SOA 02.2  
Moonlighting Plasminogen Binding Proteins: Are Old Proteins Able to Learn New Tricks?  
Malgorzata Wygrecka, Germany

08:50 – 09:15  SOA 02.3  
PA System and Infection Diseases  
Martina Sanderson-Smith, Australia

**Leukocytes in Atherosclerosis**
Chairs: Andreas Zirlik, Germany  
        Christian Weber, Germany

08:00 – 08:25  SOA 03.1  
Vaccination Strategies in Atherosclerosis  
Klaus Ley, United States

08:25 – 08:50  SOA 03.2  
Macrophage Reprogramming in Atherosclerosis  
Eicke Latz, Germany

08:50 – 09:15  SOA 03.3  
Neutrophils in Atherosclerosis  
Oliver Soehnlein, Germany

**Inflammation and Barrier Function**
Chairs: Christoph Binder, Austria  
        Silvia Fischer, Germany

08:00 – 08:25  SOA 04.1  
Endothelial Cell Junctions in Inflammation  
Beat Imhof, Switzerland

08:25 – 08:50  SOA 04.2  
Novel Strategies for the Treatment of Sepsis and Blood-Barrier Dysfunction  
Gou Young Koh, Republic of Korea

08:50 – 09:15  SOA 04.3  
Dynamic Cellular Arrangement During Vascular Remodeling  
Holger Gerhardt, Germany

**ISTH-WFH Joint Session: Novel Functions of VWF**
Chairs: Johannes Oldenburg, Germany  
        Alain Weill, France

08:00 – 08:25  SOA 05.1  
VWF and Inflammation  
Cecile Denis, France
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

08:25 – 08:50
SOA 05.2
VWF and Cerebral Malaria
James O’Donnell, Ireland

08:50 – 09:15
SOA 05.3
VWF in Tumor Thrombophilia and Metastasis
Stefan Schneider, Germany

08:00 – 09:15
Animal Models of Thrombosis and Hemostasis
Chairs: Christophe Dubois, France
Jose Lopez, United States

08:00 – 08:25
SOA 06.1
Coagulation and Sickle Cell Disease
Rafal Pawlinski, United States

08:25 – 08:50
SOA 06.2
Hemostasis in Zebrafish
Pudur Jagadeeswaran, United States

08:50 – 09:15
SOA 06.3
Integrating the Platelet Signaling Network With the Hemostatic Response In Vivo
Lawrence Brass, United States

08:00 – 08:25
SOA 07.1
Regulation of Platelet Life and Death
Benjamin Kile, Australia

08:25 – 08:50
SOA 07.2
Procoagulant ‘Zombie’ Platelets
Johan W. M. Heemskerk, the Netherlands

08:50 – 09:15
SOA 07.3
Proinflammatory Function of Dying Platelets
Shaun Jackson, Australia

09:30 – 10:45
Hall B
Oral Communications

09:30 – 09:45
OC 06.1
Rap1A and Rap1B Functional Redundancy in Platelets and Megakaryocytes
L. Stefanini (Italy)

09:45 – 10:00
OC 06.2
The Kinase-phosphatase Pair Csk-CD148 is a Critical Regulator of Platelet Reactivity to Vascular Injury
J. Mori1, Z. Nagy1, R. Al Ghaithi1, S. Heising1, J.P. van Geffen2, M.J.E. Kuijpers1, J.W.M. Heemskerk1, P. Harrison1, A. Mazharian1, Y.A. Sem1 (1United Kingdom, 2the Netherlands)

10:00 – 10:15
OC 06.3
Major Role for Rac/Cdc42 in PI3Kβ-driven Platelet Function

10:15 – 10:30
OC 06.4
CD40L Priming of Platelets and Activation of NF-κB are CD40-dependent
K. Kojok, S. El-Akoum, M. Mohsen, W. Mourad, M. Yahye (Canada)

10:30 – 10:45
OC 06.5
Essential Role of GSK3α Phosphorylation in Restricting Platelet Activation and Thrombus Formation
I. Hers, J.A. Wersall, E.O. Agbani, R.W. Hunter, A.W. Poole, S.F. Moore (United Kingdom)

10:30 – 10:45
A1
Cellular and Molecular Mechanisms of Fibrinolysis
Chairs: Guy Reed, United States
Roger Lijnen, Belgium

09:30 – 09:45
OC 01.1
The Plasminogen Receptor Plg-RKT is Expressed on Platelets and Co-localises with Platelet-derived Plasminogen upon Stimulation
C.S. Whyte1, N.A. Booth1, M.M. Jalal1, R.J. Parmer2, L.A. Miles2, N.J. Mutch1 (1United Kingdom, 2United States)
XXVI ISTH Congress and 63rd Annual SSC Meeting

**SCIENTIFIC PROGRAM**

**10:30 – 10:45**

**OC 02.5**

Absence of Platelet Thrombin Receptor Par4 Prevents Thrombotic and Stroke-like Phenotypes of Thrombomodulin Deficient mice

M. Storage, Q. Yang, M. Zhan, R. Sood (United States)

**09:30 – 10:45**

**A5**

Platelets in Development and Malignancy

*Chairs: Benjamin Kile, Australia*

Katsue Suzuki-Inoue, Japan

**09:30 – 09:45**

**OC 03.1**

Platelet Activation by CLEC-2-Podoplanin Interaction is Essential for Lung Development


**09:45 – 10:00**

**OC 03.2**

Platelet Microparticles Infiltrating Solid Tumors Transfer miRNAs and Modulate Tumor Growth


**10:00 – 10:15**

**OC 03.3**

Significance of Transforming Growth Factor-beta Signaling for Thrombofibrotic Remodeling in Murine Venous Thrombosis and Human Chronic Thromboembolic Pulmonary Hypertension

M.L. Bochenek, C. Leidinger, N.S. Rosinus, M. Lankeit, E. Mayer, T. Münzel, S. Konstantinides, M. Bosmann, K. Schäfer (Germany)

**10:15 – 10:30**

**OC 03.4**

Aspirin Therapy Reduces the Ability of Platelets to Promote Colon and Pancreatic Cancer Cell Proliferation: Implications for the Oncoprotein c-MYC

A. Mitrugno, J.L. Sylman, A.T.P. Ngo, J. Pang, R.C. Sears, C.D. Williams, O.J.T. McCarty (United States)

**10:30 – 10:45**

**OC 03.5**

Platelet Releasate Promotes Breast Cancer Growth and Angiogenesis via VEGF-integrin Cooperative Signaling

L. Jiang, Y. Luan, X. Miao, C. Sun, K. Li, Z. Huang, D. Xu, M. Zhang, F. Kong, N. Li (Sweden, China)
09:30 – 10:45  A6

Mechanisms of (Pro)Platelet Production

**Chairs:** Katya Ravid, *United States*
Alessandra Balduini, *Italy*

**OC 04.1**
Ultrastructural Characterization of the Cellular Contacts between Megakaryocytes and Endothelial Cells in the Bone Marrow
A. Eckly, J.-Y. Rinckel, F. Proamer, F. Lanza, H. de la Salle, C. Gachet (France)

**OC 04.2**
Loss of the Hematopoietic Adaptor Protein ADAP Impairs Megakaryocyte Polarization and Induces Ectopic Platelet Release
M. Spindler, J.M.M. van Eeuwijk, Y. Schurr, D. Stegner, B. Nieswandt, A. Reinhold, M. Bender (Germany)

**OC 04.3**
Centrosome Destabilization through the Ubiquitin-proteasome Pathway Regulates Proplatelet Production
K. Machlus, P. Vijey, T. Soussou, J. Italiano (United States)

**OC 04.4**
Scalable Production of Human Platelets in a Bioreactor
L. Beaulieu, B. Dykstra, C. Peters, J. Italiano, Jr, J. Thon (United States)

**OC 04.5**
Platelet Release from Infused Megakaryocytes is Largely Limited to the Pulmonary Vasculature
I. Johnston, D. Jarocha, V. Hayes, L. Rauova, M. Poncz (United States)

09:30 – 10:45  A7

Protease-Activated Receptors

**Chairs:** Justin Hamilton, *Australia*
Patricia Liaw, *Canada*

**OC 05.1**
The Lipid-raft Organizer Tetherin Negatively Regulates Platelet Receptor Function
X. Zhao, D. Alibhai, J.L. Hutchinson, S. Cross, C.M. McKinnon, R. Auengraethera, A. Poole, G. Banting, S.J. Mundell (United Kingdom)

09:30 – 10:45  New York

Rare Bleeding Disorders

**Chairs:** Flora Peyvandi, *Italy*
Nigel Key, *United States*

**OC 07.1**
ThromboGenomics: HTS Diagnosis of Inherited Bleeding, Thrombotic, Coagulation and Platelet Disorders
K. Downes1, K. Freson2, K. Gomez1, on behalf of ThromboGenomics and the Genomic Medicine Centre at Cambridge University Hospitals (GMC@CUH) (1United Kingdom, 2Belgium)

**OC 07.2**
An International Prospective Cohort of Rare Bleeding Disorders: Results of a Follow-up Study on Patients with Factor XIII Deficiency (PRO-RBDD)
M. Menegatti1, R. Palla1, M. Boscarno1, S. Halimeh2, M.A. Daoud2, M. Borhani3, N. Fatima3, N. Ozdemir4, S.M. Siboni5, D. Mikovic6, M. Saracevic7, A. Mumford8, A. Harvey9, R.E. Schutgens10, M. van Haften-Spoor10, C. McGuinn11, M. Ly12, H. Platokouki12, H. Pergantou12, A. Yimaz12, A.D. Shapiro12, A. Williamson12, P. De Moerloose12, A. Casini12, J. Payne12, L. Muszbek13, F. Peyvandi1 (1Italy, 2Germany, 3Pakistan, 4Turkey, 5Serbia, 6United Kingdom, 7the Netherlands, 8United States, 9Greece, 10Switzerland, 11Hungary)
SCIENTIFIC PROGRAM

10:00 – 10:15  OC 07.3  Profile of Mutations Identified in the 3Winters-IPS Project on a Cohort of European Patients with Previously Diagnosed Type 3 von Willebrand Disease  A. Goodeve1, R. Schnepfenheim2, L. Crookes1, N. Niksic1, F. Oyen2, L. Baronciani1, J. Batlle1, E. Berntorp1, I. Bodo1, U. Budde1, G. Castaman3, J. Eikenboom1, C. Ettorre3, J. Goudemand4, W. Hassenpflug5, C. Hay1, R. Lassila6, F. Leebeek2, M.F. Lopez Fernandez1, P.M. Mannucci3, G. Mazzucconi1, M. Morfini3, J. Oldenburg2, R. Parra Lopez1, I.R. Peake1, F. Peyvandi1, A. Tiede1, A. Tosetto2, M. Trossaert8, E. Zetterberg5, A.B. Federici3, 3WiNTERS (1United Kingdom, 2Germany, 3Italy, 4Spain, 5Sweden, 6Hungary, 7the Netherlands, 8France, 9Finland)

10:15 – 10:30  OC 07.4  Endoplasmic Reticulum Stress and the Unfolded Protein Response in Congenital FVII Deficiency  E. Andersen1, M.E. Chollet1, C.F. Myklebust1, M. Pinotti2, F. Bernardi2, E. Skarpen1, P.M. Sandset1, G. Skretting1 (1Norway, 2Italy)

10:30 – 10:45  OC 07.5  Characterization of GGCX Mutations Identified in VKCFD1 Patients  S. Ghosh, K.J. Czogalla, J. Müller, K. Hoening, V. Hornung, M. Watzka, J. Oldenburg (Germany)

10:00 – 10:45  London

VWF: Biosynthesis and Mechanisms of Action

Chairs: Simon De Meyer, Belgium  Laura L. Swystun, Canada

09:30 – 09:45  OC 08.1  A Discontinuous Autoinhibitory Module Masks the A1 Domain of VWF  W. Deng, Y. Wang, S.A. Druzak, J.F. Healey, A.K. Syed, P. Lollar, R. Li (United States)

09:45 – 10:00  OC 08.2  Allele-specific Inhibition of von Willebrand Factor p.Cys2773Ser Restores a Severe Multimerization Defect  A. de Jong, R.J. Dirven, J.A. Oud, D. Tio, J. Eikenboom (the Netherlands)

10:00 – 10:15  OC 08.3  Altered Sialylation in Patients with Low von Willebrand Factor Levels  S. Aguila1, M. Lavin1, N. Dalton1, M. Byrne1, T. Brophy1, A. Chion1, J. Di Paola2, J. O’Donnell1 (1Ireland, 2United States)

10:15 – 10:30  OC 08.4  The N-terminal TIL‘E’ Domains of von Willebrand Factor Requires a Structurally Intact WVD3 Domain for Optimal Factor VIII Binding  M. Przeradzka, H. Meems, C. van der Zwaan, M. van der Biggelaar, K. Mertens, A.B. Meijer (the Netherlands)

10:30 – 10:45  OC 08.5  The Redox State of the von Willebrand Factor A2 Domain Disulphide Bond Controls Platelet GPIbα Binding  D. Butera, F. Passam, L. Ji, P. Hegg (Australia)

09:30 – 10:45  Helsinki 1

ADAMTS 13 and TTP Basic

Chairs: Johanna Kremer Hovinga, Switzerland  Karen Vanhoorelbeke, Belgium

09:30 – 09:45  OC 09.1  Conformation of ADAMTS13 is Altered in Acquired TTP Patients  E. Roose1, A.-S. Schelpe1, B. Joly2, A. Vandenbulcke1, J. Caron1, I. Pareyn1, N. Vanderputte1, M. Peetermans1, P. Verhamme1, H. Deckmyn1, S.F. De Meyer1, P. Coppo1, A. Veyradier2, K. Vanhoorelbeke1 (1Belgium, 2France)

09:45 – 10:00  OC 09.2  PAD4 Citrullination of ADAMTS13: A New Link between NETosis and Thrombosis  N. Sorvillo, K. Martinod, C. Staudinger, D. Wagner (United States)

10:00 – 10:15  OC 09.3  The Role of ADAMTS13 Exosites in VWF Recognition and Proteolysis  A. Petri, R. de Groot, Y. Xu, J. Crawley (United Kingdom)

10:15 – 10:30  OC 09.4  Autoantibody Binding to ‘Open’ and ‘Closed’ ADAMTS13 in Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura  M.I. Underwood, M.R. Thomas, M.A. Scully, J.T.B. Crawley (United Kingdom)

10:30 – 10:45  OC 09.5  Parallel Profiling of ADAMTS13-derived Peptide Repertoires on HLA-DR and HLA-DQ  I. Hrdinová, F. Verbij, P.H.P. Kajen1, R.B. Hartholt, F.P.I. van Alphen, N. Lardy1, A. ten Brinke1, K. Vanhoorelbeke2, J. Voorberg3, A.B. Meijer1, I. Peyron1 (1the Netherlands, 2Belgium)

SCIENTIFIC PROGRAM
**Future Biotherapeutics for Hemophilia A and B**

**Chairs:** Michael Laffan, United Kingdom  
Johnny Mahlangu, South Africa

**09:30 – 09:45**  
**OC 10.1**  
An Engineered Serpin for the Treatment of Haemophilia  
S. Polderdijk¹, T. Adams¹, L. Ivanciu², R. Camire², T. Baglin¹, J. Huntington¹  
¹United Kingdom, ²United States

**09:45 – 10:00**  
**OC 10.2**  
Antithrombin Resistance and Heparosan Conjugation Synergistically Extend the in vivo Half-life of FVIII  
M.B. Hermit¹, P.S. Gandhi¹, C. Behrens¹, M. Dainiak¹, O.H. Olsen¹, A.A. Pedersen¹, G. Andersen¹, K. Lamberth¹, J.J. Hansen¹, M.A. Zundel¹, P.L. Deangelis², F.M. Haller², E. ClíÓ, J. Breinholt¹, M. Åkesson¹, M.S. Jensen¹, H. Pelzer¹, L. Hansen¹, H. Stennicke¹, I. Hilden¹, H. Østergaard¹  
¹Denmark, ²United States

**10:00 – 10:15**  
**OC 10.3**  
Pharmacokinetic and Activity Levels Achieved with Daily Subcutaneously Administered CB 2679d/ISU304 in Hemophilia B Dogs  
H. Levy, T. Nichols, E. Merricks, R. Raymer, A. Hetherington  
(United States)

**10:15 – 10:30**  
**OC 10.4**  
FcRn Mediated Recycling of Recombinant VWF D’D3-albumin Fusion Protein / rVIII-SingleChain Complex Is a Mechanism for FVIII Half-life Extension  
J. Chia¹, I. Glauser¹, A. Andrews¹, T. Weimer¹, M. Wilson¹, A. Verhagen¹  
¹Australia, ²Germany

**10:30 – 10:45**  
**OC 10.5**  
Half-life Extension of FVIII by Coadministration of a Recombinant D’D3 Albumin Fusion Protein  
S. Pestel¹, E. Raquet¹, M. Mischnik¹, P. Claar¹, A. Andrews², E. Herzog¹, T. Weimer¹  
¹Germany, ²Australia

---

**Pediatric Thrombosis**

**Chairs:** M. Patricia Massicotte, Canada  
Elizabeth Chalmers, United Kingdom

**09:30 – 09:45**  
**OC 11.1**  
Development of a Predictive Risk Model for Deep Vein Thrombosis in Pediatric Oncology Patients  
L. Mitchell¹, F. Ruehle², L. Brandão¹, J. Halton³, S. Israels¹, K. Dietrich¹, M. Spavor², M. Stoll², ABLE Investigators  
¹Canada, ²Germany

**09:45 – 10:00**  
**OC 11.2**  
External Validation of a Venous Thromboembolism Risk Prediction Tool for Critically Ill Children - The Cleveland Score  
(United States)

**10:00 – 10:15**  
**OC 11.3**  
External Validation of Risk Prediction Models for Catheter-associated Thrombosis in Critically Ill Children  
J. Rutgers¹, S. Jones¹, P. Monagle¹, F. Newall³, E.V. Faustino²  
¹Australia, ²United States

**10:15 – 10:30**  
**OC 11.4**  
Thrombophilia in Children to Predict Recurrent Line-related Thrombosis: Time to Choose Wisely  
M.L. Ayula, N. Amiri, K. Barron, T. Vu, P. Krol, N. Yue, S. Williams, L.R. Brandão  
(Canada)

**10:30 – 10:45**  
**OC 11.5**  
Predictive Factors for Central Venous Catheter-related Thrombosis and Long Term Sequelae  
S. Jones, J. Rutgers, W. Butt, F. Newall, P. Monagle  
(Australia)
SCIENTIFIC PROGRAM

09:30 – 10:45

Berlin

Predictors of Thromboembolism

Chairs: Francesco Dentali, Italy
Marc Rodger, Canada

09:30 – 09:45

OC 12.1
Prevalence of Major Medical Illnesses Associated with Venous Thromboembolism Risk in US Hospitals
A.T. Cohen1, W. Huang2, R.A. Harrington3, S.Z. Goldhaber2, R.D. Hull3, A.F. Hernandez2, C.M. Gibson2, F.A. Anderson2 (1United Kingdom, 2United States, 3Canada)

09:45 – 10:00

OC 12.2
Venous Thromboembolism and Physical Function in the Nurses’ Health Study
K. Hagan, L. Harrington, J. Kim, F. Grodstein, C. Kabrhel (United States)

10:00 – 10:15

OC 12.3
Catheter-related Venous Thromboembolism in Hospitalized Pediatric Patients with Inflammatory Bowel Disease: A Retrospective Study Assessing Prevalence, Characteristics and Role of Anticoagulant Thromboprophylaxis with Enoxaparin
J. Meldau, C. Hennessey, C. Guelcher, D. Carrie, M. Guerrera, Y. Diab (United States)

10:15 – 10:30

OC 12.4
External Validation and Comparison of the Improve Risk Assessment Model with the Geneva Risk Assessment Model in the ESTIMATE Cohort

10:30 – 10:45

OC 12.5
Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis: Improvement in Time Spent in the Therapeutic INR Range

10:45 – 11:15

Coffee break in Exhibition Halls

11:15 – 12:00

Marion I. Barnhart Memorial Lecture: Platelet Signaling

Chairs: Bernhard Nieswandt, Germany

11:15 – 12:00

PL 01
Snakes and Ladders: New Roles for Platelets in Health and Disease
Stephen Watson, United Kingdom

12:00 – 13:15

Lunch, Poster Session and Industry Exhibition in Exhibition Halls

Product Theaters

12:15 – 13:00

See page 535

Supported Symposia

13:15 – 14:30

See page 529

Abstract Symposia

14:45 – 16:15

Clinical Research and Outcomes in Hemophilia

Chairs: Donna DiMichele, United States
Christoph Königs, Germany

14:45 – 15:15

ASY 01
Outcomes in Hemophilia
Marilyn Manco-Johnson, United States

15:15 – 15:30

ASY 01.1
Efficacy, Safety and Pharmacokinetics (PK) of Emicizumab (ACE910) Prophylaxis (Px) in Persons with Hemophilia A with Inhibitors (PwHAwI): Randomized, Multicenter, Open-label, Phase 3 Study (HAVEN 1)
J. Oldenburg1, J. Mahlangu1, B. Kim1, C. Schmidt1, M. Callaghan1, G. Young2, E. Santagostino3, R. Kruse-Jarres3, C. Negrier4, C. Kessler5, N. Valente5, E. Asikianius6, G. Levy7, J. Windygaa, M. Shima8 (1Germany, 2South Africa, 3United States, 4Switzerland, 5Italy, 6France, 7Poland, 8Japan)
15:30 – 15:45  ASY 01.2  
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Interim Results from a Phase 2 Extension Study in Patients with Hemophilia A or B with and without Inhibitors  
K.J. Pasi1, P. Georgiev2, T. Mant1, M.D. Creagh1, T. Lissitchkov2, D. Bevan1, S. Austin1, C. Hay1, I. Hegemann3, R. Kazmi1, P. Chowdary1, S. Rangarajan1, C.-H. Soh4, A. Monpara4, H.V. Nguyen4, K. Madigan5, M.V. Ragni6 (‘United Kingdom, 2Bulgaria, 3Switzerland, 4United States)

15:45 – 16:00  ASY 01.3  
Musculoskeletal Ultrasound for Intra-articular Bleed Detection: A Highly Sensitive Imaging Modality Compared to Conventional Magnet Resonance Imaging  
S. Nguyen, X. Lu, Y. Ma, J. Du, E.Y. Chang, A. von Drygalski (United States)

16:00 – 16:15  ASY 01.4  
The Thunder Study: Haemophilia Epidemiology Treatment, Outcome and Unmet Needs in the UK: An Analysis from the UK National Haemophilia Database  
C.R. Hay1, B.P. Palmer1, M. Scott1, H. Xiang1, C. Sima2, D.P. Hart1, P.W. Collins3 (‘United Kingdom, 2United States)

14:45 – 16:15  A1  
Structural Biology in Coagulation  
Chairs: James Huntington, United Kingdom  
Jonas Emsley, United Kingdom

14:45 – 15:15  ASY 02  
Structural Correlates of Function in Coagulation  
Sriram Krishnaswamy, United States

15:15 – 15:30  ASY 02.1  
Human-snake Chimeras of Cofactor V Reveal Allostery between the A- and C-domains  
D. Verhoef1, G.A.F. Nicolaes1, R. Schrijver1, R.M. Camire2, P.H. Reitsma1, M.H.A. Bos1 (‘the Netherlands, 2United States)

15:30 – 16:15  A2  
Microbiota as an Environmental Risk Factor  
Chairs: Tobias A. Fuchs, Germany  
Matthew Rondina, United States

14:45 – 15:15  ASY 03  
Microbiota and Thrombosis  
Christoph Reinhardt, Germany

15:15 – 15:30  ASY 03.1  
Platelet Necrosis Induces Neutrophil Macro-aggregation and Pulmonary Thrombosis Following Gut Ischemia  

15:30 – 16:45  ASY 03.2  
Going against the Flow: How Staphylococcus Aureus and Staphylococcus Lugdenensis Adhere to the Heart Valves and Initiate Endocarditis by Binding to von Willebrand Factor  
L. Liesenborghs, J. Claes, M. Peetermans, R.T. Veloso, M. Criel, M. Lox, G. Vande Velde, T. Vanassche, M. Hoylaerts, P. Verhamme (Belgium)

15:45 – 16:00  ASY 03.3  
Soluble Short Fractions of β-1,3 Glucans Derived from Candida albicans Act as a Shield for Pathogenic Yeasts and Modulate the Activation of Platelets  
H. Vancraeynest1, R. Charlet1, Y. Guerardel1, L. Choteau1, A. Bauters1, M. Tardiveau1, N. Francois1, L. Dubuquoy1, D. Soloviev1, D. Poulain1, B. Sendid1, S. Jawhara1 (‘France, 2United States)

16:00 – 16:15  ASY 03.4  
VWF and ADAMTS-13 Modulate the Outcome of Staphylococcus aureus Sepsis  
### SCIENTIFIC PROGRAM

**14:45 – 16:15**

**A3** Platelet Diagnostics

**Chairs:** Kerstin Jurk, Germany  
Keith Neeves, United States

**14:45 – 15:15**

**ASY 04**

Platelet Diagnostics - Critical Appraisal of Current Methodology  
Paolo Gresele, Italy

**15:15 – 15:30**

**ASY 04.1**

A Microfluidic Model of Hemostasis Sensitive to Platelet Function and Coagulation  
R.M. Schoeman, N. Danes, K. Leiderman, K.B. Neeves (United States)

**15:30 – 15:45**

**ASY 04.2**

Introduction of a National Protocol for Light Transmission Aggregometry in the Netherlands: Results of More than 80 Healthy Volunteers Before and after Standardisation  
Y. Henskens, F. van der Graaf, H. Hopman-Kerkhoff, C. Hudig, M. de Maat, M. Schoorl, J. Slomp, A. Stroobants (the Netherlands)

**15:45 – 16:00**

**ASY 04.3**

Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) with a Newly Generated Activated Platelet-specific Fluoroprobe: A Unique Technology for the Diagnosis of Thrombotic Diseases  
B. Lim, Y. Yao, A.L. Huang, M.L. Yap, U. Flierl, J. Palasubramaniam, X. Wang, K. Peter (Australia, Germany)

**16:00 – 16:15**

**ASY 04.4**

Novel Integrin αIIbβ3 and GPIbα Coatings that Feature Anti-fouling Properties for Platelet Research and Clinical Diagnostics  

**14:45 – 16:15**

**A6** Antiphospholipid Syndrome

**Chairs:** Karen Schreiber, United Kingdom  
Karl Lackner, Germany

**14:45 – 15:15**

**ASY 06**

Antiphospholipid Syndrome 2017 Update  
Doruk Erkan, United States

**15:15 – 15:30**

**ASY 06.1**

IgM Antibodies against Oxidation-specific Epitopes Identify Patients with a Lupus Anticoagulant at Risk for Thrombotic Complications: The Vienna Lupus Anticoagulant and Thrombosis Study  
F. Posch, L. Alico, S. Koder, J. Gebhart, C. Ay, C.J. Binder, I. Pabinger (Austria)

**15:30 – 15:45**

**ASY 06.2**

Differences in the Platelet Proteome Between Lupus Anticoagulant Positive Individuals with or without Thrombotic Manifestations and Healthy Controls  
L. Hell, K. Lurger, J. Gebhart, S. Koder, C. Ay, I. Pabinger, M. Zellner (Austria)
15:45 – 16:00  ASY 06.3  
Antiphospholipid Antibody Induced Cellular Signal Transduction Depends on Antigen Specificity  
A. Hollerbach, N. Müller-Calleja, K. Lackner (Germany)

16:00 – 16:15  ASY 06.4  
Complement-dependent Monocyte TF Activation Triggers Antiphospholipid Antibody Internalization and ROS Signaling  
N. Müller-Calleja, K. Lackner, W. Ruf (Germany)

14:45 – 16:15  A8  
Platelet Receptor Signaling  
Chairs: Lucia Stefanini, Italy  
Stephen Watson, United Kingdom

14:45 – 15:15  ASY 08  
GPVI: More Than a Collagen Receptor and More Than an Antithrombotic Target  
Pierre Mangin, France

15:15 – 15:30  ASY 08.1  
CLEC2 Contributes to Hemostasis Independently of Classical HemiTAM Signaling in Mice  
E.J. Haining1, D. Stegner1, D. Cherpokova1, K. Wolf1, S.P. Watson2, B. Nieswandt1 (1Germany, 2United Kingdom)

14:45 – 15:15  ASY 07  
Recent Advances in FXIII  
Robert A.S. Ariëns, United Kingdom

15:15 – 15:30  ASY 07.1  
Deriving the Full Atom Structure for the Coagulation Factor XIII A2B2 Heterotetrameric Complex by Molecular Modeling Using Guiding Constraints Based on Mass Spectrometric Analysis of the Complex  
S. Singh1, A. Nazabal2, V. Ivashkevicius1, J. Doedt1, H. Philippou1, J. Oldenburg1, A. Biswas1 (1Germany, 2Switzerland, 3United Kingdom)

15:30 – 15:45  ASY 07.2  
Reciprocal Inter-tissue Regulation of Factor XIII-A and -B Subunits Determines Factor XIII Levels in Plasma  
S. Byrnes, A.S. Wolberg (United States)

15:45 – 16:00  ASY 07.3  
Plasma-, but Not Platelet-factor XIII Promotes Red Blood Cell Retention in Contracted Clots and Mediates Clot Size during Venous Thrombosis  
S. Kattula, J.R. Byrnes, S.M. Martin, B.C. Cooley, M.J. Flick, A.S. Wolberg (United States)

16:00 – 16:15  ASY 07.4  
FXIII on Cold-stored Platelet Surface Enhance Clot Contraction and Anti-fibrinolysis  
P.M. Naig, X. Wu, J.D. Keese, L. Bin, A.P. Cap, A.K. Ramasubramanian (United States)

14:45 – 16:15  New York  
Regulation of Vascular Function by Noncoding RNAs  
Chairs: Margitta Elvers, Germany  
Leon J. Schurgers, the Netherlands

14:45 – 15:15  ASY 09  
Regulation of Vascular Function by Noncoding RNAs  
Stefanie Dimmeler, Germany
**Scientific Program**

**XXVI ISTH Congress and 63rd Annual SSC Meeting**

**SCIENTIFIC PROGRAM**

15:15 – 15:30  **ASY 09.1**  
Thrombin-reduced miR-27b Attenuates Platelet Angiogenic Activities via Enhancing Platelet de Novo Synthesis of Anti-angiogenic Thrombospondin-1  
X. Miao, M.F.-U. Rahman, L. Jiang, S. Tan, H. Xie, W.-O. Lui, N. Li (Sweden)

15:30 – 15:45  **ASY 09.2**  
Human Endothelial Cells Infected with Staphylococcus aureus Leads to an Up-regulation of miR-330, Resulting in Loss of Barrier Integrity in an ex vivo Model of Sepsis  
R.L. Watkin, O. Piskereva, S. Das, S. Madden, R. Stallings, S.W. Kerrigan (Ireland)

15:45 – 16:00  **ASY 09.3**  
Identification of Eight Oestrogen-sensitive miRNAs that Regulate Coagulation Factors, One of which (miR-365a-3p) Inhibits Tissue Factor Expression  
J. Tian, J. Tay, Q. Hughes, J. Tiao, R. Baker (Australia)

16:00 – 16:15  **ASY 09.4**  
Everolimus Eluting Coronary Stenting Elicits Less Cellular Activation via Altered miRNA Levels in Plasma and Endothelial Cells  

14:45 – 16:15  **London**

**Bleeding Management Under Oral Anticoagulation**  
Chairs: Walter Ageno, Italy  
Elaine Hylek, United States

14:45 – 15:15  **ASY 10**  
Bleeding Under Direct Oral Anticoagulants  
Jeffrey I. Weitz, Canada

15:15 – 15:30  **ASY 10.1**  
Mortality in Patients with Intracerebral Hemorrhage Associated with Vitamin K Antagonists, Direct Oral Anticoagulants, Antiplatelets or No Antithrombotic Therapy  

15:30 – 15:45  **ASY 10.2**  
Rates, Management and Outcome of Bleeding Complications during Apixaban and Edoxaban Therapy in Daily Care - Results from the Dresden NOAC Registry (NCT01588119)  
S. Marten, S. Helmer, I. Beyer-Westendorf, M. Gобelt, L. Tittl, J. Beyer-Westendorf (Germany)

15:45 – 16:00  **ASY 10.3**  
Prevention of Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa in a Polytrauma Model  
O. Grottke, T. Braunshweig, N. Akman, R. Rossaint, P.B. Conley, J.M. Leeds, M. Honickel (Germany, United States)

16:00 – 16:15  **ASY 10.4**  
Reduction of Hepatic Factor XII Expression in Mice by ALN-F12 Inhibits Thrombosis without Increasing Bleeding Risk  
H. Liu, J. Qin, B. Cooley, J. Butler (United States)

14:45 – 16:15  **Helsinki 1**

**Safety of Blood Components and Blood Transfusions**  
Chairs: Hermann Eichler, Germany  
Thomas Thiele, Germany

14:45 – 15:15  **ASY 11**  
Safety and Inactivation of Blood Components  
Michael Schmidt, Germany

15:15 – 15:30  **ASY 11.1**  
Synthesis of the First GMP Grade Biotin 3-sulfo N-Hydroxysuccimide Is now Available to Label Blood Cells Intended for Human Transfusion Studies, but not Exclusively  
G. Kemperman, J. Basten, M.-C. Viaud-Massuard, C. Ravanat, P. Ohlmann (the Netherlands, France)

15:30 – 15:45  **ASY 11.2**  
French Lyophilized Plasma versus Fresh Frozen Plasma for the Initial Management of Trauma Induced Coagulopathy: A Randomized Open-label Trial  
D. Garrigue-Huet, A. Godier, A. Glacet, J. Labreuche, E. Kipnis, E. Resch, P. Goldstein, A. Bauters, B. Tavernier, A. Sailliol, S. Susen (France)
**SCIENTIFIC PROGRAM**

**ASY 11.3**
15:45 – 16:00
The Neutralization of CD40/CD40L Complex Inhibits TRALI Development in a Mouse Model Induced through Lipopolysaccharide and Anti-MHC I mAb Injection
S. Tariket, C.-A. Arthaud, A. Meneveaux, H. Hamzeh-Cognasse, O. Garraud, F. Cognasse (France)

**ASY 11.4**
16:00 – 16:15
Controlling Hydrophobicity to Minimize Thrombogenic Risk on Medical Devices in an Arterial Environment
D. Bark Jr. (United States)

**Rare Bleeding Disorders**

**Helsinki 2**

**ASY 12**
14:45 – 16:15
Lessons Learned From RBD Databases
Danijela Mikovic, Serbia

**ASY 12.1**
15:15 – 15:30
Next Generation Sequencing in Patients with No Apparent Laboratory Platelet Defect Despite Having an Extensive Bleeding History
A. Maclachlan, S.P. Watson, N.V. Morgan (United Kingdom)

**ASY 12.2**
15:30 – 15:45
An International Prospective Cohort Study of Patients with Fibrinogen Deficiency (PRO-RBDD Study)

**ASY 12.3**
15:45 – 16:00
Studying Adaptor Protein 3 Dependent Trafficking to Weibel-Palade Bodies Using Hermansky-Pudlak Syndrome Type 2 Blood Outgrowth Endothelial Cells
E. Karampini, M. Hofman, F.P.J. van Alphen, T. Kuipers, S. Meijer, J. Voorberg, B. Rierings (the Netherlands)

**ASY 12.4**
16:00 – 16:15
Involvement of OCRL, a Phosphoinositide 5-phosphatase, in Cytoskeleton Reorganization and Megakaryocyte Maturation
S. Poirault-Chassac, E. Dreano, M. Egot, D. Pidard, R. Salomon, G. Baujat, D. Lasne, P. Gussem, C. Bachelot-Loza (France)

**Risk Factors for Carotid Atherosclerosis and Stroke**

**Budapest**

**ASY 13**
14:45 – 15:15
Risk Factor for Stroke
Gregory Lip, United Kingdom

**ASY 13.1**
15:15 – 15:30
Impact of Venous Thromboembolism on Formation and Progression of Carotid Atherosclerosis - The Tromsø Study

**ASY 13.2**
15:30 – 15:45
Carotid Atherosclerotic Plaque Matrix Metalloproteinase-2 Content Predicts Adverse Outcome in Patients Undergoing Endarterectomy
G. Gubbiotti, G. Isernia, E. Falcinelli, G. Guglielmini, M. Lenti, P. Gresele (Italy)

**ASY 13.3**
15:45 – 16:00
Vascular Matrix Metalloproteinase-9 Enhances Blood Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Thromboembolic Stroke
S. Singh, T. Zhao, A. Houn, S. Saleem, G. Reed (United States)

**ASY 13.4**
16:00 – 16:15
High Risk of Ischemic Stroke in Patients with Acute Pulmonary Embolism and Patent Foramen Ovale: Paradoxical Embolism Confirmed as an Important Mechanism. The EPIC FOP Prospective Multicentre Study (ClinicalTrials.gov Number NCT01216423)
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

136 137

Monday

16:15 – 16:45 Coffee break in Exhibition Halls

Plenary

16:45 – 17:30 Hall B

Kenneth M. Brinkhous Memorial Lecture: Hemophilia Therapy - From Disease to Cure
Chair: Ingrid Pabinger, Austria

16:45 – 17:30 PL 02 Hemophilia: From Royal Gene to Gene Therapy
H. Marijke van den Berg, the Netherlands

Oral Communications

17:45 – 19:00 Hall B

Gene Therapy for Hemophilia: Clinical
Chair: Robert Klamroth, Germany
Paul Monahan, United States

17:45 – 18:00 OC 13.1 SPK-9001: Adeno-associated Virus Mediated Gene Transfer for Haemophilia B Achieved Durable Endogenous Prophylaxis at Levels of Activity Sufficient to Achieve Significant Mean Reduction in Annual Bleeding and Infusions Rates in Preliminary Data from an On-going Phase 1/2a Trial
L. George1, A. Giermasz2, S. Sullivan3, J. Ducore4, J. Rasko1, J. Teitel1, C. Mcguinn2, A. Galvao1, B. Samelson-Jones1, R. Camire1, A. Luk1, F. Wright1, K. Wachtel1, M. Carr1, X. Anguela1, K. High1 (1United States, 2Australia, 3Canada)

18:00 – 18:15 OC 13.2 Updated Results from a Dose-escalation Study in Adults with Severe or Moderate-severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy: up to 1.5 Years Follow-up
W. Miesbach1, M. Toderici, K. Meijer2, M. Coppens2, P. Kampmann3, R. Klamroth1, R. Schutgens2, G. Castaman4, E. Seifried4, J. Schwaeble1, H. Bonig1, F. Cattaneo1, F. Leebeek2 (1Germany, 2the Netherlands, 3Denmark, 4Italy)

18:15 – 18:30 OC 13.3 An Analysis of Bleeding Rates and Factor IX Consumption in the Phase I/II BAX 335 Gene Therapy Trial in Subjects with Hemophilia B
J. Chapin1, H. Rotteinstein2, F. Scheifflinger2, P.E. Monahan1 (1United States, 2Austria)

18:30 – 18:45 OC 13.4 Immunogenicity and Efficacy of FIX-Padua in Distinct Canine Models of Severe Hemophilia B Following AAV Gene Therapy to Skeletal Muscle or Liver
B.J. Samelson-Jones, R.A. French, N.B. Martin, T.C. Nichols, R.M. Camire, V.R. Arruda (United States)

18:45 – 19:00 OC 13.6 Development of SHP654, a Highly Efficient AAV-based BDD-FVIII Gene Therapy Vector for Treatment of Hemophilia A
F.G. Falkner1, F. Horling1, J. Lengler1, M. Weiller1, J. Mayrhofer1, M. Turecek1, P.E. Monahan2, W. Hoelling1, H. Rotteinstein1, F. Scheifflinger1 (1Austria, 2United States)

17:45 – 19:00 A1

Anticoagulant Regulators (Protein C, TFPI, AT)
Chair: Esteban C. Gabazza, Japan
Anne Angelillo-Scherrer, Switzerland

17:45 – 18:00 OC 14.1 Revisiting Antithrombotic Therapeutics; Sculptin a Novel Class of Specific, Competitive, Reversible, Scissile and Tight Binding Inhibitor of Thrombin
A. Iqbal, M. Barbugiani Goldfeder, R. Marques-Porto, H. Asif, J. Gabriel de Souza, F. Faria, A.M. Chudzinski-Tavassi (Brazil)

18:00 – 18:15 OC 14.2 Study of the Antithrombin Folding through the N-glycosylation
S. Águila, G. Luengo-Gil, N. Bohdan, S. Espín, V. Vicente, J. Corral, J. Martinez Martínez (Spain)

18:15 – 18:30 OC 14.3 Palmitoylation of the Cytoplasmic Domain of Tissue Factor Regulates its Encryption, Mediated through Alteration in the Orientation of the Transmembrane Domain
C. Ettelaie, M. Collier, J. Greenman, A. Maraveyaa (United Kingdom)

18:30 – 18:45 OC 14.4 Characterization of the p.Arg393Cys Variant of Antithrombin. Extracellular Formation of Antithrombin-albumin Disulphide Linked Dimers through a Conformational Dependent Mechanism and Role in Thrombosis
M. Todoricci, M.E. de la Morena-Barrio, C. de Cos, A. Miñano, S. Espín, J. Padilla, V. Vicente, J. Corral (Spain)
**SCIENTIFIC PROGRAM**

**17:45 – 19:00**  
**OC 14.5**  
Involvement of Heparanase Procoagulant Domain in Bleeding and Wound Healing  
Y. Crispel, S. Ghanem, J. Attias, E. Peled, I. Kogan, B. Brenner, Y. Nadir  
(Israel)

**17:45 – 19:00**  
**OC 15.1**  
Proteolytic Activity of Single-chain Prekallikrein  
I. Ivanov, M.-F. Sun, A. Matafonov, D. Gailani (United States)

**18:00 – 18:15**  
**OC 15.2**  
The Proline Rich Domain of Factor XII Mediates Contact Activation  
C. Naudin¹, A. Di Gennaro¹, E.X. Stavrou², T. Renné¹ (¹Sweden, ²United States)

**18:15 – 18:30**  
**OC 15.3**  
Physiological Activation of Factor XII Occurs on the Platelet Surface in a Zinc-dependent Manner  
P. Bendapudi, K. DeCeunynck, S. Koseoglu, R. Bekendam, R. Flaumenhaft (United States)

**18:30 – 18:45**  
**OC 15.4**  
Neutralizing Blood-borne Polyphosphate In vivo Provides Safe Thromboprotection  
A. Di Gennaro¹, L. Labberton¹, E. Kenne¹, A.T. Long², K.F. Nickel², R.A. Rigg¹, J.S. Hernandez³, L. Butler¹, C. Maas³, E.X. Stavrou², T. Renné¹ (¹Sweden, ²Germany, ³United States)

**18:45 – 19:00**  
**OC 15.5**  
Essential role of High-molecular-Weight Kininogen in Endotoxemia  
A. Yang¹, B. Wang¹, Z. Xie¹, R.W. Colman², J. Dai², Y. Wu¹ (¹China, ²United States)

---

**Contact Pathway**

**Chairs:** Thomas Renne, Germany  
Alvin Schmaier, United States

**17:45 – 18:00**  
**OC 15.1**  
Proteolytic Activity of Single-chain Prekallikrein  
I. Ivanov, M.-F. Sun, A. Matafonov, D. Gailani (United States)

**18:00 – 18:15**  
**OC 15.2**  
The Proline Rich Domain of Factor XII Mediates Contact Activation  
C. Naudin¹, A. Di Gennaro¹, E.X. Stavrou², T. Renné¹ (¹Sweden, ²United States)

**18:15 – 18:30**  
**OC 15.3**  
Physiological Activation of Factor XII Occurs on the Platelet Surface in a Zinc-dependent Manner  
P. Bendapudi, K. DeCeunynck, S. Koseoglu, R. Bekendam, R. Flaumenhaft (United States)

---

**FVIII/IX**

**Chairs:** Koen Mertens, the Netherlands  
Mettine Bos, the Netherlands

**17:45 – 18:00**  
**OC 16.1**  
Expression Patterns of F8 Promoter-binding-TFs and F8 Promoter Methylation in Different Endothelial Cells  
M.A. Jamil, N. Nuesgen, J. Oldenburg, O. El-Maarri (Germany)

**18:00 – 18:15**  
**OC 16.2**  
Different N-glycosylation of Factor VIII: Similarities and Differences of Plasma Derived and Recombinant Factor VIII Products  
M. Malisauskas, J. Anzengruber, P. Bärnthaler, M. Feichtinger, F. Scheiflinger, B. Reipert (Austria)

**18:15 – 18:30**  
**OC 16.3**  
Factor VIII with 237 Amino Acids B-domain Has Extended Half-life in Mice  

**18:30 – 18:45**  
**OC 16.4**  
Altered Cleavage of Human Factor VIII at the B-domain and Acidic Region 3 Interface Enhances in vitro and in vivo Function  
G.N. Nguyen, C.M. Wood, D.E. Sabatino (United States)

**18:45 – 19:00**  
**OC 16.5**  
Probing Changes in Activated Factor VIII Upon Complex Formation with Activated Factor IX on Phospholipid Membranes  
J. van Galen, E.H.T.M. Ebberink, N. Freato, C. van der Zwaan, M.G. Boon-Spijker, K. Mertens, M. van den Biggelaar, A.B. Meijer (the Netherlands)

---

**Platelets in Thrombosis**

**Chairs:** Beate E. Kehrel, Germany  
Martine Jandrot-Perrus, France

**17:45 – 18:00**  
**OC 17.1**  
Convection Denied: Platelet Packing Density is an Independent Regulator of the Hemostatic Response to Injury  
**SCIENTIFIC PROGRAM**

**18:00 – 18:15**  
**OC 17.2**  
Platelet Margination and Activation Are Essential for Thrombus Propagation in an in vitro Model of Venous Thrombosis  
_**M. Lehmann, P. Krohl, K. Neeves (United States)**_

**18:15 – 18:30**  
**OC 17.3**  
Coactosin-like 1 is a Novel Regulator of Arterial Thrombosis and Hemostasis  
_**I. Birkholz, S. Stritt, B. Beck, K.G. Heinze, G. Krohne, B. Nieswandt (Germany)**_

**18:30 – 18:45**  
**OC 17.4**  
Clathrin-mediated Endocytosis is Required for Normal Platelet Hemostatic Function  
_**S. Giannini1, H.F.G. Heijnen2, K.M. Hoffmeister1, H. Falet1 (1United States, 2the Netherlands)**_

**18:45 – 19:00**  
**OC 17.5**  
Platelet-mediated Activation of FasR and Subsequent Phosphatidylinerse Exposure of Red Blood Cells is Substantial for Thrombus Formation and Hemostasis  
_**K.J. Krott, C. Klatt, S. Zey, N.S. Gowert, A. Oberhuber, M. Schaller, M. Kelm, H. Schelzig, M. Elvers (Germany)**_

**17:45 – 19:00**  
**A6**  
**Platelet Life Span and Clearance**  
**Chairs:** Karin M. Hoffmeister, _United States_  
Markus Bender, _Germany_

**17:45 – 18:00**  
**OC 18.1**  
Platelet GPIba Is Important for Liver Thrombopoietin (TPO) Production  
_**M. Xu1, G. Zhu1, J. Li1, N. Carrim1, S. Kunishima2, J. Ware2, Z. Ruggeni3, J. Freeman1, H. Ni1 (1Canada, 2Japan, 3United States)**_

**18:00 – 18:15**  
**OC 18.2**  
Intravital Microscopy Reveals Key Role of Kupffer Cells in Clearance of Desialylated Platelets  
_**C. Deppermann, P. Kubes (Canada)**_

**18:15 – 18:30**  
**OC 18.3**  
Twinfilin 2a Is a Central Regulator of Platelet Reactivity and Turnover in Mice  
_**L. Becker1, S. Stritt1, S. Beck1, T. Vogtle1, M. Hakaia1, K.G. Heinze1, X. Du2, M. Bender1, A. Braun1, P. Lappalainen2, B. Nieswandt1 (1Germany, 2Finland, 3United States)**_

**18:30 – 18:45**  
**OC 18.4**  
Investigating the Mechanisms of Clearance of Pre-activated Platelets in Mice Lacking Function of the Rap1 GAP Rasa3  
_**R.H. Lee1, C. Casari1, D.S. Paul1, L. Stefanini2, L.L. Peters1, W. Bergmeier1 (1United States, 2Italy)**_

**18:45 – 19:00**  
**OC 18.5**  
TNF-a is an Important Factor for Platelet Hyperreactivity in Aging  
_**P. Davison-Castillo1, S. Aguila2, K. Higa1, K.J. Ashworth1, G. Hernandez1, D. Bark1, R.A. Campbell1, M. Rondina1, J. DeGregori1, E.M. Pietras1, J. Di Paola1 (1United States, 2Ireland)**_

**17:45 – 19:00**  
**A7**  
**Thrombolysis in Disease**  
**Chairs:** Alessandro Casini, _Switzerland_  
Anetta Undas, _Poland_

**17:45 – 18:00**  
**OC 19.1**  
Fibrinolysis with Clot-specific Thrombin-cleavable Microplasminogen is a Potential Alternative to Plasminogen Activators  

**18:00 – 18:15**  
**OC 19.2**  
Coagulation Factor XIIIa Is Inactivated during Thrombolytic Treatment  
_**W. Hur, L. Machan, C. Kastrup (Canada)**_

**18:15 – 18:30**  
**OC 19.3**  
Fibrinolytic System Components Uniquely Affect the Resolution of Deep Vein Thrombosis: Comparison of α2-antiplasmin and Tissue Plasminogen Activator  
_**S. Singh, A. Houng, G. Reed (United States)**_

**18:30 – 18:45**  
**OC 19.4**  
CVD-risk Associated Lipid Levels Associate Not Only with Increased Fibrinogen Concentration but also with Altered Plasma Clot Properties in a Healthy Population  
_**Z. De Lange, B. Kahler, C.M. Smuts, M. Pieters (South Africa)**_

**18:45 – 19:00**  
**OC 19.5**  
Recombinant ADAMTS-4 Enhances tPA-mediated Fibrinolysis in Ischemic Stroke  
_**S. Martinez de Lizarrondo1, M. Pruvost1, A. Anfray1, C. Ali1, J. Montaner2, M. Rubio1, M. Gauberti1, D. Vivien1 (1France, 2Spain)**
XXVI ISTH Congress and 63rd Annual SSC Meeting

**SCIENTIFIC PROGRAM**

17:45 – 19:00 A8

### Immune Aspects of Venous Thrombosis

**Chairs:** Maria M. Aleman, United States
Johannes Thaler, Austria

17:45 – 18:00 OC 20.1
Contributions of Complement-Dependent Membrane Perturbations to Myeloid Cell TF Activation in Venous Thrombosis

18:00 – 18:15 OC 20.2
Deep Vein Thrombosis Suppresses Peripheral T Cell Effector Function
J. Prochaska, N. Luther, M. Brähler, A. Schulz, P. Wild, C. Becker (Germany)

18:15 – 18:30 OC 20.3
IFNγ Induces the Formation of NETs in Venous Thrombosis
F.-R. Bertin, S. Laurance, C. Lemarie, M. Blostein (Canada)

18:30 – 18:45 OC 20.4
Natural IgM Binding Oxidation-specific Epitopes Protect from Microvesicle-driven Thrombosis
G. Obermayer, T. Afonyushkin, F. Puhm, M. Schwameis, W. Schrottmaier, B. Jiitma, A. Assinger, C. Binder (Austria)

18:45 – 19:00 OC 20.5
Hemodynamic Force Triggers NETosis within Sterile Thrombotic Occlusions
S. Diamond, X. Yu (United States)

### Cancer Associated Thrombosis: Risk Prediction

**Chairs:** Alessandro Squizzato, Italy
Marc Carrier, Canada

17:45 – 18:00 OC 21.1
Development and External Validation of a Risk Assessment Model for Cancer-associated Venous Thromboembolism
I. Pabinger1, N. van Es2, G. Heinze3, F. Posch1, N. Kraaijpoel4, H.R. Büller2, C. Ay5, on behalf of the contributors to the Vienna Cancer and Thrombosis Study (CATS) and the Multinational Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism (MICA) (1Austria, 2the Netherlands, 3Italy, 4Mexico, 5France)

18:00 – 18:15 OC 21.2
Comparison of Risk Prediction Scores for Cancer-Associated Venous Thromboembolism: A Prospective Cohort Study
N. van Es1, M. Di Nisio2, G. Cesaran3, A. Kleinjan1, H.-M. Otten1, I. Mahé4, I.T. Wilts5, D.C. Twint1, E. Porreca2, O. Arrieta3, A. Stéphanian4, K. Smit1, M. De Tursi1, S.M. Bleker1, R. Nieuwland4, P.W. Kamphuisen1, P.M. Bossuyt1, H.R. Büller1 (the Netherlands, Italy, Mexico, France)

18:15 – 18:30 OC 21.3
External Validation of a Risk Score for Occult Cancer in Patients with Unprovoked Venous Thromboembolism: Results from an Individual Patient Data Meta-Analysis
N. van Es1, L. Bertoletti2, L. Jara-Palomares3, G. Le Gal4, H.-M. Otten1, A. Piccioli5, P. Religa6, R. Lecumberri7, V. Rieu8, M. Rondina9, M. Beckers10, P. Robin11, P. Prandoni5, M. Di Nisio12, P.M. Bossuyt1, H.R. Büller1, M. Carrier4, P.-Y. Salaun12 (the Netherlands, France, Spain, Canada, Italy, Sweden, United States, Belgium)

18:30 – 18:45 OC 21.4
External Validation of a Prognostic Score for Occult Cancer in Patients with Venous Thromboembolism
L. Jara-Palomares3, R. Otero1, D. Jimenez1, J.M. Praena-Fernandez2, C. Font1, C. Faigá1, S. Soler1, D. Riesco1, P. Verhamme1, M. Monreal1, RIETE Registry (Spain, Belgium)

18:45 – 19:00 OC 21.5
Thrombin Generation Predicts for Early Cancer Recurrence in Breast Cancer Patients Undergoing Post-surgical Adjuvant Therapy: A Prospective Study

### VWF: Functional Implications in Health and Disease

**Chairs:** Caterina Casari, France
Maria Alexandra Brehm, Germany

17:45 – 18:00 OC 22.1
CRISPR/Cas9-engineered VWF Knockout BOECs Have Increased Angiogenic Properties
M. Schillemans, M. Hofman, J. Westeneng, M. Fernandez-Borja, C. Margadant, R. Bierings (the Netherlands)
SCIENTIFIC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

18:00 – 18:15  OC 22.2  
Von Willebrand Factor Free-thiols Are Critical for Function under High Shear Stress  
H. O’Brien¹, S. Shapiro¹, F. Zhang², P. Henne¹, A. Doerr¹, M. Laffan¹, T. McKinnon¹ (¹United Kingdom, ²United States)

18:15 – 18:30  OC 22.3  
Mouse VWF Propeptide Regulates Platelet Thrombus Formation in vitro  
G. Rawley, C. Brown, C. Dwyer, J. Mewburn, C. Zhang, J.W. Dennis, D. Lillicrap (Canada)

18:30 – 18:45  OC 22.4  
Protein Kinase C Signaling Dysfunction in von Willebrand Disease Type 2B Platelets  
C. Casari¹, D.S. Paull², R.H. Lee², R. Piatt², O.D. Christophe¹, P.J. Lenting¹, C.V. Denis¹, W. Bergmeier² (¹France, ²United States)

18:45 – 19:00  OC 22.5  
Silent von Willebrand Factor Variant c.4146G>T (p.Leu1382=) Causes Type 1 von Willebrand Disease via Disruption of an Exonic Splice Enhancer Motif  
A.H. Mufti, N.H. Alyami, I.R. Peake, A.C. Goodeve, D.J. Hampshire (United Kingdom)

17:45 – 19:00  Helsinki 1

Hemophilia: Animal Models of Inhibitor Formation  
Chairs: David Scott, United States  
Paul Batty, United Kingdom

17:45 – 18:00  OC 23.1  
A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice  
S. Merlin¹, E. Borroni¹, V. Bruscaggin¹, W. Tulalamba¹, M. Chuah¹, V. Arruda¹, T. Vandenendriesche¹, M. Prat¹, A. Follenzi¹ (¹Italy, ²Belgium, ³United States)

18:00 – 18:15  OC 23.2  
Cellular and transcriptional immune profiling of early factor VIII responses in hemophilia A mice  
J.D. Lai¹, C. Hough¹, R. Hartholt¹, I. Peyron¹, D. Cartier¹, K. Nesbitt¹, B. Vidal¹, A. van Velzen², J. den Haan², J. Voorberg², D. Lillicrap¹ (¹Canada, ²the Netherlands)

18:15 – 18:30  OC 23.3  
Interleukin-6 Inhibition Reduces Factor VIII Inhibitor Formation in Factor VIII-deficient Mice  
M.R. Rollins, J.A. Taylor (United States)

18:30 – 18:45  OC 23.4  
Inhibition of the bruton’s tyrosine kinase alters the anti-FVIII memory B-cell response in mice with severe hemophilia A  
S. Delignat, J. Russick, B. Gangadharan, M. Ing, S. Kaveri, S. Lacroix-Desmazes (France)

18:45 – 19:00  OC 23.5  
Targeted Depletion of Gut Microbes Increases Factor VIII Inhibitor Development in Hemophilia A Mice  
J.L. Tarrant, M.C. Cornier, K. Nesbitt, C. Dwyer, C. Hough, D. Lillicrap (Canada)

17:45 – 19:00  Budapest

Hemorrhagic Disorders: Pediatric Aspects  
Chairs: Christoph Male, Austria  
Gili Kenet, Israel

17:45 – 18:00  OC 24.1  
Efficacy, Safety and Pharmacokinetics (PK) of Once-weekly Prophylactic (Px) Emicizumab (ACE910) in Pediatric (< 12 years) Persons with Hemophilia A with Inhibitors (PwHAwI): Interim Analysis of Single-arm, Multicenter, Open-label, Phase 3 Study (HAVEN 2)  
G. Young¹, J. Oldenburg², R. Liesner³, V. Jiménez-Yuste⁴, M.E. Mancuso⁵, T. Chang⁶, M. Uguen⁷, C. Dhalluin⁷, C. Schmitt⁷, S. Fuerst-Recktenwald⁷, M. Shima⁷, R. Kruse-Jarres¹ (¹United States, ²Germany, ³United Kingdom, ⁴Spain, ⁵Italy, ⁶Switzerland, ⁷Japan)

18:00 – 18:15  OC 24.2  
Non-neutralizing FVIII Antibodies after Successful ITI Influence FVIII Pharmacokinetics  
C. Heller, S. Schultze-Strasser, D. Stichel, A. Orlowski, D. Schwabe, C. Königs (Germany)

18:15 – 18:30  OC 24.3  
Intracranial Haemorrhage in Neonates with Haemophilia - Vaginal or Caesarean Section?  
N.G. Andersson¹, E. Chalmers², G. Kenet³, R. Ljung³, A. Mäkipernaa⁴, H. Chambost⁵, PedNet Group (¹Sweden, ²United Kingdom, ³Israel, ⁴Finland, ⁵France)

18:30 – 18:45  OC 24.4  
Thai Pediatric Bleeding Assessment Tool (BAT) for the Screening of Mild Bleeding Disorders  
S. Pakdeeto¹, R. Natesrimitkul¹, P. Komwilaisak¹, S. Arj-Ong Vallipakara¹, M. Rand², V. Blanchette², N. Sirachainan¹ (¹Thailand, ²Canada)
18:45 – 19:00  
OC 24.5  
Tranexamic Acid in Adolescent Girls with Heavy Menstrual Bleeding  
S. Saini, H. Ziegler, M. Christian-Rancy, S. Ahuja, K. Hege, S. Savelli, S. Vesely, S. O’Brien (United States)

17:45 – 19:00  
OC 25.1  
The Impact of Residual Pulmonary Obstruction on the Long-term Outcome of Patients with Pulmonary Embolism  
R. Pesavento, L. Filippi, P. Prandoni, for The Scope Investigators group (Italy)

18:00 – 18:15  
OC 25.2  
The Impact of Increased Systolic Pulmonary Artery Pressure on the Late Outcome of Patients with Pulmonary Embolism  
R. Pesavento, L. Filippi, P. Prandoni, for the Scope Investigators Group (Italy)

18:15 – 18:30  
OC 25.3  
High Sensitivity of a Non-invasive Screening Strategy for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism  

18:30 – 18:45  
OC 25.4  
Residual Vein Thrombosis and Serial D-Dimer for the Long-term Management of Patients with Deep Venous Thrombosis  
P. Prandoni, The Morgagni Investigators (Italy)

18:45 – 19:00  
OC 25.5  
Site and Mortality of Major Bleedings in Patients Treated with Individual Doacs  
L. Franco¹, C. Becattini², J. Beyer-Westendorf², R. Re¹, S. Espinoza Tofalos¹, C. Nitti¹, F. Pomero¹, L. Masotti¹, R. Cappelli¹, G. Manina¹, S. Cattinelli², G. Agnelli¹ (¹Italy, ²Germany)
SCIENTIFIC PROGRAM

Tuesday, July 11, 2017
Scientific Program

State of the Art

08:00 – 09:15

Novel Therapies for Hemophilia

Chairs: David Lillicrap, Canada
       Midori Shima, Japan

08:00 – 08:25 SOA 08.1
Gene Therapy Replacement
Katherine High, United States

08:25 – 08:50 SOA 08.2
Small Molecules in the Treatment of Hemophilia
Steven Pipe, United States

08:50 – 09:15 SOA 08.3
Nanobody Based Therapy
Peter Lenting, France

08:00 – 09:15

Stem Cell Engineering

Chairs: Erhard Seifried, Germany
        Toni Cathomen, Germany

08:00 – 08:25 SOA 09.1
System of 300B In Vitro Platelet Biogenesis From iPS Cells
Koji Eto, Japan

08:25 – 08:50 SOA 09.2
Megakaryocyte Matrix Interactions and Platelet Production
Alessandra Balduini, Italy

08:50 – 09:15 SOA 09.3
Large-Scale Production of Platelets: A Clinical Perspective
Cedric Ghevaert, United Kingdom

08:00 – 09:15

Novel Regulatory Mechanisms of Coagulation

Chairs: Elisabetta Castoldi, the Netherlands
        Edward M. Conway, Canada

08:00 – 08:25 SOA 10.1
Zymogen Transition of Clotting Factors - Therapeutic Potential
Rodney Camire, United States

08:25 – 08:50 SOA 10.2
FV-Short/TFPI/Protein S in Regulation of Coagulation
Björn Dahlbäck, Sweden

08:50 – 09:15 SOA 10.3
New Coagulant Mechanisms
John Griffin, United States

08:00 – 09:15

Coagulation Signaling

Chairs: Marvin T. Nieman, United States
        Agneta Siegbahn, Sweden

08:00 – 08:25 SOA 11.1
Biased Agonism of PAR Signaling in Infection
Laurent Mosnier, United States

08:25 – 08:50 SOA 11.2
PAR Signaling in Viral Infection
Nigel Mackman, United States

08:50 – 09:15 SOA 11.3
Homeostatic Effects of PAR Signaling
Berend Isermann, Germany
SCIENTIFIC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

08:00 – 09:15 A6

Current Pathophysiological Concepts of Thrombotic Microangiopathies

Chairs: Bernhard Lämmle, Germany
       Masanori Matsumoto, Japan

08:00 – 08:25 SOA 12.1
Pathophysiology of TTP and HUS
Johanna Kremer Hovinga, Switzerland

08:25 – 08:50 SOA 12.2
New Treatments of TTP
Spero Cataland, United States

08:50 – 09:15 SOA 12.3
TMA: Current Insight Into Clinical Manifestations
Elie Azoulay, France

08:00 – 09:15 A7

Platelets In Development and Vascular Integrity

Chairs: Denisa Wagner, United States
        Ulrich Walter, Germany

08:00 – 08:25 SOA 13.1
How Do Platelets Prevent Bleeding?
Bernhard Nieswandt, Germany

08:25 – 08:50 SOA 13.2
CLEC-2 and Podoplanin in the Regulation of Vascular Integrity
Lijun Xia, United States

08:50 – 09:15 SOA 13.3
Platelet and Vascular Integrity: Role of GP6 in Securing Inflamed Vessels
Benoît Ho-Tin-Noé, France

08:00 – 09:15 A8

Venous Thromboembolism: Have We Made Progress Since the Last Guidelines?

Chairs: Giancarlo Agnelli, Italy
        James Douketis, Canada

08:00 – 08:25 SOA 14.1
Incidence and Case Fatality Rates Related to VTE: Can They be (Further) Improved?
Suzanne Cannegieter, the Netherlands

08:25 – 08:50 SOA 14.2
Diagnosis of Pulmonary Embolism
Marc Righini, Switzerland

08:50 – 09:15 SOA 14.3
Antithrombotic Treatment
Patrick Mismetti, France

Oral Communications

09:30 – 10:45 Hall B

Late Breaking Abstract Session

Chairs: Johannes Oldenburg, Germany
        Sam Schulman, Canada

09:30 – 09:48 LB 01.1
Interim Results from a Phase 1/2 AAV5-FVIII Gene Transfer in Patients with Severe Hemophilia A
J. Pasi1, S. Rangarajan1, L. Walsh2, W. Lester1, D. Perry1, B. Madan1, H. Yu2, G.F. Pierce2, W.Y. Wong2 (1United Kingdom, 2United States)

09:48 – 10:06 LB 01.2
Evaluation of Safety and Establishment of a PK/PD Relationship of Concizumab in Hemophilia A Patients
H. Eichert1, P. Angchaisuksiri2, K. Kaan Kavakli2, P. Knoebel1, J. Windygga3, V. Jiménez-Yuste4, U. Friedrich2, A. Hyseni5, P. Chowdary6 (1Germany, 2Thailand, 3Turkey, 4Austria, 5Poland, 6Spain, 7Denmark, 8United Kingdom)
SCIENTIFIC PROGRAM

10:06 – 10:24  LB 01.3  The IDEAL DVT Study, Individualised Duration of Elastic Compression Therapy against Long-term Duration of Therapy for the Prevention of Post-thrombotic Syndrome: A Randomised Controlled Trial  
A.J. ten Cate-Hoek, the IDEAL DVT investigators (the Netherlands)

10:24 – 10:42  LB 01.4  Final Results of RE-VERSE AD Study: Reversal of Dabigatran by its Specific Reversal Agent Idarucizumab in Patients with Uncontrolled Bleeding or Requiring Urgent Surgery/Procedures  
C. Pollack1, P. Reilly1, J. van Ryn2, J. Eikelboom3, S. Glund4, R.A. Bernstein5, R. Dubiel1, M.V. Huismans6, E.M. Hylek3, C.-W. Kam5, P.W. Kamphuisen4, J. Kreuzer7, J.H. Levy1, G. Royle6, F.W. Sellke1, J. Stangier5, T. Steiner5, P. Verhamme6, B. Wang1, L. Young6, J.I. Weitz3 (1United States, 2Germany, 3Canada, 4Netherlands Antilles, 5Hong Kong, 6New Zealand, 7Belgium)

09:30 – 10:45  A1
Animal Models in Hemostasis  
Chairs: Peter L. Gross, Canada  
Mario Colucci, Italy

09:30 – 09:45  OC 26.1  A Novel Mouse Model of Carotid Artery Thrombosis for the Evaluation of Thrombolytic Therapies  
J. Maclean, A. Samson, S. Sturgeon, A. Tomkins, L. Ju, S. Jackson, S. Schoenwaeelder (Australia)

09:45 – 10:00  OC 26.2  Development of an Inducible Mouse Model for Factor X Deficiency  
O.D. Christophe, A. Hamieh, V. Muczynski, C. Loubière, C.V. Denis, P.J. Lenting (France)

10:00 – 10:15  OC 26.3  Gene-based FVIIa Prophylaxis Modulates the Spontaneous Bleeding Phenotype of Hemophilia A Rats  
S.M. Zintner1, J.C. Small1, M.J. Kjelgaard-Hansen2, B. Wiinberg2, P. Margaritis1 (1United States, 2Denmark)

10:15 – 10:30  OC 26.4  Distinct Pathogenesis of Cancer-associated Venous Thrombosis Identifies Tissue Factor-Phospholipid Interactions as Selective Antithrombotic Target in vivo  
K. Stark1, I. Schubert1, U. Joshi1, S. Pfeifer1, T. Schmiedegall1, S. Stockhausen1, N. Mackman2, B. Engelmann1, S. Massberg1 (1Germany, 2United States)

10:30 – 10:45  OC 26.5  Recombinant Destabilase-isopeptidase Stimulates Destruction of Preformed Cross-linked (Old) Thrombi in Rats  
S. Kalabushev, V. Lazarev, V. Manuvera, D. Akhaev, I. Baskova (Russian Federation)

09:30 – 10:45  A2
Platelets and Extracellular Compounds in Atherothrombosis  
Chairs: Françoise Dignat-George, France  
Philip Wenzel, Germany

09:30 – 09:45  OC 27.1  Hypertension Upregulates Tissue Factor Expression in Bone Marrow Megakaryocytes and in Circulating Platelets  

09:45 – 10:00  OC 27.2  Elevated Mean Platelet Volume is Associated with Lower Risk of Death in a General Population, but is a Predictive Marker of Death in Patients with History of Cardiovascular Disease  
M. Bonaccio, A. Di Castelnuovo, S. Costanzo, A. De Curtis, M. Persichillo, C. Cerletti, M.B. Donati, G. de Gaetano, L. Iacoviello, Moli-sani Study Investigators (Italy)

10:00 – 10:15  OC 27.3  Acute Phase Serotonin-mediated Neutrophil Trafficking is Independent of Endothelial Adhesion Molecules  
C. Schönichen1, F. Glatzki1, M. Mauler1, V. Ollivier2, N. Herr1, C. Starz1, D. Stallmann2, I. Ahrens1, C. Bode1, I. Hilgendorf1, B. Ho-Tin-Noé1, D. Duersschmied1 (1Germany, 2France)

10:15 – 10:30  OC 27.4  Circulating Microparticles in Cardiovascular Disease: Predictive Value in CABG Patency  

10:30 – 10:45  OC 27.5  Proteomic Analysis of Premature Myocardial Infarction Subjects Indicates Impairment in ‘Hedge Hog’ Signaling Protein DYNC2H1  
M. Ghatge, A. Sharma, R.K. Vangala (India)
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

09:30 – 10:45

**Coagulation and Cancer**

**Chairs:** Matthew Flick, United States
                  Henri Versteeg, the Netherlands

09:30 – 09:45  **OC 28.1**  Blocking of Tissue Factor Signaling in Breast Cancer Inhibits Tumor Metastasis  
                  B. Ünlü, B. Kocatürk, W. Ruf, H.H. Versteeg (the Netherlands, United States)

09:45 – 10:00  **OC 28.2**  Thrombin Cleavage of Osteopontin Plays an Important Role in Melanoma Growth and Progression  
                  S. Peraramelli, Q. Zhou, J. Kim, T. Myles, J. Morser, L. Leung (United States)

10:00 – 10:15  **OC 28.3**  Thrombin-PAR-1 Promotes Pancreatic Ductal Adenocarcinoma Through Tumor Cell Expression of Urokinase Plasminogen Activator and Receptor  
                  M. Flick, A. Smith, J. Palumbo, J. Luyendyk, Y. Yang, S. Konieczny (United States)

10:15 – 10:30  **OC 28.4**  Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor Metastasis  
                  A.S. Remiker, L.A. Rosenfeldt, G.N. Adams, M.J. Flick, M.D. Frederick, J.S. Palumbo (United States)

10:30 – 10:45  **OC 28.5**  Biomarkers of Inflammation and Coagulation in Long-term Survivors of an Adult Cancer - Results from the Gutenberg Health Study  
                  M. Panova-Noeva, A. Schulz, N. Arnold, M.I. Hermanns, J.H. Prochaska, D. Laubert-Reh, H.M. Sprengknecht, M. Blettner, T. Münzel (Germany, the Netherlands)

09:30 – 10:45

**Platelet Function in Inflammation**

**Chairs:** Yotis A. Senis, United Kingdom
                  Patricia Maguire, Ireland

09:30 – 09:45  **OC 29.1**  Platelet-dependent Leukocyte Adhesion and Fate in Whole Blood Thrombus Formation  

09:45 – 10:00  **OC 29.2**  The Contribution of Platelet Adhesion Receptors to Vascular Integrity during Inflammation Is Stimulus and Organ Dependent  
                  J. Rayes, L. Lax, N. Arnold, M.I. Hermanns, J.H. Prochaska, D. Laubert-Reh, H.M. Sprengknecht, M. Blettner, T. Münzel (Germany, the Netherlands)

10:00 – 10:15  **OC 29.3**  Human Endoglin as a Potential New Partner Involved in Platelet-Endothelium Interactions  

10:15 – 10:30  **OC 29.4**  VWF-Mediated Platelet ‘Priming’ Potentiates Novel Leukocyte Interactions under Flow  
                  A. Constantinescu-Bercu, I.I. Salles-Crawley, K.J. Woollard, J.T.B. Crawley (United Kingdom)

10:30 – 10:45  **OC 29.5**  Platelets Protect Cardiomyocytes from Ischaemic Damage  
                  T. Walsh, A. Poole (United Kingdom)

09:30 – 10:45

**Platelet Signaling 2**

**Chairs:** Jonathan Gibbins, United Kingdom
                  Paola van der Meijden, the Netherlands

09:30 – 09:45  **OC 30.1**  NOX2 as an Anti-thrombosis Target: Small Molecule Targeting of Rac1-p67phox Signaling Prevents NOX2 Mediated GPVI- and Non-GPVI Dependent ROS Generation and Platelet Activation  
                  H. Akbar, X. Duan, S. Saleem, A.K. Davis, Y. Zheng (United States)

09:45 – 10:00  **OC 30.2**  Evidence from Protein Kinase C δ Y155F Knock-in Mice Reveal Positive Regulatory Role of Y155 in GPVI-mediated Platelet Activation  
                  A. Patel, D. Bhavanasi, J. Kostyk, R. Turaga, R. Badolia, C. Dangelmaier, S. Kim, S. Kunapuli (United States)
**SCIENTIFIC PROGRAM**

10:00 – 10:15  
Implications of eNOS-signaling Heterogeneity within Human Platelets on Adhesion and Aggregation  
G. Lesyk, A. Radziwon-Balicka, P. Jurasz (Canada)

10:15 – 10:30  
Differential Roles of Paraoxonase-2 (PON2) and NADPH Oxidase-2 (NOX2) in Murine Platelets  
V. Petermann, J. Ebert, K. Jurk, S. Horke, I. Witte, H. Kleinert (Germany)

10:30 – 10:45  
Alox12 Regulates Syk in FcγRIIA and Integrin αIIbβ3 Signaling in Platelets  
S. Abraham, Y. Zhou, M. Whitley, J. Yeung, D.J. Maloney, T.R. Holman, M. Holinstat, S.E. McKenzie (United States)

09:30 – 10:45  
VWF: Mechanisms of Clearance  
Chairs: James O'Donnell, Ireland  
Peter Lenting, France

09:30 – 09:45  
L.L. Swystun1, K. Ogiwara1, A. Mufti2, C. Notley1, K. Nesbitt1, J. Eikenboom3, A. Goodeve2, S. Lai1, K. Schledzewski2, C. Géraud2, A.S. Paine1, C. Notley1, K. L. Nesbitt1, K. Schledzewski2, C. Géraud2, S. Goerdt1, W. Hopman1, R.R. Montgomery2, P.D. James1, D. Lillicrap1 (1Canada, 2Germany, 3the Netherlands)

09:45 – 10:00  
Genetic Footprint of Endothelial Cells in Chronic Thromboembolic Pulmonary Hypertension  
M.L. Bochenek, K. Saar, F. Marini, A. Gerhold-Ay, N. Hübner, T. Münzel, E. Mayer, S. Konstantinides, K. Schäfer (Germany)

10:00 – 10:15  
Genetic Associations with Recurrent Venous Thromboembolism: A Meta-analysis of Candidate SNPs in 4 Studies  
M. Blondon1, M. Germain1, S. Armasu2, A. van Hylckama Vlieg1, K. Wiggins2, P.-E. Morange3, F. Rosendaal2, D.-A. Tregouët3, M. de Andrade2, N. Smith2 (1Switzerland, 2United States, 3France)

10:15 – 10:30  
A New Genetic Risk Score for Predicting Venous Thromboembolism Events in Cancer Patients Receiving Chemotherapy  
A. Muñoz, I. Ortega, C. Font, V. Pachón, V. Castellón, V. Martínez, M. Salgado, E. Martínez, J. Calzas, J.C. Souto, E. Salas, J.M. Soria (Spain)
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

10:30 – 10:45 OC 32.5 Prothrombotic Genotypes and the risk of Major Bleeding Events in the First Year after Incident Venous Thromboembolism
H.S. Johnsen1, E. Bjørn1, K. Hindberg1, E.N. Smith1, F.R. Rosendaal1, S.K. Brækkan1, K.A. Frazer1, J.B. Hansen1 (‘Norway, ‘United States)

09:30 – 10:45 New York

Progress in Atrial Fibrillation Management
Chairs: Cihan Ay, Austria
Sabine Eichinger, Austria

09:30 – 09:45 OC 33.1 The Role of Time in Therapeutic Range on Bleeding Risk Prediction in Atrial Fibrillation Patients under Vitamin K Antagonist Therapy
J.M. Rivera-Caravaca1, F. Marín1, M.A. Esteve-Pastor1, M. Valdés1, V. Vicente1, G.Y.H. Lip1, V. Roldán1 (‘Spain, ‘United Kingdom)

09:45 – 10:00 OC 33.2 Persistence of Oral Anticoagulant Treatment for Atrial Fibrillation in the Netherlands: A Surveillance Study
W. Lijfering, M. Teichert, N. van Rein, F. Rosendaal, F.J.M. van der Meer, M. Huisman, S. Cannegieter (the Netherlands)

10:00 – 10:15 OC 33.3 Atrial Fibrillation, Stroke, and Mortality in Patients on Hemodialysis - Prospective Results of the Vienna InVestigation of Atrial Fibrillation and Thromboembolism in Hemodialysis Patients (VIVALDI)

10:15 – 10:30 OC 33.4 Direct Oral Anti-coagulants (DOACs) Are Associated with Decreased Mortality Compared to Warfarin among Hospitalized Patients with Non-valvular Atrial Fibrillation
A. Israel, Y. Schwarz, O. Salomon, Y. Sidi (Israel)

10:30 – 10:45 OC 33.5 Perioperative Outcomes of Direct Oral Anticoagulants vs. Warfarin in Atrial Fibrillation: A Meta-analysis of Phase III Trials
B. Nazha, B. Pandya, J. Cohen, M. Zhang, A.C. Spyropoulos (United States)

09:30 – 10:45 London

HIT
Chairs: Michael Nagler, Switzerland
Ulrich J. Sachs, Germany

09:30 – 09:45 OC 34.1 Platelet Factor 4: von Willebrand Factor Complexes: An Important Antigenic Target in Heparin-induced Thrombocytopenia?
I. Johnston, J. Lopez, D. Cines, L. Rauova, M. Poncz (United States)

09:45 – 10:00 OC 34.2 A New Mechanism of Autoimmune HIT Caused by a Subset of Antibodies
T.-H. Nguyen, N. Medvedev, M. Delcea, A. Greinacher (Germany)

10:00 – 10:15 OC 34.3 A Standardized Functional Assay for Routine Reliable HIT Diagnosis: A Potential Alternative to the Serotonin Release Assay
B. Tardy-Poncet, A. Montmartin, M. Piot, F. Akhalfioui, H. Maes, B. Tardy, GFHT-HIT Study Group (France)

10:15 – 10:30 OC 34.4 Soluble Glycoprotein VI (sGPVI) Measurement Is a Useful Biomarker of Platelet Activation in Heparin-induced Thrombocytopenia (HIT) and Correlates with Thrombotic Events

10:30 – 10:45 OC 34.5 Identification of Clinical Parameters for Heparin Induced Thrombocytopenia: An International Multicenter Prospective Study
B. Tardy1, E. De Maistre1, D. Lasne1, C. Fouplard1, M. Alhenc-Gelas1, A. Serre-Sapin1, C. Lavenu-Blombed1, J. Perrin1, F. Mullier1, M.-H. Horellou1, I. Elalamy1, T. Lecompte1, A. Greinacher1, B. Tardy-Poncet1, GFHT-HIT Study Group (’France, ’Belgium, ’Switzerland, ’Germany)

09:30 – 10:45 Helsinki 1

New Approaches in Research and Diagnostics
Chairs: Marguerite Neerman-Arbez, Switzerland
Barbara A. Konkle, United States

09:30 – 09:45 OC 35.1 Exome Sequencing as a First Tier Genetic Test for Hemostatic Diseases
W. van Heerde, A. Simons, S. Schoormans, S. Krouwel, M.R. Nijsiel (the Netherlands)
### Scientific Program

#### Tuesday

**09:45 – 10:00**

**OC 35.2**

A Role for Chromatin Architecture in the Expression of the Fibrinogen Gene Cluster  
C. Espitia, R.J. Fish, M. Neerman-Arbez (Switzerland)

**10:00 – 10:15**

**OC 35.3**

A Survey of F8 and F9 Variants in My Life, Our Future for Evidence of Alternative Splicing in Hemophilia  

**10:15 – 10:30**

**OC 35.4**

Development of an Antidote-controlled RNA Probe for Molecular Thrombi Imaging  
B. Powell Gray, K.-A. Steen-Burrell, B. Sullenger, Diagnostics and OMICs (United States)

**10:30 – 10:45**

**OC 35.5**

The Design of a Novel Catheter to Deliver and Monitor Heparin Anticoagulation Therapy: Validation in a Small Cohort  
J. Wang, J. Jokerst (United States)

---

**09:30 – 10:45**

**Helsinki 2**

**Acquired Bleeding Disorders and DIC**  
Chairs: Bernd Jilma, Austria  
Christine Kempton, United States

**09:30 – 09:45**

**OC 36.1**

Results from Italian Registry of Activated Prothrombin Complex Concentrate in Acquired Hemophilia A: The FAIR Study  

**09:45 – 10:00**

**OC 36.2**

Low Dose of aPCC as Short-term Prophylaxis after the End of Initial Treatment of Acquired Hemophilia a to Reduce Bleeding Recurrences: Data from the FAIR Registry  

**10:00 – 10:15**

**OC 36.3**

Blood Pump Hemocompatibility: in vitro and in vivo Evaluation of von Willebrand Factor Degradation  
P.A. Coghlan, Z. Azartash-Namin, J.R. Stanfield, T.A. Snyder, J.W. Long (United States)

**10:15 – 10:30**

**OC 36.4**

Relationship of Markers of Inflammation, Infection, and Endothelial Function to Mortality and Severity of Coagulopathy in Patients with Sepsis-associated DIC  
A. Walborn, P. Patel, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

**10:30 – 10:45**

**OC 36.5**

Angiopoietin-2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis Associated Coagulopathy  
S. Statz, A. Walborn, M. Williams, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

---

**09:30 – 10:45**

**Budapest**

**Hemophilia: Clinical Science**  
Chairs: Roger Schutgens, the Netherlands  
Margareth Ozelo, Brazil

**09:30 – 09:45**

**OC 37.1**

Influence of Phospholipid Configuration of APPT Reagents in the Diagnosis of Mild Haemophilia A with Discrepancy  
B. Gillet, M. Sigaud, M. Fouassier, C. Ternisien, M. Trossaert (France)

**09:45 – 10:00**

**OC 37.2**

Desmopressin in Hemophilia: The Need for a Clinical Response Definition and Individualized Test Regimen Based on FVIII:C Values One Hour after Infusion  

**10:00 – 10:15**

**OC 37.3**

The Role of Vascular Remodeling and Clotting Factor Thresholds in the Context of Hemophilic Joint Bleeding: Results from a Prospective Imaging Study in Patients with Hemophilia and Advanced Arthropathy  
10:15 – 10:30  
OC 37.4  
Development and Validation of the “Joint Activity and Damage Exam” (JADE) for Quantification of Structural Abnormalities by Musculoskeletal Ultrasound (MSKUS) in Hemophilic Joints: Intra- and Inter-rater Reliability  
L. Volland, J.Y. Zhou, R.F.W. Barnes, R. Kruse-Jarres, B. Steiner, D.V.G. Quon, C. Bailey, M. Brackman, E.Y. Chang, A. von Drygalski (United States)

10:30 – 10:45  
OC 37.5  
Evaluation of the Hemostatic Effect of the Combination of Factor Concentrate with Tranexamic Acid (TXA) in vitro Using Global Assays  
M. Janbain¹, J.C. Bordet², C. Leissinger¹, C. Negrier², Y. Dargaud² (¹United States, ²France)

09:30 – 10:45  
Future Therapies for Hemophilia and VWD  
Chairs: Alok Srivastava, India  
Jim Crawley, United Kingdom

09:30 – 09:45  
OC 38.1  
Correcting the Bleeding Phenotype in Hemophilia A Using Lentivirally FVIII-corrected Endothelial Cells Differentiated from Hemophilic Induced Pluripotent Stem Cells (iPSCs)  
C. Olgasi¹, S. Merlin¹, A. Lombardo¹, A. Raya², M. Messina¹, P.C. Schinco¹, A. Follenzi² (¹Italy, ²Spain)

09:45 – 10:00  
OC 38.2  
Inhibitory Nanobodies against Antithrombin Correct Thrombin Generation and Reduce Bleeding in FVIII-deficient Mice  
G. Ayme, C.V. Denis, A. Mohamadi, O.D. Christophe, P.J. Lenting (France)

10:00 – 10:15  
OC 38.3  
Exploring Chaperone-like Compounds as Innovative Therapeutic Strategy for Hemophilia B  
S. Pignani, M. Ferrarese, S. Lombardi, S. Marchi, A. Todaro, P. Pinton, F. Bernardi, M. Pinotti, A. Branchini (Italy)

10:15 – 10:30  
OC 38.4  
Development of Nanobodies Fused to Albumin Binding Peptide: A Tool to Increase Plasmatic Levels of Endogenous Proteins  
C. Kawecki, G. Ayme, C. Casari, P. Legendre, O.D. Christophe, P.J. Lenting, C.V. Denis (France)

10:30 – 10:45  
OC 38.5  
Development of a Gene Therapy Strategy for von Willebrand Disease Based on Dual Adeno-associated Virus Vectors  
E. Barbon, C. Kawecki, F. Collaud, M. Simon-Sola, S. Charles, O.D. Christophe, C.V. Denis, P.J. Lenting, F. Mingozzi (France)

09:30 – 10:45  
Berlin
### 15:15 – 15:30
**ASY 14.1**
Two Years versus Six Months of Oral Anticoagulation after a First Episode of Unprovoked Proximal Deep Vein Thrombosis: the PADIS DVT Multicenter, Double-blind, Randomized Trial (Clinical Trials. Gov Number NCT00740493)

### 15:30 – 15:45
**ASY 14.2**
Odds of Pharmacologic Prophylaxis by Venous Thromboembolism and Bleeding Risk Groups
S. Kaatz, D. Paje, A. Conlon, S. Bernstein, B. Almasri, P. Patel, G. Salem, M. Hettiarachchi, V. Hereford, M. Cerasale (United States)

### 15:45 – 16:00
**ASY 14.3**
VTE in Acute Leukemia: Improved Survival with Anticoagulation
T. Cox, M. Khan, W. Giao, M. Nassif, M. Alzubaidi, N. Garg, T. Go, C. Rojas-Hernandez (United States)

### 16:00 – 16:15
**ASY 14.4**
Incidence of Fatal Thromboembolic and Bleeding Events in over Ninety-Year-old Patients on Treatment with Oral Anticoagulants for Non-valvular Atrial Fibrillation
M. Giustozzi, M.C. Vedovati, M. Verso, P. Verdecchia, G. Bogliari, S. Conti, L. Pierpaoli, E. Marchesini, G. Agnelli, C. Becattini (Italy)

### 14:45 – 16:15
**A1**
**TAFI and Other Inhibitors of Fibrinolysis**
*Chairs:* Paul Kim, Canada
Dorien Leenaerts, Belgium

14:45 – 15:15
**ASY 15**
TAFI
Joost C.M. Meijers, the Netherlands

15:15 – 15:30
**ASY 15.1**
The Antithrombotic Protein C Activator E-WE Thrombin Supports Fibrinolysis by Inhibiting TAFI Activation
B. Markway, M. Wallisch, N. Verbout, C. Lorentz, M. Carris, O. McCarty, A. Gruber, E. Tucker (United States)

15:30 – 15:45
**ASY 15.2**
Plasminogen Activator Inhibitor 1 is Retained on the Surface of Activated Platelets in a αIIbβ3 and Fibrin Dependant Manner
G.B. Morrow, N.J. Mutch, C.S. Whyte (United Kingdom)

### 15:45 – 16:00
**ASY 15.3**
The Signaling Lipid Sphingosine-1-Phosphate (S1P) Regulates Expression and Secretion of the Plasminogen Activator Inhibitor-1 (PAI-1) in Differentiated Fat Cells
V. Witschel, A. Böhm, C. Joseph, E. Moritz, B.H. Rauch (Germany)

16:00 – 16:15
**ASY 15.4**
CPU Inhibition with AZD9684: Effects on Fibrinolytic Rate in Different in vitro Models
D. Leenaerts1, S. Loyau2, J.C. Mertens1, M. Jandrot-Perrus2, D. Hendriks1 (1Belgium, 2France)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session A3</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 14:45 – 15:00| ASY 17                           | Stem Cells, Heterogeneity, Differentiation and Reprogramming of Cells in the Vasculature  
Shahin Rafii, United States |
| 15:00 – 15:15| ASY 17.1                         | Vascular Endothelial Cells Derived from Human PAI-1 Deficient iPS Cells  
Reveal Physiological Functions of PAI-1 in Angiogenesis  
| 15:15 – 15:30| ASY 17.2                         | Perivascular Progenitor Cells Regulate the Balance between Regeneration vs. Fibrosis via PDGFRA Signalling  
M. Reyes Gil (United States) |
| 15:30 – 15:45| ASY 17.3                         | Co-injection of Mesenchymal Stem Cells with Endothelial Progenitor Cells Accelerates Muscle Recovery in Hind Limb Ischemia by an Endoglin-dependent Mechanism  
C. Goyard1, A. Cras1, B. Dizier1, N. Bacha1, A. Lokajczyk1, C.L. Guerin1, B. Planquette1, V. Mignon1, C. Bernabeu2, O. Sanchez2, D.M. Smadja1  
(1France, 2Spain) |
| 15:45 – 16:00| ASY 17.4                         | Thromboembolic Events in Patients with BCR-ABL1-negative Myeloproliferative Neoplasms Are Not Related to in vitro Endothelial Cells Adhesiveness Nor JAK2-V617F Expression  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session A5</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 14:45 – 16:15| ASY 18                           | Extracellular Nucleosomes and NETs in Thrombosis  
Tobias A. Fuchs, Germany |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session A6</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 15:15 – 15:30| ASY 18.1                         | Citrullinated Histone H3, a Biomarker of Neutrophil Extracellular Trap Formation, is Associated with Increased Risk of Venous Thromboembolism in Patients with Cancer  
L.-M. Mauracher1, J. Thaler1, F. Poschi1, K. Martinod2, E. Grilz1, T. Däullary1, L. Heil1, S. Koder1, C. Brostjan1, C. Zielinski1, C. Ay1, D.D. Wagner1, I. Pabinger1  
(1Austria, 2United States) |
| 15:30 – 15:45| ASY 18.2                         | Elucidation of the Role of Neutrophils in Human Pancreatic Cancer-associated Thrombosis Using a Humanized NSG Mouse Model  
M.-N. Fan, C.-T. Yen, T.-Y. Cheng, S.-F. Yang, Y.-L. Yang, S.-C. Chou, C.-Y. Chang, S.-W. Lin (Taiwan) |
| 15:45 – 16:00| ASY 18.3                         | Neutrophils Prothrombotic Characteristics during Myeloproliferative Neoplasms  
A. Guy, L. Deloison, V. Gourdon-Latyszenok, C. James (France) |
| 16:00 – 16:15| ASY 18.4                         | Mice Lacking the Novel Venous Thromboembolism Susceptibility Gene Slc44a2 Have Normal Hemostasis, but Reduced Fibrin Accumulation upon Vascular Injury  
J. Tilburg1, R. Adili2, T.S. Nair2, M.E. Hawley2, B.J.M. van Vlijmen1, D.C. Tuk1, H.M. Spronk1, M. Holinstat1, T.E. Carey2, C.X. Maracle1  
(1the Netherlands, 2United States) |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session A6</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 14:45 – 16:15| ASY 19                           | Platelets From Bench to Clinic  
Karlheinz Peter, Australia |
| 14:45 – 15:00| ASY 19                           | Novel Approaches to Target Platelets in Cardiovascular Disease  
Karlheinz Peter, Australia |
| 15:00 – 15:15| ASY 19.1                         | The Platelet COX-1 Knockout Mouse as a Model to Study the Effects of Aspirin in the Cardiovascular System  
M. Crescente1, P.C. Armstrong1, M.V. Chan1, J. Jiao2, C. Gaston-Massuet1, G.S. Cottrell1, N.S. Kirkby1, J.A. Mitchell1, H.R. Herschman1, T.D. Warner2  
(1United Kingdom, 2United States) |
15:15 – 15:30 ASY 19.2
Low Platelet Count is an Independent Risk Factor for Infection in Patients with Primary Immune Thrombocytopenia
A.J.G. Jansen1, M. Qu2, Q. Liu2, H.-G. Zhao2, J. Peng2, H. Ni3, M. Hou2 (1the Netherlands, 2China, 3Canada)

15:30 – 15:45 ASY 19.3
Increased Circulating T Follicular Helper Cells in Patients with Chronic Immune Thrombocytopenia
L. Dai, M. Zhu, X. Bai, Z. Wang, C. Ruan (China)

15:45 – 16:00 ASY 19.4
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Acquired TTP Patients
E. Roose1, G. Vidarsson2, O. Verhagen2, R. Visser2, M. Berkowska2, J. Caron1, I. Mancini1, L. Desender1, I. Pareyn1, N. Vandeputte1, A. Vandenbulcke1, M.-A. Azerad1, H. Deckmyn1, S.F. De Meyer1, F. Peyvandi1, K. Vanhoorelbeke1 (1Belgium, 2the Netherlands, 3Italy)

14:45 – 15:15 ASY 20
From Genes to Systems Biology
Kathleen Freson, Belgium

14:45 – 15:15 ASY 20.1
Mutations in Tropomyosin 4 Underlie a Rare Form of Human Macrothrombocytopenia

15:15 – 16:15 A8
Regulation of Coagulation
Chairs: Steven Lentz, United States
Bernd Pörtzsch, Germany

14:45 – 15:00 ASY 21
Aptamers Targeting Coagulation Factors
Bruce A. Sullenger, United States

15:00 – 15:15 ASY 21.1
Functional Characterization of Three Novel Activated Protein C (APC) Binding Aptamers
N. Shahidi Hamedani, S. Gasper, J. Oldenburg, J. Müller, B. Pörtzsch (Germany)

15:15 – 16:15 A8
Regulation of Coagulation
Chairs: Steven Lentz, United States
Bernd Pörtzsch, Germany

14:45 – 15:00 ASY 21.2
Inhibition of Activated Protein C Aspartyl Beta-hydroxylation Restricts Anticoagulant Function but Enhances Cytoprotective Signaling Activity
O. Willis Fox, E. Gleeson, H. Rushe, A. Rehill, R. Preston (Ireland)

15:30 – 16:00 ASY 21.4
Factor V-Short and Protein S as Synergistic TFPo cofactors
B. Dahlinbäck1, L.J. Guo1, R. Livaja-Koshti1, S. Tran1, R. Camire2 (1Sweden, 2United States)
14:45 – 16:15 New York

Women’s Issues in Venous Thromboembolism

Chairs: Fionnuala Ni Ainle, Ireland
Saskia Middeldorp, the Netherlands

14:45 – 15:15 ASY 22
Women’s Issues in Venous Thromboembolism
Shannon M. Bates, Canada

15:15 – 15:30 ASY 22.1
Sex-specific Incidence Rates of Deep Vein Thrombosis and Pulmonary Embolism in the Netherlands

15:30 – 15:45 ASY 22.2
Incidence Rate and Factors Influencing Occurrence of Unprovoked Venous Thrombosis during Long Term Period of Follow-up in Women with Previous Pregnancy Related Thromboembolism
J. Bodrozic, P. Miljic, D. Lekovic, M. Mitrovic, M. Gojnic Dugalic (Serbia)

15:45 – 16:00 ASY 22.3
Aspirin, Heparin or Both to Improve Live Birth in Women with Antiphospholipid Syndrome and Recurrent Pregnancy Loss
M.C. Marijnen, L.J.J. Scheres, S. Middeldorp (the Netherlands)

16:00 – 16:15 ASY 22.4
Induced Delivery and Neuraxial Anesthesia in Pregnant Women Using Thromboprophylaxis: Data from the Highlow Study
I. Bistervels, A. Buchmüller, S. Bleker, C. Chaulier, F. Ni Ainle, J. Donnelly, P. Verhammer, A.F. Jacobsen, H. Décosus, S. Middeldorp, for the Highlow investigators (the Netherlands, France, Ireland, Belgium, Norway)

14:45 – 16:15 London

Factor VIII Inhibitors in Congenital and Acquired Hemophilia

Chairs: H. Marijke van den Berg, the Netherlands
Andreas Tiede, Germany

14:45 – 15:15 ASY 23
Factor VIII Inhibitors in Congenital and Acquired Hemophilia
Peter Collins, United Kingdom

15:15 – 15:30 ASY 23.1
Product Type and the Risk of Inhibitor Development in Nonsevere Hemophilia A Patients
A. Van Velzen, C. De Groot-Eckhardt, M. Peters, J. Oldenburg, M. Cnossen, R. Liesner, M. Morfini, G. Castaman, S. McAra, R. Keenan, A. Van der Bom, F. Fijnvandraat, INSIGHT consortium (the Netherlands, Germany, United Kingdom, Italy, Australia)

15:30 – 15:45 ASY 23.2
Risk Factors for the Progression From Low- to High-titers In 260 Children with Severe Hemophilia A and Newly Developed Inhibitors
M.E. Mancuso, K. Fischer, E. Santagostino, L. Oldenburg, H. Platokouki, C. Königs, C. Escuriola-Ettingshausen, G.E. Rivard, A. Cid, M. Carcao, R. Ljung, P. Petrini, C. Altisent, G. Kenet, R. Liesner, K. Kurnik, G. Auerswald, H. Chambost, A. Mäkipernaa, A.C. Molinari, M. Williams, H.M. van den Berg (Italy, the Netherlands, Germany, Greece, Canada, Spain, Sweden, Israel, United Kingdom, France, Finland)

15:45 – 16:00 ASY 23.3
Antigen-specific Regulatory T Cells Generated by Factor VIII-CAR Retrovirus Transduction Suppress Anti-factor VIII Immune Responses
R.Y. Fu, M.J. Lyle, X. Cai, I. Khan, X. Wang, D.J. Rawlings, C.H. Miao (United States)

16:00 – 16:15 ASY 23.4
Stabilin-2 Deficiency or Competitive Inhibition Reduces Human FVIII Immunogenicity in a VWF-dependent Manner
J.D. Lai, L.L. Swystun, I. Georgescu, K. Nesbit, K. Schledzewski, C. Géraud, S. Goerd, D. Lillicrap, for ‘Canada, Germany"

14:45 – 16:15 Helsinki 1

Gene Editing and Cellular Therapy

Chairs: Koji Eto, Japan
Torsten Tonn, Germany

14:45 – 15:15 ASY 24
Gene Editing and Cellular Therapy
Toni Cathomen, Germany
15:15 – 15:30  ASY 24.1
Sequential Mesenchymal Stromal Cell Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplant: Results from a Multicenter Phase II Trial

15:30 – 15:45  ASY 24.2
Optimization of in vitro Megakaryocyte and Platelet Production by Inducible Overexpression of Supporting Factors
K. Cullmann, K. Blokland, A. Mucci, F. Schenk, K. Boller, S. Kohlscheen, L. Latorre, T. Moritz, N. Heinz, U. Modlich (Germany)

15:45 – 16:00  ASY 24.3
Endothelial and Cancer Cell Gene Silencing by Platelet-vehiculated siRNAs
M. Malvestiti, G. Manni, A. Marturano, L. Bury, P. Gresele (Italy)

16:00 – 16:15  ASY 24.4
Targeting Peripheral Blood Mononuclear Cells to Activated Platelets Preserves Cardiac Function after Ischemia-reperfusion Injury
M. Ziegler, X. Wang, B. Lim, E. Leitner, V. Ching, K. Alt, H. Kiriazis, C.E. Hagemeyer, I. Ahrens, K. Peter (Australia)

14:45 – 16:15  Helsinki 2
Microparticles
Chairs: Leonard Edelstein, United States
Alain Brisson, France

14:45 – 15:15  ASY 25
The Diversity of Extracellular Vesicles
Eric Boilard, Canada

15:15 – 15:30  ASY 25.1
Microparticles as a Biomarker to Detect Thrombosis in Patients with Implanted Ventricular Assist Devices
T. Torres, J. Walenga, B. Menapace, E. Cogliansese, W. Jeske, E. Kumar, V. Escalante, J. Schwartz, M. Bakhos (United States)

15:30 – 15:45  ASY 25.2
Inflammatory Activities of rRNA-containing Microparticles from Mast Cells
A.-K. Esemüller, V.Y. Tomalla, K.T. Preisssner, S. Fischer (Germany)
16:00 – 16:15
Haemostatic Monitoring and Thresholds for Blood Product Replacement Therapy during Treatment of Acute Lymphoblastic Leukaemia in Children and Young People Vary between Centres in the UK

16:15 – 16:45
Coffee break in Exhibition Halls

Plenary

16:45 – 17:30
Hall B
Hanns Gotthard Lasch Plenary Lecture: Management of Thromboembolism
Chairs: Stavros Konstantinides, Germany

16:45 – 17:30
PL 04
Treatment of Venous Thromboembolism in 2017
Harry Büller, the Netherlands

Oral Communications

17:45 – 19:00
Hall B
Extending Anticoagulation: Benefits Versus Risks
Chairs: Pantep Angchaisuksiri, Thailand
Marianne Brodmann, Austria

OC 39.1
Long-term Risk of Recurrent Venous Thromboembolism with and without Effective Antithrombotic Therapy
M.H. Prins1, A.W.A. Lensing2, P. Prandoni3, J. Beyer-Westendorf4, B. van Bellien4, A.F. Pap5, M. Gebel2, P. Verhamme6, P.S. Wells4, J.I. Weitz7 (1the Netherlands, 2Germany, 3Italy, 4Brazil, 5Belgium, 6Canada)

OC 39.2
External Validation of the DASH Prediction Model: The TRIP (Thrombosis Research Italian Partnership) Collaboration

OC 39.3
Extended Anticoagulation with Two Doses of Rivaroxaban (20 mg and 10 mg) for Preventing Recurrent Venous Thromboembolism: A Benefit-risk Analysis of EINSTEIN CHOICE
J.I. Weitz1, A.W.A. Lensing2, P.S. Wells1, M. Gebel1, A.F. Pap5, M. Homerling2, J. Beyer-Westendorf4, H. Bounamaeux7, P. Prandoni4, M.H. Prins6 (1Canada, 2Germany, 3Switzerland, 4Italy, 7the Netherlands)

OC 39.4
Prediction of Major Bleeding (MB) Risk in 2514 High Recurrence Risk Venous Thromboembolism Patients Treated Beyond 3 to 6 Months with Oral Anticoagulation Therapy (OAT)
P. Wells7, M. Rodger1, M. Kovacs1, D. Anderson1, S. Kahn1, S. Solyomoss1, C. Kearon1, V. Shah7, D. Keeling1, I. Chagnon1, R. Zide2, M. Carrier1, R. Mallick1, D. Corsi1, G. Le Gal1, S. Schulman1, S. Kaatz2 (1Canada, 2United States, 1United Kingdom)

OC 39.5
External Validation of the VTE-BLEED Score for Predicting Major Bleeding in Stable Anticoagulated Patients with Venous Thromboembolism
F.A. Klok, S. Barco, S. Konstantinides (Germany)

17:45 – 19:00
A1
Intrinsic Coagulation Pathway
Chairs: Cihan Ay, Austria
Jens Müller, Germany

17:45 – 18:00
OC 40.1
Cleaved Kininogen as a Biomarker for Bradykinin Production
Z. Liu, M. Hofman1, S. de Maat1, C. Suffritti2, C.L.R. van Doorn1, D. Csuka3, A. Zanichelli1, N. Vesel1, G. Pasterkamp1, T. Renné1, M. Cicardi2, H. Farkas1, E. Hack1, C. Maas1 (1the Netherlands, 2Italy, 3Hungary, 4Sweden)

18:00 – 18:15
OC 40.2
The Pharmacokinetic Profiles of Intravenously and Subcutaneously Administered Recombinant Factor IX Fc-XTEN in Cynomolgus Monkeys
A. van der Flier, A. Ismail, N. Moore, Z. Liu, S. Bardan, L. Kurt, B. Yang, C. Liu, V. Schellenberger, J. Salas, R. Peters (United States)

18:15 – 18:30
OC 40.3
Activated FXI Regulates the Catalytic Activity of ADAMTS13 by Removing the CUB Domains
18:30 – 18:45  OC 40.4  
A Small-Molecule and Direct Inhibitor of Factor Xia Provides Strong Antithrombotic Activity with Low Bleeding in Non-Human Primate Model of Arterial Thrombosis  
P. Wong, M. Quan, C. Watson (United States)

18:45 – 19:00  OC 40.5  
New Implications of the Deleterious Role of Furin Processing on Factor VIII Biology  
B.J. Samelson-Jones, J.J. Siner, T.V. Daniel, V.R. Arruda (United States)

17:45 – 19:00  A2  
Novel Pathways in Atherosclerosis  
Chairs: Elena Tremoli, Italy  
Katerina Akassoglou, United States

17:45 – 18:00  OC 41.1  
Role of Endothelial NF-κB Signalling in Atherosclerosis  
M. Mussbacher, M. Salzmann, H. Volek, M. Kuttke, B. Hoesel, J. Basilio, A. Assinger, J. Schmid (Austria)

18:00 – 18:15  OC 41.2  
Autophagy Is Required for Endothelial Cell Alignment and Atheroprotective Signaling Under Physiological Blood Flow  
A.-C. Vion¹, M. Kheloufi¹, A. Hammoutene¹, J. Poisson¹, J. Lasselin¹, C. Devue¹, I. Pic¹, N. Dupont¹, J. Busse², K. Stark², J. Lafaurie-Janvore³, A. Barakat³, X. Loyer³, M. Souyri³, B. Viollet³, P. Julia³, A. Tedgui³, P. Codogno³, C.M. Boulanger³, P.-E. Rautou³ (¹France, ²Germany)

18:15 – 18:30  OC 41.3  
Immune Regulation by Oral Tolerance Induces Alternative Activation of Macrophages and Reduces Markers of Plaque Vulnerability in Apobtm2Sgy/Ldlrtm1Her/J Mice  
L.N.R. Thota, L. Mundkur, T. Ponnusamy, R.K. Vangala (India)

18:30 – 18:45  OC 41.4  
IL-33 Stimulates the Release of Procoagulant Microvesicles from Human Monocytes and Differentially Increases Tissue Factor in Human Monocyte Subsets  
S. Siojkovic¹, A. Thulin², L. Hell¹, B. Thaler¹, S. Rauscher¹, J. Baumgartner¹, M. Gröger¹, C. Ay¹, S. Demyanets¹, C. Neumayer¹, I. Huk¹, A. Spittler¹, K. Huber¹, A. Siegbahn², J. Wojta¹, M. Åberg² (¹Austria, ²Sweden)

18:45 – 19:00  OC 41.5  
Mir-146a from the Hematopoietic Compartment is Not Involved in Atherosclerosis Development Despite Provoking an Increased Inflammation and NET Formation  
A.B. Arroyo Rodríguez, A. del Monte, A.M. De los Reyes García, N. García Barberá, M.S. Caleprico, M.J. Andrés Manzano, V. Roldán, R. Teruel Montoya, V. Vicente, R. González Conejero, V. Andrés, C. Martínez (Spain)

17:45 – 19:00  A3  
Innate Immune Cells  
Chairs: Bjarne Osterud, Norway  
Silvio Antoniak, United States

17:45 – 18:00  OC 42.1  
Functional Characterization of Characterization of RIG-I Like Receptors (RLRs) in Megakaryocytes and Platelet  
D. Pandey, C. Heuer, J. Tossounidis, S. Endres, S. Rothenfusser (Germany)

18:00 – 18:15  OC 42.2  
SERPINE2 Expression and Function in Neutrophils  
K. Aymonnier, L. Venisse, Y. Boulaftali, V. Arcas, M.-C. Bouton (France)

18:15 – 18:30  OC 42.3  
Biophysical Regulation of Leukocyte Recruitment by the 3-Dimentional Structure of Platelet Thrombi  
I. Alwis, Y. Yuan, Z. Kaplan, F. Tovar-Lopez, W. Nesbitt, A. Ju, S. Jackson (Australia)

18:30 – 18:45  OC 42.4  
Plasmin and Plasminogen Induce Macrophage Reprogramming and Regulate Key Steps of Inflammation Resolution via Annexin A1  
M. Sugimoto¹, A.L.C. Ribeiro¹, B. R. C. Costa¹, J. P Vago¹, K. Maciel Lima¹, F. S Carneiro¹, M. Maira O. Ortiz¹, G. L. Negreiros Lima¹, A. A. F. Carmo¹, R. M. Rocha¹, D. A. Perez¹, A. C Reis¹, V. Pinho¹, L. A Miles², C. C Garcia¹, M. M Teixeira¹, L. P Sousa¹ (¹Brazil, ²United States)

18:45 – 19:00  OC 42.5  
Alternative Proteolytic Activation of Human Prothrombin by a Bacterial Serine Protease  
G. Pontarollo, L. Acquasaliente, D. Peterle, I. Artusi, V. De Filippis (Italy)
### XXVI ISTH Congress and 63rd Annual SSC Meeting

#### SCIENTIFIC PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45 – 19:00</td>
<td>A5</td>
<td>Coagulation Proteins Beyond Hemostasis</td>
<td>J. Evan Sadler, United States</td>
<td>B.M. Mohammed, Q. Cheng, A. Matafonov, C. Puy, A. Gruber, O.J.T. McCarty, D. Gallani (United States)</td>
</tr>
<tr>
<td>17:45 – 18:00</td>
<td>OC 43.1</td>
<td>A Non-circulating Pool of Factor XI</td>
<td>B.M. Mohammed, Q. Cheng, A. Matafonov, C. Puy, A. Gruber, O.J.T. McCarty, D. Gallani (United States)</td>
<td></td>
</tr>
<tr>
<td>18:00 – 18:15</td>
<td>OC 43.2</td>
<td>Complex Formation with Pentraxin-2 Regulates Factor X Plasma Levels and Macrophage Interactions</td>
<td>V. Muczynski, G. Aymé, V. Regnault, M. Vasse, D. Borgel, P. Legendre, A. Baza, A. Harel, C. Loubière, P.J. Lenting, C.V. Denis, O.D. Christophe (France)</td>
<td></td>
</tr>
<tr>
<td>18:15 – 18:30</td>
<td>OC 43.3</td>
<td>Role of the Thrombomodulin - Endothelial Protein C Receptor System in New Vessel Formation Following Ischemia</td>
<td>M.L. Bochenek, J. Orth, S. Reyda, H. Spronk, T. Münzel, W. Ruf, K. Schäfer (Germany, the Netherlands)</td>
<td></td>
</tr>
<tr>
<td>18:30 – 18:45</td>
<td>OC 43.4</td>
<td>Protective Function of Tissue Factor in Diabetic Nephropathy</td>
<td>J. Maneharan, S. Ghosh, M.M. Al-Dabet, K. Shahzad, B. Isermann (Germany)</td>
<td></td>
</tr>
<tr>
<td>18:45 – 19:00</td>
<td>OC 43.5</td>
<td>Factor XII Protects Neurons from Serum Deprivation-induced Apoptosis</td>
<td>S. Martinez de Lizarondo, E. Garnier, C. Ali, A. Cheville, D. Vivien, F. Docagne (France)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45 – 19:00</td>
<td>A6</td>
<td>Megakaryopoiesis and Platelet Biogenesis In Vivo</td>
<td>Paquita Nurden, France</td>
<td>D. Stegner, J.M.M. van Eeuwijk, O. Angay, M. Gorelashvili, J. Pinnecker, H. Schulze, B. Nieswandt, K.G. Heinze (Germany)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 – 18:15</td>
<td>OC 44.2</td>
<td>Rap1α/β Isoforms Differentially Regulate Megakaryocyte Biology</td>
<td>D. Ghalloussi, E. O'Shaughnessy, D.S. Paul, K. Hahn, R. Piatti, L. Stefanini, R.H. Lee, K. Eto, W. Bergmeier (United States, Italy, Japan)</td>
<td></td>
</tr>
<tr>
<td>18:30 – 18:45</td>
<td>OC 44.4</td>
<td>Megakaryocyte-Specific Sin1 Deficiency Leads to Thrombocytopenia and Defective Platelet Activation in Thrombosis and Myocardial Infarction</td>
<td>C. Xue, Y. Xu, L. Zhang, K. Wang, J. Liu (China)</td>
<td></td>
</tr>
<tr>
<td>18:45 – 19:00</td>
<td>OC 44.5</td>
<td>CK2β Deficiency Results in Severe Macrothrombocytopenia due to Premature Megakaryocyte Fragmentation</td>
<td>P. Münger, B. Walker-Allgaier, S. Geue, D. Eißler, D. Stegner, D. Semeniak, M. Chatterjee, L. Quintanilla-Martinez de Fend, D. Litchfield, F. Lang, B. Nieswandt, H. Schulze, M. Gawaz, O. Borst (Germany, Canada)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45 – 19:00</td>
<td>A7</td>
<td>Platelet Antagonists</td>
<td>Karlheinz Peter, Australia</td>
<td>T. Voegtle, United Kingdom</td>
</tr>
<tr>
<td>18:00 – 18:15</td>
<td>OC 44.2</td>
<td>Pharmacological Characterization of the Functional Role of Calcium-activated Potassium Channels in Platelets</td>
<td>V. Back, G. Lesyk, F. Plane, P. Juras (Canada)</td>
<td></td>
</tr>
</tbody>
</table>
### SCIENTIFIC PROGRAM

#### XXVI ISTH Congress and 63rd Annual SSC Meeting

#### 18:15 – 18:30
**OC 45.3**
Pharmacological Inhibition of the Class II PI3K, PI3KC2α, Provides Marked Anti-thrombotic Effects in Mice and Humans via a Unique Anti-platelet Mechanism  
M. Selvadurai, M. Moon, S. Mountford, Z. Zheng, I. Jennings, P. Thompson, J. Hamilton (Australia)

#### 18:30 – 18:45
**OC 45.4**
Quercetin and its Metabolites Inhibit Platelet Function and Thrombus Formation both in vitro and in vivo, and Combine with Aspirin to Increase Anti-platelet Effects  
A. Stainer, L. Holbrook, P. Sasikumar, A. Bye, A. Unsworth, J. Lovegrove, M. Tindall, J. Gibbins (United Kingdom)

#### 18:45 – 19:00
**OC 45.5**
Putative, Novel Mechanisms of Action for Citalopram-induced Platelet Inhibition  
H.G. Roweth, N. Fowler, A. Chauhan, N. Habib, S.O. Sage, R.W. Farndale, G.E. Jarvis (United Kingdom)

#### 17:45 – 19:00  
**A8**
Cancer Associated Thrombosis

**Chairs:** Marina Marchetti, Italy  
Florian Langer, Germany

#### 17:45 – 18:00
**OC 46.1**
Combined Effects of GP6 rs1613662 and Pre-cancer Platelet Count on the Risk of Cancer-related Venous Thromboembolism  
H. Skille1, O.V. Gran1, E.N. Smith2, T. Solomon3, S.K. Braekkan1, F.R. Rosendaal1, K.A. Frazer1, J.-B. Hansen1 (1Norway, 2United States)

#### 18:00 – 18:15
**OC 46.2**
Incidence and Risk Factors for Central Venous Catheter-related Venous Thromboembolism in Breast Cancer Patients under (Neo)adjuvant Chemotherapy: The CAVecCAs Study  
P. Debourdeau, M. Espié, S. Chevret, J. Gligorov, A. Elias, P.F. Dupré, J. Lelong, S. Lavau-Denes, P.Y. Dubois, M.A. Sevestre, L. Bastit, I. Kalidi, S. Villiers, A. Hij, S. Giachetti, C. Frede, D. Farje (France)

#### 18:15 – 18:30
**OC 46.3**
Statin Use and Venous Thromboembolism in Cancer: A Large, Propensity Score Matched Cohort Study in the United States  
J. Brown, S. El-Refaei, V. Adams, P. Black, J. Talbert (United States)

#### 18:30 – 18:45
**OC 46.4**
Arterial Thromboembolism in Patients with Cancer: Frequency, Risk Factors and Mortality  
E. Grilz, O. Köngisbrügge, F. Posch, I. Lang, I. Pabinger, C. Ay (Austria)

#### 18:45 – 19:00  
**OC 46.5**
Effect of Low Molecular Weight Heparin on Survival of Patients with Resected Non-small Cell Lung Cancer: The Tinzaparin in Lung Tumors (TILT) Randomized Phase III Trial  

#### 17:45 – 19:00  
**A8**
New York

**Factor VIIIa Mimetic Drugs: Pharmacodynamics and Monitoring**

**Chairs:** John Pasi, United Kingdom  
Pier Mannuccio Mannucci, Italy

#### 17:45 – 18:00
**OC 47.1**
Pharmacodynamic Data and Coagulation Biomarkers in Persons with Hemophilia A (PwHA) with Inhibitors: Results from the HAVEN 1 Emicizumab (ACE910) Phase 3 Study  
J.I. Adamkewicz1, C. Schmitt2, A. Calatzis2, G. Young1, C. Negrier3, M. Callaghan1, J.M. Venstrom1, E. Askanius1, G. Levy1, B. Kim1 (1United States, 2Switzerland, 3France)

#### 18:00 – 18:15
**OC 47.2**
Synergistic Interplay of A Sequence Identical Analog of ACE910, a Bispecific Antibody, and a Bypassing Reagent and its Components  
R. Hartmann1, T. Feenstra1, S. Knappe1, L.A. Valentino5, F. Scheiflinger1, M. Dockal1 (1Austria, 2United States)

#### 18:15 – 18:30
**OC 47.5**
Identification of FIXa- and FX-specific Antibodies for the Generation of Bispecific Antibodies with FVIIIa-like Activity  

#### 18:30 – 18:45
**OC 47.4**
Mode of Enhancement in the Global Hemostatic Potentials with Concomitant Use of Bypassing Agents and Emicizumab in Hemophilia A Patients with Inhibitor Evaluated by ROTEM  
K. Yada, K. Nagomi, T. Kitazawa, K. Hattori, M. Shima (Japan)
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

18:45 – 19:00  OC 47.3
Challenges in Quantifying FVIIIa-mimetic Bispecific Antibody Activity Relative to FVIII for Hemophilia A Treatment
A. Goodman, D. Rabinovich, M. Aleman, E. Kistanova, B. Pearse, N. Leksa, R. Peters (United States)

17:45 – 19:00  London
Thrombophilia
Chairs: Sigrid Braekkan, Norway
Paul Kyrle, Austria

17:45 – 18:00  OC 48.1
Venous Thromboembolism Risk Assessment in 2214 Relatives from 651 Families with Known Thrombophilia Defects
P. Suchon, M. Ibrahim, A. Robin, N. Resseguijer, M.-C. Barhet, D. Brunet, N. Saut, M.-C. Alessi, D.A. Trégouët, P.E. Morange (France)

18:00 – 18:15  OC 48.2
Coagulation Factor 12 and the Risk of Recurrent Venous Thromboembolism: A Prospective Cohort Study
L. Eischer, S. Eichinger, P. Kyrle (Austria)

18:15 – 18:30  OC 48.3
Indications and Outcomes after IVC Filter Insertion for Primary Prophylaxis of Pulmonary Embolism: A Population-based Cohort Study
M. Gurney, A. Ashrani, D.M. Petterson, D.J. Crusan, K.R. Bailey, J.A. Heit (United States)

18:30 – 18:45  OC 48.4
Derivation and Validation of a Prognostic Model for VTE Development in Outpatients Setting: A Nested Case-control Study
M. Dentali, A. Fontanella, G. Gussoni, M. Campanini, G. Agnelli, F. Lapi, FADOI-SIMG (Italy)

18:45 – 19:00  OC 48.5
Increased Incidence of Venous Thromboembolism in Californians with Severe Asthma
A. Mahajan, A. Brunson, B. Kuhn, T. Keegan, T. Wun (United States)

17:45 – 19:00  Helsinki 1
Management of Bleeding and Trauma
Chair: Wolfgang Korte, Switzerland
Jerrold Levy, United States

17:45 – 18:00  OC 49.1
VKA-related Major Bleeding in VTE Patients is Associated with a High Mortality Rate and is Rarely Treated with Prohemostatic Agents: Results from the RIETE Registry

18:00 – 18:15  OC 49.2
Hypofibrinolysis on ROTEM Early after Traumatic Injury Represents a Heterogenous Group with Significant Variation in Both Fibrinolytic Activity and Mortality
L.S. Gall, K. Brohi, C. Gaarder, J.C. Goslings, N.P. Juffermans, M. Maegle, P.I. Johansson, R.A. Davenport, on behalf of the International Trauma Research Network (INTRN) (1United Kingdom, 2the Netherlands, 3Germany, 4Denmark)

18:15 – 18:30  OC 49.3
Data-driven ROTEM and TEG Algorithms for the Management of Trauma Haemorrhage

18:30 – 18:45  OC 49.4
Management of Hemorrhage Using Self-propelling Particles to Deliver Thrombin or Tranexamic Acid

18:45 – 19:00  OC 49.5
A Chimeric Factor VIIa Molecule Shows Reduced Thrombogenicity in Animal Models
D. Stafford, B. Cooley, W. Bergmeier, Y. Boulaftali, D. Feng, V. Zachary, R. Jenny, D. Monroe, M. Griffith (1United States, 2France)
### Helsinki 2

#### 17:45 – 19:00

**Hemophilia: Basic Science**

**Chairs:** Kathleen P. Pratt, *United States*  
Jan Voorberg, *the Netherlands*

17:45 – 18:00  
**OC 50.1**  
Modulation of F8 Secretion by Autophagy Related Proteins  

18:00 – 18:15  
**OC 50.2**  
Clustered F8 Missense Mutations Cause Hemophilia A Phenotypic Heterogeneity by Combination of Altered Splicing, Protein Secretion and Activity  
I. Donadon¹, J. McVey², I. Garagiola¹, M. Mortarino¹, A. Branchini¹, F. Peyvandi¹, F. Bernardi¹, M. Pinotti¹ (*Italy, 2United Kingdom*)

18:15 – 18:30  
**OC 50.3**  
Vascular Remodeling in Hemophilic Arthropathy is Exacerbated by Defective TAFIa-mediated Inactivation of SDF1α (CXCL12)  
T.L. Wyseure¹, J.Y. Zhou¹, E.J. Cooke¹, P.J. Declerck², J.C.M. Meijers³, A. von Drygalski¹, L.O. Mosnier¹ (*United States, 2Belgium, 3the Netherlands*)

18:30 – 18:45  
**OC 50.4**  
90-bp Insertion of Deep Intron between E18 and E19 (E18ins90bpE19) May Be a Hot-spot Mutation for Mild Hemophilia A Patients without Found DNA Mutation  

18:45 – 19:00  
**OC 50.5**  
Imbalance between Wound Healing and Inflammation in Hemophilia  
L.M. Knowles, D. Lessig, M. Bernard, E.C. Schwarz, H. Eichler, J. Pilch (*Germany*)

### Budapest

#### 17:45 – 19:00

**Thrombo-Emolic Disease - Risk Factors and Biomarkers**

**Chairs:** Walter A. Wuillemin, *Switzerland*  
Suzanne Cannegieter, *the Netherlands*

17:45 – 18:00  
**OC 51.1**  
Impact of Genetic Variation on the Plasma Proteome in the Tromsø Study  
E.N. Smith¹, T. Solomon¹, J. Lapek¹, S.B. Jensen², K. Hindberg³, N. Latysheva¹, S.K. Brækkåna, D.J. Gonzalez¹, K.A. Frazer¹, J.B. Hansen² (*United States, 2Norway*)

### Tuesday

18:00 – 18:15  
**OC 51.2**  
Effect of Endogenous Sex Hormone Levels Overall, and as Markers for Polycystic Ovary Syndrome and Primary Ovarian Insufficiency on Risk of Venous Thromboembolism  

18:15 – 18:30  
**OC 51.3**  
Risk Prediction of Recurrent Venous Thrombosis in All Patients with a First Venous Thrombotic Event: Results from the MEGA Follow-up Study  
J. Timp, S. i.e Cessie, L. Flinterman, A. van Hylckama Vlieg, F. Rosendaal, S. Cannegieter (*the Netherlands*)

18:30 – 18:45  
**OC 51.4**  
Discovery of Plasma Biomarkers of Future Incident Venous Thromboembolism by Untargeted MS-Based Proteomics  
S.B. Jensen¹, K. Hindberg¹, E.N. Smith¹, T. Solomon², J. Lapek¹, N. Latysheva¹, S.K. Brækkåna, D.J. Gonzalez¹, K.A. Frazer¹, J.-B. Hansen¹ (*1Norway, 2United States*)

18:45 – 19:00  
**OC 51.5**  
D-dimer Measured at Diagnosis Improves the Prediction of Major Bleeding Events during the 1-yr after an Incident VTE  
H.S. Johnsen, E. Bjøri, K. Hindberg, S.K. Brækkåna, J.B. Hansen (*Norway*)
## Scientific Program

### Wednesday, July 12, 2017

**Hall B and A rooms are in the CityCube.**

**Hall 7 rooms (city names) are in the Messe Berlin.**

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:15</td>
<td><strong>State of the Art</strong></td>
<td>Hall B</td>
</tr>
<tr>
<td></td>
<td><strong>Risk Factors of Venous Thromboembolism</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Paolo Prandoni, Italy, Alexander Cohen, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>08:00 – 08:25</td>
<td><strong>SOA 15.1</strong> Contribution of Factor XIII to Thrombosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nicola Mutch, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>08:25 – 08:50</td>
<td><strong>SOA 15.2</strong> Microvesicles and Thrombosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Romaric Lacroix, France</td>
<td></td>
</tr>
<tr>
<td>08:50 – 09:15</td>
<td><strong>SOA 15.3</strong> Genetic Risk Factors of Venous Thromboembolism in Humans and Mice</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toshiyuki Miyata, Japan</td>
<td></td>
</tr>
</tbody>
</table>

**Neurobiology and Stroke**

**Chairs:** Ton Lisman, the Netherlands, Malgorzata Wygrecka, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:25</td>
<td><strong>SOA 16.1</strong> Coagulation and Fibrinolysis at the Neurovascular Interface</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Katerina Akassoglou, United States</td>
<td></td>
</tr>
<tr>
<td>08:25 – 08:50</td>
<td><strong>SOA 16.2</strong> Stroke Models: Time for a Compromise</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Denis Vivien, France</td>
<td></td>
</tr>
<tr>
<td>08:50 – 09:15</td>
<td><strong>SOA 16.3</strong> Fibrinolysis and Brain Injury</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Medcalf, Australia</td>
<td></td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM

08:00 – 09:15 A3

**Factor XI and XII in Blood Clotting and Beyond**
Chairs: Alvin Schmaier, United States  
Coen Maas, the Netherlands

- 08:00 – 08:25  
  **SOA 17.1**  
  Factor XII and the Contact System  
  Thomas Renné, Sweden

- 08:25 – 08:50  
  **SOA 17.2**  
  An Update on Factor XI Function  
  David Gailani, United States

- 08:50 – 09:15  
  **SOA 17.3**  
  Contact Pathway Under Flow  
  Owen McCarty, United States

08:00 – 09:15 A5

**Sepsis and Immunity**
Chairs: Florea Lupu, United States  
Cheng-Hock Toh, United Kingdom

- 08:00 – 08:25  
  **SOA 18.1**  
  Proteolytic Processing of Platelet Receptors in Inflammation  
  Elizabeth Gardiner, Australia

- 08:25 – 08:50  
  **SOA 18.2**  
  Platelet Dynamics in Systemic Infections  
  Matthew Rondina, United States

- 08:50 – 09:15  
  **SOA 18.3**  
  Regulation of Coagulation Signaling by Factor V  
  Hartmut Weiler, United States

08:00 – 09:15 A6

**Platelets Beyond Thrombosis**
Chairs: Peter Bugert, Germany  
Wolfgang Bergmeier, United States

- 08:00 – 08:25  
  **SOA 19.1**  
  Focus on Platelet-Tumor Crosstalk  
  Thomas Würdinger, the Netherlands

08:25 – 08:50 SOA 19.2

Platelets and Their Role as Mediators of Immunity  
John W. Semple, Sweden

08:50 – 09:15 SOA 19.3

Platelets at the Vascular Interface  
Wolfgang Bergmeier, United States

08:00 – 09:15 A7

**Metabolic Regulation and Vascular Growth Control**
Chairs: Marc Hoylaerts, Belgium  
Anna Randi, United Kingdom

- 08:00 – 08:25  
  **SOA 20.1**  
  Regulation of Angiogenesis by Endothelial Metabolism  
  Michael Potente, Germany

- 08:25 – 08:50  
  **SOA 20.2**  
  Role of HIF-Oxygen Sensing Metabolic Pathways in Disease  
  Julián Aragonés López, Spain

- 08:50 – 09:15  
  **SOA 20.3**  
  S1P Signaling in the Vasculature  
  Tim Hla, United States

08:00 – 09:15 A8

**Hereditary Platelet Disorders**
Chairs: Harald Schulze, Germany  
Kerstin Jurk, Germany

- 08:00 – 08:25  
  **SOA 21.1**  
  Inherited Thrombocytopenias Predisposing to Other Disorders  
  Alessandro Pecci, Italy

- 08:25 – 08:50  
  **SOA 21.2**  
  Update on Congenital Thrombocytopenias  
  Shinji Kunishima, Japan

- 08:50 – 09:15  
  **SOA 21.3**  
  Identifying the Genetic Determinants of Bleeding and Platelet Disorders  
  Ernest Turro, United Kingdom
**Oral Communications**

09:30 – 10:45  
**Hall B**

**Advances in Thromboprophylaxis**

**Chairs:** Ajay Kakkar, **United Kingdom**  
Jean M. Connors, **United States**

- **09:30 – 09:45**
  - **OC 52.1**
    - **Evaluation of Interventions for Implementation of Thromboprophylaxis in Hospitalized Patients at Risk for Venous Thromboembolism (VTE): An Updated Cochrane Systematic Review and Meta-analysis of Randomized Controlled Trials (RCT)**

- **09:45 – 10:00**
  - **OC 52.2**
    - **Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip or Knee Arthroplasty (EPCAT II)**
    - D. Anderson¹, M. Dunbar¹, S. Kahn¹, S. Pleasance¹, P.-A. Vendittoli¹, J. Munnaghan¹, D. Zukor², P. Gross², M. Forsythe³, S. Pelet¹, W. Fisher¹, E. Belzile¹, S. Dolan¹, M. Crowther¹, E. Bohm², S. MacDonald², W. Goffton¹, P. Kim³, P. Androué², S. Doucette², C. Theriault², A. Abianui¹, M. Carrier¹, D. Coyle¹, M. Kovacs¹, M. Rodger¹, P. Wells¹ (¹Canada, ²United States, ³Cameroon)

- **10:00 – 10:15**
  - **OC 52.3**
    - **A landmark analysis of the APEX study comparing extended duration betrixaban with standard duration enoxaparin in hospitalized medically ill patients**
    - A.T. Cohen¹, M. Yee², D. Arbetter³, R.A. Harrington², S.Z. Goldhaber², R.D. Hull², A.F. Hernandez², A. Gold², C.M. Gibson² (¹United Kingdom, ²United States, ³Canada)

- **10:15 – 10:30**
  - **OC 52.4**
    - **Rivaroxaban Use in Extensive Superficial Thrombophlebitis**

- **10:30 – 10:45**
  - **OC 52.5**
    - **Relationship between DOAC Levels and Subsequent Thromboembolic Events**
SCIENTIFIC PROGRAM

09:30 – 10:45

A2

Structural Aspects of Fibrinogen and Fibrin

Chairs: Leonid Medved, United States
        Alisa Wolberg, United States

09:30 – 09:45

OC 54.1
Intermolecular Interactions in Double-stranded Half-staggered Fibrin Oligomers
A. Zhmurov1, A.D. Protopopova2, R.I. Litvinov3, P. Zhukov1, A.R. Mukhitov2,
J.W. Weisel4, V. Barsegov5 (1Russian Federation, 2United States)

09:45 – 10:00

OC 54.2
Role of Fibrinogen αC Domain in Fibrin Fibre Lateral Aggregation and αC Connector Region that Regulate Clot Structure and Function
H. McPherson1, C. Duval1, N. Asquith1, M. Domingues2, S. Baker1, V. Ridger1,
S. Connell1, H. Philippou1, R. Aijan1, R. Aniêns1 (1United Kingdom, 2Portugal)

10:00 – 10:15

OC 54.3
Pharmacologic Enhancement of the Fibrinogen(ogen)-integrin αMβ2 Interaction Reduces Acetaminophen-induced Liver Injury in Mice through Induction of Matrix Metalloproteinase 12
A. Kopec, N. Joshi, A. Pant, H. Cline-Fedewa, M. Flick, J. Luyendyk (United States)

10:15 – 10:30

OC 54.4
Functional Characterisation of Fibrinogen γ′ Truncations
H. McPherson1, C. Duval1, M. Domingues2, S. Baker1, V. Ridger1, S. Connell1,
H. Philippou1, R. Aijan1, R. Aniêns1 (1United Kingdom, 2Portugal)

10:30 – 10:45

OC 54.5
Interaction of Fibrin with the VLDL Receptor: Mapping the VLDL Receptor-binding Site in Fibrin αN-domains
L. Medved, S. Yakovlev (United States)

09:30 – 10:45

A3

Regulation of Coagulation

Chairs: Sandip Kanse, Norway
       Paris Margaritis, United States

09:30 – 09:45

OC 55.1
Multi-ethnic Genome-wide Association Study Identifies New Loci Regulating Factor VIII and von Willebrand Factor
M. Sabater-Lleal1, P.S. de Vries2, J.E. Huffman1, J. Marten1, A. Martinez1, P.E.
Morange5, M.E. Kleber6, C. Hayward1, X. Guo2, H.G. de Haan7, S. Trompet2,
L.-R. Yanek7, A.V. Smith8, A.B. Ozel2, W. Tang7, N. Pankratz7, D.P. Strachan2,
C.J. Lowenstein2, C.J. O'Donnell2, N.L. Smith2, CHARGE Hemostasis Working
Group (1Sweden, 2United States, 3United Kingdom, 4Spain, 5France, 6Germany,
7the Netherlands, 8Iceland)

09:45 – 10:00

OC 55.2
Exome Enriched Genome-wide Association Analysis Identifies Novel Influence from The ADCY2 Locus on Circulating Levels of Factor VII Activating Protein (FSAP) Activity
M. Olsson1, T.M. Stanne1, A. Pedersen1, E. Lorentzen1, E. Kara2, A. Martinez-Palacio3, G. Engström1, O. Melander1, S.M. Kanse2, C. Jern1 (1Sweden,
2Norway)

10:00 – 10:15

OC 55.3
High Levels of Latent Antithrombin in Plasma from Patients with Antithrombin Deficiency. New Conformational Mutations and Pleiotropic Deficiency
M. E. de la Morena-Barrio1, E. Sandoval1, P. Llamas1, E. Wypasek2, M. Toderici1,
J. Navarro-Fernández1, A. Rodriguez-Alen1, N. Revilla1, R. López-Gálvez1, A.
Mifano1, J. Padilla1, B. de la Morena-Barrio1, J. Cuesta1, J. Corral1, V. Vicente1
(1Spain, 2Poland)

10:15 – 10:30

OC 55.4
Spatio-temporal Analysis of Hemostasis by Immunofluorescence Microscopy Following Transection of the Murine Caudal Vein
V. Muczynski, O.D. Christophe, P.J. Lenting, C.V. Denis (France)

10:30 – 10:45

OC 55.5
Water Channel Aquaporin-1 Regulates the Platelet Procoagulant Response and in vivo Thrombus Formation
E.O. Agbani2, C.M. Williams1, M.T.J. VanDenBosch2, S.F. Moore1, A. Maurox3,
L. Hodgson1, A.S. Verkman3, I. Hers1, A.W. Poole1 (1United Kingdom, 2Canada,
3United States)
09:30 – 10:45

**A5**

**Sepsis and Hemostatic Factors**

**Chairs:** Craig Morrell, United States
Heiko Herwald, Sweden

09:30 – 09:45

**OC 56.1**

Different Roles for Platelet Glycoprotein VI and CLEC2 during Gram Negative Pneumonia Derived Sepsis

T.A.M. Clauhsuis1, A.F. de Vos1, B. Nieswandt1, L. Boon1, J.J.T.H. Roelofs1, O.J. van ‘t Veer2, T. van der Poll1 (1the Netherlands, 2Germany)

09:45 – 10:00

**OC 56.2**

Inhibition of Factor XI Activation by Factor XIIa Blocks Coagulopathy and Provides Organ Protection and Survival Benefit in a Baboon Model of S. aureus Sepsis

R. Silasi1, R.S. Keshari1, W.J. van Rensburg2, G. Regmi1, C. Lupu1, C.U. Lorentzi1, E.J. Tucker1, D. Gailani1, A. Gruber1, O.J.T. McCarty1, F. Lupu1 (1United States, 2South Africa)

10:00 – 10:15

**OC 56.3**

Targeting Coagulase Activity in S. aureus Bacteremia: A Prospective Randomized Controlled Trial of Staphylotherombin Inhibition

M. Peetermans, T. Vanassche, L. Liesenborghs, O. Gheysens, M. Jacquemin, J. Verhaegen, M.F. Hoylaerts, W. Peetermans, P. Verhamme (Belgium)

10:15 – 10:30

**OC 56.4**

PF4 Binds and Stabilizes Neutrophil Extracellular Traps: Implications in Sepsis

K. Gollomp, I. Johnston, G. Zhao, F. Diarra, L. Zhai, M. Poncz, M.A. Kowalska (United States)

10:30 – 10:45

**OC 56.5**

Utility of Cell-free DNA, Protein C, and Multiple Organ Dysfunction Score (MODS) Components in the Assessment of Mortality Risk in Septic Patients


---

09:30 – 10:45

**A6**

**Regulation and Function of Platelet Integrins**

**Chairs:** Timothy J. Stalker, United States
Kenneth Clemetson, Switzerland

09:30 – 09:45

**OC 57.1**

Blocking the b’x Domain of PDI Interferes with its Interaction with dllb3 and Prevents Thrombus Formation

L. Lin, C. Garnier, J. Diiks, R. Bekendam, G. Merrill-Skoloff, R. Flaimenhaft (United States)

09:45 – 10:00

**OC 57.2**

Profilin 1 is a Central Regulator of Integrin Turnover and Function in Mouse Platelets

S. Beck1, S. Stritt1, S. Sorrentino2, I. Birkholz1, K.T. Sapra2, H. Schulze1, X. Du1, J.H. Hartwig1, M. Bender1, A. Braun1, O. Medalia2, B. Nieswandt1 (1Germany, 2Switzerland, 3United States)

10:00 – 10:15

**OC 57.3**

The Platelet Oxidoreductase ERp5 Modulates Fibrinogen Binding to A2b3 Integrin by Cleaving a βI Domain Disulphide Bond

F. Passam1, J. Chiu1, L. Ju1, K. Koisek2, F. Graeter2, P. Hogg1 (1Australia, 2Germany)

10:15 – 10:30

**OC 57.4**

Synergistic Inside-out and Outside-in Activation of Integrin aIIbb3

L. Ju1, Y. Chen1, C. Zhu2 (1Australia, 2United States)

10:30 – 10:45

**OC 57.5**

IκB Kinase 2 impairs GPIIb/IIa Activation in Platelets

M. Salzmann, M. Mussbacher, W.C. Schrottmaier, J.B. Kral-Pointner, B. Hoesel, A. Assinger, J.A. Schmid (Austria)

---

09:30 – 10:45

**A7**

**Platelets in Infection and Immunity**

**Chairs:** Heyu Ni, Canada
Thomas Vanassche, Belgium

09:30 – 09:45

**OC 58.1**

Platelets Kill Bacteria after Bridging Innate and Adaptive Immunity via PF4 and FcγRIIA

R. Palanker, T.P. Kohler, K. Krauel, M. Medvidov, J. Wescie, S. Hammerschmidt, A. Greinacher (Germany)
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

09:45 – 10:00 OC 58.2 Aging-Associated Increases in Platelet Granzyme A Regulates Pro-inflammatory Gene Synthesis by Target Monocytes
R. Campbell1, A. Bhatnagar, Z. Franks, J. Rowley, B. Manne, M. Supiano, H. Schwartz, A. Weyrich, M. Rondina (United States)

10:00 – 10:15 OC 58.3 Mature Murine Megakaryocytes Process and Present Both Exogenous and Endogenous Antigens to CD8+ T Cells and Transfer this Ability to Platelets
J.W. Semple1, A. Zufferey2, E.R. Speck3, K.R. Machlus3, R. Aslam2, L. Guo2, M.J. McVey1, M. Kim1, R. Kapur2, E. Boillard2, J.E. Italiano, Jr1 (1Sweden, 2Canada, 3United States)

10:15 – 10:30 OC 58.4 Platelet Desialylation: Novel Mechanism of Immune Tolerance
J. Li, Y. Wang, Y. Yucel, J. Freedman, H. Ni (Canada)

10:30 – 10:45 OC 58.5 Platelets Promote Monocyte Polarization to a M1 Phenotype upon LPS Stimulation
M. Schattner, A. Carestia, H.A. Mena, A.E. Errasti, S. Negrotto, E.A. Carrera Silva (Argentina)

09:30 – 10:45 New York

A8

09:30 – 09:45 OC 59.1 Phenotyping and Genotyping Inherited Platelet Disorders: The Iberian Peninsula Multicenter Project Experience
V. Palma-Barqueros, J.M. Bastida, K. Janusz, J.R. Gonzalez-Porras, J.M. Hernández-Rivas, V. Vicente, M.L. Lozano, J. Rivera (Spain)

09:45 – 10:00 OC 59.2 Homozygous Frameshift in ABC4 Causes a Novel Inherited Platelet Disorder Characterised by Increased CAMP Levels and Excessive Bleeding
T.K. Bariana, on behalf of the BRIDGE Consortium (United Kingdom)

10:00 – 10:15 OC 59.3 A New Dominant Platelet P2RY12 Variant Affecting Receptor Function Identified in a Family with Severe Bleeding History
M.-C. Morel-Kopp1, D. Rabbolini1, S. Mundell1, R. Aungraheeta1, S. Gabrielli1, Q. Chen1, T. Kilo1, J. Mackay1, W. Stevenson1, G. Ward1 (1Australia, 2United Kingdom)

10:15 – 10:30 OC 59.4 Characterisation of Two Novel FLI1 Variants Causing Substitution of Arginine 340 in the ETS Domain of FLI1 in Patients with Dense Granule Secretion Defects
M. Alidossary1, V. Leo1, M. Makris1, C. Thornburg2, D. Masser-Frye2, N. Morgan1, M. Daly1 (1United Kingdom, 2United States)

10:30 – 10:45 OC 59.5 A Novel Splice-specific GF11B-p32 Mutation in a Family with Recessive Macrothrombocytopenia
H. Schulze1, A. Schlagenhaus2, G. Manukjan1, O. Andres1, E. Klopocki1, E.-M. König1, S. Panzer2, C. Beham-Schmid2, K. Althaus1, A. Greinacher1, T. Bakhchoul1, M. Seidel1 (1Germany, 2Austria)

09:30 – 10:45 Predicting and Managing the Post-Thrombotic Syndrome

Chairs: Arina ten Cate-Hoek, the Netherlands
Sebastian Schellong, Germany

09:30 – 09:45 OC 60.1 Short and Long Term Incidence of and Risk Factors for Post Thrombotic Syndrome after a First Deep Vein Thrombosis

09:45 – 10:00 OC 60.2 Rivaroxaban Reduces the Rate of Post-Thrombotic Syndrome After DVT - a Cross-Sectional Study Comparing Rivaroxaban to Warfarin

10:00 – 10:15 OC 60.3 Development and Validation of a Practical Two-step Prediction Model for Post-thrombotic Syndrome
E. Amin, S.M.J. van Kuijk, M.A. Joore, H. ten Cate, A.J. ten Cate-Hoek (the Netherlands)

10:15 – 10:30 OC 60.4 Development of a Clinical Prediction Model for the Post-Thrombotic Syndrome in a Prospective Cohort of Patients with Proximal DVT: The SOX-PTS Index
A. Rabinovich1, T. Ducruet2, S.R. Kahn2 (1Israel, 2Canada)
10:30 – 10:45  OC 60.5
No Compression, Multilayer Compression Bandaging or Compression Hosiery in the Acute Phase of Deep Vein Thrombosis in Relation to the Villalta Score, Health-related Quality of Life, and Costs at 3 Months after the Diagnosis. E. Amin, M.A. Joore, H. ten Cate, A.J. ten Cate-Hoek, the IDEAL DVT investigators (the Netherlands)

09:30 – 10:45  OC 61.1

10:15 – 10:30  OC 61.4
Comparative Profiling of HLA-DR and HLA-DQ Associated FVIII Peptides Presented by Monoyte-derived Dendritic Cells. J. Peyron, R.B. Hartholt, L. Pedro-Cos, F.P.J. van Alphen, N. Lardy, A.B. Meijer, J. Voorberg (the Netherlands)

10:30 – 10:45  OC 61.5

09:30 – 10:45  London
Hemophilia: Risk of Inhibitor Formation
Chairs: Shannon Meeks, United States
Jan Astermark, Sweden

09:30 – 09:45  OC 61.2
Improved Immunogenicity Prediction Using Composite Variables that Incorporate the Known Patient, Product and Therapy Related Risk Factors for Inhibitor Development with Immunologic Parameters from the HLA-class-II (HLAcll)-factor (F)VIII Peptidome. B. Luu1, M. Hofmann2, V. Diego3, M. Almeida1, J. Hernandez1, A. Morelli1, A. Ameri1, R. Rajalingam1, J. Powell1, J. Blangero1, E. Maszkovsky1, T. Howard1 (1United States, 2Germany, 3Australia)

09:45 – 10:00  OC 61.3
Immune Monitoring by Epigenetic Cell Counting - Application in the Hemophilia Inhibitor PUP Study (HIPS). B. Gangadharam1, B.M. Reipert1, C.J. Hofbauer1, F. Scheiflinger1, J. Bowen2, E. Dornachie1, K. Fijnvandraat1, J. Kintman1, R. Gruppo1, C. Male1, S. Meeks2, C. McGuinness1, M. Recht1, M.V. Ragni2, H. Yaish2, E. Santagostino3, D.L. Brown4 (1Austria, 2United States, 3the Netherlands, 4Italy)

10:00 – 10:15  OC 62.3
Preventive Immune Suppression Using CTLA-4 IgGs Enables Re-administration in AAV8 Gene Therapy. M. Frentsch1, A. Sada Japp1, N. Matzmoor1, A. Thiel1, F. Scheiflinger2, B.M. Reipert2, M. de la Rosa2 (1Germany, 2Austria)

10:15 – 10:30  OC 62.4
Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-administration of Vector with Tolerogenic Rapamycin Nanoparticles. A. Meliani1, F. Boisgerault1, S. Marmier1, R. Hardet1, G. Ronzitti1, F. Collaud1, S. Charles1, L. van Wittenbergh1, B. Marolleau2, P. Ilyinskii2, C. Roy2, A. Michaud2, C. Leborgne1, O. Christophe1, T.K. Kishimoto2, F. Mingozzi1 (1France, 2United States)
200 201

XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

10:30 – 10:45  OC 62.5  CRISPR/Cas9-mediated Genome Editing via Postnatal Injection of AAV Vector Cures Hemophilia B in Mice
T. Ohmori, Y. Nagao, H. Mizukami, A. Sakata, S.-I. Muramatsu, K. Ozawa, S.-I. Tominaga, Y. Hanazono, S. Nishimura, O. Nureki, Y. Sakata (Japan)

10:30 – 10:45  OC 63.5  Rituximab Use Is Associated with Longer Relapse Free Survival in Patients with Acquired Thrombotic Thrombocytopenic Purpura

09:30 – 10:45  Budapest

ADAMTS 13 and TTP Clinical

Chairs: Paul Knöbl, Austria
Ross Ian Baker, Australia

09:30 – 09:45  OC 63.1  Childhood-onset Congenital Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman syndrome): The French Reference Center for Thrombotic Microangiopathies Experience

09:45 – 10:00  OC 63.2  Hereditary Thrombotic Thrombocytopenic Purpura - Incidence of Acute Events under Plasma Prophylaxis
J. Kremer Hovinga1, Z. Cermakova2, Y. Fujimura3, K. Friedman4, J. George4, I. Hrachovinova2, P. Knöbl5, A.S. von Krogh6, B. Lämmle7, M. Matsumoto3, R. Schneppenheim7 (1Switzerland, 2Czech Republic, 3Japan, 4United States, 5Austria, 6Norway, 7Germany)

10:00 – 10:15  OC 63.3  Clinical and Laboratory Characteristics of Patients Affected with Acquired Thrombotic Thrombocytopenic Purpura Enrolled in the Milan TTP Registry

10:15 – 10:30  OC 63.4  ML355, a Selective 12-LOX Inhibitor, Prevents Immune-mediated Thrombocytopenia and Thrombosis
J. Yeung, B. Tourdot, M. Jackson, R. Adili, S. Abraham, Y. Zhou, D. Maloney, T. Holman, M. Holinstat (United States)

10:30 – 10:45  Budapest

09:30 – 10:45  Berlin

Coagulation in Extracorporeal Circulation

Chairs: Barbara Zieger, Germany
Heleen Van Ommen, the Netherlands

09:30 – 09:45  OC 64.1  Extracorporeal Membrane Oxigenation (ECMO) in Neonates and Children: Prospective Single Center Study of Argentina
C. Cervio, G. Sciuiccati, M. Hepner, J.P. Fronthoth, G. Pieroni, S.E. Annetta, A. Feliu Torres, M. Bonduel (Argentina)

09:45 – 10:00  OC 64.2  Can Coagulation Parameters Guide the Way in Neonatal and Pediatric Extracorporeal Membrane Oxygenation?
Ö. Erdem, J.W. Kuiper, R.M.J. Housmes, D. Tibboel, C.H. van Ommen, E.D. Wildschut (the Netherlands)

10:00 – 10:15  OC 64.3  Intraoperative ROTEM Predicts Excessive Bleeding in Infants on Cardiopulmonary Bypass

10:15 – 10:30  OC 64.4  Antithrombotic Guideline for the PumpKIN Trial: Design and Rationale
M.P. Massicotte1, D. Rosenthal2, W. Mahle2, R. Jaquiss2, S. Siami2, T. Baldwin2, C. Almond2 (1Canada, 2United States)

10:30 – 10:45  OC 64.5  Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients with Ventricular Assist Devices
U. Geisen1, K. Brehm1, G. Trummer1, M. Berchtold-Herz1, C. Heilmann1, F. Beyersdorf1, J. Schelling1, A. Schlagenhauf2, B. Zieger1 (1Germany, 2Austria)
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

10:45 – 11:15 Coffee break in Exhibition Halls

Plenary

11:15 – 12:00 Hall B

Oscar D. Ratnoff Memorial Lecture: Tissue Factor Biology
Chair: John Griffin, United States

11:15 – 12:00
PL 05
Tissue Factor Flip-Flopping Between Coagulation and Signaling
Wolfram Ruf, Germany

12:00 – 13:15 Lunch, Poster Session and Industry Exhibition in Exhibition Halls

Product Theaters

12:15 - 13:00 See page 537

Supported Symposia

13:15 - 14:30 See page 533

Abstract Symposia

14:45 – 16:15 Hall B

Clinical Management of Bleeding Disorders

Chairs: Charles Hay, United Kingdom
Guy Young, United States

14:45 – 15:15 ASY 27
Tailored Treatment of Bleeding Disorders: Where Do We Stand?
Claude Negrier, France

15:15 – 15:30 ASY 27.1
A Sparse Sampling Method for FVIII Population Pharmacokinetic (PK) Analyses in Males with Severe Hemophilia A (SHA)
V. Blanchette1, S. Jackson2, L. Tiseo1, V. Bouskill1, S. Ito1, D. Lillicrap2, M. Morfini1, M. Rand1, D. Stephens1, K. Usuba1, C. Wakefield2, E. Zapotocka1, M. Carcao1 (1Canada, 2Italy)

15:30 – 16:15

A1

New Aspects of Fibrinogen

Chairs: Helen Philippou, United Kingdom
Shirley Uitte de Willige, the Netherlands

14:45 – 15:15 ASY 28
Fibrinogen: What’s New?
Marguerite Neerman-Arbez, Switzerland

15:15 – 15:30 ASY 28.1
Fibrin Protofibril Structure at the Atomic Level
V. Barsegov1, A. Zhmurov2, A.D. Protopopova1, R.I. Litvinov1, P. Zhukov2, A.R. Mukhitov1, J.W. Weisel1 (1United States, 2Russian Federation)

15:30 – 16:15 ASY 28.2
Extended D-E Interaction Sites Near the Classical Knob-hole Binding Site Play an Important Role in Fibrin Polymerisation and Clot Formation
N. Asquith1, C. Duval1, M. Domingues1, H. McPherson1, F. Macrae1, S. Connell1, V. Barsegov2, R. Ariens1 (1United Kingdom, 2Portugal, 3United States)
**Scientific Program**

### XXVI ISTH Congress and 63rd Annual SSC Meeting

#### Scientific Program

**14:45 – 16:00**

**ASY 28.3**

**The Factor VII Activating Protease (FSAP) Accelerates Fibrinolysis by Altering Fibrin Clot Structure**

M. Etscheid¹, S. Subramaniam², G. Lochnti³, M. Zabczyk⁴, K.-M. Hanschmann¹, A. Undas⁵, S. Kanse⁶ (¹Germany, ²United States, ³Poland, ⁴Norway)

**16:00 – 16:15**

**ASY 28.4**

**Relevance of Fibrinogen α-chain Cross-linking in Clot Formation, Structure, and Stability**

C. Duval⁷, M. Gold⁷, H. McPherson⁷, N. Asquith⁷, S. Baker⁷, M. Domingues⁷, R. Ajan⁸, V. Ridger⁸, S. Connell⁸, H. Philippou⁸, R. Ariens⁸ (¹United Kingdom, ²Portugal)

**14:45 – 16:15**

**A2**

**Pathogenesis in Thrombosis: Basic**

**Chairs:** Jose A. Diaz, United States  
Roopen Arya, United Kingdom

**14:45 – 15:15**

**ASY 29**

**Protein Disulfide Isomerase and Thrombosis**

Robert Flaumenhaft, United States

**15:15 – 15:30**

**ASY 29.1**

**Variety of Activators and Intracellular Sources Determine the Structural Diversity of Platelet-derived Microparticles**

R. Litvinov¹, A.A. Ponomareva¹, T.A. Nevzorova¹, E.R. Mordakhanova¹, I.A. Andrianova², L. Rauova¹, J.W. Weisel¹ (¹United States, ²Russian Federation)

**15:30 – 15:45**

**ASY 29.2**

**Tissue Factor-Positive Microvesicles from a Human Pancreatic Tumor Grown Orthotopically Enhance Venous Thrombosis in Mice**

Y. Hisada¹, C. Ay², B. Cooley¹, N. Mackman¹ (¹United States, ²Austria)

**15:45 – 16:00**

**ASY 29.3**

**Serpine2 Deficiency Accentuates Coagulation and Inflammation and Promotes Pulmonary Fibrosis**

L. Venisse, D. François, Y. Boulaftali, K. Aymonnier, M. Jandrot-Perrus, E. Camer, V. Arocas, M.-C. Bouton (France)

**16:00 – 16:15**

**ASY 29.4**

**Von Willebrand Factor Regulates Deep Vein Thrombosis in a Mouse Model of Diet-induced Obesity**

A. Michels, C. Dwyer, L.L. Swystun, D. Lillicrap (Canada)

**14:45 – 16:15**

**A3**

**Signaling Mechanisms in the Vasculature**

**Chairs:** Florence Sabatier, France  
Rafal Pawinski, United States

**14:45 – 15:15**

**ASY 30**

**Signaling Mechanisms in the Vasculature**

Ingrid Fleming, Germany

**15:15 – 15:30**

**ASY 30.1**

**Targeting the Angiopoietin-Tie2 Axis to Regulate Microvascular Thrombosis in Sepsis**

K. De Ceunynck, S.J. Higgins, S.A. Chaudhry, S.M. Parikh, R. Flaumenhaft (United States)

**15:30 – 15:45**

**ASY 30.2**

**AMPK Promotes VEGF-induced Angiogenesis via GFAT1 Inhibition**

D. Zibrova¹, F. Vandermore², O. Göransson³, M. Peggie³, K.V. Mariño³, A. Knierim³, K. Spengler³, C. Weigert³, B. Viollet³, N.A. Morrice³, K. Sakamoto³, R. Heller³ (¹Germany, ²France, ³Sweden, ⁴United Kingdom, ⁵Argentina)

**15:45 – 16:00**

**ASY 30.3**

**Endothelial Primary Cilia Coordinate Vascular Regression During Development**

A.-C. Vion, T. Zheng, A. Klaus, E. Bartels-Klein, I. Hoffinger, H. Gerhardt (Germany)

**16:00 – 16:15**

**ASY 30.4**

**Nterm-Phosphatase of Soluble Epoxide Hydrolase (sEH) in the Regulation of Vascular Endothelial Inflammation**


**14:45 – 16:15**

**A5**

**Ischemic Injury in Heart and Brain**

**Chairs:** Lina Badimon, Spain  
Elizabeth Gardiner, Australia

**14:45 – 15:15**

**ASY 31**

**Protection From Ischemic Injury in Heart and Brain**

Derek Hausenloy, Singapore
SCIENTIFIC PROGRAM

15:15 – 15:30 ASY 31.1
Targeted Termination of Plasminogen Activation after Tissue Plasminogen Activator Therapy Reduces Ischemic Brain Injury and Hemorrhage in Experimental Ischemic Stroke
T. Zhao, S. Lane, Y. Zhang, A. Houng, G. Reed (United States)

15:30 – 15:45 ASY 31.2
A Novel and Effective Fibrinolytic Approach in a Murine Model of Diabetes-associated Ischemic Stroke

15:45 – 16:00 ASY 31.3
Late Administration of a new Antifibrinolytic Strategy (CM352) Reduces Lesion Size and Improves Functional Outcome in a Collagenase-Induced Rat Model of Intracerebral Hemorrhage

16:00 – 16:15 ASY 31.4
Restoring Cardiac Function after Myocardial Infarction by Targeting CD39 to Activated Platelets
M. Ziegler, J.D. Hohmann, A.K. Searle, M.-K. Abraham, H. Nandurkar, X. Wang, K. Peter (Australia)

14:45 – 16:15 A6
The Role of Platelets in Immunocompetence
Chairs: John W. Semple, Sweden
Eric Boilard, Canada

14:45 – 15:15 ASY 32
The Role of Platelets in Immune Regulation
Craig Morrell, United States

15:15 – 15:30 ASY 32.1
Platelets Modulate the Proinflammatory Phenotype of Macrophages via the Interaction of CLEC-2 and Podoplanin
J. Rayes, S. Lax, M. Zuidscherwoude, S. Wichaiyo, B. Grygielska, S. Watson, S.P. Watson, Birmingham platelet group (United Kingdom)

15:30 – 15:45 ASY 32.2
Activation of Circulating Platelets Leads to Innate-like Delivery of Potent Antiviral Antibodies
W.C. Schrottmaier1, A.-L. Luik1, M. Salzmann2, S. Badrnya2, S. Morava2, J.B. Kral-Pointner3, M. Karlsson1, A. Assinger2, M. Forsell1 (1Sweden, 2Austria)

15:45 – 16:00 ASY 32.3
Platelets Orchestrate Bleomycin-induced Lung Fibrosis in Circuitry with NETs
M. Bosmann1, D.R. Riehl1, J. Roeve1, S. Klebow1, N.L. Esmon2, S. Erming1, G. Colucci1, M. Gunzer1, A. Waisman1, K. Schäfer1, C.T. Esmon2, W. Ruf1 (1Germany, 2United States, 3Switzerland)

16:00 – 16:15 ASY 32.4
Platelets Interact with Neutrophils and Promote Intravascular Neutrophil Activation in Acute Glomerulonephritis
M. Finsterbusch, M.J. Hickey (Australia)

14:45 – 16:15 A7
New Technology to Study Platelets
Chairs: Lawrence Brass, United States
David Stegner, Germany

14:45 – 15:15 ASY 33
Superresolution Microscopy
Steven G. Thomas, United Kingdom

15:15 – 15:30 ASY 33.1
Differential Signaling through Platelet Collagen Receptors Investigated Using Metabolomics
A. Bussey, Z. Ament, J.-D. Malcor, J. Griffin, R.W. Farndale (United Kingdom)

15:30 – 15:45 ASY 33.2
Characterization of the Gp1ba-Cre Transgenic Mouse: A Novel Approach for Generating Megakaryocyte/Platelet-specific Knockout Mice
Z. Nagy1, T. Vögtle1, G. Di Nunzio1, J. Mori1, M. Geer1, S. Heising1, R. Gareus2, A. Mazharian1, Y.A. Senis1 (1United Kingdom, 2United States)

15:45 – 16:00 ASY 33.3
Real-time Platelet Production from Human iPS-derived Megakaryocytes in a Micropillar-textured Microfluidic Chip
SCIENTIFIC PROGRAM

16:00 – 16:15  ASY 33.4  Quantification of Platelet Contractile Movements during Thrombus Formation
K. Claesson, N. Boknäs, T. Lindahl, L. Faxäll (Sweden)

14:45 – 16:15  A8

Coagulation and Immune Responses
Chairs: Björn Dahlbäck, Sweden
Madhusudhan Thati, Germany

14:45 – 15:15  ASY 34
Immunothrombosis
Bernd Engelmann, Germany

15:15 – 15:30  ASY 34.1
Tissue Factor-PAR2 Signaling Promotes Cutaneous Inflammation in Mice
M.I. Schmidgen, T. Schmidt, N. Lorenz, V. Raker, J. Haub, G. Carlino, S. Reyda, W. Ruf, K. Steinbrink (Germany)

15:30 – 15:45  ASY 34.2
Protease Activated Receptor 2 Cleavage by Coagulation Factor VIIa Contributes to Lung Inflammation
M. Zelaya, C. Graf, W. Ruf (Germany)

15:45 – 16:00  ASY 34.3
Effector-memory T cells Attenuate Thrombus Resolution
F. Shahneh, N. Luther, B. Kleis-Fischer, C. Reinhardt, H.C. Probst, P. Wenzel, K. Schäfer, C. Becker (Germany)

16:00 – 16:15  ASY 34.4
Caveolin-1 is a Novel Key Player in the Crosstalk between Tissue Factor and the IGF-1R
M. Åberg, A. Siegbahn (Sweden)

14:45 – 16:15  New York

Management Strategies in Acute VTE
Chairs: Guy Meyer, France
David Jiménez, Spain

14:45 – 15:15  ASY 35
Evidence for Interventional Treatment of Acute VTE and Beyond
Akhilesh K. Sista, United States

VTE - Gaps of Evidence
Chairs: Menno Huisman, the Netherlands
Alex Spyropoulos, United States

14:45 – 15:15  ASY 36
Calf Deep Vein Thrombosis
Jan Beyer-Westendorf, Germany
SCIENTIFIC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

15:15 – 15:30
ASY 36.1
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent
M.P.A. Brekelmans¹, H.R. Buller¹, M.F. Mercuri², W. Ageno², C.Z. Chen², A.T. Cohen¹, N. van Es¹, M.A. Grosso², A.P. Medina³, G. Raskob², A. Segers¹, T. Vanassche³, P. Verhamme³, P.S. Wells⁵, G. Zhang⁵, J.I. Weitz⁶ (*the Netherlands, ¹United States, ²Italy, ³United Kingdom, ⁴Belgium, ⁵Canada)

15:30 – 15:45
ASY 36.2
Validation of the IMPROVE Bleeding Risk Assessment Model in Hospitalized Medical Patients: A Multi-center Study
S. Kaatz, D. Paje, S. Bernstein, B. Almasri, M. Hettiarachchi, P. Patel, G. Salem, V. Hereford, M. Cerasale (United States)

15:45 – 16:00
ASY 36.3
Tinzaparin for Treatment of Fetal Growth Retardation: A Randomized Multicenter-trial
A.T. Hansen, P. Sandager, M. Ramsing, J.D. Salvig, N. Uldbjerg, A.-M. Hvas (Denmark)

16:00 – 16:15
ASY 36.4
Puerperium But Not Pregnancy Is a Risk Factor for Cerebral Venous Thrombosis
S.M. Silvis¹, L.J.J. Scheres¹, S. Hiltunen², E. Lindgren³, K. Jood⁴, S.M. Zuurbier¹, S. Middeldorp¹, T. Tatlisumak², J.M. Coutinho¹ (*the Netherlands, ¹Finland, ²Sweden)

14:45 – 16:15
Helsinki 1

Women’s Issues in Thrombosis and Hemostasis
Chairs: Claire McLintock, New Zealand
Rochelle Winikoff, Canada

14:45 – 15:15
ASY 37
Hormonal Therapy-Related Thrombosis
Marc Blondon, Switzerland

15:15 – 15:30
ASY 37.1
Adverse Pregnancy Outcomes in Women with Persistent Lupus Anticoagulant - Experiences from the Prospective Vienna Lupus Anticoagulant and Thrombosis Study (LATS)
S. Koder, J. Gebhart, F. Posch, P. Quehenberger, C. Ay, I. Pabinger (Austria)

15:30 – 15:45
ASY 37.2
Identification of Gene-environment Interactions in Pregnancy-related Venous Thromboembolism
M. deAndrade¹, S.M. Armasu¹, B.M. McCauley¹, T.M. Petterson¹, H.G. de Haan², J.A. Heit¹ (*United States, ¹the Netherlands)

15:45 – 16:00
ASY 37.3
Cancer and Venous Thromboembolism in Pregnancy
V. Barros, E. Hase, A.M. Igai, R. Francisco, M. Zugaib (Brazil)

16:00 – 16:15
ASY 37.4
Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism: A Case-Only Study
J. Hugon-Rodin, M.H. Horellou, J. Conard, A. Gompel, G. Plu-Bureau, COREVE investigators (France)

14:45 – 16:15
Helsinki 2

miRNA as Diagnostic Biomarkers
Chairs: John-Bjarne Hansen, Norway
Astrid van Hylckama Vlieg, the Netherlands

14:45 – 15:15
ASY 38
miRNA as Diagnostic Biomarkers
Manuel Mayr, United Kingdom

15:15 – 15:30
ASY 38.1
Plasma miRNA Expression as Risk Marker of Stroke in Patients with Atrial Fibrillation

15:30 – 15:45
ASY 38.2
Identification of a microRNA Profile for Predicting the Thrombotic Risk of Biliopancreatic Cancer Patients
J. Oto¹, A.C. Larsen², E. Plana², D. Hervás³, L. Martos³, L.A. Ramón³, M.J. Solmiraglio³, A. Fernández-Pardo¹, F. España¹, S. Navarro¹, S.R. Kristensen², O. Thorlacius-Ussing², P. Medina¹ (*Spain, ²Denmark)

15:45 – 16:00
ASY 38.3
Septic Conditions Modulate the Level of miRNAs in Platelets and Megakaryocytes that May Contribute to Abnormal Platelet Reactivity
Z. Fejes¹, T. Orosz, S. Póliska, Z. Czimmerer, G. Nagy, B. Fülesdi, J. Kappelmayer, B. Nagy Jr. (Hungary)

16:00 – 16:15
ASY 38.4
miR-125a-5p Regulates Megakaryocyte Differentiation and Proplatelet Formation
S. Blatkekar, S. Nagalia, C. Lindsey, L. Ma, X. Kong, I. Basak, R. Pellegrino da silva, L. Yichuan, M. Rondina, A. Weyrich, L. Edelstein, P. Bray (United States)
SCIENTIFIC PROGRAM

14:45 – 16:15  
**Budapest**

**HIT**

**Chairs:** Theodore Warkentin, Canada  
Tamam Bakchoul, Germany

14:45 – 15:15  
**ASY 39**  
Management of the Multiple Phases of HIT  
Adam Cuker, United States

15:15 – 15:30  
**ASY 39.1**  
Elevated Plasma Soluble GPVI (sGPVI) Can Aid Detection of Platelet-activating Autoantibodies in Heparin-induced Thrombocytopenia (HIT)  
C. Lee¹, M. Al-Tamimi², M. Berndt¹, R. Baker¹, R. Andrews¹, P. Choi¹, A. Cuker³, E. Gardiner⁴ (¹Australia, ²Jordan, ³United States)

15:30 – 15:45  
**ASY 39.2**  
Pathogenic Antibodies in Heparin-induced Thrombocytopenia (HIT) Activate Monocytes and Induce Profound Membrane Remodeling  
I.A. Andrianova¹, V. Hayes², R.I. Litvinov², D.B. Cines³, M. Poncz³, J.W. Weisel³, L. Rauova² (¹Russian Federation, ²United States)

15:45 – 16:00  
**ASY 39.3**  
Dynamic Redistribution of Platelet Factor 4 on Vascular and Intravascular Cell Surfaces: Implications for Heparin-induced Thrombocytopenia (HIT)  
J. Dai, V. Hayes, I. Johnston, K. Golomp, G.M. Arepally, D.B. Cines, M. Poncz, L. Rauova (United States)

16:00 – 16:15  
**ASY 39.4**  
Neutrophils and Released Neutrophil Extracellular Traps (NETs) Contribute to the Prothrombotic State in HIT  
K. Golomp, V. Hayes, I. Johnston, G. Zhao, L. Rauova, M. Poncz (United States)

16:15 – 16:45 Coffee break in Exhibition Halls

---

**Plenary**

**16:45 – 17:30**  
**Hall B**

Erwin Deutsch Plenary Lecture: Transfusion Medicine and Cell Therapies

**Chairs:** Andreas Greinacher, Germany

**16:45 – 17:30**  
**PL 06**  
From HSC to Megakaryocytes: The Uncovered Role of Glycans in Hematopoiesis  
Karin M. Hoffmeister, United States
Scientific Program

Thursday, July 13, 2017

Hall B and A rooms are in the CityCube.

Hall 7 rooms (city names) are in the Messe Berlin.

Legend

- Plenary Sessions
- State-of-the-Art Sessions
- Oral Communication Sessions
- Abstract Symposia Sessions
- Supported Symposia
- Product Theater Presentations

State of the Art

08:00 – 09:15

Megakaryopoiesis

Chairs: Mortimer Poncz, United States
Catherine Léon, France

08:00 – 08:25
SOA 22.1
Regulation of Hematopoietic Stem Cell Quiescence by Megakaryocytes
Paul Frenette, United States

08:25 – 08:50
SOA 22.2
Emergency Megakaryopoiesis Under Inflammation
Marieke A.G. Essers, Germany

08:50 – 09:15
SOA 22.3
Visualization of Platelet Life: Thrombopoiesis and Thrombus Formation
Satoshi Nishimura, Japan

Epigenetic and Genetic Determinants of Hemostasis and Thrombosis

Chairs: Pierre Emmanuel Morange, France
Sven Danckwardt, Germany

08:00 – 08:25
SOA 23.1
Genetics of Pediatric Bleeding Disorders
Jorge Di Paola, United States

08:25 – 08:50
SOA 23.2
Epigenetics and Platelet Function
Chris Van Geet, Belgium

08:50 – 09:15
SOA 23.3
New Approaches to Understand Genetic Risk of Venous Thrombosis
John-Bjarne Hansen, Norway
**Nanotechnology and Microfluidics in Diagnostic Approaches**

**Chairs:** John Weisel, United States  
Mihaela Delcea, Germany

08:00 – 08:25  
SOA 24.1  
Microfluidic Analysis of Whole Blood Hemostasis  
Scott Diamond, United States

08:25 – 08:50  
SOA 24.2  
Diagnostic Approaches for Polyphosphate  
James H. Morrissey, United States

08:50 – 09:15  
SOA 24.3  
Pico Newtons and Nanometers: Single Molecule Analysis in Thrombosis and Hemostasis  
Mihaela Delcea, Germany

08:00 – 09:15  
A5  
**Managing Thrombosis in Children**

**Chairs:** Manuela Albisetti, Switzerland  
Paul Monagle, Australia

08:00 – 08:25  
SOA 25.1  
Which Risk Groups of Children Should Receive Thromboprophylaxis?  
Brian Branchford, United States

08:25 – 08:50  
SOA 25.2  
Challenges of Anticoagulant Therapy in Children: Which Agent, Intensity, Duration?  
Fiona Newall, Australia

08:50 – 09:15  
SOA 25.3  
Direct Oral Anticoagulant: Are We Ready to Use Them in Children? Christoph Male, Austria

08:00 – 09:15  
A6  
**Inflammation and Atherothrombosis**

**Chairs:** Steffen Massberg, Germany  
Rory R. Koenen, the Netherlands

08:00 – 08:25  
SOA 26.1  
Oxidation-Specific Epitopes and Atherosclerosis  
Christoph Binder, Austria

08:25 – 08:50  
SOA 26.2  
Clotting Factors and Atherothrombosis  
Hugo ten Cate, the Netherlands

08:50 – 09:15  
SOA 26.3  
NETosis and Cardiovascular Disease  
Denisa Wagner, United States

08:00 – 09:15  
A7  
**ISTH-EHA Joint Session: Cancer-Associated Thrombosis**

**Chairs:** Per Morten Sandset, Norway  
Francesco Rodeghiero, Italy

08:00 – 08:25  
SOA 27.1  
Mechanisms of Cancer-Associated Thrombosis  
Anna Falanga, Italy

08:25 – 08:50  
SOA 27.2  
Etiology and Risk Assessment of Thrombosis in Cancer  
Cihan Ay, Austria

08:50 – 09:15  
SOA 27.2  
Managing Thrombosis in Cancer Patients  
David Garcia, United States
XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

08:00 – 09:15

Inhibitors in Hemophilia

Chairs: Roshni Kulkarni, United States  
Alfonso Iorio, Canada

08:00 – 08:25  SOA 28.1  
Immune Tolerance Induction in Hemophilia  
David Lillicrap, Canada

08:25 – 08:50  SOA 28.2  
Therapeutic Potential of Engineered Regulatory T Cells: From CARs to BARS  
David Scott, United States

08:50 – 09:15  SOA 28.3  
Product Type and Other Environmental Risk Factors for Inhibitor Formation  
Flora Peyvandi, Italy

Oral Communications

09:30 – 10:45  Hall B

Proficiency Testing and Quality Control

Chairs: Isobel D. Walker, United Kingdom  
Michael Spannagl, Germany

09:30 – 09:45  OC 65.1  
Commutability - The Importance of Valid Material for Proficiency Testing Purposes  
I. Jennings, D. Kitchen, S. Munroe-Peart, S. Kitchen, T. Woods, I. Walker (United Kingdom)

09:45 – 10:00  OC 65.2  
Chromogenic and One Stage FIX Assays in the Presence of Idelvion (rFIX-FP), Alprolix (rFIXFc) Benefix and Replene: Data from a UK NEQAS for Blood Coagulation Survey  
S. Kitchen, I. Jennings, M. Makris, D. Kitchen, T. Woods, I. Walker (United Kingdom)

09:30 – 10:15  OC 65.3  
The ECAT External Quality Assessment Programme: Larger Variation in FVIII Activity <0.05 IU/ml with One-stage Assay Compared to Chromogenic Assay  
I. van Moort, P. Meijer, F.W.G. Leebeek, M.H. Cnossen, M.P.M. de Maat (the Netherlands)

10:15 – 10:30  OC 65.4  
North American Special Coagulation Laboratories (NASCOLA): Laboratory Practices for aPTT Based One-stage Factor Assays and their Outcomes on Results: A Survey  
D. Castellone¹, K. Moffat², E. Plumhoff¹ (¹United States, ²Canada)

10:30 – 10:45  OC 65.5  
Efficiency of Bayesian Logic in Detecting and Characterizing Loss of Precision, and or Loss of Accuracy: Application to aPTT Statistical Process Control  
F. Sobas¹, K. Bourazas², E. Jousselme¹, C. Nougier¹, C. Négrier¹, P. Tsiamyrtzis² (¹France, ²Greece)

09:30 – 10:45  A8

Platelet Receptors

Chairs: Renhao Li, United States  
Andrew L. Frelinger III, United States

09:30 – 09:45  OC 66.1  
Platelet Collagen Receptor GPVI-dimer Binds to Fibrinogen D-fragment and D-dimer and May Contribute to Platelet Activation and Adhesion during Thrombus Formation  
I. Induruwa, M. Moroi, A. Bonna, J.-D. Malcor, J.-M. Howes, E.A. Warburton, R. Farndale, S.M. Jung (United Kingdom)

09:45 – 10:00  OC 66.2  
Gp6 Signaling is Compromised in Early Young Platelets in Mice  
S. Gupta, D. Cherpokova, M. Morowski, M. Bender, B. Nieswandt (Germany)

10:00 – 10:15  OC 66.3  
Dissecting PAR1 Specific Signaling in Platelets Using Quantitative Mass Spectrometry Based Phosphoproteomics  
S.B.G. Jansen, F.P.J. van Alphen, A.B. Meijer, M. van den Biggelaar (the Netherlands)

10:15 – 10:30  OC 66.4  
Perlecan: a Physiological Ligand for the Inhibitory Platelet Receptor G6b-B  
T. Vögtle, S. Rajesh, M.R. Douglas, Y.A. Senis (United Kingdom)

10:30 – 10:45  OC 66.5  
Structural Analysis of Protease Activated Receptor 4 (PAR4) with Histidine Hydrogen Deuterium Exchange  
M. de la Fuente, M. Miyagi, M. Nieman (United States)
09:30 – 10:45

**Vessel Wall and Angiogenesis**

**Chairs:** Judith Cosemans, *the Netherlands*
Annette von Drygalski, *United States*

**09:30 – 09:45**

**OC 67.1**
Endothelial Cells Are Important Players in the Pathogenesis of Thrombosis in Myeloproliferative Neoplasms
A. Guy, V. Gourdon-Latyszenok, N. Le-Lay, J. Vieira Dias, B. Kilani, C. Peghaire, C. Duplaa, C. Denis, J.-L. Villeval, M. Jandrot-Perrus, T. Couffinhal, C. James (France)

**09:45 – 10:00**

**OC 67.2**
Modification of the VEGF165 C-terminus by Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFia) Inhibits Neuropilin-1 (Nrp1)-dependent Induction of Angiogenesis in vitro and in vivo
T.L. Wyseure1, R.K. Sinha1, P.J. Declerck2, J.C.M. Meijers3, A. von Drygalski1, L.O. Mosnier1 (1United States, 2Belgium, 3the Netherlands)

**10:00 – 10:15**

**OC 67.3**
Deficiency of Androgen Dependent TFPI-Regulating Protein (ADTRP) Promotes Vascular Malformations via Wnt-mediated up-regulation of Metalloproteases
C. Lupu, M.M. Patel, A. Behar, R.S. Keshari, R. Silasi, G. Regmi, F. Lupu (United States)

**10:15 – 10:30**

**OC 67.4**
The von Willebrand Factor-binding Protein Bridges the Bacterial Cell Wall via Clumping Factor A and Endothelial von Willebrand Factor Allowing Shear-resistant Binding of Staphylococcus aureus to Inflamed or Damaged Endothelium
J. Claes1, L. Liezenborghs1, M. Peetermans1, T.R. Veloso1, D. Missiakas2, O. Schneewind2, S. Mancini2, J.M. Entenza2, M.F. Hoyleerts2, R. Heying2, P. Verhamme1, T. Vanassche1 (1Belgium, 2United States, Switzerland)

**10:30 – 10:45**

**OC 67.5**
Cadherin 6 (cdh6) is Required for Thrombus Formation in vivo
E. Bouck, M. de la Fuente, W. Li, M. Mumaw, M. Nieman (United States)

09:30 – 10:45

**Platelet Proteomics and Genomics**

**Chairs:** Willem H. Ouwehand, *United Kingdom*
Ángel García, *Spain*

**09:30 – 09:45**

**OC 68.1**
Platelet Transcriptome Analysis of Mice with Altered Thrombin Regulation
S. Schubert, F. Marini, C. Santos, H. Binder, W. Ruf (Germany)

**09:45 – 10:00**

**OC 68.2**
Identification of eQTLs for Platelet and Hemostasis Related Genes in Platelets and Leukocytes within the Framingham Heart Study
J.E. Huffman, J.D. Eicher, K. Tanriverdi, J.E. Freedman, A.D. Johnson (United States)

**10:00 – 10:15**

**OC 68.3**
The First Quantitative Phosphoproteome after Selective cGMP/PKG Stimulation by Riociguat In Human Platelets and Comparison to the cAMP/PKA Phosphoproteome
O. Pagel1, E. Walter1, S. Makhouli1, H. Gonczarowska-Jorge1, A. Smolenski2, S. Gambaryan1, U. Walter1, K. Jurk1, R. Zahedi1 (1Germany, 2Ireland)

**10:15 – 10:30**

**OC 68.4**
Reversible Protein Lysine Acetylation as a Novel Regulatory Modality Orchestrating Platelet Function

**10:30 – 10:45**

**OC 68.5**
The Platelet Releasate is a ‘Barcode’ for the Health Status of an Individual
P.B. Szklanna, M.E.M. Parsons, K. Wynne, H. O’Connor, K. Egan, F. Ni Ainle, P.B. Maguire (Ireland)
Inherited Platelet Disorders

**Chairs:** Kathleen Freson, **Belgium**  
Tadbir K. Bariana, **United Kingdom**

**09:30 – 09:45**

**OC 69.1**

**New Insights in Pathogenesis, Diagnosis and Phenotype of FLI1-associated Thrombocytopenia**


**09:45 – 10:00**

**OC 69.2**

**Identification of the DIA6H1 R1213* Variant in a Family with Macrotrombocytopenia and Hearing Loss**

N. Mota-Pérez1, V. Palma-Barqueros1, J.M. Bastida1, C. Martínez1, J. Padilla1, V. Vicente1, B. Johnson2, S.P. Watson2, N. Morgan2, M.L. Lozano1, J. Rivera1  
(1Spain, 2United Kingdom)

**10:00 – 10:15**

**OC 69.3**

**Genotype-phenotype Correlation in Wiskott-Aldrich Syndrome: Four Novel Mutations in WAS Gene**

S.S. Medina, L.H. Siqueira, M.P. Colella, M.M.S. Vilela, M.C. Ozelo (Brazil)

**10:15 – 10:30**

**OC 69.4**

**Identification of Two Novel Mutations in RASGRP2 Affecting Platelet CalDAG-GEF1 Expression and Function in Patients with Bleeding Diathesis**

T. Sevivas1, J.M. Bastida1, D.S. Paul1, E. Caparros-Pérez2, V. Palma-Barqueros2, M. Couce1, D. Marques1, F. Ferrer-Marin2, J.R. González-Porras2, V. Vicente1, J.M. Hernández-Rivas2, S.P. Watson4, M.L. Lozano1, W. Bergmeier3, J. Rivera2  
(1Portugal, 2Spain, 3United States, 4United Kingdom)

**10:30 – 10:45**

**OC 69.5**

**Phenotyping of Platelets of Patients with Inherited Platelet Disorders on Blood Smears by Immunofluorescence Microscopy - Experience of the Greifswald Laboratory**

K. Althaus, C. Blumentritt, U. Strobel, T. Bakchoul, A. Greinacher (Germany)
**SCIENTIFIC PROGRAM**

**Thursday**

09:45 – 10:00 OC 71.2
Lack of FXI on Top of Platelet Depletion Does Not Increase Gastrointestinal Bleeding in Mice
M.V. Schmidt, J. Mueller, S. Heitmeier, F. Buehning, U. Lange, A. Buchmuller, V. Laux (Germany)

10:00 – 10:15 OC 71.3
Defining Differential Effects of Direct fXa versus FIIa Inhibition on Coagulation and Inflammation
S. Nazir, K. Shahzad, I. Gadi, M. Al-Dabet, S. Kohli, S. Ranjan, B. Iserrmann (Germany)

10:15 – 10:30 OC 71.4
Characterization of Activated Protein C (APC) Antibodies: Preferential Inhibition of APC’s Anticoagulant Activity over Cytoprotective Activity
L.O. Mosnier, C. Patel, X.-Y. Zhao, S. Yegneswaran (United States)

10:30 – 10:45 OC 71.5
Establishment of a Reporter Cell Line for the Functional Screening of Vitamin K Cycle Enzymes
J.-K. Tie, D.-Y. Jin, D. Stafford (United States)

09:30 – 10:45 A8
**Coagulation Factors and Inhibitors**

Chairs: Tilman Hackeng, the Netherlands
Hartmut Weiler, United States

09:30 – 09:45 OC 72.1
The Role of Fibrinogen’s αC Regions in the Early Stages of Fibrin Polymerization
A.D. Protopopova1, R.I. Litvinov1, D.K. Galanakis1, N.A. Barinov1, A.R. Mukhitov1, D.V. Klinov2, J.W. Weisel1 (1United States, 2Russian Federation)

09:45 – 10:00 OC 72.2
The Role of Thrombin Exosites 1 and 2 in the Activation of Factor XI by Thrombin
V. Patel, K. Chen, B. Leslie, A. Stafford, J. Fredenburgh, J. Weitz (Canada)

10:00 – 10:15 OC 72.3
Clot-bound Thrombin Characterization of Plasma Clots in a Flow Reactor
L.M. Haynes, T. Orfeo, K.E. Brummel-Ziedins (United States)

10:15 – 10:30 OC 72.4
Thrombospondin 1 is Required for Fibrin Accumulation during Thrombus Formation
S. Grover, R. Flaumenhaft, B. Furie (United States)

10:30 – 10:45 OC 72.5
A Critical Role of Factor XI Feedback Activation for Placental Hemostasis
A. Jämsä1, H.M.H. Spronk2, D. Gailani3, N. Mackman3, T. Renne´1 (1Sweden, 2the Netherlands, 3United States)

09:30 – 10:45 New York
**Anticoagulation in the Real World**

Chairs: Philipp Wild, Germany
Bettina Kemkes-Matthes, Germany

09:30 – 09:45 OC 73.1
VTE Risk Factors in an Irish Urban Obstetric Population
F. O'Shaughnessy, K. Bennett, F. Ní Ainle, B. Cleary (Ireland)

09:45 – 10:00 OC 73.2
Low Persistence to Direct Oral Anticoagulants at Routine Treatment for Acute Venous Thromboembolism

10:00 – 10:15 OC 73.3
Management Strategies and Long-term Outcomes in Patients with Isolated Distal Deep Vein Thrombosis: Findings from the XALIA Study
W. Agno1, L.G. Mantovani1, S. Haas1, R. Kreutz2, D. Monje2, J. Schneider2, M. van Eickels1, M. Gebel1, A.G.G. Turpie2 (1Italy, 2Germany, 3Canada)

10:15 – 10:30 OC 73.4
Impact of BMI on Clinical Outcomes in Daily Care DOAC Recipients - Results of the Prospective Dresden NOAC Registry (NCT01588119)
L. Titt, S. Marten, E. Sebastian, A. Reitter, T. Schreier, J. Beyer-Westendorf (Germany)

10:30 – 10:45 OC 73.5
Risk Factors for Death Following Major Bleeding Whilst on Warfarin or Direct Oral Anticoagulants: Results from a Prospective UK Study (ORANGE)
L. Green, J. Tan, R. Alikhan, N. Curry, T. Everington, R. Maclean, K. Saja, S. Stanworth, C. Tait, J. Morris, P. MacCallum (United Kingdom)
226

SCIENTIFIC PROGRAM

XXVI ISTH Congress and 63rd Annual SSC Meeting

SCIENTIFIC PROGRAM

227

Thursday

Orals

09:30 – 10:45 Helsinki 1

Platelet Disorders, Acquired

Chairs: Donald Arnold, Canada
        Yves Gruel, France

09:30 – 09:45 OC 74.1
Low-dose Decitabine Improves Platelet Recovery in Patients with Isolated Thrombocytopenia Following SCT
Y. Han, Y. Tang, Y. Zhao, M. Huang, J. Qi, J. Chen, X. Wu, X. Ma, F. Chen, X. Feng, C. Ruan, D. Wu (China)

09:45 – 10:00 OC 74.2
Circulating Histone-associated Thrombocytopenia Has a Significant Adverse Impact on Outcome in Critically Ill Patients

10:00 – 10:15 OC 74.3
Lack of Effect of Inhaled Nitric Oxide on Platelet Function or Bioenergetics in Patients with Acute Submassive Pulmonary Embolism: Results of a Randomized, Placebo-controlled Trial
J. Kline, M. Puskarich, A. Jones, R. Mastouri, T. Lahm, E. Gundert, C. Hall (United States)

10:15 – 10:30 OC 74.4
The Hypercoagulable State in Patients with Immune Thrombocytopenia (ITP) and its Association with Bleeding Symptoms
T. Chiasakul, B. Akkawat, P. Rojnuckarin (Thailand)

10:30 – 10:45 OC 74.5
Effects of the Btk Inhibitor Ibrutinib on Platelet Function during Inflammation and in Primary Hemostasis
R. H. Lee, R. Piatt, P. B. Conley, W. Bergmeier (United States)

09:30 – 10:45 Budapest

Future Gene and Cell Based Therapies for Hemophilia

Chairs: Federico Mingozzi, France
        Qizhen Shi, United States

09:30 – 09:45 OC 75.1
Pharmacological Intervention and Improved Platelet-factor VIII Functionality Enhanced Efficacy of in vivo Platelet-targeted Gene Therapy of Murine Hemophilia A via Intravenous Delivery
X. Wang, R. Fu, C. Miao (United States)

09:45 – 10:00 OC 75.2
Persistent Expression of FVIII Following Intravenous Administration of Lentiviral Vectors in Neonatal Hemophilia A Mouse and Dog Models
T. Lui1, D. Drager1, S. Patarroyo-White1, A. Seregín1, A. Cantore2, L. Harpelli2, D. Lillicrap3, L. Naldini2, R. Peters1 (1United States, 2Italy, 3Canada)

10:00 – 10:15 OC 75.3
Vector Dose-dependent Delayed CD8+ T Cell-mediated Clearance of AAV Encoded Antigen in the Liver
R. W. Herzog, G. Q. Perrin, S. Kumar (United States)

10:15 – 10:30 OC 75.4
Prophylactic Platelet Factor (F) VIII Infusions Established from Induced Pluripotent Stem Cell (iPSC)-derived Megakaryocytes in Hemophilia A

10:30 – 10:45 OC 75.5
Targeted FVIII Expression under the Control of its Native Promoter for Hemophilia A Gene and Cell Therapy
R. Famà, S. Merlin, E. Borroni, V. Bruscaggin, S. Zucchelli, A. Follenzi (Italy)

09:30 – 10:45 Berlin

DOACs and Beyond: Translational Aspects

Chairs: Jeffrey I. Weitz, Canada
        Stefano Barco, Germany

09:30 – 09:45 OC 76.1
High Affinity FXII Inhibitor Macrocycle Peptide for Safe Anticoagulation Therapy
R. Prince, J. Wilbs, S. J. Middendorp, C. Heinis, A. Angelillo-Scherrer (Switzerland)

09:45 – 10:00 OC 76.2
Improving the Therapeutic Index with JNJ-375: A Novel Long Acting Exosite-1 Thrombin Inhibitor In Animal Models
M. Chintala1, Q. Li1, Z. Huang Devine1, P. Andrade-Gordon1, J. Verbeeck2, T. Baglin2, J. Huntington2, D. Grainger2, R. Mason2, K. Conde-Knape2 (1United States, 2United Kingdom)

10:00 – 10:15 OC 76.3
Different Effects of Heparin and Bilvairudin on Thrombin-induced Platelet Activation via PAR1 and PAR4
N. Boknäs, L. Faxälvi, M. Wallstedt, T. L. Lindahl (Sweden)
SCIENTIFIC PROGRAM

10:15 – 10:30  OC 76.4
Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Factor Xa Inhibitors in Patients with Acute Major Bleeding
J.M. Leeds1, J.W. Mandema1, G. Lu1, J.T. Curnutte1, T.J. Milling1, M. Crowther2, S.J. Connolly2, P.B. Conley1 (1United States, 2Canada)

10:30 – 10:45  OC 76.5
Plasma Level of Apixaban is Inversely Correlated with Hemoglobin Level due to Apixaban Binding to Deoxy-hemoglobin
R. De Cristofaro, M. Sacco, F. Berruti, S. Lancellotti (Italy)

10:45 – 11:15  Coffee break

11:15 – 12:30  Hall B
Plenary

Sol Sherry Memorial Lecture: From Genomes to Stem Cells
Chairs: Christine Mannhalter, Austria
        Paul Frenette, United States

11:15 – 11:53  PL 07
The 100,000 Genomes Project: Which Results Do I Share With My Patient and Why?
Willem H. Ouwehand, United Kingdom

11:53 – 12:30  PL 08
Bone Marrow Niches
Sean Morrison, United States

12:30 – 13:45  Hall B
Highlights of ISTH
Chairs: Johannes Oldenburg, Germany
        Robert Medcalf, Australia

12:30 – 13:00  Highlights of the Basic Science at the ISTH 2017
Klaus T. Preissner, Germany

13:00 – 13:30  Highlights of the Clinical Science at ISTH 2017
Anne Angelillo-Scherrer, Switzerland

13:30 - 13:45  Closing Remarks
## Atherothrombosis & Stroke

### PB 001
**ErbB Signaling Gene EGFR Centric Network Plays an Important Role in Coronary Artery Disease**
M. Ghatge, J. Nair, A. Sharma, R.K. Vangala (India)

### PB 002
**Immunization with Recombinant Atherosclerosis Vaccine Candidate (AHhHmR) Does Not Promote Melanoma Lung Metastasis in B6;129S-Ldlrtm1herApobtm2sgy/J Mice**
M. Xia¹, V. Endresz², I. Lantos², K. Buzas², X. Lu³ ¹(United Kingdom, ²Hungary)

### PB 003
**Pro-inflammatory and Pro-thrombotic Phenotype of Spontaneously Differentiated Human Monocyte-derived Macrophages in Coronary Heart Disease Patients: Implications for Plaque Morphology and Activity**
S. Eligini¹, N. Cosentino¹, S. Fiorelli¹, F. Fabbiocchi¹, G. Niccoli¹, H. Refaat¹, M. Camera¹, G. Calligaris¹, D. Martini¹, A. Bonomi¹, F. Veglia¹, F. Fracassi¹, F. Crea¹, G. Marenzi¹, E. Tremoli¹ (Italy)

### PB 004
**Regression of Atherosclerosis in ApoE Null Mice through Targeting Coagulation Factor Xa**
J.J. Posthuma¹, J.J.N. Posma¹, R. van Gorpi², A. Jaminoni², R. van Oerle², S. Heitmeier², L.J. Schurgers², H. ten Cate², H.M.H. Spronk² ¹(The Netherlands, ²Germany)

### PB 005
**The Effect of Factor XIII on the Proliferation and Migration of Vascular Smooth Muscle Cells**
R. Bogáti¹, É. Katona¹, A.H. Shemiraní¹, E. Balogh¹, V. Jeney¹, L. Muszbek¹ (Hungary)

### PB 006
**Insights Into the Genetic Architecture of Coronary Artery Disease in Asian Indians**
J. Nair¹, J. Shanker¹ (India)

### PB 007
**Oral Anticoagulants as Modulators of Arterial Calcification**
R. van Gorpi¹, A. Jaminon¹, M. Bauwens¹, J. Bucerius¹, V. Brandenburg¹, W. Jahnne-Dechent¹, H.M.H. Spronk¹, C.P. Reutelingsperger¹, L.J. Schurgers¹ ¹(The Netherlands, ²Germany)

## Other Topics

### PB 008
**Involvement of PAR Signaling in Thrombin Generation on Vascular Smooth Muscle Cells from Abdominal Aortic Aneurysms**
M. Didelet¹, J.B. Michel¹, P. Lacolley¹, V. Regnaut¹ (France)

### PB 009
**Commensal Microbiota Contribute to Atherosclerotic Plaque Formation and Thrombogenicity in the Carotid Artery of Ldlr-/- Mice**
S. Jäckel¹, K. Kiouptsi¹, E. van der Vorst¹, C. Neideck¹, M. Kuijpers², K. Jurk³, S. Ascher³, S. Subramanian³, D. Tsiantoulas³, J. Heemskerk³, C.J. Binder³, C. Weber³, H. Dörr³, C. Reinhardt³ ¹(Germany, ²The Netherlands, ³Austria)

### PB 010
**C3-Complement Activation is Found in Human Severe Atherosclerotic Plaques**
T. Pedro¹, M. Garcia-Arquinzonis¹, A. Deya¹, L. Badimon¹ (Spain)

### PB 011
**Relationship of Elevated Levels of Visfatin with Insulin Resistance and Prothrombotic State in Coronary Artery Disease**
O. Kozh¹, E. Lavrova¹, P. Pavlova¹ (Ukraine)

### PB 012
**Parameters of Complete Blood Count Do Not Predict On-treatment Platelet Reactivity in Acute Coronary Syndrome Patients**
L. Bonello¹, M. Laine¹, V. Baccini¹, C. Frere¹ (France)

### PB 013
**Impairment of Weight Gain and Lipoprotein Lipase Mediated-triglyceride Clearance in Integrin β3 (CD61) Deficient Mice**
B. Xiao¹, J. Mao¹, W. Zhang¹, Z. Ruan¹, X. Shi¹, X. Xi¹ (China)

### PB 014
**Platelet Acetyl-CoA Carboxylase Phosphorylation: A Potential Marker for Atherothrombotic Coronary Artery Disease**
S. Kautbally¹, S. Lepropre¹, A. Lerigoleur¹, B. Gerber¹, J. Kefer¹, D. Castanares¹, S. Eeckhoudt¹, C. Oury¹, J.-L. Vanoverschelde¹, L. Bertrand¹, S. Horman¹, C. Beauloye¹ (Belgium)

### PB 015
**Recombinant Atherosclerosis Vaccine Candidate Antigen (AHhHmR)-induced Tregs in B6;129S-Ldlrtm1herApobtm2sgy/J Mice Do Not Promote Melanoma Cell (MC) Proliferation**
M. Xia¹, V. Endresz², I. Lantos², X. Lu³ ¹(United Kingdom, ²Hungary)

### PB 016
**Peripheral Immune Changes and Persistence of Tolerance to Atherosclerosis by Immune Modulation with Multi-antigenic Construct in Apobtm2SgyLdlrtm1Her/J Mice**
L.N.R. Thota¹, L. Mundkur¹, P. Ponnusamy¹, M. Ghatge¹, R.K. Vangala¹ (India)

### PB 017
**Association of vWF Antibody in ADAMTS13 Activity Ratio with Gensini Score in Type 2 Diabetes Mellitus**
S. Lasm¹, N. Komanasin¹, N. Setwasatian¹, C. Settasatian¹, U. Kukongviriyapan¹, P. Intharapetch¹, V. Senthong¹ (Thailand)
PB 018
Activated Protein C Protects against Accelerated Atherosclerosis in Diabetes by Epigenetically Restricting p65Shc Expression in Macrophages
K. Shahzad1, I. Gadi2, S. Nazir3, M. Aldabet4, S. Kohli5, S. Ranjan2, B. Isermann2 (1Pakistan, 2Germany)

PB 019
Restoration of Blood Flow Contributes to the Regression of Atherosclerosis Plaque in Mice
L. Ren, Y. Liu, Y. Wang, Y. Cao, L. Wang, T. You, L. Zhu, C. Tang (China)

PB 020
Nanoliposomes for Transfection Of CD39 mRNA: A Step towards Nanotheranostics for Delivery of Anti-inflammatory Therapeutics against Thrombosis
M.-K. Abraham1, K. Peter2, T. Michel1, H.P. Wendel1, S. Krajewski1, X. Wang2 (1Germany, 2Australia)

PB 021
Association of Plasma Soluble Thrombomodulin and HDL-C with Coronary Artery Stenosis
N. Komanasin1, N. Sittidedpachone1, N. Settasatian1, C. Settasatian1, U. Kukongviriyapan1, P. Intharapetch1, V. Senthong1 (Thailand)

PB 022
Protective Auto Antibodies and their Inverse Correlation with Antigen Levels in Indian Patients with Acute Coronary Syndrome
T. N. Poummasamy1, L. Mundkur1, S.K. Venkatachala1, R.K. Vangala1 (India)

PB 024
Role of RhoA/Rho Kinase Pathway Activation in Cocaine-induced Leukocyte Transendothelial Migration
J. Pereira1, C.G. Sáez1, M. Palominos1, G. Valenzuela1, A. Pastore1, I. Solar-Costabal1, D. Mezzano1 (Chile)

PB 025
High Circulatory Level of Inflammatory Cells and their Relation to Recurrent Cardiac Events in Indian Population
T. N. Poummasamy1, L. Mundkur1, S.K. Venkatachala1, R.K. Vangala1 (India)

PB 026
Lipoprotein a (Lp[a]) and Hemostatic Variables in Young and Post Menopausal Women: Are their Levels Affected by Hormones Use?
M.G. Carvalho1, D.B. Serenini1, C.N. Ferreira1, E. Reis1, I.F. Silva1 (Brazil)

PB 027
Selected Factors of Haemostasis and Some Clinical Parameters in Patients with Peripheral Arterial Disease with Regard to Atherosclerosis
R. Wieczór1, T. Iwaki2, V. Ploplis2, K. Umemura1, F. Castellino2 (1Japan, 2Armenia)

PB 028
MicroRNA Target Prioritization to Identify Potential Therapeutic Candidate in Cardiovascular Disease
V. Deshpande1, A. Sharma1, L.N. Thota1, R. Vangala1 (India)

PB 029
Plasminogen Deficiency Attenuates Atherosclerosis in a Murine Model of Type 1 Familial Hypercholesterolemia
C. Miyai1, T. Iwaki2, V. Ploplis2, K. Umemura1, F. Castellino2 (1Japan, 2Armenia)

PB 030
Integrated microRNA and mRNA Expression Profiling to Identify mRNA Targets of Dysregulated miRNAs in Coronary Artery Disease Condition
J. Nair1, J. Shanker1 (India)

PB 032
Predictive Value of Neutrophil to Lymphocyte Ratio in Long-term Outcomes of Left Main and/or Three-Vessel Disease in Patients with Acute Myocardial Infarction
N. Xu1, X.-F. Tang1, Y. Yao1, J.-J. Xu1, Y. Song1, L. Jiang1, P. Jiang1, R. Liu1, J.-Q. Yuan1, R.-L. Gao1 (China)

PB 034
Myocardial Infarction is a Risk Factor for Venous Thromboembolism (VTE) Recurrence in Women with a First VTE
N. Arshad1, W. Lijfering2, F. Rosendaal1 (1Norway, 2The Netherlands)

PB 035
Free Ubiquitin Promotes Cardiomyocytes Proliferation and Survival In vitro and In vivo via CXCR4 Pathway
J. Yao1, K. Lv1, Q. Zhang1, M. Tong1, W. Chen1 (China)

PB 037
Development of a Novel Flow Cytometric ImmuneDend Array to Quantify von Willebrand Factor Antigen and Ristocetin Cofactor Activity and its Application in Acute Myocardial Infarction
Y. Zhan1 (China)

PB 039
Post-infarct Survival and Cardiac Remodeling Depends on the Interplay of Neutrophils, Monocytes and Interferon Gamma in a Mouse Model of Myocardial Infarction
S. Finger1, W. Lijfering2, F. Rosendaal1 (1Norway, 2The Netherlands)

PB 040
Control of Thrombosis and Inflammation by Platelet p38α in Acute Myocardial Infarction
P. Shi1, X. Fan1, Y. Xu1, X. Chen1, L. Zhang1, K. Wang1, J. Liu1 (China)
**POSTER SESSIONS**

**PB 041** Identification of a Plasma microRNAs Profile Related to Arterial Thrombosis  

**PB 042** Platelet Serotonin Aggravates Myocardial Reperfusion Injury via Degranulation  
M. Mauler1, N. Herr1, C. Schoenichen1, T. Witsch1, T. Marchini1, C. Haerdner1, C. Koentges1, M. Schell1, L. Dorner1, D. Stallmann1, H. Bugger1, P. Walther1, D. Wolf1, I. Ahrens1, K. Ley1, C. Bode1, I. Hilgendorf1, D. Dueschmied1 (1Germany, 2United States)

**PB 043** Smoking and Fibrinogen Levels Modify the Risk of MI due to FXII V34L: Results from the MAMI Study  
J. Debattista1, R. Attard1, C. Tabone1, T. Lisman2, K. Cassar1, C.J.M. Doggen2, S. Bezzina Wettinger1, R. Farrugia1 (1Malta, 2The Netherlands)

**PB 044** Levels of Beta-thromboglobulin and Platelet Factor 4 Are Different between NSTEMI and STEMI: Results from the MAMI Study  
J. Bonaci1, R. Attard1, P. Dingli1, T. Lisman2, K. Cassar1, C.J.M. Doggen2, S. Bezzina Wettinger1, R. Farrugia1 (Malta, The Netherlands)

**PB 045** CD41 Distribution within Platelet-Monocyte Complexes in Patients with Acute Myocardial Infarction  
M. Loguinova1, N. Pinegina1, M. Vagida1, A. Shpektor1, L.B. Margolis2, E. Vasilieva1 (1Russian Federation, 2United States)

**PB 046** Cardiomyocyte Extracellular Vesicles Increase after Experimental Myocardial Infarction and Promote Endothelial Dysfunction in vitro  
C. Roncal1, J.A. Rodriguez, J. Orbe, G. Abizanda, F. Prosper, J.A. Paramo (Spain)

**PB 047** T Lymphocyte Microparticles Are the Major Determinant of Acute Coronary Syndrome  

**PB 049** Specificity of Various Haemostatic Markers in Young and Elderly Patients with Myocardial Infarction  
N. Antonijevic1, M. Bozic Mijovski1, M. Pohar Perme1, A. Blinc1 (1Slovenia)

**PB 048** Soluble P-selectin Levels Are higher in Patients with NSTEMI vs STEMI  
C. Aguas1, R. Attard1, P. Dingli1, T. Lisman2, K. Cassar1, C.J.M. Doggen2, S. Bezzina Wettinger1, R. Farrugia1 (1Malta, 2The Netherlands)

**PB 051** On-treatment Platelet Reactivity in Peripheral and Coronary Blood in Patients Undergoing Primary PCI for ST-segment Elevation Myocardial Infarction (STEMI)  
L. Spiezia, A. Al Mamary, E. Campello, D. Piazza, S. Maggiolo, F. Dalla Valle, M. Nanopado, P. Simioni (Italy)

**PB 052** Ultrasound Elastography: A New Technique to Distinguish between Acute and Chronic Deep Vein Thrombosis  
F. Dentali1, M. Mumoli1, R. Pesavento1, M. Mochi1, W. Agno1 (Italy)

**PB 053** General Practitioner-performed Compression Ultrasound for Deep Vein Thrombosis (Practicus Study): A Prospective, Multicenter Cohort Study  
F. Dentali1, M. Mastroiacovo1, M. Giorgi-Pierfranceschi1, R. Tulino1, N. Mumoli1 (Italy)

**PB 054** Targeted MiR126 Therapy of Abdominal Aortic Aneurysm  
X. Wang1, A.K. Searle1, Y.C. Chen1, A. Liu1, K. Peter1 (Australia)

**PB 055** On-treatment Platelet Reactivity in Peripheral and Coronary Blood in Patients Undergoing Primary PCI for ST-segment Elevation Myocardial Infarction (STEMI)  
L. Spiezia, A. Al Mamary, E. Campello, D. Piazza, S. Maggiolo, F. Dalla Valle, M. Nanopado, P. Simioni (Italy)

**PB 056** Risk Prediction Model for Peripheral Arterial Disease Patients Undergoing Revascularization within Two Years of Diagnosis  
R. Olie1, S. Petersohn1, B. Ramaekers2, S. van Kuijk3, A.J. ten Cate-Hoek3, M.-C. Kleinegris3, M. Joore1, H. ten Cate1 (The Netherlands)

**PB 057** Repetitive Intravenous Thrombin Injections Result in Pulmonary Arterial Endothelial Dysfunction in a Mouse Model of Sublethal Acute Pulmonary Embolism  
V.S. Garlapati1, M. Brandt1, E. Giokoglou1, T. Schoenfelder1, S. Kossmann1, M. Knorr1, T. Muenzel1, P. Wenzel1 (Germany)

**PB 058** Lack of Association between Candidate Gene Polymorphisms and Ischemic Events in Patients with Peripheral Arterial Disease  
V. Boc1, M. Bozic Mijovski1, P. Perme1, A. Blinc1 (Slovenia)

**PB 059** Restenosis is a Predictor of Poor Outcome in Patients Undergoing Endovascular Intervention for Peripheral Arterial Disease  
M. Sarzoi1, A. Facelli1, E. Fava1, E. Conti1, B. Cosmi1 (Italy)

**PB 060** Venous Thromboembolism Following Hantaviral Infection  
A. M. Connelly-Anderson1, H. Whitaker2, J. Klingström1, C. Ahlm1 (1Sweden, 2United Kingdom)

**PB 062** Abdominal Aortic Calcification in Patients with Peripheral Arterial Disease: Hemostasis Changes in Relation to Calcinosis Grade  
V. Zelinski1, A. Svetlikov1, V. Andrevev1 (Russian Federation)
## POSTER SESSIONS

**PB 063**  
**Thrombophilic and Cardiovascular Risk Factors for Retinal Vein Occlusion**  
P. Bucciarelli, S.M. Passamonti, F. Gianniello, A. Artoni, F. Peyvandi, I. Martineili (Italy)

**PB 064**  
**Patients with Cryptogenic Acute Limb Ischemia Have High Recurrence Rates Off Anticoagulation: Results of a Single Institution Retrospective Cohort Study**  
D. Mart, J. Shatzel, T. Deloughery (United States)

**PB 065**  
**Gene-sodium Interaction on the Developing of Hypertension: A Cohort-based Case-control Study**  
M.-L. Chen, T.-P. Huang, B.-F. Hwang (Taiwan)

**PB 066**  
**Drug Induced Venous Thrombosis**  

**PB 067**  
**Retinal Vascular Occlusions: A Retrospective Study**  

**PB 068**  
**Thrombosis Events in Antiphospholipid Syndrome**  
F. Said, M. Khedher, M.S. Hamdi, I. Ben Ghorbel, M. Lamloum, T. Ben Salem, M. Khanfar, M.H. Houman (Tunisia)

**PB 069**  
**Mean Platelet Volume (MPV) as a Predictor of Venous Thromboembolism (VTE) in Colorectal Cancer**  
C. Wilasrusmee, B. Siribumrungwong, N. Poprom (Thailand)

### Coagulant & Anticoagulant Mechanisms

**PB 071**  
**The Chimeric Monoclonal Antibody MHCSZ-123 against Human von Willebrand Factor A3 Domain Inhibits High Shear Arterial Thrombosis Model in Rhesus Monkeys**  
S. Ji, M. Jiang, F. Shen, Y. Zhao, C. Ruan (China)

**PB 072**  
**Effects of Two Plant Protein Inhibitors on Haemostasis and Thrombosis**  
M.L. Vilela Oliva1, B. Salu1, S.C. Pando1, M. Vilela de Brito1, F. Odei-Addo2, C. Frost3, R. Johannes Naude4, J. Emsley1, M. Uemura Sampaio1, F. Humberto de Abreu Mattel1 (1Brazil, 2South Africa)

**PB 073**  
**Slouname, a Modified Snake Venom Hemocoagulase Combined with FXa, Enhances Hemostasis and Limits Bleeding in Both Normal and Hypocoagulant Conditions**  
R. Adili1, X. Dai2, B.X. Li2, M. Holinstat1 (1United States, 2China)

**PB 074**  
**Platelet Defects Upon Surgical Liver Disease Models in Mice**  
F. Reusswig, N.S. Gowert, M. Klier, M. Reich, L. Donner, V. Keitel, D. Häussinger, M. Elvers (Germany)

**PB 075**  
**D-Insight - An Integrated Animal and Cell Model System to Interrogate the Expression and Secretion Dynamics of F2 Real-time in vivo**  
S. Khokhar, L.K. Schott, K. Mühlbach, S. Tolak, S. Danckwardt (Germany)

**PB 076**  
**Role of Disruptive Hydrodynamic Forces in Determining Occlusive and Non-occlusive Arterial Thrombosis Scenarios**  
A. Yakusheva1, N. Receveur2, D. Nechipurenko1, A. Eckly2, F. Attaullahkova1, C. Gachet2, P. Mangiri2, M. Panteleev1 (1Russian Federation, 2France)

**PB 077**  
**Sickle Cell Red Blood Cells Alter Properties of Mouse and Human Clot**  
C. Faes, E.M. Sparkenbaugh, S. Wang, K.I. Ataga, A.S. Wolberg, N.S. Key, R. Pawlinski (United States)

**PB 078**  
**Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Disseminated Intravascular Coagulation (DIC) and Multiple Organ Dysfunction Syndrome (MODS)**  

**PB 079**  
**Role of bone morphogenetic protein receptor type II in vascular remodeling during thrombosis**  
S. Sharma, A. Alimohammadi, A. Panzenboeck, I.M. Lang (Austria)

**PB 080**  
**In Vivo Neutralization of Unfractionated Heparin (UFH) and a Bioengineered Heparin Dodecasccharide (12-mer) by Protamine Sulfate in a Primate Model**  

**PB 081**  
**Hemostatic Profile in Mouse Models of Advanced Chronic Liver Disease**  
N.C. Dewarrat, C. Quaroaz, J. Jankovic, M.D. Reina Caro, R. Prince, A. De Gottardi, S. Calzavarini, A. Angelilillo-Scherrer (Switzerland)

**PB 082**  
**A Dual Antiplatelet (AP) and Anticoagulant (AC) Compound - AP-AC - Inhibits Collagen-induced Platelet Aggregation in Mice and Protects against Arterial Thrombosis**  
N.R. Bonetti1, A. Jouppila2, S. Gobbato1, S. Stivala1, G.G. Camici1, R. Lassila2, J.H. Beer1 (1Switzerland, 2Finland)

**PB 083**  
**Blood Microsampling as a Refined Model of Platelet Thromboembolism in vivo**  
F. Rauzi, E. Smyth, K. Taylor, M. Emerson (United Kingdom)
### Posters Sessions

<table>
<thead>
<tr>
<th>PB 084</th>
<th>Thromboelastography in Mice: Impact of Blood Collection Method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H. Kaur, M. Othman (Canada)</td>
</tr>
<tr>
<td>PB 085</td>
<td>Quantitative Proteomics of Plasma-derived Macroversicles Identifies Early Systemic Protein Markers of a Hemophilic Bleed in Rats</td>
</tr>
<tr>
<td></td>
<td>I.R. León, K. Roepstorff, B. Vandahl, M.R. Larsen, M. Kjelgaard-Hansen (Denmark)</td>
</tr>
<tr>
<td>PB 086</td>
<td>Improved Anticoagulant Effect of Fucosylated Chondroitin Sulfate Orally Administered as Gastro-resistant Tablets</td>
</tr>
<tr>
<td></td>
<td>R.J. Fonseca, I.D. Sucupira, S.-N.M.C.G. Oliveira, G.R.C. Santos, P.A.S. Mourão (Brazil)</td>
</tr>
<tr>
<td>PB 087</td>
<td>Three Point Ligation of Inferior Vena Cava in Rats: Experimental Approach to Study Mechanism of Venous Thrombosis</td>
</tr>
<tr>
<td></td>
<td>N. Gupta, A. Sahu, M.Z. Ashraf (India)</td>
</tr>
<tr>
<td>PB 088</td>
<td>Activated factor VII for Hemostasis Enhancement in Factor XI and XII Inhibitor-treated Primates</td>
</tr>
<tr>
<td></td>
<td>M. Walisch, A. Buchmüller, J. Johnson, E.I. Tucker, M.T. Hinds, A. Wilmen, V. Laux, A. Gruber (Germany)</td>
</tr>
<tr>
<td>PB 089</td>
<td>The Electrolytic IVC Model of Venous Thrombosis (EIM): A Cost-effective, Highly Reproducible, and Easily Controlled Tool to Investigate Venous Thrombosis under Flow Conditions</td>
</tr>
<tr>
<td></td>
<td>O.R. Palmer, M.E. Shaydakov, J.M. Greve, J.A. Diaz (United States)</td>
</tr>
<tr>
<td>PB 090</td>
<td>A Functional and Thromboelastometric-based Micromethod for Assessing Crotoxin Anticoagulant Activity and Antiserum Relative Potency against Crotaulus Durissus Terrificus Venom</td>
</tr>
<tr>
<td></td>
<td>B. Prezoto, A. Tanaka-Azevedo, J. Kapronezai, J. Marcelino, J. Mota, M. Rocha, C. Silva, N. Oguiura (Brazil)</td>
</tr>
<tr>
<td>PB 091</td>
<td>Hemostasis and Fibrinolysis during Learning in Rats</td>
</tr>
<tr>
<td></td>
<td>K. Nikolskaya, L. Podorolaskaya (Russian Federation)</td>
</tr>
<tr>
<td>PB 092</td>
<td>In the Cath Lab - A Novel Rabbit Bleeding Model</td>
</tr>
<tr>
<td></td>
<td>J. Meyer, J. Strasser, A. Trabandt, A. Gaecke (Germany)</td>
</tr>
<tr>
<td>PB 093</td>
<td>Von Willebrand Factor Effects Vessel Conformation and the Expression of Integrin αvβ3 and Ang-2 in the Porcine Female Reproductive Tract</td>
</tr>
<tr>
<td></td>
<td>H. Allerkamp, S. Lehner, M. Eklhasi-Hundrieser, C. Detering, C. Pfarrer, M. von Depka (Germany)</td>
</tr>
</tbody>
</table>

### Posters Sessions

| PB 094 | Antithrombotic In-vivo Effects of Quercetin-tetra-sulphate (QTS) Isolated from Flaveria bidentis in an Experimental Thrombosis Model in Mice |
|        | H.A. Guglielmone, A.M. Agnese, S.G. Nufiez-Montoya, J.L. Cabrera, G.R. Cuadra (Argentina) |
| PB 095 | Increase of Fibrinolytic and Anticoagulant Activity by Per Os Administration of Proteinase Complex Longolytin in Rats |
|        | T. Sharkova, L. Podorolaskaya (Russian Federation) |
| PB 096 | The Anti-factor Xia Antibody BAY 1213790 is a Novel Anticoagulant that Shows Strong Antithrombotic Efficacy without an Increased Risk of Bleeding in Rabbit Models |
|        | A. Buchmueller, A. Wilmen, J. Strassburger, M.V. Schmidt, V. Laux (Germany) |
| PB 097 | Concomitant Administration of Factor IX Replacement Therapy with Immunosuppression Decreases Immunogenicity in Hemophilia B Mice Expressing a Human Major Histocompatibility Complex |
|        | Y. Ahujas, J. Sun, G. Hu, S. Vanleeuwen, P. Monahan (United States) |
| PB 098 | Factor VIII Memory Immune Responses, von Willebrand Factor Makes a Difference |
|        | J. Chen, J. Schroder, X. Luo, Q. Shi (United States) |
| PB 099 | New Insights into FV-short Function and Interaction with TFPIa |
|        | T. Petirillo, R.M. Camire (United States)                    |
| PB 100 | Structural and Functional Characterization of Anticoagulant TIX-5, the Specific Inhibitor of the Activation of FV by FXa |
| PB 101 | Inhibition of Contact Activation by Histidine Rich Glycoprotein is Mediated by its Histidine-rich Domain |
|        | T. Truong, A. Stafford, B. Leslie, J. Fredenburgh, J. Weitz (Canada) |
| PB 102 | Dabigatran and Rivaroxaban Inhibit Thrombin Generation Much Stronger than the Growth of a Fibrin Clot |
|        | N. Dashkevich, E. Pivovarova, R. Owsepyan, Y. Kotova, D. Ayusheev, A. Bernakevich, F. Ataulakhunov (Russian Federation) |
| PB 103 | Factor VII Activating Protease (FSAP) and Marburg I (G534E) Polymorphism; How One Amino Acid Determines Function |
**POSTER SESSIONS**

**PB 104**  
Acquired Hemophilia A in Dutch Patients, a Single Center Experience  
**W.E.M. van Dijk, A. Huisman, K.P.M. van Galen, E.P. Mauser-Bunschoten, P.R. van der Valk, K. Fischer, R.E.G. Schutgens** (The Netherlands)

**PB 105**  
Salvianolic Acids Inhibit Blood Coagulation and Platelet Aggregation: A New Class of Herb Derived Dagibatran Analogs  
**Y. Wang, M. Neves, D. Zhang, X. Xu, X. Lei, G. Zhu, Y. Wang, L. Xuan, J. Ding, H. Ni** (Canada, China)

**PB 106**  
Fusion to Albumin Extends the Circulatory Half-life and Antithrombotic Effects of the Kunitz Protease Inhibitor Domain of Protease Ninex 2 in Mice  
**W. Sheffield, L. Eltringham-Smith, V. Bhakta** (Canada)

**PB 107**  
Immunogenicity Assessment of OBIZUR, a Recombinant B-domain Deleted Porcine sequence FVIII, in Patients with Acquired Hemophilia A  
**F. Horling, H. Koppensteiner, S. Dom, M. Malaisauskas, B. Hartlieb, P. Allacher, A. Novack, F. Scheiflinger, B.M. Reipert** (Austria, United States)

**PB 108**  
Affimers as a Tool to Understand Mechanistic Pathways that Control Fibrin Clot Structure and Lysis  
**N. Pechlivan, R. King, C. Tiede, K. Simmons, K. Kearney, K. Smith, F. Phoenix, R. Cheah, R.A.S. Arians, D. Tomlinson, R.A. Aijan** (United Kingdom)

**PB 109**  
The Most Significant Physiological Function of Protein S is Inhibition of Thrombin Generation  
**E. Goldfeld** (United States)

**PB 110**  
Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia A  
**F.M. Horling, P. Allacher, H. Koppensteiner, W. Engl, F. Scheiflinger, B. Abbühl, B.M. Reipert** (Austria)

**PB 111**  
Validation of a FVIII Nijmegen Bethesda Assay for the Detection of Inhibitors to Porcine FVIII  
**M. Robinson, S. Tiefenbacher, D.M. Adcock, M. Schlager, H. Gritsch** (United States, Austria)

**PB 112**  
Single-dose Safety and Toxicological Studies of Long-acting FVIIa (MOD-5014) in Rats and Monkeys Support the Initiation of Clinical Phase 1 Subcutaneous (SC) Study in Healthy Volunteers  
**L. Israeli Yagev, A. Bar-Ilan, M. Hoffmann, G. Hart** (Israel)

**PB 113**  
Low Plasma FVII:C and Activated FVII as Predictive Markers for Overt Disseminated Intravascular Coagulation  
**S. Lertthammakiat, N. Anantasit, U. Anurathapan, N. Sirachainan, P. Kadegasem, A. Chuansumrit** (Thailand)

**PB 114**  
imbalance of Factor VII/Protein C System as Major Determinant of Hypercoagulability in Cushing’s Syndrome  
**S. Maggiori, E. Campello, C. Bulato, C.M. Radu, S. Gavasso, L. Spiezia, P. Simioni** (Italy)

**PB 115**  
Anti-Hemostatic Compounds Isolated from Coral Snake Micrurus tener tener VENOM  
**A.M. Salazar, B. Guerrero, K. Perez, J. Vivas, I. Ibarra, E. Salazar, E. Sanchez, A. Rodriguez-Acosta** (Venezuela, United States)

**PB 116**  
Zinc Binds and Regulates the Activity of the Natural Anticoagulant Protein Z  
**T. Sengupta, W. Plautz, N. Manoj, R. Majumder** (India, United States)

**PB 117**  
Effects of SERPINC1, PROC, PROS1 and EPCR Polymorphisms on the Plasma Levels of Natural Anticoagulants in Healthy Individuals  
**G. Balla, T. Miklós, J. Kállai, S. Kovács, B. Kovács, É. Katona, É. Molnár, Z. Bereczky** (Hungary)

**PB 118**  
Identification of a Novel Factor VII Activating Protease (FSAP) Zymogen-activating Peptide by Phage Display  
**S. Seidel, G. Äge Læset, N.V. Nielsen, P. Declerck, S. Kansel** (Norway, Belgium)

**PB 119**  
Stability of Plasma for Add-on Coagulation Tests  
**M. Blois, F. Fischer, A. Appert-Flory, D. Jambou, P. Toulon** (France)

**PB 120**  
Microplate-based Method for Quantifying Polyphosphate in Biological Samples  
**S. Smith, R. Breitenfeld, K. Mcevoy, J. Morrissey** (United States)

**PB 121**  
Differential Investigation of Post-translational Modifications in Recombinant and Plasma-Derived Human Coagulation FIX  
**P. Soupourmas, S. Ow, M. Pelzing** (Australia)

**PB 122**  
Clinical Significance of Prothrombin G20210A Mutation in Homozygous Patients  
**A. Shemesh, R. Hoffman, Y. Nadir, A. Keren-Politansky, M. Monreal, B. Brenner, L. Tzoran** (Israel, Spain)

**PB 123**  
Impact of Reagents on FVIII Inhibitor Titration  
**C. Nouger, C. Pouplard, Club des Biologistes on behalf of the ‘French Study Group on Haemostasis and Thrombosis’** (France)

**PB 124**  
Evaluation of endogenous thrombin potential among patients with antithrombin deficiency-Serbian AT deficiency study group results  
**M. Kovač, G. Milčić, S. Lalčić-Cosić, V. Djordjević, B. Tomic, Z. Bereczky** (Serbia, Hungary)
POSTER SESSIONS

PB 125 Anti-FVIII IgG1 Antibody in Previously Untreated Patients with Hemophilia A Might Be Protective Against Inhibitor Development: Preliminary Results from the Hemfil Cohort Study
D. Gonçalves Chaves, A. Cardoso Oliveira Silveira-Cassette, L. Lemos Jardim, M. Antônio Portugal Santana, M. Hermida Cerqueira, A. Prezotti, C. Lorenzato, V. Franco, S. Meireles Rezende (Brazil)

PB 126 Cost-effectiveness of Recombinant Porcine Factor VIII (OBIZUR) for Treatment of Hemorrhagic Events in Acquired Hemophilia A (AHA)
M. Najafzadeh, A.O. Oladapo, B.M. Ewenstein, T. Raj, R.L. Bohn, J. Avorn (United States)

PB 127 APC-Resistance Testing Based on Genetic or Functional Assays: To Be or Not to Be?
A.C. Brisset, C. Stocker, M. Janssen, F. Prüller (Switzerland, Austria)

PB 128 Alteration of the Hemostatic System in Cirrhotic Patients
C. Dubocca, J. Ceresetto, M. Rodrigues Grazi, G. Stemmelin, F. Villamil (Argentina)

PB 129 In vitro Antithrombin is the Main Inhibitor of Thrombin Generation at the Surface of Endothelial Cells Acting Independently to Heparan Sulfates
B. Catieau, S. Chtourou, J.-L. Plantier (France)

PB 130 Pregnancy and Delivery Experiences in a Patient with Severe Factor X (FX) Deficiency Treated with a High-purity Plasma-derived Factor X (pdFX) Concentrate
G. Auerswald, M. Bührlen (Germany)

PB 131 Impact of Thrombin (Dabigatran) and FXa Inhibitors (Rivaroxaban, Apixaban, Edoxaban) on Hemostasis Assays
J. Hammellburger, R. Bottenus, M. Triscott (United States)

PB 132 Characterization of Interactive Sites of the Blood Coagulation Factor VIII and the Low-density Lipoprotein Receptor using Macromolecular Docking Prediction Algorithms
B. Fochtman, S. Shestopal, V. Simonyan, T. Lee, A. Sarafanov (United States)

PB 133 How Full-length FVIII Benefits from its Heterogeneity - Insights into the Role of the B Domain
J. Anzengruber, M. Feichtinger, B.M. Reipert, M. Malisauskas (Austria)

PB 134 Monoclonal Antibodies to FcγRIIB (CD32) Modulate FVIII-specific Recall Response in vitro
N. Vollack, J. Friese, S. Bergmann, A. Tiede, S. Werwitzke (Germany, United Kingdom)

PB 135 Causes of Isolated Prolonged Activated Partial Thromboplastin Time in a Haemostasis Reference Hospital
N. Vilalta, M. Carrasco, J.A. Millón, H. Cerdà, D. Llobet, C. Vailvé, J. Fontcuberta (Spain)

PB 136 Evaluation of Lupus Anticoagulant and Anti Cardiolipin Antibodies in Poly Transfused Beta Thalassemia Major Patients at Hyderabad
I. Ujjan, A. Memon, A. Naz (Pakistan)

PB 137 Reference Ranges for Hemostasis Parameters in Pregnant Women from the Krasnoyarsk Area
A. Tatyana (Russian Federation, United States)

PB 138 Recombinant FVIII-Fc-VWF-XTEN Promotes Normal Fibrin Formation, Structure and Stability
M. Aleman, E. Kistanova, E. Seth-Chhabra, R. Peters, J. Salas (United States)

PB 139 Dissecting the Catalytic Enhancement of Activated Factor IX via Foot-printing Mass Spectrometry
N. Freato, E.H.T.M. Ebberink, F.P.J. van Alphen, M.G. Boon-Spijker, M. van den Biggaera, A.B. Meijer, K. Mertens (The Netherlands)

PB 140 Comparison of Bleeding Efficacy of FIX-FC and FIXWT 7 Days Post-infusion
B. Cooley, F.-C. Lin, D. Stafford (United States)

PB 141 rFVIIIFc-VWF-XTEN Demonstrates Comparable Efficacy to Recombinant Human FVIII in Mice by Acute Bleeding and Intravital Microscopy Models
M. Demers, Z. Liu, A. van der Flier, E. Seth Chhabra, T. Liu, R. Peters, J. Salas (United States)

PB 142 How Full-length FVIII Benefits from its Heterogeneity - Insights into the Role of the B Domain
J. Anzengruber, M. Feichtinger, B. Bärnthaler, N. Haider, J. Ilas, F. Scheiffinger, B.M. Reipert, A. Malsauskas (Austria)

PB 143 Monoclonal Antibodies to FcγRIIB (CD32) Modulate FVIII-specific Recall Response in vitro
N. Vollack, J. Friese, S. Bergmann, M. Crapp, A. Tiede, S. Werwitzke (Germany, United Kingdom)
PB 146  Factor VIII A1 Residues 346-349 is a Novel Thrombin-binding Site Responsible for cleavage at Arg372 in the Heavy Chain
H. Minami, K. Nogami, K. Sasai, S. Furukawa, M. Takeyama, M. Shima (Japan)

PB 147  Recombinant FVIII.Fc-WVF-XTEN (BIVV 001) Demonstrates Equivalent Thrombin Generation and Whole Blood Clotting Profiles to Advate®
Y. Buyue, E. Seth Chhabra, J. Sommer, J. Salas, R. Peters (United States)

PB 148  Altering FIX Zymogenicity Extends Procoagulant Function and Improves Hemostatic Function in Murine Hemophilia B
L. Ivančić, V.R. Arruda, R.M. Camire (United States)

PB 149  Evaluation of Recombinant FVIII.Fc-WVF-XTEN (BIVV 001) Activity in One-stage Clotting and Chromogenic Assays and its Correlation with in vivo Efficacy in Hemophilia A Mice
Y. Buyue, A. van der Flier, D. Rabinovich, S. Bardan, Z. Liu, E. Seth Chhabra, J. Salas, J. Sommer, R. Peters (United States)

PB 150  Evaluation of Impact of Codon-Optimization on the Functional Activity of the Blood Coagulation Factor VIII by Clotting, Chromogenic and Thrombin Generation Assays
S. Shrestopali, Y. Liang, M. Lin, M. Ovanesovli, T. Lee, J. McVey II, A. Sarafanovii (United States, United Kingdom)

PB 151  An In silico and In vitro Approach to Elucidate the Impact of Residues Flanking the Cleavage Scissile Bonds of FVIII
B. Pezeshkpoor, U. Schreck, A. Biswas, J. Driesen, A.-C. Berkemeier, A. Pavlova, J. Müller, J. Oldenburg (Germany)

PB 152  In vitro Characterization of the Factor 8 Gene Mutations Associated with Assay Discrepancy
B. Pezeshkpoor, M. Gazorpak, A.-C. Berkemeier, J. Müller, A. Biswas, A. Pavlova, J. Oldenburg (Germany)

PB 153  Corn Trypsin Inhibitor Mediates Differential Effects on Thrombin Generation Parameters in Hemophilic Patients Compared with Healthy Volunteers
B. Tardy-Poncet, M. Piot, A. Montmartin, P. Chelle (France)

PB 154  Influence of Pharmacodynamics of Factor VIII on Bleeding Phenotype of Children under Long-term Prophylactic Regimen

PB 155  Influence of Neighbourhood Socioeconomic Status on Mortality Is Mediated by Factor VIII: Results from a Cohort Study
B. Vučković, A. Eikenboom, L. Doetsch, F. Rosendaal, S. Cannegieter, W. Lijfering (Serbia, The Netherlands)

PB 156  Novel F9 Gene Variants in Hemophilia B Patients from Turkey
S. Colakoglu, B. Koc, E. Berber, B. Zulfikar (Turkey)

PB 157  Evaluations of the Activated Partial Thromboplastin Time-based One-stage Clot Assays for Monitoring of Half-life Extended Factors VIII and IX Formulations

PB 158  Population Pharmacokinetic Analysis of Perioperative Factor IX Dosing in Hemophilia B

PB 159  Which Tests Can Better Indicate Clinical Phenotype of Pediatric Patients with Hemophilia on Prophylaxis?
Y. Ay, E. Toret, S. Gozmen, D. Cubukcu, T.H. Karapinar, Y. Oymak, R.C. Vergin (Turkey)

PB 160  Acquired Haemophilia and Eosinophilic Fasciitis
M. Mrouki, S. Hamrouni, F. Ben Dahmen, Y. Cherif, M. Abdallah (Tunisia)

PB 161  Affimers for Modulation of Fibrinolysis: An Alternative Approach for Bleeding Disorders
K. Kearney, C. Tiede, K. Smith, F. Phoenix, N. Oxley, R. Ariëns, N. Pechlivanii, D. Tomlinson, R. Aijan (United Kingdom)

PB 162  A Novel Tick Salivary Protein Modulates Fibrinolysis by Interacting with Plasminogen and Tissue Plasminogen Activator, and Prevents Arterial Thrombosis in vivo
I. Francischetti, T. Assumpcao, D. Mizurini, D. Ma, R. Monteiro, H. Kaneku, M. Reyes, M. Kotsyfakis, J. Andersen, J. Lukszo, J. Ribeiro (United States, Brazil, Czech Republic)
POSTER SESSIONS

XXVI ISTH Congress and 63rd Annual SSC Meeting

PB 163  Comparison and Characterization of Two Assays (TAFIa/ai ELISA vs. Activity Based Selective CPU Assay) for the Monitoring of Carboxypeptidase U (CPU, TAFIa, CPB2) Levels in Patients
  J.C. Mertens, D. Leenaerts, L. Yperzeele, Y. Sim, P. Van Der Veken, D. Hendriks (Belgium)

PB 164  Optimising the Degradation of NETs to Destabilise Fibrin Clot Structure and Promote Fibrinolysis
  M. Locke, C. Longstaff (United Kingdom)

PB 165  Extracellular Histones Enhance Fibrin Degradation by Prourokinase in a Factor Seven Activating Protease (FSAP)-dependent Manner
  F. Semeraro, M. Colucci, N. Semeraro, C.T. Ammollo (Italy)

PB 166  Localization of the C-terminal Cleavage Site of Human Alpha-2-antiplasmin
  S. Abdul1, D.H. Dekkers2, J.J. Demmers1, R.A. Ariëns, F.W. Leebeek1, D.C. Rijken1, S. Uitte de Willige1 (1The Netherlands, 2United Kingdom)

PB 167  PAI-1 Inhibition with MDI-2001: Towards a Safer and More Effective Treatment for Deep Vein Thrombosis
  M.E. Shaydakov, M. Warnock, D.A. Lawrence, J.A. Diag (United States)

PB 168  A Phase 2/3, Open-label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia (HPLG)
  C. Nakar1, B. Hardesty1, N. Thukral1, G. Albert1, M. Rubinacci1, K. Thibaudeau1, J. Parker1, A. Shapiro1 (1The Netherlands, 2United Kingdom)

PB 169  Colistin Dampens Fibrinolysis and Endothelial Activation during Endotoxemia: A Randomized, Double Blind Trial
  C. Schoergenhofer, P. Matzneller, M. Mußbacher, J. Schmid, P. Jilma-Stohlawetz, B. Jilma (Austria)

PB 170  A Novel Fluorescent Assay for the Measurement of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa) Activity
  T. Marar, K. Picco, M. Boffa (Canada)

PB 171  Global Assay of Fibrinolysis in Sickle Cell Disease: Contrasting Results in Plasma and Whole Blood
  A. Illic, M. Piegore, R. Pawlinski, N. Key (United States)

PB 174  Generation and Characterization of Monoclonal Antibodies against the N-terminus of Alpha-2-antiplasmin
  S. Abdul1, M. Peeters2, E. Brouwers2, J.J. Malfliet1, F.W. Leebeek1, P.J. Declerck1, D.C. Rijken1, S. Uitte de Willige1 (1The Netherlands, 2Belgium)

PB 175  Stretching Fibrin Fibers Hampers their Lysis
  M. Guthold, W. Li, T. Lucioni, R. Li, S. Cho (United States)

PB 176  Performance and Determinants of whole Blood and Plasma Fibrinolysis Assays in Patients with Mild Bleeding Symptoms
  M.J.A. Vries1, F. Macrae2, P.J. Nelemans1, G.J.A.J.M. Kuiper1, R.J.H. Wetzel1, P. Bowman1, P.W.M. Vertezen1, H. ten Cate1, R.A.S. Ariëns1, Y.M.C. Henskens1 (1The Netherlands, 2United Kingdom)

PB 177  Characterisation of the Different Pathways of Neutrophil Extracellular Trap (NET) Formation Triggered by Treatment with phosphol-12-myristate-13-acetate (PMA) or Calcium Ionophores
  M. Locke, R. Francis, C. Longstaff (United Kingdom)

PB 178  Effect of Alpha-2 Plasmin Inhibitor p.Arg6Trp Polymorphism and Antigen Level on the Risk of Myocardial Infarction in Young Patients
  É. Katona, A. Orosz, Z. Mezei, L. Balogh, R. Bogáti, I. Édes, L. Muszbek (Hungary)

PB 179  Effect of PAI-1 on Vascular Smooth Muscle Cells Phenotype
  X. Deng, M. Luo, J. Wu (China)

PB 180  Study of Fibrinolytic Factors along with Thrombophilia Screening Gives a Comprehensive Picture of the Cause of Venous Thrombosis in Indian Patients
  A. Prabhudesai, M. Rapala-Kozik, A. Undas (Poland)

PB 181  Impaired Plasminogen Binding in Patients with Venous Thromboembolism: Association with Protein Carbonylation
  M.T. Sartori, S. Sivolella, I. Di Pasquale, G. Saggiorato, F. Boscaro, M. De Biagi (Italy)

PB 182  Ligneous Gingivitis due to Severe Plasminogen Deficiency: Results of a Prophylactic Protocol for Dental Care
  R. Arina, L. Mukhametova, E. Ivanova, K. Gerchikovich, E. Zakharov, S. Varfolomeyev (Russian Federation)

PB 183  Effect of Polyamidoamine (PAMAM) Dendrimers on the Activity of the Fibrinolytic System in vitro
  I.P. Antropova, T.A. Zhirova, A.N. Varaksin, B.G. Yushkov (Russian Federation)
POSTER SESSIONS

PB 185  Hyperfibrinolysis during Liver Transplantation Detected by Classical Parameters and Thromboelastometry
S. Maggiolo, E. Campello, L. Spiezia, A. Tredese, G. Saggiorato, S. Gavasso, P. Feltracco, P. Simioni (Italy)

PB 186  The Use of Antiplasmin-Specific Affimer as a Tool to Modulate Fibrin Clot Properties and Thrombosis Risk
M. Almutairi, C. Tiede, K. Kearney, N. Pechlivan, F. Phoenix, N. Oxley, D. Tomlinson, R. Aijan (United Kingdom)

PB 187  Application of the CloFLAL Assay, a Global Assay which Evaluates Coagulation and Fibrinolysis in a Cohort of Venous Thromboembolism (VTE)

PB 188  Simultaneous Thrombin Plasmin Generation Assay in Haemorrhagic and Non-Haemorrhagic Caesarean Section: Pilot Study

PB 189  Simultaneous Thrombin Plasmin Generation Assay: Effect of Tranexamic Acid Concentration in vitro

PB 190  Association of Fibrinolytic Parameters with Coagulation Activity and Fibrin Clot Permeability in Patients with Hemophilia A
M. Milos, D. Coen Herak, S. Zupancic-Salek, J. Pavic, N. Mahmoud Hourani Soutari, J.P. Antovic (Croatia, Bosnia and Herzegovina, Sweden)

PB 191  Consequences of Tranexamic Acid on Fibrinolysis in Patients with Hereditary Bleeding Disorders Compared with Healthy Controls
I. Goncalves, D. Draxler, B. Niego, V. Sonia, R. Medcalf, H. Tran (Australia)

PB 192  Association of TAFI Polymorphisms and Fibrinolytic Status with Obesity in Subjects Suspected for Coronary Artery Disease
C. Rattanawan, N. Komanasin, N. Settasatian, C. Settasatian, U. Kukongviriyapan, P. Intharapetch, V. Senthong (Thailand)

PB 193  Nattokinase Easily Hydrolyzed Fish Elastin and Collagen, and Produced Anti-platelet Aggregation Activity
H. Sumi, M. Maruyama, T. Ito, N. Toki (Japan)

PB 195  A New Functional Food “Coix-Natto” for Fibrinolysis
H. Sumi, S. Naito, C. Yatagai, T. Ohsugi, E. Yoshida (Japan)

PB 197  Fibrinolytic Effects of Regulatory Leucine-containing Peptides in the Organism
L. Lyapina, T. Obergan (Russian Federation)

PB 198  Very High Production of Nattokinase by D-amino Acids
Y. Yanagisawa, T. Ito, H. Sumi (Japan)

Hemorrhagic Disorders, Hemophilia

PB 199  Evaluation of the Ankle Brachial Index in Persons with Hemophilia: Unexpected Findings
H. Hop, P.W. Kamphuisen, A.M. van Roon, J.D. Leffandt, K. Meijer (The Netherlands)

PB 200  A Single Center Cross-sectional Study of the Age Related Effects of Intensive Prophylactic Therapy on Annual Bleed Rate and Joint Arthropathy in 338 Patients with Severe Haemophilia A
J. Oldenburg, C. Causemann, H.-H. Brackmann, N. Marquardt, G. Goldmann (Germany)

PB 201  Patient, Regional and Center-level Variation in Utilization of Arthroplasty and Arthrodesis Interventions in Persons with Hemophilia: An Analysis of the American Thrombosis and Hemostasis Network (ATHN) Dataset
T. Buckner, D. Cheng, A. Ginde, M. Manco-Johnson (United States)

PB 202  New Tools for the Optimization of the Primary and Secondary Prophylaxis in Pediatric Patients with Severe Hemophilia: Ultrasound Thromboelastography (UT) and Joint Echotomography
F. Lioni, V. Dicembre, F. Gagliano, G. Corsello (Italy)

PB 203  Responsiveness and Construct Validity of Goal Attainment Scaling for Hemophilia (GAS-Hem): A Novel, Personalised, Patient-reported Outcome for Haemophilia

PB 204  Compartamental High Resolution 3D Imaging by XtremeCT Reveals Low Bone Mineral Density in Hemophilia Patients is Attributed to Loss of Trabecular Bone
A. lee, D. Raymond, S. Jackson, G. Kline, S. Boyd, M.-C. Poon (Canada)

PB 205  No Association between HFE and HMOX1 Polymorphisms, Important in Iron and Heme Handling, and the Severity of Haemophilic Arthropathy
L. van Vulpen, W. Poppen, K. Fischer, S. Mastsbergen, F. Lafebe, R. Schutgens (The Netherlands)
## POSTER SESSIONS

### PB 206
**Factors Associated with Perception of Functional Abilities in US Adults with Hemophilia Beyond Joint Status: Analysis of the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study**  
C. Kempton, T. Buckner, M. Fridman, N. Iyer, D. Cooper (United States)

### PB 207
**Long-term Treatment with Human-cl rhFVIII in Previously Treated Children with Severe Haemophilia A**  
R. Liesner¹, A. Klukowska², V. Ydovin², T. Szczepasński², J. Bichler², I. Dzhuonova³ (¹Poland, ²Russian Federation, ³Switzerland)

### PB 208
**Real-world Health Care Utilization and Costs of Extended and Standard Half-life Recombinant Factor IX Products in Hemophilia B Patients**  
A. Chhabra¹, J. Alvir¹, B. Tortella¹, D. Spurden², P. Fogarty¹, M. McDonald¹, A. Pleil¹ (¹United States, ²United Kingdom)

### PB 209
**Three-year Bleeding Frequency in >1000 Haemophilia A Patients on Prophylaxis: A Reliable Effectiveness Benchmark**  
K. Khair¹, J. Oldenburg¹, C. Santoro¹, K. Kurnik², R. Parra³, A. Huth-Kühne³, R. Klamroth³, K. Steinitz-Trost³, H. Bronde³, A. Gringeri³ (¹United Kingdom, ²Germany, ³Italy, ⁴Spain, ⁵Austria)

### PB 210
**Bleeding Phenotype In Non-severe Hemophilia A Has a Better Association with the One-stage Than the Chromogenic Assay**  

### PB 211
**Inhibitor Development and Efficacy in Previously Untreated Patients with Severe Haemophilia A Treated with Human-cl rhFVIII, a 4th Generation Recombinant FVIII of Human Origin**  
R. Liesner¹, M. Jansen², L. Belyanskaya³, E.J. Neufeld⁴ (¹Austria, ²Austria, ³Switzerland, ⁴United States)

### PB 212
**Long-term Impact of rFVIIIFc Prophylaxis in Paediatric, Adolescent, and Adult Subjects with Target Joints and Severe Haemophilia A**  
K.J. Pasi¹, J. Fabinger², M. Wang³, B. Kerlin³, R. Kulkarni³, B. Nolan³, R. Liesner¹, S. Brown³, E. Tao³, B. Winding³, S. Lethagen³, N. Jain³ (¹United Kingdom, ²Austria, ³Switzerland, ⁴United States)

### PB 213
**Administration of Recombinant Factor VIII by Continuous Infusion (CI) versus Intermittent Bolus Infusion (BI) in the Intra- and Post-operative Setting**  
J. Fabinger¹, G. Spotts¹, W. Engl¹, B. Pavlova¹, J. Doralt¹, L.A. Valentino¹ (¹Austria, ²United States)

## POSTER SESSIONS

### PB 214
**Assessment of Clot Kinetics of Recombinant Human Factor VIII (rhFVIII), Recombinant Porcine Factor VIII (rpFVIII) Recombinant Factor VIII (rFVIIIa) and Activated Prothrombin Complex Concentrate (APCC) Utilizing Thromboelastography in Patients with Severe Hemophilia A and Inhibitors**  
R. Carmona, E. Marquez, H.S. Lee, G. Young (United States)

### PB 215
**Obesity in Patients with Hemophilia: Prevalence by Age, Clinical Correlates and Impact on Joint Bleeding**  
C.-Y. Chang, T.-Y. Li, S.-N. Cheng, R.-Y. Pan, H.-J. Wang, S.-H. Hu, Y.-C. Chen (Taiwan)

### PB 216
**Influence of Genetic Polymorphisms of Biological Mediators on the Phenotypic Heterogeneity in Hemophilic Arthropathy**  
Y.-C. Chen, S.-N. Cheng, T.-Y. Li, R.-Y. Pan, S.-H. Hu (Taiwan)

### PB 217

### PB 218
**The Impact of Switching Recombinant Factor VIII Product Concentrates on Inhibitor Development among Haemophilia A Patients in Australia**  
H. Tran, S. Parikh, S. McRae (Australia)

### PB 219
**Sociodemographic, Clinical and Psychosocial Characteristics of People with Haemophilia (PHW) in Portugal: Preliminary Results of the First National Survey**  
A.C. Paredes, S. Pedras, P. Costa, M. Carvalho, M. Lopes, S. Fernandes, M. Crato, A. Almeida, P.R. Pinto (Portugal)

### PB 220
**Understanding Burden of Illness of People with Hemophilia A with or without a Current Inhibitor**  
W.E. Owens, Y. Xu, A. Cyhaniuk, E. Chan, P. Kuebler, R.H. Ko, P.G. Solari, J. Chupka (United States)

### PB 221
**The Continued Use of Cryoprecipitate and Plasma to Treat Bleeding Disorders**  
M. Brooker, C. Herr, F. Robinson, D. Coffin (Canada)
POSTER SESSIONS

PB 223  Anti-CD20 and Sirolimus for Immune Tolerance in Congenital Hemophilia A with Inhibitors
B. Doshi, V.R. Arruda, L.J. Raffini, L.A. George (United States)

PB 224  A Prospective Surveillance Study of Inhibitor Formation in Quebec Hemophilia A Patients Following a Population Switch to a Third-generation B-Domain-deleted Recombinant Factor VIII

PB 225  Evaluation of Reagent Substitutions in the Centers for Disease Control and Prevention Modified Nijmegen-Bethesda Assay (CDC-NBA) for Factor VIII (FVIII) Inhibitors in Hemophilia A
C.H. Miller, A.B. Payne, J. Driggers, D. Ellingsen, B. Boylan, C. Bean (United States)

PB 226  Evaluation of an Optimized Thrombin Generation Assay for Measurement of rFVIIa in Haemophilia A Patient Plasma
I. Fernandez-Bello1, N.V. Butta1, V. Jimenez-Yuste1, L.F. Larsen2, V. Lind2, M. Ezban2 (1Spain, 2Denmark)

PB 227  Efficacy and Safety of Human-cl rFVIII in Patients with Severe Hemophilia A Undergoing Surgical Procedures
N. Zozulya1, J. Bichler2, A. Kukurowska1 (1Russian Federation, 2Switzerland, 3Poland)

PB 228  Comparison of Biomarkers and Immunological Parameters between Hemophilia Patients, Rheumatoid Arthritis Patients, and Control Subjects
R. Toenges, A. Wittenbrink, S. Gundermann, W. Miesbach (Germany)

PB 229  Frozen Autologous Platelet Gel and Fibrin Glue in Hemophilia A, B and von Willebrand Surgical Patients
A. Misiak, E. Lachert, B. Ceglarek, A.J. Sikorska, K. Bykowska, A. Szczepanik (Poland)

PB 230  Safety and Efficacy Of Morocotocog Alfa (AF-CC) in Patients with Hemophilia A: Results of a Post-authorization Study in Usual Care Settings in China
R. Yang1, R. Wu1, J. Sun1, C. Jin1, F. Sun1, P. Rendo2, J. Rupon2, F. Huard3, J.M. Korth-Bradley2, L. Xu1, B. Luo1, Y. Liu1 (1China, 2United States, 3France)

PB 231  Post-authorization Study to Evaluate Pharmacokinetics of FVIII after Morocotocog Alfa (AF-CC), as Well as Safety and Efficacy in Previously Treated Pediatric Patients with Severe Hemophilia A
L. Rusen1, J.M. Korth-Bradley2, J. Rupon2, F. Huard3, A. Borodin4, C. Alvey2, L. Smith2, J. Fuiman2, M. Kuzmanovic6, P. Rendo2 (1Romania, 2United States, 3France, 4Ukraine, 5Serbia)

PB 232  Understanding Care Utilization and Perceptions of People with Hemophilia A with or without a Current Inhibitor
W.E. Owens, Y. Xu, A. Cyhaniuk, E. Chan, P. Kuebler, R.H. Ko, P.G. Solari, J. Chupka (United States)

PB 233  Utilisation of Smartphone Technology in Managing Prophylaxis for Patients with Haemophilia

PB 234  Retrospective Analysis of Hemostatic Efficacy by Continuous Infusion of Recombinant Factor VIIa: A Single Institution Study
N. Suzuki, M. Kishimoto, T. Kanematsu, A. Suzuki, M. Ogawa, H. Kiyoi, T. Matsushita (Japan)

PB 235  An Evaluation of the Pharmacokinetics of Turoctocog Alfa in Relation to Body Mass Index (BMI) in Patients with Haemophilia A (HA)
S. Zupančić-Salek1, M.C. Ozelo2, L. Korsholm3, I. Matytsina3 (1Croatia, 2Brazil, 3Denmark)

PB 236  Pharmacokinetic Studies of FVIII in Chinese Boys with Severe Hemophilia A
Z. Chen, P. Li, G. Li, L. Tang, Y. Zhen, X. Wu, R. Wu (China)

PB 237  Preliminary Results of a Personalized One-year Program to Individualize the Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Hemophilia A Patients
J.E. Megías Vericat, M.R. Marqués Miñana, S. Haya, A.R. Cid, F. Querol, E. Monte, M. García Dasi, P. Caunedo, P. Bosch, R. Curats, J.L. Poveda, S. Bonanad (Spain)

PB 238  International Clinical Study Investigating the Incidence of Inhibitors in Previously Untreated Patients with Severe Haemophilia A Treated with a High Purity FVIII/VWF Concentrate in a 1:1 Ratio
M. Jansen1, T. Andreeva2, V. Vdovin3 (1Austria, 2Russia, 3Kazakhstan)

PB 239  Magnitude of Dosing Adjustment of AFSTYLA in Clinical Trials
S. Yan1, R. Wang1, A. Veldman2, M. Fries1, G. Krishnarajah1 (1United States, 2Germany)

PB 240  Validity of Angiography and Therapeutic Embolization in the Treatment of Acute Bleeding in Hemophilia Patients
Y.S. Park, M. Kim (Republic of Korea)

PB 241  Posttraumatic Anterior and Posterior Thigh Pseudotumor in Young and Adolescent with Hemophilia
R. Silva, J. Marun, D. Perez (Colombia)
**POSTER SESSIONS**

| PB 242 | Vitamin D Deficiency in Patients with Haemophilia: Initial Workup and Follow-up of Supplementation  
B. Krammer-Steiner, C. Schneider, R. Toenges, M. Steiner (Germany) |
| PB 243 | Severe Haemophilia A Patients Born between 2000-2015 at a Single Haemophilia Centre: Characteristics and Inhibitor Development  
M. Martorell, S. Alonso, R. Parra, M. Constans, C. Altisent (Spain) |
| PB 244 | The Effectiveness of PK-Tailored Tertiary Prophylaxis for Severe Hemophilia A Children: A Pilot Study from BCH  
P. Li, Z. Chen, X. Cheng, Y. Wang, N. Zhang, Y. Zhen, X. Wu, R. Wu (China) |
| PB 245 | Korea Hemophilia Foundation Registry Trends 1991-2015: Patient Registry, Demographics, Health Services Utilization  
S.K. Kim, S.K. Park, K.Y. Yoo (Republic of Korea) |
| PB 246 | Safety and Efficacy of Nonacog Alfa in Patients with Hemophilia B: Results of a Post-authorization Study in usual Care Settings in China  
R. Yang1, R. Wu1, J. Sun1, F. Sun1, J. Rupon2, F. Huard3, J.M. Korth-Bradley2, L. Xu1, R. Luo1, Y. Liu1, P. Rendo1 (1China, 2United States, 3France) |
| PB 247 | Spinal & Cranial Neurosurgical Procedures in Patients with Hemophilia  
C. Nakar, B. Hardesty, M. Karimi, A. Greist, R. Thukral, A. Shapiro (United States) |
| PB 248 | Pseudotumors in Hemophilia: Effective Surgery with Application of Frozen Autologous Platelet Gel  
A. Misial, B. Ceglarek, A.J. Sikorska, K. Bykowska, J. Swornög, E. Lachert, A.J. Meissner, A. Szczepanik (Poland) |
| PB 249 | Rationale and Study Design for a Prospective, Non-interventional Phase 4 Study Evaluating the Effectiveness of Recombinant Factor VIII Fc Compared with Conventional Factor VIII Concentrates in the Prophylactic Treatment of Haemophilia A: The A-SURE Study  
B. Winding1, J. Oldenburg2, C. Hay3, F. Peyvandi4, V. Jiménez-Yuste5, J. Szamosi1, L. Lethagen1 (1Sweden, 2Germany, 3United Kingdom, 4Italy, 5The Netherlands, 6Spain) |
| PB 250 | Outcomes in Acquired Hemophilia A Based on the Choice of Hemostatic Agent: A Single Institution Retrospective Cohort Study  
M. Daughety, J. Shatzel, T. Deloughery (United States) |
| PB 251 | The Use of Multiple Drugs in a Sample of Adult Patients with Hemophilia: Considerations and Perspectives on Aging  
S. Riva, A. Nobili, E. Mancuso, G. Pravettoni, L. Cortesi, P.M. Mannucci, E. Santagostino (Italy) |

**POSTER SESSIONS**

| PB 252 | Sudden Decrease of High-titer Anti-FVIII Antibodies with Anti-inhibitor Coagulant Complex in a Patient with Severe Hemophilia A and Poor Response to Immune Tolerance Induction  
I. Soto, L.F. Ávila, D. Martínez, Á. Bernardo (Spain) |
| PB 253 | Projecting Product Consumption of AFSTYLA vs. ADVATE in the United States  
G. Krishnarajah1, S. Yan1, L. Stern1, R. Hutcheson2 (1United States, 2Canada) |
| PB 254 | Correlation between Pharmacokinetic of Factor VIII and Bleeding Frequency of Children withsevere Hemophilia A in China - A Single Center Data Analysis  
X. Cheng, Z. Chen, P. Li, Y. Wang, N. Zhang, Y. Zhen, X. Wu, R. Wu (China) |
| PB 255 | Assessment of the Quality of Life in Korean Hemophiliacs: Impact of Disease-related Factors, Social Status and Treatment Factors on the Quality of Life of Korean Hemophiliacs  
C.W. You, H. Shin, S. Lee, M.K. Kim (Republic of Korea) |

**Management of Thromboembolism**

| PB 256 | Relevance of Polypharmacy for the Clinical Outcome of Patients Receiving Oral Anticoagulation Therapy - Results from the thrombEVAL Study  
| PB 257 | Thromboembolic and Bleeding Risk of Patients with Left-sided Mechanical Heart Prosthesis: The FCSA-START-Valvole Study  
D. Poli, R. De Caterina, V. Prego, E. Antonucci, L. Migliaccio, E. Grifoni, N. Maggini, M. Moia, S. Testa, G. Palareti, FCSA-START group (Italy) |
| PB 258 | Warfarin Binds to a Hydrophobic Pocket within the Opened Oxidized State Human VKORC1 Conformation  
K.J. Czogalla, A. Biswas, K. Hönig, H. Hornung, K. Liphardt, M. Watzka, J. Oldenburg (Germany) |
| PB 259 | The Contribution of Genetic Variants that Are Associated with Venous Thrombosis or with Vitamin K Antagonist Dosage, alone or Combined, to the Risk of Major Bleeding in Patients Treated with Vitamin K Antagonists  
N. van Rein, W.M. Lijfering, M.H.A. Bos, J.J. Swen, F.J.M. van der Meer, P.H. Reitsma (The Netherlands) |
| PB 260 | Assessment of the Efficacy of a Novel Tailored Vitamin K Dosing Regimen in Lowering INR in Over-anticoagulated Patients  
E. Kampiloukas, P.J. Avery, H. Wynne, T. Biss, J. Hanley, K. Talks, F. Kamali (United Kingdom) |
POSTER SESSIONS

PB 261
Clinical Usefulness of the SAMe-TT2R2 Score: A Systematic Review and Meta-analysis
J.H.A. van Miert, S. Bos, N.J.G.M. Veeger, K. Meijer (The Netherlands)

PB 262
Safety of Long Term Warfarin Therapy in Real Clinical Practice: Predictors of Major and Non-Major Clinically Relevant Bleedings
E. Kropacheva, O. Zemlyanskaya, A. Dobrovolsky, E. Panchenko (Russian Federation)

PB 263
Decreased Bone Mineral Density in Fontan Patients Receiving Long-term Warfarin

PB 264
Predicting Recurrent Venous Thromboembolism in Patients with Deep-vein Thrombosis: Development and Internal Validation of an Simply Applicable Prediction Model (Continu-8)
M. Nagler1, S.M. van Kuijk2, H. ten Cate2, M.H. Prins2, A.J. ten Cate-Hoek2
(1Switzerland, 2The Netherlands)

PB 266
Anticoagulation Control in Premenopausal Women with Mechanical Heart Valves Using Vitamin K Antagonists: Room for Improvement
C.S.B. Veen, J.S. Biedermann, F.W.G. Leebeek, M.J.H.A. Kruip (The Netherlands)

PB 267
Involvement of Antithrombotic Therapy in Intracranial Bleeding: A Tertiary Hospital Experience
V. Pons, P. Raheja, K.J. Flores, P. Olivera, T. Canals, E. Johansson, V. Cortina, M. Constans, F. Bosch, A. Santamaria (Spain)

PB 268
One-year Medical Costs and Predictors of Costs of Pulmonary Embolism: A Prospective Study
J.P. Galanaud, A. Ternisien-Payerols, V. Georgescu, D. Pontal, P. Aubas, I. Quéré, G. Mercier (France)

PB 269
The Impact of Antiphospholipid Syndrome and Related Comorbidities in the Quality of Oral Anticoagulation
G.G. Yamaguti-Hayakawa, M.P. Coiella, E.V. de Paula, J.M. Annichino-Bizacchi, F.A. Orsi (Brazil)

PB 270
Predicting Recurrent Venous Thromboembolism in Patients with Deep-vein Thrombosis: External Validation of a Prediction Model
M. Nagler1, S.M. van Kuijk2, H. ten Cate2, M.H. Prins2, A.J. ten Cate-Hoek2
(1Switzerland, 2The Netherlands)

PB 271
Clinical Characteristics Associated with Diagnostic Delay of Pulmonary Embolism in Primary Care: A Retrospective Observational Study
J. Hendriksen, M. Koster-van Rees, M. Morgenstern, R. Ouodega, R. Schutgens, K. Moons, G.-J. Geersing (The Netherlands)

PB 272
Variability in Calculation of Time in Therapeutic Range for Quality Control Measurement of Warfarin
S. Siddiqui, C. De Remer, J. Waller, R. Abraham, J. Gujral (United States)

PB 273
D-dimer Levels Predict Clinical Outcomes in Patients with Mechanical Heart Valve Replacement during Oral Anticoagulation Therapy
L. Zhang, L. Yanli, J. Yang, Z. Zhang (China)

PB 274
Risk of Recurrence after Stopping Anticoagulation in Patients with a First Episode of Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis
F. Khan1, A. Rahman1, M. Carrier1, C. Keano1, S. Schulman1, F. Couturaud2, P. Prandoni1, S. Eichinger3, C. Becattini3, G. Agnelli3, H. Buller4, E. Sabriel, B. Hutton1, G. Neils1, M. Rodger1 (1Canada, 2France, 3Italy, 4Austria, 5Netherlands Antilles)

PB 275
Outcome of Vitamin K Antagonist Associated Bleeding in Patients Treated with Prothrombin Complex Concentrate: The ROVAP Study

PB 276
Association of S’untranslated Region / Exonic VKORC1 Mutations with Vitamin K Antagonist Resistance: Results of the GFHT Cohort Study
E. Lesteven, J. Fréchaud, C. Moreau, M. Babayan, A. Veyradier, P. Gaussem, J.-L. Golmard, M.-A. Loriot, V. Sigurö, on behalf of the GFHT (France)
POSTER SESSIONS

PB 279  Repeated Serial D-Dimer (DD) Measurement after Anticoagulation Therapy (AT) withdrawal to Identify Patients (PTS) at Risk for Venous Thromboembolism (VTE) Recurrence
B. Cosmi, C. Legnani, M. Cini, G. Guazzaloca, G. Rodorigo, G. Palareti (Italy)

PB 280  Safety and Efficacy of Warfarin in Patients with Thrombocytopenia

PB 281  AF Patients on VKAs: Heart Failure is Associated with Worst Quality of Anticoagulation and Higher Bleeding Risk. Results from the START Register
D. Poli, E. Antonucci, L. Migliaccio, S. Testa, V. Pengo, F. Marongiu, A. Tripodi, G. Palareti, START-Register participants (Italy)

PB 282  Thrombotic Complication Rates Following Anticoagulation Reversal: A Retrospective Evaluation of Prothrombin Complex Concentrates

PB 284  Assessment of the Quality of Oral Anticoagulation Control at Two Hospital-based Clinics in Brazil
M.A.P. Martins, R.G.L. Silva, I.G. Ferreira, L.C. Brant, C.M. Bertollo (Brazil)

PB 285  Factors Associated with Postoperative Hemorrhage in Patients Undergoing Dental Surgery

PB 287  Thrombin Generation Test: A Reliable Tool to Evaluate the Pharmacodynamics of Vitamin K Antagonist Rodenticides in Rats
G. Jourdi, S. Lefebvre, B. Le Bonnic, E. Curis, P. Gaussem, V. Lattard, V. Siguret (France)

PB 288  The Efficacy of 3-mg versus 5-mg Warfarin Initiating Dose and Corresponding Dosing Schedule in Thai Patients Diagnosed with Venous Thromboembolism
B. Suwanawiboon, W. Rotchanapanya, K. Mahaprom, N. Sermthamnasawadi, Y. Lalerd, W. Thongnoppakhun, C. Limwongse (Thailand)

PB 289  Barriers to Implementing an Extended INR Testing Interval Policy for Stable Warfarin Patients: A Mixed Methods Study in Five Anticoagulation Clinics
G. Barnes, S. Misirliyan, S. Kaatz, E. Jackson, B. Haymart, E. Kline-Rogers, J. Kozlowski, G. Krol, J. Froehlich, A. Sales (United States)

PB 290  Vitamin K Antagonists Compared to Low-molecular-weight Heparins for Treatment of Cancer-associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice
P. den Exter, J. Hooijer, T. van der Hulle, J.P. van Oosten, O.M. Dekkers, F.A. Klok, M.V. Huisman (The Netherlands)

PB 291  External Quality Assessment of the POCT Prothrombin Time Determination - the 6-Year Experience with the Evaluation of the Postanalytical Phase
P. Kesler, M. Budina (Czech Republic)

PB 292  The Incidence of Thromboembolic and hEMorrhagic (ITEM) Complications in Patients on Anticoagulant Therapy. A Dynamic Parallel-group Cohort Study

PB 293  Specific Inhibition of Endogenous VKOR Enzymes by Oral Anticoagulants Reveals Lower VKORC1L1 Susceptibility due to Different Binding Site
K. Liphardt, K.J. Czogalla, K. Höning, V. Hornung, M. Watzka, J. Oldenburg (Germany)

PB 294  A comparison of management strategies for patients with warfarin-induced bleeding
P. Dobesh, B. Trevarrow, C. Duncan, P. Malinowski, K. Giuliano, K. Gundabolu (United States)

PB 295  Provision of External Quality Assurance for Post Analytical Assessment of Point of Care Haemostasis Tests

PB 296  Warfarin Toxicities: Risk Factors and Management - Data from a Developing Country
S.A. Ali, A. Rashid, B. Moiz (Pakistan)

PB 297  Use of a 4-factor Prothrombin Complex Concentrate for Warfarin Reversal prior to Urgent Surgery
B. Trevarrow, P. Dobesh, M. Wolfe, K. Gundabolu (United States)

PB 298  Can Results Be Improved on Vitamin K Antagonists (AVKs) Therapy?
A.B. Vilaseca, G. Vidmar, R. Barbera, H. Beccari (Argentina)
<table>
<thead>
<tr>
<th>POSTER SESSIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PB 299</strong></td>
</tr>
<tr>
<td><strong>PB 300</strong></td>
</tr>
<tr>
<td><strong>PB 301</strong></td>
</tr>
<tr>
<td><strong>PB 303</strong></td>
</tr>
<tr>
<td><strong>PB 304</strong></td>
</tr>
<tr>
<td><strong>PB 305</strong></td>
</tr>
<tr>
<td><strong>PB 307</strong></td>
</tr>
<tr>
<td><strong>PB 308</strong></td>
</tr>
</tbody>
</table>

**Transfusion & Biotherapeutics**

<table>
<thead>
<tr>
<th>POSTER SESSIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PB 310</strong></td>
</tr>
<tr>
<td><strong>PB 311</strong></td>
</tr>
<tr>
<td><strong>PB 312</strong></td>
</tr>
<tr>
<td><strong>PB 313</strong></td>
</tr>
<tr>
<td><strong>PB 314</strong></td>
</tr>
<tr>
<td><strong>PB 315</strong></td>
</tr>
<tr>
<td><strong>PB 316</strong></td>
</tr>
<tr>
<td><strong>PB 317</strong></td>
</tr>
<tr>
<td><strong>PB 318</strong></td>
</tr>
<tr>
<td><strong>PB 320</strong></td>
</tr>
</tbody>
</table>
**Poster Sessions**

**PB 321** Characterization of a Universal Reversal Agent for Anticoagulants
K. Bakhtiari¹, S.L.M. Peters¹, D.M. Monroe², J.C.M. Meijers¹ (¹The Netherlands, ²United States)

**PB 322** Antiaggregant Effect of Rubia tinctorum Butanolic Extract on Human Platelets
M. Fatimazahra¹, Z. Younes², K. Haouach¹, C. Abderrahim¹, B. Abdellah¹, B. Hicham¹ (¹Morocco, ²Canada)

### Poster Session

**12:00 – 13:15**  
**Exhibition Hall 4.2**

**PB 323** Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis-associated Coagulopathy
A. Walborn, P. Patel, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

**PB 324** Mediators of Inflammation and Infection in Sepsis Associated Disseminated Intravascular Coagulation and Their Prognostic Role
P. Patel, A. Walborn, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

**PB 325** Crotoxin, a phospholipase A2 from Crotalus durissus terrificus rattlesnake venom, attenuates coagulation and inflammatory parameters in endotoxin-induced DIC
M.A. Sartim, G.N. Cezarette, S.V. Sampaio (Brazil)

**PB 326** Evaluation of the Diagnostic Utility of Individual Parameters in the Disseminated Intravascular Coagulation (DIC) Panel for Use in Under-resourced Settings
S. Louw, E.S. Mayne, A. Mayne (South Africa)

**PB 327** Circulating Nucleosomes and Neutrophil Activation Predict for Disseminated Intravascular Coagulation but Not for Mortality in Patients with Severe Sepsis or Septic Shock
M.N. Lauw¹, W.A. Wuillemin², G.J. Van Mierlo¹, S. Zeerleder¹ (¹The Netherlands, ²Switzerland)

**PB 328** A Prospective Observational Study for the Evaluation of New Diagnostic Criteria for Disseminated Intravascular Coagulation by the Japanese Society on Thrombosis and Hemostasis

**PB 329** A comparison of Disseminated Intravascular Coagulation (DIC) Screening Parameters with and without Human Immunodeficiency Virus Infection in an African Academic Hospital Setting
E. Mayne, A. Mayne, S. Louw (South Africa)

**PB 330** International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation
D. Hoppensteadt, A. Walborn, S. Abro, J. Walenga, M. Mosier, K. Tsuruta, J. Fareed (United States)

**PB 331** Epidemiological Evaluation of Patients Presenting with Disseminated Intravascular Coagulation (DIC) at an Academic Hospital in an African Middle-income Country
E. Mayne, A. Mayne, S. Louw (South Africa)

**PB 332** Real Word Difficulties in the Diagnosis and Management of Hyperfibrinolysis
W. Thomas, J. Russell, E. Symington, M. Besser (United Kingdom)

**PB 333** Fulminant Disseminated Intravascular Coagulation as Initial Manifestation of Pulmonary Adenocarcinoma
S. Teixeira, C. Monteiro, M. Carvalho, L. Gonçalves, C. Koch (Portugal)

**PB 334** Platelet-mimicking Synthetic Nanoparticles (SynthoPlateTM) Improve Hemostasis and Survival Following Uncontrolled Hemorrhage

**PB 335** Early Fibrinolytic Activation and Hypofibrinogenaemia Are Associated with Mortality in Isolated Traumatic Brain Injury
P. Vulliamy, S.E. Breukers, S. Gillespie, T. Walton, V. Carneiro Gimenez, C. Uff, K. Brohi, R.A. Davenport (United Kingdom)

**PB 336** Platelets Loaded with Thrombin-encapsulated Liposomes Have Increased Coagulability
V. Chan, M. Sarkari, R. Sunderland, C. Kastrup (Canada)

**PB 337** S100B in Suspected Intracranial Hemorrhage in Patients after Minor Head Injury Older than 65 Years and on Antiplatelet Therapy
H.W. Thaler, J. Schmidsfeld (Austria)

**PB 338** Antifibrinolytic Therapy to Prevent Oral Bleeding in People on Anticoagulants Undergoing Oral or Dental Procedures: A Cochrane Systematic Review
E.T. Engelen, R.E.G. Schutgens, E.P. Mauser-Bunschoten, R.J.J. Van Es, K.P.M. Van Galen (The Netherlands)
PB 339  Management of Rivaroxaban or Apixaban Associated Major Bleeding with Prothrombin Concentrate: A Prospective Cohort Study  
A. Majeed\textsuperscript{1}, A. Ågren\textsuperscript{1}, M. Bruzelius\textsuperscript{1}, R. Chaireti\textsuperscript{1}, J. Odeberg\textsuperscript{1}, M. Holmström\textsuperscript{1}, E.L. Hempel\textsuperscript{1}, M. Magnusson\textsuperscript{1}, T. Frisk\textsuperscript{1}, S. Schulman\textsuperscript{2} (\textsuperscript{1}Sweden, \textsuperscript{2}Canada)

PB 340  Favorable Thrombogenicity Profile of a Prothrombin Complex Concentrate (4F-PCC) in Animal Models of Venous and Arterial Thrombosis  
F. Kaspereit, W. Krege, E. Raquet, F. Musch, M. Mischnik, E. Herzog (Germany)

PB 341  Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors  

PB 342  Reversal of Dabigatran-associated Major Bleeding with Activated Prothrombin Concentrate: A Prospective Cohort Study  
S. Schulman\textsuperscript{1}, B. Ritchie\textsuperscript{1}, S. Nahiriak\textsuperscript{1}, P. Gross\textsuperscript{1}, M. Carrier\textsuperscript{1}, A. Majeed\textsuperscript{4}, H.-G. Hwang\textsuperscript{3}, M. Zondag\textsuperscript{1} (\textsuperscript{1}Canada, \textsuperscript{2}Sweden, \textsuperscript{3}Korea, Republic of)

PB 343  A randomized study of 4-factor prothrombin complex concentrate and tranexamic acid on bleeding, thrombin generation, and pharmacodynamics after punch biopsies in rivaroxaban treated subjects with supratherapeutic drug levels  
J. Levy\textsuperscript{1}, K.T. Moore\textsuperscript{1}, M. Neal\textsuperscript{1}, D. Schneider\textsuperscript{1}, V. Marcisini\textsuperscript{1}, J. Ariyawansa\textsuperscript{1}, J. Weitz\textsuperscript{2} (\textsuperscript{1}United States, \textsuperscript{2}Canada)

PB 344  Idarucizumab for Dabigatran Reversal in Daily Practice - First Experiences from Slovenia  
N. Vene, A. Mavri, M. Bozic Mijovski, P. Gradisek, M. Gregoric, S. Frol, J. Pretnar (Slovenia)

PB 345  The Influence of Histones on the Generation of Factor Xa in Trauma Patient Blood  
S. Prior, N. Dow, K. Freeman, C. Esmon, K. Mann, S. Butenas (United States)

PB 346  Markers of Platelet Activation Are Elevated Specifically on Leukocytes after Major Injury  
S. Gillespie, P. Vulliamy, J. Shepherd, R. Davenport, K. Brohi (United Kingdom)

PB 347  Evaluation of Early Metrics of Clot Amplitude from New Generation Thromboelastogram (TEG6s) in Capturing Trauma Induced Coagulopathy  
B. Mathew, C. Lopez-Espina, J. O’Mara (United States)

PB 348  Implementation and Migration of Haemophilia-treatment-diaries from Paper Based to Electronic Documentation at Haemophilia CCC at the University of Bonn  
J. Oldenburg, R. Langenkamp, G. Goldmann (Germany)

PB 349  Development and Validation of the Warfarin-Aspirin Bleeding Assessment Tool (WA-BAT)  
C. Attard, P. Monagle, Y. d’Udekem, V. Ignjatovic (Australia)

PB 350  Prothrombin Concentrate Complex for Major Bleeding in Patients Receiving Direct Oral Anti-coagulants: A Single Center Retrospective Study  
M. Barzilai, D. Salzer Gotier, I. Avivi, I. Kirgner (Israel)

PB 351  Chemical Composition of Malian Medicinal Plants Used to Treat Bleeding Events  
Y.L. Diallo, A. Togola, I. Sanogo, D. Traore, A.H. Babana, R. Sanogo, D. Dallio (Mali)

PB 352  First Italian Experience of Clinical Use of Obizur, Recombinant Porcine Sequence Factor VIII (RPFVIII), for Acquired Haemophilia A (AHA)  
C. Lodigiani, P. Ferrazzi, L. Libre', V. Pacetti, A. Colombo, M.C. Beltrametti, I. Quaglia (Italy)

PB 353  The Effect of PCC on ROTEM Parameters in Patients with Coagulopathy of Liver Disease  
C. Hamid\textsuperscript{1}, J. McVey\textsuperscript{1}, A. Riddell\textsuperscript{1}, T. Fox\textsuperscript{1}, E. Brodkin\textsuperscript{1}, A. Gatt\textsuperscript{2}, R. Morris\textsuperscript{1}, P. Chowdary\textsuperscript{2} (\textsuperscript{1}United Kingdom, \textsuperscript{2}Malta)

PB 354  Factor VIII and von Willebrand levels at Desmopressin (DDAVP) Challenge Test: A Single Center Results  
C. Casas, M.H. Solano, M.L. Parra, D. Espinosa, V. Abello, A. Palacios (Colombia)

PB 355  Correlation between Platelet Count and Platelet Component in Thromboelastometry  
M. Milic, J. Jonjic, V. Seric (Croatia)

PB 356  Favorable Effect of Combined Use of Prothrombin Complex Concentrate and Plasma in vitro-Induced Coagulopathy  
H.J.M. Brinkman\textsuperscript{1}, M. Zuurbeld, R. Lassila\textsuperscript{2}, J.C.M. Meijers\textsuperscript{1} (\textsuperscript{1}The Netherlands, \textsuperscript{2}Finland)

PB 357  Towards a Clinically Relevant Hybrid Adenovirus-Sleeping Beauty Transposon Vector for Gene Therapy for von Willebrand Disease  
J. Portier\textsuperscript{1}, M. Solanki\textsuperscript{2}, H. Deckmyn\textsuperscript{1}, K. Vanhoorelbeke\textsuperscript{1}, A. Ehrhardt\textsuperscript{1}, S.F. De Meyer\textsuperscript{2} (\textsuperscript{1}Belgium, \textsuperscript{2}Germany)
**POSTER SESSIONS**

**PB 358**
Comprehensive Functional and Structural Studies to Characterize von Willebrand Factor Propeptide Novel Missense Variants with Unknown Pathological Significance
H. Yadeegari, A. Biswas, S. Ahmed, A. Naz, J. Oldenburg (Germany, Pakistan)

**PB 359**
Triggering Receptor Expressed on Myeloid Cells Like Transcript-1 (TLT-1) is a Novel Ligand for von Willebrand Factor
A. Doerr, C. Gardiner, M. Laffan, T. McKinnon (United Kingdom)

**PB 360**
A2 Domain Unfolding Might Significantly Increase Shear and Elongation-mediated WVF Unfolding in the Bloodstream
D. Nechipurenko, I. Krauz, K. Vladislav, I. Gudich, V. Alferov, C. Cardona, V. Isidorova, T. Kurakina, E. Morales, D. Yarotskiy (Russia, the United States)

**PB 361**
Acquired von Willebrand Disease (aVWD) in Plasma Cell Dyscrasias (PCD): Variable Underlying Pathophysiology as Evidenced by the Analysis of Proteolytic Willebrand Factor (VWF) Cleavage Fragments
J. Irl, F. Langer, C.C. Dicke, J. Fuchs, C. von Auer, S. Schneppenheim, H. Rossmann, Z. Rücker, B. Lämmlle, K. Jurk (Germany, the United States)

**PB 362**
Axial Structure and Collagen Binding of the von Willebrand Factor Multimer M.C. Osanyi, T. Feller, T. Bozo, M.S.Z. Kellermayer, J. Harsfalvi (Hungary)

**PB 363**
Safety and Efficacy of Recombinant von Willebrand Factor (rVWF) in Patients with Severe von Willebrand Disease (VWD) Undergoing Major and Minor Elective Surgical Procedures: A Prospective Clinical Trial
F. Peyvandi, A. Mamaev, J.-D. Wang, C.A.M. von Auer, O. Stasysyn, M. Timofeeva, N. Curry, A.R. Cid, T.T. Yee, K. Kavakli, M. Chapman, A. Grigorian, B. Ploder, A. Syltowski (Italy, Russia, Federation, Taiwan, Germany, Ukraine, United Kingdom, Spain, Turkey, United States, Austria)

**PB 364**
Recombinant Activated Factor VII-Induced Correction of Bleeding Tendency in Genetically-engineered von Willebrand Disease Type 2B Mice Evaluated Using New Tail Transection Bleeding Models
V. Proulle, C. Auditeau, H. Petit, F. Adam, A. Kauskot, F. Moreau, O.D. Christophe, P.J. Lenting, C. Denis (France)

**PB 365**
VWF D'D3 Mutations Associated with Type 1 von Willebrand Disease Demonstrate Impaired Gp1Bα-VWF Binding under High Shear Stress
N. Christopher, K. Ashworth, T. White-Adams, J. Di Paola (United States)

**PB 366**
Diagnostic Challenges of Acquired von Willebrand Syndrome
S. Schneppenheim, R. Dittmer, U. Budde (Germany)

**POSTER SESSIONS**

**PB 367**
Multimer Size Distribution and Monomerization Defects of von Willebrand Factor Investigated at the Single-molecule Level by AFM Imaging
A. Lüt, G. König, S. Schneppenheim, T. Obser, S. Schneppenheim, M. Benoit, U. Budde, J.P. Müller, M.A. Brehm (Germany)

**PB 368**
Exploration of Interim Bleeding Scores in VWD Subjects from Irish LoVrC, Canada and the US Zimmerman Program

**PB 369**
Does Ageing Modify Hemostatic Parameters in Type 1 von Willebrand Disease (VWD-1)?
G. Guglielmini, M. Borghi, A.M. Mezzasoma, E. Falcinelli, P. Gresele (Italy)

**PB 370**
Common Single Nucleotide Variants in the von Willebrand Factor Gene Associate with “Mutation Negative” Type 1 VWD
C. Notley, M. Bowman, C. Brown, K. Tyryshkin, L. Swystun, P. James, D. Lillicrap (Canada)

**PB 371**
Functional Polymorphisms of the von Willebrand Factor Gene in Patients with Mild to Moderate Bleeding Tendency and Low von Willebrand Factor Antigen or von Willebrand Factor Ristocetin Cofactor
S. Hofer, J. Gebhart, J. Rejtó, G. Hörmann, I. Pabinger, R. Sunder-Plassmann (Austria)

**PB 372**
Expression of the von Willebrand Factor C-domains in E.coli
H. O’Brien, F. Hansen, T. Tuddenham, M. Laffan, T. McKinnon (United Kingdom)

**PB 373**
Quantitative ELISA Assay for in vivo Proteolysis of von Willebrand Factor and Bleeding: A Pilot Study in Type 2A (IIA) von Willebrand Disease

**PB 374**
Bleeding Symptoms in Patients Previously Diagnosed as Type 3 von Willebrand Disease: Results from a Multicenter, Multinational Cross-sectional Study
**POSTER SESSIONS**

**PB 375**  
Fluorescence Intensity-based Analysis of the Shear-dependent Internalization of Von Willebrand Factor Mutants by Macrophages  
U. Klemm, G. Ahmari, T. Obser, G. König, R. Schnepenheim, M. Brehm (Germany)

**PB 376**  
Von Willebrand Factor Multimer Analysis in 255 Patients Previously Diagnosed as VWD Type 3 from the Iranian Republic and Nine European Countries (3WINTERS-IPS Study)  

**PB 377**  
Interaction between the A3 and A2 Domains of von Willebrand Factor Reduces the Binding of the A1 Domain to Glycoprotein Ibα  
S. Cirlos, M. Auton, M. Cruz (United States)

**PB 378**  
Incidence and Economic Burden of Thromboembolic Events (TEEs) among US Patients with von Willebrand Disease (VWD) - A Large Claims Database Analysis  
M. Lu, A. Oladapo, E. Fadli, A. Khachatryan, E. Brouwer, M. Bron, T. Kauf (United States)

**PB 379**  
periOperative Management of Replacement Therapy in von Willebrand Patients: Steps towards Individualization of Treatment?  

**PB 380**  
Deficiency of von Willebrand Factor (VWF) High Molecular Weight Multimers (HMWM) in the Presence of Normal/Increased Activity of both VWF Cofactor Activity (VWF:RCo) and VWF Antigen (VWF:Ag) in Patients with Severe Aortic Stenosis  
K. Bykowski, D. Zakrzewski, B. Baran, P. Kunicki, T. Hryniewiecik, J. Windyga (Poland)

**PB 381**  
Usefulness of VWF Propeptide in the Differential Diagnosis between Patients with VWD and AIVWS  
F. Stufano, M. Boscarino, L. Baranciani, P. Bucciarelli, G. Cozzi, F. Peyvandi (Italy)

**POSTER SESSIONS**

**PB 382**  
Lack of Discontinuous von Willebrand Factor Multimer Organization Associated with the c.2269_2270del Mutation in the von Willebrand Factor Gene  
V. Daidone, E. Galletta, A. Casonato (Italy)

**PB 383**  
Surgeries in adults and Children with von Willebrand’s Disease - Results from the Ongoing Study Wilate-STATE  
S. Halimeh, M. Daoud, M. Rieke, T. Lang, J. Kadar, S. Alesci, J. Koscielny, J. Feddern, S. Seeger (Germany)

**PB 384**  
Laboratory Diagnosis of von Willebrand Disease Type 2A versus LVAD-Induced Acquired von Willebrand Syndrome  
S. Deconinck1, C. Tersteeg1, E. Bailleul1, L. Delrue5, N. Vandeputte1, I. Pareyn1, H. Deckmyn1, S.F. De Meyer1, N. Itzhar-Baikian6, M. Vanderheyden6, K. Vanhoorelbeke1 (1Belgium, 2France)

**PB 385**  
Elevated Levels of vWF Antigen and Activities, Factor VIII and Fibrinogen Inversely Correlated with the Estimated Glomerular Filtration Rate in Patients with Non-dialysis Chronic Kidney Disease  
B. Suwanawiboon, R. Chainarongsiriporn, Y. Nakkinkun, R. Chawanasuntarapoj (Thailand)

**PB 386**  
Measurement of Platelet von Willebrand Factor (VWF) Antigen Concentration and Activity Using Automated Latex-immunoturbidometric (LIA) Assays  
H. Rühl, K.M. Orschulik, J. Müller, J. Oldenburg, B. Pötzsch (Germany)

**PB 387**  
Impact of Changes in Laboratory Diagnostic Criteria in the Classification of von Willebrand Disease  
P. Batty, J.N. Hodgetts, J. Uprichard (United Kingdom)

**PB 388**  
Combined Lenalidomide and Dexamethasone Treatment of Multiple Myeloma Cures Acquired von Willebrand Syndrome: A Case Report  

**PB 389**  
Profile of Mutations Identified in the 3WINTERS-IPS Project on Iranian Patients with Previously Diagnosed Type 3 von Willebrand Disease  
L. Baranciani1, F. Peyvandi1, F. Stufano1, P. Eshghi6, Z. Badiee2, M.-R. Baghaipour3, U. Budde4, J. Eikenboom4, A. Goodeve6, J. Goudemand6, H. Hoorfar2, M. Karimi2, B. Keikhaei2, P.M. Mannucci1, I.R. Peake6, R. Schnepenheim3, G. Toogeh2, A. Tosetto1, S.O.R. Zekavat2, A.B. Federici1 (1Italy, 2Iran, Islamic Republic of, 3Germany, 4The Netherlands, 5United Kingdom, 6France)
**POSTER SESSIONS**

PB 390  
Self-reported Experiences with Menorrhagia in Women with von Willebrand Disease: A Patient-oriented Survey Study  
(United States)

PB 391  
Primary Hemostasis in Severe von Willebrand Disease Patient’s Blood Is Reconstituted in vitro by Ultralarge von Willebrand Factor Multimers  
T. Kragh, I. Pekrul, M. Spannagl  
(Germany)

PB 392  
Ristocetin Cofactor Latex Immunoassay, High Sensibility to Acquired von Willebrand Disease with Subtle Loss of High Molecular Weight Multimers  
B. Montaruli, P. Sivera, D. Cosseddu, C. Fornelli, I. Canta, N. Renzi, O. Ruggia, M. Migliardi  
(Italy)

PB 393  
Von Willebrand Factor Antigen Levels in 255 Patients Previously Diagnosed as VWD Type 3 from the Iranian Republic and Nine European Countries (3WINTERS-IPS Study)  
(1Germany, 2Iran, Islamic Republic of, 3Italy, 4Spain, 5Sweden, 6Hungary, 7The Netherlands, 8United Kingdom, 9France, 10Finland)

PB 394  
Clinical Characterization of 76 Families with von Willebrand Disease  
(Brazil)

PB 395  
Clinical Evaluation of the Sebia Hydragel von Willebrand Factor Assay in Comparison to Electrophoresis and Blotting Based Multimer Analysis  
(1Germany, 2Iran, Islamic Republic of, 3Italy, 4Spain, 5Sweden, 6Hungary, 7The Netherlands, 8United Kingdom, 9France, 10Finland)

PB 396  
Can a One-time von Willebrand Testing Rule out Type 1 von Willebrand Disease in Young Women with Menorrhagia?  
E. Morita, E. Soundar, K. Bruzdoski, V. Kostousov, J. Teruya, S.-K. Hui  
(United States)

PB 397  
Screening of von Willebrand’s Disease in a Region of High Consanguinity  
Y. Ouarhlent, H. Laiadhi, M.R. Makhloufi, R. Chafai, S. Chichoune  
(Africa)

**Diagnostics and OMICS**

PB 398  
Management of a Spontaneous Ileo-psoas Haematoma in a Girl with Type 3 von Willebrand Disease and Allantibodies to von Willebrand Factor  
C. Ambazglio, G. Giorgiani, N. Decembrino, F. Zane, M. Russo, C. Sacco, E. Genini, P.S. Preti, M. Zecca, G. Gamba  
(Italy)

PB 399  
Failure of Wells Score and D-dimer to Safely Exclude Diagnosis of Deep Vein Thrombosis: A Single Centre Experience of over 3500 Patients  
S. Badle, E. Friedman, L. Bowles, P. MacCallum  
(United Kingdom)

PB 400  
Residual Vein Thrombus Does Not Predict for Recurrent Venous Thrombosis in the ASPIRE Study  
(1Australia, 2Canada)

PB 401  
Utility of Thromboelastometry Analysis in Patients with Mild Bleeding Disorders  
A. Wieland Greguare-Sander, W.A. Wulillemen, M. Nagler  
(Switzerland)

PB 402  
Increased Maximum Lysis of ROTEM in Pregnancy: It Is Not Hyperfibrinolysis  
J. Teryua, A. Shamshirsaz, H. Erfani, K. Fox, K. Bruzdoski, S.K. Hui, V. Kostousov  
(United States)

PB 403  
Significant von Willebrand Disease Can Be Missed if a von Willebrand Factor Activity Assay Is Not Performed  
S. Platton  
(United Kingdom)

PB 404  
Validation of Flow Cytometric Mepacrine Uptake and CD63 Expression in the Diagnosis of Storage Pool Disease  
(The Netherlands)

PB 405  
Post-analytical External Quality Assessment - Interpretation of UK NEQAS (Blood Coagulation) Results  
J. Jennings, D. Kitchen, S. Kitchen, T. Woods, I. Walker  
(United Kingdom)

PB 406  
Different D-dimer Assays Have Similar Performance Using the Age-adjusted Threshold for the Diagnosis of Pulmonary Embolism  
N. Kraaijpoel, N. van Es, F.A. Klok, M.V. Huisman, P.M. Bossuyt, H.R. Büller  
(The Netherlands)

PB 407  
Safety of Multidetector Computed Tomography Pulmonary Angiography to Exclude Pulmonary Embolism in Patients with a Likely Pretest Clinical Probability  
H. Robert-Ebadi, G. Le Gal, M. Righini  
(1Switzerland, 2Canada)
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 408</td>
<td>Familial Multiple Coagulation Factor Deficiencies - Need for Deeper Clinical and Scientific Assessment</td>
<td>B. Preisler, B. Pezeshkpoor, I. Schwarz, R. Kuhlemann, J. Junen, R. Maurer, L. Rademacher, L. Rothbrust, J. Beckedahl, J. Oldenburg, A. Pavlova (Germany)</td>
</tr>
<tr>
<td>PB 409</td>
<td>Performance of Anti-factor Xa Heparin Assays in External Quality Control Surveys</td>
<td>C. Bon, G. Matar, R. Meley, C. Sotta, J.C. Eynard, B. Poggi (France)</td>
</tr>
<tr>
<td>PB 410</td>
<td>Ex-vivo Plasma Clot Formation and Lysis as a Universal Measure for Anticoagulation in Patients on Vitamin-K-antagonist, Dabigatran, Rivaroxaban, Apixaban, or Low-molecular-Weight Heparin</td>
<td>O. Königsbrügge, G. Weigel, P. Quehenberger, I. Pabinger, C. Ay (Austria)</td>
</tr>
<tr>
<td>PB 411</td>
<td>Thrombin Generation Response of rFVIIa in Haemophilia A Patient Plasma when Using Different Triggers and Phospholipids</td>
<td>L.F. Larsen, H. Østergaard, M.B. Hermit, V. Lind, M. Ezban (Denmark)</td>
</tr>
<tr>
<td>PB 412</td>
<td>Performances of the Hydragel 5 von Willebrand Multimers - A New within-Day von Willebrand Factor (VWF) Multimer Screening Method</td>
<td>A.E. Bowyer¹, K.J. Goodfellow¹, G. Nouadje², G. Beaulieu², S. Kitchen², M. Makris¹ (¹United Kingdom, ²France)</td>
</tr>
<tr>
<td>PB 413</td>
<td>The Selective Use of Computer-assisted Strain Gauge Plethysmography as an Additional Screening Test for Suspected DVT Can Decrease the Need for Compression Ultrasonography: A Validation Study</td>
<td>A. Hughes, B. Hall, C. Smith, V. Webb, J. King, K. Jennings, G. Page, S. Macdonald, F. Charova (United Kingdom)</td>
</tr>
<tr>
<td>PB 414</td>
<td>Semi-automated Platelet Aggregometry Employing the Sysmex CS-2x00: Preliminary Findings in a Multi-centre Study</td>
<td>A.N. McCormick, S. Platton, M. Bukht, D.A. Gurney, G.W. Moore (United Kingdom)</td>
</tr>
<tr>
<td>PB 415</td>
<td>The Impact of Repeated Freeze-thaw Cycles on Antiphospholipid Antibody Titer</td>
<td>K. Meelegher, M. Luypaert, K. Devreese (Belgium)</td>
</tr>
<tr>
<td>PB 416</td>
<td>Suitability of a Liquid High-sensitivity Recombinant Human Prothrombin Time Reagent with Two Year Half Life on an Automated Coagulation Laboratory Platform</td>
<td>K. Cawthern, C. Kung, R. Bottenus, V. Sarquella (United States)</td>
</tr>
<tr>
<td>PB 417</td>
<td>Discrepancy in Optical and Impedance Platelet Count in Platelet Rich Plasma Prepared for Light Transmission Aggregation as a Possible Sample Quality Indicator</td>
<td>A. Milanic, D. Coen Herak, M. Milos, D. Rogic (Croatia)</td>
</tr>
</tbody>
</table>

---

**Monday**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 419</td>
<td>A New Chromogenic DTI Assay for the Quantitative Determination of Dabigatran in Human Plasma</td>
<td>J. Mueller*, A. Hesse, I. Kieper-Rupp, D. Koch, J. Kurz, S. Vollmerhausen, D. Bussfeld (Germany)</td>
</tr>
<tr>
<td>PB 420</td>
<td>Comparison of Thrombin Generation Profiles among Patients Treated with Three Different Direct Oral Anticoagulants and Warfarin</td>
<td>O. Paoletti, C. Dellanoce, A. Zimmermann, R. Morandini, E. Cancellieri, S. Zambelli, M. Tala, C. Beati, M. Stramezzi, S. Testa (Italy)</td>
</tr>
<tr>
<td>PB 421</td>
<td>Multicenter Evaluation of D-Dimer on Two New Coagulation Systems</td>
<td>T. Wissel¹, D. Christie², V. Janssen³, K. Purr¹, U.-P. Schobel¹ (¹Germany, ²United States)</td>
</tr>
<tr>
<td>PB 423</td>
<td>Thromboelastometry to Detect Anticoagulant Effect of Apixaban in Patients with Non Valvular Atrial Fibrillation</td>
<td>M.C. Vedovati, M.G. Mosconi, F. Isidori, G. Agnelli, C. Becattini (Italy)</td>
</tr>
<tr>
<td>PB 424</td>
<td>Assessment of Single-factor Deficiency Sensitivity of Three Thromboplastin Reagents</td>
<td>V. Juif, P.O. Sevenet, M. Lubineau, N. Masset (France)</td>
</tr>
<tr>
<td>PB 427</td>
<td>Usefulness of Waveform Analysis of APTT on the ACL-TOP® When Troubleshooting Unexpected Abnormal APTT</td>
<td>N. Tokunaga, C. Inoue, T. Sakata, Y. Inoue, S. Akaiwa, H. Yoshida, T. Nakao, T. Doi (Japan)</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

PB 428  Evaluating the Analytical Performance of Six New Coagulation Assays
S. Kitchen1, U. Geisen2, J. Kappelmayer3, P. Quehenberger4, R. Jones1, A. Lowe1, J. Boehm1, G. Miles1, G. Rozsnyai2 (1United Kingdom, 2Germany, 3Hungary, 4Austria, 5United States, 6Switzerland)

PB 429  Performance Evaluation of the microINR® Point-of-Care INR-testing System
J. Joubert, M.C. Van Zyl, J. Raubenheimer (South Africa)

PB 430  Statistical Evaluation of APTT Clot Waveform Patterns (CWP) in Sequential Samples of Severe Haemophilia A Patients Receiving Long Acting Clotting Factor Concentrates (CFC) - An Observational Study

PB 431  Divergence of Normal Ranges Using Thromboelastography as Measured by Clot Viscosity versus Clot Harmonic Resonance
G. Wool, K. Mikrut, J. Miller (United States)

PB 432  Identification of Triple Positivity Patients with Major Risk for Thromboses Is Dependent of Methodology Applied at the Lab Investigation

PB 433  Performance Evaluation of the ZL 6000i Cone Plate Viscometer
J. Lee, S. Yu, S. Song, S. Oh, J. Shin, H. Kim, K. Jun, J. Lee (Republic of Korea)

PB 434  Standardization and Automation of Thrombin Generation Assay: on the Way to the Clinical Lab
J. Douxfils, J. Baudar, M. Guldenpfennig, B. Chatelain, J.-B. Nicolas, F. Mullier (Belgium)

PB 435  Accurate Recovery of N9-GP in a One-stage Ellagic Acid Based Clot Assay on the ACL Top Analyzer
A. Khan, M. Doyle, M. Triscott (United States)

PB 436  A Performance Evaluation of a New Lupus Sensitive APTT Reagent
C. Gardiner1, E. Kinoshita2, K. Akatsuchi2, P. Lane1, I. Patel1, S.J. Machin1, I.J. Mackie1 (1United Kingdom, 2Japan)

PB 437  Standardization and Automation of Thrombin Generation (TG) Assay Measured in Presence and Absence of Thrombomodulin: TG on its Way to the Clinical Lab
C. Bulato, S. Gavasso, E. Campello, D. Tormene, L. Spiezia, P. Simioni (Italy)

PB 438  Establishment of Oral Anticoagulant Monitoring Facility at Tertiary Care Teaching Hospital in Western India: Four Years Experience
A. Kelkar, A. Nisal, P. Doshi, A. Moses, N. Gaikwad, R. Nimbargi, N.S. Mani (India)

POSTER SESSIONS

PB 439  Do Chinese Patients with Heart Valve Replacement Benefit from Warfarin Pharmacogenetic Test: A Pilot Retrospective Study
Y. Hao, Y. Hu, X. Yan, S. Cao, Z. Zhang, X. Zheng (China)

PB 440  Analytical Performance of an Anti Xa Assay with Rivaroxaban Specific Calibrators
C. Dubosco, J. Ceresetto, C. Shanley, O. Rabinovich, S. Palmer, G. Stemmelin (Argentina)

PB 441  Multicenter Study on the Interference of Spontaneous Hemolysis at Blood Sampling on Five Main Hemostasis Tests
C. Novelli, B. Morelli, M. Vidali, Study Group of Hemostasis and Thrombosis of Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC) (Italy)

PB 442  Performance Evaluation of the Coag-Sense® Point-of-Care INR-testing System
J. Joubert, M.C. Van Zyl, J. Raubenheimer (South Africa)

PB 443  Thrombin Generation in Patients with Coronary Complications during the First Year after Percutaneous Intervention
T. Vavilova, V. Udina, O. Napalkova, E. Vasilieva, M. Karpenko (Russian Federation)

PB 444  Prediction of Partial Thromboplastin Time (PTT) and Prothrombin Time (PT) on the Basis of Factor Assay Activities Using Data from a Clinical Data Warehouse
A. Obstfeld, M. Lambert (United States)

PB 445  Use of a Synthetic Collagen to Monitor Platelet Function in Patients Receiving Dual Antiplatelet Therapy
W. Jeske, V. Escalante, W. Klein, C. Kartje, J. Walenga, M. Bakhos (United States)

PB 446  Stability of TGA Parameters in Patients Treated with Anticoagulants Using the Fully Automated ST-Genesia System
J. Douxfils, J.-B. Nicolas, A.-S. Larock, B. Devalet, Y. Vandermeeren, V. Gérard, M. Guldenpfennig, K. De Fays, J. Baudar, F. Mullier (Belgium)

PB 447  First European Evaluation of ClarityCor Plasma Set for Instrument to Instrument Reproducibility Assessment
M. W. De Sloovere, K. M. Devreese (Belgium)

PB 448  Comparison of Activated Clotting Time Measured by I-STAT, Sonoclot and ACTPlus and Correlation with Anti-Xa during Cardiopulmonary Bypass Procedures
S. Vandendriessche, F. De Sormer, H. Laverge, K. Devreese (Belgium)
## POSTER SESSIONS

### PB 449
Presence of Residual Venous Thrombus at Warfarin Withdrawal: A Predictor for Recurrence After a First Episode of Symptomatic Provoked Proximal Deep Venous Thrombosis in an Asian Population?
N. Sermsathanasawadi (Thailand)

### PB 450
Hemolyzed Samples: Should Be Accepted in Hemostasis Laboratories?

### PB 451
Coag S: A Professional INR Monitoring Device. Comparison with the Laboratory INR Testing
E. Pap, L. Nagy, Z. Vajda (Hungary)

### PB 452
Evaluation of the New Tcoag Pre-calibrated TrinILIAATM D-Dimer II Assay
H. Lewis, K. Harrison, J. Needham (United Kingdom)

### PB 453
Safety and Efficacy of Edoxaban Compared with Warfarin for the Treatment of Acute Symptomatic Deep-vein Thrombosis in the Outpatient Setting

### PB 454
Reliability and Validity of a Point of Care Test from Urine Samples of Patients on Therapy with Apixaban, Rivaroxaban and Dabigatran
J. Harenberg, U. Warttinger, S. Hetjens, R. Schreiner, C. Giese, H.-J. Roth, R. Krämer, C. Weiss (Germany)

### PB 455
XALIA-LEA, a Non-interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-term Therapy in Deep Vein Thrombosis
A.G.G. Turpie, L.G. Mantovani, S. Haas, R. Kreutz, D. Monje, J. Scheinder, M. van Eickels, M. Gebel, M. Tamm, W. Ageno (Canada, Italy, United Kingdom, Netherlands Antilles, Belgium, Canada)

### PB 456
Rivaroxaban for Initial Therapy in Patients with Pulmonary Embolism. A Real-life Study
P. Di Micco, J. Trujillo-Santos, A. Merah, A. Fidalgo, J.R. Vela, I. Mahe, A. Bura-Riviere, J. Bascunana, B. Valero, M. Monreal, RIETE Investigators (Italy, Spain, France)

### PB 457
Impact of Age, Comorbidity and Polypharmacy on the Efficacy and Safety of Edoxaban for the Treatment of Venous Thromboembolism: An Analysis of the Randomized, Double-blind Hokusai-VTE Study

### PB 458
Prothrombin Complex Concentrate for Reversal of KA Inhibitors - Real Life Data
G. Spectre, A. Steimatzky, A. Shacham, Y. Yahalom, S. Nakav, Y. Belnick (Israel)

### PB 459
Clinical Characteristics and Treatment of Patients with Cancer-associated Venous Thromboembolism: Results from the GARFIELD-VTE Registry

### PB 460
Rivaroxaban for Scheduled Work-up of Patients with Suspected Deep Venous Thrombosis: A Prospective Interventional Outcome Study - The Ri-Schedule study
W. Ghanima, M. Qarboush, C. Tøvik Jørgensen, N. Raouf, J. Gleditich, A. Dahm, P.M. Sandset (Norway)

### PB 461
Real-world Adherence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation

### PB 462
Oxygen Saturation to Improve Risk Stratification in Hemodynamically Stable Patients with Acute Pulmonary Embolism
C. Becattini, M.C. Vedovati, P. Pruszczyk, S. Vanni, M. Colugno, V. Stefanello, M.G. De Natale, M. Kozlowska, F. Mannucci, L. Guirado Torrecillas, G. Agnelli (Italy, Poland, Spain)

### PB 463
Direct Anticoagulants and Vitamin K-antagonists Exert Differential Effects on Markers of Subclinical Cardiovascular Disease: Results from the MyoVasc Study
PB 465  Lifelong Apixaban Treatment Is Cost-effective for Idiopathic Venous Thromboembolism  
L. de Jong, M. Huisman, M. Postma (Netherlands Antilles)

PB 466  Factors Associated with the Anticoagulant Regimen and Duration of Hospitalization in Patients with Acute Pulmonary Embolism: FOCUS, a Prospective Multicenter Cohort Study  

PB 467  Real-life Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Cancer Associated Venous Thromboembolism: Data from a Prospective Cohort  

PB 468  The YEARS Algorithm for Suspected Pulmonary Embolism Leads to Much Shorter Diagnostic Turnaround Time than Conventional Algorithms  

PB 469  The Assessment of Apixaban Reversal in a Porcine Trauma Mmodel by Thrombelastography (TEG)  
M. Honickel, N. Akman, O. Grottke (Germany)

PB 470  Plasma Fibrin Clot Properties in the G20210A Prothrombin Mutation Carriers Following Venous Thromboembolism: The Effect of Rivaroxaban  
J. Siudut, A. Janion-Sadowska, J. Natorska, M. Zabczyk, A. Stanisz, A. Undas (Poland)

PB 471  A Cross-Sectional, Multinational, Multidisciplinary Survey of Physicians Surrounding the Management of Bleeding Complications in the Setting of Direct Oral Anticoagulant Use  
J. Shaw, L. Castellucci, D. Siegel, I. Stiel, S. Syed, J. Lampron, P. Dorian, H. Dhalwal, G. Stotts, P. Wells, M. Carrier (Canada)

PB 472  Apixaban in Mechanical Circulatory Support - Evaluation in a Mock Circulatory Loop with Human Blood  
S. Rao, D. Connor, K. Nicholas, J. Joseph, P. Jansz, C. Hayward (Australia)

PB 473  Management of Major Bleeding and Outcomes in Patients Treated with DOACs: Results from the START SSC Event Register  
S. Testa1, W. Ageno1, E. Antonucci1, V. Pengo1, D. Poli1, J. Beyer-Westendorf2, M. Righini2, T.-F. Wang3, P. Verhamme3, P. Rojnaruckin4, B. Caramelli4, P. Angchaisuksiri5, M. Paciaroni6, E. Grifoni6, G. Quazzaloca6, P. Sivera7, D. Colaiazzo8, A. Torrisi8, S. Rupoli8, A. Tosetto8, P. Michela8, G. Palareti8, START SSC Event Register (1Italy, 2Germany, 3Switzerland, 4United States, 5Belgium, 6Thailand, 7Brazil)

PB 474  High Recanalization Rate in Patients with Proximal-vein Thrombosis Treated with the New Direct Oral Anticoagulants  

PB 475  Clot Waveform Analysis of Activated Partial Thromboplastin Time Measurement Curves Reveals How Direct Oral Anticoagulants Impact In Vitro Coagulation  
Y. Fujimori, M. Waki, H. Katagiri, Y. Kondo, S. Nakamuro, N. Shimizu, M. Murata (Japan)

PB 476  Concentration Correlation of Direct Oral Anticoagulants as Measured by the TEG® 6s Oral Anticoagulant Assay  
F. Zaman, B. Matthew, C. Lopez-Espina, M. Doubleday, A. Muresan (United States)

PB 477  Self-poisoning with Direct Oral Anticoagulants: A Series of Five Cases Admitted to the Intensive Care Unit  

PB 478  New Insights in Interindividual Variability of Pharmacodynamic (PD) Response to Rivaroxaban through Thrombin Generation in the Presence of an Active Protein C Pathway: DRIVING Study Results in Healthy Volunteers  
J.-E. Salem1, P. Gaussem1, C. Funck-Brentano1, M. Azizi1, P. Mismetti1, M.-A. Loriot1, T. Lecompte2, I. Gouin-Thibault1 (1France, 2Switzerland)

PB 479  DTI/DXI Interferences with Global Coagulation Tests in Daily Care Emergency Admissions - Results of the Prospective Dresden NOAC Registry (NCT01588119)  
L. Wunder, U. Hänsel, S. Hauswald-Dörschel, K. Daschkow, L. Tittl, J. Beyer-Westendorf (Germany)
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 484</td>
<td>Management Strategies and Long-term Outcomes in Patients with Upper Extremity Deep Vein Thrombosis: Findings from the XALIA Study</td>
<td>W. Ageno1, L.G. Mantovani1, S. Haas1, R. Kreutz1, D. Monje1, J. Schneider2, M. van Eickels2, M. Gebel2, A.G.G. Turpie1 (Italy, Germany, Canada)</td>
</tr>
<tr>
<td>PB 486</td>
<td>Comparison of Bleeding and Thromboembolic Event Rates in Atrial Fibrillation Patients with Good and Poor Warfarin Control before and after Switching to Direct Oral Anticoagulants</td>
<td>B. Haymart, X. Kong, X. Gu, S. Almany, J. Kozlowski, G. Krol, M. McNamara, M. Dahu, E. Kline-Rogers, J. Froehlich, G. Barnes, S. Kaatz (United States)</td>
</tr>
<tr>
<td>PB 488</td>
<td>Use of a 4-factor Prothrombin Complex Concentrate for Management of Direct Xa Inhibitor-induced Major Bleeding</td>
<td>P. Dobesh, B. Trevarrow, P. Malinowski, K. Guiliano, C. Duncan, K. Gundabolu (United States)</td>
</tr>
<tr>
<td>PB 489</td>
<td>Is Rivaroxaban Associated with Headache and Dizziness? A Retrospective Study</td>
<td>S. Piran, S. Schulman (Canada)</td>
</tr>
<tr>
<td>PB 490</td>
<td>Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment Naïve Atrial Fibrillation Patients: 2013-2014</td>
<td>J. Brown, J. Talbert (United States)</td>
</tr>
<tr>
<td>PB 491</td>
<td>Determination of Rivaroxaban, Apixaban, Edoxaban and Dabigatran by Ultra-performance Liquid Chromatography-tandem Mass-Spectrometry and Chromogenic Assays from Urine Samples of Patients</td>
<td>R. Schreiner, S. Hetjens, C. Giese, H.-J. Roth, C. Weiss, R. Krämer, J. Harenberg (Germany)</td>
</tr>
<tr>
<td>PB 492</td>
<td>Length of Hospital Stays Following Acute Pulmonary Embolism in England: Observational Cohort Study Using the CPRD-HES Databases</td>
<td>R. Atikhan, M. Lumley, S. Lister, N. Hill, C. Lefevre (United Kingdom)</td>
</tr>
<tr>
<td>PB 493</td>
<td>Early Uptake of Edoxaban: A Danish Nationwide Cohort Study</td>
<td>M. Herrfritzsch, E. Grove, A. Pottegård (Denmark)</td>
</tr>
<tr>
<td>PB 495</td>
<td>Adherence to Rivaroxaban for the Management of Acute Venous Thromboembolism (VTE) - Early Results from the 'Follow-up in Rivaroxaban Patients in Setting of Thromboembolism' (FIRST) Registry</td>
<td>V. Speed, V. Auyeung, J. Patel, L. Roberts, J. Czuprynska, J. Samuel, R. Patel, R. Arya (United Kingdom)</td>
</tr>
<tr>
<td>PB 496</td>
<td>Level of Fatigue after Initiation of Rivaroxaban for Treatment of Venous Thromboembolism</td>
<td>T.M. Karlsvik, K. K. Utne, T.L. Borgenvik, E. Førssand, C. Jærgensen, W. Ghanima (Norway)</td>
</tr>
<tr>
<td>PB 497</td>
<td>The Combination of Rivaroxaban and Dabigatran Is Superior to Either Agent Alone in Suppressing Mechanical Heart Valve-induced Thrombin Generation</td>
<td>J. Jaffer, A. Stafford, J. Fredenburgh, R. Whitlock, J. Weitz (Canada)</td>
</tr>
<tr>
<td>PB 498</td>
<td>Oral Rivaroxaban for the Treatment of Antiphospholipid Syndrome (APS)</td>
<td>Y. Du, X.-X. Yan, K. Sun, T.-Y. Lian, Z.-C. Jing (China)</td>
</tr>
<tr>
<td>PB 499</td>
<td>Improving Appropriate Use of NOACs: Success of Online CME</td>
<td>J. Spyropoulos, J. Marko, A. Spyropoulos (United States)</td>
</tr>
</tbody>
</table>
**POSTER SESSIONS**

**PB 500**  
Influence of Anthropometric, Hematological and Biochemical Parameters on Plasma Levels of Direct Oral Anticoagulants  
S. Lancellotti, M. Sacco, E. De Candia, R. De Cristofaro (Italy)

**PB 501**  
Non Vitamin-k Oral Anticoagulants (NOAC) Dose Reduction and Adverse Outcomes - A Single Center Experience  
A. Lubetsky, M. Misgav, S. Lalezari, J. Luboshitz, O. Salomon, G. Kenet (Israel)

**PB 502**  
Reversal of Rivaroxaban Using Prothromplex Total, a 4-Factor Prothrombin Complex  

**PB 503**  
Similar Rivaroxaban Plasma Concentrations Induce Different Anticoagulant Effects in Individual Obese Patients  
D. Bertaggia Calderara, D. Kröll, C. Gerschheimer, N. Nicolas, G. Stirnimann, L. Alberio (Switzerland)

**PB 504**  
Reversal of Dabigatran in Emergency Situations  
A. Fernandez, T. Arias, J. Zanabili (Spain)

**PB 505**  
Can we Successfully Reverse a “Massive Overdose” of Dabigatran?  
I. Freire, T. Gago, A.P. Azevedo (Portugal)

**PB 506**  
Routine Coagulation Tests for Assess Anticoagulant Activity of Direct Oral Anticoagulants  
H. Cruz Gomes, L. Gonçalves, C. Monteiro, V. Cunha, M. Carvalho, C. Koch (Portugal)

**PB 507**  
Direct Oral Anticoagulants in the Treatment of Deep Vein Thrombosis: The Experience of a Hemostasis Unit  
E. Papadakis, N. Petridis, A. Banti, V. Papadopoulou, S. Efremidou, A. Kiotou (Greece)

**PB 508**  
Reversal of Dabigatran with Idarucizumab in Five Patients Admitted to the Emergency Department of Centro Hospitalar São João, Porto  
L. Gonçalves, M. Carvalho, F. Correia, G. Oliveira, C. Koch (Portugal)

**PB 509**  
Do All Patients Respond to Treatment with Direct Oral Anticoagulants?  
J. Janukonyte, D. Svenstrup Moeller, G. Dahlmann Oddseshede, J. Refsgaard (Denmark)

**PB 510**  
Measurement of Direct Factor Inhibitors Concentration in Practice Laboratory  
T. Vavilova, A. Bekoeva, P. Zubkova, Y. Skorobogatova, I. Yurinok, E. Vasilieva (Russian Federation)

**POSTER SESSIONS**

**Pediatrics**

**PB 511**  
Safety, Efficacy and PK/PD of Rivaroxaban Tablets in Children with VTE. An Einstein Junior Phase II Evaluation  

**PB 512**  
Safety, Efficacy and PK/PD of a Rivaroxaban Suspension in Children with VTE. An Einstein Junior Phase II Evaluation  
A. Chan, D. Kubitz, A. Santama, E. Samochatova, I. Martielli, P. Connor, G. Young, C. Male, G. Kenet, P. Massicotte, S. Willmann, S. Kraff, M. Becka, J.F. Heubach, A.W.A. Lensing (Canada, Germany, Spain, Russian Federation, Italy, United Kingdom, United States, Austria, Israel)

**PB 514**  
Long-term Outcome in Children on Anticoagulant Therapy after Extracardiac Fontan Operation (FO)  

**PB 516**  
e-Health Usefulness in Oral Anticoagulation Therapy in Children: Point of Care Instruments and Mobile APPs  

**PB 517**  
Feasibility and Safety of Full Dose Anticoagulation Therapy in the Context of Thrombocytopenia in Children with Symptomatic Thromboembolism during Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Treatment  
M. Bhatt, N. Parmar, J. Fowler, A. Chan, U. Athale (Canada)

**PB 518**  
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials  
H. Maas, S. Gropper, F. Huang, J. Stangier, I. Tartakovsky, M. Brueckmann, J. Halton, L. Mitchell (Germany, United States, Canada)

**PB 519**  
Factor Levels in Heparinized Critically Ill Pediatric Patients  
J. Byrnes, J. Palumbo (United States)

**PB 520**  
Dosing and Therapeutic Drug Monitoring of Tinzaparin in the Pediatric Intensive Care Unit (PICU)  
P.P. Roolveld, D. Hartwich, R. de Wilde, F. Smiers, J. Eikenboom, H. Bunker-Wiersma (The Netherlands)
PB 521
C. Male1, K. Thelen2, L.R. Brandao1, G. Young3, A. Santamaría4, I. Martinelli5, P. Saracco6, A. Chan1, J. Halton1, P. Monagle1, S. Willmann2, M. Becka2, J.F. Heubach2, A.W.A. Lensing6, D. Kubitzka1 (1Austria, 2Germany, 3Canada, 4United States, 5Spain, 6Italy, 7Australia)

PB 522
Neonatal Portal Vein Thrombosis: Characteristics and Role of Anticoagulation
E. Zapotocka1, V. Labarque1, L.R. Brandao1, S. Williams1 (1Canada, 2Belgium)

PB 523
The Incidence, Assessment and Management of Mental Health Issues in Young People on Anticoagulation Therapy Secondary to Idiopathic Venous Thromboembolism
L. Seneviratna, J. Hislop, S. Jones, F. Newall (Australia)

PB 524
Investigating the Experience of Parents who Have Given their Children Enoxaparin at Home
S. Monagle, H. Gilmore, S. Lima, F. Newall (Australia)

PB 525
A Pilot Feasibility and Safety Multicenter Trial of Administering Weight Adjusted FIXed Dose of Low Molecular Weight Heparin (Enoxaparin) to Neonates with Thrombosis (FIXET): Study Protocol
M. Bhatt1, K. Hamilton1, S. Shivananda1, K. Kulkarni1, L. Raffini2, A. Chan1 (1Canada, 2United States)

PB 526
Secondary Antithrombotic Prophylaxis in Children with Right Atrium Thrombosis
P. Zharkov, N. Ershov, A. Pshonkin, D. Fedorova (Russian Federation)

PB 527
Thrombotic Storm in an 11 Year Old Boy
S. Singh, A. Jindal, M. Singhal (India)

PB 528
Variation in Practice in Relation to Antithrombotic Therapy and Monitoring After Paediatric Cardiac Surgery: Results of a United Kingdom Survey
T. Biss, J. Alamelu, D. Arachchilage, E. Chalmers, M. Mathias, M. Richards, M. Williams, O. Tunstall (United Kingdom)

PB 529
Successful Endovascular Thrombectomy of an Extensive Cerebral Venous Thrombosis with Bilateral Thalamic Infarction in A 16 Year Old Girl: Case Report and Therapeutic Algorithm
S. Holzhauer, B. Weschke, M. Nikolaus, T. Liebig, A. Gratopp (Germany)

PB 530
Management of Henoch-Shönlein Purpura in Children with Heparin. Russian Long-term Experience
N. Sokolova, N. Vaynyunskaya (Russian Federation)

PB 531
Inherited Antithrombin Deficiency in Children: Treatment of Massive Cerebral Sinus Venous Thrombosis in a Neonate with a Mutation in Gene SERPINC1 (Exon 3 C481c>t)
S. Izquierdo Sebastiá, B. Argilés Aparicio, C. Garcia Blanes, J. Corral de la Calle, M.A. Dasi Carpio (Spain)

PB 532
Venous Thromboembolism Prevention in Children
A.M. Pizzini, V. Montemaggiori, D. Galimberti, M.C. Leone, A. Ghirarduzzi (Italy)

PB 533
Development of a Thrombus in Giant Coronary Aneurysm of a Child with Kawasaki Disease - An Unusual Clinical Manifestation
S. Singh, A. Jindal, M. Singhal (India)

PB 534
Management of Anticoagulation Therapy in Patients with Thromboembolism in The Context of Renal Diseases: Case Series and Practical Suggestions
A. Bahabri, V. Belostotsky, A. Chan, M. Bhatt (Canada)

PB 535
Successful Use of Low Molecular Weight Heparin (LMWH) in Intracardiac Thrombus of a Premature Infant: Case Report
A.M. Velez Escobar, A. Jaramillo Yepes, C. Jimenez Alvarez, L.N. Builes Restrepo (Colombia)

PB 536
Petechial Rash and Thrombocytopenia with Unfractionated Heparin (UFH) Use: Heparin Induced Thrombocytopenia (HIT) in a Child with Non-vegetative Infective Endocarditis
M.-P. Schlosser, J. Chan, J. Halton, L. Abbott (Canada)

PB 537
Resolution of Cerebral Sino-venous Thrombosis (CSVT) without Anticoagulation in a Neonate with Co-existing Protein C and Anti-thrombin Deficiency: A Case Report
V. Khatri, A. Chan, N. Stein, M. Bhatt (Canada)

PB 538
Selected Expression and Functional Importance of alpha4a-Tubulin in Platelet Biogenesis
C. Strassel1, A. Hovasse1, S. Moog1, M. Mageira1, M. Batzenschläger1, C. Schaeffer-Reiss1, B. Klie1, C. Gachet1, C. Janke1, F. Lanza1 (1France, 2Australia)

PB 539
Redundant and Non-redundant Roles of RhoA and Cdc42 in Platelet Biogenesis and Function
D. Cherpokova1, M. Popp1, S. Dötting1, P. Nurden2, I. Pleines1, M. Morowski1, A. Baig1, K. Aurbach1, G. Krohne1, C. Brakebusch1, B. Nieswandt1 (1Germany, 2France, 3Denmark)
PB 540  PDK1 is Crucial to Proplatelets Formation and Thrombopoiesis
B. Walker-Algayer, P. Münzer, S. Geue, D. Eißler, F. Lang, H. Schulze, M. Gawaz, O. Borst (Germany)

PB 541  Inhibition of MAP Kinase-interacting Kinase-1 (Mnk1) Regulates Platelet Functional Responses and Protein Synthesis in Megakaryocytes
B. Manne, R. Campbell, R. Badolia, S.P. Kunapuli, A. Weyrich, M. Rondina (United States)

PB 542  On-track to Producing Commercially-Feasible cGMP-Compliant Human Platelets from induced Pluripotent Stem Cells at Clinical Scale
J. Thon, B. Dykstra, L. Beaulieu, C. Peters, J. Italiano (United States)

PB 543  Disruption of the Cholesterol Efflux Transporters ABCA1 and ABCG1 Alters Megakaryocyte Proplatelet Production
A.B. Ouweneel1, M. van der Stoep1, H.F. Heijnen1, C. Strassel2, M. Van Eck1, S.J.A. Korporaal1 (1The Netherlands, 2France)

PB 544  Environmental Chronic Stress Induces Abnormal Megakaryopoiesis Predisposing to Thrombosis: Protective Effects of Apocynin
L. Sandrini, A. Ieraci, P. Amadio, M. Popoli, E. Tremoli, M. Rondina (Italy)

PB 546  Calcium/calmodulin-dependent Protein Kinase II (CamKII) Regulates Platelet Formation
R. Campbell, D. Shi, J. Winters, S. Bhatlekar, B. Manne, A. Jiang, S. Saperstein, M. Rondina, P. Bray, A. Weyrich (United States)

PB 547  Presence and Absence of Platelet Proteins in Differentiating Megakaryocytes
J.M. Koornneef, F.P.J. van Alphen, C. van der Zwaan, M. Hansen, E. van den Akker, K. Mertens, M. van den Biggelaar, A.B. Meijer (The Netherlands)

PB 548  Platelet Factor 4 (PF4) Levels Correlate with Platelet Count and Ability to Inhibit Megakaryopoiesis in Pediatric Patients with ITP
E. Tkaczynski, A. Arulselvan, M. Lambert (United States)

PB 549  Role of NOD-like receptors (NLRs) in Megakaryo/thrombopoiesis
L.P. D’Atri, M. Centurión, S. Negrotto, M. Schattner (Argentina)

PB 550  In vitro Generation of Functional Megakaryocytes Derived from Induced Pluripotent Stem Cells of Parahaemophilia Patients
C. Radu, M. Trevisan, C. Bulato, E. Campello, F. Sartorello, L. Spiezia, L. Barzon, P. Simioni (Italy)

PB 553  The Application of High throughput Sequencing to the Diagnosis of Thrombocytopenia
R. Wheeler, J. Cutler, M. Mitchell (United Kingdom)

PB 554  PEAR1 Methylation Is a Determinant of Platelet and Plasma P-selectin Levels, Platelet-leukocyte Aggregates and Platelet Distribution Width
B. Izzi1, F. Gianfagna2, K. Cludts1, A. De Curtis2, P. Verhamme1, A. Di Castelnuovo2, C. Cerletti2, G. de Gaetano2, M. Hoylaerts1, L. Iacoviello2, Moli-family investigators (1Belgium, 2Italy)

PB 555  Single Cell Transcriptome Analysis in Living Human Platelets
C. Zara, R. D’Alessandro, M. Brambilla, E. Tremoli, M. Camera (Italy)

PB 556  Uncovering GEnetic NEtworks Underlying Platelet Response to Thienopyridines by EXome Sequencing of Extreme Phenotype Patients: Discovery and Validation Results
J.-L. Reny1, M. Iberson1, B. Stevenson1, Y. Daali1, M. Docquier1, I. Xenarios1, T. Cuisset2, M.-A. Alessi2, P. Fontana1 (1Switzerland, 2France)

PB 557  Poorly Controlled Diabetes Mellitus Is Associated with Decreased Aspirin-mediated Acetylation of Platelet Cyclooxygenase-1 (COX-1) at Serine 529
F. Finamore, J.-L. Reny, S. Malacarne, P. Fontana, J.-C. Sanchez (Switzerland)

PB 559  A Combination of Biochemical and Functional Approaches Shows a Hyperactivation of Src Family Kinases-mediated Signaling Pathways in Platelets from Obese Patients
M.N. Barrachina, A.M. Sueiro, F.F. Casanueva, M. Pardo, Á. Garcia (Spain)

PB 560  First Quantitative Proteomic Approaches of Platelet Protein Expressions and Networks in Human MYH9-Related Disorders

PB 562  Platelets in Severe Aortic Stenosis Have an Altered Protein Profile and Are More Vulnerable upon Activation Compared to Coronary Artery Disease
C. Christersson, A. Dimberg, U. Alström, E. Ståhle (Sweden)

PB 563  Characterization of Large and Small Platelets

PB 564  TREM-like Transcript-1: A More Sensitive Marker of Platelet Activation than P-selectin Detectable in the Core and Shell of Thrombi
C.W. Smith, Z. Raslan, P Patel, Y.A. Senis, A. Mazharian (United Kingdom)

PB 565  WASH-complex Subunit Strumpellin Selectively Regulates Integrin αIbβ3 Expression
Y. Schurr1, L. Reil1, B. Nieswandt1, L. Machesy2, M. Bender1 (1Germany, 2United Kingdom)
PB 566 Mechanisms of Platelet Adhesive-receptor Shedding in Platelet Populations in Thrombus Formation  
C.C.F.M.J. Baaten1, F. Swieringa1, T. Misztal1, T.G. Mastenbroek1, M.A.H. Feijel1, P.E. Bock1, M.M.P.C. Donners1, P.W. Collins4, P.E.J. van der Meijden1, J.W.M. Heemskerk1 (1The Netherlands, 2United States, 3United Kingdom)

PB 567 The GYPsIE (GlYcoProtein Six in Stroke) Study: GPVI-dimer Level Is Increased in Ischaemic Stroke Patients, But Total GPVI Is Not  
H. McKinney1, P. Thomas1, I. Induruwa1, J. Batista1, C. Kempster1, A. Bonna1, K. Soejima2, W.H. Ouwehand1, E.A. Warburton1, K. Downes1, R.W. Farndale1, M. Moroi1, S.M. Jung1 (1United Kingdom, 2Japan)

PB 568 Gradient-dependent Modulation of Platelet Stimulatory G-protein Coupled Receptors (GPCR) Signaling  
A. Macwan, N. Boknäs, S. Ramström, S. Berg, L. Faxälv, T. Lindahl (Sweden)

PB 569 Activation of αIIb3 Integrin Involves the Cys608-Cys655 Disulfide Bond and the Electrostatic Network of the β-tail Domain  
R. Mor-Cohen, L. Levin, E. Nachliel, M. Gutman, Y. Tsafadia, Y. Einav (Israel)

PB 570 Clathrin Mediated αIIb3 Endocytosis Plays an Important Role in Platelet Activation  

PB 571 An Inhibitory Mutant of Snake Venom Rhodocytin Blocks CLEC-2/Podoplanin Interaction-dependent Platelet Aggregation and Experimental Lung Metastasis  

PB 572 Human and Murine Neonatal Platelets Display Reduced CLEC-2 and GPVI Expression and Function Profiles Compared with Adult Platelets  
V. Palma-Barqueros1, A.T. Hardy1, R. Teruel-Montoya1, J.E. Blanco1, E. Casarros-Pérez2, R. Guijarro-Campillo2, V. Vicente1, M.L. Lozano1, S.K. Watson1, Y. Sensi3, S.P. Watson4, F. Ferrer-Marin1, J. Rivera1 (1Spain, 2United Kingdom)

PB 573 DCBLD2 but Not GARP Has A Minor Role in Thrombus Formation in Mice which is Not in Line with the Findings in Zebrafish  
E. Vermersch1, B. Nuyttens1, K. Broos1, W. Maes1, S.F. De Meyer1, K. Vanhoorelbeke1, D. Unutmaz2, H. Fujii3, C. Tersteeg1, H. Deckmyn1 (1Belgium, 2United States, 3Japan)

PB 574 The Association of PAR4 Polymorphism with Human Platelet Reactivity in Japanese  
Y. Morikawa, H. Kato, N. Nishiura, K. Akuta, H. Kashiwagi, S. Honda, Y. Kanakura, Y. Tomiyama (Japan)
PB 583  Extracellular Histones Can Inhibit Complement Activation through C4 Binding  

PB 584  Complement Activation in Patients with Venous Thromboembolism  
M. Efthymiou, I. Mackie, A. Chitoile, P. Lane, T. Gkouleli, H. Cohen (United Kingdom)

PB 585  C5B9 Deposits on Endothelial Cells for the Evaluation of Complement Function in Thrombotic Microangiopathies of Different Origin and Therapy Monitoring  
M. Palomo, M. Blasco, P. Molina, G. Escolar, J. Campistol, M. Diaz-Ricart (Spain)

PB 586  The Complement Lectin Pathway in Post Cardiac Arrest Patients: A Randomized Clinical Study  
S. Haugaard, A.N. Jeppesen, A. Troldborg, H. Kirkegaard, S. Thiel, A.-M. Hvas (Denmark)

PB 587  The Effect of Platelets and Extracellular Vesicles on Complement Activation in Human Plasma  

PB 588  Fibrinogen and Clot Structure is Affected by Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria  
F. Macrae, P. Bowman, E. Linton, B. Peacock-Young, D. Newton, R. Arien, A. Hill (United Kingdom)

PB 589  Hemocompatibility Analysis of Silk Nanoparticles Leads to Different Results under Static and Flow Conditions  
M.F. Maitz, F.P. Seib, M. Herklots, C. Sperling, C. Werner (Germany)

PB 590  Character of Haemostatic System in Preterm Labor in Women with Thrombophilia  
B. Kurbanov (Uzbekistan)

PB 591  Role of Protease-activated Receptor-1 in Poly I:C Induction of Tissue Factor Expression in Endothelial Cells and in the Activation of Coagulation in Mice  
S. Subramaniam, S. Antoniak, C. Fletcher, N. Mackman (United States)

PB 592  Role of Helicobacter Pylori Eradication Therapy in Platelet Recovery in Chronic Immune Thrombocytopenic Purpura  
I. Ujjian, S. Khan, A. Memon, A. Naz, F. Naz, I. Sheikh (Pakistan)

PB 593  Intravascular Parasitic Worms and Hemostasis  
A. Da'darah, R. Bhardwaj, B. Figueiredo, S. Oliveira, A. de Laforcade, P. Skelly (United States, Brazil)

PB 594  Comparative Functional Studies of Thrombin and Staphylococcal In Terms of Clotting Kinetics and Properties of the Resultant Fibrin  
C. Thelwell, A.Z. Farkas, V.J. Farkas, K. Kolev (United Kingdom, Hungary)

PB 595  Liver Fibrosis and Thrombophilia: Is There a Real Connection? Preliminary Results among HIV/HCV Co-infection  
S. Peres, F. Aranda, M. Moiana, C. Julian, A. Lucero, K. Bendezu, G. de Larragona (Argentina)

PB 596  Anticoagulants Increase Alveolar Hemorrhage after Influenza A Infection in Mice  
K. Tatsumi, S. Antoniak, S. Subramaniam, B. Gondouin, S. Neidich, M. Beck, J. Mickelson, D. Monroe, J. Bastarache, H. Kaji, N. Mackman (United States, Japan)

PB 597  Comparison of Fibrin Generation Markers in Septic Shock  
G. Lissalde-Lavigne, E. Cochery-Nouvellon, S. Bouvier, E. Mercier, J.-C. Gris, Sepsi-Coag Group (France)

PB 598  Thoracic Manifestations in Behcet's Disease  
L. Belhadi, A. Hariz, I. Boukhris, I. Kechou, S. Azzabi, L. Ben Hassine, E. Cherif, N. Khalfallah (Tunisia)

PB 599  Macrophages Release Tissue Factor-bearing Microparticles upon Stimulation with Histoplasmosommi  
J.J. Rivera Rivas, C. Czuprynski (United States)

PB 600  A Systems Biology Approach to Elucidate the Post-translational Regulome of Coronary Artery Disease  
A. Sharma, V. Deshpande, M. Ghatge, R.K. Vangala (India)

PB 601  A Translational Approach for Identifying Shared Molecular Function and Pathways between CAD and its Risk Factors  
A. Sharma, V. Deshpande, M. Ghatge, R.K. Vangala (India)
POSTER SESSIONS

PB 603  
Efficiency of Bayesian Logic in Reagent Batch Change Management: Application to aPTT  
F. Sobas1, K. Bourazas2, E. Jousselme1, C. Nougier1, C. Négrier1, P. Tsiamyrtzis2  
(1France, 2Greece)

PB 604  
aPTT as an Independent Risk Factor for 30-day Survival for Patients on Extracorporeal Membrane Oxygenation (ECMO): 8-year Experience at Albert Einstein College of Medicine, Montefiore Medical Center  
I. Francischetti, J. Szymanski, D. Rodriguez, M. Heo, L. Wolgast (United States)

PB 605  
Sensitivity of Spatial Thrombin Generation and Fibrin Clot Growth to Clotting Factors Deficiency  
A. Kuprash1, A. Balandina1, R. Vijay2, S. Nair2, F. Ataullakhanov1, A. Srivastava2, M. Panteleev1 (1Russian Federation, 2India)

PB 606  
In-cardiome: A Knowledgebase Integrating Molecular and Clinical Worlds for Translational Research and Drug Development in Coronary Artery Disease  
A. Sharma, V. Deshpande, M. Ghatge, R.K. Vangala (India)

PB 607  
Addressing Reproducibility Concerns for Mechanistic Models of Clot Formation  
M. Anand, M. Susree (India)

PB 608  
Epigenetic Regulation of PAR-4-mediated Platelet Activation Underlies Smoking-related Cardiovascular Disease  
C.M. Williams1, L.J. Corbin1, S.J. White1, M. Van Den Bosch1, A. Taylor1, M.T. Harper1, M.L. Jones1, M. Bond1, G. Davey Smith1, C.L. Relton1, L. Falk1, A. Groom1, B.G. Nordestgaard2, A. Tybjaerg-Hansen1, S. Egil Bojesen1, A.D. Mumford1, A.W. Poole1, N.J. Timpson1 (1United Kingdom, 2Denmark)

PB 609  
Polymorphic Variation in Glutathione-S-transferase Genes among Chronic Myeloid Leukemia Patients in Pakistan  
A. Shahni, S.N. Mukry, T. Farzana, M. Nadeem, T.S. Shamshi (Pakistan)

PB 610  
Gene Expression Profile of Schistosoma Mansoni Adult Worms after Treatment with an Anti-schistosomal Drug that Inhibits Lysine Demethylase LSD1  

PB 611  
T. Feller, J. Harsfalvi, G. Domján, K. Gado, K. Varnai, M. Kellermayer (Hungary)

PB 612  
Analysis of Platelet Activation by Stable Isotope-resolved Metabolomics (SIRM)  
S. Joshi, M. Banerjee, Z. Qi, P. Lin, M.O. Warmoes, Q. Sun, H.N.B. Moseley, R.M. Higashi, A.N. Lane, T.W.M. Fan, S.W. Whiteheart, Q.J. Wang (United States)

PB 613  
Metabolites Associated with Massive versus Submassive Pulmonary Embolism - A Pilot Study  
O. Zeleznik1, E. Poole1, S. Lindstrom1, P. Kraft1, A. Van Hylckama Vlieg2, B. Parry3, N. Giordano1, C. Kabrhel1 (1United States, 2The Netherlands)

Pathogenesis of Thromboembolism

PB 614  
Efficacy of Dabigatran Etexilate in a Cancer Associated Thrombosis Murine Model  
Y. Kassim1, C. Lemarie1, J. Van Ryn2, M. Blostein1 (1Canada, 2Germany)

PB 615  
Incidence of Venous Thromboembolism in Cancer Survivors: The Scandinavian Thrombosis and Cancer (STAC) Cohort  
I.L. Gade1, S.K. Brakkani1, I.A. Naess1, J.-B. Hansen1, F.R. Rosendaal1, S.C. Cannevijeter1, K. Overvad1, H. Jensvoll1, J. Hammarstrom2, O.V. Gran2, H.H. Eriksen1, S.R. Kristensen1, M.T. Severinsen1 (1Denmark, 2Norway, 3The Netherlands)

PB 616  
Incidence of Occult Cancer in the Year Following a Second Unprovoked Venous Thromboembolism Event  
A. Delluc, S. Rezig, J.-C. Ianotto, C. Tromeur, M. Guillouf, F. Coutraud, K. Lacut, D. Mottier (France)

PB 617  
Risk Factors of Occult Malignancy in Patients with Unprovoked Venous Thromboembolism: Results from the MVTEP Study  
P. Rob1, P.-Y. Le Roux1, C. Tromeur1, B. Planquette1, N. Prévot-Blot1, C. Lavigne1, J. Pastre1, A. Merah1, G. Le Ga11, P.-Y. Salaun1, MVTEP study group (1France, 2Canada)

PB 618  
Impact of Tumor Grade on the Risk of Venous Thromboembolism in Cancer; the Scandinavian Thrombosis and Cancer (STAC) Cohort  
I.L. Gade1, S.K. Brakkani1, I.A. Naess1, J.-B. Hansen1, F.R. Rosendaal1, S.C. Cannevijeter1, K. Overvad1, H. Jensvoll1, J. Hammarstrom2, O.V. Gran2, H.H. Eriksen1, S.R. Kristensen1, M.T. Severinsen1 (1Denmark, 2Norway, 3The Netherlands)

PB 619  
Thromboembolic Events in Cancer Patients on Active Treatment with Cisplatin-based Chemotherapy; Another Look!  
**POSTER SESSIONS**

**PB 620** Low Discriminating Power of the Modified Ottawa VTE Risk Score in a Cohort of Patients with Cancer from The RIENTE Registry
A. Alatri1, L. Mazzolai1, C. Font1, A. Tafur1, R. Vallee2, M. Monreal2, RIENTE Investigators (1Switzerland, 2Spain, 3United States)

**PB 621** End of Life Management of Venous Thromboembolism in Metastatic Cancer: Current Practice, Place of Death and Complications
S. Banerjee, N. Pease, S. Noble (United Kingdom)

**PB 622** Outcomes of Extended Anticoagulant Treatment of Venous Thromboembolism in Patients with Cancer
M. Stalc, U. Cvajnar, A. Mavri (Slovenia)

**PB 623** Joint Effects of Body Height and Cancer on the Risk of Incident Venous Thromboembolism: The Tromsø Study
H. Skille, O.V. Gran, B. Paulsen, J.-B. Hansen (Norway)

**PB 624** Patients with Cancer-associated Thrombosis Benefit from Anticoagulant Treatment Beyond 6 Months
I.T. Wils1, J. Trujillo-Santos2, P.W. Kamphuisen1, L. Hernández-Blasco2, M. Lumbierres3, M.D.C. Díaz-Pedroche3, M.A. Lorente3, J.B. López-Sáez2, M. Ciammaichella3, M. Monreal2, the RIENTE Investigators (1The Netherlands, 2Spain, 3Italy)

**PB 625** Impact of Time Since Diagnosis and Mortality Rate on Cancer-associated Venous Thromboembolism in a General Population - The Scandinavian Thrombosis and Cancer (STAC) Cohort
K. Blix1, M.T. Severinsen2, S.C. Cannegieter3, H. Jensvoll1, K. Overvad2, O.V. Gran1, J. Hammarström1, A. Tjønneland1, I.A. Naess1, F.R. Rosendaal1, S.R. Kristensen1, S.K. Braekkan1, J.-B. Hansen1 (1Norway, 2Denmark, 3The Netherlands)

**PB 626** Quality of Life Related to Health in Cancer Associated Thrombosis. Pilot of Qca Study

**PB 627** Differential Impact of Triggers on the Risk of Venous Thromboembolism in Subjects with and without Cancer - Results from a Population-based Case-crossover Study
O.V. Gran, H. Skille, B. Paulsen, T. Isaksen, S.K. Braekkan, J.-B. Hansen (Norway)

**POSTER SESSIONS**

**PB 628** Venous Thromboembolism in Patients with Lymphoma
S. Phusanti, P. Anghaisuksiri (Thailand)

**PB 629** Cancer Associated Thrombosis in Cancer Patients Receiving Chemotherapy or Hormonal Therapy in an Ambulatory Setting
S. Rhodes, G. Bond, L. Moore, F. Rozycki, S. Abbrook (United Kingdom)

**PB 630** Long-term Impact on Mortality of Isolated Superficial Venous Thrombosis in Patients with Active Cancer
J.-P. Galanaud1, H. Rerrisse1, M.A. Sevestre1, G. Pernod1, S. Kahn2, I. Quéré1, J.-L. Bosson1 (1France, 2Canada)

**PB 631** Prediction of Venous Thromboembolism in Newly Diagnosed Patients Treated for Lymphoid Malignancies - Validation of the Khorana Risk Score among Patients with Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma
J. Rupa-Matyszek, L. Gil, M. Kazmierczak, M. Baranśka, M. Komarnicki (Poland)

**PB 632** High Real-life Incidence of Venous Thromboembolism in Multiple Myeloma: A Need for More Effective Thromboprophylaxis at a Lower Thrombosis Risk Threshold

**PB 633** The Procoagulant Fingerprint of Breast Cancer Cells Varies in Function of Their Aggressiveness and the Tissue Factor Expression
A. Camara, M. Sabah, E. Mbemba, A. Rousseau, P. Van Dreden, H. Mokrani, A. Katherchi, A. Larsen, I. Elalamy, G. Gerotziafas (France)

**PB 634** Joint Effect between Smoking Status and Cancer on the Risk of Venous Thromboembolism: The Scandinavian Thrombosis and Cancer Cohort
B. Paulsen1, O.V. Gran1, M.T. Severinsen2, J. Hammarström1, S.K. Braekkan1, S.R. Kristensen1, S.C. Cannegieter2, H. Skille1, A. Tjønneland1, F.R. Rosendaal1, K. Overvad2, I.A. Naess1, J.B. Hansen1 (1Norway, 2Denmark, 3The Netherlands)

**PB 635** The Impact of Traditional Triggers on the Risk of Venous Thromboembolism in Cancer - Results from a Population-based Case-crossover Study
O.V. Gran, B. Paulsen, H. Skille, T. Isaksen, S.K. Braekkan, J.-B. Hansen (Norway)

**PB 636** Impact of a Novel Version 2.0 of an Electronic Alert System for Venous Thromboembolism (VTE) Prevention in Hospitalised Cancer Patients
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 639</td>
<td>Clinical History of Thrombosis before Diagnosis of Overt Myeloproliferative Neoplasms in Triple Negative Patients</td>
<td>M. Napoliotto, S. Siragusa, S. Mancuso, M. Santoro, F. Di Piazza, A. Perez, A. Russo, V. Accurso</td>
<td>Italy</td>
</tr>
<tr>
<td>PB 640</td>
<td>Importance of the Association Cancer Cells and Microparticles on the Hypercoagulable Power of Cancer</td>
<td>A. Rousseau, A. Amrane, P. Van Dreden, A. Larsen, I. Elalamy, G. Gerotziafas</td>
<td>France</td>
</tr>
<tr>
<td>PB 641</td>
<td>Variability of Khorana Score and its Validity after First Chemotherapy in Patients with Gastric Cancer</td>
<td>H. Fuentes, L. Paz, X. Andrade, D. Oramas, A. Tafur</td>
<td>United States</td>
</tr>
<tr>
<td>PB 642</td>
<td>Venous Thromboembolism in Patients Undergoing Allogeneic Stem Cell Transplantation with Umbilical Cord Blood</td>
<td>G. Moyer, J. Gutman, J. Di Paola, T. Buckner</td>
<td>United States</td>
</tr>
<tr>
<td>PB 643</td>
<td>Joint Effects of FGG rs2066865 and Pre-cancer Fibrinogen Level on Cancer-related Venous Thromboembolism</td>
<td>B. Paulsen, O.V. Gran, H. Skille, S.K. Braekkan, E.N. Smith, T. Solomom, F.R. Rosendaal, K.A. Frazer, J.B. Hansen</td>
<td>Norway, United States</td>
</tr>
<tr>
<td>PB 644</td>
<td>Performance of Current Risk Assessment Models for Prediction of Venous Thromboembolism in Patients with Gastric Cancer</td>
<td>H. Fuentes, L. Paz, D. Oramas, Y. Wang, A. Tafur</td>
<td>United States</td>
</tr>
<tr>
<td>PB 645</td>
<td>Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry</td>
<td>C. Frere, J. Trujillo-Santos, C. Fernández-Capitán, J. Del Toro, V. Rosa, L. Lopez-Jimenez, J.M. Pedrajas, C. Tolosa, D. Farge, M. Monreal</td>
<td>France, Spain</td>
</tr>
<tr>
<td>PB 646</td>
<td>Mean Platelet Volume (MPV) and MPV/Platelet (plt) Identify Essential Thromboctyhemia (ET) Patients at High Thrombotic Risk</td>
<td>C. Verzeroli, M. Marchetti, G. Giaccherini, S. Gamba, A. Vignoli, L. Russo, G. Finazzi, A. Rambaldi, A. Falanga</td>
<td>Italy</td>
</tr>
<tr>
<td>PB 647</td>
<td>Interleukin Profile in Polycythemia Vera and its Correlation with the Risk of Thrombosis</td>
<td>P. Diop, P. Malhotra, S. Varma, N. Varma, M.U.S. Sachdeva, P. Jeeyaraman, G. Prakash, A. Khadwal, D. Lad</td>
<td>India</td>
</tr>
<tr>
<td>PB 648</td>
<td>Joint Modeling of Longitudinal Haemostatic and Inflammatory Biomarker Trajectories and Mortality in Patients with Cancer</td>
<td>F. Posch, E.-M. Reitter, J. Riedl, P. Quehenberger, C. Ay, I. Pabinger</td>
<td>Austria</td>
</tr>
<tr>
<td>PB 649</td>
<td>LMWH First Dose Program to treat Cancer-associated Thrombosis in a Pharmacy Setting</td>
<td>J. Easaw, S. McCall, A. Azzim</td>
<td>Canada</td>
</tr>
<tr>
<td>PB 650</td>
<td>Biomarkers for Venous Thromboembolism (VTE) in Newly Diagnosed Multiple Myeloma (NDMM): Early Results from the Thromboprophylaxis in Multiple Myeloma (TITM) Trial at King's College Hospital</td>
<td>T. Sayar, J. Czuprynska, R. Benjamin, J.P. Patel, L.N. Roberts, R.K. Patel, R. Arya</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>PB 651</td>
<td>The CATs out of the Bag: Alternatives to Low Molecular Weight Heparin (LMWH) in Patients with Cancer Associated Thrombosis (CAT)</td>
<td>M.P. Crowley, D. McClellton, K.A. Breen, V. McDonald</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>PB 654</td>
<td>Predictors of Prolonged Hospitalization Deep Vein Thrombosis Patients</td>
<td>A. Kurniawan, N.P.H. Lugito</td>
<td>Indonesia</td>
</tr>
<tr>
<td>PB 656</td>
<td>Inaugural Thrombotic Events in Myeloproliferative Neoplasms</td>
<td>H. Baccouche, D. Bahri, A. Chakroun, Z. Manai, S. Mahjoub, N. Ben Romdhane</td>
<td>Tunisia</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

PB 657  Biological Pro-coagulant and Pro-inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms
N. Ajzenberg, D. Faille, L. Lamrani, S. Loyau, M.-G. Huisse, M. Jandrot-Perrus, S. Alkhaiyer, B. Cassinat, C. Chomienne, C. Dosquet (France)

PB 659  Audit: Use of Khorana Score in Oncology Patients in Belfast Trust
C. Carson, G. Benson (United Kingdom)

PB 660  Treatment Tactics of Ulcerous Hemorrhage in Patients with Coronary Disease
R. Rakhimov (Uzbekistan)

PB 661  Venous Thrombosis and Thromboembolic Risk Factors in Outpatients with Lymphoma on Chemotherapy
M.E. Mingot-Castellano, I. Sánchez Bazán, J. Díaz Pastor, O.M. Benítez Hidalgo, M. Espeso de Haro (Spain)

PB 662  Investigation of Plasma Microparticles in Patients with Type 1 Diabetes May Be Interfered by Elevated Endogenous Lactadherin Levels in this Patient Group
K. Bergen, F. Mobarrez, G. Jörneskog, H. Wallén, S. Tehrani (Sweden)

PB 663  Circulating Platelet Microparticles with Regards to Microvascular Complications and Sex Differences in Patients with Type 1 Diabetes
K. Bergen, F. Mobarrez, G. Jörneskog, H. Wallén, S. Tehrani (Sweden)

PB 664  Effects of Low- and High-dose Doxorubicin and Paclitaxel on Tumorigenic, Thrombogenic and Angiogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines
A. Abaroa, A. Rebiboo-Sabbah, L. Issman, Y. Abboud, B. Brenner (Israel)

PB 665  Functional Tissue Factor Activity on Endothelial Cells Conveyed by Bloodcell Microparticles
A. Brandtner, G.F. Lehner, A.-M. Mokina, B. Zassler, S. Klein, M. Joannidis (Austria)

PB 666  Impact of All Trans Retinoic Acid on the Plasmin Generation of Leukemic Cells and Microparticles in Acute Promyelocytic Leukemia
D. Franckel1, C. Judicone1, R. Lacroix1, I. Weiss2, A. Muller1, C. Chareyre1, S. Cointe1, F. Dignat-George1, H.C. Kwaan2 (1Poland, 2The Netherlands)

PB 667  Circulating Microparticles Trend in Patients with HCV-related Liver Cirrhosis who Underwent Direct-acting Antiviral Therapy
E. Campello, A. Zanetto, C. Radu, L. Spiezia, C. Bulato, S. Shalaby, M. Senzolo, P. Burra, F.P. Russo, P. Simioni (Italy)

PB 668  P2Y1 and P2Y12 Antagonists Mediate the Release and Composition of Platelet Extracellular Vesicles
A. Gasecka1, E. van der Pol2, A.N. Böing2, N. Hajji3, A. Sturk4, P. Siljander5, P. Harrison6, K.J. Filipiak1, G. Opolski1, R. Nieuwland7 (1Poland, 2The Netherlands, 3‘Finland, 4‘United Kingdom)

PB 669  Characterization of Plasma Microvesicles in Patients with Diabetic Nephropathy
M. Uijl, C.M. Hau, M. Ahdi, V. Gerdes, S. Florquin, R. Nieuwland, J.J.T.H. Roelofs (The Netherlands)

PB 670  Coagulo-fibrinolytic Properties of Circulating Microparticles, and Subsequent Intravascular Coagulation, in Women with Ovarian Hyper Stimulation for In vitro Fertilization
S. Cointe, E. Dos Santos, R. Lacroix, F. Vialard, C. Judicone, P. Poncelet, V. Serazin, B. Wainer, A. Fauconnier, F. Dignat-George, F. Boitrelle, F. Sabatier, A. Torre (France)

PB 671  Immune Response Favors the Release of Leukocyte-derived Microparticles Mediating Endothelial Senescence, and Pro-coagulant and Pro-inflammatory Phenotype
A. El Habhab, M. Abbas, G. Kreutter, M. Kassem, S. Khemais, F. Zobairri, B. Yer, V. Schini-Kerth, L. Kessler, F. Toti (France)

PB 672  Increase in Microparticles TF/TFPI Procoagulant Ratio in Carriers of Inherited Bleeding Disorders
F. Campello, L. Spiezia, C. Radu, C. Bulato, G. Saggiorato, F. Sartorello, S. Maggioleti, P. Simioni (Italy)

PB 673  Factor Xa Inhibitors Apixaban and Rivaroxaban Suppress the Release of TF-bearing Microvesicles from Cancer Cell Lines
S. Featherby, C. Ettelaie, A. Maraveyas (United Kingdom)

PB 674  Endothelial Nitric Oxide Synthase Gene Polymorphisms Influence on Endothelial Microparticles Levels in Renal Transplantation

PB 675  Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Colorectal Cancer Patients
L. Traby, H. Pur, M. Kollars, M. Kammer, G. Prager, W. Scheithauer, G. Kornek, P.A. Kyrie, S. Eichinger (Austria)

PB 676  The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular Vesicles in Paroxysmal Nocturnal Hemoglobinuria Patients
A. Wannez, B. Devalet, C. Bouvy, B. Bihin, J. Douxfils, J.-M. Dogné, F. Mullier (Belgium)
**POSTER SESSIONS**

**PB 677**  
Magnetic Capture of Extracellular Vesicles: A Quantitative Flow Cytometry Study  
A. Brisson, R. Linares, Y. Boucaud, C. Gounou, S. Tan, L. Adumeau, S. Mornet (France)

**PB 678**  
Procoagulant Extracellular Vesicles in Amniotic Fluid  
J. Thaler1, L. Hell1, L. Wisgrill1, C. Ay1, A. Spittler1, M. Schwameis1, B. Jilma1, P. Altevogt1, I. Pabinger1 (Austria, Germany)

**PB 679**  
Thrombin Generation Associated with Extracellular Vesicles is Increased Two Weeks Post-partum  
C.E. Henriksson, M. Hellum, S. Sandberg, A.-H. Kristoffersen (Norway)

**PB 680**  
Enumeration of Circulating Microparticles in Healthy Medical Workers Occupationally Exposed to Low Doses of Ionizing Radiation  
G. Al Massarani, F. Najjar (Syrian Arab Republic)

**PB 681**  
A High Throughput Flow Cytometry Assay for the Detection of Platelet Microparticles  
C.J. Reddel, G.J. Pennings, V.M.Y. Chen, L. Kritharides (Australia)

**PB 682**  
Visualization of Tissue Factor-positive Microvesicles from Patients with Pancreatic Cancer Using Laser Scanning Confocal Microscopy  
Y. Hisada1, A. Aunemma2, W. Alexander3, C. Ay4, N. Mackman1 (United States, Austria)

**PB 683**  
New Specific and Highly Sensitive Procoagulant Test to Measure Tissue Factor Activity on Microparticles  
L. Valler, T. Bouriche, A. Bonifay, J. Bež, R. Lacroix, F. Dignat-George (France)

**PB 684**  
Circulating Microparticles in Women with Polycystic Ovary Syndrome: Preliminary Results  
F. Campello1, R. Mioni, A. Dalla Cà, S. Maggiolo, C. Radu, C. Bulato, P. Simioni (Italy)

**PB 685**  
Plasma Platelets Microparticles Evaluation in Thrombotic Thrombocytopenic Purpura  
L. Tahmasbi, S. Amini Kafiabadi, M. Karimi, M. Nikougoftar, S. Haghpanah (Islamic Republic of Iran)

**PB 686**  
Endothelial and Platelet Microparticles in Kidney Transplanted Recipients: Influence of Time Post Transplantation and Donor Type  

**POSTER SESSIONS**

**PB 687**  
The Relation between Circulating Endothelial Microparticles and Asymmetric Dimethylarginine in Vitamin B12 Deficient  
M.A. Dundar, Y. Altuner Torun, F. Cupi, S. Celik, C. Karakukcu (Turkey)

**PB 688**  
Circulating Microparticles as Predictive Biomarkers for Tumor Progression in Advanced Non-small Cell Lung Cancer  
F. Hajjar, M. Alammari, A. Al Massarani (Syrian Arab Republic)

**PB 689**  
Microparticles with Platelet Pro-aggregation Potential Are Present in Patients with Acute Coronary Syndrome and No Perfusion (TIMI-0)  
A. De la Peña Díaz1, M. Flores García1, A. Candia Ramirez2, O. Zepeda García1, R. Botello Maraver1, C. García Meré1, E.J. Guerrero Casillas1, M.A. Peña Duque1, M.A. Martínez Rios1, A.M. Mejía Domínguez1, E. Anglés-Cano1, Genetica Intervencionista (Mexico, France)

**Platelets - Clinical**

**PB 690**  
Obesity and ADAMTS13 Deficiency as Risk Factors for TTP  
L. Geys1, E. Roose, I. Scroeny, C. Tersteeg, K. Vanhoorelbeke, R. Lijnen (Belgium)

**PB 691**  
Acute Thrombotic Thrombocytopenic Purpura (TTP) - Diagnostic and Prognostic Implications of Highly Sensitive Troponin Assays, ECG and ECHO  
I. Karpha, T. Dutt (United Kingdom)

**PB 692**  
Plasmin Cleavage of ADAMTS-13 Enhances its Activity  

**PB 694**  
Unraveling Immunoprofiles of Acquired TTP Patients Using Anti-idiotypic Antibodies  
A.-S. Schelp1, E. Roose1, F. Peyvandi2, B. Joly1, I. Pareyn1, H. Deckmyn1, J. Voorberg2, P. Coppo1, A. Veyradier3, S.F. De Meyer1, K. Vanhoorelbeke1 (Belgium, Italy, France, The Netherlands)

**PB 695**  
The in vitro and in vivo Effects of Streptokinase in a Papio ursinus Baboon Model of Acquired Thrombotic Thrombocytopenic Purpura (TTP) - A Pilot Study  
J. Joubert1, W.J. Janse van Rensburg1, S.M. Meiring1, C. Tersteeg2, K. Vanhoorelbeke1 (South Africa, Belgium)

**PB 696**  
mRNA Identification of a Novel Isoform (ISF) and ISF3 from ADAMTS13 in Different Types of Cells  
J. Paiva, A.C. Kempfer, M.F. Alberto, A.I. Woods, C. Dos Santos, A. Sánchez-Luceros, M.A. Lazzari (Argentina)
POSTER SESSIONS

XXVI ISTH Congress and 63rd Annual SSC Meeting

POSTER SESSIONS

XXVI ISTH Congress and 63rd Annual SSC Meeting

PB 698
Splenic Anti-ADAMTS13 Response in Relapsing Thrombotic Thrombocytopenic Purpura (iTTP) Patients Mirrors the Acute Immune Response in Plasma
M. Skowronska, J.A. Kremer Hovinga, M. Schaller (Switzerland)

PB 699
The Incidence of Thrombotic Thrombocytopenic Purpura in Israel, as Determined by ADAMTS-13 Activity and Anti-ADAMTS-13 Antibody Levels
A. Keren-Politansky, E.J. Dann, G. Tennenbaum, B. Brenner, G. Sarrig (Israel)

PB 700
A Rapid and Simple Assay for the Determination of ADAMTS-13 Activity
M. Griffiths, H. Vetr, N. Binder (Austria)

PB 701
Retrospective Analysis of the Relapse Rate in Patients Surviving Acute Acquired Thrombotic Thrombocytopenic Purpura (TTP) Treated with or without Rituximab

PB 702
Epidemiology of Thrombotic Microangiopathy in Malaysia
Y.Y. Yap, P.A. Zulkarnain, K.B. Law, S. Carlo, J. Sathar, K.M. Chang (Malaysia)

PB 703
Highly Sensitive Fully Automated Chemiluminescent Immunoassay for Rapid Quantification of ADAMTS13 Activity
M. Mirabet, S. Blanch, J. Puig, J. Serra (Spain)

PB 704
Clinical Characteristics and Outcome of Patients with Thrombotic Thrombocytopenic Purpura at Siriraj Hospital
Y. Chinthammitr, W. Wangchinda (Thailand)

PB 705
Characteristic of ADAMTS13 in Patients with Acute Phase of Kawasaki Disease

PB 706
Acquired TTP in Prague: More than 20 Years Single Centre Experience
P. Salaj, J. Louzil, V. Pohlreichova, V. Geierova, I. Capova, I. Hrachovinova (Czech Republic)

PB 707
Complements are Activated to a Similar Level in both Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome
D. Oh1, S.J. Lee1, J.O. Kim1, N.K. Kim1, S.Y. Chong1, J.Y. Huh1, R.I. Baker2 (1Republic of Korea, 2Australia)

PB 708
aPreliminary Report on the Genetic Background and Clinical Course of Upshaw-Schulman Syndrome in Polish Patients
J. Windyga1, M. Gorska-Kosicka1, K. Bykowska1, E. Odnooczko1, B. Baran1, M. Letowska1, E. Stefanska-Windyga1, J.A. Kremer Hovinga Strebel2 (1Poland, 2Switzerland)

PB 709
A Murine Anti-ADAMTS13 Monoclonal Antibody against the Disintegrin-like Domain Inhibit the Enzyme Activity
Z. Ma, F. Shen, J. Su, J. Ling, J. Yin, C. Ruan (China)

PB 710
Relationship between ADAMTS13 Antigen (Ag) and Free IgG Anti-ADAMTS13 Antibody (Free IgG ab), Functional ADAMTS13 Inhibitor (FI) and Circulating Immune Complexes (CIC) Using two ELISA Techniques, in Patients (P) with Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
A.C. Kempfer, J. Paiva, A. Sanchez-Luceros, A. Woods, M.M. Casinelli, M.A. Lazzari (Argentina)

PB 711
‘Predisposed' Hemophagocytosis in a Patient with Thrombotic Thrombocytopenic Purpura
T. Shimomura, T. Takafuta, H. Niimi, S. Munemasa, M. Kadono, Y. Tachiya (Japan)

PB 712
Technozym® ADAMTS-13 Activity Assay for Determination of Inhibitory Antibodies against ADAMTS-13
L. Wagner, M. Kafka, F. Nasufi, N. Binder (Austria)

PB 713
Evolution of ADAMTS13 Activity in Patients with Relapsing Acquired Thrombotic Thrombocytopenic Purpura

PB 714
Evaluation of Sample Interferences on ADAMTS-13 Activity Measurement
L. Wagner, M. Griffiths, H. Vetr, S. Geiter, N. Binder (Austria)

PB 715
Early Detection of Refractoriness and Silent Relapse in Acquired Thrombotic Thrombocytopenic Purpura

PB 716
Upshaw-Schulman Syndrome: The Importance of the Modulating Effect of the Different Genetic Variations

PB 717
Charaterization of a Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Misdiagnosed as HELLP Syndrome
X. Bai, J. Su, L. Cao, Z. Yu, C. Ruan (China)

PB 718
The Next Case Report of Thrombotic Thrombocytopenic Purpura (TTP) after Influenza Vaccination
D. Kasprák, Z. Kořistek, M. Navrátil, P. Richterová, J. Gumulec (Czech Republic)
**POSTER SESSIONS**

**PB 719**
Thrombotic Thrombocytopenic Purpura as an Initial Presentation of Systemic Lupus Erythematosus in a Thai Child: A Case Report

**PB 720**
A Case of SLE with Different Types of Thrombotic Microangiopathy during the Course

**PB 721**
Congenital Thrombotic Thrombocytopenic Purpura without Nephropathy and Neutropathy
C. Albayrak, D. Albayrak (Turkey)

**PB 722**
Thrombotic Microangiopathies (TMA): First Report of 250 Cases from a Single Institution Experience in Latin America

**PB 723**
Successful International Standardisation of the ADAMTS13 Assays - Results from the APMAT (Asia Pacific Microangiopathic Thrombocytopenia) Network

**PB 724**
Treatment of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Pediatric Patients - A Single Center Experience
O. Serbic, B. Andric, Z. Radonjic, N. Stajic, D. Jevtic, M. Syrdjic (Serbia)

**PB 725**
Successful Treatment of Renal Infiltration Complicated by Atypical Hemolytic Uremic Syndrome in a Child with Acute Leukemia
Z. Kaya, E. Ö. Özen, M. Akgül, B. Topuz, E. Akkuzu, N. Alıcı, N. Buyan (Turkey)

**PB 726**
Transplant/Imunosuppresser Related Thrombotic Microangiopathy
F. Mousinho, A. P. Azevedo, C. Pimenta da Silva, C. Jorge, E. Cacheira, P. Sousa e Santos, A. M. Batalha Reis, J. Viana (Portugal)

**PB 727**
A Heterozygous Mutation of G-protein-Coupled Receptor 25 in a Family with inherited Thrombocytopenia and Thrombosis
J. Yamanouchi, T. Hato, Y. Ikeda, H. Takeda, M. Yasukawa (Japan)

**POSTER SESSIONS**

**PB 728**
Seven Years’ Experience of Healthcare Cards Delivery from the French Reference Center on Inherited Platelet Disorders (CRPP)

**PB 729**
Novel RUNX1 Mutations in Families with Inherited Thrombocytopenia
P. Nour1, D. De Rocco1, F. Melazzini1, C. Marconi1, A. Pecci1, R. Bottega1, C. Gran1, F. Palombo1, P. Giordano1, M. S. Coccoli1, A. C. Glembotsky2, E. Cigelini1, P. Heller2, M. Seri1, A. Savoia1 (Italy, Argentina)

**PB 730**
A Novel Mutation in TXB2A2R Impairs the Expression of the TPβ Isoform of the Platelet Thromboxane Receptor and Associates with Bleeding Diathesis
L. Bury, E. Falcinelli, A. M. Mezzasoma, G. Manni, E. Cesarì, P. Gesele (Italy)

**PB 731**
Spontaneous Loss of Mitochondrial Potential and Phosphatidylserine Exposure in Fibrinogen-bound Platelets of Patients with Wiskott-Aldrich Syndrome
S. Obyonennyi, D. Pershin, A. Maschan, A. Shcherbina, M. Panteleev (Russian Federation)

**PB 732**
ACTN1 Macrothrombocytopenia: Deleterious Effects of Rod-domain ACTN1 Variants
A. Vincent1, M. Poggi1, N. Schlegel1, O. René1, S. Binard1, P. Saultier1, S. Kunishima2, M. C. Alessi1 (France, Japan)

**PB 733**
Complete Failure of Integrin αIIIbβ3 Activation in Kinetic Assay Associates with Severe Bleeding Problems in a Patient with Kindlin-3 Deficiency

**PB 734**
Identification of Two New P2RY12 Heterozygous Mutations Responsible for Hemorrhagic Diathesis in Two Unrelated Families
A. Dupuis1, V. Heim1, D. Desprez1, P. Chilmann1, A. Lorenzo2, C. Gachet1 (France, Switzerland)

**PB 735**
Glanzmann’s Thrombasthenia in China: New Insights into its Pathogenesis
Z. Lu, M. Jiang, Z. Yu, Z. Wang, L. Xia, C. Ruan (China)

**PB 736**
A New Form of Inherited Thrombocytopenia (IT) Due to Monallelic Loss-of-function Mutation in the Thrombopoietin (THPO) Gene
P. Nours, C. Marconi, D. De Rocco, F. Melazzini, T. Pippucci, G. Goffredo, T. Giangregorio, A. Pecci, E. Cigelini, M. Seri, A. Savoia (Italy)
**POSTER SESSIONS**

**PB 737**

MYH9 Variants Defined by Next-generation Sequencing: Predicting Variants Likely Causing MYH9-related Disorder

L. Bury¹, I. Simeoni², P. Gresele³, on behalf of the BRIDGE-BPD and the ThromboGenomics Consortia (¹Italy, ²United Kingdom)

**PB 738**

Aberrant Gsalpha Signalling in Platelets from AHO Patients Linked to Impaired Platelet Function

F. Swieringa¹, F.A. Solari¹, M.A.H. Feijge², N.J.A. Mattheij³, O. Pagel¹, F. Beck¹, C.T.R.M. Stumpel¹, J. Pohlenz², J. Faber¹, A. Russo¹, O. Schwab³, B. Zieger¹, K. Jurk¹, A. Sickmann¹, P.E.J. van der Meijden³, I.M.L.W. Körver-Kuelsarts¹, R.P. Zahedi¹, J.W.M. Heemskerk² (¹Germany, ²The Netherlands)

**PB 739**

Pseudo-Glanzmann Thrombathenia due to Mutation in RasGRP2 Gene Encoding for CalDAG-GEFI

N. Rosenberg, R. Dardik, H. Hauschner, S. Nakav, O. Barel, J. Luboshitz, J. Yacobovich, H. Tamary (Israel)

**PB 740**

GATA1 T296P Mutation Causes a Severe Bleeding Disorder due to Platelet A-Granule and Partial δ-Storage Pool Deficiency

K. Jurk, S. Sollfrank, O. Pagel, K. Groß, A. Czwalinna, J. Erkel, K.J. Lackner, U. Walter, H. Rossmann, R.P. Zahedi, F. Bergmann (Germany)

**PB 741**

Detection and Analysis of Gene Mutations in Patients with Glanzmann Thrombasthenia by Next Generation Sequencing

D. Zhang, Y. Jia, L. Zhang, L. Qin, Y. Lin, F. Xue, R. Yang, K. Ru (China)

**PB 743**

Refined Detection and Characterization of Delta Storage Pool Disorders: A Cohort Study on Pediatric Patients

G. Manukian, J. Eilenberger, O. Andres, C. Schambeck, S. Eber, H. Schulze (Germany)

**PB 744**

Multiplex PCR and Cycle Sequencing for Detection of Mutations in ACTN1, TUBB1 and ANKRD26

L. Dai, J. Cutler, M. Mitchell (United Kingdom)

**PB 745**

Delta Storage Pool Deficiency in a Patient with a R216Q Mutation of GATA1

M. Blaauwgeers, I. van Asten, A. Huismann, S. Korporaal, E. Beekers, M. Coppens, J. Eikenboom, M. Kruip, M. Nijziel, R. Tamminga, E. Beckers, R. Urbanus, R. Schutgens (The Netherlands)

**PB 746**

Genetic Heterogeneity in Familiar Macrothrombocytopenia with Decreased Expression of GpIb/IIa

C. Lau, J. Oliveira, M. Sampaio, A. Gonzalez, M. Pereira, M. Gonzalez, E. Cruz, R. Santos, M. Lima, S. Morais (Portugal)

**POSTER SESSIONS**

**PB 747**

Pseudodominance in a Family with Bernard-Soulier Syndrome due to a Homozygous Variant in the Platelet Glycoprotein IX (GP9) Gene

C. Lau, J. Oliveira, A. Gonzalez, M. Gonzalez, M. Pereira, E. Cruz, R. Santos, M. Lima, S. Morais (Portugal)

**PB 748**

Highly Significant Bleeding Diathesis in Patients with Platelet Dysfunction due to a Novel Mutation in RASGRP2, Encoding CalDAG-GEFI (p.Gly305Asp)

E. Bermejo¹, M.F. Alberto¹, P. David S.¹, P. Norden¹, A. Sanchez Luceros¹, A.T. Norden¹, W. Bergmeier¹ (¹Argentina, ²United States, ³France)

**PB 749**

Positive Impact of Social Media as a Support Group for Females with Glanzmann Thrombasthenia in Saudi Arabia - A Mother's Initiative

M. Saleh, T. Owaidah, A. Aljeﬁri, H. Alzahrani, S. Parween, R. Barmada, M. Zulfiqar, S. Jose, V. Mohammed (Saudi Arabia)

**PB 750**

Five New Cases of Hermansky-Pudlak Syndrome: Identification of Novel Genetic Variants in HPS4 and HPS3 Associated to Relevant Clinical Complications

J.M. Bastida, J.R. Gonzalez-Porras¹, M.L. Lozano¹, M. del Rey¹, R. Benito¹, N. Bermejo¹, M. Karkuak¹, M. Traper¹, K. Janusz¹, Y. Yuco³, J.M. Hernandez-Sanchez¹, V. Palma-Barqueros¹, J. Vicente¹, J.M. Hernandez-Rivas¹, J. Rivera¹ (¹Spain, ²Turkey)

**PB 751**

Quality of Life Is Reduced in Patients with (Suspected) Congenital Platelet Function Disorders


**PB 752**

The Diagnostic Performance of Impedance Aggregometry and Platelet Function Analyzer Regarding Platelet Function Disorders as Detected by Light Transmission Aggregometry

F. Moenen, M. Vries, H. ten Cate, P. Verhezen, R. Wetzels, E. Beckers, Y. Henskens (The Netherlands)

**PB 753**

Evaluation of the Platelet Function in Different Inherited Thrombocytopenias. Correlation of Platelet Response Measured by Flow Cytometry with Bleeding Scores and Clinical Phenotypes

M.A. Alberelli, A. Savoia, E. De Cndia (Italy)

**PB 754**

Management of a Patient with Glanzmann Thrombasthenia during a Coronary Artery Bypass Graft Surgery: A Case Study

M. Kurdi, A. Ankri, J. Amour, C. Brumpt, J. Delort, G. Lebreton, L. Croisille, R. D’orion, I. Martin-Toutain (France)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 756</td>
<td>Quantitative Evaluation of Bleeding due to Platelet Disorders Associated with Dense Granule Deficiency and/or Impaired Aggregation Responses</td>
<td>J. Iyer², M. Badin¹, J. Brunet¹, L. Graf¹, G. Pare¹, A.D. Paterson¹, G.E. Rivard¹, C.P.M. Hayward¹ (Canada, Switzerland)</td>
</tr>
<tr>
<td>PB 757</td>
<td>MYH9 Disorders Are the Most Common Cause of Macrothrombocytopenia in Australia: Importance of Mean Platelet Diameter Measurement and Döhle Body Detection for Improved Diagnosis</td>
<td>M.-C. Morel-Kopp¹, D. Rabbollini¹, Y. Chun¹, K. Fixter¹, S. Kunishima², S. Gabrielli², Q. Chen¹, W. Stevenson¹, P. Tan¹, K. Radhakrishnan¹, R. Bird¹, O. Paul¹, L.P. Chew¹, C. Ward¹ (Australia, Japan, New Zealand, Malaysia)</td>
</tr>
<tr>
<td>PB 758</td>
<td>Hemorrhagic Diathesis in Four Patients with the Heterozygous Pro258Thr Mutation of the P2RY12 Gene</td>
<td>M. Blaauwgeers, I. van Asten, A. Huisman, S. Korporaal, E. Beckers, M. Coppens, J. Eikenboom, M. Krup, M. Nijziel, R. Tamminga, R. Urbanus, R. Schutgens (The Netherlands)</td>
</tr>
<tr>
<td>PB 759</td>
<td>Nine-year Effective Management of an LAD III Patient with Conventional Pro-hemostatic and Immunological Treatment</td>
<td>P. Saultier, S. Szepetowski, C. Falaise, L. Vidal, M. Canault, V. Barlogis, M.-C. Alessi, H. Chambost (France)</td>
</tr>
<tr>
<td>PB 760</td>
<td>Assessment of the Severity of the Epistaxis by Epistaxis Severity Score in the Inherited Platelet Disorders</td>
<td>R. Messaoudi, M. Lahmer, D. Saidi, Z. Zouaoui, H. Touhami, M.A. Bekkadja, A. Arabi, N. Sidi-Mansour (Algeria)</td>
</tr>
<tr>
<td>PB 762</td>
<td>A Study of Comparison of Platelet Aggregation Response Obtained on Sysmex CS-2000i with Chrono-log Light Transmission Aggregometer</td>
<td>A. Abraham¹, S.C. Nair¹, T. Geevar¹, P. Tavkar², S. Singh¹, H.F. Margaret¹, R. V¹ (India, Japan)</td>
</tr>
<tr>
<td>PB 764</td>
<td>Flow Cytometric Mepacrine Uptake Related to Platelet Size in Patients with Moderate Macrothrombocytopenia</td>
<td>S.J. Rodriguez Moreno, M.F. Alberto, E. Bermejo, M.L. Romero, S. Meschengieser, A. Sachez Luceros (Argentina)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 756</td>
<td>Quantitative Evaluation of Bleeding due to Platelet Disorders Associated with Dense Granule Deficiency and/or Impaired Aggregation Responses</td>
<td>J. Iyer², M. Badin¹, J. Brunet¹, L. Graf¹, G. Pare¹, A.D. Paterson¹, G.E. Rivard¹, C.P.M. Hayward¹ (Canada, Switzerland)</td>
</tr>
<tr>
<td>PB 757</td>
<td>MYH9 Disorders Are the Most Common Cause of Macrothrombocytopenia in Australia: Importance of Mean Platelet Diameter Measurement and Döhle Body Detection for Improved Diagnosis</td>
<td>M.-C. Morel-Kopp¹, D. Rabbollini¹, Y. Chun¹, K. Fixter¹, S. Kunishima², S. Gabrielli², Q. Chen¹, W. Stevenson¹, P. Tan¹, K. Radhakrishnan¹, R. Bird¹, O. Paul¹, L.P. Chew¹, C. Ward¹ (Australia, Japan, New Zealand, Malaysia)</td>
</tr>
<tr>
<td>PB 758</td>
<td>Hemorrhagic Diathesis in Four Patients with the Heterozygous Pro258Thr Mutation of the P2RY12 Gene</td>
<td>M. Blaauwgeers, I. van Asten, A. Huisman, S. Korporaal, E. Beckers, M. Coppens, J. Eikenboom, M. Krup, M. Nijziel, R. Tamminga, R. Urbanus, R. Schutgens (The Netherlands)</td>
</tr>
<tr>
<td>PB 759</td>
<td>Nine-year Effective Management of an LAD III Patient with Conventional Pro-hemostatic and Immunological Treatment</td>
<td>P. Saultier, S. Szepetowski, C. Falaise, L. Vidal, M. Canault, V. Barlogis, M.-C. Alessi, H. Chambost (France)</td>
</tr>
<tr>
<td>PB 760</td>
<td>Assessment of the Severity of the Epistaxis by Epistaxis Severity Score in the Inherited Platelet Disorders</td>
<td>R. Messaoudi, M. Lahmer, D. Saidi, Z. Zouaoui, H. Touhami, M.A. Bekkadja, A. Arabi, N. Sidi-Mansour (Algeria)</td>
</tr>
<tr>
<td>PB 762</td>
<td>A Study of Comparison of Platelet Aggregation Response Obtained on Sysmex CS-2000i with Chrono-log Light Transmission Aggregometer</td>
<td>A. Abraham¹, S.C. Nair¹, T. Geevar¹, P. Tavkar², S. Singh¹, H.F. Margaret¹, R. V¹ (India, Japan)</td>
</tr>
<tr>
<td>PB 764</td>
<td>Flow Cytometric Mepacrine Uptake Related to Platelet Size in Patients with Moderate Macrothrombocytopenia</td>
<td>S.J. Rodriguez Moreno, M.F. Alberto, E. Bermejo, M.L. Romero, S. Meschengieser, A. Sachez Luceros (Argentina)</td>
</tr>
</tbody>
</table>
Late Breaking Abstracts
12:00 – 13:15  Exhibition Hall 6.2

**LB 02**
A Large-scale Exome-wide Association Study of Venous Thromboembolism: Meta-analysis from the INVENT Consortium
S. Lindstroem1, M. Germain2, T. Bartz2, C. Turman1, E.N. Smith1,2, M.-H. Chen1, M. Puurunen1, J.S. Brody1, P. Suchon2, J.-P. Empana1, R. Olaso2, S.K. Braakkan2, B. McKnight1, J.F. Deleuze2, C.J. O'Donnell1, X. Jouven2, J.-B. Hansen1, B.M. Psaty1, K.L. Wiggins1, K.T. Taylor1, S.R. Heckbert1, K.A. Frazer1, A.D. Johnson1, P. Kraft1, P.-E. Morange2, D.-A. Trégouët2, N. Smith1, C. Kabrhel1 The INVENT Consortium (1United States, 2France, 3Norway)

**LB 03**
Anticoagulant Effects of Rosuvastatin in Patients with a History of Venous Thromboembolism: The STATins Reduce Thrombophilia (START) Trial
J. Biedermann, M. Kruip, F. van der Meer, F. Rosendaal, F. Leebeek, S. Cannegieter, W. Lijfering (The Netherlands)

**LB 04**
rFVIIIFc for Immune Tolerance Induction in Severe Hemophilia A Patients with Inhibitors - A Retrospective Analysis
M. Carcao1, A. Shapiro2, J. Staber2, N. Hwang2, C. Druzgal2, K. Liew2, M. Belluttriti1, C. Thornburg2, S. Ahuja2, J. Morales-Arias2, J. Dumont2, K. Jaworski2, G. Miyasato2, E. Tsao2, N. Jain2, S. Pipe2 (1Canada, 2United States)

**LB 05**
Analysis of VTE Prophylaxis Therapy among Hospitalized General Medical and Cancer Patients: Is There an Opportunity to Benefit from Reduced Use of VTE Thromboprophylaxis?
A. Budd, M. Rhodes, P. Wells (Canada)

**LB 06**
Prospective Randomized Placebo-controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) - Effects on Tissue Factor Pathway of Blood Coagulation
A.K. Rao, F. Del Carpio-Cano, S. Janapati, H. Zhao, G. Criner, NIH COPD Clinical Research Network and Canadian Institute of Health Research Investigators (United States)

**LB 07**
Effect of Pregnancy on the Course of ITP Pregnant Women and their Offspring. Results of a Spanish Case-Series of 230 Primary ITP Pregnancies
POSTER SESSIONS

Tuesday, July 11, 2017
Poster Session
12:00 – 13:15  Exhibition Hall 2.2

Atherothrombosis & Stroke

PB 772  Regular Physical Activity and Risk of Incident Venous Thromboembolism in the General Population
L. H. Evensen, T. Isaksen, S.K. Braekkan, J.B. Hansen (Norway)

PB 773  Impact of Regular Physical Activity on the Risk of Recurrent Venous Thromboembolism and All-cause Mortality
L. H. Evensen, T. Isaksen, S.K. Braekkan, J.B. Hansen (Norway)

PB 775  Associations between Serum Levels of Calcium, Parathyroid Hormone and Future Risk of Venous Thromboembolism - The Tromsø Study

PB 776  Repeated Measures of Fish Consumption, n-3 PUFA Intake and Future Risk of Incident VTE
T. Isaksen, H. Kristian, E. Line Holtet, B. Sigrid, H. John-Bjarne (Norway)

PB 777  Residual Vein Thrombosis in Subjects with Proximal DVT: An Association with Subclinical Atherosclerosis. The VERITAS Study

PB 778  Elevated Circulating CD40-L in Atrial Fibrillation and Its Modulation by Ablation

PB 779  Elevated Cellular Fibronectin is a Modifier of Clot Properties in Type 2 Diabetes: Association with Cardiovascular Disease
A.H. Bryk, M. Konieczyńska, K.P. Malinowski, K. Draga, A. Undas (Poland)

PB 780  Thrombin Generation Potential is Increased in Anabolic Androgenic Steroid Abuse Years after Cessation
S. Chang, J. Rasmussen, M. Frandsen, M. Schou, J. Faber, J.J. Sidelmann, C. Kistorp (Denmark)
POSTER SESSIONS

PB 792  High Antithrombin Levels in Women Are Associated with a Lower Risk of Recurrent Arterial Thromboembolism or Death. Results from the Observational ATTAC-Study
  F.N. Croles, M.P.M. De Maat, F. Leebeek (The Netherlands)

PB 793  The Role of Fasting Glucose Levels and Self-reported Diabetes in the Risk of a First Event of Venous Thrombosis: The MEGA Case-control Study
  R. Li-Gao, V.M. Morelli, W.M. Lijfering, S.C. Cannegieter, F.R. Rosendaal, A. van Hylckama Vlieg (The Netherlands)

PB 794  Urinary 11-dehydrothromboxane B2 Measurement Assays and their Clinical Correlation
  U. Tantry, R. Chaudhary, L. Lopez, K. Blijden, P. Gurbel (United States)

PB 795  The Value of sPESI for Risk Stratification in Patients with Pulmonary Embolism

PB 796  D-Dimer but Not Platelet Function Testing Improves Risk Stratification in Patients Treated with Elective PCI

PB 797  Increased Extracellular Nucleosome Levels, Biomarkers of Cell Death, in Atrial Fibrillation Patients Compared to the Normal Population
  D. Hoppensteadt, S. Jabati, T. Phan, J. Liles, T. Rowe, J. Fareed, M. Syed (United States)

PB 798  vWF Thr789Ala Genetic Variants Correlates with the Type of Myocardial Ischemia in Egyptian Patients
  N. Osman, R. Yaseen (Egypt)

PB 799  The Incidence and Prognosis of Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE) Associated with Oral Contraceptives by Age Groups in Japan
  K. Sugiuara, T. Kobayashi, T. Ojima (Japan)

PB 800  Implementation of CHA2DS2-VASc and HAS-BLED Scoring E-tool for Atrial Fibrillation Patients into Routine Clinical Practice in North Estonia Medical Centre
  A. Arjakes, R. Berner, H. Illumets, S. Kaarna, J. Kostjuk, M. Mark, T. Marandi (Estonia)

PB 801  Heightened Thrombogenicity in Women with Myocardial Infarction No Obstructive Coronary Artery Disease: The Difference between the Sexes
  P. Gurbel, R. Chaudhary, H. Tran, K. Blijden, A. Fitzgerald, U. Tantry (United States)

PB 802  Role of Matrix Metalloproteinase-2 and Correlation with the Anticoagulant System in Diabetes

PB 804  Extracellular Nucleosomes, Markers of Cell Death, are Elevated in End-Stage Renal Disease Independent of Circulating Microparticle-associated Tissue Factor
  T. Phan, R. Mcmilian, A. Walborn, D. Hoppensteadt, J. Fareed, V. Bansal (United States)

PB 805  Stroke Prevalence in Patients with Different Patterns of Atrial Fibrillation: Cross-sectional Study of Moscow Registry
  A. Melekhov, G. Gendlin, E. Dadashova, E. Alekseeva, I. Zaigraev, I. Nikitin (Russian Federation)

PB 806  Validation of a Patient-completed Caprini Risk Assessment Tool in a Spanish-speaking Population
  H. Fuentes, L. Paz, D. Oramas, C. Acob, X. Andrade, A. Tafur, J. Caprini (United States)

PB 807  The Procoagulant Contribution of Tissue Factor Expressing Platelets in Hypertension
  M. Brambilla, L. Rossetti, L. Lodi, P. Canzano, E. Tremoli, M. Camera (Italy)

PB 808  Patients with Multiple Cardiovascular Risk Factors Show a Characteristic Decrease in Circulating MAIT Cells
  S. Fuji, K. Akasaka (Japan)

PB 809  Protein Z Deficiency: A Reliable Risk Factor for Acute Coronary Syndrome
  D. Samir Elissa, M. Fawzy Ghozlan, A. Abd El-Hameed Mohamed, H. Shehata Eldawy (Egypt)

PB 810  Cardiac and Inflammatory Biomarkers and their Role in the Pathogenesis of Heart Failure in End-Stage Renal Disease
  R. Mcmilian, V. Bansal, D. Hoppensteadt, J. Fareed (United States)

PB 811  Risk Factors for Recurrent Venous Thromboembolism in the Elderly
  M. Al Subieg, F. Al-Eidain (Saudi Arabia)

PB 812  Increased von Willebrand Factor Platelet Interactions in Patients with Chronic Pain
  J. Scharrer, M. Hoffmann (Germany)
**POSTER SESSIONS**

**PB 813** Routine Care Data in Prediction Research  
**S. van Doorn**, T. Brakenhoff, G.-J. Geersing, A.W. Hoes, K.G.M. Moons (The Netherlands)

**PB 814** Markers of Plasma and Platelet Hemostasis Function as the Risk Factors for Leg Amputation in Patients with Critical Limbs Ischemia  

**PB 815** Validation of a Patient-completed Caprini Risk Assessment Tool  
**H. Fuentes**, L. Paz, A. Al-Ogaili, D. Oramas, C. Acob, A. Tafur, J. Caprini (United States)

**PB 816** Patients with Diabetes Mellitus 2 on Treatment, with or without Previous Cardiovascular Events, Have Delayed Clot Lysis, but Not Hyperactive Platelets Nor Increased Thrombin Generation  
**G. Panes**, L. Quiñiñir, J. Pereira, R. Corbalán, D. Mezzano (Chile)

**PB 817** Haemorrhologic and Fibrinolytic Activities in Diabetic Patient with Hypertension in Calabar, Nigeria  
**M.S. Edem**, D.C. Okpokam, A.O. Emeribe (Nigeria)

**Coagulant & Anticoagulant Mechanisms**

**PB 818** Efficacy, Safety, and Pharmacokinetics of a High-purity Plasma-derived Factor X (pdFX) Concentrate in the Prophylaxis of Bleeding Episodes in Children < 12 Years with Moderate to Severe Congenital Factor X Deficiency (FXD)  
**R. Liesner**, M.Gattens, C. Akanesi, J. Payne (United Kingdom)

**PB 819** Characterization of an Apptamer Inhibiting Coagulation Factor Xla Identified through in vitro Screening of a Single-stranded DAN Library  
**D. Donker**, V. Bhakta, L. Eltringham-Smith, A. Stafford, J. Weitz, W. Sheffield (Canada)

**PB 820** Three Dimensional Thrombus Architecture Formed under Flow Conditions  
**L. Hardy**, F. Macrae, E. Hethershaw, R. Ariens, R. Foster, H. Philippou (United Kingdom)

**PB 821** Administration of Dexamethasone during Initial Exposure to Factor VIII Reduces Inhibitor Development in Hemophilia A Mice Via Thymic Tolerance Induction Mechanisms  
**M.T. Georgescu**, P.C. Moorehead, K. Nesbitt, C. Hough, D.P. Lillicrap (Canada)

**PB 822** Dual Mode of Interaction of Fibrinogen with the Staphylococagulase-Prothrombin* Complex  
**A.A. Maddur**, M. Voehler, P.R. Panizzi, J. Sheehan, J.M. Verhamme, J. Meiler, P.E. Bock (United States)

**PB 823** Sensitive, Functional Assay for Detecting Polyphosphate in Plasma  
**C. Baker**, S. Smith, M. Kalathottukaren, C. Haynes, J. Kizhakkedathu, J. Morrissey (United States, Canada)

**PB 824** Combined IV and SC administration of Long-acting FVIIa (MOD-5014) Significantly Improves the Pharmacokinetics (PK), Pharmacodynamics (PD) and Pharmacological Long-term Outcome in Preclinical and Toxicological Models, Supporting the Initiation of a Clinical Study Combining Prophylactic and On-demand Treatments  
**M. Hoffmann**, L. Israeli Yagev, A. Bar-Ilan, G. Hart (Israel)

**PB 825** Factors Influencing the Recanalization of Deep and Superficial Venous Thrombosis of Lower Limbs  
**A. Spirkoska**, P. Poredos (Slovenia)

**PB 826** Effect of Platelet Depletion and Thrombin Inhibition on Tail Bleeding in Wild Type and FXI-deficient Mice  
**J. Mueller**, M.V. Schmidt, S. Heitmeier, C. Luecker, V. Laux (Germany)

**PB 827** Interrelation between Levels of Hemostatic Factors, Lipids and C-reactive Protein in Population Controls  

**PB 828** Selective Inhibition of Protein S Anti-coagulant Functions Restores in vitro Thrombin Generation in Haemophilia A and B Plasma  
**J. Lund**, E. Waters, L.M. Andersen, G. Ræder, B. Olsen Krogh, H. Demuth, M. Brunsgaard Hermit, H. Lindgreen Holmberg (Denmark)

**PB 829** Treatment of a Subdural Hematoma and Long-term Secondary Prophylaxis in a Patient with Severe Factor X (FX) Deficiency Treated with a High-purity Plasma-derived Factor X (pdFX) Concentrate  
**K. Kavakli**, C. Balkan, D. Yilmaz Karapinar (Turkey)

**PB 830** Differential Coagulotoxic Effects of Asian Pitviper Snake Venoms: Evolutionary, Pathophysiology and Biodiscovery Implications  
**I. Debono**, B. Fry (Australia)

**PB 831** The Effect of Histone H4 on Coagulation Enzymes and Complexes in Purified Systems  
**S. Prior**, S. Butenas (United States)
POSTER SESSIONS

PB 832  
CP-5-001: A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics Profile of a Long-acting Recombinant Factor VIII (MOD-5014) in Adult Men with Hemophilia A or B  
G. Young1, D.V. Quon1, M.A. Escobar1, L.N. Boggio1, M.E. Eyster1, M.V. Ragni1, N.P. Ewing1, A. Shapiro1, M.D. Tarantino1, G. Hart2, G. Kenet1 (1United States, 2Israel)

PB 833  
Age-related Variation in the Glycosylation of Alpha-2-Macroglobulin  
L. Calvert, H. Atkinson, J. Macri, L. Berry, A. Chan (Canada)

PB 834  
First Evaluation of the Safety, Pharmacokinetics and Pharmacodynamics of BAY 1213790, a Full Human IgG1 Antibody Targeting Coagulation Factor Xla, in Healthy Young Men  
D. Thomas, K. Thelen, D. van der Mey, S. Schwers, S. Schiffer, S. Unger, J. Heubach, A. Yassen, S. Boxtick (Germany)

PB 835  
Case Study of Successful Transition to Human Cell Line Fc Fusion Factor IX Replacement without Premedication in an Adolescent Male with Severe Hemophilia B, Anaphylactoid Reaction to FIX Replacement, and Previous History of Inhibitor and Nephrotic Syndrome  
A. Federizzo (United States)

PB 836  
Estimates of within-subject Biological Variation of Factor VIII, von Willebrand Factor Antigen, Fibrinogen, Prothrombin Time, INR and APTT in Pregnant Women  
A.H. Kristoffersen, P. Hyltoft Petersen, T. Roraas, S. Sandberg (Norway)

PB 837  
A Snake-venom Enzyme (Noscarin)-based Assay for APC-resistance Is Not Influenced by Non-vitamin K Antagonist Oral Anticoagulants (NOAC)  
A.C. Brisset1, C. Stocker1, M. Janssen1, W. Renner1, H. Mange1, F. Prüller1 (1Switzerland, 2Austria)

PB 838  
APC and TFPI Cofactor Activities of Thrombin-cleaved Protein S and C4BP-protein S Complex  
N. Alshaikh, J. Rosing, T. Hackeng (The Netherlands)

PB 839  
Anticoagulants Differentially Affect Procoagulant Platelet Formation  
S. Wang, H. Campbell, G. Pennings, C. Reddel, L. Pasalic, Y. Chen (Australia)

PB 840  
A Novel Hypoxia Response Element Regulates Oxygen-related Repression of Tissue Factor Pathway Inhibitor Expression  
X. Cui, G. Skretting, B. Stavik, M. Tinholt, A.E.A. Dahm, S. Kanske, N. Iversen, P.M. Sandset (Norway)

POSTER SESSIONS

PB 841  
Impact of Thrombomodulin on Spatial Clot Growth and Fibrin Polymerization in Cirrhotic Patients  
A. Lebreton1, T. Sinégre1, C. Duron1, A. Abergel1, A. Casini2 (1France, 2Switzerland)

PB 842  
Biomechanisms of a Severe Hypersensitivity Reaction Induced by Factor IX in Hemophilia B Complicated by Factor IX Inhibitor  
M. Cugno, M.E. Mancuso, A. Tedeschi, E. Santagostino, M. Lorini, V. Carbonelli, F. Peyvandi, P.M. Mannucci (Italy)

PB 843  
The Thrombomodulin Resistance in Prothrombin Belgrade Mutation Carriers Y. Djordjevic1, P. Miljic1, Y. Takagi2, A. Takagi2, M. Gvozdenov1, I. Pruner1, J. Bodrozi1, B. Tomic1, D. Radojkovic1, T. Kojima2 (1Serbia, 2Japan)

PB 844  
Hereditary Factor X (FX) Deficiency in Females: Treatment with a High Purity Plasma-derived Factor X Concentrate  
R. Kulkarni1, A. James1, M. Norton1, A. Shapiro1 (1United States, 2United Kingdom)

PB 845  
Factor VII Deficiency: A Center Experience  
A.R. Fernandes, M. Antunes, M.J. Diniz (Portugal)

PB 846  
ADP and ATP Inhibit Factor X Activation by Factor VIIa/Tissue Factor  
Y. Wang, J. Morrissey (United States)

PB 847  
Intracranial Hemorrhage in Neonates and Infants with Congenital Bleeding Disorders: The Experience of Çukurova University Hemophilia Center  
B. Antmen, I. Sasmaz, B. Karagun, G. Leblebisatun, Y. Kilinc (Turkey)

PB 848  
A Novel Mutation in the F7 Gene in a Tunisian Patient with Factor VII Deficiency  
H. Elmahmoudi, C. Ouardani, M. Achour, A. Jlizi, H. Ben Neji, K. Zahra, B. Meddeb, E. Gouider (Tunisia)

PB 849  
A Rat-human Cross-species Compatibility Study: Catalytic Efficiency for Activation of Rat FX Is Decreased for Human FVIIa Compared to Rat FVIIa  
J. Tunee, M. Kjelgaard-Hansen, J. Lund, L. Moreau Andersen (Denmark)

PB 851  
Investigations of Plasma-soluble Fibrin: Implications of Enhanced Functionally-assayed Fibrinogen Level, Erythrocyte Sedimentation, Fibrin Self-assembly, and Clot Lysis  
D.K. Galanakis, C. Marmorat, L. Zhang, M. Golightly, M. Rafailovich (United States)
POSTER SESSIONS

PB 852 Correlation Analysis of Standard Bethesda Method versus Modified Nijmegen Assay in Detecting Factor VIII Inhibitors, and Impact of Marginal Titer Inhibitors on FVIII Pharmacodynamics and Pharmacokinetics in Patients with Hemophilia A
A. Batorova, A. Morongova, D. Jankovicova, T. Prigancova, M. Mistrik (Slovakia)

PB 853 Differences in Levels of Markers of Inflammation and Endothelial Damage between the Blood from Varicose Veins and Systemic Blood
A. Spirkoska, P. Poredos, M.K. Jezovnik (Slovenia)

PB 854 Intracranial Hemorrhage in an Infant with Factor V Deficiency
E. Turkan, F. Aygun, Y. Turkmengolu (Turkey)

PB 855 Detection of Specific and Non-specific Inhibitors in Patients of Hemophilia A
A. Naz, F. Ahmed, S. Ansari, T. Shamsi (Pakistan)

PB 856 Interim Safety of a Long-acting Recombinant Factor VIIIa (MOD-5014): A Phase I Study in Adult Subjects Following Subcutaneous Administration
G. Hart, R. Arison, L. Binder, G. Kenet (Israel)

PB 857 Replacement Therapy in ALL Patients Treated with L-asparaginase
A. Freixo, P. Chorão, C. Monteiro, M. Carvalho, L. Gonçalves, F. Principe, J.E. Guimarães, M.C. Koch (Portugal)

PB 858 Hemarthrosis in Rare Factor Deficiencies
Z. Salcioglu, H. Şen, G. Aydoğan, F. Akici, Z. Başlar (Turkey)

PB 859 Amyloidosis Induced Abnormal Coagulopathy Associated with Multiple Coagulation Factor Deficiencies
U.Y. Malkan, H. Demiroglu, S. Aksu, I.C. Haznedaroglu, N. Sayınalp (Turkey)

PB 860 Protein S Inhibits Apoptosis of Islet β Cells via Regulating BIRC3 Expression and AKT Signaling

PB 861 Spatiotemporal Modulation of the Protease Activated Receptors Signaling Proteins Activated by Thrombomodulin in Patients with Diabetic Nephropathy
S. Ghosh1, T. Madhusudhan1, H. Wang1, J. Manoharan1, D. Gupta1, B. Isermann1 (Germany, China)

PB 862 Overexpression of Protein S Exacerbates Carbon Tetrachloride-induced Liver Injury and Fibrosis in Mice

POSTER SESSIONS

PB 863 Signal through the Regulatory Subunits of PI3Kinase Endows Coagulation Protease Activated Protein C with Hormone Like Function
M. Thali, H. Wang, S. Ghosh, W. Dong, W. Ruf, B. Isermann (Germany)

PB 864 Rivaroxaban Ameliorates Neuroinflammation
M. Merker, S. Eichler, A.M. Herrmann, H. Wiendl, C. Kleinschnitz, K. Göbel, S.G. Meuth (Germany)

PB 865 Novel Role of Protein S in Clot Retraction: Induction of Apoptosis in Activated Platelets
V. Pilili, A. Datta, E. Lazartigues, R. Majumder (United States)

PB 866 Thrombomodulin Dependent PC Activation Protects from a Senescence-like Tubular Phenotype in Diabetic Nephropathy (dNP)
M.M.A. Al-Dabet, K. Shahzad, I. Gadi, S. Kohli, F. Bock, S. Nazir, B. Isermann (Germany)

PB 867 Coagulation Proteases are Potential Regulators in the Development of Exercise-associated arterial Endofibrosis
J.J. Posthuma, J.J.N. Posma, G. Schep, M. Bender, R. van Oerle, H. ten Cate, H.M.H. Spronk (The Netherlands)

PB 868 Biochemical and Pharmacological Differentiation of APC and Recombinant Thrombomodulin with Reference to the Effect on the Hemostatic and Fibrinolytic Processes

PB 869 Plasminogen-deficient Patients
H. Kızılocak1, G.N. Özdemir1, G. Dikme1, B. Koç1, G. Iskeleli1, B. Dönmez Demir1, N.M. Christiansen2, M. Ziegler2, H. Özdağ1, V. Schuster1, T. Celkan1 (Turkey, Germany)

PB 870 Direct Factor Xa Inhibitor Apixaban Prevents Endothelial Activation and Damage Associated with Chronic Kidney Disease
S. Torramade-Moix, M. Palomo, M. Vera, A. Cases, G. Escolar, M. Diaz-Ricart (Spain)

PB 871 A Factor X Activator from Caterpillar Triggers Cell Survival on Fibroblasts in Response to Serum Deprivation by Inhibition of Apoptosis
M.P. Alvarez-Flores, R.V. Bosch, D.A. Maria, A.M. Chudzinski-Tavassi (Brazil)

PB 872 Protective Effect of Protein S against the Development of Diabetic Nephropathy in Mice
POSTER SESSIONS

PB 873  A Significant Change in Laboratory Markers of Thrombosis Very Early in the First Trimester of Pregnancy May be Linked to a Concurrent Increase in Estradiol
C.N. Bagot, E. Leishman, C.C. Onyiaodike, F. Jordan, D.J. Freeman (United Kingdom)

PB 874  Analysis of Estrogen Mediated Expression of TFPI-2 by miRNAs in Breast Cancer Cells
M.S. Andresen, N. Iversen, M. Tinholt, C.F. Myklebust, K.K. Sahlberg, B. Stavik, P.M. Sandset, G. Skretting (Norway)

PB 875  Comparative Studies on the Inhibition of Thrombin by Recombinant Thrombomodulin in Activated Protein C and Whole Blood Plasma

PB 876  Activation of the Hepatocyte Growth Factor/c-met Pathway during Experimental Envenomation of Rats with Bothrops Jararaca or Crotalus Durissus Terrificus Snake Venoms
B. Prezoto, L. Gonçalves, S. Sampaio, I. Sano-Martins (Brazil)

PB 877  Targeted Inhibition of Activated Protein C by an Exosite Antibody to Treat Hemophilia
X.Y. Zhao1, A. Wilmen2, X. Wang3, L. Linden2, U. Egner2, J. Glueck2, K. McLean1, S. Yegneswaran1, K. Jiang1, V. Evans1, J. Ivens1, Y. Xu1, A. Hesslein1, V. Laux1, C. Patel1 (1United States, 2Germany, 3China)

PB 878  Silencing of Anticoagulant Protein C Evokes Low Incident but Spontaneous Atherothrombosis in Apolipoprotein E Deficient Mice
M. Heestermans, A.B. Ouweneel, R.A.F. Verwilligen, M. Gijbels, P.H. Reitsma, M. van Eck, B.J.M. van Vlijmen (The Netherlands)

PB 879  Protection of the Endothelial Protein C Receptor (EPCR) against Inactivation by P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) Domains with a Non-inhibitory Anti-EPCR Antibody
J. Barber-Singh1, E.A.M. Bouwens1, J.E.V. Petersen1, K.F.E. Lee1, P. Cowan1, H. Gock1, H. Weiler1, K. Fukudome1, L. Turner1, T. Lavstsen1, L. Mosnier1 (1United States, 2Germany, 3Japan)

PB 880  Characterization of an In vivo Mouse Model for the Binding of P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) Domains to the Endothelial Protein C Receptor (EPCR)
J. Barber-Singh1, L. Turner2, K.F.E. Lee3, P. Cowan1, H. Gock1, H. Weiler1, T. Lavstsen1, L. Mosnier1 (1United States, 2Denmark, 3Australia, 4Japan)

PB 881  Antithrombin and Protein C Plasma Levels at Admission Are Associated to Mortality at Six Months in Patients with Pulmonary Embolism with and without Malignant Disease
S. Obradovic, B. Dzudovic, B. Subotic, M. Stavric, V. Subota, D. Mikovic (Serbia)

PB 882  Positive Correlation of Plasma Protein S Levels to Apolipoprotein C-II in Middle-aged Obese Women and Non-obese Young Women

PB 883  Hepatocyte Growth Factor Reduces Protein C Inhibitor Expression in HepG2 Cells via MEK and PI3 Kinase

PB 884  Differential Modulation of Plasminogen Activator Mediated Thrombolysis by Recombinant Thrombomodulin and Activated Protein C

PB 885  G-quadruplex-Directed Aptamer Selection against Activated Protein C (APC)
N. Shahidi Hamedani, S. Gasper, J. Oldenburg, G. Mayer, B. Pützsch, J. Müller (Germany)

PB 886  The Protective Effect of Activated Protein C as the Baised Agonism in Activation of Protease-activated Receptor 1
L. Gorbacheva, S. Strukova (Russian Federation)

PB 887  Function and Prevalence of Host-derived Coagulation Factors on the Virus Surface
B.H. Lin, M.R. Sutherland, E.L.G. Pryzdial (Canada)

PB 888  Decryption of Hepatocyte Tissue Factor Procoagulant Activity by Bile Acids Requires Non-apoptotic Phosphatidylserine Externalization
K. Baker, A. Kopek, N. Joshi, H. Cline-Fedewa, J. Luyendyk (United States)

PB 889  Clustering of CD98 on Monocytic THP1 Cells Increases Tissue Factor Procoagulant Activity
F. Langer, B. Spath, C. Lehr, B. Sievers, W. Ruf (Germany)

PB 890  A First-in-Human (FIH) Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-06741086, an anti-TFPI Monoclonal Antibody, Following Administration of Single Subcutaneous or Intravenous Doses in Healthy Adult Male Volunteers
M. Cardinal1, C. Kantaridis1, T. Zhu1, P. Sun1, D. Pittman1, J. Murphy1, S. Arkin1 (1United States, 2Belgium)
POSTER SESSIONS

PB 891
Hypoxia Augments Tissue Factor Expression in Inflammatory Stimulated Macrophages but Not in Smooth Muscle Cells or in Endothelial Cells
K. Maekawa, A. Yamashita, K. Hatakeyama, K. Nishihira, Y. Asada (Japan)

PB 892
BAY 1093884 Binds to the Kunitz 1 and 2 Domain Interface of Tissue Factor Pathway Inhibitor and Inhibits its Function
S. Yegneswaran1, V. Evans1, X. Jiang1, L. Leong1, H. Steuber2, U. Egner2, M. Koellinberger2, C. Patel1 (1United States, 2Germany)

PB 893
mTOR Inhibitors Reduce Expression of Tissue Factor Isoforms in Neuroendocrine Tumors of the Pancreas
C.S. Lewis1, H. Elnakat Thomas1, M. Orr-Asman1, L.C. Green1, F.V. Lucas1, N. Mackman1, H.H. Versteeg2, V.Y. Bogdanov1 (1United States, 2The Netherlands)

PB 894
High Plasma Concentration of Activated Factor VII-antithrombin Complex is Associated with an Increased Activated Factor X Generation
F. Stefanoni1, M. Baroni1, B. Lunghi1, A. Castagna1, N. Ziliotto1, F. Tos1, D. Minguzzi1, S. Udali1, B. Woodhams1, D. Girelli1, O. Olivieri1, N. Martinelli1, F. Bernardi1 (Italy, 2United Kingdom)

PB 895
Renin-angiotensin System Blockade Downregulates Tissue Factor Expression Induced by γ-Glutamyltransferase in Human Peripheral Blood Mononuclear Cells Exposed to High Glucose
V. Scalise, C. Balia, S. Cianchetti, T. Neri, V. Carnicelli, R. Zucchi, A. Celi, R. Pedrinelli (Italy)

PB 896
Over-activation of Src1 Mediates Tissue Factor-induced Apoptosis in Endothelial Cells
A. Ethaeb, J. Greenman, C. Ettelaie (United Kingdom)

PB 897
Indoleamine 2,3-dioxygenase 1 Enhances Tissue Factor Expression in Coronary Atherosclerotic Plaque
A. Yamashita, Y. Watanabe, K. Maekawa, K. Kitamura, Y. Asada (Japan)

PB 898
Application of a Quantitative Systems Pharmacology (QSP) Model of Human Blood Coagulation to Understand the Response of Clinical Biomarkers from a Recent Anti-TFPI Trial in Healthy Subjects
S. Novak1, T. Zhu1, C.N. Lim1, D.D. Pittman1, M.H. Cardinal1, S.W. Martin1, L.O. Harnisch1, S. Arkin1, J. Murphy1 (1United States, 2United Kingdom)

PB 899
Coagulation and Angiogenesis Parameters in Essential Thrombocythemia
D. Rośc, G. Gadomska, K. Stankowska, J. Boinska, J. Filipiak (Poland)

PB 900
Simulation of Factor X Activation by Extrinsic Tenase on Phospholipid Vesicles: Size Matters!
T. Kovalenko, M. Panteleev, A. Sveshnikova (Russian Federation)

POSTER SESSIONS

PB 901
Rutin (quercetin-3-rutinoside) Modulates Hemostatic Disturbances and Reactive Species Levels in Experimental Bothrops jararaca Envenomation
M.L. Santore, A.T.A. Sachetto (Brazil)

PB 902
Measurement of Tissue Factor Molecules and Factor Xa Generation on Vascular Cells
M. Rosas, C.P. Thomas, D.A. Slatter, V. Jenkins, V.B. O'Donnell, P.W. Collins (United Kingdom)

PB 903
Tissue Factor Pathway Inhibitor Polymorphism 399C>T Predisposes to Idiopathic DVT in Young Indians
R. Saxena, K. Kishor, A. Sharma, R. Ranjan, P. Mishra, M. Mahapatra (India)

PB 904
Role of Tissue Factor 603A>G and 5466A>G Polymorphisms in the Development of DVT in Young Indians
K. Kishor, A. Sharma, R. Ranjan, H. Pandey, P. Mishra, R. Saxena (India)

PB 905
Tissue Factor Gene Polymorphisms (A603G, C1322T, C1812T, G1442C) in Healthy Individuals and Patients with Erysipelas in Transbaikalian Region
A. Emelianov, A. Emelianova, Y. Vitkovsky (Russian Federation)

Fibrinolysis & Proteolysis

PB 906
Thrombin-activable Fibrinolysis Inhibitor (Procarboxypeptidase B2) Deficiency Protects from Carbon Tetrachloride-induced Liver Fibrosis

PB 907
Transcriptional Regulation of the Tissue Factor Gene is Mediated by the Androgen Receptor
B. Hoerl1, M. Mussbacher1, M. Salzmann1, H. Paar1, A. Assinger1, N. Mackman2, J. Schmid1 (1Austria, 2United States)

PB 908
Factor V Expression in Aggressive Breast Cancer Modifies Patient Survival, Tumor Cell Growth and Response to Treatment
M. Tinholt, M. Sletten, Ø. Garred, K.K. Sahlberg, P.M. Sandset, N. Iversen (Norway)

PB 909
Low Phosphatase Activity Mediates L-selectin Shedding in B-CLL
I. Beke Debrescani, R. Szász, Z. Kónya, F. Erdől, G. Vereb, J. Kappelmayer (Hungary)
POSTER SESSIONS

XXVI ISTH Congress and 63rd Annual SSC Meeting

PB 910 Platelet-dependent von Willebrand Factor Activity in Acute Myeloid Leukemia Patients: Role in Haemostatic Alterations
B. Farweez, H. Abaza, S. Samaan (Egypt)

PB 911 Fibronectin Supports Glioma Invasion and Colonization of Fibrin in Cooperation with Slug/Snail2
L.M. Knowles, C. Wolter, A. Burkardt, S. Urbschat, R. Ketter, D. Lessig, I. Müller, H. Eichler, J. Pilch (Germany)

PB 912 Altered Fibrin Clot Properties in Advanced Lung Cancer: Impact of Chemotherapy
M. Zabczyk, G. Kroczuk, G. Czyzewicz, A. Undas (Poland)

PB 913 The Effect of Neoadjuvant Chemotherapy on the Activated Protein C (aPC) Pathway in High Grade Serous Ovarian Cancer Patients

PB 914 Inhibition of Tumour Cell-induced Platelet Aggregation by a Novel Stat3 Inhibitor in Podoplanin Positive Cancer Cells
K.-Y. Chong, P.-S. Lu, P.-Y. Lin, Y.-W. Chang, T.-T. Huang (Taiwan)

PB 915 Cancer Stromal Targeting Therapy Using MMAE Conjugated Anti-insoluble Fibrin Antibody
H. Fuchigami, S. Manabe, T. Obonai, M. Yasunaga, Y. Matsumura (Japan)

PB 916 A Linkage between ERBB2 Expression and the Pro-coagulant Properties of Breast Cancer Cells is Mediated by the PI3k/Akt Signaling Pathways
C. Yunliang, M. Scully, A. Kakkar (United Kingdom)

PB 917 Exosomes from Heparin-treated Cancer Cells Exhibit Transferable Anti-tumorigenic Activity
C. Yunliang, M. Scully, A. Kakkar (United Kingdom)

PB 918 Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry to Identify Hypercoagulability in Patients with Cancer
E. McLoughlin, E. Ferrante, F. Viola, H. Maitland (United States)

PB 919 Direct Oral Anticoagulants Do Not Inhibit Growth and Metastasis of Orthotopically Growing Claudin-low MDA-MB-231 Human Breast Cancer Cells in Immunodeficient mice
J.T. Buijn, C. Tieken, K. van der Molen, J. Crooijmans, C. Kroone, N. Swier, G. van der Pluijm, S.E. de Dévédec, H.H. Versteeg (The Netherlands)

PB 920 Does Remote Ischemic Preconditioning Increase Fibrinolysis in Head and Neck Cancer Surgery? Preliminary Results from a Randomized Controlled Trial
A.E. Krag, B.J. Kift, C.L. Hvas, A.-M. Hvas (Denmark)

PB 921 The Role of asTF in Glioblastoma Multiforme
M.Y. Kapteijn, B. Uínlí, H.H. Versteeg (The Netherlands)

PB 922 Tumoral Factor VII Expression Changes TGF-β-mediated Intercellular Communication in Breast Cancer
M. Paauwe, R. Hikmet, E.H. Laghmani, H.H. Versteeg (The Netherlands)

PB 923 Chemotherapy as a Factor in the Pathogenesis of Thrombosis in Patients with Ovarian Cancer
A. Vorobev, A. Makatsariya, A. Sologova (Russian Federation)

PB 924 Preoperative Panel Scores of CA 19-9, FVIII and D-dimer Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma
N. Matilla, H. Seppänen, C. Haglund, R. Lassila (Finland)

PB 925 Expression of Coagulation Proteases from the Activated Protein C Pathway in Ovarian Tumours

PB 926 Mucin1 Acts as a Potential Mediator of the Pro-coagulant Properties of Breast Cancer Cells by Altering the Activity of Key Phosphokinase Pathways
C. Yunliang, M. Scully, A. Kakkar (United Kingdom)

PB 927 Coagulation Factor Xa Promotes Melanoma Metastasis
M. Arce, M. Galleguillos, C. Ramirez, R. Erices, L. Lobos, L. Leyton, A. Quest, G. Owen (Chile)

PB 928 Identification of Novel Molecular Targets of the Kunitz-type Molecule Amblyomin-X Using Immuno-fishing Interactomics Approach
A.M. Chudzinski-Tavassi, A. Iqbal, K.L.P. Morais, M.B. Goldfeder (Brazil)

PB 929 Dissolution of Platelet-rich Thrombus by Perfusion of N-acetyl Cysteine
S.M. Hastings, D.N. Ku (United States)

PB 930 Thrombolysis by rt-PA Combinated with Anticoagulant and Antiaggregant Molecules under Flow Conditions
S. Loyau, Y. Boulaffali, N. Ajzenberg, B. Ho Tin Noe, M. Jandrot-Perrus (France)
PB 932  Systematic Review and Meta-analysis of Treatments for Massive and Submassive Pulmonary Embolism  
L.A. Castellucci, S. Gupta, M. Carrier (Canada)

PB 933  Structure and Function of Trypsin-loaded Fibrinolytic Liposomes  
A. Tank Salamon, A. Bota, A. Wacha, L. Szabo, J. Mihaly, M. Lovas, K. Kolev (Hungary)

PB 934  Changes in Treatments and Outcomes after Creation of a Pulmonary Embolism Response Team (PERT)  

PB 935  Comparing Emergency Department Patients to Inpatients Receiving a Pulmonary Embolism Response Team (PERT) Activation  
E. Deadmon, N. Giordano, K. Rosenfield, R. Rosovsky, B. Parry, R. Al-Bawardi, C. Kabrhel (United States)

PB 936  Indications and Results of Treatment with Ultrasound Assisted Catheter Thrombolysis in Patients with Pulmonary Embolism  
S. Obradovic, B. Subotic, B. Dzudovic, M. Stavric, V. Subota, N. Antonijevic (Serbia)

PB 937  In vitro Thrombolytic Action of New Fibrinolytic Enzyme Complexes - Strictoliase and Lilasyn  
I. Kornienko, A.A. Bobrovskaya, N.S. Fokichev, A.A. Osmolovsky, T.S. Sharkova (Russian Federation)

PB 938  A Case Series of Low Dose Alteplase for Submassive Pulmonary Embolism (PE)  
B. Shakerian, N. Razavi (Iran, Islamic Republic of)

PB 939  Successful Thrombolysis of Huge Right Atrial Thrombus in a Patient with Primary Repair of Atrial Septal Defect  
B. Shakerian, N. Razavi (Iran, Islamic Republic of)

PB 940  Thrombolytic Properties of Longolitin - Proteinase Complex from Imperfect Fungi Arthrobotrys Longa - in Dependence on its Fibrinolytic Activity  
T. Shakerian, V. Podoroskaya, I. Pavlova (Russian Federation)

PB 941  Sub-massive PE - A Role for Low Dose Thrombolysis?  
J. Lozier, T. Mason, K.A. Breen, B.J. Hunt, N. Karunanithy, B. Lams, A. West (United Kingdom)
PB 949  Perioperative Replacement Therapy in Hemophilia B: Should We “B” More Precise?
H.C.A.M. Hazendonk1, R. Liesner2, P. Chowdary2, M.H.E. Driessen1, D. Hart2, D. Keeling2, B.A.P. Laros-van Gorkom1, F.J.M. van der Meer1, K. Meijer1, R.A.A. Mathôt1, K. Fijnvandraat1, F.W.G. Leebeek1, P.W. Collins2, M.H. Cnossen1, OPTI-CLOT Study Group (1The Netherlands, 2United Kingdom)

PB 950  Identification of Patient and Disease-related Characteristics Influencing the Risk of Bone Fracture in Individuals with Haemophilia
P. Miljic, J. Bodrozic, D. Miljic, D. Lekovic, M. Mitrovic (Serbia)

PB 951  Post-partum Bleeding in Women who Are Carriers of and Who Have Bleeding Disorders: A Case-Control Study
S. Wolf, S. Montes-Otalvaro, B. Shohreh, J. Pasi, H. Daniel, C. Foley, K. Forsyth, A. Morris, W. Maposa, B. Louise (United Kingdom)

PB 952  Prophylaxis with rIX-FP Reduces Consumption Compared with Previous FIX in Both Adult and Pediatric Patients
M. Escobar1, E. Santagostino2, C. Lessinger1, A. Shapiro1, J. Oldenburg3, B. Pan-Petesch4, W. Seifert5, the PROLONG-9FP Investigators (1United States, 2Italy, 3Germany, 4France)

PB 953  Dosing of rVIII-SingleChain Based on Clinical Bleeding Phenotypes Results in Low Bleeding Rates in Pediatric Patients Treated with Prophylaxis Two or Three Times Weekly
M. Simpson1, K. Fischer1, J. Oldenburg1, M.T. Álvarez-Román4, T. Lambert5, M. Wang6, D. Bensen-Kennedy1, O. Stasyshyn6 (1United States, 2The Netherlands, 3Spain, 4France, 5Ukraine)

PB 954  Factor VIII (FVIII) Inhibitor Testing Using a Validated Chromogenic Bethesda Assay (CBA) in HAVEN 1 (BH29884), a Phase 3 Trial of Emicizumab in Persons with Hemophilia A (PwHA) with Inhibitors
J.J. Adamkewicz1, C. Schmitt2, E. Asikanius1, J. Xu1, G. Levy1, B. Kim1, A. Calatriz3 (1United States, 2Switzerland)

PB 955  Recombinant FVIII Product Type and the Risk of Inhibitor Development in Previously Treated Patients with Hemophilia A: Preliminary Results of a Systematic Review and Meta-analysis
A. Cannavo1, S. Hassan2, S. Gouw3, F.R. Rosendaal2, J. van der Bom2 (1Italy, 2The Netherlands)

PB 956  Preliminary Observations from a Prospective, Dose Escalating, Prophylaxis Study in Young Boys with Severe Hemophilia A in China: The China Hemophilia Individualized Prophylaxis Study (CHIPS)
R. Wu1, W. Yao1, X. Luo1, L. Tang1, M. Zhou1, Y. Wang1, P. Ding1, N. Zhang1, S. Yang1, P. Hilliard1, K. Usuba2, N.L. Young2, A.S. Doria1, A. Audrey1, Z. Chen2, Y. Peng1, J. Wu1, K.H. Luke2, V.S. Blanchette2, X. Li1 (1China, 2Canada)

PB 957  Pilot Study to Determine the Frequency of Cerebral Microbleeds among Adult Patients with Hemophilia a or B
H. Husseinzadeh1, T. Chiasakul2, B. Pukenas1, R. Wolf1, M. Kelt1, P. Gimotty1, E. Chiang1, P.F. Fogarty1, A. Cuker1 (1United States, 2Thailand)

PB 958  Thrombo-Embolinc Events Reported with the Use of Activated Prothrombin Complex Concentrate (APCC) in Congenital Haemophilia: A Cumulative Review on Four Decades
R. Crea1, A. Novack2, J. Kennedy2, S. Raf2, N. Bajwa2, A. Gringeri1 (1Austria, 2United States)

PB 959  Effects of Acute Moderate Physical Activity on Haemostatic Parameters in Severe Haemophilia A Subjects Using a Third Generation B-Domain Deleted Recombinant Factor VIII
C. Merlen1, N. Zourikian, C. Thibeault, E. Dubé, A. Bonnefoy, T. Nava, J. St-Louis, G.-E. Rivard (Canada)

PB 960  Clinical Characteristics of Patients with Hemophilia A and B: Preliminary Results of the Hemfil Cohort Study
C.C. Brommonschenkel1, L.L. Jardim, D.G. Chaves, M.P. Santana, M.H. Cerqueira, A. Prezotti, C.S. Lorenzato, V. Franco, S.M. Rezende (Brazil)

PB 961  Target Joint Outcomes with Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Updated Results from B-YOND
R. Kulkarni1, K.J. Pasi2, J. Feng1, B. Winding3, A. Ramirez-Santiago1, N. Jain1 (1United States, 2United Kingdom, 3Sweden)

PB 962  Pressure Pain Thresholds Hint at Structural Findings in Knees of Patients with Haemophilia
S. Krüger, M. Hoffmeister, T. Hilberg (Germany)

PB 963  Once-weekly Prophylaxis with GlycoPEGylated Recombinant Factor VIII (N8GP) in Severe Haemophilia A: Safety and Efficacy Results from a Randomised Phase 3 Trial (pathfinder™2)
N. Curry1, C. Albayrak2, M. Escobar3, P.A. Holme4, S. Kearney5, R. Klamroth6, M. Misgav7, C. Négrier8, E. Santagostino9, M. Shima9, A. Wheeler8, S.M. Tender9, S. Lentz10 (1United Kingdom, 2Turkey, 3Italy, 4United States, 5Norway, 6Germany, 7Israel, 8France, 9Italy, 10Japan, 11Denmark)
POSTER SESSIONS

PB 964 End-of-trial Results from a Large Multinational Extension Trial (guardian™2) Using Turoctocog Alfa for Prophylaxis and Treatment of Bleeding in Patients with Severe Haemophilia A
S. Lentz1, D. Janić2, M.C. Ozelo3, A. Tiede4, I. Matysitina4, L. Korsholm5, S. Zupančić-Šalek6, J. Oldenburg7 (1United States, 2Serbia, 3Brazil, 4Germany, 5Denmark, 6Croatia)

PB 965 rVIII-SingleChain in Surgical Prophylaxis: Efficacy and Safety in 35 Surgeries
F. Abdul Karim1, C. Djambas Khayat2, J. Mahlangu3, R. Baker4, C. Male5, J. Oldenburg6, J. Ong7, S. Ping8, M.E. Mancuso9, C. Leissinger10, A. Veldman11, S. Lucas12, J. Pabinger13 (1Malaysia, 2Lebanon, 3South Africa, 4Australia, 5Austria, 6Germany, 7Philippines, 8Italy, 9United States)

PB 966 Platelet Aggregation and Clinical Phenotype in Pediatric Patients with Severe Hemophilia A (SHA)
M. Rand, H. Wang, E. McMillan-Ward, V.S. Blanchette, S.J. Israels (Canada)

PB 967 Characterisation of the Inhibitor Status of Patients with Haemophilia A in Australia
S. McRae, S. Parikh, H. Tran (Australia)

PB 968 Long-term Quality-of-Life Outcomes with rFIXFc in Adults with Hemophilia B: Results from B-LONG and B-YOND
J. Su1, J. Feng2, K.-J. Myren2, C. Barnowski1 (1United States, 2Sweden)

PB 969 Lower Risk of Factor VIII Inhibitors among Severe Hemophilia A Patients with Indigenous Background from Brazil

PB 970 Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgery in Patients with Severe Haemophilia a - Results from the Guardian™ Trials
E. Santagostino1, M. Miggav1, P. Chowdary2, F. Abdul Karim3, S. Lejniec4, S. Zupančić-Šalek5, P.S. Miljic6, B. Brand7, I. Matysitina8 (1Italy, 2Israel, 3United Kingdom, 4Malaysia, 5Latvia, 6Croatia, 7Serbia, 8Denmark)

PB 971 Improved Pharmacokinetics of BAY 81-8973 versus Sucrose-formulated Recombinant Factor VIII (rFVIII-FS): Noncompartimental and Population PK Assessment Based on a Single-dose, Randomized, Crossover, Pharmacokinetics Study in Patients with Severe Hemophilia A
A. Solms1, D. Garmann1, A. Shahi2 (1Germany, 2United States)

PB 972 Towards the Development of a Core Set of Outcome Measures for Standardized Assessment of Outcomes in Persons with Hemophilia
B. Feldman1, A. Srivastava2, S. Dover3, A. Abad4, V. Blanchette1 (1Canada, 2India)

PB 973 Low-dose Factor VIII Infusion in Chinese Adult Haemophilia A Patients: Pharmacokinetics Evidence that Daily Infusion Results in Higher Trough Level than with Every-other-day Infusion with Similar Factor VIII Consumption
B. Huang1, A. Lee2, J. Gu1, K. Li1, M.-C. Poon1, Y. Zhao1 (1China, 2Canada)

PB 974 Association of Factor VIII and Factor IX Mutations, HLA Class II, Tumor Necrosis Factor-Alpha and Interleukin-10 on Inhibitor Development among Thai Hemophilia A and B
A. Chuansumrit, W. Sasanakul, N. Sirachainan, P. Kadegasem, P. Wongwerawattanakoorn, L. Mahakan, O. Nathalang (Thailand)

PB 975 Participation of Clinical Psychologist in a Non-hemophilia Treatment Center
A. Nakao, J. Yamanouchi, T. Hato, E. Ishii, M. Yasukawa (Japan)

PB 976 Continuous Infusion of Recombinant Factor IX Fc Fusion Protein during Major Surgery
T. Kanematsu, N. Suzuki, M. Ogawa, M. Kishimoto, A. Suzuki, H. Kiyoi, T. Kojima, T. Matsushita (Japan)

PB 977 United States Post-marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Enrollment Data
R. Creai1, J.-F. Huang2, J. Jiang2, A. Gringeri1, N. Bajwa2 (1Austria, 2United States)

PB 978 Initial Safety Results from a Prospective Post-marketing Surveillance Study Using rFVIII Fc in the Real World Setting in Japanese Hemophilia A Patients
M. Taki, K. Fukutake, M. Kobayashi, A. Nagao, H. Makioka, M. Shiraishi (Japan)

PB 979 Factor Utilization and Costs in Patients with Hemophilia B Using Standard and Extended Half-life Recombinant Factor IX Replacement Products: Real-world Analysis in Japan
T. Karumori1, S. Hiro1, A. Chhabra2, D. Spurden3, A. Pleil2, J. Alvir2, B. Tortella2 (1Japan, 2United States, 3United Kingdom)

PB 980 Long Term Hemostatic Efficacy of Once a Week Administration with a Combination Medicine of Plasma Derived Factor Viia and Factor X for a Hemophilia B Patient with Inhibitor
T. Suzuki, Y. Chikasawa, T. Hagiwara, M. Bingo, Y. Yamamoto, K. Arano, K. Fukutake (Japan)
## POSTER SESSIONS

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
<th>Authors</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 981</td>
<td>Economic Impact of Recombinant FVIII (rFVIII) vs Plasma-derived FVIII with von Willebrand Factor (pdFVIII/VWF) and Low-dose vs High-dose Immune Tolerance Induction in Previously Untreated Hemophilia A Patients (PUPs) in Germany</td>
<td>J. Oldenburg1, E. Neufeld2, M.C. Runken1, K. O'Day2, K. Meyer2, J. Spears2</td>
<td>Germany, United States</td>
</tr>
<tr>
<td>PB 982</td>
<td>Low Dose Long Acting CFC (Eloctate, Biogen) Replacement during Bilateral Total Knee Replacement Surgery (TKA) for Hemophilia A - Feasible and Extremely Cost Effective Approach</td>
<td>S. Apte, M. Swamy, A. Raiyani, A. Joshi, K. Subramanian, D. Vagasiya, H. Balar, R. Phatale, R. Dange (India)</td>
<td>India</td>
</tr>
<tr>
<td>PB 983</td>
<td>Improving Care in Haemophilia: A Qualitative Study</td>
<td>E. van Balen1, M. Krawczyk2, D. Gue2, S. Jackson2, S. Gouw1, J. van der Bom1, R. Sawatzky2</td>
<td>The Netherlands, Canada</td>
</tr>
<tr>
<td>PB 984</td>
<td>Improving the Survival for Life-threatening Hemorrhage with Hemophilia Patient in One Hemophilia Treatment for 34 Years</td>
<td>K. Lee, J. Kim, J. Seo, S. Hyun, H.-J. Yoon (Republic of Korea)</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>PB 985</td>
<td>Single Centre Experience of Obstetric Management of Women with Inherited Bleeding Disorders (IBD) in a Multidisciplinary Joint Women's Bleeding Disorders / Obstetric Clinic</td>
<td>B. Madan, F. Al-Fararjeh, G. Gray (United Kingdom)</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>PB 986</td>
<td>At Home PK to Tailor Prophylaxis</td>
<td>M. Morfini (Italy)</td>
<td>Italy</td>
</tr>
<tr>
<td>PB 987</td>
<td>Bayesian Approach to Individualize Prophylaxis of Simoctocog Alfa in Haemophilia</td>
<td>X. Delavenne, J. Mercy, S. Dantin, C. Nègrier (France)</td>
<td>France</td>
</tr>
<tr>
<td>PB 989</td>
<td>Preferences of Hemophilic Patients and their Parents on the Characteristics of Replacement Treatment Used in Prophylaxis</td>
<td>M.E. Mancuso, E. Santagostino, L. Scalone, P.A. Cortesi, P. Cazzolino, G. Cesana, L.G. Mantovani, P.M. Mannucci (Italy)</td>
<td>Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
<th>Authors</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 990</td>
<td>Evaluation of Unmet Medical Needs of Hemophilia Patients in Bavaria</td>
<td>H. Lechner, A. Schleiermacher, K. Berger, D. Schopohl, W. Schramm (Germany)</td>
<td>Germany, United States</td>
</tr>
<tr>
<td>PB 992</td>
<td>The Impact of a Comprehensive Hemophilia Management Programme in Vulnerable Population</td>
<td>C.A. Montano Mejia, S. Sarmiento (Colombia)</td>
<td>Colombia</td>
</tr>
<tr>
<td>PB 993</td>
<td>The Impact of Long-term Secondary Prophylaxis on Health-related Quality of Life in Adolescents and Adults with Severe Haemophilia A treated with rFVIII-FS</td>
<td>A. Tagliaferi1, A. Coppola1, C. Santoro1, S. Amoresano1, S. von Mackensen2</td>
<td>Italy, Germany</td>
</tr>
<tr>
<td>PB 994</td>
<td>FEIBA Global Outcome Study (FEIBA GO) First Data Read-Out: Real-world Bleeding Frequency in Patients with Inhibitors on Prophylaxis with APCC</td>
<td>C. Escuriola-Ettinghausen1, J. Windyga2, P.A. Holme3, C. Hermanns4, C. Negrier5, A.R. Cid6, S. Rangarajan6, A. Rocino7, A. Gringeri8, R. Crea8</td>
<td>Germany, Poland, Norway, Belgium, France, Spain, United Kingdom, Italy, Austria</td>
</tr>
<tr>
<td>PB 996</td>
<td>Pharmacokinetics and Annual Bleeding Rate (ABR) during Prophylaxis with a Full-length Recombinant FVIII: One Center Experience</td>
<td>D. Neme, L. Elhelou, E. Honorat, A. Coca, M. Tezanos Pinto (Argentina)</td>
<td>Italy, United States</td>
</tr>
<tr>
<td>PB 997</td>
<td>A Unique Case Involving Delivery of Bolus rFVIIa via an Innovative Syringe Pump to a Patient with Hemophilia and Inhibitors Undergoing a Kidney Transplant</td>
<td>J. Stanley, S. Austin (United Kingdom)</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
### POSTER SESSIONS

#### Management of Thromboembolism

**PB 1000**  
The Prevalence of Concomitant Deep Vein Thrombosis, Symptomatic or Asymptomatic, in the Patients with Symptomatic Pulmonary Embolism  
J. Hirmerova, J. Seidlerova, Z. Chudacek (Czech Republic)

**PB 1001**  
Predicting Post-thrombotic Syndrome with Ultrasonographic Measurements after Proximal Deep Vein Thrombosis  
C.E.A. Dronkers¹, G.C. Mol¹, G. Maraziti², M.A. van de Ree¹, M.V. Huisman¹, C. Becattini³, F.A. Klok¹ (The Netherlands, °Italy)

**PB 1002**  
Can Ultrasonographic and Laboratory Measurements One Year after Proximal Deep Vein Thrombosis Predict Post-thrombotic Syndrome?  
G.C. Mol, C.E.A. Dronkers, M.A. van de Ree, F.A. Klok, M.V. Huisman (The Netherlands)

**PB 1003**  
Patient-reported Reasons for and Predictors of Non-compliance with Elastic Compression Stockings in the SOX Trial  
S.R. Kahn¹, A. Akaberi¹, J.-P. Galanaud², D. Morrison¹, S. Shapiro¹, for the SOX Trial Investigators (Canada, °France)

**PB 1004**  
External Validation of the Patient Reported Form of the Villalta Scale  
K.K. Uhne, A. Dahm, H.S. Wik, L.-P. Jelsness-Jørgensen, P.M. Sandset, W. Ghanima (Norway)

**PB 1005**  
High Accuracy and Reproducibility of CT Right-to-left Ventricular Diameter Measurement by Non-radiologists in Patients with Acute Pulmonary Embolism  

**PB 1006**  
Nationwide Study on the Management and Outcomes of Patients with Superficial Vein Thrombosis under Real-life Conditions (INSIGHTS-SVT)  

**PB 1007**  
Post-Thrombotic Syndrome in Patients Treated with Rivaroxaban or Warfarin for Venous Thromboembolism  
C.J. Coleman, T.J. Bunz (United States)

**PB 1008**  
Possible Predictors of Long-term Dyspnea in Patients with Pulmonary Embolism - A Cross Sectional Study  
M. Tavoly¹, H. Skuterud Wik¹, L.-P. Jelsness-Jørgensen¹, J. Ghanima¹, F.A. Klok¹, P.M. Sandset¹, W. Ghanima¹ (Norway, °The Netherlands)

**PB 1009**  
Reliability Testing of the CAPTSureTM Pediatric Post-thrombotic Syndrome Tool  
M.L. Avila, C.M. Lumia, M.I. Montoya, J. Vincelli, S. Williams, L.R. Brandão (Canada)

**PB 1010**  
Measuring Limb Edema in Children at Risk of Post Thrombotic Syndrome: Do I See what You Feel?  
M.L. Avila, M.I. Montoya, J. Vincelli, S. Williams, C.M. Lumia, L.R. Brandão (Canada)

**PB 1011**  
Laboratory and Clinical Parameters at Diagnosis of Venous Thromboembolism (VTE) Are Not Associated to the Presence of Residual Vein Thrombosis (RVT)  
S.M.S. Soares, F.M. Hassenman, A.V.C. Romano, L.F.B. Sckayer, F.A. Orsi, E.V. de Paula, J.M. Annichino-Bizzacchi (Brazil)

**PB 1012**  
An Innovative Approach to an Age-old Problem: Piloting a Smart Compression Garment Device  
M.L. Avila, K.L. Tam, T. Chau, M.I. Montoya, S. Stephens, C.M. Lumia, L.R. Brandão (Canada)

**PB 1013**  
Post-Pulmonary Embolism Syndrome Development among Patients who Needed Pulmonary Embolism Response Team Assessment  
A. Ahsan, O. Iftikhar, A. Tafur (United States)

**PB 1014**  
Patients Treated with Rivaroxaban Presented Low Prevalence of Post-thrombotic Syndrome  
T. Ferreira, L.F. Bittar, S. Carens, S. Soares, A.V. Calazans Romano Marina Pereira Colella, F. Andrade Orsi, E.V. de Paula, J. M. Annichino-Bizzacchi (Brazil)

**PB 1015**  
Non-invasive Detection of Fresh Deep Vein Thrombosis with Diffusion Weighted Magnetic Resonance Imaging  
Y. Kuroiwa, A. Yamashita, T. Gi, Y. Konishi, T. Asanuma, T. Miyati, T. Imamura, Y. Asada (Japan)

**PB 1016**  
Patients’ Experience of Post-thrombotic Syndrome: A Qualitative Study with Focus Groups Aiming at a More Accurate Diagnosis  
M. Engeseth, T.R. Enden, M.H. Andersen, P.M. Sandset, H.S. Wik (Norway)

**PB 1017**  
Optimizing Treatment for Post-thrombotic Syndrome (PTS): A Systematic Review  
S. Abegunde, I. Ajayi (Nigeria)
PB 1022  Inferior Vena Cava Filters: Experience of 133 Patients in a Tertiary Referral Center  
A. Riera-Mestre, J. Ribas Sola, E. Cuevas Sales, E. Alba Rey, E. Escalante Porrúa, X. Corbella Virós, J. Dorca Sargatal (Spain)

PB 1023  Sex Specific Prevalence and Performance of Diagnostic Algorithms for Pulmonary Embolism  

PB 1024  Clinical Course of Lemierre Syndrome: An Individual-Patient Data Meta-Analysis of 518 Subjects  
S. Barco1, F. Zane2, C. Sacco2, S. Granziera2, S.V. Konstantinides1, M. Di Nisio1, A. Pecci1, Lemierre Study Group (1Germany, 2Italy)

PB 1025  Comparison of Pulmonary Embolism Severity Index Score and Hestia Criteria to Identify Pulmonary Embolism Patients for Outpatient Treatment  
P. Nona, A. Tawney, D. Tirunagari, C. Klochko, S. Ahsan, Y. Shah, S. Ellsworth, S. Kaatz (United States)

PB 1026  Clinical Courses of Portal Vein Thrombosis (PVT) in Children  
P. Komvilaisak, S. Sutra, R. Komvilaisak, N. Tewattanarat, K. Wichajarn (Thailand)

PB 1027  The Incidence and of Catheter-related-Thrombosis during Induction Chemotherapy and Follow-up in Chinese Acute Lymphocytic Leukemia Children  
Y. Wei, R. Wu (China)

PB 1028  Behcet and Thrombosis in Children: Hacettepe Experience  
S. Aytaç, İ. Altan, İ. Yaman Bajin, M. Çetin, S. Ozen, F. Gumruk (Turkey)

PB 1029  Relevance of the Pulmonary Embolism with and without Cancer of for 3 Years in an Academic Medical Center  
C. Yasuda, M. Shiina (Japan)

PB 1030  Pulmonary Thromboembolism in Children: Tuberculosis May Be the Underlying Problem  
M. Çetin, İ. Yaman Bajin, S. Aytaç, İ. Altan, E. Yalçın, A.B. Cengiz, F. Gümrük (Turkey)

PB 1031  Inherited Prothrombotic Risk Factors in Turkish Children with Hereditary Anjioedema. Single Center Experience  
T. Patiroglu, M. Canser, A. Ozcan, F. Tahan, Y. Ozkul (Turkey)

PB 1032  Intraoperative Patient Blood Management: A Role for Very-low-Dose Recombinant Activated Factor VII  
T. Hoffmann, S. Sixt, A. Albert, A. Dierksen, E. Roussel, A. Lichtenberg, A. Assmann (Germany)

PB 1033  Preoperative Assessment of Bleeding Risk - Implementing Strategies in the Pursuit of Effective Patient Blood Management  
J. Joseph, D. Behan, G. Mills, G. Lepar, E. Bean (Australia)

PB 1034  Indications for the Use of Fresh Frozen Plasma in Neonatal Intensive Care Unit in a Tertiary Care Hospital  
R. Akbar, A. Khan (Pakistan)

PB 1035  Intermittent Intravenous Deferoxamine for the Treatment of Transfusional Iron Overload  
M. Varma (United States)

PB 1036  Reasons for Blood Donor Deferral among Voluntary Blood Donors in a Tertiary Care Hospital in Kathmandu, Nepal  
B. Nepal, B. Gautam (Nepal)

PB 1037  Haemovigilance Reports of Adverse Blood Donor Reaction among Voluntary Blood Donors in Tertiary Care Hospital in Kathmandu, Nepal  
B. Nepal, B. Gautam (Nepal)

PB 1038  Re-infusion of Heparinized Shed Blood in Aortic Surgery to Maintain Hemostatic Levels of Fibrinogen  
M. Reyes, O. Preventza, C. Letheridge, J. Coselli, J. Anton, A. Bracey (United States)

PB 1039  Use of Molecular Biology to Reveal the Mechanism of Non-hemolytic Febrile Transfusion Reaction to Enhance the Transfusion Safety  
D.-P. Chen, Y.-H. Wen, C.-P. Tseng (Taiwan)

PB 1040  Pseudomyxoma Peritonei Surgery: Potential for Predicting Fibrinogen Use using Thromboelastometry  
C. Rea, S. Stanford, J. Needham, A. Roy, N. Sargant, S. Rangarajan (United Kingdom)

PB 1042  Comparison of Arterial and Venous Coagulation Parameters Measured with the QuantaTM System in Cardiac Surgery  
F. Viola, D. Winegar, L. Fernandez, D. Groves, J. Huffmyer (United States)
POSTER SESSIONS

PB 1043  The Quantra Surgical Cartridge: A Novel Assay for the Rapid Assessment of Coagulation Function from Whole Blood
F. Viola, C. Lloyd, T. Higgins, A. Hornyk, D. Bryant, T. Givens, P. Braun (United States)

PB 1044  Five Years of Hemovigilance Reports of Complications of the Blood Donation Reported at a Tertiary Care Centre in Karachi
B. Nepal (Pakistan)

PB 1046  Performance Evaluation of the Quantra Surgical Cartridge for Rapid Point-of-Care (POC) Assessment of Coagulation Function
P. Braun, C. Wang, V. Sekaran, M. Koren, C. Lloyd, F. Viola (United States)

PB 1047  ABO Discrepancies and Errors in a Routine Blood Bank
B. Nepal (Pakistan)

PB 1048  Is the Thrombin Generation Test, a Useful Research Tool, Suitable to Characterize Therapeutic Plasmas?

PB 1049  Viral Inactivation and Enrichment of Factor VIII, Factor XIII, Fibrinogen and von Willebrand Factor (VWF) Multimers from Fresh Frozen Plasma (FFP) using, “VIPS Plasma, Virus Inactivation Treatment System”
B. Nepal (Pakistan)

PB 1050  Prolonged Platelet Storage Associated with Increased Incidence of Platelet Transfusion Adverse Events
J. Chen, L. Blower, D. Hamed, S. Yang, S. Cataland (United States)

Nurses and Allied Health

PB 1051  Remote 'Bridging Clinics' Maximise Efficiency and Patient Satisfaction in the Perioperative Management of Anticoagulation
S. Brookman (United Kingdom)

PB 1052  Expanding the Role of the Anticoagulation Nurse
S. Rivera, E. Gee (United Kingdom)

PB 1053  Nurse-led Clinic Initiative for Patients Commencing Direct Oral Anticoagulants (DOACs) in the National Coagulation Centre, Dublin, Ireland
L. Solomon, M. Blake, R. Diaz, N. Flynn, V. Graham, J. Benson, N. O Connell (Ireland)

POSTER SESSIONS

PB 1054  Haemorrhheologic and Fibrinolytic Activities of Sickle Cell Subjects in Steady and Crisis States in Abuja Metropolis, Nigeria

PB 1055  Social Work Research and Funding Opportunities: The Canadian Experience
Claude Bartholomew, St. Paul’s Hospital, Vancouver, Canada Neale Smith, University of British Columbia
C. Bartholomew, N. Smith (Canada)

PB 1056  Scapular Injection of Low Molecular Weight Heparin in Neonates Receiving Treatment for Thrombosis
R. Goldsmith, K. Hamilton, B. Paes, A. Chan (Canada)

PB 1057  Empowering a Link Practitioner Network to Enhance Venous Thromboembolism (VTE) Prevention and Anti-coagulation Care
R. Greenall, E. Gee, L. Bonner, C. Doyle, G. Mulla (United Kingdom)

PB 1059  Has the Introduction of the Direct Oral Anticoagulants (DOACs) Made Any Difference to Telephone Calls to a Secondary Care Led Anticoagulant Clinic?
S. Bond, S. Rhodes (United Kingdom)

PB 1061  When the Absence of Prophylaxis in Patients with Hemophilia, Surgery is Inevitable
L. Rakic (Serbia)

Poster Session
12:00 – 13:15  Exhibition Hall 4.2

Hemorrhagic Disorders, Hemophilia

PB 1062  Abnormal Plasma Clot Formation and Stability Distinguish Bleeding Risk in Patients with Severe or Partial Factor XI Deficiency
G. Pike1, L. Holle1, J. Burthem1, P. Bolton-Maggs1, F.-C. Lin2, A. Wolberg2 (1United Kingdom, 2United States)

PB 1063  Anti FIIa/FX Bispecific Antibody (Emicizumab) Enhances Plasma Procoagulant Activity In Hemophilia B in the Presence of Very Low Level of Factor IX
K. Ogawa, H. Minami, K. Nogami, T. Matsumoto, T. Kitazawa, K. Hattoni, M. Shima (Japan)

PB 1064  Abrogating Fibrinolysis Does Not Markedly Affect the Bleeding Phenotype or Response to rFVIII Therapy in Mice with Haemophilia A
R. Stagaard1, M.J. Flick2, B. Bojko3, K. Gorylski1, P.Z. Gorylska1, C.D. Ley1, L.H. Olsen1, T. Knudsen1 (1Denmark, 2United States, 3Poland)
POSTER SESSIONS

PB 1065  Vascular Remodeling in Hemophilic Joint Bleeding is Associated with Vascular Leak: A Possible Mechanism for Re-bleeding

PB 1066  Development of a Pharmacokinetic-Pharmacodynamic (PK-PD) Model of Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia in Patients with and without Inhibitors
H. Attarwala, V. Goel, K. Madigan, A. Akinc, G.J. Robbie (United States)

PB 1067  Electrostatic Analysis of Hemophilia B Caustive Mutations
M. Meireles, E. Bandinelli, G. Vieira, F. Salzano (Brazil)

PB 1068  Identification of Regulatory B Cells in Severe Hemophilia A Patients
D. Matino, M. Gargaro, A. Turco, S. Linari, P. Puccetti, A. Iorio, G. Castamam, F. Fallarino (Italy, Canada)

PB 1069  Prophylactic Treatment with Turoctocog Alfa Pegol (N8-GP), a GlycoPEGylated Recombinant Factor VIII, Completely Prevents Development of Arthropathy in a F8 - Knockout Mouse Model of Induced Knee Bleeding
J.B. Hebsgaard, M. Petersen, K. Roepstorff, M. Ezban, C.D. Ley (Denmark)

PB 1070  Two Large F8 Deletions Possibly Related to the Mechanism of Microhomology-mediated Break-induced Replication (MMBIR) as a Cause of Severe Haemophilia a and Inhibitors

PB 1071  Measurement of Basal Levels of TF, FVII, FVIIa, Free and Total TFPI and FVIIa. AT Complex Levels in Patients with Haemophilia A and B
E. Fosbury (United Kingdom)

PB 1072  F8-deficiency in Mice is Associated with Increased von Willebrand Factor (VWF) Content in the Hepatic Endothelium and with Increased VWF Plasma Levels

PB 1073  Feasibility of Prospective Transcriptome Profiling in Previously Untreated Patients with Severe Hemophilia A: NuProtect Gene Expression Satellite Study
P. Batty, E. Wozniak, E. Savage, C.A. Mein, D.P. Hart (United Kingdom)

PB 1074  The Bone Disease in Haemophilia: A Possible Role of Coagulation Factors?
M. Sacco, S. Lancellotti, A. Arcovito, G. Battafarano, A. Del Fattore, R. De Cristofaro (Italy)

PB 1075  Determinants of Thrombin Generation in Haemophilia A and B
B. Tardy-Poncet, F. Chelle, A. Montmartin, M. Piet, M. Cournil, C. Morin (France)

PB 1076  Unusual Genomic Rearrangement Combined with Inv22 and Wild-type X-chromosome in Severe Hemophilia A Patients
S. Tamura, M. Kikihara, Y. Hattori, E. Hashimoto, H. Sakane, Y. Takagi, M. Ogawa, T. Kanematsu, N. Suzuki, A. Takagi, T. Matsushita, T. Kojima (Japan)

PB 1077  Biochemical and Biophysical Characteristics of Commercially Available FVIII Products
R. De Cristofaro, M. Sacco, S. Lancellotti, I. Garagiola, C. Valsecchi, G. Scaglione, M. Basso, E. Di Stasio, F. Peyvandi (Italy)

PB 1078  Global Assays of Hemostasis among Severe Hemophilia A Boys Detects Variation
F. Pluthero, M. Rand, V. Blanchette, W. Kahr (Canada)

PB 1079  A Bispecific Antibody Lacks Measurability in Routine Coagulation Assays and Comparability to Factor VIII
R. Hartmann, S. Knappe, G. Schrenk, L.A. Valentino, F. Scheiflinger, M. Dockal (Austria, United States)

PB 1080  Efficacy of Anti-TFPI Antibody PF-06741086 Compared to rFactor VIIa in Mouse Hemophilia A Bleeding Models
R. Jasuja, J.E. Murphy, D.D. Pittman (United States)

PB 1081  X Chromosome Inactivation and Plasma Level of Factor VIII and IX in Carriers of Hemophilia A and B
I. Garagiola, M. Mortarino, M. Biganzoli, M.E. Mancuso, E. Santagostino, F. Peyvandi (Italy)

PB 1082  Turoctocog AlfaPegol (N8-GP) Is Cleared from Subcutaneous Injection Sites without Local Degradation
M. Petersen, L.F. Larsen, H. Pelzer, G. Bolt, A.L. Nielsen, F. Rode, K. Almholt (Denmark)

PB 1083  Thrombin Generation Profiling in Amish Factor IX Carriers and Controls: Plasma Composition and Bleeding Phenotype
M.C. Bravo, S. Gupta, C. Nakar, M. Heiman, A. Shapiro, K. Brummel-Ziedins (United States)

PB 1084  The Global Annual Bleed Rate in Haemophilia: A 2015 Estimate
C. Thompson, A. Srivastava, M. Skinner, J. Stonebraker, J. Epstein, T. Kauf, L. Valentino (United States, India)
PB 1085  Mortality of Hemophilia in Brazil: First Report
L. Lemos Jardim1, J. van der Bom2, C. Caram Deelder1, S. Claudia Gouw1, M.
Leal Cherchiglia1, S. Meireles Rezende1 (1Brazil, 2The Netherlands)

PB 1086  Alternative Payment Models in Hemophilia
B. Jönsson1, G. Dolan2 (1Sweden, 2United Kingdom)

PB 1087  Rapid and Cost-effective FVIII Intron Inversion 22 Screening of the Central
South African Haemophilia A Population
W. Janse van Rensburg, J. Kloppers (South Africa)

PB 1088  Patient Satisfaction of Home Delivery Program in Haemophilia through an
Association of Patients
M. Martin-Cerezuela, J.E. Megías-Vericat, E. Monte-Boquet, P. Pérez-Huertas,
M.J. Cuellar-Monreal, M.V. Tarazona-Casany, J.L. Poveda-Andrés, S. Bonanad-
Boix (Spain)

PB 1089  Contribution to the Molecular Study of Hemophilia B in an Algerian Population
A. Zidani1, Y. Ouarhlent1, M. Yahia1, N. Lannoy2, K. Belhadi1 (1Algeria,
2Belgium)

PB 1090  A Hand-held Electronic Patient Diary for Haemophilia Home Care-pilot Study in
Poland
P. Laguna, H. Bobrowska, A. Janik-Moszant, A. Klukowska, A. Koltan, T.
Urasinski, I. Woznica –Karczmarz (Poland)

PB 1091  Induction of FVIII Tolerance by Gene Transfer of IL2 and Factor VIII Plasmids
in Hemophilia A Mice
M.J. Lyle, R.Y. Fu, C.H. Miao (United States)

PB 1092  Therapeutic Expression of Factor VIII Following Ultrasound-mediated Gene
Delivery of High-expressing FVIII Variant Plasmids and Immunomodulation in
Haemophilia A Mice
M.J. Lyle, J. Harrang, D. Tran, R.Y. Fu, C.H. Miao (United States)

PB 1094  Integration Site Analysis in Mice Demonstrates Excellent Biosafety Profile of a
Recombinant (R) FVIII Adeno-associated Virus (AAV8) Gene Therapy Product
W. Hoellriegl1, F.G. Falkner2, M. Weiller1, M. Schmidt3, F. Scheifflinger1, H.
Rottensteiner1 (1Austria, 2Germany)

PB 1095  A Novel Strategy for Liver Cell-based Therapy in a Hemophilia B Model
Y.C. Hsu, Y.J. Huang, I.S. Yu, Y.M. Wu, S.W. Lin (Taiwan)

PB 1096  Immunity to AAV8 and Other AAV Serotypes in Healthy Individuals
A. Kruzik, D. Fetahagic, B. Hartlieb, F.M. Horling, F. Scheifflinger, B.M. Reipert,
M. de la Rosa (Austria)
POSTER SESSIONS

PB 1106  Hyperfibrinolysis in Children. Prevalence of Hyperfibrinolysis in Mucocutaneous Bleeds of Unknown Cause in a Pediatric Cohort
P. Zuñiga, N. Orellana, O. Panes, D. Mezzano (Chile)

PB 1107  Pregnancy in Factor XI-deficient women
R. Santoro, P. Iannaccaro, S. Morgione, M.T. Paparo (Italy)

PB 1108  Factor XIII Deficiency and Noonan Syndrome: A Tricky Association
M. Albisetti, T. Boesten, K. Steindl, V. Schröder, S. Kroiss Benninger (Switzerland)

PB 1109  Dysprothrombinemia Caused by the Homozygote Mutation Ala563Val in the F2 Gene Was Associated with Reduced Thrombin Generation in a Patient with Bleeding Disorder
H. Glosli, N. Iversen, M.S. Le, M. Sletten, P.A. Holme, C.E. Henriksson (Norway)

PB 1110  Severe Acquired Hemophilia A, B and C Associated with Lupus Anticoagulant in a Child. A Case Report
S. Arghirescu, E. Ursu, D. Savescu, L. Cernat, C. Jinca, M. Serban (Romania)

PB 1111  A Novel Thrombin-activatable Factor X Corrects Acquired Hemophilia A in Rabbit

PB 1112  Recombinant Factor VIII-Albumin Fusion Protein Undergoes Endothelial Cell Protein C Receptor Mediated Internalization and Recycling
J. Glauser1, J. Chia1, S. Cattepoel1, S. Dower1, A. Verhagen1 (Australia, Switzerland)

PB 1113  Treatment of Hemophilia A by Injection of FVIII-encoding mRNA
J. Russkikh1, S. Delignat1, K. Kariko2, S. Lacroix-Desmazes1 (1France, 2Germany)

PB 1114  Clinically-relevant Bioavailability of rIX-FP after Subcutaneous Administration to Rodent and Non-rodent Species
M.W. Nolte1, S. Herrmann1, E. Raquet1, F. Kaspereit1, W. Krege1, B. Doerr1, S. Zollner2, E. Herzog1 (1Germany, 2Switzerland)

PB 1115  Rescue of Multiple Hemophilia B-causing Mutations in F9 Exon 3 by a Unique ExSpeU
D. Balestra, D. Scala, F. Bernardi, M. Pinotti (Italy)

PB 1116  Dose-response and Duration of Effect of a Half-life Extended Recombinant Factor VIII in the Tail Vein Transection Bleeding Model in Haemophilia A Rats
T. Elmq, C. Behrens, M. Dainiak, M. Åkesson, J.J. Hansen, M.S. Jensen, I. Hilden, H. Østergaard, M.B. Hermit (Denmark)

PB 1117  Defining Extended Half-life rFVIII: A Critical Review of the Evidence
J. Mahlangu1, E. Santagostino2, G. Young1, C. Hermans1, V. Blanchette1, E. Berntorp3 (1South Africa, 2Italy, 3United States, 4Belgium, 5Canada, 6Sweden)

PB 1118  Nonclinical Immunogenicity and Safety of SHP656 (BAX826), a Next Generation Extended Half-life Recombinant Factor VIII Product

PB 1119  Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Marzepatocag Alfa (Activated) in Hemophilia B Mice
H. Levy, A. Hetherington, N. Usman (United States)

PB 1120  Underestimation of N-glycoPEGylated Factor IX (N9-GP) Activity in One-stage Clotting Assay Owing to Contact Activator Impairment of N9-GP Activation
E. Persson1, C. La Cour Christoffersen (Denmark)

PB 1121  Analysis of the Novel Recombinant Factor VIII-SingleChain Protein Predicts A Lower Immunogenic Potential as Compared to Full-length Recombinant FVIII
J. Mahlangu1, E. Santagostino2, G. Young1, C. Hermans1, V. Blanchette1, E. Berntorp3 (1South Africa, 2Italy, 3United States, 4Belgium, 5Canada, 6Sweden)

PB 1122  Identification of Amino Acid Substitutions in the D’D3 Region of von Willebrand Factor that Increase the Binding Affinity for FVIII
A. Andrews, M. Hardy, K. Emmrich, C. Panousis1, T. Weimer2, S. Dower1, M. Wilson1 (1Australia, 2Switzerland, 3United States)

PB 1123  Administration of rFVIIa to Concizumab-dosed Monkeys Is Safe and Concizumab Does Not Affect the Potency of rFVIIa in Haemophilic Rabbits
B. Lauritzen, J. Olling, K. Abel, C. Augustsson, K. Balling, I. Hilden (Denmark)

PB 1124  A Monoclonal Antibody with TFPI Neutralizing Activity, Improves the Coagulation Parameters of Hemostatic Assays Performed with Hemophilic Whole Blood
POSTER SESSIONS

PB 1125  Protein Engineering of Factor X to Restore Coagulation: Building an Alternate Amplification Loop

PB 1126  Pharmacodynamic Efficacy of a Recombinant Fusion Protein Linking Activated Factor VIIa to Human Albumin (rVIIa-FP) in FVIII and FIX Depleted Plasma with or without Inhibitors
E. Raquet, P. Niebl, B. Doerr, E. Herzog (Germany)

PB 1127  Effect of Phospholipid Vesicle Composition on Activity of FVIIla-mimetic Bispecific Antibodies
M. Aleman, A. Goodman, E. Kistanova, N. Leksa, R. Peters (United States)

PB 1128  A New Long-acting Pegylated Recombinant Factor VIII Derived from Single-Chain Factor VIII Engineered to Be Highly Expressed in CHO Cell Line

PB 1129  Pharmacodynamic Efficacy of a Recombinant Fusion Protein Linking Activated Factor VIIa to Human Albumin (rVIIa-FP) in FVII Depleted Plasma
E. Raquet, P. Niebl, B. Doerr, E. Herzog (Germany)

PB 1130  Extended Hemostatic Efficacy of rIX-FP is Confirmed in a Hemophilia B Mouse Model of Arterial Injury
E. Raquet, F. Musch, M. Mischnik, M. Nolte, E. Herzog (Germany)

PB 1131  A Model of the Minimum Half-life Extension Ratio Needed to Reduce the Dosing Frequency of Extended Half-life Recombinant FVIII Products
J. Booth1, H. Schütz2, K. Steinitz-Trost2, H.-Y. Lee3, A. Bauer4, M. Wolfsegger2 (1United States, 2Austria, 3Switzerland)

PB 1132  The Safety and Efficacy of IB1001 in Previously Treated Children 12 Years of Age or Younger with Hemophilia
R. Liesner1, R. Fritz2, B. MacPherson2, D. Schaal2 (1United Kingdom, 2United States)

POSTER SESSIONS

PB 1133  A Single Analysis for Simultaneous Measurement of All 4 DOACs
J. Emmerechts, S. Ameye, V. Engelrelst, D. Borrey (Belgium)

PB 1134  Interest of PERC Rule (Pulmonary Embolism Rule-out Criteria) to Exclude Pulmonary Embolism in European Patients with Low Implicit Clinical Probability: PERCEPIC Study
A. Penaloza1, C. Soulie-Chavignon2, A. Ghysens1, D. El Kouri2, C. Brice2, N.S. Marjanovic2, A. Trinh-Duc2, T. Moumneh2, Q. Delmez2, P.-M. Roy2 (1Belgium, 2France)

PB 1135  Validation of STA-Latest D-Di Assay for Exclusion of Deep Vein Thrombosis According to the Latest Clinical and Laboratory Standard Institute/Food and Drug Administration Guideline. Results of a Multicenter Management Study
C. Aguilar1, M. Sartori2, A. D’Angelo2, D. Richardson3, C. Kabrhel3, J. Groce3, E. Demaistre4, S. Rathbun5, J. Kassis6, J. Lazarchick6, K. Kase7, P. Marco Vera8, J. Kline1, M. Courtney1, M. Sharafuddin8, A. Rubin1, G. Pernod1 (1Spain, 2Italy, 3United States, 4France, 5Canada)

PB 1136  Variation in Practice for FVIII and FIX Inhibitor Investigations - Results from a UK NEQAS (Blood Coagulation) and UK HCDO Multicentre Exercise

PB 1137  Improving aPTT Test and Resource Utilisation in Manitoba, Canada - A Successful Provincial Experience
C. T. Musuka, P. Sun, C. Mc Mahon, C. Morales (Canada)

PB 1138  Prediction of Coagulation Testing in Underfilled Patient Samples
A. Cloe, K. Mikrut, G. Wool, J. Miller (United States)

PB 1139  Thrombin Generation Based Factor VIII Assay is Sensitive to Low FVIII Levels in Hemophilia
R. Kremers, C. Bai, J. Remijn, I. van Moort, D. Huskens, M. Ninivaggi, B. de laat, M. de Maat (The Netherlands)

PB 1140  Novel Biochip Detects Drug Effects in Patients with Cardiovascular Disease in a Near Patient Setting

PB 1141  Microfluidic Systems with Vascular Biomimetic Surfaces for Assessment of Platelets and Fibrin Components of Hemostasis: Comparison with a Classic Annular Device in the Evaluation of the Antithrombotic Effects of Apixaban
I. Lopez-Vilchez, E. Mir-Fuertes, J. Casals-Terre, M. Puegueroles, E. Arellano-Rodrigo, M. Diaz-Ricart, G. Escolar (Spain)
| PB 1142 | Automated CH50-like Assays for Assessment of the Complement System and Complement Inhibitor Drugs  
I. Mackie1, C. Gardiner1, P. Lane1, A. Chitolie1, H. Kurono2, M. Nunn1, S. Machin1 (1'United Kingdom, 2'Japan) |
| PB 1143 | Prenatal diagnosis for Inherited Bleeding Disorders in India  
| PB 1144 | Availability of Age-specific Coagulation Laboratory Values in Pediatric Hospitals vs. Combined Pediatric/Adult Hospitals: An International Perspective  
Z. Solh1, R. Rajagopal2, J. Thachil3, A. Chan1, N. Heddie1, P. Monagle2 (1'Canada, 2'Australia, 3'United Kingdom) |
| PB 1145 | The Use of the ADJUST (Age Adjusted) D-dimer Cut-off in Screening Patients Aged over 50 Years Presenting with Suspected DVTs Can Decrease the Need for Compression Ultrasonography  
A. Hughes, B. Hall, C. Smith, J. King, G. Page, K. Jennings, S. Macdonald, V. Webb, F. Charrova (United Kingdom) |
| PB 1146 | Is the Application of a Single Conversion Factor Suitable for the Laboratory Monitoring of Single Chain FVIII by One-stage FVIII:C Assay?  
A.E. Bowyer1, S. Kitchen1, D. Dalton2, N.S. Key1, M. Makris1 (1'United Kingdom, 2'United States) |
| PB 1147 | Impact of Pneumatic Tube System Transportation for the Monitoring of Heparin Therapy  
A. Lebreton, A. Casini, O. Bulla, P. Fontana (Switzerland) |
| PB 1148 | Comparison of von Willebrand Factor Collagen Binding Activity (VWF:CB) Determined by a Chemiluminescent Assay on AcustarTM to an ELISA Kit  
E. Joussemie, L. Rugeri, C. Nougier (France) |
| PB 1149 | Validation of a Flow Cytometric Platelet Function Test in a Cohort of Patients with a Suspected Platelet Function Disorder  
J. van Asten, M. Baaij, J. Zandstra, A. Huisman, G. Pasterkamp, R. Schutgens, S. Korpooaal, R. Urbanus (The Netherlands) |
| PB 1150 | Comparison of light transmission aggregometry and multiple electrode aggregometry for the evaluation of platelet aggregation in patients with mucocutaneous bleeding  
S.J. Israels, E. McMillan-Ward, R. Mian, D. Murariu, P. Sun (Canada) |
| PB 1151 | Clot Waveform Analysis Has the Potential to Detect Fibrinogen Abnormalities  
A. Suzuki, N. Suzuki, M. Kishimoto, T. Kanematsu, T. Matsushita (Japan) |
| PB 1152 | Effect of Anticoagulant Adjustment on Prothrombin Time Test Using 2 Different Thromboplastins in Patients with Elevated Hematocrit  
V.M. Silva, C. Cavelheiro Filho, D.C. Rezende, C.C. Strunz (Brazil) |
| PB 1153 | Methodology of Thrombogenicity Assessment Intended for Biomaterials Utilized in Blood Pumps  
M. Gawlikowski, K. Janiczak, B. Zawidlak-Wegrzynska, R. Kustosz (Poland) |
| PB 1154 | LC-MS/MS Nonradioactive Serotonin Release Assay for Platelet Function Analysis in Whole Blood  
S.L. Chan, X. Yi, E. Wysocki, R. Bridgman, K. Mikrutz, J. Gutierrez, E.K.-Y. Leung, K.-T.J. Yeo, J. Miller (United States) |
| PB 1155 | Thromboelastometry can Generate Significant Disagreement in the Management of Patients after Cardiopulmonary Bypass due to Analytical Variability  
B. Bachellerie, H. Charbonneau, S. Voisin, F. Labaste, A. Caussanel, F. Guerrero (France) |
| PB 1156 | Establishing of Therapeutic Range for Unfractionated Heparin Therapy: Activated Partial Thromboplastin Time vs. Anti-Xa Measurement  
L. Zhang1, P. Toulon2, X. Zheng1, J. Yang1, Q. Fan1, C. Liu1, Z. Zhang1 (1'China, 2'France) |
| PB 1157 | Impact of Rivaroxaban and Dabigatran on Clotting Screens as Performed Using the Roche Cobas t 711 Analyser  
A. Lowe1, A. Jones1, A. Stankiewicz2, S. Kitchen1 (1'United Kingdom, 2'United States) |
| PB 1158 | Genotypic Characteristics of Polish Patients with Antithrombin, Protein C and Protein S Deficiency  
E. Odnoczko1, E. Stefanska-Windyga1, A. Buczma1, B. Baran2, J. Oldenburg2, A. Pavlova2, V. Ivankevicius1, J. Windyg1 (1'Poland, 2'Germany) |
| PB 1159 | Assessment of Overall Coagulation and Fibrinolytic Activity in Hemophilia A Patients by Using Global Hemostatic Laboratory Methods: Overall Hemostasis Potential, aPTT-waveform Analysis and Endogenous Thrombin Potential  
M. Milos1, D. Coen Herak1, S. Zupancic-Salek1, J. Pavic2, N. Mahmoud Hourani Soutari1, J.P. Antovic3, R. Zadro1 (1'Croatia, 2'Bosnia and Herzegovina, 3'Sweden) |
| PB 1160 | Thrombin Generation in Patients with Systemic Lupus Erythematosus (SLE)  
N.K. Tóth, T. Tarr, P. Soltész, L. Muszbek, Z. Bagoly (Hungary) |
| PB 1161 | Comparison of Three Different Anti-Xa Assays in Major Orthopedic Surgery Patients Treated with Edoxaban  
H. Wada (Japan) |
POSTER SESSIONS

XXVI ISTH Congress and 63rd Annual SSC Meeting

PB 1162  Assessment of Two Chromogenic FVIII Assays In Haemophilia A Patients Infused with B-domain Truncated or Deleted Products: Results from a French Multicentric Study

PB 1163  Effects of Interfering Substances on Factor Assays Performed Using Q Smart Analyser and DG-PT RecombiLiQ or DG-APTT Synth Reagents
A. Woolley, S. Kitchen (United Kingdom)

PB 1164  Comparison of Point-of-Care Instruments I-STAT, ACTPlus and Hemochron Signature Plus for Measurement of Activated Clotting Time (ACT)
S. Vandendriessche, H. Laverge, K. Devreese (Belgium)

PB 1165  Extracellular Proteases of Micromicetes as New Agents for Protein C, Factor X and Plasma Prekallikrein Diagnostics
A.A. Osmolovskiy, A.V. Orechova, E.S. Zvonareva, V.G. Kreyer, N.A. Baranova, N.S. Egorov (Russian Federation)

PB 1166  Laboratory Expert System in the Field of Hemostasis and Thrombosis: A Pilot Project for the Diagnosis of von Willebrand Disease

PB 1167  A New and Improved Euglobulin Clot Lysis Time Assay (iECLT)
A. Ilich, N. Key (United States)

PB 1168  Platelet Estimation from Peripheral Blood Smear: Does it Really Works?
I. Bachiri, Z. Yahiaoui, N. Fenni (Algeria)

PB 1169  Comparison of Rotational Thromboelastometry Reference Ranges with Normative Ranges across Trimesters in Pregnancy
A.A. Shamshirsaz, K.A. Fox, H. Erfani, K. Brudozski, V. Kostousov, H. Rocky, J. Teruya (United States)

PB 1170  Enhanced Coagulation Decreases Probability of Positive Outcome during in vitro Fertilization

PB 1171  Development and Implementation of a Coagulation Factor Testing Method Utilizing Autoverification in a High Volume Clinical Reference Laboratory Environment
P. Riley¹, B. Valcour¹, B. Gallea² (¹United States, ²France)

XXVI ISTH Congress and 63rd Annual SSC Meeting

PB 1172  Factors VII and VIII Assays: Analytical Performance and Reference Ranges for Argentinian Population
R. Raimondi, V. Monserrat, S. Aguirre, L. Herrera, S. Pons, A. Grinspoin, A. Scazziota (Argentina)

PB 1173  Can Thromboelastography Accurately Assess Coagulation in Anemic Patients?
A.A. Kuperman, E. Shaoul, R. Pollack, A. Braester (Israel)

PB 1174  Standardization of a Cytometry Test to Measure the von Willebrand Factor Collagen Binding Activity
L. Maira Moura de Oliveira, M.V. de Almeida Amorim, D. Gonçalves Chaves (Brazil)

PB 1175  Implementing Autoverification of Coagulation Screen Tests in University Hospital Laboratory in Brazil
M.L. Pereira Gonçalves, P. Orlandi Mourão (Brazil)

PB 1176  Assessment of a Pre-analytical Check System on ACL TOP 750 CTS®

PB 1177  Results of Implemented Postanalytical Quality Indicator - Turnaround Time (TAT) Monitoring for Urgent Coagulation Tests
S. Margetic, I. Vukasovic, N. Vrkic (Croatia)

PB 1178  Is it Helpful for Physicians the Laboratory Post Analytical Comments on a Prolonged APTT?
M.D.V. Arias, R.E. Sueldo, M. Avalos, M. Gurfinkel (Argentina)

PB 1179  Sensitive Method for Determination of Blood Hypercoagulation
V. Sukhanov, O. Petrova (Russian Federation)

PB 1180  Variants of FVII Deficiency at an Elderly Care Hospital
R.E. Sueldo¹, G. Guerrero¹, P. Do Nascimento¹, A. Baques², A. Girolami², G. Scoles², M.D.V. Arias¹ (¹Argentina, ²Italy)

PB 1181  Towards Harmonization of Critical International Normalized Ratio Values Reporting: The Croatian Survey
A. Bronic, D. Coen Herak, S. Margetić, M. Milic Gall (Croatia)

PB 1182  Improving Laboratory Operational Efficiency with the Implementation of a Specialized Hemostasis Lab Automation
V. Cortina, A. Marin, F. Bosch, A. Santamaria (Spain)
POSTER SESSIONS

PB 1183  
In Search of a Sensitive and Reliable Laboratory Tool to Assess Hypercoagulability  
D. Bertaggia Calderara, D. Kröll, P. Nett, A. Aliotta, D. Pratte, N. Weiland-Jäggi, G. Stirnimann, L. Alberio (Switzerland)

PB 1184  
HIL Interferences in Coagulation Testing: Evaluation of Automatic Check with the New ACL TOP 550 CTS Analyzer  
A. Skibowska-Bielinska, E. Wierszylo, E. Czajkowska, K. Lewandowski (Poland)

PB 1185  
Comparison of Clot Waveform Analysis from Sepsis Patients and Healthy Control Group  
N. Zamalek (Indonesia)

PB 1186  
Impact of New Oral Anticoagulants on Routine Coagulation Assays  
A. Bronic, M. Pavic, L. Milevoj Kopcinovic (Croatia)

Management of Thromboembolism

PB 1187  
Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation: An Ancillary Analysis from the Edoxaban versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (Ensure-AF) Study  
G.Y. Lip1, J.L. Merino2, A.G. Dan3, S. Themistoclasakis4, K.A. Ellenbogen5, R. De Caterina5, A. Goudev6, J. Jin7, M. Melino8, S.M. Winters8, B. Merkely9, A. Goette9 ('United Kingdom', 'Spain', 'Romania', 'Italy', 'United States', 'Bulgaria', 'Hungary', 'Germany')

PB 1188  
Anticoagulation Treatment Patterns of Venous Thromboembolism in GARFIELD-VTE Patients  

PB 1189  
Clinical Outcomes in Fragile Patient with Venous Thromboembolism  
F. Moustafa1, M. Giorgi Pierfranceschi2, P. Di Micco2, E. Bucerini2, A. Lorenzo2, A. Villalobos3, J.A. Nieto4, B. Valero5, A.L. Samperiz6, M. Monreal7, RIETE Investigators ('France', 'Italy', 'Spain')

PB 1190  
Comprehensive Characteristics of the Anticoagulant Activity in Relationhip to the Plasma Concentration of Dabigatran  
W.J. Cornuth1, L.O. Henriksen1, D. van de Kerkhof2, S. Husted3, S.D. Kristensen1, M.P.M. de Maat4, A.-M.B. Münster5 ('Denmark', 'The Netherlands')

POSTER SESSIONS

PB 1191  
Menstrual Bleeding Patterns in Women Treated with Rivaroxaban: Data from the EINSTEIN CHOICE Trial  
K. Boonyawat1, A.W. Lensing2, M.H. Prins3, P. Prandoni4, J.I. Weitz5, M. Crowther6 ('Canada', 'Germany', 'Netherlands Antilles', 'Italy')

PB 1192  
Absence of Interaction between Rivaroxaban, Tacrolimus and Everolimus in Renal Transplant Recipients Anticoagulated for Proximal Deep Vein Thrombosis or Atrial Fibrillation  
G. Camporese, M.T. Sartori, D. Bernardi, F. Marchini, G. Averscuso (Italy)

PB 1193  
Impact of Evolving ACCP Guidelines on Estimates of Venous Thromboembolism Risk in US Hospitals  
W. Huang1, A. Cohen2, Z. Maksim3, A. Wyman4, F. Anderson5 ('United States', 'United Kingdom')

PB 1194  
Healthcare Resource Use in the Non-interventional XALIA Study of Rivaroxaban versus Standard Anticoagulation for Deep Vein Thrombosis  
L.G. Mantovani1, S. Cano2, M. Gebel3, K. Sahin4, K. Folkerts5, S. Haas6, R. Kreutz2, D. Monje7, J. Schneider7, M. van Eckels8, W. Ageno9, A.G.G. Turpie10 ('Germany', 'United Kingdom', 'Italy', 'Canada')

PB 1195  
Oral Anticoagulation with Direct Thrombin Inhibitors Prevents the Early Events of Atrial Remodeling and the Thrombin-activated ErbB Signaling in a Rat Model of Atrial Dilation  
C. Jumeau, F. Loisel, G. Dilanian, N. Mougenot, N. Villeneuve, S. Hatem, M. David-Dufilho (France)

PB 1196  
6-months Outcomes of Patients: Results from GARFIELD-VTE  

PB 1197  
Outcomes, Interventions and DOAC Plasma Concentration Assay Utility in DOAC-treated Patients Presenting with Major Haemorrhage or Thrombosis - Results from the Anticoagulant Reversal and Events Study Collaborative (ARES1)  
R.I. Baker1, J. Curnow1, L. Young2, S.R. McGregor1, T. Brighton1, P. Harper2, J. Joseph3, A. Hugman4, G.V. D'Aulerio4, A. Gallus5, Thrombosis and Haemostasis Society of Australia and New Zealand ('Australia', 'New Zealand')

PB 1198  
Direct Oral Anticoagulants in Patients with Venous Thromboembolism Usually Excluded for Clinical Trials  
F. Moustafa1, R. Pesavento2, P. Di Micco2, J. Gonzalez-Martinez2, R. Quintavalla3, L. Peris4, J.A. Porras5, N. Falvo5, P. Banos6, M. Monreal7, RIETE investigators ('France', 'Italy', 'Spain')
PB 1199  A New Method for Determining Concentrations of Direct Oral Anticoagulants  
S. Bloemen1, S. Zwaveling2, J. Douxfils2, T. Peters1, R. Wagenwoord1, H.C. Hemker1, F. Mullier2, B. de Laat1, M. Roest1, R. Kremers1 (1The Netherlands, 2Belgium)

PB 1200  Patients with Dabigatran Circulating Concentration above 200 ng/ml Have a Rebound after Neutralization by a Single Dose of Idarucizumab  
N. Gendron1, J. Gay, M. Lemoine, A. Lillo-Le Louët, D. Smadja (France)

PB 1201  Patient-reported Treatment Satisfaction with Oral Rivaroxaban: Results from the Non-interventional XALIA Study of Deep Vein Thrombosis  
L.G. Mantovani1, S. Cano2, M. Gebel3, K. Sahin4, K. Folkerts5, S. Haas5, R. Kreutz5, D. Monje5, J. Schneider5, M. van Eckels5, W. Agano5, A.G.G. Turpie6 (1Italy, 2United Kingdom, 3Germany, 4Canada)

PB 1202  Comparison of Applying TTR Proportion of Tests and TTR Rosendaal to a Sample Population Attending a Warfarin Clinic  
T.O Halloran, O. Power, J. Conway, M. Watts (Ireland)

PB 1204  Development and Characterization of Neutralizing Monoclonal Antibodies Targeting the Direct Oral Anticoagulant Apixaban  
E. Maurer, S. Crosnier, C. Baltus, M.-C. Viaud-Massuard, M. Canton, P. Ohlmann (France)

PB 1205  Pulmonary Embolism Rule-out Criteria (PERC) Has No Added Value to the YEARS Algorithm to Rule out Pulmonary Embolism  

PB 1206  Evaluation of Different Coagulation Laboratory Methods to Monitor Apixaban, Rivaroxaban and Dabigatran Treatment  
A. Rasmuson, M. Berndtsson, L. Söderblom, M. Skeppholm, R.E. Malmström, J.P. Antovic (Sweden)

PB 1207  Effect of Rivaroxaban on Expression of Monocyte Platelet Aggregates and P Selectin in Patients with Atrial Fibrillation  
R.C.F. Duarte, E.L. Figueiredo, L.G. Freitas, E. Reis, C.N. Ferreira, F.F.M. Campos, M.G. Carvalho (Brazil)

PB 1208  Gastrointestinal Bleeding in Patients on Warfarin and Direct Oral Anticoagulant Therapy: An Observational Study in a District General Hospital  
A. McSorley, C. Dinning, M.D. Creagh, J. Blundell (United Kingdom)

PB 1209  Select-d Trial Qualitative Sub-study: Patient and Carer Experience of Anticoagulation for Cancer-Associated Thrombosis  
A. Hutchinson, S. Rees, K. Date, A. Young, A. Maraveyas, M.J. Johnson (United Kingdom)

PB 1210  TRAP-induced Platelet Aggregation is Reduced in Patients Receiving Dabigatran  
J. Sokol, F. Nehaj, M. Mokan, J. Ivanikova, J. Stasko (Slovakia)

PB 1211  An Oral Factor Xa Inhibitor Edoxaban Ameliorates Neointima Formation Following Vascular Injury in ApoE KO Mice  
Y. Morishima, Y. Honda (Japan)

PB 1212  Thrombelastography (TEG) for Assessing Dabigatran Reversal in a Preclinical Trauma Model  
M. Honickel, N. Akman, O. Grottke (Germany)

PB 1213  Lower Prevalence of Isolated Subsegmental Pulmonary Embolism in the YEARS Diagnostic Algorithm Compared with the Conventional Algorithm for Suspected Pulmonary Embolism  

PB 1214  Renal Clearance is Able to Predict Drug Discontinuation in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants  

PB 1215  What’s the Optimal Cut-off Value of the Prothrombin Time (PT) Assay for Determining Overdose Status of Rivaroxaban?  
B. Kim, S. Jang, Y.-U. Cho, C.-J. Park (Republic of Korea)

PB 1216  DOAC Reversal with Low (< 20 Units/kg) or Moderate Dose (≥ 20 Units/kg) FEIBA in the Urgent Management of Major Bleeding  
W. Dager, A. Roberts (United States)

PB 1217  Treatment Effect Estimates for Extended Treatment of VTE Using Network Meta-analysis from Clinical Trials with Rivaroxaban, Aspirin or Placebo  
Á.F. Pap, A.W.A. Lensing1, M.H. Prins2, P. Prandoni3, U. Krahn1 (1Germany, 2The Netherlands, 3Italy)
## POSTER SESSIONS

| PB 1218 | Is LMWH-calibrated Anti-Xa Assay Useful to Estimate Apixaban Concentration in Patients Undergoing Apixaban Treatment? | M.D.L. Herrera, A. Scazzotta, A. Grinspon, S. Aguirre, R. Raimondi, A. Brodsky, S. Pons | Argentina |
| PB 1219 | Calibrated Automated Thrombogram II: A New Thrombin Generation Test Able to Measure in the Presence of a Direct Thrombin Inhibitor | P.L.A. Giesen, A.J.W. Gulpen, R. van Oerle, H. ten Cate, H.M. Spronk | The Netherlands |
| PB 1220 | Inability of Idarucizumab 5gm to Completely Reverse Excessively High Dabigatran Concentrations | W. Dager, A. Roberts | United States |
| PB 1222 | Management of Pulmonary Embolism in a Short Stay Medical Unit: A Cohort Study | M. Donadini, A. Squizzato, M. Caprioli, N. Macchi, W. Ageno | Italy |
| PB 1223 | The Safety of a Nurse Led Pathway to Transition Patients with Acute Venous Thromboembolism (VTE), Treated with Rivaroxaban, into the Community | T. Indran, A. Cummins, H. Tran, S. Brown, A. Bennett, E. Wood, Z. McQuilton, N. Chan, S. Chunilal | Australia |
| PB 1224 | Performance of a Chromogenic Assay for the Measurement of Edoxaban Concentration in Plasma | C. Hamon, C. Godefroy | France |
| PB 1226 | Assay Availability for Measurement the Anticoagulant Effect of Direct and Indirect Xa Inhibitors | S. Platten, M. Dave | United Kingdom |

## POSTER SESSIONS

| PB 1228 | Selection of Long-term Anticoagulation Therapy after Acute Pulmonary Embolism in Real Life | V. Gilbietis, D. Kigitovića, B. Višča, S. Strautmane, A. Skride | Latvia |
| PB 1230 | Do the Direct Oral Anticoagulants (Doacs) Make Managing Anticoagulant Therapy during the Peri-operative Period Easier? | K. Kittoe, J. Patel, R. Arya | United Kingdom |
| PB 1232 | Choice of Anticoagulation in the Obese | G. McCaughan, H. Crowther, J. Curnow | Australia |
| PB 1233 | Antithrombotic Effects of Edoxaban, a Direct Factor Xa Inhibitor, and Antiplatelet Agents and their Combination Effects on Stent Thrombosis in Rats | Y. Morishima, C. Kaminato, Y. Honda | Japan |
| PB 1236 | Comparing the Performance of Different Assays for Monitoring Dabigatran Plasma Concentrations in Real-practice | L. Goncalves, M. Carvalho, V. Cunha, C. Monteiro, C. Koch | Portugal |
POSTER SESSIONS

PB 1238 Evaluation of Dabigatran Concentrations in Patients Plasma. Comparison of Four Commercially Available Assays
P. Toulon, N. DePooter, A. Appert-Flory, D. Jambou, F. Fischer (France)

PB 1239 Comparison of the LMWH Tinzaparin and the Direct Inhibitors of Factor Xa and Thrombin on the Kinetics and Qualitative Characteristics of Blood Clot. An in vitro Thromboelastometric Study
S. Saita, C. Soulier, P. Van Dreden, L. Papageorgiou, A. Larsen, I. Elalamy, G. Gerotzafas (France)

PB 1240 Measurement of Direct Oral Anticoagulants Levels in Patients Admitted for Bleeding Events: A Prospective Study
A.-L. Sennesael, A.-S. Larock, J. Douxfils, J.-M. Dogné, A. Spinewine, F. Mullier (Belgium)

PB 1241 Direct Oral Anticoagulants for Pulmonary Embolism in Patients Initially Admitted to Sub Intensive Care Unit for Intermediate High Risk Index Event
D. Arioli, M. Casella, M. Calzolari, A. Casali, L. Morini, M.C. Leone, M. Granito, A. Ghirarduzzi, G. Tortorella, E.A. Negri (Italy)

PB 1242 Oral Anticoagulant Associated Bleeding Events - A Single Centre Experience

PB 1243 Influence of Direct Oral Anticoagulants in Fibrinolysis Testing
M. Pereira, R. Matos, E. Cruz, S. Morais (Portugal)

PB 1244 The Incidence and Assessment of Post-thrombotic Syndrome in Critically Ill Children Two Years Post-central Venous Catheter Placement
S. Jones, J. Rutgers, W. Butt, F. Newall, P. Monagle (Australia)

PB 1245 Venous Thromboembolism (VTE) in Pediatric Recipients of Hematopoietic Stem Cell Transplant (HSCT): Principal Findings from a Multicenter Cohort Study
R. Kaur, J. Stanek, H. Rangarajan, S. O’Brien (United States)

PB 1246 Chronic Blood Transfusion Therapy Corrects Abnormalities of Coagulation and Fibrinolysis in Children with Sickle Cell Disease
S. Williams1, C. Segbefia2, F. Pluthero2, W. Kahr2 (1Canada, 2Ghana)

PB 1247 Evaluating the Relationship between von Willebrand Factor, ABO Blood Group and Circulating Lymphoblasts in the Development of All-associated Thromboembolism in Children

PB 1248 Central Venous Catheter Associated Thrombosis in Congenital Heart Disease Patients: A Preliminary Analysis of the Children’s Hospital Acquired Thrombosis (CHAT) Registry
M. Silvey, B. Branchford, E. Krala, J. Jaffray, A. Mahajerin, S. Carpenter (United States)

PB 1249 Neutrophil Extracellular Traps (NETs) and Inflammatory Biomarkers in Patients with Hereditary Spherocytosis. Influence of Splenectomy
C. Garcia, A. Moscardó, S. Izquierdo, A.M. Latorre, B. Argiles, M.T. Santos, J. Valls, M.A. Dasi (Spain)

PB 1250 Paget-Schroetter Syndrome in Children and Young Adults: The Bane of Athletes of Either Gender
D. Warad, A. Nageswara Rao, R. Pruthi, V. Rodriguez (United States)

PB 1251 The Association between Central Venous Catheter Placement and Central Venous Catheter Related Thrombus
S. Jones, J. Rutgers, P. Monagle, W. Butt, F. Newall (Australia)

PB 1252 Acute Ischemic Stroke in Children on Left Ventricular Assist Device. Is There a Role For Endovascular Treatment?
M. Hunfeld, H. van Ommen, B. Emmer, A. van Es, U. Kraemer, R.J. Hounes, D. Tibboel (The Netherlands)

PB 1253 Thrombotic and Hemorrhagic Complications in Pediatric Recipients of Hematopoietic Stem Cell Transplant (HSCT): Mayo Clinic Experience
D. Evstratov, P. Zharkov, L. Potapenko, A. Pshonkin, N. Myakova (Russian Federation)

PB 1254 Venous Thromboembolism in Children with Hodgkin’s Lymphoma
D. Evstratov, P. Zharkov, L. Potapenko, A. Pshonkin, N. Myakova (Russian Federation)

PB 1255 Thrombin Generation in Venous Thromboembolism, Arterial Ischaemic Stroke and Bleeding Events in Children
V. Ignjatovic1, S. Thedieck1, P. Monagle1, U. Nowak-Goetti2 (1Australia, 2Germany)

PB 1256 Paroxysmal Nocturnal Hemoglobinuria Spectrum among Pediatric Age Group of Patients: Single Center Experience without Any Thrombotic Events
S. Unal, F. Gumruk, M. Cetin (Turkey)
**POSTER SESSIONS**

**PB 1257**  
Incidence and Risk Factors for Childhood Thrombosis: Ten Years Experience of a Paediatric Haematology Center from Turkey  
A. Meral Güneş, B. Baytan, M. Sezgin Evim, T. Ersoy Kuzucu (Turkey)

**Platelets - Basic**

**PB 1258**  
A Default in Acetyl-CoA Carboxylase Phosphorylation Increases Thrombus Growth in vitro and in vivo, and in a Collagen-dependent Manner  
S. Leprouet1, S. Kautbally1, L. Bertrand1, G.R. Steinberg2, B.E. Kemp3, A. Hego2, O. Wéra1, S. Brouns4, F. Swieringa4, J. Heemskerk4, C. Oury5, C. Beauloye1, S. Horman1 (1Belgium, 2Canada, 3Australia, 4The Netherlands)

**PB 1260**  
Fibrin Activation and Not GPCR Activation Induces Shedding of Platelet GPVI: Soluble GPVI is Elevated in Thermal Injury and ICU Patients  

**PB 1261**  
A Humanized Monoclonal Antibody that Inhibits Platelet-surface ERp72 Reveals a Role for ERp72 in Platelet Function and Thrombus Formation  
L.-M. Holbrook, G. Sandhar, P. Sasikumar, M. Schenk, A. Bye, A. Stainer, K. Sahl, G. Flora, A. Bicknell, J. Gibbins (United Kingdom)

**PB 1262**  
Patient Derived HLA Monoclonal Antibodies Induce FcγRIa Dependent Platelet Activation  
M. Rijkers, F.H.J. Claas, A. Mulder, L. Venisse, V. Arocas, M.-C. Bouton (France)

**PB 1263**  
Platelet PN-1 Regulates Clot Structure and Retraction  
S. Loyau, Y. Boulaffali, L. Venisse, V. Arocas, M.-C. Bouton (France)

**PB 1264**  
Statins Inhibit Platelet Function and Attenuate Clot Structure  
M.M. Jalal, F.P. Coxon, N.J. Mutch (United Kingdom)

**PB 1265**  
Cyclophilin D Restricts the Lytic Susceptibility of Fibrin via Modulation of Platelet Functions  
V.J. Farkas, L. Kühidai, L. Szabó, C. Chinoopoulos, L. Polgár, K. Kolev, I. Varjú (Hungary)

**PB 1266**  
Biomechanical Mechanisms of Platelet-fibrin Interactions as a Basis of Blood Clot Contraction  
R.I. Litvinov, O.V. Kim, M.S. Alber, J.W. Weisel (United States)

**PB 1267**  
Non-genomic Effects of the Pregnane X Receptor: Inhibition of Platelet Functions  

**PB 1268**  
A Potential Role of Platelet Activation in the Progression of Atrial Fibrillation  
S. Dolleman, H. de Boer, A.J. van Zonneveld (The Netherlands)

**PB 1269**  
Analysis of Microparticles Associated with Procoagulant Platelets by Imaging Flow Cytometry  

**PB 1270**  
Controlled Adhesion of Endothelial Cell and Platelets onto Patterned CoCr Alloy Surfaces by Direct Laser Interference Patterning Technique for Cardiovascular Applications  
M. Pino1, R. Schieber1, F. Lasserre2, M. Hans3, M. Fernandez-Yagüe1, M.P. Ginebra1, F. Möcklich2, M. Pegueroles1, G. Escolar1, M. Diaz-Ricart1 (1Spain, 2Germany)

**PB 1271**  
Autophagy of Microparticles by Platelets is Partially Mediated through TLR-4 and Enhances Thrombogenicity  
I. Lopez-Vilchez, R.M. Hernandez, P. Molina, M. Pino, M. Diaz-Ricart, G. Escolar (Spain)

**PB 1272**  
Analysis of Venous and Arterial Hemostatic Plugs Reveals Strikingly Similar Composition and a Gradient of Platelet Activation  
C. Matzko, M. Tomaiuolo, I. Poventud-Fuentes, L. Nettey, J. Weisel, L. Brass, T. Stalker (United States)

**PB 1273**  
Platelet Reactivity and Receptor Density in Platelets with Different MPV  
A. Södergren, S. Ramström (Sweden)

**PB 1274**  
Connexin 62 Hemichannels and Gap Junctions Regulate Platelet Function  

**PB 1275**  
Chloride Intracellular Channel 1 Cooperates with Integrins to Promote Thrombus Formation and Angiogenesis  
L.M. Knowles, E. Ampofo, P. Niewald, A. Drawz, I. Müller, H. Eichler, J. Pilch (Germany)

**PB 1276**  
A Novel Role for the Membrane Protein G6f in Platelet Activation Induced by Weak Stimulation  
A. Amirkhosravi, M. Davila, L. Robles-Carrillo, M. Brodie, J. Francis (United States)
PB 1277  Biomimetic Surfaces for Studying Neutrophil-platelet Interactions  
L. Erpenbeck1, J. Spatz1, R.K. Andrews2, M.P. Schön1, S. Kruß1  
1(Germany, 2(Australia)

PB 1278  Heparin Decreases Thrombin Induced Procoagulant Platelet Formation via a Direct Platelet Effect  
S. Wang, M. Bourcy, H. Campbell, V. Chen  
(Australia)

PB 1279  Changes in Platelet Surface Receptor Expression upon Activation Are Mainly Contributed by Large Platelets  
M. Moroi, S. Jung  
(United Kingdom)

PB 1280  Autophagy Inhibitors Reduce Platelet Function by Preventing Granule Exocytosis  
D. Groeneveld, J. Adelmeijer, T. Lisman  
(The Netherlands)

PB 1281  Kinetics of Prothrombin Interaction with Subpopulations of Activated Platelets  
N. Podoplelova1, S. Obydennyi1, M. Canault2, F. Ataullakhanov1, M.-C. Alessi1, M. Panteleev1  
1(Russian Federation, 2(France)

PB 1282  Inhibition of MRP4 Mediated Transport Reduces Platelet Function in a cAMP-cGMP Independent Manner  
L. Alemanno1, V. Klaus2, I. Massimi1, G. Maria1, D. Angiolillo1, F.M. Pulcinelli1  
1(Italy, 2(Germany, 3(United States)

PB 1283  Single Platelet Screening Platform Based on Cytoskeletal Adhesion Morphology  
S. Lickert, I. Schön, V. Vogel  
(Switzerland)

PB 1284  Systemic Alteration of Platelet Activity during Each Trimester of Normal Pregnancy  
S. Cullen, M.A. Aloibaidly, C. Regan, N. Moran  
(Ireland)

PB 1285  The Inhibitory Effect of Protamine on Arterial Thrombosis and Platelets in Rats  
I. Miki2, B. Kalaska, D. Pawlak, A. Mogielnicki  
(Poland)

PB 1286  The Role of Neuraminidases in Platelet Function  
D.E. van der Wal, A.M. Davis, M. Mach, D.C. Marks  
(Australia)

PB 1287  Platelet Procoagulant Activity Development and Thrombin Generation in Recalcified ADP-supplemented Platelet-rich Plasma  
E. Artemenko, F. Ataullakhanov, M. Panteleev  
(Russian Federation)

PB 1288  Role of HSP47 in Platelet Collagen Interaction  
S. Alouda, K. Sahli, P. Sasikumar, L. Holbrook, J. Gibbins  
(United Kingdom)

PB 1289  Assessment of Platelet Procoagulant State - Significance of Different Methods  
S.A. Fiedler, A.-C. Junker, G.J. Praefcke, C. Grundmann, R. Seitz  
(U. Salzg. Bartels  
(Germany)

PB 1290  Exploration of additional parameters of multiple electrode aggregometry is encouraged  
M.T. Skipper, P. Rubak, O.H. Larsen, A.-M. Hvas  
(Denmark)

PB 1293  Nicotine Suppresses the Collagen-induced Platelet Aggregation  
Y. Suganuma, T. Kano, K. Ikemoto, C. Ichinose, T. Matsui, K. Kondo  
(Japan)

PB 1294  Platelets Enhance Freshly Isolated Lymphocytes Adhesion to Fibrin  
O. Solpova, A. Solpov  
(Russian Federation)

PB 1295  Synergistic Inhibitory Effect of Capsaicin and Dihydrocapsaicin on the Arachidonic Acid Pathway of Platelet Aggregation  
S. Almaghrabi, K. Ahuja, D. Geraghty, M. Adams  
(Australia)

PB 1296  Crosstalk between P13K Pathway and MAPK Pathway Regulates Platelet Activation and Protein Synthesis via Phosphoinositide-dependent Kinase-1  
B. Manne1, P. Munzer2, R. Badolia1, R. Campbell1, S. Kunapuli1, O. Borst1, A. Weyrich1, M. Rondina1  
1(United States, 2(Germany)

PB 1298  Diacylglycerol Kinase Zeta is a Negative Regulator for GPVI-Mediated Platelet Activation  
A. Moroi, H. Zhi, M. Riese, P. Newman  
(United States)

PB 1299  ELMO1 Negatively Regulates Glycoprotein VI-mediated Signaling by RhoG in Platelets  
A. Patel, J. Kostyak, R. Badolia, D. Bhavanasi, C. Dangelmaier, S. Kim, J. Aslan, M. Serati, S. Kunapuli  
(United States)

PB 1300  All Roads Lead to Filamin A: Ligand Binding and Shear Force Signal to Calpain-mediated Cleavage of Filamin A upon Platelet Activation  
C.L. Buitrago, B. Collier  
(United States)

PB 1301  Kindlin-3 identified as a key negative regulator of the small Rho GTPase, Cdc42 during platelet spreading  
D. Ghalloussi, L. Vidal, M. Poggi, P. Saultier, F. Peiretti, L. Limozin, H. Chambost, M.-C. Alessi, M. Canault  
(France)

PB 1302  RGS-insensitive G Proteins as a Model to Study G Protein-dependent Signaling  
S. Gupta, D. DeHelian, L. Brass, P. Ma  
(United States)
### POSTER SESSIONS

**XXVI ISTH Congress and 63rd Annual SSC Meeting**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1303</td>
<td>Arp2/3 is Critical for Platelet Homeostasis but Dispensable for Hemostatic Plug Formation</td>
<td>D.S. Paul, C. Casari, C. Wu, R. Piatt, S. Pasala, R. Campbell, R.H. Lee, B.C. Cooley, K.R. Machliss, J.E. Italiano Jr., A. Weyrich, J.E. Bear, W. Bergmeier (United States)</td>
</tr>
<tr>
<td>PB 1304</td>
<td>Cold-induced Binding of von Willebrand Factor Facilitates Fast Clearance of Refrigerated Platelets</td>
<td>W. Chen, S.A. Druza, K.M. Hoffmeister, J. Ware, R. Li (United States)</td>
</tr>
<tr>
<td>PB 1305</td>
<td>RGS Proteins Shape the Hemostatic Response by Regulating the Platelet Signaling Networks</td>
<td>S. Gupta, S. Sampietro, D. Dehelian, L. Brass, P. Ma (United States)</td>
</tr>
<tr>
<td>PB 1308</td>
<td>A Role of TNF Receptor-associated Factor 3 in Platelets A and Thrombosis</td>
<td>R. Zhang, G. Zhang, B. Xiang, P. Xie, Z. Li (United States)</td>
</tr>
<tr>
<td>PB 1309</td>
<td>Annexin A7 (ANX7) Regulates Collagen-dependent Platelet Ca2+ Increase and Activation</td>
<td>S. Geue, B. Walker-Allgaier, D. Eißler, P. Münzer, F. Lang, M. Gawaz, O. Borst (Germany)</td>
</tr>
<tr>
<td>PB 1310</td>
<td>Four-receptor Platelet Signaling Computational Model Reveals a New Role of Protein Kinase A in the Control of Platelet Response</td>
<td>A. Sveshnikova1, F. Balabin1, E. Shylov1, S. Shakhidzhanov1, J. Dunster2, J. Gibbins3, M. Panteleev4 (1Russian Federation, 2United Kingdom)</td>
</tr>
<tr>
<td>PB 1312</td>
<td>Sustained Inhibition of Acetyl-CoA Carboxylase Decreases Platelet Dense Granules Secretion and Aggregation</td>
<td>S. Lepropre1, M. Octave1, S. Kautbally1, G. Muccioli1, V.M. Darley-Ussmar2, L. Bertrand2, C. Beauloye1, S. Hormani1 (1Belgium, 2United States)</td>
</tr>
</tbody>
</table>

**XXVI ISTH Congress and 63rd Annual SSC Meeting**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1313</td>
<td>The G12/13 Signaling Pathway Contributes to the Racial Difference in PAR4 Signaling</td>
<td>B. Tourdot, H. Stoveken, D. Trumbo, P. Bray, G. Tall, M. Holinstat (United States)</td>
</tr>
<tr>
<td>PB 1315</td>
<td>Calcium Homeostasis in Platelets in Pregnancy Women with Preeclampsia</td>
<td>V.D. Bichan, A.A. Bakunovich, A.A. Krivolap, V.N. Sidorenko, L.M. Lobanok, K.Y. Bulanova (Belarus)</td>
</tr>
<tr>
<td>PB 1316</td>
<td>PDK1 Regulates Platelet Activation through Phosphorylation of S6K on Thr229</td>
<td>W. Gao, K. Wang, L. Zhang, J. Liu, X. Luo, X. Chen (China)</td>
</tr>
<tr>
<td>PB 1317</td>
<td>Reverse Phosphorylation of the Protein Phosphatase 2A Inhibitor ß-endosulfine (ENSA) at Two Distinct Sites (S67, S109) in Activated and Inhibited Human Platelets</td>
<td>E. Walter1, O. Pagel1, S. Makhoul1, R.P. Zahedi1, A. Smolenski2, S. Gambaryan3, U. Walter1, K. Jurk1 (1Germany, 2Ireland)</td>
</tr>
<tr>
<td>PB 1318</td>
<td>Integration of Platelet Agonist Signaling during the Hemostatic Response in vivo</td>
<td>J. Shen1, S. Sampietro2, J. Wu2, J. Tang1, C. Matzko2, C. Tang1, Y. Yu1, L.F. Brass2, T.J. Stalker2 (1China, 2United States)</td>
</tr>
<tr>
<td>PB 1319</td>
<td>The Identification and Characterization of a Novel, Selective Platelet-surface ERp57 Inhibitor that Modulates Platelet Function Independently of Outside-in Signaling through Integrin ßIIbß3</td>
<td>J.-M. Holbrook1, E. Brun1, A. Stainer1, A. Bye1, A. Feldenzer2, C. Galinski2, D. Kennedy2, J. Gibbins1 (1United Kingdom, 2United States)</td>
</tr>
<tr>
<td>PB 1320</td>
<td>Platelet Proteomic Profiling in a Patient with Severe Platelet Dysfunction Associated to an Anti-ßIIbß3 Autoantibody Triggering Outside-in Signaling</td>
<td>M. Fiore, X. Pillois, M. Jandrot-Perrus, F. Cognasse, A. Debesset, A. Chansavang, S. Claverol, B. Payrastre, S. Laradi (France)</td>
</tr>
<tr>
<td>PB 1321</td>
<td>STAT3 Phosphorylation Is Regulated by Thromboxane A2 Receptor in Platelets</td>
<td>A.M. Latorre, J. Vallés, M.T. Santos, S. Bonanad, A. Moscardó (Spain)</td>
</tr>
<tr>
<td>PB 1322</td>
<td>Guanosine Exerts Antiplatelet and Antithrombotic Properties through CAMP-PKA Signaling and Independently of Platelet Adenosine Receptors</td>
<td>E. Fuentes1, M.A. Alarcón1, I. Palomo1, L. Badimon1, G. Vilahur1, T. Padro2, K.-N. Klootz2, S. Kachler1, M. Fuentes1 (1Chile, 2Spain, 3Germany)</td>
</tr>
</tbody>
</table>
**POSTER SESSIONS**

**PB 1323**  
Anti-thrombotics from Snake Venom as Selective Inhibitor of αIIbβ3 Outside-in Signaling  
Y.-J. Kuo, W.-J. Chuang, T.-F. Huang (Taiwan)

**PB 1324**  
The Involvement of αIIbβ3 Integrin on the Release of Extracellular Vesicles and the Chemokines CXCL4 and CCL5 by Platelets  

**PB 1325**  
Neuromedin U Potentiates ADP and Epinephrine Activation of Human Platelets  

**PB 1326**  
Real-time Flow Cytometry Can Identify Differences in the Kinetics of Platelet Activation in Response to Different Agonists  
J.L. Mitchell, C.I. Jones (United Kingdom)

**PB 1327**  
Interplay between Calcium and Zinc: Implications for Platelet Activation  
K. Taylor, N. Pugh (United Kingdom)

**PB 1329**  
Btk Kinase Activity is Not Critical for Platelet Activation by GPVI  

**PB 1330**  
ERKS Associates Casein Kinase II to Regulate GPIb-IX-mediated Platelet Activation via PI3K/Akt Pathway  
Z. Cheng, X. Fan, X. Chen, H. Mei, J. Liu, Y. Hu (China)

**PB 1331**  
Agonist-induced Protein Disulfide Isomerase Activity in Platelets: Different Effect of Different Agonists  
R. More-Cohen, J. Mostafa, U. Seligsohn (Israel)

**PB 1332**  
Dose-dependent Inhibitory and Stimulatory Effects of Sphingosine-1-phosphate on Platelet Adhesion to Endothelium  
B. Knoop, B. Levkau, A. Ayhan, A. Mohring, L. Dannenberg, M. Kelm, T. Zeus, A. Polzin (Germany)

**PB 1333**  
Calcium Signalling Patterns in Adherent Single Platelets during Activation with Collagen-related Peptide  
S. Obydenru, F. Ataulakhanov, M. Panteleev (Russian Federation)

**PB 1334**  
Reelin Modulates PLCγ2 Phosphorylation upon Platelet Activation and Integrin Outside-in Signaling  
I. Krüger, N.S. Gower, H.H. Bock, M. Elvers (Germany)

**POSTER SESSIONS**

**PB 1335**  
Calcium Monitoring in Platelets: Tool for Diagnosing Platelet Function Defects  
A. Aliotta, D. Bertaglia Calderara, L. Alberio (Switzerland)

**PB 1336**  
Modelling Intracellular Zinc Release in Platelets  
N.S. Ahmed, N. Pugh (United Kingdom)

**PB 1337**  
Role of Heterotrimeric G Proteins in Platelet Activation and Clot Formation in Platelets Treated with Integrin αIIbβ3 Inhibitor  
I. Budnik, B. Shenkman, H. Hauschner, U. Martinowitz, N. Savion (Israel)

**PB 1338**  
In vitro Assessment of Catecholamines to Restore Platelet Aggregation in the Presence of Ticagrelor and Aspirin  
A.-C. Martin, T. Nunes, B. Decouture, P. Gaussem, A. Godier, C. Bachelot-Loza (France)

**PB 1339**  
Emerging Role for TL1 at the Interception of Inflammation and Hemostasis  
I. Morales, F. Reyes, F. Staback, O. Santiago, A. Pacheco, C. Con Yost, M. Rondina, A. Washington (United States)

**PB 1340**  
Uptake of Influenza Virus by Platelets Occurs via Sialic Acid Binding  
A.-C. Jansen, H. Low, J. van den Brand, D. van Riel, A. Osterhaus, E. van der Vries (The Netherlands, Germany)

**PB 1341**  
Platelets Express and Release Immune-modulatory CXCL14 upon Activation  
A. Witte, J. Lu, M. Gawaz (Germany)

**PB 1342**  
CD8 T Cells Are Important Mediators of Platelet Refractoriness  
C. Mayer, S. Patel, C. Arthur, A. Bennett, A. Duncan, S. Stowell (United States)

**PB 1343**  
Endothelial Expression of TL1 T-1 Binding Pockets Mediate Platelet-endothelial Interaction, Leukocyte Transmigration, and Angiogenesis  
Y. Ferrer-Acosta, J. Morales, K. Lugo-Citron, J. Thon, B. Madera, A.V. Washington (Puerto Rico, United States)

**PB 1344**  
Extracellular Vesicles from Activated Platelets: A Quantitative Cryo-electron Microscopy and Immuno-Gold Labeling Study  
A. Brisson, S. Tan, R. Linares, C. Gounou, S. Mornet (France)

**PB 1345**  
Renal Denervation Decreases the Platelet Activation Status in Hypertensive Patients  
POSTER SESSIONS

PB 1346  Upregulation of Inflammatory Transcripts in Platelets of Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Role of Platelets in the "Inflammatory Network" of NAFLD
M.A. Alberelli, L. Miele, G. Marrone, A. Liguori, M. Biolato, R. Landolfi, A. Gasbarrini, A. Grieco, E. De Candia (Italy)

PB 1347  Characterization of PF4-heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential
S. Bertini1, J. Fareed2, L. Madaschi3, G. Risi1, G. Torri1, W. Jeske2, A. Naggi1 (1Italy, 2United States)

PB 1348  Acetylsalicylic Acid Differentially Limits Activation and Apoptosis of Human Platelets Exposed to Various Staphylococcus aureus Strains

PB 1349  Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in vitro and in Renal Cell Carcinoma Patients

PB 1350  Tunable Activation of Therapeutic Platelet-Rich Plasma by Pulse Electric Fields: Differential Effects on Clot Formation, Growth Factor Release and Platelet Morphology

PB 1351  Bacteria Educated Platelets (BEPs) - Altered RNA expression in Human Platelets Induced by Gram Negative Bacteria
A.V. Fejes1, W.A. van der Heijden2, M.G. Best1, A. Vancura2, Q. de Mast2, T. Wurdinger3, C. Mannhalter1 (1Austria, 2The Netherlands)

PB 1352  Ascorbic Acid on Platelet Activation. New Functions for an Old Drug
R.G. Pozner, P.C. Ivani, S. Suarez, M.A. Marti (Argentina)

PB 1353  Lipopolysaccharide Do Not Affect Platelet Activation in vitro
A.S. Majorov, A.N. Sveshnikova (Russian Federation)

PB 1354  Intercellular Signalling between Platelets and a Myeloid Leukemic Cell Line
T. Iftikhar, C. Vial, M.P. Mahaut-Smith (United Kingdom)

PB 1355  An Optimized Protocol for Platelet Rich Plasma Preparation to Improve its Angiogenic and Regenerative Properties

PB 1357  Treatment of Patients with Autologous Platelet Rich Fibrin is Dependent on the Composition of Peripheral Blood Cells: Dental Implant Stability is Associated with Red Blood Cells and Not with Platelets

PB 1358  Identification of a Novel Regulator Platelet P2Y12 Receptor Function: Tetherin, a Lipid-raft Organizing Protein Negatively Regulates Receptor Activity
X. Zhao, D. Alibhai, J.L. Hutchinson, S. Cross, R. Aungraheeta, C.M. McKinnon, A. Poole, G. Banting, S.J. Mundell (United Kingdom)

PB 1359  Platelet Endocytosis in Immune Responses to Viral Infection
M. Banerjee, S. Whiteheart (United States)

PB 1360  Pharmacologic Blockade of Platelets Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis
S. Eichler, H. Böhmlein, K. Loser, H. Wiendl, B.E. Kehrel, K. Göbel, S.G. Meuth (Germany)

PB 1361  Exploring Pro-thrombotic HMGB-1 Release from Platelets
J. Davies, M. Harper (United Kingdom)

PB 1362  Platelets Enhance Distinct Dynamics of Effector Cell Responses of Naive and Effector Memory CD4+ T cells
S. Tanimoto, C.-L. Liu, Y. Min, X. Liu, N. Li (Sweden)

PB 1363  The Staphylococcal Toxin Panton-Valentine Leukocidin (PVL) Induces Neutrophil Extracellular Trap (NET) Formation that Leads to Platelet Activation
A. Bertiing, S. Niemann, M.F. Brodke, F. Anke C., H. Van de Vyver, B. Schlott, C. Heilmann, G. Peters, B. Löffler, B.E. Kehrel (Germany)

PB 1364  Platelets Play a Protective Role in the Host Defense against Burkholderia pseudomallei (Melioidosis)
F. Birnie1, T.A.M. Claushuis1, G.C.K.W. Koh1, J. Ware1, A.F. de Vos1, T. van der Poll1, C. van ‘t Veer1, W.J. Wiersinga1 (1The Netherlands, 2United Kingdom, 3United States)
POSTER SESSIONS

XBVI ISTH Congress and 63rd Annual SSC Meeting

PB 1365 Plant Food Cyanidin-3-glucoside Attenuates Atherosclerosis via Inhibiting Platelet-derived Chemokines and Chemokine Receptors in ApoE/- Mice
Y. Yang, Y. Yanling, Z. Xian, Y. Fuli, L. Qingshan, L. Dan, L. Wenhua (China)

PB 1366 Platelets Promote Immunosuppression and Colorectal Tumor Formation: Inhibition by Clopidogrel
L. Servais, C. Delierneux, O. Wera, A. Hego, A. Ncimi, P. Lancellotti, C. Oury (Belgium)

PB 1367 Interplay between Platelets, Neutrophils and Coagulation in Bleeding in a Mouse Model of Inflammatory Bowel Disease

PB 1368 Platelet-leukocyte Interactions after Major Trauma Primarily Involve Platelet-derived Microvesicles and Are More Frequent in Patients with Poor Clinical Outcomes
P. Vulliamy, P.C. Armstrong, S. Gillespie, H.E. Allan, T.D. Warner, K. Brohi (United Kingdom)

PB 1369 Complete Attenuation of PrP(106-126)-mediated Pathological Responses by Flufenamic Acid in Platelets
R. L. Mallick1, S.N. Chaurasiaa, D. Dash1 (1Nepal, 2India)

PB 1370 Platelet Functional Activity Is Altered in Multiple Sclerosis
L. Schüngel, S. Eichler, M.F. Brodde, C. Korsukewitz, S.G. Meuth, K. Göbel, B.E. Kehrel (Germany)

PB 1371 Contributions of von Willebrand Factor to the Development of Angiotensin II-induced Vascular Inflammation
J. Lagrange1, S. Kosmann1, T. Münzel1, Z. Ruggeri2, W. Ruf2, P. Wenzel1 (1Germany, 2United States)

PB 1372 Platelets Are Effectors of Articular Degradation in Rheumatoid Arthritis
E. Pettor, E. Falcinelli, A. Alunno, S. Momi, E. Bartoloni, A. Marturano, F. Luccioli, G. Mirabelli, R. Gerli, G. Mirabelli (Italy)

PB 1373 Procoagulant Extracellular Vesicles Impair Trophoblast Function by a Thrombo-inflammatory Pathway
S. Kohli, M.M. Al-Dabet, F. Lochmann, P. Marmeyer, S. Ranjan, K. Shahzad, B. Isermann (Germany)

PB 1374 Procoagulant Platelets as a Biomarker in Suspected Sepsis - A Pilot Study
L. Pasalic, A. Shetty, E. Lau, S. Sparenberg, V. Chen, J. Iredell (Australia)

PB 1375 Contraction of Blood Clots is Promoted by Tissue Factor-expressing Activated Monocytes
A. Peshkova1, L.M. Giang1, Y. Tutviler2, I. Andrianova1, J. Weisel2, R. Litvinov2 (1Russian Federation, 2United States)

PB 1376 Different Cytokine and Chemokine Patterns in Pediatric Patients with Acute and Chronic Immune Thrombocytopenia (ITP) Compared with Healthy Children
N. Gönczy1, J.M. Eekels1, M.L. Rand2, M. Schmugge1, O. Speer1 (1Switzerland, 2Canada)

PB 1377 Therapeutics of Multiple Sclerosis, Except of Glatiramer Acetate, Are Unlikely to Alter Platelet Functional Activity
L. Schüngel, S. Eichler, S.G. Meuth, B.E. Kehrel, K. Göbel (Germany)

PB 1378 Anticoagulant and Anti-inflammatory Properties of the Novel Antimicrobial Peptide Centrocitin 1 from Green Sea Urchin
E. Andreassen, B. Østerud, K.-E. Eilertsen (Norway)

PB 1379 Deficiency of Sirtuin 3 Elevates Mitochondrial ROS in Neutrophils and Platelets but Does not Exacerbate NETosis or Venous Thrombosis

PB 1380 Neutrophil Extracellular Traps (NETs) in Septic and Burn Patients

PB 1381 Platelets Release Pathogenic Serotonin in Response to Immune Complexes
N. Cloutier1, I. Allaays1, G. Marcoux1, B. Mailhot1, T. Levesque1, Y. Becker1, M. Rondina1, S. Mckenzie2, F. Cote3, B. Nieswandt3, W. Khan1, B. Mathew3, P. Newman3, N. Lacroix1, F. Fortin1, E. Boilard1 (1Canada, 2United States, 3France, 4Germany)

PB 1382 Platelets Release Pathogenic Serotonin in Response to Immune Complexes
N. Cloutier1, I. Allaays1, G. Marcoux1, B. Mailhot1, T. Levesque1, Y. Becker1, M. Rondina1, S. Mckenzie2, F. Cote3, B. Nieswandt3, W. Khan1, B. Mathew3, P. Newman3, N. Lacroix1, F. Fortin1, E. Boilard1 (1Canada, 2United States, 3France, 4Germany)

PB 1383 Influence of Intravenous Immunoglobulin and Methylprednisolone on Cytokines Secreted by T Lymphocyte in Children ITP
M. Jingyao, C. Zhenping, W. Runhui (China)

PB 1384 Evaluation of a New D-dimer Concept for Venous Thrombosis Exclusion: A Prospective Study (FSET Study) ClinicalTrials.gov ID: NCT02523937
I. Mahé, E. Peynaud-Debayle, H. Helfer, J. Chidiac, B. Dumont, R. Omezzine, M. Pinson, N. Javaud (France)

Diagnostics and OMICS

PB 1385 Evaluation of a New D-dimer Concept for Venous Thrombosis Exclusion: A Prospective Study (FSET Study) ClinicalTrials.gov ID: NCT02523937
I. Mahé, E. Peynaud-Debayle, H. Helfer, J. Chidiac, B. Dumont, R. Omezzine, M. Pinson, N. Javaud (France)
POSTER SESSIONS

PB 1385
A New D-dimer concept for More Specific Detection of Venous Thromboembolism
G. Contant, S.S. Mirshahi, F. Depasse, J. Soria (France)

PB 1386
GDF-15 Alters the expression of Actin Associated Protein, Increases Migration and the Phosphorylation of Smad2 is Mediated via TGFβRII
L. Kas, K. Hörneaus, M. Åberg, A. Jorsback, J. Bergquist, A. Siegbahn (Sweden)

PB 1387
Validation of Plasma Marker Candidates for VTE Using Affinity and Mass Spectrometry-based Proteomics Indicate a Link to Alternative Complement Pathway

PB 1388
Proteomic Profiling to Find Candidate Biomarkers Associated with the Risk of First and Recurrent Venous Thrombosis
A. van Hylckama Vlieg, C. Kabrhel, S.C. Cannegieter, F.R. Rosendaal (The Netherlands, United States)

PB 1389
Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets - Results from the Gutenberg Health Study
M. Panova-Noeva, M.-A.M. Miriam, M. Pauli, A. Schulzi, H.M. Sprok, D. Laubert-Reh, F. Haydi, N. Arnold, J.H. Prochaska, M. Beutel, N. Pfeiffer, T. Münzel (Germany, The Netherlands)

PB 1390
Metabolomic Study in Plasma Samples to Identify a Metabolite Profile Associated to Venous Thromboembolism

PB 1391
Prevalence of Deep Vein Thrombosis and Wells Score Accuracy for Inpatient with Suspected Deep Vein Thrombosis
M. Sartori, F. Gabrielli, E. Favaretto, M. Filippini, E. Conti, B. Cosmi (Italy)

PB 1392
Impact of Chronic Inflammation, Assessed by C-reactive Protein, on the Association between Red Cell Distribution Width and Risk of Incident Venous Thromboembolism

PB 1393
Improved Exclusion of the Pulmonary Embolism Diagnosis in the Emergency Department Using a New D-dimer-Based Assay

PB 1394
Plasma Leptin is Not a Mediator of the Association between Obesity and Risk of Venous Thromboembolism

PB 1395
Identifying a Common Biochemical Background for Thrombotic Events in Patients with Deep Vein Thrombosis (DVT) and Peripheral Artery Disease (PAD)
A.J. ten Cate-Hoek, S. Birocci, R. van Oerle, S. Zeerleder, H. Sprok, B. Luken, H. ten Cate (The Netherlands, Italy)

PB 1396
Plasma Levels of miRNAs Are Associated with Risk of Cancer-related Venous Thromboembolism

PB 1397
A Global Metabolomic Analysis Comparing Low-risk and High-Risk Pulmonary Embolism
O. Zeleznik, E. Poole, S. Lindstrom, P. Kraft, A. Van Hylckama Vlieg, B. Parry, N. Giordano, C. Kabrhel (United States, The Netherlands)

PB 1398
Changes in the Fibrinolytic Status and Cardiovascular Profile in Obese Patients Undergoing Bariatric Surgery
A. Marco, P. Marco (Spain)

PB 1399
Evaluation of Risk Factors for Postpartum Hemorrhage after Vaginal Delivery in Uncomplicated Pregnancy
K. Nishioka, N. Furukawa, K. Horie (Japan)

PB 1400
Analysis of the Substrate Specificity of Factor VII Activating Protease (FSAP) and Design of a Specific and Sensitive Peptide Substrate
E. Kara, D. Manna, G. Age Løset, E. Schneider, C. Craik, S. Kanse (Norway, United States)

PB 1401
Von Willebrand Factor Propeptide May Identify the Patients Susceptible for Renal Dysfunction in Collagen Disease

PB 1402
Age-related Diagnostic Value of D-dimer Testing and the Role of Inflammation in Patients with Suspected Deep Vein Thrombosis - Results from the VTEval Study
POSTER SESSIONS

PB 1404  Characterization of a Transient Procoagulant Phenotype Induced by Recombinant Activated Factor VII (rFVIIa)
H. Rühl, C. Berens, F.I. Winterhagen, J. Müller, J. Oldenburg, B. Pötzsch (Germany)

PB 1405  The Effects of Shear Stress on Platelet Activation and Incipient Clot Characteristics: Exploring the Mechanisms of Shear Induced Clot Formation
R. Hambiy, B. Thomas, C. Thornton, P.R. Williams, K. Hawkins (United Kingdom)

PB 1406  VWF and ADAMTS13 Levels in Early Onset Preeclampsia: Prothrombotic Mechanisms in Mothers with Elevated Risk of Venous Thromboembolism
T. McKinnon1, K. Egan2, L. Belmokhtar1, P. Henne1, H. O’Conner2, J. Donnelly2, C. Monteith2, P. Maguire2, P. Szklanna2, S. Allen2, F. Ñ Åinle2 (1United Kingdom, 2Ireland)

PB 1407  Changes in Thrombin Generation in Obese Patients Undergoing Bariatric Surgery: Improvement in the Hypercoagulable Status
A. Marco, P. Marco (Spain)

PB 1408  Combined Detection of Factor XIII and D-Dimer Is Helpful for Differential Diagnosis in Patients with Suspected Pulmonary Embolism
N. Tang (China)

PB 1409  Clinical Significance of Circulating Endothelial-derived Microparticles and Coagulation Profiles in Patients with Advanced Solid Tumors
S. Der Sheng, H.K. Lee, Y. Kim, H.S. Won, Y.H. Ko, H. Kim (Republic of Korea)

PB 1410  Markers of Neutrophil Extracellular Traps in Patients with Thrombosis and Sepsis
L. Cavanaugh, K. Lee, H. Leung, F. Yan, Z. Ahmadi, B. Chong, F. Passam (Australia)

PB 1411  A Quantitative Clot-based Assay for Antithrombin Activity
B. Woodhams1, S. Gavass0, W. Calhoon, L. Spiezia, E. Campello, M. Morris, P. Simioni1 (1United Kingdom, 2Italy, 3United States)

PB 1412  Identification of microRNAs as Biomarkers for Predicting the Risk of Venous Thromboembolism
J. Gabler, O. Steinbrecher, M. Kollars, P. Kyrle, S. Eichinger (Austria)

PB 1413  Platelet Counts and Plateletcrit are Associated with an Increased Risk of Venous Thrombosis in Females. Results from the RETROVE Study
POSTER SESSIONS

PB 1421  Sensitivity of Different D-dimer Cut-off Levels In Unselected Patients with Confirmed Acute Pulmonary Embolism: FOCUS, a Prospective Multicenter Cohort Study

PB 1422  Assessment of Endothelial and Inflammatory Markers in Brazilian Renal Transplant Recipients

PB 1423  Remote Platelet Function Testing Using Platelet-Bound P-selectin as a Marker of Platelet Activation
S. Heptinstall (United Kingdom)

PB 1424  Endothelial Microparticles, Thrombomodulin and D dimer in Women with Systemic Lupus Erythematosus under treatment
F. Campos, W. Cicarini, K. Ferreira, C. Loures, L. Alves, T. Guimarães, V. Toledo, R. Consoli, C. Neiva, P. Pádua, E. Reis, M.G. Carvalho (Brazil)

PB 1425  Chronic Lymphocytic Leukemia: Is there a Role for Circulating Microparticles or Trombin Generation in Clinical Heterogeneity?
M.G. Carvalho, A. Ferrão, F. Evangelista, F. Campos, R. Duarte, T. Braga, L. Gomes, M. Santiago, W. Cicarini, S. Araújo, A. Sabino (Brazil)

PB 1426  Determinants of Clot Strength in Polycythemia Vera and Primary Myelofibrosis using Rotational Thromboelastometry
N. Nytofte, O. Pedersen, H. Hasselbalch (Denmark)

PB 1427  Identification & Characterization of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients with Continuous Flow Left Ventricular Assist Device Implants
N. Mcclane, W. Jeske, J. Walenga, V. Escalante, E. Coglianese, D. Hoppensteadt, J. Schwartz, M. Bakhos (United States)

PB 1428  Haemostasis in Children with Acute Lymphoblastic Leukemia

PB 1429  Association between FTO rs9939609 Polymorphism and Risk of Recurrent Venous Thromboembolism
A. Ahmad, K. Sundquist, B. Zöller, P.J. Svensson, J. Sundquist, A.A. Memon (Sweden)

PB 1430  The Protein Z System Dynamic in Patients Undergoing Off-pump Coronary Artery Bypass Surgery
E. Zokanowska, A. Stomka, A. Piekuś, M. Kowalewski, W. Pawliszak, L. Anisimowicz (Poland)

PB 1431  Relevance of Co Morbidities, D-Dimer, Red Cell Distribution Width and Factor VIII Levels in Thrombosis
A. Kurien, S. Badagubettu, A.S. Babu, P. Ramachandran (India)

PB 1432  Longitudinal Assessment of Coagulation and Fibrinolysis in Pregnant Women with Risk Factors for Preeclampsia
L. Dusse, F. Lucena, P. Alpoim, A. Barbosa, A. Cabral, R. Diniz, E. Lage, P. Teixeira (Brazil)

PB 1433  Role of Oxidized High-density Lipoprotein (oxHDL) on Coagulation and Platelet Adhesion Modulation
L. Pérez, F. Simón (Chile)

PB 1434  Inter-individual Variability and Normal Ranges of Whole Blood and Plasma Thrombin Generation and Correlation with Clotting Factor Levels in a Large Healthy Control Population
S. Bloemen, D. Huskens, J. Konings, R. Kremers, A. Miszta, B. De Laat, H. Kelchtermans (The Netherlands)

PB 1435  Venous Thromboembolism Events over Five Years Presenting with a Normal D-Dimer
H. Rowswell, T. Nokes (United Kingdom)

PB 1436  Biomarkers for the Diagnosis of Venous Thromboembolism: D-dimers, Thrombin Generation, and Phospholipid-dependent Clotting Time

PB 1437  Risk Factors and Clinical Characteristics Favoring Pulmonary Embolism Vs DVT in Hormonal Therapy (HT) Associated Thromboembolism. Retrospective Analysis of 73 Cases from a Single Hemostasis Unit
E. Papadakis, D. Theocharidou, A. Banti, S. Efremidou, A. Kioumi (Greece)

PB 1438  The Influence of Ethnicity on Thrombin Generation

PB 1439  Is Platelets - Bound C4d a Marker for Active Disease and Correlates with Hypercoagulability in Patients with Systemic Eritematosus Lupus?
K. Ferreira, W. Cicarini, C. Loures, F. Campos, R. Consoli, C. Neiva, P. Pádua, L. Alves, E. Reis, T. Guimarães, V. Toledo, M.G. Carvalho (Brazil)
POSTER SESSIONS

PB 1440  Profiling of Thrombotic and Inflammatory Mediators in Synovial Fluid from Patients Undergoing Primary Total Joint Arthroplasty  
E. Finkler, C. Wanderling, C. Thorson, K. Galicia, S. Statz, A. Otto, J. Fareed, W. Hopkinson (United States)

PB 1441  The Proteins with Prothrombine Origine in Blood Plasma of Ischemic Stroke Patients as a Markers of Hipercoagulation  
T. Katrii, T. Vok, O. Savchuk (Ukraine)

Pathogenesis of Thromboembolism

PB 1442  Anti-β2-Glycoprotein I Antibodies Cause Lupus Anticoagulant and Activated Protein C Resistance via Coagulation Factor V  
J.E. Molhoek, J.C.M. Meijers, S. Verhoef, P.G. de Groot, R.T. Urbanus (The Netherlands)

PB 1443  Plasma Clot Properties, Disease Phenotype, and Thrombotic Risk in Patients with a Lupus Anticoagulant: Results from the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)  

PB 1444  Biophysical Characterization of Clot Retraction in Platelet Rich Plasma of Patients with Primary Anti-phospholipid Syndrome  
J. Harsfalvi, T. Feller, G. Domjan, K. Gado, K. Varnai, M.S.Z. Kellermayer (Hungary)

PB 1445  Patient-derived Anti-β2GP1 Antibodies Recognize a Peptide Motif Pattern and Not a Specific Sequence of Residues  
P. de Moerloose, C. Fickentscher, F. Boehlen, J.-M. Tiercy, E.K.O. Kruithof, K.J. Brandt (Switzerland)

PB 1446  Longitudinal Anti-phospholipid-Antibody Trajectories for Dynamic Thrombotic Risk Prediction in Patients with the Lupus Anticoagulant: A Joint Model  
F. Posch, J. Gebhart, S. Koder, P. Quehenberger, C. Ay, I. Pabinger (Austria)

PB 1447  Impact of Adding Antiphosphatidylserine/Prothrombin Antibodies in the Thrombotic Risk of Patients with APS Laboratory Criteria: A Prospective Study  
R. Forastiero, M. Martinuzzo, A. Rossi, D. Puente, C. Colorio (Argentina)

PB 1448  Triple Positive Antib phospholipid Antibodies: Away with Titres and Ratios?  
P.R.J. Ames1, V. Marottoli2, L. Iannaccone3, A. Ciampa1 (1Portugal, 2Italy)

POSTER SESSIONS

PB 1449  oThe Effect of Treatment with Hydroxychloroquine on Soluble Tissue Factor Levels in Patients with Antiphospholipid Antibodies and Antiphospholipid Syndrome  
K. Breen, K. Schreiber, K. Parmar, B.J. Hunt (United Kingdom)

PB 1450  Increased Plasma Cell-free DNA (cfDNA) and Myeloperoxidase (MPO) and Impaired Fibrinolysis in High-risk Patients with Antiphospholipid Antibodies (aPL)  
F. Semeraro, C.T. Ammollo, E. Bion, A. Banzato, V. Pengo, M. Colucci (Italy)

PB 1451  Alteration of Beta 2 Glycoprotein I Conformation upon Domain V Sulfide Bond Reduction  
J. Buchholz1, P. Nestler1, T. McDonnell2, A. Radziszewska2, A. Rahman2, M. Delcea1 (1Germany, 2United States)

PB 1452  High Prevalence of Activated Protein C Resistance Associated with High Avidity Anti-protein C Antibodies in Various Antiphospholipid Syndrome Clinical Phenotypes  
M. Efthymiou1, I. Mackie1, P. Lane1, D. Erkan2, H. Cohen1 (1United Kingdom, 2United States)

PB 1453  Clinical Impact of Triple Positivity of Antiphospholipid Antibodies in Primary Thrombotic Antiphospholipid Syndrome  
S. Saraiva, B. Mazzeto, F. Talge, I.R. Brito, L. Quinteiro, M. Colella, E.V. de Paula, J. Annichino Bizzacchi, F. Orsi (Brazil)

PB 1454  β2GpI Binds to Fibrinogen and Alters Fibrin Generation and Degradation  
L. Acquasaliente1, D. Peterle1, G. Pontarollo1, R. De Crisofaro1, V. Pengo1, N. Pozzi1, V. De Filippis1 (1Italy, 2United States)

PB 1455  Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome is Related to the Autoantibodies against High Density Lipoprotein and its Associated Proteins  
K. Oku1, J. Batuca2, O. Amengual1, N. Ohnishi1, Y. Ogata1, K. Ohmura1, Y. Fujiieda1, M. Kato1, T. Bohgaki1, S. Yasuda1, D. Alves2, T. Atsumi1 (1Japan, 2Portugal)
### POSTER SESSIONS

#### XXVI ISTH Congress and 63rd Annual SSC Meeting

- **PB 1458** Platelet Activation by Antiphospholipid Antibodies through the IgG Receptor FcγRIIa: Possible Role in Thrombosis Associated with Antiphospholipid Syndrome?
  - E. Coll¹, M. Brodie¹, L. Robles-Carrillo¹, E. Lindhoff-Last², J.L. Francis³, A. Amirkhosravi¹ (*United States, Germany*)

- **PB 1459** Prognostic Impact of Antiphospholipid Antibodies on the Clinical Course of Primary Immune Thrombocytopenia or Autoimmune Hemolytic Anemia
  - A.C. Ladeira Cruz, M. Pereira Colella, G. Yamaguti Hayakawa, E.V. de Paula, J. Annichino-Bizzacchi, F. Andrade Orsi (Brazil)

- **PB 1460** Identifying "Second Hit" Risk Factors Associated with Thrombosis and Pregnancy Morbidity in aPLs Positive Patients
  - Y. Zuo, J. Fan, R. Sarode, D. Karp, Y.-M. Shen (United States)

- **PB 1462** Are Antiβ2-glycoprotein I IgG Domain I a Useful Tool to Predict Thrombosis?
  - A. Marco, A. Palazon-Bru, P. Marco (Spain)

- **PB 1463** Oral Anticoagulation Cost in Primary Antiphospholipid Syndrome: Comparison between Warfarin and Hypothetical Rivaroxaban
  - A. Ciampa¹, S. Vivolo¹, C. Salapete¹, P. Ames² (*Italy, Portugal*)

- **PB 1464** Comprehensive Characterization of Platelet Parameters for Thrombosis Risk Prediction in Patients with the Lupus Anticoagulant
  - J. Gebhart, F. Posch, S. Koder, P. Quehenberger, C. Ay, I. Pabinger (Austria)

- **PB 1465** Severe Vitamin D Deficiency a Potentially Risk Factor for Recurrent Miscarriages in Women with Positive Antiphospholipid Antibodies
  - E. Lefkou¹, S. Petousis¹, V. Gogou¹, A. Mamopoulos¹, T. Dagklis¹, A. Nikolopoulou¹, G. Gerotziafas², A. Athanasiadis¹ (*Greece, France*)

- **PB 1466** Antibodies against Domain I of Beta2-glycoprotein I Have No Added Value for Prediction of Antiphospholipid Syndrome Compared to Classical Antiphospholipid Antibodies
  - N. Pequeriaux, D. Hammann-Wenzlau, E. Gemen, I.-A. Haagen, M.J. Hollestelle (The Netherlands)

- **PB 1467** Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): Comparison of Real World and Core Laboratory Lupus Anticoagulant Results
  - M. Ethymiou¹, I. Mackie¹, P. Lane¹, V. Pengo¹, D. Andrade¹, R. Willis¹, S. Krell¹, D. Erkan¹, H. Cohen⁴ (*United Kingdom, Italy, Brazil, Australia*)

#### POSTER SESSIONS

- **PB 1469** Thrombocytopenia is Uncommon in High-risk Patients with Antiphospholipid Syndrome (APS)
  - E. Pontara, A. Banzato, M.G. Cattini, E. Bison, G. Baroni, A. Hoxha, A. Ruffatti, V. Pengo (Italy)

- **PB 1470** Circulating Neutrophil-Extracellular Traps (NETs) in Patients with the Antiphospholipid Syndrome
  - J.C. Reverter, J. Bravo, G. Espinosa, R. Cervera, D. Tassies (Spain)

- **PB 1471** Catastrophic Antiphospholipid Syndrome: Onset and Outcome

- **PB 1472** Effect of Hydroxychloroquine on Circulating Levels of Inflammatory Cytokines in Patients with Primary Antiphospholipid Syndrome

- **PB 1473** A High Molecular Weight Protein Is Responsible of Anticoagulant Activity in Isolated Lupus Anticoagulant
  - A. Banzato, M.G. Cattini, T. Del Ross, S. Testa, C. Legnani, D. Petterle, E. Pontara, E. Bison, A. Ruffatti, V. De Filippis, V. Pengo (Italy)

- **PB 1474** DNA Methylation Pattern Analyses in Patients with Antiphospholipid Syndrome: Screening Study
  - J.Y. Kim, H.-J. Kim, H.-J. Yoon, K.S. Lee (Republic of Korea)

- **PB 1475** What Is the Risk of First Thrombosis in Asymptomatic Antiphospholipid Antibodies Carriers?
  - L. Costa, R. Matos, L. Moreira, E. Cruz, S. Morais (Portugal)

- **PB 1476** Clinical Relevance of Anti Phospholipid Antibodies in Deep Venous Thrombosis
  - D. Eissa, H. Affify, M. Ismail, A. Saad, N. Abo Shanab (Egypt)

- **PB 1477** Results of Lupus Anticoagulant Investigation in Unselective Population of Patients Referred for Testing
  - S. Margetic, B. Getaldic, D. Ferenec Ruzic, I. Vuga, N. Vrkic (Croatia)

- **PB 1478** Detection of Thrombogenicity Positive Antiphospholipid Antibodies in Antiphospholipid Syndrome Diagnosis
  - J. Ulehlova, L. Slavik, J. Prochazkova, A. Hlusi, V. Krcova (Czech Republic)

- **PB 1479** Tissue Factor-bearing Microvesicles and Acquired Protein S Deficiency Contribute to DIC in a Patient with Elevated Antiphospholipid Antibodies
  - C. Dicke, K. Holstein, M. Voigtlander, F. Stahl, U. Schnoor, C. Bokemeyer, F. Langer (Germany)
**POSTER SESSIONS**

**PB 1481**  
Use of Direct Oral Anticoagulant in Antiphospholipid Syndrome: Systematic Review of Literature  
V. Dufrost, J. Risse, S. Zuily, D. Wahl (France)

**PB 1482**  
Plasma Thrombogenic Potential in Patients with Granulomatosis with Polyangiitis in Comparison to Antiphospholipid Syndrome  
M. Celińska-Lowenhoff, T. Iwaniec, J. Kosalka, J. Musiał (Poland)

**PB 1483**  
Evaluation of Antiphospholipid Antibodies Level in Patients with Type 2 Diabetes mellitus in Enugu South East Nigeria  
T. Nwagha, O. Agwu, O. Ibegbulam (Nigeria)

**PB 1484**  
Antiphospholipid Antibodies Related with Thrombosis  
I. Nikoloska, R. Apostolovska, V. Neceva, S. Krstevska Balkanov, E. velkova (Macedonia, the Former Yugoslav Republic of)

**PB 1485**  
Outcomes in Patients with Antiphospholipid Antibodies at a Tertiary Care Center  
G. Abu Zeinah, M.T. DeSancho (United States)

**PB 1486**  
Recurrent Arteriovenous Fistula Thrombosis in Female Patient with Antiphospholipid Syndrome (APS), Factor V Leiden Mutation and MTHFR C677 T Mutation  
B. Ceglarek, A.J. Sikorska, K. Bykowska, J.M. Teliga Czajkowska, J. Windyga (Poland)

**PB 1487**  
Comparison of Genetic Risk Score Models to Predict First Venous Thromboembolism in a Population-based Case-cohort. The Tromsø Study  

**PB 1488**  
Next-Generation DNA Sequencing Approach to Study Burden of Rare Variants in Loc6 Susceptible to Cerebral Vein Thrombosis  

**PB 1489**  
Impact of Age and Prothrombotic Genotypes on the Risk of Incident Venous Thromboembolism  
B. Smárekke, L. Balteskard Rinde, E.N. Smith, F.R. Rosendaal, S. Brækkan, K.A. Frazer, J.-B. Hansen (Norway)

**POSTER SESSIONS**

**PB 1490**  
Joint Effects of Ischemic Stroke and Prothrombotic Genotypes on the Risk of Venous Thromboembolism. The Tromsø Study  
L.B. Rinde1, B. Smårekke1, E. Mathiesen4, M.-L. Løchen1, I. Njølstad1, E.M. Hald1, T. Wilsgaard1, E. Smith2, T. Solomon2, K.A. Frazer2, S. Brækkan1, J.-B. Hansen1 (‘Norway, ‘United States)

**PB 1491**  
Joint Effects of Myocardial Infarction and Prothrombotic Genotypes on the Risk of Venous Thromboembolism. The Tromsø Study  
L.B. Rinde1, B. Smárekke1, E. Mathiesen4, M.-L. Løchen1, I. Njølstad1, E.M. Hald1, T. Wilsgaard1, E. Smith2, K.A. Frazer2, S. Brækkan1, J.-B. Hansen1 (‘Norway, ‘United States)

**PB 1492**  
Population-based Incidence of Venous Thromboembolism in Oklahoma County, OK April 1, 2012-March 31, 2014  
A. Wendelboe, J. Dvorak, M. McCumber, N. Feland, J. Campbell, K. Ding, D. Bratzer, N. Reyes, M. Beckman, G. Raskob (United States)

**PB 1493**  
Differential Impact of Surgery as a Trigger Factor for Venous Thromboembolism in Patients with and without Prothrombotic Genotypes  
E. Bjøri, H.S. Johnsen, J.-B. Hansen, S.K. Brækkan (Norway)

**PB 1494**  
Hospitalization as a Trigger for Venous Thromboembolism - Results from a Large Population-based Case-crossover Study  
E. Bjøri, H.S. Johnsen, J.-B. Hansen, S.K. Brækkan (Norway)

**PB 1495**  
The Rare Allele of the K858R Variant of Factor V Protects from the Risk of Venous Thrombosis but Only in Non Carriers of the FV Leiden Mutation  

**PB 1496**  
Joint Effects of Prothrombotic Genotypes and Body Height on Risk of Venous Thromboembolism: The Tromsø Study  
L.D. Horvei1, S. Erin N.2, K. Hindberg1, K.A. Frazer1, S.K. Brækkan1, J.-B. Hansen1 (‘Norway, ‘United States)

**PB 1497**  
Factor XIII Val34Leu Polymorphism Reduces Whole Blood Clot Weight in a Fibrinogen-dependent Manner  
S. Kattula1, Z. Bagoly2, N.K. Tóth2, L. Muszbek2, A.S. Wolberg1 (‘Italy, ‘The Netherlands)

**PB 1498**  
Impact of Prothrombotic Genotypes on the Association Between Red Cell Distribution Width and Risk of Venous Thromboembolism. The Tromsø Study  
J. Lappegård1, T.S. Ellingsen1, E. Smith2, S.K. Brækkan1, K.A. Frazer2, J.-B. Hansen1 (‘Norway, ‘United States)
**POSTER SESSIONS**

**PB 1499**

Homozygous and Heterozygous Factor V Leiden Mutation (FVL) Is Associated with an Increased Risk for Recurrent Venous Thromboembolism (VTE) after First VTE

R.B. Zotz, R.E. Scharf, A. Gerhardt (Germany)

**PB 1500**

Genotype-phenotype Correlations in a Large Cohort of Subjects with Suspcion of Inherited Protein C or Protein S Deficiency

C. Geisen, L. Boeff, S. Koerber, F. Bergmann, A. Czwalina, C. Heller, M. Krause, W. Miesbach, E. Seifried (Germany)

**PB 1501**

Identification and Characterization of a Novel Mutation at the C-terminal Region of Antithrombin Leading to in vivo Polymerization and Venous Thrombosis

T. Bhakuni, A. Sharma, M. Mahapatra, R. Saxena, M.A. Jairajpuri (India)

**PB 1502**

Genetic Characterization of Antithrombin, Protein C and Protein S Deficiencies in Slavic Thromboembolic Patients

E. Wypasek, J. Corral, M. Alhenc-Gelas, D.P. Potaczek, T. Iwaniec, W. Sydor, M. Celisfska-Lownhoff, J. Musial, A. Undas (Poland, Spain, Germany)

**PB 1503**

The Association between Genetic Variants in Cholesteryl Ester Transfer Protein (CETP) Gene and Hemostatic Factor Levels in Healthy Controls and the Associated Risk of a First Venous Thrombosis

R. Li-Gao, S.C. Cannegieter, F.R. Rosendaal, A. van Hylckama Vlieg (The Netherlands)

**PB 1504**

Molecular Genetic Diagnostics of Protein S and Protein C Deficiency

O.H. Larsen, A.D. Kjørgaard, A.-M. Hvas, P.H. Nissen (Denmark)

**PB 1505**

GPX1 Pro198LEU Polymorphism as a Risk Factor for Venous Thromboembolism in Young Men from North-Western Russia

P. Vrtel, R. Vodicka, J. Ulehlova, L. Slavík, J. Prochazka, M. Margaglione (Czech Republic)

**PB 1506**

Genetic Association Study between Candidate SNPs and Brazilian Patients with Venous Thromboembolism (VTE)

A.V.C. Romano, J.L. Cunha, A. Barnabé, L.F.B. Sckayer, R. Secolin, J.C.C. Guerra, I. Oldenburg, R. Saxena (Brazil)

**PB 1507**

Absolute Quantification of Jak2 V617F in Patients with Splanchnic Venous Thrombosis by Droplet Digital PCR

C. Geisen, L. Boeff, S. Koerber, F. Bergmann, A. Czwalina, C. Heller, M. Krause, W. Miesbach, E. Seifried (Germany)

**POSTER SESSIONS**

**PB 1508**

Screening of Deletions in Protein S Deficient Families

T. Fenclova, D. Provaznikova, M. Matyskova, F. Marecek, I. Hrachovinova (Czech Republic)

**PB 1509**

microRNA gene (miR -146a>C>G, miR -149>T>C, miR -196a2>T>C and miR -499>A>G) Polymorphisms in Korean Patients with Venous Thromboembolism


**PB 1510**

The Association of Arg485Lys Polymorphism with FV Levels, APC Ratio and its Role in DVT: A Study from India

A. Sharma, T. Bhakuni, A. Biswas, R. Ranjan, K. Kishor, J. Oldenburg, R. Saxena (India, Germany)

**PB 1511**

A Novel Splice Site Mutation Leading to AT Deficiency


**PB 1512**

Gender Differences in the Incidence of Venous Thromboembolism among Chronic Lung Diseases and Rheumatoid Arthritis in Korea

W.-I. Choi (Republic of Korea)

**PB 1513**

Application of Massive Parallel Sequencing Searching for Rare Genetic Variants of Protein C and S Associated with Thrombophilia - Implementation to Clinical Practice

P. Vrtel, R. Vodicka, J. Ulehlova, L. Slavik, J. Prochazka, R. Vrtel, M. Prochazka (Czech Republic)

**PB 1514**

Combined Protein C / Protein S Deficiency: Genotype-Phenotype Relationship in an Italian Family Carrying Two Novel Mutations

G. Favuzzi, G. D’Andrea, G.L. Tiscia, F. Cappucci, E. Chinni, P. Vergura, E. Grandone, M. Margaglione (Italy)

**PB 1515**

Impact of Factor V-Leiden, Prothrombin G20210A and MTHFR C677T Mutations on Egyptian Patients with Sickle Cell Disease

A. Saad, H. Sedky, A. Osman, A. Abu-skeen, A. Abd El Maksoud, D. Gamal Eldin (Egypt)

**PB 1516**

Heightened Hypercoagulability in Sickle Cell Anemia Patients with Chronic Leg Ulcers

E. Olayemi, D. Sackey, Y. Dei-Adomakoh (Ghana)

**PB 1517**

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Trombophilia: What Should We Know?

V. Shemenkova, A. Klimenko, N. Shostak (Russian Federation)
### POSTER SESSIONS

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1521</td>
<td>Risk Factors of Cerebral Venous Sinus Thrombosis - Single Center Experience</td>
<td>A. Gwozdowska, E. Odnoczko, B. Baran, K. Bykowska, J. Windyga (Poland)</td>
</tr>
<tr>
<td>PB 1522</td>
<td>Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thromboembolism</td>
<td>A. Artoni, M. Abbattista, P. Bucciarelli, F. Gianniello, I. Martinelli (Italy)</td>
</tr>
<tr>
<td>PB 1523</td>
<td>Quantification of the Effect of NET-derived Cell-free DNA on Thrombosis and Haemostasis Phenotypes</td>
<td>S. Lopez, A. Martinez-Perez, N. Vilalta, C. Muñoz, J.C. Souto, J.M. Soria (Spain)</td>
</tr>
<tr>
<td>PB 1525</td>
<td>Complete Protein S Deficiency and Pregnancy Outcome in Murine Model</td>
<td>R. Prince, N. Dewarrat, M.D. Reina Caro, J. Brodard, C. Quarriz, F. Saller, S. Calzavarini, A. Angelillo-Scherrer (Switzerland, France)</td>
</tr>
<tr>
<td>PB 1526</td>
<td>Thrombophilic Phenotype in a Neonate and Five Young Siblings of a Family with Homozygous Antithrombin Type 2 (Budapest III) Deficiency</td>
<td>H.-J. Hertfelder, M. Scheler, S. Kapustin, O. Smirnova, J. Sidorova, L. Papayan (Russian Federation)</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

PB 1540  Analysis of Factor V Leiden Paradox from a Large Monocentric Cohort Study: A Role for Distal Thrombosis?
E. Campello, L. Spiezia, F. Dalla Valle, P. Simioni (Italy)

PB 1541  Paroxysmal Nocturnal Hemoglobinuria (PNH) and Thrombosis: Experience from an Asian Tertiary Centre
R.J. Lim, H.T. Mya, H.J. Ng, L.H. Lee (Singapore)

PB 1542  Results of Thrombophilia Testing in Infertile Women and Women Experienced a Miscarriage
S. Margetic, B. Getaldic, D. Ruzic Ferenc, I. Vuga, N. Vrkic (Croatia)

PB 1543  Importance of Thrombophilia Screening in Patients with Ocular Thrombosis
M. Alrifai, R. Fischer, K. Heidinger, B. Kemkes-Matthes (Germany)

PB 1544  Screening of Thrombophilia in Latin America
C. Guillermo1, A. Blanco2, M. Echenagucia3, D.N. García2, B. Steffano1, V. Mérola1, S. Grille1, P. Turcatti1, M. Stevenazzi1, L. Diaz1, R. Martínez1
(1Uruguay, 2Argentina, 3Venezuela)

PB 1545  First Do Not Harm: Questioning Ethics Aspects of Thrombophilia Law in Argentina
B. Grand, A. Rossi (Argentina)

PB 1546  Extensive molecular characterization of a family with thrombophilia: implication of multiple genetic alterations of low thrombotic risk profile
M. Carrasco Exposito, I. Tirado Garcia, L. Romero Roman, N. Vilalta Seto, J. Mateo Arranz, J.A. Millon Caño, J. Fontcuberta Boj (Spain)

PB 1547  Inherited Thrombophilia and Infertility
E. Petkovikj, A. Hristova-Dimcheva, R. Grubovic, R. Apostolovska, S. Simeonova-Krstevska, M. Jakimovska, B. Todorovski (Macedonia, the Former Yugoslav Republic of)

PB 1548  Impact of the Molecular Study of the PROC, PROS1 and SERPINC1 Genes in Patients with Venous Thrombosis

PB 1549  Cutaneous Necrosis Revealing Paroxysmal Nocturnal Haemoglobinuria
Z. Tazi Mezalek, W. Ammouri, M. Bourkia, H. Harrmouch, N. Bouigaa, M. Maamar, W. Mounfaloti, M. Adnaoui (Morocco)

PB 1550  Venous Thromboembolism (VTE) in Homozygous Carriers of Factor V Leiden Mutation Patients (FVL)
B. Cegla, A.J. Sikorska, K. Bykowska, A. Bućko, J. Windyga (Poland)

PB 1551  Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis in Oman
K. Al Hashmi, K. Al-Wahaibi, M. Al-Khabori, S. Al Lamki (Oman)

PB 1552  Anticoagulant Therapy in Disorders in the Fibrinolysis System among Patients with Primary Infertility
I. Kurtov, T. Gritsenko, Y. Berman, V. Kuvaev, A. Kurtova, I. Davydkin (Russian Federation)

PB 1553  Pattern of Thrombophilia Testing in Patients with Venous Thromboembolism at a Tertiary Care Hospital
M. Gaddh, E. Cheng, Y. Lin, R. Sharma, I. Bodo (United States)

PB 1554  Meanings of Hereditary Thrombophilia in the Diagnosis of Thrombotic Complications during Combat Gunshot Injury
K. Nikolaev, S. Kapustin, V. Zubritskij, A. Koltovich, I. Zolobov (Russian Federation)

PB 1555  Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Patient with Decompensated/Uncontrolled Hypertension, Hyperhomocysteinemia, Hypercholesterolemia and Hyperlipidemia
B. Ceglarek, A.J. Sikorska, K. Bykowska, J.M. Teliga Czajkowska, A. Bućko, J. Windyga (Poland)

PB 1556  Twice-daily Low-dose Aspirin Improves Platelet Inhibition in Patients with Essential Thrombocytoysis
M.L. Larsen, O.H. Pedersen, A.M. Hvas, S.D. Kristensen, E.L. Grove (Denmark)

PB 1557  Long-term Aspirin (ASA) Use Significantly Attenuates Platelet Interactions with von Willebrand Factor (VWF) in Acute Coronary Syndromes (ACS)
D. Kenny, R. Walsh, D. Foley, A.J. Ricco, E. Dunne (Ireland)

PB 1558  Patients with Coronary Artery Disease Have a Pathological P2Y12 Platelet Response with Heightened Procoagulant Platelet Potential
L. Pasalic, J. Lau, G. Pennings, H. Campbell, E. Wing-Lun, E. Lau, D. Connor, D. Muller, L. Kritharides, V. Chen (Australia)

PB 1559  Platelet Inhibition with Ticagrelor Versus Clopidogrel in Patients with Peripheral Artery Disease: The EUCLID Platelet Substudy
**POSTER SESSIONS**

**PB 1561**

Antiplatelet Agents are the Key Drugs for the Prevention of Recurrent Arterial Thrombosis in Patients with Antiphospholipid Syndrome  

**PB 1562**

Cyclic Nucleotide Modulators and P2Y12 Antagonists as Novel Anti-platelet Combination Therapy  
P.C. Armstrong, P. Ferreira, M.V. Chan, C.-C. Shi, H. Lundberg, Slingsby, T.D. Warner (United Kingdom)

**PB 1563**

Prasugrel vs. Ticagrelor after STEMI: Results from the Düsseldorf STEMI Registry  
M. Golabkesh, D. Dimitroulis, A. Mohring, L. Dannenberg, A. Fürnkranz, H. Makimoto, T. Zeus, M. Kelm, A. Polzin (Germany)

**PB 1564**

Acetazolamide and Methazolamide Suppress Platelet Procoagulant Responses and Thrombosis in vivo  
E.O. Agbani, C.M. Williams, R. Auengaheet, A.W. Poole (United Kingdom)

**PB 1565**

Effect of Aspirin Therapy on Abacavir-associated Platelet Hyperreactivity in HIV-infected Patients: A Randomized, Double-blind, Placebo-controlled, Cross-over Study  

**PB 1566**

Investigation of the Physiological Mechanisms Leading to the Release of BDNF by Platelets and their Susceptibility to Antiplatelet Agents  

**PB 1567**

Clopidogrel Efficiency in Cerebral Aneurysm Stenting: Are Biological Tests Useful?  
N. Ajzenberg, R. Abbas, F. Tubach, D. Faille, M.-G. Huisse, L. Ikka, J. Moret, L. Spelle (France)

**PB 1568**

Comparison of Platelet Function Tests in a Trial of Different Aspirin Dose Regimens in Type 2 Diabetes  
P. Harrison, M.A. Bethel, I. Kennedy, S. White, R.L. Coleman, R.R. Holman (United Kingdom)

**PB 1569**

The Offset of Ticagrelor Prior to Coronary Artery Bypass Graft (CABG) Surgery  
K.W. Ow, M. Thomas, W. Parker, H. Judge, R. Storey (United Kingdom)

**POSTER SESSIONS**

**PB 1570**

Nanoparticle Inhibition of Shear Induced Platelet Aggregation  
D.N. Ku, C. Aidun, M. Griffin, Y. Zhu, Z. Liu (United States)

**PB 1571**

Plasma Fibrinogen Level is an Important Determinant of Platelet Reactivity in the VerifyNow Assay  
A. Dobrovolsky, P. Laguta, E. Titaeva, E. Guskova, E. Yarovaya, E. Panchenko (Russian Federation)

**PB 1572**

Effects of Clopidogrel with or without Aspirin on the Generation of Extracellular Vesicles in the Microcirculation and in Venous Blood in Healthy Young Males  
L. Traby, A. Kaider, M. Kollars, S. Eichinger, M. Wolzt, P.A. Kyrle (Austria)

**PB 1573**

Assessment of Low Platelet Reactivity (LPR) with Multiple Electrode Impedance Aggregometry (MEA) and Risk of Bleeding in Patients Receiving P2Y12 Receptor Inhibitors  
D. Díneva, Paskaleva I., Baycheva B, Gocheva N., Georgiev G., Trendafilova E. (Bulgaria)

**PB 1574**

Concomitant Use of Antiplatelet and Direct Oral Anticoagulants Increase but Not Significantly the Bleeding Risk in Patients with Atrial Fibrillation  

**PB 1575**

Arginine-containing Oligopeptides as Antiplatelet Agents Under Experimental Type-2 Diabetes Mellitus  
M. Grigorjeva, L. Luapina (Russian Federation)

**PB 1576**

Combined Effect of CYP2C19 G681A Polymorphism and Plateletcrit on Clopidogrel Low-responsiveness in Thai Patients with Acute Coronary Syndrome  
S. Jirungda, N. Komanasin, V. Senthong, B. Pussadhamma, P. Makarawate, K. Anutarapongpan, D. Kaewkes (Thailand)

**PB 1577**

Inhibition of Platelet Aggregation by Fibrinogenase from the Antarctic Scallop Adamussium colbecki  
N. Raksha, D. Gladun, L. Ostapchenko (Ukraine)

**PB 1578**

Platelet (plt) reactivity in patients with essential thrombocythemia (ET) receiving antiplatelets therapy with aspirin (ASA)  
S. Gambo, M. Marchetti, A. Vignoli, L. Russo, C.J. Tartari, C. Giaccherini, C. Verzeroli, F. Marchesi, G. Finazzi, A. Rambaldi, A. Falanga (Italy)
**POSTER SESSIONS**

**PB 1579**
The Influence of Prostaglandin E1 on the Correlation between the Multiple Electrode Aggregometry ADP and the VerifyNow P2Y12 Test in Patients Using P2Y12 Inhibitors
P.W.M. Verhezen, M.J.A. Vries, M.J.J. Haartmans, R.J.H. Wetzel, C.G.M. van Oerle, Y.M.C. Henskens (The Netherlands)

**PB 1580**
Could Aspirin Play a Role in Diminishing ADP Induced Platelet Aggregation in Clopidogrel Naïve Patients?
S. Georgantis, G. Soulia, M. Katayfogiato, T. Kanellopoulos, T. Kostelidou (Greece)

**PB 1581**
Obesity Is Associated with Reduced Platelets SERCA3 Isoform Expression and Subsequent Platelet Inhibition, Reversible after Weight Loss

**PB 1582**
Patterns and Levels of Platelet Glycosylation in Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus
L. Liping, Q. Chenxue, W. Xuelian, D. Juhua, L. Yao, G. Yan, Y. Ran, L. Yaqi (China)

**PB 1583**
Hemostatic Abnormalities in Patients with Ehlers-Danlos Syndrome
M. Abbattista, A. Antoni, B. Marinelli, A. Lecchi, S. Lamarca, A. Bassotti, I. Martinielli (Italy)

**PB 1584**
Acquired Glanzmann Thrombasthenia due to Marked Reduction of Surface αIIbβ3 Expression with Non-function Blocking Anti-αIIbβ3 Antibodies
K. Akuta, H. Kashiwagi, T. Yujiri, N. Nishiura, Y. Morikawa, H. Kato, S. Honda, Y. Kanakura, Y. Tomiyama (Japan)

**PB 1585**
Platelet Function and Ibrutinib Treatment in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma: Effects of Drug and of Disease Itself
A. Ignatova1, E. Nikitin1, A. Tharmakulanathan2, S. Ramström2, A. Poletaiev1, D. Polokhov1, A. Fedotov1, E. Seregina1, A. Pshonkin1, V. Vorobiev2, V. Plushkin1, M. Panteelev1 (1Russian Federation, 2Sweden)

**PB 1586**
Chronic Immune Thrombocytopenic Purpura (ITP) in Egyptian Children: A 10 Year Single Center Retrospective Study
M. Abdelwahab, M. Aydeen, D. Ezzat (Egypt)

**PB 1587**
Acute Episodes of Atrial Fibrillation Cause Altered Platelet Function and Procoagulant Microparticle Consumption
L. Pourtau, J.M. Sellal, R. Lacroix, P. Poncet, O. Bernus, G. Clofent-Sanchez, J.C. Bordet, M. Hocini, M. Haissaguerre, F. Dignat-George, F. Sacher, P. Nurden (France)

**POSTER SESSIONS**

**PB 1588**
Impaired Platelet Responsiveness in Thrombocytopenic Cancer Patients after Chemotherapy as a Consequence of Mitochondrial Dysfunction
C.F.M.J. Baaten1, F.C.J.I. Moenen1, Y.M.C. Henskens1, F. Swierenga1, R. Wetzel1, R. van Oerle1, H.F.G. Heijnen1, H. ten Cate1, G.P. Holloway2, E.A.M. Beekers1, J.W.M. Heemskerk1, P.E.J. van der Meijden1 (1The Netherlands, 2Canada)

**PB 1589**
Coated-platelet Formation is a Sensitive Indicator of Dasatinib Elicited Side-effects
J. Kappelmayer, I. Beke Debreceni, A. Kerényi, V. Treszkai, G. Mezei, P. Batár (Hungary)

**PB 1590**
Thrombocytopenia and Altered Coagulation as Independent Predictors of the Etiology of “Tropical Jaundice” in Adults Presenting to Emergency in a Tertiary Care Hospital in North India
A. Bhalla, V. Suri, M. Singh, M. Biswia, R. Ratho, M.P. Singh, A. Duseja, P. Malhotra (India)

**PB 1591**
Plasma microRNAs Characterizing patients with Immune Thrombocytopenia
Y. He, B. Zou, C. Ruan (China)

**PB 1592**
Evaluation of in vitro Effects of Tyrosine-kinase Inhibitors on Primary Haemostasis
F. Eckart, M. Suttrop, R. Ursula, R. Knoefler (Germany)

**PB 1593**
What Do We Know about Post Transfusion Purpura? A Novel Insight into the Correlation between HPA Antibodies and Clinical Picture
I. Farkash, T. Rashal, S. Chen, M. Hareuveni, L. Bonstein, D. Stavi, Y. Bar-on, I. Avivi, I. Kirgner (Israel)

**PB 1594**
Further Characterization of Platelets Bearing Mutations in Calreticulin or JAK2 Genes in Essential Thrombocythemia Patients
H. Hauschner, N. Rosenberg, U. Seligsohn, M. Koren-Michowitz (Israel)

**PB 1595**
Clinical Evaluation of the Revised International Prognostic Score of Thrombosis for Essential Thrombocythemia Patients (IPSET-Thrombosis) in a Cohort of 746 Chinese Adult Patients
R. Fu, H. Li, F. Xue, X. Liu, L. Zhang, R. Yang (China)

**PB 1596**
Variations of Mean Platelet Volume with Time Since Blood Sampling in Different Anticoagulants
G.M. Podda, P. Soru, G. Casazza, E.A. Femia, G. Carpani, M. Cattaneo (Italy)

**PB 1597**
Cytosolic Calcium Concentrations in Platelets from Patients with Pulmonary Embolism and Implications for Therapy
J. Pike, N. Alves, J. Kline (United States)
### POSTER SESSIONS

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1598</td>
<td>Probable Risks and Benefits of Second Line Therapy Splenectomy versus TPO Mimetics in Chronic Idiopathic Thrombocytopenic Purpura an Experience of a Third World Country, Pakistan</td>
<td>T. Imran (Pakistan)</td>
</tr>
<tr>
<td>PB 1600</td>
<td>High Incidence of Platelet Dysfunction is unmasked in Newly-diagnosed Multiple Myeloma</td>
<td>T. Ruchutrakool, B. Buasatit, P. Plurksathaporn, W. Owattanapanich (Thailand)</td>
</tr>
<tr>
<td>PB 1601</td>
<td>Effects of Time and Different Anticoagulants on Platelet Count in Blood Donors and in Thrombocytopenic Patients</td>
<td>G.M. Podda, P. Soru, G. Casazza, E.A. Femia, G. Carpani, M. Cattaneo (Italy)</td>
</tr>
<tr>
<td>PB 1602</td>
<td>In vitro Ibrutinib Effect (Inhibitor of Bruton’s Tyrosine Kinase) on Platelets Function. A Single Centre Study</td>
<td>S. Gkotsi, M. Dimou, A. Chanos, O. Katsarou, P. Panayiotidis, P. Kotsi (Greece)</td>
</tr>
<tr>
<td>PB 1603</td>
<td>The Platelet Function Analyzed by Flow Cytometry in Psoriatic Patients on Reference Therapy</td>
<td>A. Ermakov, L. Gaikovaya, L. Karyakina, R. Pavlova, T. Vavilova (Russian Federation)</td>
</tr>
<tr>
<td>PB 1604</td>
<td>PANDA, a Biomarker for Diagnostic of Leaky Gut Syndrome</td>
<td>M. Lopez, G. Nowak (Germany)</td>
</tr>
</tbody>
</table>

### Vascular Biology & Angiogenesis

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1605</td>
<td>Role of the Extracellular Matrix Protein Biglycan for Platelet Adhesion and Thrombus Formation</td>
<td>N. Maurus, H. Hörmann, J.W. Fischer, M. Elvers (Germany)</td>
</tr>
<tr>
<td>PB 1606</td>
<td>Platelet Inhibition Augments Rupture-induced Death in a Mouse Model of Abdominal Aortic Aneurysm</td>
<td>K. Saum1, N. Robbins1, S. Jones1, W. Bergmeier1, A. Wanhainen1, N. Mackman1, P. Owens1 (1United States, 2Sweden)</td>
</tr>
<tr>
<td>PB 1607</td>
<td>Protein Disulfide Isomerase Is Regulated by S-nitrosylation: Implications for Vascular Quiescence and Thrombus Formation</td>
<td>R.H. Bekendam1, D. Iyu2, F. Passam1, K. Deceunynck2, C. Garnier2, L. Crescence1, L. Panicot-Dubois1, R. Flamenhaft1, C. Dubois1 (1France, 2United States, 3Australia)</td>
</tr>
</tbody>
</table>

### POSTER SESSIONS

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1609</td>
<td>Contribution of the P2X1 Receptor Expressed by Lung Macrophages to Experimental TRALI</td>
<td>M.-B. El Mdawar, B. Maitre, S. Magenenat, C. Gachet, B. Hechler, H. de la Salle (France)</td>
</tr>
<tr>
<td>PB 1611</td>
<td>Blood Platelets Bind Aβ Peptides via Integrin αllβ3 and Induce Amyloid-β Aggregation in Cerebral Vessels</td>
<td>L. Donner, L. Gremer, G. Pagani, H. Gohike, D. Willbold, M. Elvers (Germany)</td>
</tr>
<tr>
<td>PB 1612</td>
<td>Platelet Extracellular Vesicles Induce a Proinflammatory Smooth Muscle Cell Phenotype</td>
<td>T. Vajen1, B.J. Benedikter1, A.C.A. Heinzmann1, E.M. Vasina1, Y. Henskens1, M. Parsons2, P.B. Maguire2, F. Stassen1, J.W.M. Heemskerk1, L.J. Schurgers1, R.R. Koenen1 (1The Netherlands, 2Ireland)</td>
</tr>
<tr>
<td>PB 1613</td>
<td>Conditional Knockout of Heme Oxygenase-1 in Lysosome M Positive Cells Attenuates Angiotensin II Induced Vascular Inflammation</td>
<td>J. Lagrange, S. Kossmann, T. Münzel, P. Wenzel (Germany)</td>
</tr>
<tr>
<td>PB 1614</td>
<td>Defective Fibrin Accumulation and Thrombus Stability in Endothelial Cell-specific BAMBI Knockout-mice</td>
<td>J.J. Salles-Crawley, A. Zalli, J.H. Monkman, D.A. Lane, J.T.B. Crawley (United Kingdom)</td>
</tr>
<tr>
<td>PB 1615</td>
<td>FXI Inhibition Protects from Vascular Inflammation and Endothelial Dysfunction in Arterial Hypertension</td>
<td>S. Kossmann1, J. Lagrange1, S. Jäckel1, K. Jurk1, M. Ehlken1, T. Schönfelder1, Y. Weihe1, M. Knorr1, M. Brandt1, A. Daiber1, M. Oelze1, C. Reinhardt1, K. Lackner1, A. Gruber1, B. Monia2, S. Karbach1, U. Walter1, Z. Ruggeri1, T. Renné1, W. Ruf1, T. Münzel1, P. Wenzel1 (1Germany, 2United States, 3Sweden)</td>
</tr>
<tr>
<td>PB 1616</td>
<td>Function of an Endothelial-specific GPCR in Thrombosis</td>
<td>L. Gottlob1, P. Dusart1, L. Fagerberg1, D.-A. Trégoù shuts, P. Morange2, M. Germain1, M. Civelek1, T. Renné1, J. Odeberg1, L. Butler1 (1Sweden, 2France, 3United States)</td>
</tr>
</tbody>
</table>
**POSTER SESSIONS**

**PB 1617**  
Factor VII Activating Protease (FSAP) Regulates the Expression of Inflammatory Genes through Protease Activated Receptor (PAR1) in Vascular Smooth Muscle and Endothelial Cells  
K. Byskov¹, T. Boettger², P.F. Ruehle³, N.V. Nielsen¹, M. Etscheid², S.M. Kanse¹  
(¹Norway, ²Germany)

**PB 1618**  
Regulation of Platelet String Formation on Endothelial Cells in the Presence of Coagulation under Shear  

**PB 1619**  
Recombinant Adeno-associated Virus Vector Carrying the Thrombomodulin Lectin-like Domain Suppresses the Development of Abdominal Aortic Aneurysm in Mice  
H.-L. Wu, C.-H. Lai, K.-C. Wang, G.-Y. Shi (Taiwan)

**PB 1620**  
A2 Domain of von Willebrand Factor (VWF) Mediates Human Vascular Smooth Muscle Cells (VSMCs) Proliferation and Migration  
M.E. Worou, M. Didelot, P. Legendre, V. Muczynski, P.J. Lenting, P. Lacolley, C.V. Denis, V. Regnault (France)

**PB 1621**  
Dietary Alpha-linolenic Acid Reduces Platelet Activation and ex vivo Thrombus Formation in Sickle Cell Disease Mice  
S. Stivala, S. Gobbato, N. Bonetti, G. Camici, T. Lüscher, J. Beer (Switzerland)

**PB 1622**  
Podoplanin Overexpression on Endothelial Cells Promotes Superficial Erosive Injury and Thrombus Formation in Rat Carotid Artery  
E. Furukoji, A. Yamashita, T. Hirai, Y. Asada (Japan)

**PB 1623**  
Evaluation of a Novel Mouse Model of Abdominal Aortic Aneurysm to Study Platelet Mechanisms of the Proinflammatory Thrombus  
Y. Boulatallah, S. Delbos, M.-C. Bouton, J.-B. Michel, M. Jandrot-perrus, B. Ho-Tin-Noé (France)

**PB 1624**  
Increased Inflammatory Properties of Neutrophils and Endothelial Cells (ECs) in Patients with Venous Thromboembolism (VTE), Long after the Acute Disease  

**PB 1625**  
Analysis of Body-wide Unfractionated Tissue Data to Identify a Core Human Endothelial Transcriptome  
L. Butler, B. Hallström, L. Fagerberg, F. Pontén, M. Uhlén, T. Renné, J. Odeberg (Sweden)

---

**POSTER SESSIONS**

**PB 1626**  
Effects of Aspirin and Rivaroxaban on Murine Arterial Vessel Wall Remodelling after Vascular Injury  
T. Mastenbroek¹, M. Kuijpers¹, M. Nagy¹, W. Chayouâ¹, A. Bourens-Strzelecka¹, P. Leenders¹, H. van Essen¹, S. Reitsma, C. Puy, T. Shirai, A. Mitrugno, O.J.T. McCarty (¹The Netherlands, ²Germany)

**PB 1627**  
Plasminogen Activator Inhibitor Type 1 in Platelets Evokes Thrombogenicity and Increases Thrombus Size by Elevating Thrombolysis Resistance under Shear Stress  

**PB 1628**  
Tissue Engineered Small Vessel Conduits - The Anti-thrombotic Effect of Re-endothelialisation of Decellularised Baboon Arteries  
M. Mairing, M. Khemisi, L. Fagerberg, F. Pontén, M. Uhlén, T. Renné, J. Odeberg (Sweden)

**PB 1629**  
APAC, a Dual Antiplatelet and Anticoagulant Heparin Proteoglycan Mimetic, Integrates with Extravascular Matrix during Vascular Injury  
K.A. Barreiro, M. Jouppila, R. Tulamo, R. Lassila (Finland)

**PB 1630**  
Protein Kinase C-Dependent Loss of Tissue Factor by Human Pericytes Results from Altered Synthesis, Trafficking and Degradation  
M. Hoffman, L. Sommerville, D. Monroe (United States)

**PB 1631**  
Design and Utility of Extracellular Matrix-embedded Microvessels to Study the Platelet-endothelium Interface  

**PB 1632**  
Micropatterning Induced Alterations of Endothelial Outgrowth Cells  
M. Hagedoorn, B. Van, M. Hinds (United States)

**PB 1633**  
Endothelial Dysfunction in Idiopathic Thromboembolism Investigated through Gene Expression Profiling of Endothelial Colony Forming Cells  
C. Lodigiani, F. Calcateria, P. Ferrazzi, L. Libre', E. Banfi, C. Carenza, D. Mavilio, S. Della Bella (Italy)

**PB 1634**  
The Role of Lysosome M+ Cells in the Development of Angiotensin II-induced Vascular Inflammation  
J. Lagrange, S. Kossmann, T. Münzel, W. Ruf, P. Wenzel (Germany)

**PB 1635**  
The Response of HUVEC to Prolonged Shear Stress for Use in vitro Studies  
B.A. Apte, C. Arnold, L. Huang, M. Harper (United Kingdom)
PB 1636  Serum Sphingosine-1-phosphate is Not Associated with Age and Gender but with Blood Cell-related Parameters: Analysis of the Study of Health in Pomerania Cohort
E. Moritz, D. Wegner, S. Groß, M. Bahls, M. Dörr, S.B. Felix, T. Ittermann, S. Oswald, M. Nauck, N. Friedrich, R.H. Böger, G. Daum, E. Schwedhelm, B.H. Rauch (Germany)

PB 1637  Plasma Modification of Poly(Vinyl Alcohol) for Enhanced Endothelialization and Anti-thrombogenicity
P. Jurney¹, D. Anderson¹, M. Hagen¹, E. Yim², M. Hinds¹ (¹United States, ²Canada)

Wednesday, July 12, 2017
Poster Session
12:00 – 13:15
Exhibition Hall 2.2

Atherothrombosis & Stroke

PB 1638  Platelet α-granule Deficiency Protects Local and Distal Organs in Intestinal Ischemia Reperfusion Injury
K. Ashworth, P. Davison-Castillo, L. Johnson, B. Branchford, D. Bark, J. DiPaola (United States)

PB 1639  Structure-function Relationships of Krait Natriuretic Peptide: Design of Natriuretic Peptide Analogues with Vasodilatory or Renal Activities for Personalized Care of Heart Failure Patients
S. Sridharan, M. Kini (Singapore)

PB 1640  Development of a Novel Strategy to Target CD39 Antithrombotic Activity to the Endothelial-platelet Microenvironment in Kidney Ischemia-reperfusion Injury
M. Sashindranath¹, K. Dwyer¹, S. Dezfooli¹, C. Selan¹, S. Criks¹, B. Lu¹, Y. Yuan¹, M. Hickey¹, K. Peter¹, S.C. Robson¹, P. Cowan¹, H. Nandurkar¹ (¹Australia, ²United States)

PB 1641  Toll-deficiency Impairs Leukocyte Adhesion and Netosis in Mesenteric Ischemia-reperfusion
S. Ascher, E. Wilms, K. Schwierczek, K. Jurk, C. Reinhardt (Germany)

PB 1642  Inhibition of Coagulation Factor Xa Attenuates Myocardial Ischemia Reperfusion Injury in Mice
J.J.J. Posma¹, J.J. Posthuma¹, R. Van Oerle¹, S. Heitmeier², H. Ten Cate¹, H.M.H. Spronk¹ (¹The Netherlands, ²Germany)

PB 1643  Biomarkers of Oxidative Stress in Venezuelan Sickle Cell Patients: Association with the Clinical Severity
D. Higuera, A. Salazar, E. Hergueta, N. Estepa, E. Salazar, K. Perez, C. Ibarra, B. Guerrero (Venezuela)

PB 1644  Contribution of Neutrophil Extracellular Trap (NET) Components to the Structure of Thrombi from Therapeutic Intervention in Ischemic Coronary, Peripheral and Cerebral Artery Disease
Á.Z. Farkas, V.J. Farkas, K. Bálint, I. Gubucz, I. Szikora, A. Nagy, P. Sótonyi, L. Hidi, B. Merkely, K. Kolev (Hungary)
POSTER SESSIONS

PB 1645  A Novel Easy-to-Perform Thromboembolic Stroke Model in Mice: Application to the Study of the Thrombolytic Effect of N-acetylcysteine
M. Gauberti, S. Martinez de Lizarrondo, M. Rubio, S. Goursaud, D. Vivien, C. Gakuba (France)

PB 1646  Human Platelet Alloantigens and P-Selectin Gene Polymorphisms in Pediatric Arterial Ischemic Stroke
D. Coen Herak, M. Pavic, A. Ceri, J. Lenicek Krleza, V. Djuranovic, N. Barisic, R. Zadro (Croatia)

PB 1647  MicroCT Imaging of Cerebral Thromboemboli In vivo: The Effects of Tissue Plasminogen Activator
D.-E. Kim (Republic of Korea)

PB 1648  Incidence Rates and Case Fatality Rates of Cerebral Vein Thrombosis: A Population-based Study
F. Dentali, V. Gessi, F. Pomero, A. Squizzato, M. Bonzini, W. Ageno (Italy)

PB 1649  Biomarkers for the Symptomatic Carotid Atheroma

PB 1650  Neutrophil Extracellular Traps (NETs) in Patients with Acute Stroke Are Associated with Stroke Severity and Progression

PB 1651  Case-fatality after Venous Thromboembolism and Ischemic Stroke in Subjects without and with Atrial Fibrillation. The Tromso Study

PB 1652  Role of ARHGEF10 in Platelet Function and Thrombosis

PB 1653  The Efficacy and Safety of a Laser Thrombolytic System in Animal Thrombosis Models

PB 1654  Thrombi Retrieved from Patients Suffering Acute Ischemic Stroke Show both Active and Mechanical Interaction between Stent Retrievers and Thrombus, and is Associated with Specific Thrombus Surface Characteristics
A.S.A. Autar, H. Hund, S.A. Ramlal, D. Hansen, M. de Maat, A. van der Lugt, D. Dippel, A.C.G.M. van Es, H.M.M. van Beusekom (The Netherlands)

PB 1655  The Effect of Recanalization on Long-term Neurologic Outcome after Cerebral Vein Thrombosis
F. Dentali, I. Martinelli, E. Rezoagli, D. Poli, S.M. Passamonti, W. Ageno (Italy)

PB 1656  Hyperglycemia Precipitates Infarct Growth and Hemorrhagic Transformation in Ischemic Stroke Though Exacerbation of Thromboinflammation
J.-P. Desilles, V. Syvannarath, V. Ollivier, C. Journé, C. Ducroux, W. Boisseau, S. Loyau, M. Jandrot-Perrus, J.-B. Michel, M. Mazighi, B. Ho-Tin-Noé, inserm U1148 (France)

PB 1657  The Association between Ring Finger Protein213 (RNF213) Polymorphisms and Ischemic Stroke Risk in Korean Patients

PB 1658  Effects of Phosphodiesterase 3A Modulation on Murine Cerebral Microhemorrhages

PB 1659  Coding Variants in ADAMTS Genes Derived from Next Generation Sequencing Associated with Pediatric Stroke
F. Rühle, A. Witten, A. Barysenka, C. Strauss, M. Hiersche, A. Arning, U. Nowak-Götti, M. Stoll (Germany)

PB 1660  Long-term Stroke Risk Prediction in ‘Real World’ Atrial Fibrillation Patients: A Comparison of the ABC-stroke and CHA2DS2-VASc Scores
J.M. Rivera-Caravaca, V. Roldán, M.A. Esteve-Pastor, M. Valdés, V. Vicente, G.Y.H. Lip, F. Marini (Spain, United Kingdom)

PB 1661  Time-restricted Feeding Disturbs Circadian Expression of Thrombomodulin in the Mouse through Peripheral Clock Molecules
S. Hone, K. Oishi, Kagawa Nutrition University (Japan)

PB 1662  Reduced ADAMTS13 Levels in Patients with Acute and Chronic Cerebrovascular Disease
F. Denorme, P. Kraft, I. Pareyn, C. Drechsel, H. Deckmyn, K. Vanhoorebeke, C. Kleinschnitz, S.F. De Meyer (Belgium, Germany)
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1663</td>
<td>High Level of von Willebrand Factor Ristocetin Cofactor Activity is Associated with Poor 2-years’ Prognosis in Cerebral Infarction</td>
<td>W. Shen (China)</td>
<td></td>
</tr>
<tr>
<td>PB 1664</td>
<td>Evaluation of the Thrombolytic Potential of N-acetyl Cysteine in a Mouse Model of Thrombotic Stroke</td>
<td>F. Denomme, H. Deckmyn, K. Vanhoorelbeke, S.F. De Meyer (Belgium)</td>
<td></td>
</tr>
<tr>
<td>PB 1665</td>
<td>Is There a Difference in Inherited Prothrombotic Polymorphisms between Arterial Ischemic Stroke and Cerebral Sinus Venous Thrombosis in Children?</td>
<td>A. Ceri, D. Coen Herak, A. Grzunov, J. Lenicek Krijeza, V. Djuranovic, N. Barisic, R. Zadro (Croatia)</td>
<td></td>
</tr>
<tr>
<td>PB 1666</td>
<td>Alpha-2-antiplasmin Arg407Lys Polymorphism and Cryptogenic Ischemic Cerebrovascular Events: Association with Neurological Deficit</td>
<td>J. Wzorek, M. Karpinski, E. Wypasek, A. Undas (Poland)</td>
<td></td>
</tr>
<tr>
<td>PB 1669</td>
<td>Early Plasma Fibrinogen Level after Thrombolytic Therapy in Acute Ischemic Stroke Patients Cannot Predict Intracranial Hemorrhage</td>
<td>T. Ruchutrairat, Y. Nakkinkun, Y. Nilanon (Thailand)</td>
<td></td>
</tr>
<tr>
<td>PB 1671</td>
<td>Safety of Aspirin for Secondary Stroke Prevention: POoled Data Reanalysis of Aspirin for Cerebral Infarction Prevention: POOLEAD Study</td>
<td>N. Nagao (Japan)</td>
<td></td>
</tr>
<tr>
<td>PB 1672</td>
<td>Abnormal Red Cell Indices and the Risk of Arterial Ischemic Stroke in Children</td>
<td>N. Sirachainan, W. Sasakakul, P. Kadegasem, P. Wongwerawattanakoon, C. Khongkhathithum, A. Chuansumrit (Thailand)</td>
<td></td>
</tr>
<tr>
<td>PB 1673</td>
<td>Remote Platelet Function Testing Using Platelet-bound P-selectin as a Marker of Platelet Activation. Findings in Patients with Stroke or TIA Treated with Clopidogrel</td>
<td>N. Dovlatova, S. Heptinstall, J. May, P. Bath (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PB 1675</td>
<td>Unhelpful Use of Hereditary Thrombophilia Tests in Young Patients with Ischemic Stroke. Final Results of the AISYF’s Trial</td>
<td>J.M. Ceresetto, C. Duboscq, P. Bonardo, L. Leon Cejas, V. Genoud, S. Palmer, G. Stammel, R. Reisin (Argentina)</td>
<td></td>
</tr>
<tr>
<td>PB 1676</td>
<td>Association of PAI-1 4G/5G Polymorphism with Ischemic Stroke in Young Indians</td>
<td>M. Akhtar1, A. Biswas2, S. Abdullah1, M. Behari1, R. Saxena3 (1Saudi Arabia, 2Germany, 3India)</td>
<td></td>
</tr>
<tr>
<td>PB 1677</td>
<td>Serotonin and von Willebrand Factor Serum Content under Ischemic Stroke with or without Type 2 Diabetes Mellitus</td>
<td>O. Kravchenko, T. Tsarenko, O. Savchuk, L. Ostapchenko (Ukraine)</td>
<td></td>
</tr>
<tr>
<td>PB 1678</td>
<td>Incidence and Outcome of Childhood Stroke in Thailand</td>
<td>P. Komvila, S. Tiamkao, S. Sutra, N. Sirachainan, K.T. Thpsamthammarat (Thailand)</td>
<td></td>
</tr>
<tr>
<td>PB 1679</td>
<td>Another Indication to DOACs</td>
<td>A.M. Pizzini, D. Galimberti, G. Malferri, M.C. Leone, D. Arioli, A. Ghirarduzzi (Italy)</td>
<td></td>
</tr>
<tr>
<td>PB 1680</td>
<td>Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI</td>
<td>I. Stroo, A. Marquart, A. Meijer, J. Meijers (the Netherlands)</td>
<td></td>
</tr>
<tr>
<td>PB 1681</td>
<td>Acute Lowering of Factor XII Induces Accelerated Spontaneous Venous Thrombosis in Mice: New Evidence for the Contact System that “Idles”?</td>
<td>M. Heestermans1, K.F. Nickel2, R. van Oerle1, H.H. Versteeg1, P.H. Reitsma1, T.A. Fuchs1, T. Renné1, H.M. van Vlijmen1 (1The Netherlands, 2Germany)</td>
<td></td>
</tr>
<tr>
<td>PB 1682</td>
<td>A Two-step Mechanism for Factor XII Activation in Solution</td>
<td>S. de Maat1, Z.L.M. Hofman1, N. Parr1, G. Pasterkamp1, T. Renné1, C. Maas1 (1The Netherlands, 2Sweden)</td>
<td></td>
</tr>
</tbody>
</table>
## POSTER SESSIONS

### PB 1685
**Cell Receptor Interactions of the Contact System**

J. Emsley¹, A. Slater¹, B. Kaira¹, K. Mccrae¹, M. Searle¹ (¹United Kingdom, ²United States)

### PB 1686
**Endothelial Cell Serpins, Including PAI-1, Form a Complex with FXia Blocking its Activity and Inducing the Clearance, Internalization and Degradation of FXIa**

C. Puy, A. Ngo, E. Tucker, D. Gailani, A. Gruber, O. McCarty (United States)

### PB 1687
**Characterization of Polyphosphate in Endothelial Cells under Cellular Stress**

R. Bugi¹, L. Labberton², K.F. Nickel¹, A.T. Long¹, L.M. Butler², O.J.T. McCarty¹, T. Renne² (¹United States, ²Sweden, ³Germany)

### PB 1688
**Identification of F11 Gene Variations Involved in the Interindividual Variability of Factor XI in Subjects with Congenital Deficiency Caused by Recurrent Mutations**

S. Salloum-Asfar, J. Esteban, M.E. de la Morena-Barrio, A. Miñano, J. Padilla, V. Vicente, J. Corral (Spain)

### PB 1689
**Long-chain Polyphosphate Promotes FXII-dependent Platelet Consumption under Shear Flow**

J. Zilberman-Rudenka², S.E. Reitsma¹, C.P. Wiesenekker¹, C. Puy¹, A.T.P. Ngo¹, S.A. Smith¹, E.L. Tucker¹, R.J. Travers¹, C. Maas², R.T. Urbanus², D. Gailani¹, J.H. Morrissey¹, A. Gruber¹, O.J.T. McCarty¹ (¹United States, ²Netherlands Antilles)

### PB 1690
**Fibrin is a strong activator of FXII**

H. Kozarcanin, K. Nilsson Exkåhl, B. Nilsson, K. Fromell (Sweden)

### PB 1691
**Increased Kallikrein Generation Potential in Patients Suffering from Hereditary Angioedema**

D. Biltoft, J.J. Sidelmann, A. Bygum, Y. Palarasah, J.B. Gram (Denmark)

### PB 1692
**Red Cell and Platelet Microvesicles Activate the Contact System of Coagulation**

D. Noubouossie, M. Piegore, M. Henderson, M. Mooberry, N.S. Key (United States)

### PB 1693
**Contaminating Silica Particles Contribute Substantially to the Procoagulant Activity of DNA Isolated Using Commercial Kits**

S. Smith, C. Baker, R. Breitenfeld, J. Morrissey (United States)

### PB 1694
**Genetic Determinants of Levels of Contact Activation Coagulation Factors**

J.L. Rohmann¹, H.G. de Haan², A. Algra¹, F.R. Rosendaal¹, B. Siegerink¹ (¹Germany, ²The Netherlands)

### PB 1695
**Role of the Platelet Surface in the Activation of FXI by FXIIa**

S.E. Reitsma¹, C. Puy¹, R.T. Urbanus², D. Gailani¹, E. Tucker¹, A. Gruber¹, O.J.T. McCarty¹ (¹United States, ²The Netherlands)

### PB 1696
**Contribution of Intrinsic Coagulation Factors on ex vivo Thrombus Formation and Lysis**

J. Konings¹, J.M. Cosemans¹, B. de Laat¹, H. ten Cate¹, Y. Dargaud², J.W. Goverts-Riemslag¹ (¹The Netherlands, ²France)

### PB 1697
**Generation of a Monoclonal Antibody against “Fast Form” Alpha-2-macroglobulin and Development of a Method to Measure Artificial Surface Driven Protease Activation in Plasma**

D. Biltoft, J.J. Sidelmann, J.B. Gram, Y. Palarasah (Denmark)

### PB 1698
**Haemocompatibility Properties of Polyethersulfone Based Haemodialysis Membrane with Different Amounts of Polyurethane**

F. Kamal, S.H. Sheikh Abdul Kadir, M.H.D. Othman (Malaysia)

### PB 1699
**Comparison of Nine Different Blood Collection Tubes for Contact Activation of Coagulation**

C. Kluft¹, J. Jespersen², J.W. Goverts-Riemslag¹, J.J. Sidelmann² (¹The Netherlands, ²Denmark)

### PB 1700
**CD40L Induces Association of PRDX-2 and TRAF-2 to CD40 of Platelets from IBD Patients**


### PB 1701
**CD40L Induces Association of PRDX-2 and TRAF-2 to CD40 of Platelets from IBD Patients**


### PB 1702
**Temporal Contribution of the Platelet Body and Balloon to Thrombin Generation**

E.D. Agbani, I. Hers, A.W. Poole (United Kingdom)

### PB 1703
**Mechanism of Growth and Inhibition of Plasma Clots Growing from a Surface with Immobilised Tissue Factor**

C. Kluft¹, N.A. Podoplelova², N.M. Dashkevich² (¹The Netherlands, ²Russian Federation)

### PB 1704
**Co-operative Binding of WFV to the TSP8 and CUB Domains of ADAMTS13 is Required for its Conformational Activation**

K. South, M. Freitas, D. Lane (United Kingdom)
<table>
<thead>
<tr>
<th>PB 1706</th>
<th>α-Synuclein Binds to Human α-Thrombin and Inhibits Thrombin-mediated Platelet Aggregation: Possible Implications in Parkinson's Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G. Pontarollo, L. Acquasaliente, F. Ulliana, A. Negro, V. De Filippis (Italy)</td>
</tr>
<tr>
<td>PB 1707</td>
<td>The Effect of Short Chained Polyphosphates on Coagulation Activation in a Whole Blood Model</td>
</tr>
<tr>
<td></td>
<td>I. Heiland¹, R.A. Liang², N. Latysheva³, S. Beck Jensen¹, B. Østerud¹, S.A. Smith⁴, J.H. Morrissey⁵, T.E. Molines⁶, O.-L. Brekke⁷, J.-B. Hansen⁷, K. G. Jebsen – Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø (¹Norway, ²United States)</td>
</tr>
<tr>
<td>PB 1709</td>
<td>Evidence for Direct and Indirect Modulation of Haemostatic Factors by miR-494</td>
</tr>
<tr>
<td>PB 1710</td>
<td>Situation-adjusted Anticoagulant Release System with Response to Different Coagulation Factors</td>
</tr>
<tr>
<td></td>
<td>M.F. Mahtz, J. Zitzmann, J. Hanke, C. Renneberg, M.V. Tsurkan, C. Sperling, U. Freudenberg, C. Werner (Germany)</td>
</tr>
<tr>
<td>PB 1711</td>
<td>Liver Hypoxia Regulates Protein S Levels in Obese Patients</td>
</tr>
<tr>
<td></td>
<td>V. Pilli, A. Dorsey, H. Chodavarapu, E. Lazartigues, R. Majumder (United States)</td>
</tr>
<tr>
<td>PB 1712</td>
<td>Thrombin is a Selective Inducer of Heparanase Release from Platelets and Granulocytes via Protease-activated Receptor-1</td>
</tr>
<tr>
<td>PB 1713</td>
<td>Effects of Exercise and Erythropoietin on Thrombotic Risk in Well-trained Cyclists</td>
</tr>
<tr>
<td>PB 1714</td>
<td>Fibrinogen Polymorphisms Predict Fibrinogen and Clot-related Phenotypes Independently and through Interactions with IL-6</td>
</tr>
<tr>
<td></td>
<td>H.T. Cronø², C. Nienaber-Rousseau¹, L. Zandberg¹, Z. de Lange¹, F.R. Green², M. Pieters³ (¹South Africa, ²United Kingdom)</td>
</tr>
<tr>
<td>PB 1715</td>
<td>Integrative Analysis of Hemostatic Gene Regulation in the Human Liver</td>
</tr>
<tr>
<td></td>
<td>M. Ölsön, T.M. Stanne, M. Davila, C. Jern (Sweden)</td>
</tr>
</tbody>
</table>

**POSTER SESSIONS**

| PB 1716 | Effects of the fibrinogen γ'-C-terminal Peptide on Thrombin-catalyzed Activation of Factor XI, Factor XIII and TAFI |
|         | F. Omarova¹, J. Rosing¹, R.A.S. Ariens², H.R. McPherson², R.M. Bertina¹, E. Castoldi¹ (¹The Netherlands, ²United Kingdom) |
| PB 1717 | Characterization of GGCX Mutations Identified in the First Clinical Case of a VKCFD Patient |
|         | D.-Y. Jin, B. Ingram, D.W. Stafford, J.-K. Tie (United States)                                                                 |
| PB 1718 | Comprehensive Identification of miRNA-gene Interactions Reveals Extensive Regulation of the Plasmatic Coagulation Network |
|         | J. Nourse, J. Braun, S. Hüttemaier, S. Danckwardt (Germany)                                                                 |
| PB 1719 | Resolving the Roles of Platelets and (Anti)Coagulation Pathways in Whole-blood Fibrin Formation under Flow to Phenotype Hemostatic Disorders |
|         | J.P. van Geffen¹, F. Swieringa¹, S.L.N. Brouns¹, R.W. Farndale¹, K.J. Clemenson², E. Castoldi¹, P.E.J. van der Meijden¹, M.E.J. Kuijpers¹, J.W.M. Heemskerk (¹The Netherlands, United Kingdom, Switzerland) |
| PB 1720 | Temperature Effects on Thrombin Generation |
|         | M. Moorlag, R. Kremers, B. de Laat, H.C. Hemker (The Netherlands)                                                                 |
| PB 1721 | Thrombin Generation in Schizophrenia Patients Treated with Antipsychotic Medications |
| PB 1722 | Blood Clot Contraction is Reduced in Sickle Cell Disease due to Increased Rigidity of Erythrocytes |
|         | V. Tutwiler, R. Litvinov, C. Nagaswami, E. Russell, D. Seigel, C. Villa, D. Pan, V. Muzykantov, J. Weisel (The Netherlands) |
| PB 1723 | Tissue Factor-dependent Heme-induced Whole Blood Coagulation Activation: A Thromboelastometry Study |
|         | B.W. Hounkpe, G.R. de Souza, M.M.L. Fiusa, M. Pereira Colella, J.M. Annichino-Bizzacchi, F. Traina, F. Reirre Costa, E.V. De Paula (Brazil) |
| PB 1724 | Salivary EV: A New Link between Primary and Secondary Hemostasis |
|         | Y. Yu, E. Gool, R. Berckmans, A. Sturk, A. Barendrecht, C. Maas, R. Nieuwland (The Netherlands) |
| PB 1725 | Heme-regulated Proteins within the Blood Coagulation Cascade: Insights into the Molecular Basis of Protein Binding to Free Heme |
|         | D. Imhof, S. Mai, C.A. Bäuml, A. Wöllbrock (Germany)                                                                 |
POSTER SESSIONS

PB 1726  Heparan Sulfate Chains Contribute to an Anticoagulant Milieu in Malignant Pleural Effusion
E. Hardak, E. Peled, Y. Crispel, S. Ghanem, J. Attias, I. Kogan, B. Brenner, Y. Nadir (Israel)

PB 1727  Myeloperoxidase (MPO) is a Negative Regulator of Phospholipid-dependent Coagulation
L. Beckmann, C. Dicke, B. Spath, B. Sievers, C. Lehr, A. Klinke, S. Baldus, V. Rudolph, F. Langer (Germany)

PB 1728  Procoagulant Properties of Microparticles Produced by Monocytes, Granulocytes, Platelets and Endothelial Cells
A. Mazurov, O. Antonova, N. Golubeva, S. Khaspekova, O. Shustova, V. Yakushkin, I. Alchinova, M. Karganov (Russian Federation)

PB 1729  Ventricular Assist Devices without Anticoagulation: An Impossible Dream?
P.A. Coghill, Z. Azartash-Namin, J.R. Stanfield, T.A. Snyder, J.W. Long (United States)

PB 1730  Beta-adrenergic Receptor Blockage Reduces Exercise-induced Alterations in Haemostasis
J.J. Posthuma, J.J.N. Posma, R. van Oerle, H.M.H. Spronk, H. ten Cate (The Netherlands)

PB 1731  The Modification of Thrombin Generation Assay Parameters in Patients with Recurrent Pregnancy Loss
D. Bahri, H. Baccouche, A. Chakroun, Z. Manai, S. Mahjoub, N. Ben Romdhane (Tunisia)

PB 1732  Desmopressin Administration in a Splenectomised Hemophilia A Patient Does Not Affect FVIII, VWF and tPA Plasma Levels: An Evidence for an Indirect Effect of DDAVP
T. Shahani1, Z. Pirdel1, H. Dinmohammadi1, L. Salarilak1, M. Karimi1, M. Jacquemin2 (1Iran, Islamic Republic of, 2Belgium)

PB 1734  Haemostatic Function after Spontaneous Intracerebral Haemorrhage

PB 1735  Anticoagulant effects of peptide Pro-Gly-Arg in aging rats
T. Obergan, M. Grigorjeva (Russian Federation)

PB 1736  A Polydeoxynucleotide Derived Drug Defibrotide Inhibits Nucleosome Generation in Whole Blood. Implications in the Management of VOD
J. Farre, U. Cornelli, D. Hoppensteadt, A. Walborn, J. Walenga, M. Iacobelli, W. Jeske (United States)

POSTER SESSIONS

PB 1737  Influence of Polyamidoamine (PAMAM) Dendrimers on the Activity of Key Enzymes of the Coagulation System in vitro
L. Mukhametova, R. Aisina, E. Ivanova, E. Zakharyan, K. Gerchkovitch (Russian Federation)

PB 1738  Repetitive Strenuous Exercise Leads to Exhaustion of Haemostatic System
A. Misztal, V. Strijbis, L.N. van der Vorm, D. Huskens, S. Zwaal, P. de Groot, M. Roest, B. de Laat (The Netherlands)

PB 1739  Absence of Thrombotic Events in the Gastric Signet-ring Cell Adenocarcinoma Patients with High Expression of Heparanase

PB 1740  Anti-TFPI Antibody Targeting the Kunitz-2 Domain of Human TFPI Efficiently Recovers FVII Activity Comparing Kunitz 1 Domain Targeted TFPI Antagonist
S. Lee, H. Kwak, S.-H. Hwang (Republic of Korea)

PB 1741  The State of Hemostasis after Nonselective Thrombolysis in Patients with Ischemic Stroke
S. Sinkov, K. Zibin (Russian Federation)

Fibrinolysis & Proteolysis

PB 1742  FXIII and EACA Increase Thrombus Stability and Decrease Pulmonary Embolism in an in vivo Mouse Model of Venous Thromboembolism, but EACA Increases Thrombus Size
S.A. Shaya, J.J. Weitz, P.L. Gross (Canada)

PB 1743  Fibrinogen May Possess a Second Factor XIII Cross-linking Site for α2-AP in Fibrin
C. Duval1, H. McPherson1, K. Bridge1, M. Domingues2, R. Ajjan1, V. Ridger1, S. Connell1, H. Philippou1, R. Ariens1 (1United Kingdom, 2Portugal)

PB 1744  Fibrin-derived B815-42 Peptide Is a Gatekeeper of Thrombus Resolution
S. Chaushева, S. Sharma, A. Alimohammadi, P. Petzelbauer, I. Lang (Austria)

PB 1745  Theoretical Model for Thrombin-FXIII-A2 Complex and the Effect of Ca2+ Ions on the Dynamic Behavior of FXIII-A2'
I. Komáromi, G. Balogh, A. Fekele, L. Muszbek (Hungary)

PB 1747  Platelet and Plasma Factor XIII Levels after Replacement Therapy in Severe Congenital Factor XIII Deficiency: Is there a Role for Factor XIII Uptake by Megakaryocytes?
C. Radu, C. Bulato, E. Campello, F. Sartorello, E. Zanon, M. Milan, S. Gavasso, L. Spiezia, P. Simioni (Italy)
POSTER SESSIONS

PB 1748  Investigating the Role that a Factor XIII Binding Site on Fibrinogen αC (233-425) Plays in Controlling Glutamine Substrate Specificity
M. Maurer1, K. Mouapi2, L. Wagner2, C. Stephens3 (1United States, 2France)

PB 1749  Genetic and Clinical Epidemiology of Congenital Fibrinogen Disorders
A. Casini, M. Blondon, P. de Moerloose, M. Neerman-Arbez (Switzerland)

PB 1750  Calcium Binding Sites in Coagulation Factor XIII and Other Transglutaminases: Their Evolution, Diversity, Conservation and Functional Relevance
S. Singh1, S.L.S. Swaminathan1, C. Reinhart1, C. Krettl1, V. Ivaskevicius1, J. Dodt1, H. Philippou2, J. Oldenburg1, A. Biswas1 (1Germany, 2United Kingdom)

PB 1751  On-demand Treatment with Fibrinogen Concentrate in Acute Bleeding and for Surgery in Patients with Congenital Fibrinogen Deficiency
C. Ross1, B. Madan2, M. Karimi3, T. Lissitchkov4, B.A. Schwartz5, S. Knaub6, F. Peyvandi2, J. Oldenburg1, A. Biswas1 (1India, 2United Kingdom, 3Iran, Islamic Republic of, 4Bulgaria, 5United States, 6Switzerland, 7Italy)

PB 1752  Congenital FXIII Deficiency in Pakistan: An Update
M. Borhany1, N. Fatima1, M. Abid1, T. Shamsi1, V. Schroeder2, H.P. Kohler2 (1Pakistan, 2Switzerland)

PB 1753  Pharmacokinetics of Fibrinogen Concentrate and Efficacy in Treating Acute Bleeding in Children and Adolescent Patients with Congenital Fibrinogen Deficiency
M. Karimi1, C. Ross3, G.R. De Angulo3, B.A. Schwartz5, C. Reinhart1, V. Ivaskevicius1, F. Peyvandi2 (1Iran, Islamic Republic of, 2India, 3United States, 4Switzerland, 5Italy)

PB 1754  Factor XIII in Tears and its Possible Role in Corneal Wound Healing
Z.Z. Orosz, A. Szőr, Z. Veréb, Z. Hassan, É. Katona, G. Vereb, A. Fасskó, L. Muszbek (Hungary)

PB 1755  A Role for Factor XIII in Clot Formation and Clot Contraction of Whole Blood
T. Plug, H.M. van Beusekom, R. van Bruggen, J.C.M. Meijers (The Netherlands)

PB 1756  Structural and Phylogenetic Analysis of Coagulation Factor XIII Explains its Uniqueness in the Transglutaminase Family
A. Biswas1, D. Davray1, S. Singh1, V. Ivaskevicius1, H. Philippou2, J. Oldenburg1 (1Germany, 2India, 3United Kingdom)

PB 1757  In silico Analysis of Extended Promoter Regions of F13A1 and F13B Genes Indicates Putative Sites Might Underlie Regulatory Variation in Factor XIII Levels
M.A. Jamil1, S. Singh1, V. Ivaskevicius1, J. Dodt1, H. Philippou2, J. Oldenburg1, A. Biswas1 (1Germany, 2United Kingdom)

PB 1758  Fibrinogen Caracas IX a Novel Fibrinogen Mutation: FGA g. 3057 C>T (p. 104 Arg>Cys) Impair Fibrinogen Secretion
R. Marchi1, M. Linares1, H. Rojas1, A. Ruiz-Sáez1, M. Meyer2, S. Brennan3 (1Venezuela, 2Germany, 3New Zealand)

PB 1759  Effect of Mutations in the Fibrinogen αR95G96D97 Sequence on Clot Structure and on the Interaction of Fibrinogen with Red Blood Cells
A. Sabbán1, C. Duval1, A.F. Guedes2, H. McPherson1, F. Macrae1, S. Saha1, R. Ajjan1, N.C. Santos3, R.A.S. Ariens1 (1United Kingdom, 2Portugal)

PB 1760  Evidence for the Presence of Cross-beta Structures in Fibrin Clots
S. Talens, F.W.G. Leebeek, D.C. Rijsk (The Netherlands)

PB 1761  Prevalence of Mild Factor XIII Deficiency Phenotype: Preliminary Results of a WFH Sponsored CRGP Study
A. Biswas1, S. Singh1, N. Mir-Montazeri1, I.P. Claus2, V. Ivaskevicius1, E. Heathershaw2, H. Philippou2, P. Volkers1, J. Dodt1, J. Oldenburg1 (1Germany, 2United Kingdom)

PB 1762  Development of Fibrinogen Formulation with High Resistance to Thermal Stress
J. Soo, M. Yoo, J. Kim, J. Seol, J. Choi (Republic of Korea)

PB 1763  Cellular Factor XIII in Human Cornea
L. Muszbek, Z.Z. Orosz, H. Bárdos, A.H. Shemirani, B. Nagy, J. Kappelmayer, R. Ádány, A. Berta, A. Fасskó (Hungary)

PB 1764  Fibrin-associated ROTEM Variables and Thrombin Generation in Patients with Congenital Fibrinogen Defects
T. Szanto1, A. Jouppila1, E. Armstrong1, A. Casini2, R. Lissitchkov4, B. Kovács, T. Miklós, É. Ajzner, L. Muszbek (Hungary)

PB 1765  Studies to Determine Novel Interacting Partners and Functional Roles for Factor XIII B Subunit
S. Singh1, M.S. Akhter1, V. Ivaskevicius1, A. Reuter1, J. Dodt1, H. Philippou2, J. Oldenburg1, A. Biswas1 (1Germany, 2United Kingdom)

PB 1766  The Effect of Factor XIII Levels and Factor XIII B Subunit Polymorphisms on the Risk of Venous Thromboembolism
Z.A. Mezei, É. Katona, J. Kállai, Z. Bereczky, L. Somodi, B. Kovács, T. Miklós, É. Ajzner, L. Muszbek (Hungary)

PB 1767  Novel Immunoassay Reagent for Fibrinogen without Cross-reactivity to FgDP and XDP in Plasma
Y. Magari (Japan)
## POSTER SESSIONS

### PB 1768

**Galactosemia Presenting with Afibrinogenemia**  
F. Gümrük, İ. Yaman Bajin, S. Aytaç, Ş. Yiğit, M. Çetin, A. Tokatlı  
(Turkey)

### PB 1769

**Plasma Tromboelastometry (ROTEM) Could be a Complement in Study Fibrinogen Disorders**  
A.B. Vilaseca, R. Barbera, G. Vidmar, G. Begue, H. Beccari  
(Argentina)

### PB 1770

**A Fibrinogen Activity Method on Photo-optical Coagulation Analyzers without Interference from Hydroxyethyl Starch**  
Z. Cao, A. Belanger, J. Mathew, C. Kung, R. Bottenus  
(United States)

### Hemorrhagic Disorders, Hemophilia

### PB 1771

**Construct and Known Group Validity of Patient-reported Outcome (PRO) Instruments in US Adults and Caregivers of Children with Hemophilia B: Results from the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) Study**  
T. Buckner, R. Sidonio Jr, M. Witkop, C. Guelcher, D. Clark, W. Owens, N. Frick, N. Iyer, D. Cooper  
(United States)

### PB 1772

**High and Sustained Observed trough FIX Activity Levels with Prophylactic Dosing of IDEL VION (rFIX-FP) in Patients with Hemophilia B**  
G. Castaman, J.C. Gill, J. Roberts, J. Jochems, Y. Li, W. Seifert  
(United States)

### PB 1773

**Pharmacokinetics of Recombinant Fusion Protein Linking Activated Factor VIIa to Human Albumin (rVIIa-FP) and Eptacog Alfa in Hemophilia Patients with Inhibitors**  
(United States, Germany, South Africa, Italy)

### PB 1774

**Efficacy and Safety of rFVIII:Fc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Severe Hemophilia A over 3-4 Years: The ASPIRE Study**  
(Ireland, United States, South Africa, United Kingdom, Sweden)

### PB 1775

**Comparing the One-stage and Chromogenic Assay: Factor VIII Assay Discrepancy at Baseline Does Not Reflect Assay Discrepancy after DDAVP in Non-severe Hemophilia A**  
(The Netherlands)

### PB 1776

**Risk Differential in Inhibitor Development in the First Days of Treatment by Product Class: A SIPPET Analysis**  
(Italy, The Netherlands, Egypt, India, Iran, Islamic Republic of, United States, Mexico, South Africa, Spain, Brazil, Austria, Saudi Arabia, Chile, Turkey, Argentina)

### PB 1777

**Pocket Handheld Ultrasound Has High Accuracy in Identification of Effusions and Major Landmarks in Normal and Hemophilic Joints: Expanding Point of Care for Patients with Hemophilia with Joint Disease**  
J.Y. Zhou, K.C. Rappazzo, L. Volland, M. Brackman, B. Steiner, R. Kruse-Jarres, D.V. Quon, C. Bailey, E.Y. Chang  
(United States)

### PB 1778

**Influence of Family History on Mode of Delivery in Severe Haemophilia in the UK**  
(United Kingdom, United Arab Emirates)

### PB 1779

**Inhibitor Development in Previously Untreated Patients Treated with Octocog Alfa (ADVATE)**  
A. Gringeri, K. Steinitz-Trost, H. Chehadeh  
(Austria)

### PB 1780

**Predictors of Patients with 0 Bleeds during Every-7-days Prophylaxis with BAY 94-9027 in PROTECT VIII**  
(Norway, United States)

### PB 1781

**Individualizing Hemophilia Prophylaxis using Thromboelastography (TEG)**  
R. Carmona, H.S. Lee, E. Marquez, G. Young  
(United States)

### PB 1782

**Impact of a Product-Specific Reference Standard for the Measurement of a PEGylated rFVIII Activity: The Swiss Multicentre Field Study**  
(Switzerland)
### POSTER SESSIONS

**PB 1783**

**Long-term Quality-of-Life Outcomes with rFVIIIFc Prophylaxis in Adult Subjects with Severe Hemophilia A**

J. Su1, E. Tsao1, J. Feng1, K.-J. Myren2, D. Glazebrook1 (1United States, 2Sweden)

**PB 1784**

**Bleeding Events and Safety Outcomes in Persons with Hemophilia A (PwHA) with Inhibitors: The First Large, Prospective, Multicenter, Non-interventional Study (NIS) from a Real World Setting**

J. Mahlangu1, J. Oldenburg2, M. Callaghan3, M. Shima4, E. Santagostino5, M. Moore6, M. Recht7, C. Garcia8, R. Yang9, M. Lehle10, H. Macharia11, E. Asikianus12, G. Levy13, R. Kruse-Jarres14 (1South Africa, 2Germany, 3United States, 4Japan, 5Italy, 6Costa Rica, 7China, 8Switzerland)

**PB 1785**

**Disparities in Age at Diagnosis and Initial Treatment between People with Moderate and Severe Haemophilia A: Evidence from the KAPPA Register**

M. Osooli1, F. Sahin2, Y. Walli3, C. Ar2, P. Holme4, S. Saulyte-Trakymiene4, L. Hvitfeldt4, M. Holmström5, E. Gouider6, A. Khelif7, O. Kassar7, S. Rauchensteiner8, K. Steen Carlsson1 (1Sweden, 2Turkey, 3Oman, 4Norway, 5Lithuania, 6Denmark, 7Tunisia, 8Switzerland)

**PB 1786**

**Low Dose Prophylaxis for Children With Haemophilia - One Year Experience from a Haemophilia Comprehensive Treatment Centre, Kerala, India**

N. Sidharthan, R. Sudevan, V. Narayana Pillai, S. Mathew, M. Raj, D. Viswam, C. Joseph, A. Sudhakar (India)

**PB 1787**

**Final Results from the PUP-GCP Clinical Trial: A Low Inhibitor Rate in Previously Untreated Patients with Severe Haemophilia A Treated with Octanate**

A. Klukowska1, M. Jansen1, V. Komrska1, V. Vdovin1, L. Belyanskaya1, P. Laguna1 (1Poland, 2Austria, 3Czech Republic, 4Russian Federation, 5Switzerland)

**PB 1788**

**Intracranial Hemorrhage in Hemophilia Patients: The Status of Ongoing Retrospective-Prospective Italian Registry (2009-2016)**

F. Zanoni, F. Demartis, A. Tagliaferri, P. Schinco, I. Cantori, M. Milan, A.C. Molinari, C. Biasoli, A. Coppola, G. Castaman, M. Luciani, G. Sottilotta, E. Santagostino (Italy)

**PB 1789**

**Evaluation of Outcomes from Long-term Prophylaxis or Episodic Treatment of Patients with Haemophilia A: A Systematic Review**

G. Sima1, J. Frintrop1, F. Paliargues1, P. Chu2, I. Fresch2 (1United States, 2Switzerland)

---

**POSTER SESSIONS**

**PB 1790**

**Comparison of the Relationship between Factor IX Activity and Bleeding Risk during Prophylaxis with Nonacog Beta Pegol (N9-GP)**

G. Young1, W.H.O. Clausen2, C. Négrier3, B.B. Rønn2, E. Santagostino4, J. Oldenburg5 (1United States, 2Denmark, 3France, 4Italy, 5Germany)

**PB 1791**

**Efficacy of rVIII-SingleChain in the Treatment of Adult and Adolescent Patients with Severe Hemophilia A in Europe**

R. Kiamroth1, J. Oldenburg1, P. Chowdary2, M. von Depka-Prondzinski1, D. Bensen Kennedy3, I. Pabinger4 (1Germany, 2United States, 3Austria)

**PB 1792**

**Chronic Liver Disease in Elderly People with Hemophilia**

C. Quigstad1, R.C. Tait2, S. Rauchensteiner3, C. Combescentre4, E. Berntorp5, P. de Moerloose6, R. Schutgens7, P.A. Holme1 (1Norway, 2United Kingdom, 3United States, 4Switzerland, 5Sweden, 6The Netherlands)

**PB 1793**

**Once Weekly Rfix Prophylaxis for Severe-Phenotype Haemophilia B in Normal Clinical Practice: Data from UKHCDO and Finland**

M. Scott1, V. Nummi2, R. Lassila2, H. Xiang1, C. Hay1 (1United Kingdom, 2Finland)

**PB 1794**

**Pharmacokinetic Guided Personalized Prophylaxis with Human-cl rhFVIII in Adult Patients with Severe Hemophilia A**

C. Kessner1, M. Shima2, A.-E. Armstrong2, J. Bichler1, S. Knaub1, G. Pezeshki1, M. Wangi3, J. Ducore1 (1United States, 2Japan, 3Finland, 4Switzerland)

**PB 1795**

**Application of Pharmacokinetic-tailored Approach to Prophylaxis in Routine Hemophilia Care**

S.E. Croteau1, E.J. Neufeld (United States)

**PB 1796**

**Prevalence of Cerebral Microbleeds and Macrobleeds in Neurologically Asymptomatic Patients of Congenital Hemophilia**

P. Malhotra1, S. Kumar, S. Mahi, J. Ahluwalia, P. Singh, V. Suri, S. Kumari, N. Varma, S. Varma (India)

**PB 1797**

**Long-term Safety and Efficacy of Recombinant Factor VIII Fc (rFVIIIFc) for the Treatment of Severe Haemophilia A: European Subgroup Interim Analysis of the ASPIRE Study**

B. Nolan1, J. Oldenburg2, G. Castaman3, I. Woźnica-Karczmarsz3, B. Winding6, J. Szamosi3, S. Lethagen5 (1Ireland, 2Germany, 3Italy, 4Poland, 5Sweden)

**PB 1798**

**Evaluation of the Impact of Polymorphism/Mutations in Genes Associated to Hemostasis in Clinical Diversity in Patients with Severe Hemophilia**

F.M.L. Fonseca, N. Temba, L.M.M. Oliveira, M.V.A. Amorim, M.G. Carvalho, D.G. Chaves (Brazil)
PB 1799  The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPET Cohort

PB 1800  Extensions of F9 Mutation Spectrum and Genotype-phenotype Heterogeneity in Haemophilia B

PB 1801  Evaluate the Situation Diagnosis and Treatment of Hemophilia in Vietnam in 2015
T.M. Nguyen (Viet Nam)

PB 1802  Low Dose (20 IU/kg/week) Single Infusion Prophylaxis per Week Using Long Acting FVIIIc (ELOCTATE, Biogen) in Severe Hemophilia A: A Cost Effective & Feasible Protocol for Resource Constraint Situation
S. Apte1, A. Joshi, K. Subramanian, R. Dange, R. Phatale (India)

PB 1803  Development of the Education Interventions to Enhance Adherence to Prophylactic Treatment in Korean Hemophilia Patients

PB 1804  Immune Tolerance Induction in Patients with Haemophilia using Fc Fusion Recombinant Factor VIII
A. Nagao, H. Katayama, K. Amano (Japan)

PB 1805  Spectrum and Origin of Mutations in Sporadic Cases of Haemophilia A in China
Y. Lu (China)

PB 1806  The Utility of Activated Partial Thromboplastin Time Clot Wave Form Analysis in the Investigation of Hemophilia A Patients Using Destiny Max TM Analyzer
A. Abraham1, P.O. Sevenet1, M.-L. Delalande2, H.F. Margaret1, T. Geevar1, S. Singh1, R. V2, S. Deivasigamani1, S.C. Nair1 (1India, 2France)
POSTER SESSIONS

PB 1818 PROTECT VIII: Can Patient Characteristics Predict Eligibility for Less-frequent Prophylaxis Dosing Regimens?
J. Oldenburg¹, L.A. Michaels², M. Wang², O. Afonja², on behalf of PROTECT VIII investigators (¹Germany, ²United States)

PB 1819 Is Intermediary Intensity Prophylaxis with Factor VIII Sufficient for Improvement of Overall Hemostasis Potential in Hemophilia A Patients?
I. Djunic¹, V. Dopsaj¹, I. Elezovic¹, P. Miljic¹, M. Mitrovic¹, A. Novkovic¹, N.M. Hourani Soutari², J.P. Antovic² (¹Serbia, ²Sweden)

PB 1820 Can Tertiary Prophylaxis Bring about Zero Bleed in Adult Persons with Hemophilia? A Single Center Observation Study in Japan
T. Fujii, T. Fujii, N. Yamasaki, S. Saito (Japan)

PB 1821 Personalized Treatment of Pediatric Patients with Severe Haemophilia A. Importance of Pharmacokinetics. Assessment Benefits from Kinetics of Factor VIII (Simoctocog Alpha)
E. Spallino, G. D’Antona, V. Dicembre, F. Gagliano (Italy)

PB 1822 Splenectomy for Liver Cirrhosis Improved Systemic Condition in HIV/HCV Co-infected Patients with Hemophilia
H. Katayama (Japan)

PB 1823 Two Effective Cases of Immune Tolerance Induction Using Turoctocog Alfa Combined with Immunosuppressive Therapy in Non-severe Hemophilia A
C. Yushi, K. Amano, Y. Kamikubo, A. Ichiki, M. Bingo, T. Hagiwara, T. Suzuki, K. Fukutake (Japan)

PB 1824 Tailored Prophylaxis: A Bridge between QoL and Retrenchment. Our Experience with Simoctocog Alfa
J. Agnelli Giacchello, A. Valpreda, E. Dosio, M. Boccadoro, A. Borchelli (Italy)

PB 1825 Therapeutic Efficacy of Low-dose Immune Tolerance Induction in 5 Chinese Severe Hemophilia A Children with Inhibitor in Good Risk
Y. Li, G. Li, Z. Chen, X. Wu, Y. Zhen, L. Tang, R. Wu (China)

PB 1826 Efficiency of Prophylaxis in an Adult with Hemophilia after Dose Adjustment Using a Bayesian Model for Pharmacokinetics Estimation
M. Canaro, B. Galmes (Spain)

PB 1827 Evaluating the Frequency of Haemophilia and Bleeding Parameters of Persons with Bleeding Disorder in South East, Nigeria
T. Nwagba, S. Okparoka (Nigeria)
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1838</td>
<td>Direct Oral Anticoagulants (DOAC) vs Low Molecular Weight Heparin (LMWH) as Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation (NVAF) and Concomitant Active Cancer</td>
<td>A. Varela-Magallon, P. Olivera, G. Oristrell, J. Limeres, E. Johansson, T. Canals, V. Pons, F. Bosch, A. Santamaria (Spain)</td>
</tr>
<tr>
<td>PB 1840</td>
<td>Variation of Renal Function during Treatment with Direct Oral Anticoagulants and Risk of Major Bleeding in Patients with Non-valvular Atrial Fibrillation</td>
<td>M. Giustozzi, C. Becattini, M. G. Ranalli, G. Bogliari, F. Cianella, G. Agnelli, M. C. Vedovati (Italy)</td>
</tr>
<tr>
<td>PB 1841</td>
<td>Global Public Awareness about Atrial Fibrillation</td>
<td>A. Wendelboe1, P. Anghchaisuksiri2, A. Blance3, H. Ddungu4, J. Dvorak1, B. Hunt5, E. Hylek6, A. Kakkar7, S. Konstantinides8, M. McCumber9, C. McLintock10, T. Urano11, H. Buller12, J. Weitz13, G. Raskob14 (1United States, 2Thailand, 3Argentina, 4Uganda, 5United Kingdom, 6Germany, 7New Zealand, 8Japan, 9The Netherlands, 10Canada)</td>
</tr>
<tr>
<td>PB 1842</td>
<td>VKA Treatment and Bleeding Rate of Patients Aged Older than 90 Years: Results from a Prospective Multicentre START Register Study</td>
<td>D. Poli, E. Antonucci, S. Fumagalli, L. Migliaccio, F. Marongiu, A. Tripodi, V. Pengo, S. Testa, G. Palareti, START-Register participants (Italy)</td>
</tr>
<tr>
<td>PB 1844</td>
<td>Improving Appropriate Use of NOACs in AF: Success of Online CME</td>
<td>J. Spyropoulos (United States)</td>
</tr>
<tr>
<td>PB 1845</td>
<td>Optimisation of Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation Using a Virtual Clinic Model</td>
<td>A. Brown, R. Byrne, H. William, N. Hamed, A. Hodgkinson (United Kingdom)</td>
</tr>
<tr>
<td>PB 1846</td>
<td>Evaluation of Antithrombotic Management in Patients with Atrial Fibrillation at a Tertiary Care Academic Medical Center</td>
<td>S. Bhatt, M. Adra, J. Lacoste, E. Sceane-Vazquez (United States)</td>
</tr>
<tr>
<td>PB 1847</td>
<td>Recent Years Trends in Real-life Antithrombotic Therapy for In- and Out-patients with Atrial Fibrillation in Moscow</td>
<td>A. Melekhov, G. Gendlin, E. Dadashova, E. Alekseeva, I. Zaigraev, I. Nikitin (Russian Federation)</td>
</tr>
<tr>
<td>PB 1848</td>
<td>Should we Abandon the APTT for Monitoring the Anticoagulant Effect of Unfractionated Heparin?</td>
<td>D. Jayakody Arachchilage, F. Kamani, S. Deplano, S. Fox, M. Mcevoy, L. Tillyer, M. Laffan (United Kingdom)</td>
</tr>
<tr>
<td>PB 1850</td>
<td>Risk of Thromboembolic Disease in Renal Transplant Patients</td>
<td>V. Privitera, N. Schultz, S. Vifualbes, V. Otero, D. Penchasky, N. Imperiali (Argentina)</td>
</tr>
<tr>
<td>PB 1851</td>
<td>Validation of Risk Assessment Models for Venous Thrombosis in Hospitalized Medical Patients</td>
<td>B. Nemeth, M. Cobben, W. Lijfering, S. Cannegieter (The Netherlands)</td>
</tr>
<tr>
<td>PB 1852</td>
<td>In ECMO Patients Anticoagulated with Heparin the Dose-response Relationship Disappears when the Dose is Adjusted by ACT but it is Preserved with Anti-Xa Activity</td>
<td>F. Guerrero, J. M. Conil, A. Jacquesmin, C. Delmas, T. Seguin, B. Marcheix, V. Memir, N. Savy, B. Georges (France)</td>
</tr>
<tr>
<td>PB 1854</td>
<td>A Post Hoc Analysis of Dalteparin versus Vitamin K Antagonist (VKA) for the Treatment of Cancer-associated Venous Thromboembolism (VTE) in High-risk Patients with Metastatic Disease and Recent Antineoplastic Treatment</td>
<td>S. Woodruff1, A. Lee2, M. Carrier3, F. Feugère4, P. Abreu5, J. Heissler1 (1United States, 2Canada)</td>
</tr>
</tbody>
</table>
**POSTER SESSIONS**

**PB 1856**  
Structural and Haemostatic Features of Pharmaceutical Heparins from Different Animal Sources: Challenges to Define Thresholds Separating Distinct Drugs  
M.S. Pereira, A.M.F. Tovar, G.R.C. Santos, N. Capille, B.F. Glauser, E. Vilanova, P.A.S. Mourão (Brazil)

**PB 1857**  
The Effect of Prolongation of Initial Enoxaparin Therapy to One Month on the Risk of VTE Recurrences and the Recanalization of Deep Veins  
N. Vorobyeva, O. Ermolina, T. Balakhonova, A. Krienko, E. Panchenko (Russian Federation)

**PB 1858**  
Validation of the Pulmonary Embolism Severity Index (PESI) and Simplified PESI in Asian Patients with Acute Pulmonary Embolism  

**PB 1859**  
Help the Aged? Are we Failing to Protect Patients with Dementia from the Risks of Developing Hospital Associated Venous Thrombo-Embolism?  
A. McSorley, M.D. Creagh, A. Mabin, S. Gupta (United Kingdom)

**PB 1860**  
The Efficacy and Safety of Anticoagulations in Cerebral Vein Thrombosis: A Systematic Review and Meta-analysis  
B. Al Rawahi1, M. Almegren1, M. Carrier2 (1Oman, 2Canada)

**PB 1861**  
Study of Bioaccumulation of Tinzaparin in Renally Impaired Patients when Given at Prophylactic Dose: The STRIP Study  

**PB 1862**  
Thromboembolic Events Following Spleenectomy: Risk Factors, Prevention, Management and Outcomes  
A. Rottenstreich, G. Kleinstern, G. Spectre, N. Da'as, E. Ziv, Y. Kalish (Israel)

**PB 1863**  
Low and High Responders to Unfractionated Heparin Can Be Distinguished in Vitro by Inhibition of Thrombin Generation  
L.N. van der Vorm, H. de Haan, D. Huskens, J.A. Remijn, B. de Laat (the Netherlands)

**PB 1864**  
Should Anticoagulation Therapy for Cancer Associated Pulmonary Embolism (PE) Be Modified in Individuals with Brain Metastasis or Thrombocytopenia?  
K. Musgrave1, L. Stuart, J. Hanley, P. Kesteven, J. Simpson (United Kingdom)

**PB 1865**  
Comparison of the Injection Site Reactions Elicited by Two Subcutaneously Injected Heparins, Nadroparin Calcium and Enoxaparin Sodium  
J.J. van Tonder, S. Mathijs, J.M. Dippenaar, O. Greeff (South Africa)

**PB 1866**  
The Incidence of Adverse Events in Patients Treated with Therapeutic Dose Enoxaparin in Relation to Body Mass Index  
R.M.M. Al-Shehristani (Iraq)

**PB 1867**  
Management of Venous Thromboembolism in Patients with Gliona  
M. Almegren1, C. De Wit2, M. Carrier2 (1Saudi Arabia, 2Canada)

**PB 1868**  
Resistance of Liquid Anti-Xa Assay (IL) to Platelet Factor 4 Interference  
J. Gabbeta, V. Krougliak, C. Kung, R. Bottenus, M. Triscott (United States)

**PB 1869**  
A Matched Case-control Study to Determine Early Post-operative Haematological Complications after Renal Transplantation in Chronic Renal Failure Patients Receiving Therapeutic Anticoagulation  
E. Meeks, E. Thompson, P. Goldsmith, J. Sexton, S. Mehra (United Kingdom)

**PB 1870**  
Factors Associated with Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy  
A. Rottenstreich, Y. Kalish, G. Kleinstern, A. Ben Yaacov, J. Dux, A. Nissan (Israel)

**PB 1871**  
Clinical Course of Patients Presenting with Acute Superficial Vein Thrombosis: A Post-hoc Analysis of the ICARO Study on 488 Patients  
F. Dentali1, S. Barco2, F. Pomerio1, M.N.D. Di Minno1, G. Barilliari1, M.S. Napolitano1, W. Ageno1 (1Italy, 2Germeny)

**PB 1872**  
The Assessment of Safe Prescribing and Cost-effectiveness of Low Molecular Weight Heparin (LMWH) Treatment  
J.K. Chahal, C.Y. Zhang, V. Vakulenko, P.K. MacCallum, S. Antoniou (United Kingdom)

**PB 1873**  
Sustained Anticoagulant Effect and High Inter-individual Variability of Treatment with Rivaroxaban. An ex vivo Analysis of Thrombin Generation and Thromboelastometry  
S. Sallte, P. Van Dreden, E. Lefkou, H. Ketatni, A. Khaterchi, L. Papageorgiou, I. Elalamy, G. Gerotziafas (France)

**PB 1874**  
Comparison of UFH and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays  
G. Gerotziafas1, P. Van Dreden1, W. Jeske2, J. Walenga2, D. Hoppensteadt2, M. Grusse1, A. Larsen1, I. Elalamy1, Y. Yao1, J. Fareed2 (1France, 2United States)

**PB 1875**  
Efficacy and Safety of Pharmacological Thromboprophylactic Agents for the Prevention of Venous Thromboembolism after Major Abdominal Surgery: A Systematic Review and Meta-Analysis  
B. Al Rawahi1, G. Le Gal1, R. Auer2, M. Carrier2 (1Oman, 2Canada)
### POSTER SESSIONS

**PB 1876** Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications  

**PB 1877** Nuts and Bolts of Running a Pulmonary Embolism Response Team: Results from an Organizational Survey of the National PERT™ Consortium Members  
G. Barnes, J. Giri, D.M. Courtney, S. Naydenov, T. Wood, R. Rosovsky, K. Rosenfield, C. Kabrhel, National PERT Consortium Research Committee (United States)

**PB 1878** Long Term Anticoagulant Treatment Management in Patients with Portal Vein Thrombosis at High Bleeding Risk  
M. Napolitano, S. Mancuso, S. Raso, M.R. Lanza Cariccio, M.F. Mansueto, S. Siragusa (Italy)

**PB 1879** Antikoagulant Effects of New Vegetable Heparinoid  
M. Lyapina, M. Grigorjeva (Russian Federation)

**PB 1880** Establishing the Heparin Therapeutic Range Using aPTT and Anti-Xa Measurements for Monitoring Unfractionated Heparin Therapy  
A. Rashid, B. Moiz, N. Kazmi, B. Rizvi (Pakistan)

**PB 1881** Patients Are More Adherent to Treatment with LMWH Nadroparin than Enoxaparin for Cancer Related Venous Thromboembolism  
S. van der Wall1, F. Kokk1, P. den Exter1, D. Barrios1, R. Morillo1, S. Cannegieter2, D. Jimenez2, M. Huisman1 (1The Netherlands, 2Spain)

**PB 1882** Prevalence of FOXD1 Mutations in Primigravidae with Pregnancy Loss  
J.-C. Gris, E. Mercier, S. Bouvier, E. Cochery-Nouvellon, G. Lissalde-Lavigne (France)

**PB 1883** Prothrombin Fragment F1+2 (F1F2) in Pregnancy Is Associated with a History of Venous Thromboembolism (VTE) and Thrombophilia  
R.B. Zotz, R.E. Scharf, A. Gerhardt1 (Germany)

**PB 1884** Incidence and Risk Factors of Pregnancy-associated Venous Thromboembolism in Singhealth, a Major Healthcare Cluster in Singapore  
S.L. Jaya-Bodystyne, S.Y. Tan, C.K. Ng, T.C. Tan, L.K. Tan, J.C. Allen, Y. Yang, S.X.S. Tan, L.H. Lee (Singapore)

### POSTER SESSIONS

**PB 1886** The Features of Pregnancy Management in Paroxysmal Nocturnal Hemoglobinuria  
M. Vinogradova, A. Kulagin, T. Kirsanova, R. Smakov (Russian Federation)

**PB 1887** High Levels of Complement C3 Increases the Risk for Postnatal Venous Thrombosis  
A.E.A. Dahm, E.M. Jacobsen, A.F. Jacobsen, H. Skuterud Wik, P.M. Sandset (Norway)

**PB 1888** Risk of Venous Thromboembolism in Unsuccessful ART Cycles: An Italian Cohort Study  
M. Villani, D. Colaizzo, F. Cappucci, P. Totaro, G. Favuzzi, M. Margaglione, E. Grandone (Italy)

**PB 1889** Incidence and Risk Factors of Pregnancy-associated Venous Thromboembolism in Singhealth, a Major Healthcare Cluster in Singapore  
S.L. Jaya-Bodystyne, S.Y. Tan, C.K. Ng, T.C. Tan, L.K. Tan, J.C. Allen, Y. Yang, S.X.S. Tan, L.H. Lee (Singapore)
PB 1896 Management of Venous Thromboembolism in Women during Pregnancy and Puerperium (SAVE): A cross-sectional registry in Africa, Eurasia, Middle East and South Asia
J.-C. Gris, J. Aoun, SAVE Study Group (France)

PB 1897 Genetic Variants Associated with Thrombophilia and Gestational Complications in an Argentinian Cohort
G. de Larrañaga, F. Aranda, S. Udry, M. Moiana, A. Lucero, V. Lara, O. Latino, S. Perés (Argentina)

PB 1898 Risk Factors for Venous Thromboembolism and Pregnancy Outcomes in Women with Pelvic Vein Thrombosis during Pregnancy - A Retrospective Study from a Stockholm Cohort, Ranging from 2000 to 2014
R. Chaireti, S. Lundgren Hinnerdal, K. Bremme (Sweden)

PB 1899 Maternal Carriage of the Annexin A5 M2 Haplotype is Associated with a Higher Risk of Suffering from Gestational Vascular Complications
F. Aranda¹, S. Udry¹, S. Perés¹, L.C. Amshoff², N. Bogdanova², P. Wieacker², M. Moiana¹, J.O. Latino¹, G. de Larrañaga¹, A. Markoff² (¹Argentina, ²Germany)

PB 1900 Pregnancy-associated Hemolytic Uremic Syndrome as a Cause of Maternal Mortality
T. Kirsanova, M. Vinogradova (Russian Federation)

PB 1901 The Role of Acquired von Willebrand Syndrome in Bleeding during Pregnancy and Cesarean Section in Patients with Hereditary Connective Tissue Diseases (Marfan Syndrome, Ehlers-Danlos Syndrome, Hereditary Hemorrhagic Telangiectasia)
L. Radetskaya, A. Makatsariya, O. Kaplina (Russian Federation)

PB 1902 Impact of Blood Hypercoagulability on in vitro Fertilization Outcomes: A Prospective Longitudinal Observational Study
P. Van Dreden, E. Lefkou, E. Mathieu d’Argent, M. Grusse, M. Comtet, R. Sangare, H. Ketatni, A. Larsen, I. Elalamy, G. Gerotziafas (France)

PB 1903 Women with Homozygous AT Deficiency Type II Heparin Binding Site (HBS) Are at High Risk of Pregnancy Loss and Pregnancy Complications
J. Kraft, R. Sunder-Plßsmann, P. Quehenberger, G. Tews, M. Langer, I. Pabinger (Austria)

PB 1904 Use of Intravenous Immunoglobulin in the Antenatal Management of Haemolytic Disease of the Fetus and Newborn (HDFN): A Case Series from the East Midlands, United Kingdom
G. Swallow, B. Myers, J. Davis, A. Dillon, E. Millen, A. Mahendru (United Kingdom)
**POSTER SESSIONS**

**PB 1915**  
Management of Pregnancy in Cobalamin C Defect Causing Homocystinuria and Methylmalonic Aciduria  
E. Grandone, M. Villani, G. Vecchione, A. Leccese, R. Santacroce, P. Martinelli, G.M. Maruotti, L. Fischetti, G. Corso, M. Margaglione (Italy)

**PB 1916**  
Clinical Value of Antiphospholipid Antibodies Assessment in Women Undergoing IVF with History with IVF Failure  
D. Khizroeva, N. Stuleva, N. Makatsariya, N. Khamani (Russian Federation)

**PB 1917**  
Antiphospholipid Antibodies in Women with of Severe Preeclampsia  
D. Khizroeva, V. Bitsadze, N. Makatsariya (Russian Federation)

**PB 1918**  
The Clinical Significance of Determining the Activity and Inhibitor of Adams-13 in the Management of Pregnant Women with Severe Preeclampsia and Thrombotic Microangiopathy History  
A. Makatsariya, V. Bitsadze, D. Khizroeva (Russian Federation)

**PB 1919**  
Different Approaches of Thromboprophylaxis during Pregnancy in the Routine Clinical Practice. Results from the TEAM Project  
A. Santamaria, E. Marti, TEAM Project of the SETH (Spain)

**PB 1920**  
In the TEAM PROJECT, the Management of Placental-mediated Pregnancy Complication (PMC) Reflects a Real Gap between Evidence-based Guidelines and Routine Clinical Practice  
A. Santamaria, E. Marti, on behalf of the TEAM Porject form the SETH (Spain)

**PB 1921**  
Risk Assessment of Venous Thromboembolism in Women Furing Pregnancy and Puerperium (SAVE): A Cross-Sectional Registry in Africa, Eurasia, Middle East and South Asia  
J.-C. Grie, J. Aoun, SAVE study group (France)

**PB 1922**  
Evaluation of Venous Thrombo-embolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in Saudi Arabia (The Saudi Arabian Pregnancy Venous Thromboembolism Registry)  
S. Abu-Harbesh, H. Yousef, F. Al-Qahtani, M. Kolkaiah, The Saudi Arabian Pregnancy Venous Thromboembolism Registry (Saudi Arabia)

**PB 1923**  
Ischemic-stroke due to an Embolic Thrombus in Carotid Artery in Recent Postpartum: Case Report and Review of the Literature  
C. Bom, V. Barros, R. Francisco, M. Zugaib (Brazil)

**PB 1924**  
Hypodysfibrinogenemia: A Challenge in Maternity Ward - Course of Pregnancy and a Literature Review  
J.M. Teliga-Czajkowska, A. Sikorska, B. Cegłarek, K. Bykowska, B. Baran, E. Dmoch-Gajzlerska, K. Czajkowski (Poland)

**PB 1926**  
Perinatal Outcomes in Women with History of Ischemic Stroke  
A. Makatsariya, S. Akinshina, V. Bitsadze, D. Khizroeva, V. Nemirovski (Russian Federation)

**PB 1927**  
Pregnancy Complications in Women with Thrombophilia and their Future Pregnancy Outcome after Anti-coagulant Treatment  
N. Daily, G. Jries, Y. Zivony, B. Eshel, M. Kashlikov (Israel)

**PB 1928**  
What is the Actual Role of Antiphospholipid Antibodies in Obstetric Morbidity?  
L. Costa, R. Oliveira, N. Pinho, N. Seidi, F. Leite, E. Cruz, J. Braga, S. Morais (Portugal)

**PB 1929**  
Low Molecular Weight Heparin for Women with Pathologic Evidence of Placental Malperfusion  
A. Gomez-Arteaga, M.T. DeSancho (United States)

**PB 1930**  
Pregnancy and Perinatal Outcomes in Women with History of Venous Thromboembolism  
A. Makatsariya, S. Akinshina, V. Bitsadze, D. Khizroeva (Russian Federation)

**Hemorrhagic Disorders, Hemophilia**

**PB 1931**  
Intracranial Haemorrhage Associated with during the Course of Extracorporeal Membrane Oxygenation for Severe Respiratory Failure  

**PB 1932**  
Classic Pathways of Fibrinolytic Activation Are Secondary in Non-traumatic Hyperfibrinolysis  
J. Zipperle, S. Bahrami, H. Redl, H. Schönfeld (Austria)

**PB 1933**  
Soluble Fibrin Causes an Acquired Platelet GPVI-deficiency in Response to Convulxin, Collagen-related Peptide and Collagen: Implications for Trauma Induced Coagulopathy  
S. Diamond, M. Lee, B. Herbig (United States)

**PB 1934**  
Acquired Hemophilia A and Concomitant Factor XII Consumption: A Case Series  
J. Abdurehman, B.L. Houston, J.M. Teitel, M. Sholzberg (Canada)
**POSTER SESSIONS**

| PB 1935 | Von Willebrand Factor and ADAMTS13 in Bothrops jararaca Envenomation: Involvement of Snake Venom Metalloproteinases and Botrocitin C. Martos Thomazini, M. Larami Santoro (Brazil) |
| PB 1937 | Prediction of Outcome in Acquired Hemophilia A M. Escobar, E. Donnachie (United States) |
| PB 1938 | Severe Bleeding Diatheses in an Elderly Patient due to Autoantibody against Factor XIII A Subunit; Novel Approach to the Diagnosis and Classification of Anti-FXIII Antibodies M. Kun1, N. Szuber2, É. Katona1, K. Pénzes1, A. Bonnefoy2, B. Bécsi1, F. Erdödi1, G.-E. Rivard2, L. Muszbek1 (1Hungary, 2Canada) |
| PB 1939 | Usefulness of Anti-factor VIII IgG Antibodies Detection by ELISA in the Management of Patient with Acquired Hemophilia A L. Maugé, I. Bozinovic, D. Helley, D.M. Smadja, M. Ahenc-Gelas, L. Darnige (France) |
| PB 1941 | Acquired von Willebrand Syndrome in Infants with Aortopulmonary Shunt G. Wiegand, V. Ichcka, U. Budde, M. Hofbeck (Germany) |
| PB 1943 | Successful Inhibitor Eradication with Ofatumumab in a Patient with Acquired Hemophilia A R. Fischer, M. Alrifai, K. Heidinger, B. Kemkes-Matthes (Germany) |
| PB 1944 | Individualization of Treatment with Recombinant Porcine FVIII (rpFVIII) Depending on Inhibitor Titres in a Patient with Acquired Hemophilia A (AHA) M. Stemberger, M. Spannagl, M. Angstwurm (Germany) |
| PB 1946 | Thrombin Generation in Healthy Controls and Patients with Cirrhosis of the Liver: Comparison between Platelet-rich and Platelet-poor Plasma T. Siegemund, S. Rabe, R. Siegemund, S. Petros (Germany) |

**POSTER SESSIONS**

| PB 1947 | Acquired von Willebrand Syndrome (AVWS): Diagnostic and Treatment, a Single Centre Experience J. Costa Pinto Prego de Farig, M.D.C. Gómez del Castillo Solano, M. Fernández Docampo, A. Pérez Rodríguez, M.F. López Fernández (Spain) |
| PB 1948 | Heparin-Like Substance in Patients with Dengue Infection and Prolonged Activated Partial Thromboplastin Time Y. Chinthammit, N. Tirachaimongkol, T. Ruchutrakool, B. Suwannawiboon, T. Akarawirat, C. Washirasaksiri, Y. Nakkinkun, T. Binhamma, S. Sonprasert (Thailand) |
| PB 1950 | Two Patient Cases of Acquired Hemophilia Treated with Recombinant Porcine Sequence FVIII (rpFVIII, OBIZUR®) E. Armstrong, E. Poikonen (Finland) |
| PB 1951 | Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy: Importance of Hemostasis Screening in the Preoperative Management of Three Case Studies M. Kurdi, K. Maloum, C. Settegrana, H. Rouatbi, A. Ankri, I. Martin-Toutain (France) |
| PB 1952 | Study of Clinical Characteristics, Laboratory Findings and Response to the Treatment ofPatient with Acquired Hemophilia in National Institute of Hematology and Blood Transfusion of Vietnam T.M. Nguyen (Viet Nam) |
| PB 1953 | Acquired Hemophilia A in China: A Result of a Multicenter, Prospective Study in China B. Sun (China) |
| PB 1954 | Clinical Importance of Vascular Wall Antithrombotic Activity Disorder Detection in the Course of Hormonal Replacement Therapy (HRT) and its Pharmacological Correction S. Ermoshina, N. Khamani, V. Bitsadze (Russian Federation) |
| PB 1955 | Some Haemostatic Parameters and International Normalized Ratio (INR) Values of Patients with Snakebite Envenomation Before, During and After Treatment with Antivenom Snakebite Research, Training and Treatment Centre, General Hospital, Kaltungo, Gombe State, North-Eastern Nigeria R.A. Anyanwu, N. Mohammed (Nigeria) |
## POSTER SESSIONS

| PB 1961 | Acquired Haemophilia: Overcoming Practical Challenges to Deliver Optimal Nursing Care | D. Pollard, J. Stanley, C. Harrison, K. Couatts, A. Jones, C. Forrester, S. Johns, E. Warner (United Kingdom) |
| PB 1962 | Pulmonary Thromboembolism due to Lead Poisoning in Opium Addict Patients | B. Shakerian, N. Razavi (Iran, Islamic Republic of) |
| PB 1966 | IPS Derived Vascular Endothelial Cells (vECs) from HA-patients with Nonsense Mutations Are a Potential Cell-model to Study the MHC-driven Risk for Inhibitor Development | H. Singer, N. Nüsgen, J. Müller, J. Oldenburg, O. El-Maarri (Germany) |
| PB 1968 | Stoichiometry of Immunodominant Factor VIII Immune Complexes | P. Lollar, E.T. Parker, C.B. Doering (United States) |
| PB 1969 | Analysis of WVF-FVIII Interaction in Natural pdFVIII/VWF Complex Compared with rFVIII+VWF Complex through a Novel Flow Cytometry Technique | M.I. Bravo, A.M. Ortiz, M. Costa, S. Granha, J.I. Jorquera (Spain) |
| PB 1971 | 40 kDa PEG of N9-GP is Eliminated from Tissues and Will Reach Steady State after Chronic Dosing | I. Bjoernsdottir, O. Sternebring, H. Jacobsen (1Denmark, 2Switzerland) |
| PB 1972 | Spectrum of F8 Gene Mutations with FVIII Assay Discrepancies in an Irish Patient Cohort with Mild/Moderate Haemophilia A | C. Keenan, R. Campbell, M. Doyle, M. Byrne, K. Ryan, J. O'Donnell, B. White, N. O'Connell (Ireland) |
| PB 1973 | Identification of High-molecular Weight Species in Commercial Recombinant Factor VIII Products | J.F. Healey, E.T. Parker, P. Lollar (United States) |
| PB 1974 | Pharmacokinetics (PK) of N8-GP (Turoctocog Alfa Pegol) Dosed Subcutaneously (SC) to Non-human Primates (NHPs) and Prediction of Human PK Profile | F. Rode, M. Loftager, D.M. Karpf, J.H. Faber, A.V. Groth, J. Haaning (Denmark) |
PB 1976  Clinical Trials and Registries in Rare Diseases: Opponents or Collaborators?  
C. Keiper1, C.J. Jonker2, H.M. van den Berg3, A. Hilger1 (1Germany, 2The Netherlands)

PB 1977  In Haemophilic Patients, Individual Factor VIII or IX Level for the Correction of Thrombin Generation Is Predictable  
B. Tardy-Poncet, P. Chelle, A. Montmartin, M. Piot, M. Courin, C. Morin (France)

PB 1978  Factor 8 Assay Discrepancy in a United States Non-severe Hemophilia A Cohort  
H.C. Okoye1, B.I. Nielsen2, K. Lee2, N.S. Key2, M.A. Rollins-Raval2 (1Nigeria, 2United States)

PB 1979  Aberrant Inflammatory Cytokines, Skew T Helper Cells and Decreased Regulatory T Cell Numbers in Hemophilia A Patients with FVIII Inhibitor  
D. Zhang, F. Xue, R. Yang (China)

PB 1980  Hemophilia A and the Role of Factor VIII in Balancing Pro- and Anticoagulant Processes  
V.J.F. Strijbis, R.M.W. Kremers, I. van Moort, D. Huskens, S. Bloemen, H. Kelchtermans, M. de Maat, B. de Laat (the Netherlands)

PB 1981  Towards a Methylation Based Detection of F8 Rearrangements  
O. El-Maarri, A. Sharma, A. Jamil, N. Nüsgen, B. Pezeshkpoor, A. Pavlova, J. Oldenburg (Germany)

PB 1982  The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors  
T. Livnat1, A. Sehgal2, K. Qian2, H.V. Nguyen2, B. Sorensen2, G. Kenet1 (1Israel, 2United States)

PB 1983  Plasma Steady State PEG Concentrations Are Reached in Patients after Once Weekly Prophylactic Treatment with N9-GR  
O. Sternebring1, A. Benie1, B.O. Petersen1, M. Panduro1, H. Jacobson1, J. Sims2 (1United States, 2Denmark)

PB 1984  Thrombin Generation Assay as Additional Tool in Diagnosis of Mild/Moderate Haemophilia A Patients with Discrepancies in FVIII Activity Assays  
B. Baran, E. Stefanska-Windyg, A. Buczma, E. Odnoczko, J. Windyg (Poland)

PB 1985  Burden of Comorbidities in Persons Living with Haemophilia: Insight from the PROBE Phase 2b Study Database  
M. Skinner1, M. Cachi-Adisaksohpe2, R. Curtis1, N. Frick1, M. Nichol1, D. Noone3, B. O'Mahony3, D. Page4, J. Stonebraker1, A. Iorio4 (1United States, 2Canada, 3Ireland)
PB 1995

Importance of the ADP-dependent Amplification Pathway in Platelet Activation is Influenced by CatDAG-GEF1 Expression Level
G. Florence1, M. Poggi2, A. Henneuse1, D. Ghalloussi1, R. Piatt1, J.-C. Gris1, S. Claeyssens1, P.E. Morange1, P. Norden1, A.T. Norden1, W. Bergmeier2, M.-C. Alessi1, M. Canault1 (1France, 2United States)

PB 1996

Association of Homozygous PAI-1 Deficiency with Cardiac Fibrosis in Humans

PB 1997

Molecular, Diagnostic and Clinical Features of 216 Patients from 46 Unrelated Families with FXI Deficiency Caused by Different Recurrent and Sporadic Mutations. Data from A 60000 Inhabitants Spanish Town

PB 1998

The International Society on Thrombosis and Haemostasis - Bleeding Assessment Tool (ISTH-BAT) and the Risk of Future Bleeding
M.R. Fasulo1, E. Biguzzi1, M. Abbattista1, F. Stufano1, M.T. Pagliari1, I. Mancini1, M. Gorski1, A. Cannavò1, M. Corgiolu1, F. Peyvandi1, F.R. Rosendaal2 (1Italy, 2Netherlands Antilles)

PB 1999

Efficacy and Safety of a New Fibrinogen Concentrate for the Treatment of Bleeding Episodes and Prevention of Excessive Bleeding during Surgery in Children with Congenital Fibrinogen Deficiency
C. Djambas Khayat1, M. El Khorassani1, S. Aytaç1, D. Lahm1, S. Pujol1, C. Henriët1, F. Bridey1, C. Berbenni1, P. Simioni1 (1France, 2Lebanon, 3Morocco, 4Turkey, 4France)

PB 2000

In Vitro Study of a New Plasma-derived Factor V (FV) Concentrate: Dose-response Evaluation in Plasma from Patients with Congenital FV Deficiency
P. Simioni, C. Novembrino, C. Bulato, M. Boscolo Anzoletti, G. Tagariello, S. Gavasso, C. Berbenni, L. Spiezia, E. Campello, F. Peyvandi (Italy)

PB 2001

Multi-platform Characterization and Application of a Bleeding Assessment Tool in a Cohort of Patients with Factor XIII Deficiency
A. Abraham1, H.F. Margaret1, T. Geevar, S. Singh1, R. V. J. Mammen, S.C. Nair (India)

PB 2002

New Bleeding Disorder with Enhanced Fibrinolysis due to Lysinuric Protein Intolerance and Renal Failure
H. Pilkama, M. Kärki, L. Tanner, K. Näntö-Salonen, H. Niinikoski, R. Lassila (Finland)

PB 2003

Mutation Profile of Factor X Deficiency
A. Pavlova1, B. Bezeshkpoor, U. Scholz, B. Zieger, J. Oldenburg (Germany)
POSTER SESSIONS

PB 2013 Bernard-soulier Syndrome in Pakistan: Biochemical and Molecular Analysis Leading to Identification of a Novel Mutation
D. Böckelmann1, M.Y. Jamal2, E. Lerner1, A. Naz2, B. Zieger1 (1Germany, 2Pakistan)

PB 2014 Genotypic Abnormalities in Phenotypic Confirmed Patients with Rare Bleeding Disorders
W. van Heerde, A. Simons, S. Krouwel, S. Schoormans, M.R. Nijziel (The Netherlands)

PB 2015 Evaluation of the Use of Bleeding Assessment Tools in FXI Deficiency
G. Gidley, A. Cumming, J. Thachil, C. Hay, M. Sutherland, S. Keeney, B. Sempasa, P. Bolton-Maggs, J. Burthem (United Kingdom)

PB 2016 Clinical Presentation and Management of Glanzmann’s Thrombasthenia: A Case Study
I. Sasmaz, B. Antmen, B. Karagun, G. Leblebisatan, Y. Kilinc (Turkey)

PB 2017 Prevalence of Menorrhagia in Women Diagnosed with Congenital Bleeding Disorders
M. Borhany, N. Fatima, M. Abid, T. Shamsi (Pakistan)

PB 2018 Thrombotic Complications in a Patient with Congenital Afibrinogenemia
S. Vakalopoulou, A. Papagianni, M. Stagou, P. Kotsi, G. Vasilieia (Greece)

PB 2019 Identification of Novel and Recurrent Mutations in F13B Gene Causing Mild FXIII Deficiency
V. Ivaskevicius, A. Biswas, S. Singh, A. Pavlova, J. Oldenburg (Germany)

PB 2020 Bleeding Score as a Diagnostic Tool in Patients of Autosomal Recessive Inherited Bleeding Disorders
A. Naz, N. Ahmed, S. Tariq, S. Amanat, F. Raziq, T.S. Shamsi (Pakistan)

PB 2021 Acute Coronary Syndrome in a Patient with Factor V Deficiency: A Case Report
S. Anzej Doma, D. Andoljsek, I. Preloznik Zupan (Slovenia)

PB 2022 Congenital Hypoprothrombinemia Presenting in the Neonatal Period: Report of 2 Cases in South of Iran
M. Bordbar, M. Aali, K. Kamali (Iran, Islamic Republic of)

PB 2023 Rare Bleeding Disorders in the Netherlands (RBIN)

PB 2024 Factor VII Deficiency: One Novel Mutation and Genotype-phenotype Correlation in Patients from Southern Italy
G. Tiscia, G. Fava, E. Chinni, D. Colaizzo, L. Fischetti, M. Intri, G. Margaglione, E. Grandone (Italy)

PB 2025 Spotting of Two Novel Mutations in FGG Gene: In Unrelated Patients of Congenital Afibrinogenemia in Pakistan
T. Khan1, A. Naz1, A. Biswas2, A. Goodeve3, N. Ahmed1, S. Ahmed1, T. Shamsi1, J. Oldenburg2 (1Pakistan, 2Germany, 3United Kingdom)

PB 2026 Identification of Two Novel F5 Compound Heterozygous Mutations in Two Norwegian Patients with Severe Factor V Deficiency

PB 2027 Retrospective Evaluation of Phenotype and Management of A-hypo- fibrinogenemia in a Cohort of Italian Patients
C. Santoro, F. Massaro, E. Baldacci, G. Ferrara, A. Ferretti, R. Santoro, S. Pasca, G. Castaman, F. Peyvandi, M.G. Mazzucchoni (Italy)

PB 2028 Factor X Deficiency Followed by a Tertiary Pediatric Hematology Center

PB 2029 Correlation of Hemorrhagic Complications with Novel Mutations in FGA And FGG: In Punjabi Congenital Afibrinogenemia Patients
T. Khan, A. Naz, A. Imran, T. Shamsi (Pakistan)

PB 2030 Treatment of a Rare Case of Congenital A/Hypo Dysfibrinogenemia with Fibrinogen Concentrates: Comparison between Fibrinogen Levels and ROTEM® Parameters
H.A. Guslielmone, F. Gonzalez, B. Rossi, S. Marun (Argentina)

PB 2031 A New Autosomal Dominant Inherited FVIII Defect: Evidence of a Novel Genetic Determinant of Circulating FVIII Levels
V. Daidone, E. Galletta, A. Casonato (Italy)

PB 2032 Rare Bleeding Disorders: Snapshot from a Tertiary Care Hospital of Pakistan
A. Rashid, A.M. Memon (Pakistan)

PB 2033 Severe Congenital Factor VII Deficiency in Northern Region of Turkey
D. Albayrak, C. Albayrak (Turkey)

PB 2034 Evaluation of Rare Factor Deficiencies in Presurgical Plasma Samples
Z. Kaya, Ç. Özütok (Turkey)

PB 2035 Spotting of Two Novel Mutations in FGG Gene: In Unrelated Patients of Congenital Afibrinogenemia in Pakistan
T. Khan1, A. Naz1, A. Biswas2, A. Goodeve3, N. Ahmed1, S. Ahmed1, T. Shamsi1, J. Oldenburg2 (1Pakistan, 2Germany, 3United Kingdom)

PB 2036 Factor VII Deficiency: One Novel Mutation and Genotype-phenotype Correlation in Patients from Southern Italy
G. Tiscia, G. Fava, E. Chinni, D. Colaizzo, L. Fischetti, M. Intri, G. Margaglione, E. Grandone (Italy)
## POSTER SESSIONS

**PB 2037** Successful Delivery in an Afibrinogenemia Patient after Three Abortions: A Case Report and Review of Literature
M. Karimi, M. Bordbar, M. Aali, A. Bazarfashan, H. Tavoosi, J. Gerdabi (Iran, Islamic Republic of)

**PB 2038** Are Screening Coagulation Tests Useful to Predict the Clinical Phenotype in Patients with A/Hypo/Dysfibrinogenemia? A Single Institution Experience
H.A. Guigliaimone, S. Minoldo, M.A. Alvarez Boilea, G.D. Jarchum (Argentina)

**PB 2039** Congenital Afibrinogenemia Case Presenting with Surrenal Bleeding and Cervical Hematoma
H. Kızılocak, N. Özdemir, Z. Şalcıoğlu, B. Koç, E.P. Uysalol, C. Bayram, G. Dikme, T. Celkan (Turkey)

**PB 2040** Severe Congenital Factor X Deficiency in the Northern Region of Turkey: Successful Prophylaxis with Activated Prothrombin Complex Concentrates
C. Albayrak, D. Albayrak (Turkey)

**PB 2041** Pseudoaxanthoma Elasticum-like Disease with Deficiency of Vitamin K-dependent Clotting Factors, Hypofibrinogenemia and Cutis Laxa Features: A Case Report
K. Taouli Allal, M. Hanini, O. Boudghene Stambouli, S. Bouali, I. Gaouar (Algeria)

**PB 2042** Rare Inherited Coagulation Disorder (RICD) in Females - Data from a Developing Country
S. Hussain, S. Baloch, A. Gaffar, A. Najmuiddin, S. Aqeel, F. Musheer, S. Nawaz (Pakistan)

**PB 2043** Congenital Factor V Deficiency
E. Yakovleva, N. Konyashina, L. Gorgidze, O. Polevodova, E. Likhacheva, M. Kumskova, N. Zouzua (Russian Federation)

**PB 2044** Von Willebrand Factor Deficiency Reduces Experimental Liver Fibrosis in Mice
J. Luyendyk1, N. Joshi1, A. Kopec1, J. Ray1, H. Cline-Fedewa1, D. Groeneveld2, T. Lisman2 (1United States, 2The Netherlands)

**PB 2045** Genotypical Classification of Patients with von Willebrand Disease
W. van Heerde, A. Simons, S. Krouwel, S. Schoormans, B. Laros, P. Brons, M.R. Nijziel (The Netherlands)

**PB 2046** Common VWF Sequence Variants Associated with Higher VWF and FVIII Are Less Frequent in Subjects Diagnosed with Type 1 VWD
V. Flood, J. Johnsen, P. Christopherson, S. Haberichter, R. Udani, D. Bellissimo, K. Friedman, R. Montgomery (United States)

---

**POSTER SESSIONS**

**PB 2047** Interactomics of the Weibel-palade Body Exocytotic Machinery
M. Schillemans, M. Wahedi, D. van Breevoort, M. van den Biggelaar, J. Voorberg, R. Biering (The Netherlands)

**PB 2048** Structural Thermodynamics of a Clinically Elusive High-affinity von Willebrand Factor Binding to Platelet GPIba
A. Tischer1, V. Machha1, J. Frontoth2, M. Brehm3, T. Obser3, R. Scheppenheim2, L. Mayne1, S.W. Englander1, M. Auton1 (1United States, 2Argentina, 3Germany)

**PB 2049** Pro-angiogenic Signal in Plasma of Left Ventricular Assist Device Patients
A. Sharma, Y. Wang, D. Mukhopadhyay, R. Safford, J. Blackshear (United States)

**PB 2050** Characterisation of Q1541R, a Novel von Willebrand Factor Variant Causing Type 2A von Willebrand Disease - ADAMTS13 Cleavage of Type 2A Variants under Shear Stress
T. McKinnon1, V. Jenkins1, F. Zhang2, M. Laffan1, J. O’Donnell2 (1United Kingdom, 2United States, 3Ireland)

**PB 2052** FVIIIa Mimicking Bispecific Antibody (Emicizumab) Improved Thrombus Formation of Type 2N von Willebrand Disease (VWD) under Both High and Low Shear Conditions
H. Yaoi, Y. Shida, T. Kitazawa, K. Hattori, M. Shima, K. Nogami (Japan)

**PB 2053** Perioperative Management of von Willebrand Patients with Desmopressin; Towards a Predictive Population PK Model

**PB 2054** In-Frame Heterozygous Large Deletion in von Willebrand Factor (VWF) Gene in a Patient with Severe Bleeding Manifestations Might Accelerate VWF Clearance
H. Yadegari1, N.M. Marquardt1, V. Ivannevicius1, O. Rawley2, L. Siwstun2, D. Lillicrap1, J. Oldenburg1 (1Germany, 2Canada)

**PB 2055** Acquired von Willebrand Disease in Patients with Extracorporal Membrane Oxygenation: The VWF:GPIbM/VWF:Ag Ratio is a Sensitive Diagnostic Tool
S. Flommersfeld, K. Dielmann, T. Vassiliou, U.J. Sachs (Germany)

**PB 2056** Different Modes of Association between Protein Disulfide Isomerase PDIa1 and VWF in von Willebrand Disease
M.A. Brehm, S. Vollmers, G. König, T. Obser, R. Scheppenheim (Germany)
POSTER SESSIONS

PB 2057  Mutational Screening of a Type III VWD Cohort from Cohort Reveals 19 Novel Mutations in the VWF Gene
S. Ahmed1, A. Biswas2, A. Naz1, H. Yadegari1, N. Ahmed1, N. Saqlain1, A. Imran1, F. Raziq1, T.S. Shamsi1, J. Oldenburg1 (1Pakistan, 2Germany)

PB 2058  Effect of Elongational Flow on von Willebrand Factor Cleavage by ADAMTS13
M. Bortot1, D. Bark1, K. Keeves1, K. Leiderman1, A. Fogelson1, S. Aguila Martinez2, C. Ng1, J. Di Paola1 (1United States, 2Ireland)

PB 2059  Wound Healing is Not Delayed in Mice with Reduced von Willebrand Factor in Spite of the Presence of a Severe Bleeding Tendency
M. Hoffman, K. Gorman, G. Pitoc, B. Sullenger, D. Monroe (United States)

PB 2060  Variability in von Willebrand Factor Parameters in Blood Outgrowth Endothelial Cells from Healthy Controls
A. de Jong1, E.M. Weijers1, R.J. Dirven1, M.J. Streur1, J. Eikenboom1 (The Netherlands)

PB 2061  A Cell-based Assay to Quantify αIIbβ3 Integrin Binding of von Willebrand Factor Mutants
G. König1, T. Obser1, S. Schneppenheim1, M. Brehm1 (Germany)

PB 2062  Heterozygous Splicing Mutations Associated with Severe Type 1 von Willebrand Disease
G. Castaman1, A. Coppola1, A. Volta1, A. Kura1, S. Linari1, L. Pieri1, F. Demartis1, B. Giusti1 (Italy)

PB 2063  Single Centre Audit of Laboratory Testing in Sub-classification of Type 2 von Willebrand Disease
R. Kohli1, P. Batty1, S. Platon1, K.J. Pasi1, L. Bowles1 (United Kingdom)

PB 2064  Von Willebrand Factor Testing through the Ages: A Review of Recent Results from the ‘Royal College of Pathologists of Australasia Quality Assurance Program’
R. Bonar1, E. Favaloro1 (Australia)

PB 2065  Comparing Platelet-dependent von Willebrand Factor Activity Assays in 661 Patients with von Willebrand Disease - from the WiN Study
J. Boender1, J. Eikenboom1, J. van der Bom1, K. Meijer1, J. de Meris1, K. Fijnvandraat1, M.H. Crossen1, B. Baro-van Gorkom1, E. Mauser-Bunschoten1, M.P.M. de Maat1, F.W.G. Leebeek1, WiN Study Group1 (The Netherlands)

PB 2066  Occurrence of Subclinical and Late Arthropathy in Patients with von Willebrand Disease
G. Castaman1, S. Linari1, F. Demartis1, L. Pieri1, C. Martinoli1 (Italy)

POSTER SESSIONS

PB 2067  The Effect of Thioredoxin-1 on von Willebrand Factor Function
V. Ruiz De Miguel1, M. Laffan1, T. McKinnon1 (United Kingdom)

PB 2068  The Prevalence of Bleeding Disorders in Women with Histologically Proven Endometriosis
S. Heynemann1, R. Dauer1, C. Barnes2, S. Grover3 (Australia)

A. Lemaître1, G. Nouradje1, H. Bautista1, S. Eeckhoudt1 (1Belgium, 2France)

PB 2070  Comparison of Three Different Factor VIII Assays in 154 Patients with Type 3 von Willebrand Disease: Results from the 3WINTERS-IPS Cohort
J. Goudemand1, C. Caron1, E. Jeanpierre1, Z. Badiee2, M.-R. Baghaipour2, L. Baronciani2, J. Battle3, E. Berntorp4, P. Batty1, G. Castaman3, J. Eikenboom3, P. Eshghi1, C. Hay1, H. Hoorfar1, M. Karimi2, B. Keikhaei1, R. Lassila1, F. Leebeek1, M.F. Lopez Fernandez1, P.M. Mannucci1, M.G. Mazzucconi1, M. Morfini2, J. Oldenburg1, R. Parra López1, I. Peake1, F. Peyvandi1, R. Schneppenheim1, A. Tiede1, G. Toogeh1, A. Tosetto1, J. Trossaert1, S.O.R. Zekavat1, E. Zetterberg1, A. Federici2 (1France, 2Iran, 3Italy, 4Spain, 5Sweden, 6Hungary, 7Germany, 8The Netherlands, 9United Kingdom, 10Finland)

PB 2071  Treatment of Gastrointestinal Bleeding Episodes with Recombinant von Willebrand Factor (rVWF) in Patients with Severe von Willebrand Disease (VWD): Sub-analysis from Pivotal Phase III On-demand Study
F. Leebeek1, M. Chapman2, B. Ploder2, A. Sytkowski2, A. Goodeve2, M.H. Cnossen2, B. Laros-van Gorkom2, E. Mauser-Bunschoten2, F.W.G. Leebeek2, WiN Study Group2 (The Netherlands)

PB 2072  Type of Renal Replacement Therapy, Access and von Willebrand Factor (VWF) Function
J. Blakemore1, D. Chen1, R. Safford1, N. Aslam1 (United States)

PB 2073  Trends in Severity of Acquired von Willebrand Syndrome with Lower Rotational Speed Left Ventricular Assist Device
J. Blackshear1, S. Schettle1, D. Joyce1, D. Chen1 (United States)

PB 2074  Prevalence of von Willebrand Disease among Saudi Students: from Saudi Screening Program for Bleeding Disorders (SSBD)
T. Owaidah1, E. Abu-Douleh1, A. Abdul Albanyan1, H. Al Zahrani1, M. Saleh1, A. Almomen1, K. Alsaleh1 (Saudi Arabia)

PB 2075  Retrospective Single Centre Study of On-demand and Treatment Prophylaxis in 24 Patients with Type 3 von Willebrand Disease
M. Hendelmeier1, V. Hornick1, D. Wirtz1, N. Marquardt1, H.-H. Brackmann1, G. Goldmann1, J. Oldenburg1 (Germany)
PB 2076 Molecular Caracterization of Type 2 von Willebrand Disease
S. Freitas, D.C. Gonçalves, C. Velloso-Rodrigues, A.N.L. Pezotti, M.S. Renni, S.M. Rezende (Brazil)

PB 2077 Validation of a Rapid Diagnostic Approach with Automatic Tests in a Cohort of Chinese Patients with von Willebrand Disease: Results from the Chinese-Italian CReWiAct Study
Z. Yu1, J. Yin1, W. Zhang1, Z. Wang1, Z. Ma1, X. Bai1, C. Ruan1, C. Bianchi2, D. Intini2, A. Lattuada2, A.B. Federici2 (1China, 2Italy)

PB 2078 The Self-association of Ristocetin
P. Lollar, W. Deng (United States)

PB 2079 VWD2M Genotype Carrying Double Heterozygous Mutations with More Severe Phenotype than Classic VWD2M
A.I. Woods, J. Paiva, A.C. Kempfer, A. Blanco, A. Sanchez Luceros, M.A. Lazzari (Argentina)

PB 2080 The Occurrence of Prothrombotic Mutations in a Patient with von Willebrand Disease and Symptomatic Bleeding Disorder
A. Sikorska, J.M. Teliga-Czajkowska, B. Ceglarek, K. Bykowska, B. Baran, J. Windyga (Poland)

PB 2081 Von Willebrand Factor (VWF) Propeptide (VWFpp) and VWFpp to VWF Antigen (VWF:Ag) Ratio in Assessment of Inherited (VWD) and Acquired (AVWS) von Willebrand Disease

PB 2082 Extensive Bilateral Mandibular Pseudotumor in a Boy with Type 3 von Willebrand Disease (VWD) Treated with Plasma Derived VW/Factor VIII Concentrate (FC): Diagnosis, Treatment and Outcome
J.P. Frontroth, G. Sciuccati, M. Hepner, L. Galluzzo, C. Pepe, S.E. Annetta, G. Pieroni, M. Bonduel (Argentina)

PB 2083 Laboratory Identification of von Willebrand Disease: A Contemporary Approach
E.J. Favaloro, S. Mohammed, S. Oliver, K.K.E. Lau, L. Pasalic (Australia)

PB 2084 Importance of Classification and Genetic Tests in the Diagnosis of von Willebrand Disease Type 2B and 2N
POSTER SESSIONS

PB 2095  The Detection of Cross-reactive Antibodies to Recombinant Porcine FVIII  
A.E. Bowyer, M.F. Shepherd, S. Kitchen, M. Makris (United Kingdom)

PB 2096  Mixing Test to Discriminate between Lupus Anticoagulant and Direct Oral Anticoagulant in Diluted Russell's Viper Venom Time Test  
O. Kuman, Y. Komiyama (Japan)

PB 2097  Assessment of Three Contact Activation Reagents for the Diagnosis of Factor XI Deficiency  
S. Salloum-Asfar, M.E. de la Morena-Barrio, J. Esteban, A. Miñano, C. Aroca, J. Padilla, V. Vicente, V. Roldán, J. Corral (Spain)

PB 2098  Platelet Reactivity in a Large Population with the Bruneck Cohort  
M.V. Chan\textsuperscript{1}, T. Barwari\textsuperscript{1}, J.E. Huffman\textsuperscript{2}, P.C. Armstrong\textsuperscript{2}, L. Chan\textsuperscript{1}, A.A. Oliveira, P.S. Elídio, H.J. Aguiari, A.A.L. Sambo, M.M.T. Hosokawa, M.C. Della-Piazza, C.S. Costa-Lima, S.S. Medina, M.C. Ozelo (Brazil)

PB 2099  Comparison of Age-adjusted D-dimer and Clinical Probability-adjusted D-dimer for Diagnosing Pulmonary Embolism  
S. Sharif, C. Kearon, M. Li, M. Eventov, R. Jiang, P. Sneath, R. Leung, K. de Wit (Canada)

PB 2100  The Screening aPTT Mixing Test Is Not Sufficient to Rule Out the Presence of Inhibitor  

PB 2101  Quantitation of Dabigatran by Global and Specific Coagulation Assays  
J. Lozier, K. Nghiem, O. Bätz, M. Haddad, C. Huisman, G. Kooijman, E. Knoch, J. Van de Velde, Y. Henskens, K. Devreese (The Netherlands)

PB 2102  The Influence of the Statistical Approach on Cut-off Values of IgG/IgM Anticardiolipin and Anti-β2 Glycoprotein I Antibodies in Classification of Antiphospholipid Syndrome  
L. Vanoverschelde\textsuperscript{1}, H. Kelchtermans\textsuperscript{2}, J. Musial\textsuperscript{3}, B. de Laat\textsuperscript{2}, K. Devreese\textsuperscript{1}  
\textsuperscript{1}{\textsuperscript{1}}Germany, \textsuperscript{1}The Netherlands, \textsuperscript{2}Poland

PB 2103  The Reference Interval Mean clotting Times Should Not Be Used to Calculate Lupus Anticoagulant Mixing Test Ratios Unless They Match the Normal Pooled Plasma Clotting Time  
G.W. Moore, J.C. Maloney, N. de Jager, C. Dunsmore, D.K. Gorman, R.F. Polgaren (United Kingdom)

PB 2104  Lupus Anticoagulant-hypoprothrombinemia Syndrome (LAHPS): Report of 4 Cases  

PB 2105  Fibrinogen Prothrombin Time Derived Method Is Not Useful in Anticoagulated Patients by LMWH or Rivaroxaban  

PB 2106  Development of Novel Assays for Factor VIII Potency Determination  
M. Kusch, S. Rosenkranz, A. Schrada, C. Grundmann, S. Keitel, A. Hunfeld, R. Seltz, G.J.K. Praefcke (Germany)

PB 2107  Evaluation of Automated Chromogenic Assays for the Diagnosis and Monitoring of Haemophilic Patients  
C. Novembrino, M. Boscolo Anzoletti, E. Biguzzi, M.R. Fasulo, F. Peyvandi (Italy)

PB 2108  Evaluation of Utility of ISTH Scoring System and its Modifications in Diagnosis of Disseminated Intravascular Coagulation in a Tertiary Care Centre in Southern India  
P.S. Muddana, R. Kar, S.S. Kar (India)

PB 2109  Method Comparison of the Atellica COAG 360 System* with Sysmex CS-2000i System and BCS XP System  
E. Knocht, O. Bätz, C. Haas, M. Haddad, Y. Henskens, T. Renné (The Netherlands)

PB 2110  Evaluation of an Automated Chemiluminescent Assay and two ELISAs for Detection of Heparin Induced IgG Antibodies in the Diagnosis of Heparin Induced Thrombocytopenia (HIT)  
L. De Cooman, K. Devreese (Belgium)

PB 2111  The Influence of a High Fat Meal, Smoking, Coffee, Exercise and Sample Storage on Light Transmission and Impedance Aggregometry in Healthy Volunteers  
Y. Henskens, J. Krekels, D. van den Kerkhof, R. Wetzes, P. Verhezen (The Netherlands)
POSTER SESSIONS

PB 2114  Automated Data Management for Thrombin Generation
K.G. Guria, H. Elsinga, P.W. Hemker, H.C. Hemker (The Netherlands)

PB 2115  The Laboratory Control of Anticoagulant Thromboprophylaxis during Early Postpartum Period after the Caesarean Delivery

PB 2116  Forty Years of Riddle Solving to Decipher Puzzling Test Results in the Coagulation Laboratory
A. Zivelin (Israel)

PB 2117  “Function over Form”? Low Dose V/Q SPECT is Superior to Planar V/Q and Has a Diagnostic Yield Approaching that of CTPA in the Diagnosis of Acute Pulmonary Thromboembolic Disease
L. Stephens, I. Niematailah, M. Memmott, R. Sajjan, J. Thachil, S. Muthu (United Kingdom)

PB 2118  Point-of-care INR with CoaguChek XS Pro is comparable to laboratory INR in a hospital setting
A.K. Stroobants, B.S. van der Veen, A. Sturk (The Netherlands)

PB 2119  Evaluation of Assay Performance Monitoring Edoxaban Plasma Concentration with Technoview® Edoxaban and Technochrom® Anti-Xa
S. Geiter, M. Unterberger, M. Llusa, N. Griffiths, L. Wagner, N. Binder (Austria, United States)

PB 2120  Evaluation of Platelet Response by Whole Blood Multiple Electrode Aggregometry Method in Patients Using Antiplatelet Therapy
M. Matos, E. Taniguchi, C. Finazzo, E. Sanches, A. Maia (Brazil)

PB 2121  Evaluation and Comparison of the Productivity of the Atellica COAG 360 System* and the BCS XP System in Daily Routine Setting
S. Echternacht, K.-P. Kienle, I. Hoberg, M. Haddad (Germany)

PB 2122  Rotational Thromboelastometry Parameters Have Variable Correlation with Plasma-based Assays of Coagulation across Trimesters of Pregnancy: A Cross-sectional Study
K. Fox, A. Shamshirsaz, H. Erfani, V. Kostousov, K. Bruzdoski, S.-K. Hui, J. Teruya (United States)

PB 2123  Thrombin Generation Assay CANNOT Identify Antithrombin Resistance During Anticoagulant Therapy

PB 2124  Clot Wave Form Parameters of Prolonged APTT in Different Situations: Is There Any Difference between Them?

PB 2125  Hereditary Angioedema: Role of Genetic Test in Diagnosis
P. Martinez, P. Rozenfeld (Argentina)

PB 2126  Alterations in the Parameters of Classic, Global and Innovative Assays of Hemostasis Caused by Sample Transport via a Pneumatic Tube System

PB 2127  Productivity Evaluation of a Novel Blood Coagulation Analyzer in the 24/7 Clinical Coagulation Laboratory Environment
S. Echternacht, A. Patapovas, S. Kuehn, E. Langer, K. Hegel (Germany)

PB 2128  Mutation Screening for the C677T Variant in the MTHFR Gene by Melting Point Analysis with the Real Time PCR: Detection of a Rare Variant Val225Ile

PB 2129  Evaluation of Potential Sources of Variation in 1-stage Factor IX Assays
J. Needham, H. Lewis, M. Stringer, S. Mangles, S. Rangarajan (United Kingdom)

PB 2130  The Calibrated Automated Thrombography in Normal Pregnancy
N. Silina, O. Smirnova, A. Nikolaeva, O. Golovina, L. Papayan (Russian Federation)

PB 2131  The Impact of Pre-analytical Variables and Reagents on the Results of Thrombin Generation - Lessons Learned from the Generation of Normal Reference Ranges
E. Fosbury (United Kingdom)

PB 2132  High Level of Concordance for Routine Assays between Results Obtained with Two Automated Coagulation Analyzers
S. Just, D. Zebeljan, L. Smith, J. Loats, K. Hill, G. Lakos (Australia, United States)
POSTER SESSIONS

PB 2133
Current Practice Related to D-dimer Testing in Croatia
S. Margetić, A. Bronić, D. Coen Herak, M. Milic Gall (Croatia)

PB 2134
Usefulness of APTT Reagents for LA Detection and Frequency of LA Positive Patients in APTT Prolonged Patients
S. Anun, A. Pirunsarn, K. Boonyoung, P. Mitreejit (Thailand)

PB 2135
An Evaluation of the Activated Partial Thromboplastin Time Waveform in Various Diseases
T. Matsumoto, H. Wada, K. Ohishi, N. Katayama (Japan)

PB 2136
Identification of Rare Inherited Diseases by Next Generation Sequencing
S. Shahid, S. Ahmed, S. Munzir, T. Shamsi (Pakistan)

PB 2137
Type and Frequency of Hemoglobinopathies, Diagnosed in the Area of Karachi, in Pakistan
S. Shabbir (Pakistan)

Management of Thromboembolism

PB 2138
Evaluation of a Novel Short-acting Direct Dual FXa/FIIa Inhibitor for its Use in Acute Anticoagulation
S. Heitmeier, S. Allerheiligen, J. Strassburger, A. Buchmueller, C. Gerdes, M.J. Gnoth, B. Riedl, V. Laux (Germany)

PB 2139
Discovery of ONO-5450598, a Highly Orally Bioavailable Small Molecule Factor Xa Inhibitor: The Pharmacokinetic and Pharmacological Profiles

PB 2140
Discovery and Profiling of BAY-224 - A Novel Active Site Inhibitor of Thrombin for Oral Treatment of Thrombosis
S. Heitmeier, S. Allerheiligen, K.M. Gericke, A. Tersteegen, M.V. Schmidt, J. Strassburger, A. Buchmueller, C. Gerdes, P. Ellinghaus, B. Riedl, V. Laux (Germany)

PB 2141
Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review
L.-H. Lee1, W. Chen2, J. Rauvi3, C.-C. Wu4, A. Gallus5 (1Singapore, 2China, 3India, 4Taiwan, 5Australia)

PB 2142
Thrombin Exosite 1 Inhibition with JNJ-375 Causes Anti-coagulation and Inhibits Thrombus Formation in a Human Translational Model of Thrombosis
S. Wilson1, T. Connolly2, G. Peters3, A. Gosh4, M. Johnson5, D. Newby6 (1United Kingdom, 2United States)

POSTER SESSIONS

PB 2143
Vena Cava Filter Retrieval Rates and Factors Associated with Retrieval in the United States
J. Brown, V. Adams, J. Talbert (United States)

PB 2144
Dabigatran Neutralizing Antibody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood
Z. Siddiqui, O. Iqbal, D. Hoppensteadt, M. Lewis, R. Rege, S. Abro, E. Ramacciotti, I. Elalamy (United States, France)

PB 2145
ONO-5450598, an Orally Available Small-molecule Inhibitor of Activated Blood Coagulation Factor XI, Inhibits Arterial Thrombus Formation without Increasing Bleeding when Used in Combination with Clopidogrel in Rabbits

PB 2146
Inter-individual Variation in Plasma Levels of Direct Oral Anticoagulants in Patients with Non-valvar Atrial Fibrillation
I. Paskaleva, E. Doncheva, D. Dineva (Bulgaria)

PB 2148
Idarucizumab, a Specific Antidote for Dabigatran, Cross-reacts with Melagatran and May also Interact with other Benzamidine-containing Compounds

PB 2149
Influence of Dabigatran on Rotational Thromboelastometry
M. Bozic Mijovski, N. Vene, N. Snoj, P. Gradisek, A. Mavri (Slovenia)

PB 2150
Direct Oral Anticoagulants for Thromboprophylaxis in Orthopedic Surgery in the Real World: A Systematic Review of Population Based Studies
F. Al-Ani, A. Garcia-Horton, A. Lazo-Langner (Canada)

PB 2151
Heparin Calibrated Anti-Xa Assays for the Measurement of Low Levels of Direct Factor Xa Inhibitors
L. Sabor, M. Raphaël, J.-M. Dogné, F. Mullier, J. Douxfils (Belgium)

PB 2152
Efficacy of a Novel Contact Pathway Inhibitor, Ir-CPI, on in vitro Clotting Induced by PCI Catheter Segment

PB 2153
New Parenteral Poly (2-(acrylamide)-2-methylpropanesulfonic Acid) - Based Anticoagulants (NPACs): Efficacy and Safety Studies in Rats
B. Kalaska, K. Kaminski, M. Klimosz, I.-I. Yusa, K. Nakai, K. Szczubialka, D. Pawlak, M. Nowakowska, A. Mogielnicki (Poland, Japan)
PB 2154  INR Might Be a Useful Predictor for Upcoming Minor to Major Bleedings in Patients Treated with NOAC  P. Bhardwaj, L.B. Petersen, T.S. Binko, T.B.S. Jørgensen, M.L. Nepper, A.M.K. Andersen, J.R. Petersen, G. Gleerup Fornitz (Denmark)

PB 2155  Correlation between Thromboelastometry and HPLC-MS/MS for Rivaroxaban Monitoring  V. Aranda, D. Priscilla, M. Colombini, M. Claudio, M. Cristovão, F. Carlos, J. Guerra (Brazil)

PB 2156  Comparative Studies on the Anticoagulant Actions of Recombinant Thrombomodulin and Heparin and their Neutralization by FEIBA as Measured by Thromboelastography  P. Aggarwal, Z. Siddiqui, O. Iqbal, W. Jeske, D. Hoppensteadt, K. Tsuruta, J. Fareed (United States)

PB 2157  Diclofenac for the Treatment of Acute Symptomatic Intermediate-risk Pulmonary Embolism  D. Jimenez1, R. Nieto1, J. Corres1, C. Fernandez-Golfín1, J.L. Zamorano1, D. Barrios1, R. Morillo1, E. Barbero1, M. Huisman1, J. Kline1, R. Yusen2 (1Spain, 2The Netherlands)


PB 2160  Sulodexide Efficiently Inhibits Thrombin Generation and Clot Formation via the Anti-Xa and Anti-IIa Activity. An in vitro Comparison with the LMWH Exonaparin and UFH  G. Gerotziafas1, P. Van Dreden1, S. Salta2, L. Papageorgiou1, W. Jeske2, J. Walenga2, D. Hoppensteadt2, M. Grusse1, O. Bouchard2, M. Lewis2, A. Silva de Castro, E. Kumar, N. Guler, D. Kahn, J. Walenga, J. Fareed (1United States, 2The Netherlands)

PB 2161  Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives are Comparable in Contrast to Their Bovine Equivalents  W. Jeske, O. Bouchard, M. Lewis, D. Hoppensteadt, P. Maia, A. Silva de Castro, E. Kumar, N. Guler, D. Kahn, J. Walenga, J. Fareed (United States)
POSTER SESSIONS

PB 2171  Acquired von Willebrand Syndrome (aVWS) in Severely Ill Pediatric Patients with Bleeding Complications
I. Wieland, K.-W. Sykora (Germany)

PB 2172  Thrombopoietin Receptor Agonists for Children with Refractory Immune Thrombocytopenia

PB 2173  An Unusual Cause of Bleeding in a Young Girl with Systemic Lupus Erythematosus: Lupus Anticoagulant Hypoprothrombinemia Syndrome
S. Singh, A. Jindal, N. Kumar, J. Ahluwalia (India)

PB 2174  Cost-benefit Relationship of the Collagen-binding Assay on von Willebrand Disease Study in Children
P. Zúñiga C, J.G. Martínez Órdenes, P. Sepulveda M, G. Muñoz S (Chile)

PB 2175  Severe Factor VII Deficiency in Lebanon: The Impact of Molecular Studies, Prenatal Diagnosis and Primary Prophylaxis
R. Farah1, J. Al Danaf1, H. Farhat1, M. Giansily-Blaizot2 (1Lebanon, 2France)

PB 2176  PB 2177  Genetic Confirmation and Identification of Novel Mutations in Glanzmann Thrombasthenia and von Willebrand Disease Families by Diagnostic Exome Sequencing

PB 2178  Application of Different Technologies during Prenatal Diagnosis in Glanzmann’s Thrombasthenia
M. Jiang (China)

PB 2179  Continuous Infusion of Recombinant Factor IX in a Neonate with Severe Hemophilia B and A Vascular Ring Requiring Surgical Correction
C. Hugger, C. Huddleston, L. Cerny, N. Hillman (United States)

PB 2180  Tailored Prophylaxis in Children with Hemophilia A: A New Approach for the Future
S. Pasca, P. Cogo, M. Milan, L. Sarolo, E. Zanon (Italy)

PB 2181  Normal aPTT in Children with Mild Factor XI Deficiency
J. Puetz, C. Hugger, K. Moser (United States)

A. Al-Huniti, A. Sharathkumar (United States)

PB 2183  Intraosseous Infusion of Recombinant Factor IX
C. Hugger, J. Puetz, R. Fleming (United States)

PB 2184  The Differential Diagnosis of Acute Rheumatic Fever in a Hemophilic Child
M. Sezgin Evim, A. Meral Güneş, B. Baytan (Turkey)

PB 2185  Proteomic Analysis of Changes Induced by Infant Cardiopulmonary Bypass
U. Nag, J. Otto, C. Mccoy, H. Leraas, J. Kim, C. Brady, J. Turek, J. Lawson, E. Tracy (United States)

PB 2186  Spatial Clot Propagation in Neonates and Adults
A. Schlagenhauf, S. Pohl, E. Zoehrer, B. Leschnik, H. Haidl, W. Muntean, S. Gallistl (Austria)

PB 2187  Platelet-leukocyte Aggregates as Possible Biomarkers of Thrombotic Risk in Children with Hereditary Spherocytosis and Splenectomy
C. Garcia, A. Moscardi, S. Izquierdo, A.M. Latorre, B. Argiles, M.T. Santos, J. Vallés, M.Á. Dasi (Spain)

PB 2188  Pediatric Chronic Kidney Disease: Assessment of Endothelial Function and Hemostasis
L. Dusse, R. Silva, L. Sousa, C. Loures, M. Carvalho, E. Reis, A. Simões-Silva (Brazil)

PB 2189  Derivation of a Clinical Prediction Rule to Use with D-dimer to Exclude Pulmonary Embolism in Children
J. Kanis, J. Pike, C. Hall, J. Kline (United States)

PB 2190  Thrombin Generation in Pediatric Patients with Generalized Infectious Diseases and Multiple Organ Dysfunction Syndrome
L. Papayan, O. Smirnova, O. Golovina, L. Alekseeva, A. Vilnits, S. Bessmeltsev (Russian Federation)

PB 2191  A New ADAMTS13 Mutation and Pharmacokinetic Properties in Congenital Thrombotic Thrombocytopenic Purpura (TTP)

PB 2192  Thromboelastographic (TEG) Parameters in Newly Diagnosed Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) and Central Venous Catheters (Cvcs)
R. Ko, L. Ji, R. Carmona, R. Sposto, G. Young (United States)

PB 2193  Look, Feel, Move: A Case of Idiopathic Femoral Artery Thrombosis in a Neonate
C. Williams, C. Mayes, C. Macartney (United Kingdom)
<table>
<thead>
<tr>
<th>Platelets - Basic</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 2194 Inhibitors of Apoptosis Signal-regulating</td>
<td>M. Naik, X. Chen, J. Wu,</td>
<td></td>
</tr>
<tr>
<td>Kinase 1 (MAP3K5), as Anti-thrombotic Agents</td>
<td>T. Stalker, D. Maloney,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. JadHAV, U. Naik</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(United States)</td>
<td></td>
</tr>
<tr>
<td>PB 2195 The Oral Bruton's Tyrosine Kinase Inhibitor</td>
<td>B. Kristina, J. Janina,</td>
<td></td>
</tr>
<tr>
<td>Ibrutinib Selectively Blocks Atherosclerotic Plaque-</td>
<td>Prof. Dr. med. Wolfgang</td>
<td></td>
</tr>
<tr>
<td>induced Platelet Thrombus Formation</td>
<td>Siess (Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PB 2196 The anti-asthma therapeutic zaflurukast is a</td>
<td>L.-M. Holbrook1, S.</td>
<td></td>
</tr>
<tr>
<td>broad spectrum thiol isomerase inhibitor that</td>
<td>Nock1, S. Ryan1, J.</td>
<td></td>
</tr>
<tr>
<td>inhibits platelet function</td>
<td>Romanowski2, D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kennedy2, J. Gibbins1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1United Kingdom, 2United</td>
<td></td>
</tr>
<tr>
<td></td>
<td>States)</td>
<td></td>
</tr>
<tr>
<td>PB 2197 Potentiation of TRAP-6-induced Platelet</td>
<td>A. Mitrugno, R.A. Rigg,</td>
<td></td>
</tr>
<tr>
<td>Dense Granule Release by Blockade of P2Y12 Signaling</td>
<td>N.B. Laschober, A.T.P.</td>
<td></td>
</tr>
<tr>
<td>with MRS2395</td>
<td>Ngo, J. Pang, C.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Williams, J.E. Aslan,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>O.J.T. McCarty (United</td>
<td></td>
</tr>
<tr>
<td></td>
<td>States)</td>
<td></td>
</tr>
<tr>
<td>PB 2198 Discovery and in vitro Pharmacology of BAY-</td>
<td>C. Gerdes1, M. Jeske1,</td>
<td></td>
</tr>
<tr>
<td>386 - A Novel, Reversible PAR-1 Antagonist</td>
<td>M.J. Gnoth1, E. Bender1,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>K. Zimmermann1, A.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buchmueller1, P.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ellinghaus1, A. Itakura2,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>V. Laux1, O.J. McCarty1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1Germany, 2United States)</td>
<td></td>
</tr>
<tr>
<td>PB 2199 Selective Serotonin Reuptake Inhibitors</td>
<td>Y.-L. Tseng, J.P.-C.</td>
<td></td>
</tr>
<tr>
<td>Inhibit Convulxin- and Fibrinogen-induced</td>
<td>Chang, H.-Y. Lane</td>
<td></td>
</tr>
<tr>
<td>Phosphorylation of Syk in Human Platelets</td>
<td>(Taiwan)</td>
<td></td>
</tr>
<tr>
<td>PB 2200 Citalopram Inhibits Platelet Function</td>
<td>H.G. Roweth, R. Yan,</td>
<td></td>
</tr>
<tr>
<td>through a SERT-Independent Mechanism</td>
<td>A.H. Watson, R.W.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Farndale, G.E. Jarvis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PB 2202 What is the Optimal Treatment Option for A</td>
<td>M. Gresikova1, T.</td>
<td></td>
</tr>
<tr>
<td>Patient with X-linked Thrombocytopenia?</td>
<td>Freiberger2, B. Ravúková2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1Slovakia, 2Czech Republic)</td>
<td></td>
</tr>
<tr>
<td>PB 2203 The Effect of Vorapaxar on Platelet-mediated</td>
<td>A. Tsuoka, I. Moschonas,</td>
<td></td>
</tr>
<tr>
<td>Inflammatory Response</td>
<td>S. Papadaki, A. Tselepis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Greece)</td>
<td></td>
</tr>
<tr>
<td>PB 2204 APAC, a Dual Antiplatelet and Anticoagulant</td>
<td>A. Jouppila, M. Lemponen,</td>
<td></td>
</tr>
<tr>
<td>Attenuates Collagen-induced Platelet Aggregation</td>
<td>R. Lassila (Finland)</td>
<td></td>
</tr>
<tr>
<td>and Fibrin Elasticity in Blood</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**POSTER SESSIONS**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 2205 Citrated Iron</td>
<td>S. Moise, N. Telling,</td>
<td></td>
</tr>
<tr>
<td>Oxide Nanoparticles</td>
<td>A. Harper (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Inhibit Thrombin-evoked</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca2+ Signalling in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Platelets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PB 2206 Induction of</td>
<td>A. Sugidachi1, K. Ohno1,</td>
<td></td>
</tr>
<tr>
<td>Diabetes Attenuates the</td>
<td>J.A. Jakubowski2, Y.</td>
<td></td>
</tr>
<tr>
<td>Antithrombotic Effect</td>
<td>Ito1, A. Tomizawa1, M.</td>
<td></td>
</tr>
<tr>
<td>of Clopidogrel in</td>
<td>Mizuno1</td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein E-deficient Mice</td>
<td>(1Japan, 2United States)</td>
<td></td>
</tr>
<tr>
<td>PB 2208 With an ASA Dose</td>
<td>R. Ni1, N. Vaezzadeh1, J.</td>
<td></td>
</tr>
<tr>
<td>that Inhibits Prostacyclin Formation, Clopidogrel</td>
<td>Zhou1, J.I. Weitz1, M.</td>
<td></td>
</tr>
<tr>
<td>Has a Lesser Antithrombotic Effect</td>
<td>Cattaneo2, P.L. Gross1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1Canada, 2Italy)</td>
<td></td>
</tr>
<tr>
<td>PB 2209 Inhibition of</td>
<td>T. Halenova, I.</td>
<td></td>
</tr>
<tr>
<td>Human Platelet Aggregation by Some Newly Synthesized</td>
<td>Nakonechna, V. Lubenets,</td>
<td></td>
</tr>
<tr>
<td>S-Esters of Thiosulfonic Acid</td>
<td>O. Savchuk (Ukraine)</td>
<td></td>
</tr>
<tr>
<td>PB 2210 Looking for the</td>
<td>B. Decouture, B. Dizier,</td>
<td></td>
</tr>
<tr>
<td>Best Experimental Conditions for Studying the Effect</td>
<td>P. Gausssem, C. Bachelot-</td>
<td></td>
</tr>
<tr>
<td>of Aspirin on Murine Hemostasis</td>
<td>Loza (France)</td>
<td></td>
</tr>
<tr>
<td>PB 2211 Platelet Microvesicle Formation during the</td>
<td>M. Tomatiuolo, C.</td>
<td></td>
</tr>
<tr>
<td>Hemostatic Response is Regulated by P2Y12 Signaling</td>
<td>Matzko, I. Poventud-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fuentes, J. Weisel, L.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brass, T. Stalker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(United States)</td>
<td></td>
</tr>
<tr>
<td>PB 2212 Convection through Platelet Thrombi</td>
<td>S. Kobayashi1, M.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Komatsu1, D. Kuri2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Japan, 2United States)</td>
<td></td>
</tr>
<tr>
<td>PB 2213 Different Prothrombotic Phenotypes of</td>
<td>J.P. van Geffen, F.</td>
<td></td>
</tr>
<tr>
<td>Atherosclerosis-prone ApoE-/- and Ldlr-/- Mice</td>
<td>Swieringa, J.C. Sluimer,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E.A.L. Biessen, J.W.M.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heemskerk, M.E.J.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuipers (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>PB 2214 PCSK9, Not only A Modulator of Cholesterol</td>
<td>L. Rossetti, N. Ferri,</td>
<td></td>
</tr>
<tr>
<td>Levels but Also of Platelet Function</td>
<td>S. Marchianò, B.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Canciani, D. Trabattoni,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>F. Santilli, G. Davi,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. Tremoli, M. Camera</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Italy)</td>
<td></td>
</tr>
<tr>
<td>PB 2215 Increased Platelet P2Y12 Expression in Diabetes and the Therapeutic Implication of Inverse Agonist for Antiplatelet Therapy</td>
<td>L. Hu, L. Chang, Z. Ding (China)</td>
<td></td>
</tr>
</tbody>
</table>
POSTER SESSIONS

PB 2216 Elevated Activity of Fibrinogen-like Protein 2, (FGL2/fibroleukin) in Platelets of Cancer Patients
E. Rabizadeh, Y. Zimra, I. Cherny (Israel)

PB 2217 Dynamics of Single Platelet Dense Granule Release Induced by Various Concentrations of Thrombin and ADP
T. Shepelvuk, D. Nechipurenko, F. Ataullakhanov, M. Panteleev (Russian Federation)

PB 2218 Comparison of Reticulated and Non-reticulated Platelet Function and Releasates
M.A. Hayman, P.C. Armstrong, T.D. Warner (United Kingdom)

PB 2219 Platelet S1P: Evidence for the Involvement of the Membrane Transporter MRP4 during its Secretion, and Identification of Surface Receptors

PB 2220 The Framingham Heart Study (FHS): Results from >900 Individuals with Detailed Platelet Function Testing
J. Huffman1, M.-H. Chen1, C. Wallace de Melendez1, A. Lachapelle1, C. Song1, P. Sutherland1, M. Hayman2, P. Armstrong2, M. Chan2, T. Warner2, A. Johnson2 (1United States, 2United Kingdom)

PB 2221 Polyphosphate Nanoparticles on the Platelet Surface Trigger Contact System Activation
J.J.F. Verhoef1, A.D. Barendrecht1, K.F. Nickel1, K. Dijkxhoorn1, E. Kenne1, L. Labberton1, O.J. McCarty1, R. Schiffer1, A.P. Hendricke1, H. Schellekens1, M.H. Fens1, S. de Maat1, T. Renne1, C. Maas1 (1The Netherlands, 2Germany, 3United States)

PB 2222 Analysis of Integrin β3 Clustering and Kindlin Association Using a Novel STORM Microscopy Method
M. Abo Hassan, C. Jones (United Kingdom)

PB 2223 Shear-mediated Platelet Activation (SMPA) Yields a Differing "Activation Signature" than that of Biochemical Agonists
Y. Roka-Moiia1, N. Bajaj1, D.E. Palomares1, A. Dimasi2, A. Redaelli2, D. Bluestein1, M.J. Stipan1 (1United States, 2Italy)

PB 2225 Investigating Platelet Functional Heterogeneity Using Droplet Microfluidics
M.S.A. Jongen, N.A. Englyst, J.J. West (United Kingdom)

PB 2226 Sickle Cell Disease Patients under Regular Transfusion Program Have Decreased in vitro Platelet Aggregation

PB 2227 Microthrombocytopenia and Defective GPVI/ITAM Signaling in Mice Lacking the Small GTPase RhoB
K. Aurbach1, S. Dütting1, C. Brakebusch1, U.G. Knaus3, I. Pleines1, B. Nieswandt1 (1Germany, 2United Kingdom, 3Ireland)

PB 2228 Characterization of in Vitro Cell-free Induced Fibrillar Fibronectin: Morphology Dependent Effects on Platelet Function
K. Huynh1, P. Le1, N. Mai1, V. Stoldt2, H. Nguyen1, T. Vo1 (1Viet Nam, 2Germany)

PB 2229 Extracellular Histones Stimulate Clot Retraction and Induce Resistance to Fibrinolysis
C.T. Ammollo, N. Semeraro, M. Colucci, F. Semeraro (Italy)

PB 2230 Evaluation of the Total Thrombus-formation System (T-TAS): Application to Human and Mouse Blood Analysis
R. Al Ghaithi, J. Mori, L. Hardy, H. Philippou, E. Hethershaw, N.V. Morgan, Y.A. Senis, P. Harrison (United Kingdom)

PB 2231 The Mechanisms Underlying Core-and-Shell Architecture of Arterial Thrombus and it’s Dynamics Described with Computational Modeling
V.N. Kaneva, D.Y. Nechipurenko, F.I. Ataullakhanov, M.A. Panteleev (Russia)

PB 2232 Effects of pH and Concentration of Sodium Citrate Anticoagulant on Platelet Aggregation Measured by Light Transmission Aggregometry Induced by Adenosine Diphosphate
K. Germanovich1, E.A. Femia1, C. Cheng1, N. Dovlatova2, M. Cattaneo1 (1Italy, 2United Kingdom)

PB 2233 Idelalisib and Platelet Aggregation in Patients with Chronic Lymphocytic Leukemia (CLL)
A. Artoni, P. Bucciarelli, R. Cassin, A. Lecchi, F. Peyvandi (Italy)

PB 2234 Platelet Investigations in Patients with Essential Thrombocytosis
O.H. Pedersen1, M.L. Larsen, E.L. Grove, P.H. Nissen, S.D. Kristensen, A.M. Hvas (Denmark)
## POSTER SESSIONS

<table>
<thead>
<tr>
<th>PB 2235</th>
<th>Computational Analysis of Shear Stress Distribution during Thrombus Formation in a Blood Vessel and Parallel Plate Flow Chamber</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Megalinskiy, D.Y. Nechipurenko, F.I. Ataullakhanov, M.A. Panteleev (Russian Federation)</td>
</tr>
<tr>
<td>PB 2236</td>
<td>Platelet Function during Prolonged Targeted Temperature Management after Cardiac Arrest: A Randomised Clinical Trial</td>
</tr>
<tr>
<td></td>
<td>A. Jeppesen, H. Kirkegaard, S. Ilkjær, A.-M. Hvas (Denmark)</td>
</tr>
<tr>
<td>PB 2237</td>
<td>An Absence of Platelet Activation Following Thalidomide Treatment in vitro or in vivo</td>
</tr>
<tr>
<td></td>
<td>J. Qiao¹, Y. Wu¹, X. Wu¹, Y. Liu¹, X. Li¹, W. Ju¹, L. Zeng¹, E. Gardiner², R. Andrews², K. Xu² (¹China, ²Australia)</td>
</tr>
<tr>
<td>PB 2238</td>
<td>Reduced Left Ventricular Function Compared to Preserved Function after Myocardial Infarction is Associated with a Different Platelet Pattern</td>
</tr>
<tr>
<td></td>
<td>C. Christersson, Å. Thulin, A. Siegbahn (Sweden)</td>
</tr>
<tr>
<td>PB 2240</td>
<td>Lymphocyte-platelet Adhesion and Clusters Formation in Patients Infected with Influenza A/H3N2</td>
</tr>
<tr>
<td></td>
<td>A. Emelianov, A. Emelianova, N. Belozerceva, O. Solpova, A. Solpov, Y. Vitkovsky (Russian Federation)</td>
</tr>
<tr>
<td>PB 2241</td>
<td>Detection and Characterization of Extracellular Vesicles at Different Stages of Platelet Concentrate Storage Using High-resolution Flow Cytometry</td>
</tr>
<tr>
<td></td>
<td>O. Sirotkina, V. Kishenko, A. Golovkin, M. Belyakova, K. Kondratov, A. Fedorov, T. Vavilova (Russian Federation)</td>
</tr>
<tr>
<td>PB 2242</td>
<td>New Opportunities in Express-evaluation of Living Platelets</td>
</tr>
<tr>
<td></td>
<td>I. Vasilenko, E. Vlasova, V. Metelin, A. Balkanov, R. Lifenko, V. Khvatov, M. Makarov (Russian Federation)</td>
</tr>
<tr>
<td>PB 2243</td>
<td>Comparing Platelet Reactivity in Patients with Chronic Kidney Disease to that in Healthy Volunteers</td>
</tr>
<tr>
<td></td>
<td>H.E. Allan, M.X. Chan, P.C. Armstrong, M.M. Yaqoob, T.D. Warner (United Kingdom)</td>
</tr>
<tr>
<td>PB 2244</td>
<td>Disaggregation Following Agonist-induced Platelet Activation in Patients on Dual Antiplatelet Therapy</td>
</tr>
<tr>
<td></td>
<td>P.P. Wadowski, B. Eichelberger, C. Kopp, J. Pultar, D. Seidinger, R. Koppensteiner, I.M. Lang, S. Panzer, T. Gremmel (Austria)</td>
</tr>
<tr>
<td>PB 2245</td>
<td>In vitro Study on the Effects of Ibrutinib (Ibr) on Platelet (Plt) Function via Light Transmission Aggregometry (LTA): Platelet Aggregation (PA) Results</td>
</tr>
<tr>
<td></td>
<td>J. Ninomoto¹, A. Mokatrin¹, T. Kinoshita¹, C. Marimpietri², B.Y. Chang¹, J. Sukbuntherng¹, D.F. James¹, M. Crowther² (¹United States, ²Canada)</td>
</tr>
</tbody>
</table>

## POSTER SESSIONS

### Coagulation Signaling & Immunity

| PB 2246 | The Use of Laser Therapy for Muscle Bleeding in Glanzmann Thrombasthenia - A Case Report                                    |
|         | B. Choisnka, P. Laguna, K. Scipio del Campo, M. Matysiak (Poland)                                                      |
| PB 2247 | Amniotic Fluid-derived Mesenchymal Stem Cells (AF-MSCs) Decrease Agonists Platelet Response                            |

### Poster Session

**12:00 – 13:15**

**Exhibition Hall 6.2**

**Coagulation Signaling & Immunity**

| PB 2248 | Clopidogrel Does Not Protect Mice from Sepsis or Septic Shock                                                       |
|         | Y. Rabouel, S. Magenet, F. Lefebvre, J. Boisramé-Helms, F. Meziani, B. Hechler, C. Gachet (France)                  |
| PB 2249 | Dysregulation of NET Formation Following Thermal Injury and its Association with Multiple Organ Failure            |
|         | R. Dim starts, J. Hazeldine, K. Altarrah, P. Hampson, A. Devi, C. Wearn, A. Bamford, J. Bishop, J. Lord, N. Moiemen, P. Harrison (United Kingdom) |
| PB 2250 | Hageman Factor Regulates Inflammatory Responses in Human Lungs                                                      |
|         | L. Wu1, R. Hess1, C. Hesse1, K. Sewald1, S. de Maat2, C. Maas2, F. Bonella1, K. Preissner1, P. Markert1, M. Wygrecka1 (1Germany, 2The Netherlands) |
| PB 2251 | Differential Impact of Triggers on the Risk of Incident Venous Thromboembolism in Hospitalized Subjects with and without Acute Infection - Results from a Population-based Case-crossover Study |
|         | G. Grimnes, T. Isaksen, V. Tichelaar, S.K. Braekkan, J.B. Hansen (Norway)                                           |
| PB 2252 | Inhibition of the Major Endothelial Cell Integrin αvß3, Both Pre- and Post-infection, Prevents Bacterial Binding in 2D Dynamic and 3D ex vivo Models of Sepsis |
|         | C. Garciarena1, A. Wong4, S. Peter4, S. Kerrigan4 (1Ireland, 2United States)                                         |
| PB 2253 | RNA and Histones in Dead Cells Synergistically Provoke FSAP Activation in Serum                                    |
|         | G. Marsman, I. Bulder, F. Stephan, B. Luken, S. Zeerleder (The Netherlands)                                         |
POSTER SESSIONS

PB 2254  Impact of Acute Infection during Hospitalization on the Risk of Incident Venous Thromboembolism - Results from a Population-based Case-crossover Study
G. Grimnes, T. Isaksen, V. Tichelaar, S.K. Braekkan, J.B. Hansen (Norway)

PB 2255  C-reactive Protein and Risk of Venous Thromboembolism - Results from a Population-based Case-crossover Study
G. Grimnes, T. Isaksen, S.K. Braekkan, J.B. Hansen (Norway)

PB 2256  DNA and Factor VII-activating Protease Protect against the Cytotoxicity of Histones
G. Marsman1, H. von Richthofen1, I. Bulder1, F. Lupu2, J.A. Hazelzet1, B.M. Luken1, S. Zeerleder1 (1The Netherlands, 2United States)

PB 2257  Nucleated Platelet Response to a Single Stranded RNA Viral Product through Pattern Recognition Receptors Revealed by RNA Sequencing
F. Ferdous, C. Saski, W. Bridges, M. Burns, K. Elliott, H. Dunn, T. Scott (United States)

PB 2258  MiR146a-5p Deficiency Exacerbates Neutrophil Extracellular Trap Formation
A.B. Arroyo Rodríguez, A.M. de los Reyes García, N. García Barbera, V. Roldán, R. Teruel Montoya, V. Vicente, R. González Conejero, C. Martínez (Spain)

PB 2259  Inflammation Augments NFkB Dependent Production of TF in Preadipocytes
T. Sovershaev1, C. Ramberg1, M. Wabitsch2, L. Wilsgard1, N. Latysheva1, J.-B. Hansen1 (1Norway, 2Germany)

PB 2260  Evaluation of the Impact of Hypofibrinolysis Induced by Tranexamic Acid in Murine Experimental Sepsis

PB 2261  Elevated Levels of Endogenous Activated Protein C Predict Mortality in Septic Shock
J. Müller, B. Pötzsch, J. Oldenburg, D. Loßnitzer, T. Becher (Germany)

PB 2262  In vitro Disruption of Endothelial Barrier Integrity by Serum from Patients with Septic Shock
M. Lopez1, L.N.G. Costa1, G.R. de Souza1, R.N. Angerami1, M.A. Carvalho-Filho1, D. García-Weber2, J. Millán2, E.V. de Paula1 (1Brazil, 2Spain)

PB 2263  The Potential Roles of IL-33 and TGF-β1 in the Pathogenesis of Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis
O. Igual, C. Bouchard, M. Mosier, S.D. Till, J. Fareed (United States)

PB 2264  Assessment of the Concentration and the Functional Activity of Plasma Inter-alpha Trypsin Inhibitor in Patients with Inflammatory Diseases
J.-L. Plantier, V. Devos, S. Jorieux (France)
POSTER SESSIONS

PB 2277  Interleukin-6 in the Development of Venous Thrombosis
S. H. Karbach1, R. Schüller1, A. Gabele1, F. Ridder1, K. Schäfer1, H. Rossmann1, T. Korn1, H. M. H. Spronk1, B. Lämmler1, T. Münzel1, A. Wisman1, P. Wenzel1 (1Germany, 2The Netherlands)

PB 2278  The First Year after Diagnosis of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis is Critical for Development of Venous Thromboembolism (VTE) in These Patients
A. Antovic, E. Svensson, O. Börjesson, A. Bruchfeld, I. Gunnarsson (Sweden)

PB 2279  Protein Arginine Deiminase-4 Does Not Influence Antibacterial, Inflammatory or Procogulant Responses during Gram-negative Pneumonia Derived Sepsis
T. A. M. Claushuis1, A. Luitse1, L. A. van Vught1, J. H. de Boer1, J. M. Lankelma1, L. Boon1, A. Zychlinsky2, A. F. de Vos1, C. van ’t Veer1, T. van der Poll1 (1The Netherlands, 2Germany)

PB 2280  NETs, FSAP and their Complicity in the Context of Immunity and Thrombosis
S. Grasso1, A. Neumann2, M. von Köckritz-Blickwede2, S. Kanse1 (1Norway, 2Germany)

PB 2281  Immunology Studies on Recombinant Factor VIII Fc Fusion Protein
K. Kis-Toth, A. Simpson, K. Henry, C. Loh (United States)

PB 2282  Luminex© Bead-based Assay for Early Detection of GPIIbIIIa Alloimmunization in Glanzman Thrombasthenia

PB 2283  Tranexamic Acid Blocks Fibrinolysis but Not Overall Plasmin Generation and Modulates the Immune Response in Patients Undergoing Coronary Artery Surgery. A Sub-study of the “Aspirin and Tranexamic Acid for Coronary Artery Surgery” (ATACAS) Trial

PB 2284  Role of Protease-activated Receptor 4 in Regulating Platelet-leukocyte Interactions in Whole Blood

PB 2293  External Validation of Generic and Cancer-Specific Risk Stratification Tools for Predicting 30-day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer
J. Caranfa, E. Weeda, E. Nguyen, S. Zeichner, C. Coleman, C. Kohn (United States)

PB 2294  Predictors of 30-day Mortality among Patients with Cancer-associated Thrombosis in the RIETE Database
A. Tafur1, H. Fuentes1, J. Caprini1, A. Rivas2, F. Uresandi2, R. Lopez-Reyes3, A. Visona4, M. Monreal5, RIETE Group (1United States, 2Spain, 3Italy)

PB 2295  Thrombosis after Orthotopic Liver Transplantation for Hepatocellular Carcinoma: Incidence, Implications and Risk Factors
POSTER SESSIONS

PB 2296 Predicting the Risk of Recurrent Venous Thromboembolism in Patients with Cancer: The REMARK Study  
N. van Es¹, M. Louzada², M. Carrier², V. Tagalakis², P. Gross², S. Shivakumar², M. Rodger⁴, P.S. Wells² ¹(The Netherlands, ²Canada)

PB 2297 Comparative Analysis of Predictive Models for Thromboembolic Events in Lymphoma Patients  

PB 2298 Outcomes of Subsegmental Pulmonary Embolism (SSPE) in Cancer Population  
M. Yan, C.C. Wu, W. Qiao, C.M. Rojas-Hernandez (United States)

PB 2299 Screening for Cancer in Patients with Unprovoked Venous Thromboembolism: A Systematic Review and Individual Patient Data Meta-Analysis  
N. van Es¹, G. Le Gal², H.-M. Otten¹, P. Robin¹, A. Piccioli¹, R. Lecumberri⁵, M. Rodger², P. Prandoni⁴, P.-Y. Salaun³, M. Di Nisio⁴, P.M. Bossuyt¹, H.R. Bülter¹, M. Carrier² ¹(The Netherlands, ²Canada, ³France, ⁴Italy, ⁵Spain, ⁶Sweden, ⁷United States, ⁸Belgium)

PB 2300 Cancer Cell Derived Extracellular Vesicles Increase Extracellular Vesicle Dependent Tissue Factor Activity of Peripheral Blood Mononuclear Cells in the Presence of Platelets  
T. Däullary, L. Hell, E. Grilz, L.-M. Mauracher, J. Schmid, C. Ay, I. Pabinger, J. Thaler (Austria)

PB 2301 Impact of Regular Physical Activity on the Risk of Cancer-related Venous Thromboembolism - The Scandinavian Thrombosis and Cancer (STAC) Cohort  
L. Papageorgiou¹, P. Van Dreden₁, D. Fotiou², M.S. Guyé¹, L. Garderet¹, E. Terpos², S. Salta¹, T. Sergentanis², M. Dimopoulos², A. Larsen¹, I. Elalamy¹, G. Gerotziafas¹ ¹(France, ²Greece)

PB 2302 Immunomodulatory Changes at the Tumor Microenvironment Induced by a Kunitz-type Inhibitor Improve Antitumoral Activity CDB₈⁺T-dependent Manner on Orthotopic Kidney Tumor Model  
J.G. de Souza, F.V. Pereira, P. Boufleur, J.M. Sciani, C.S. Origassa, M. Amano, N.O.S. Câmara, A.M. Chudzinski-Tavassi (Brazil)

PB 2303 Elevated Risk of Venous Thrombosis Post Allogeneic Transplantation for Leukemia: Patient Characteristics of a Single Centre Cohort  
R. Ikesaka, N. Cantor, M. Carrier, M. Sabloff (Canada)

PB 2304 Combination of Podoplanin Expression and IDH-1 Mutation Status in Primary Malignant Brain Tumors Identifies Patients at Risk of Venous Thromboembolism  
J. Riedl, P.M.S. Nazari, M. Preusser, F. Posch, C. Marosi, P. Birner, J. Thaler, G. Ricken, J.A. Hainfellner, I. Pabinger, C. Ay (Austria)

PB 2305 Podoplanin Promotes Oral Cancer Malignancy by Inducing Intravascular Coagulation in Orthotopic Xenograft Mice Model  
H.-Y. Lee, J.-C. Cheng, C.-P. Tseng (Taiwan)

PB 2306 Thrombin Generation in Patients with Active Multiple Myeloma and Impact of Immunomodulators. The ROADMAP Study  
L. Papageorgiou¹, P. Van Dreden¹, D. Fotiou², M.S. Guyé¹, L. Garderet¹, E. Terpos², S. Salta¹, T. Sergentanis², M. Dimopoulos², A. Larsen¹, I. Elalamy¹, G. Gerotziafas¹ ¹(France, ²Greece)

PB 2307 Impact of the Extensive Cancer Screening in Patients with a First Episode, Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis  
C. Chai-Adisaksopha, E. Tseng, M. Crowther, A. Iorio, M. Carrier (Canada)

PB 2308 Paradoxical Roles of Platelets in Colorectal Cancer Behavior  
J. Plantureux, L. Crescenz, F. Dignat-George, L. Panicot-Dubois, C. Dubois (France)

PB 2309 The Modified Ottawa Score and Clinical Events in Hospitalized Patients with Cancer-associated Thrombosis from the Swiss VTE Registry (SWIVTER)  

PB 2310 Predictive Value of D-dimers and Microparticle-associated Tissue Factor Activity for the Risk of Thrombosis in Pancreatic Cancer  
D. Faille, N. Ajzenberg, E. de Raucourt, P. Hammel, P. Lévy, P. Ruszniewski, V. Rebours (France)

PB 2311 Venous Thromboembolism Leads to Poor Survival in Patients with High Grade B Cell Lymphoma - A 7-year Single Centre Analysis  
M. Grech, M. Debono, D. Farrugia, D.J. Camilleri, A. Gatt (Malta)

PB 2312 Performance of Khorana Score Models in Predicting Occurrence of Incidental Venous Thromboembolism (VTE) in Cancer  
V.K. Tang, C.P. Escalante, T.P. Lam, M.N. Richardson, C.M. Rojas Hernandez (United States)

PB 2315 Audit: Use of Khorana Score in Newly Diagnosed Patients with Pancreatic Cancer  
C. Carson, G. Benson (United Kingdom)
## POSTER SESSIONS

**PB 2316**  
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: A Meta-analysis of Randomized Controlled Trials  
F. Dentali¹, M.N.D. Di Minno¹, R. Lupoli¹, G. Conte¹, N. Van Es², H. Buller², W. Ageno³ (¹Italy, ²The Netherlands)

**PB 2317**  
Podoplanin-dependent Platelet Aggregation Mediated by Human Glioblastoma Cell Lines  
P. Mir Seyed Nazari, J. Riedl, L. Hell, C. Brostjan, W. Berger, D. Lötisch, C. Marosi, M. Preusser, S. Panzer, I. Pabinger, C. Ay (Austria)

**PB 2318**  
Tumor cell-induced Platelet Secretion: Role of Protease-activated Receptors  
A. Mitrugno, R.A. Rigg, C. Pui, O.J.T. McCarty (United States)

**PB 2319**  
Can NETs or miRNAs Predict Early Surgery-related Pulmonary Embolism in Patients with Intracranial Tumors?  
J. Oto¹, E. Plana¹, D. Hervás¹, L. Martos¹, L.A. Ramón¹, M.J. Solmoirago¹, Á. Fernández-Pardo¹, F. España¹, S. Navarro¹, A. Artoni², P. Bucciarelli², G. Carrabba², G. Merati², P. Medina¹ (¹Spain, ²Italy)

**PB 2320**  
Thromboprophylaxis Strategy in Cancer Outpatients: CAT AXIS, a Case-vignette Study on Clinical Practice In France  
I. Elalamy, F. Scotte, D. Mayeur, G. Meyer (France)

**PB 2321**  
Peripherally Inserted Central Catheter (PICC) Related Thrombosis in 230 Patients with Hematological Malignancies. A 6 Years Single Experience Center  

**PB 2322**  
The Management of Non DVT-PE Cancer-associated Thrombosis: A Single Centre Experience  
A. Doyle, D. McClinton, V. McDonald (United Kingdom)

**PB 2323**  
Bioinformatic Analysis of Collaborative Interaction between Platelet and Cancer Cell Derived Microparticles in Evolving a Post Code Mechanism for Breast Cancer Metastasis and Identification of CD9 as Potential Drug Resistance Marker  
R.K. Vangala, A. Sharma, M. Ghatge (India)

**PB 2324**  
Tumour Microvesicles Interact with Endothelial Cells under Venous Flow in vitro  
A. Algarni, J. Greenman, L. Madden (United Kingdom)

---

**POSTER SESSIONS**

**PB 2325**  
The STEP-CAT Cohort Management Study: Step-Down to Prophylactic Doses of Enoxaparin after a Minimum of 3-6 Months of Anticoagulation for the Treatment of Cancer-associated Thrombosis  

**PB 2326**  
Myeloma Plasma Cells Express Tissue Factor and Trigger Thrombin Generation  
L. Papageorgiou, H. Mokrani, L. Garderet, C. Mazurier, A. K.Larsen, P. Van Dreden, I. El Alamy, G. Gerotziafas (France)

**PB 2327**  
Radiotherapy Does Not Affect Coagulation  
K.M. Bejtrun, J.A. Højbjerg, B. Offersen, A.-M. Hvas (Denmark)

**PB 2328**  
Usefulness of D-dimer in the Diagnosis of Deep Vein Thrombosis after Neurosurgery for Glioblastoma and Meningioma  

**PB 2329**  
Predictors of Mortality in Lung Cancer with Pulmonary Embolism: Concordance of Pulmonary Embolism with Lung Cancer and Central Emboli  
S.-I. Cha, Y.H. Lee, H. Seo (Republic of Korea)

**PB 2330**  
Patients with Venous Thromboembolism Events Admitted in a Tertiary Care Hospital: Follow-up for One Year and Correlation with Cancer  
F. Sabio, L. Gonçalves, C. Monteiro, C. Marujo, C. Koch (Portugal)

**PB 2331**  
Cement Pulmonary Embolism as a Complication of Percutaneous Vertebroplasty in Cancer Patients  
A. Mansour¹, H. Abuali¹, S. Salah², M. Ma'koseh¹, N. Shaikh-Salem¹, K. Abushalha¹, H. Abdel-Razeq² (¹Jordan, ²Canada)

**PB 2332**  
Renal Cell Carcinoma with Neoplastic Thrombosis: A Treatment Challenge for a Rare Entity  
V. Pons, P. Raheja, P. Olivera, A. Varela, T. Canals, E. Johansson, V. Cortina, M. Constans, F. Bosch, A. Santamaria (Spain)

**PB 2333**  
Silent Venous Thromboembolism in Patients Undergoing Thoracic Surgery in the Course of Lung Cancer  
B. Kazanecka, P. Kuca, M. Dybowska, J. Burakowski, C. Czajka, F. Grzegorczyk, W. Tomkowski (Poland)

**PB 2334**  
Demographic Data and Outcomes of Pediatric Patients with Tumor and Thrombosis  
P. Wongmas, P. Komvilaisak, S. Wiangnon, A. Jetsrisuparb (Thailand)
POSTER SESSIONS

PB 2335  Retrospective Cohort Study of Venous Thromboembolism (VTE) Rates in Ambulatory Cancer Patients, and Association with Khorana Score
K. Austin, J. Borrowman, L. Blake, M. Scully, M. Thomas (United Kingdom)

PB 2337  Subclinical Portal Vein Thrombosis in Liver Cirrhosis Patients Increase Risk of 30 Days Mortality: Preliminary Study
A. Kurniawan, N.P.H. Lugito (Indonesia)

PB 2338  Relationship of Platelets Parameters with JAK2 V617F Mutation Status and Thrombotic Risk in Myeloproliferative Disorders
H. Baccouche, D. Bahri, A. Chakroun, S. Mahjoub, Z. Manai, N. Ben Romdhane (Tunisia)

PB 2339  Genetic Forms of a Thrombophilia in Cancer Patients with Recurrent VTE
V. Vorobev, A. Makatsariya, A. Solopova (Russian Federation)

PB 2340  Acute Pulmonary Embolism in Cancer Patients: Clinical Findings and Outcome
B. Vitola, D. Kigitovica, V. Gibietis, S. Strautmane, A. Skride (Latvia)

PB 2341  Subarachnoid Hemorrhage and General Anesthesia Inhibit the Brain (G) Lymphatic System in Mice and Non-human Primates
M. Gauberti, T. Gaberel, S. Goursaud, S. Martinez de Lizarrondo, D. Vivien, C. Gakuba (France)

PB 2342  Association between Hepatic Triglyceride Content and Coagulation Factor Levels: The Netherlands Epidemiology of Obesity (NEO) Study

PB 2343  Portal Vein Thrombosis Associated with Abdominal Inflammatory Conditions
V. Tran, A. Acuna-Villaorduna, H. Billett (United States)

PB 2344  Role of ADAMTS13 Deficiency in the Pathogenesis of Portal Vein Thrombosis Complicating Liver Cirrhosis
S. Lanciellotti, M. Basso, M. Sacco, L. Riccardi, M. Pompili, R. De Cristofaro (Italy)

PB 2345  Haemostatic Changes in Cirrhotic Patients Treated with Direct-acting Antiviral Therapy

PB 2346  The Risk of Venous Thromboembolism in Women with Polycystic Ovarian Syndrome: An Italian Study

PB 2347  Fibrinogen Estimation in Patients with Liver Disease

PB 2348  A Rat Model to Evaluate Formation of Venous Thromboembolism after Prolonged Tourniquet Application

PB 2349  Increased Baseline TF Activity in Women with Unexplained Pregnancy Loss: An Additional Argument for a Basal Endothelial Dysfunction?
E. Pasquier, P. Van Dreden, A. Rousseau, L. de Saint Martin, D. Mottier, F. Couturaud (France)

PB 2350  HABP2 (PHBP/FSAP) is the Major Plasma Protease that Promote Extracellular Histone Degradation
Y. Amemiya, J. Mutoh, E. Suzuki, K. Hasumi (Japan)

PB 2351  Adjunctive Hemostatic Application of Highly Adhesive Drug Loadable Powder for Partial Hepatectomy Bleeding in a Swine Model
L. Eunhye, M. Jin Hee, A. Sukyung, K. Keunsu, L. Don Haeng (Republic of Korea)

PB 2352  The ratio “Tissue Factor / Tissue Factor Pathway Inhibitor” as a Major Determinant of Hypercoagulability in Cirrhotic Patients
P. Van Dreden, M. Grosse, D. Francois, R. Bironien, M. Vasse (France)

PB 2353  Upper Regulation of Plasma Endocan and D-Dimers in Individuals with Compensated Liver Disease
D. Van Thiel, M. George, D. Hoppensteadt, D. Syed, R. Wahi, D. Fareed, J. Fareed (United States)

PB 2355  Effect of Extract Ethanol of Poguntano Leaves in Hemostasis Disturbances in Alloxan Induced Diabetic Rats
S.S. Widjaja, D. Munir (Indonesia)

PB 2356  Recurrent Budd-Chiari Syndrome (BCS) in a Patient with Polycythemia Vera (PV), Protein S Deficiency and Hyperhomocysteinemia (HH) and Abnormal Resistance to Activated Protein (APCR) in the Absence of Factor V Leiden Mutation (FVL) Following Liver Transplant
A. Sikorska, B. Ceglarek, B. Baran, E. Pleban, K. Bykowska, P. Szopiński (Poland)
**POSTER SESSIONS**

### Platelets - Clinical

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 2357</td>
<td>Knock down the CD70 Expression in DCs Could Inhibit the CD4+ T Cells Differentiating to Tregs in ITP</td>
<td>Z. Zhou, Y. Wang, H. Li, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2358</td>
<td>IL-10 Producing B Cells Induced by CD72 Ligation Suppress Th1 and Th17 Polarization in Primary Immune Thrombocytopenia</td>
<td>M. Lu, Y. Hao, Y. Li, C. Lyu, H. Li, F. Xue, X. Liu, L. Zhang, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2359</td>
<td>Impact of Platelet Transfusion on Thromboembolic Events in Patients with Acute Heparin-induced Thrombocytopenia</td>
<td>S. Miyata, T. Maeda, H. Yamamoto, H. Okazaki (Japan)</td>
</tr>
<tr>
<td>PB 2361</td>
<td>Anticoagulation Stewardship Program for Heparin Induced Thrombocytopenia: A Cooperative Effort between a Community Hospital System Pharmacy Anticoagulation Service and an Associated Reference Laboratory</td>
<td>C. Mahan, L. Kelly, A. Pierce, A. Burnett, A. Haghamed (United States)</td>
</tr>
<tr>
<td>PB 2362</td>
<td>IP-10 and MCP-1 Gene Polymorphisms in Chinese Patients with Chronic Immune Thrombocytopenia</td>
<td>X. Zhang, D. Zhang, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2363</td>
<td>Decreased TLR4 Expression on Monocytes May Cause Regulatory T Cells Abnormality in Patients with Primary Immune Thrombocytopenia</td>
<td>Y. Hao, H. Li, Y. Li, M. Lyu, R. Fu, L. Zhang, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2364</td>
<td>The Abnormal Expression of Rap1 in Various Cells of Patients with Immune Thrombocytopenia</td>
<td>W. Liu, H. Li, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2365</td>
<td>Resequencing of GWAS Loci Identifies New Candidate Genes on Chromosome 5 for Heparin-induced Thrombocytopenia</td>
<td>A. Witten, J. Bolbrinker, A. Barysenka, F. Rühle, E. Garbe, R. Kreutz, M. Stall (Germany)</td>
</tr>
<tr>
<td>PB 2366</td>
<td>Elevated Plasma sCXCL16 Correlated with Th1 Polarization in Patients with Primary Immune Thrombocytopenia</td>
<td>Y. Hao, Y. Li, H. Li, M. Lyu, R. Fu, L. Zhang, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2367</td>
<td>Time to Disappearance of Platelet-activating Antibodies Depends on the Strength of Their Platelet Activating Properties in Patients with Heparin-induced Thrombocytopenia</td>
<td>T. Maeda, H. Okazaki, S. Miyata (Japan)</td>
</tr>
<tr>
<td>PB 2369</td>
<td>The Th17/Treg Imbalance and Fatigue in Primary Chronic Immune Thrombocytopenia</td>
<td>Y. Li, Y. Hao, M. Lyu, H. Li, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2370</td>
<td>Predictors of Fatigue among Individuals with Primary Immune Thrombocytopenia in China</td>
<td>Y. Li, Y. Hao, M. Lyu, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2371</td>
<td>Elevated Plasmacytoid DCS Proportion and Plasma IFNα Concentration in Active ITP Patients</td>
<td>H. Li, Y. Hao, R. Yang (China)</td>
</tr>
<tr>
<td>PB 2372</td>
<td>A Prospective, Double-blind, Multicenter Study on FCM-based Measurement of Circulating Reticulated Platelets as a Diagnostic Assay for Immune Thrombocytopenia</td>
<td>Y. Hou, R. Xu, D. Li, K. Bi, X. Wang, C. Zheng, M. Hou, J. Peng (China)</td>
</tr>
<tr>
<td>PB 2373</td>
<td>Comparison Head-to Head of Two Functional Assays in the Assessment of Heparin-induced Thrombocytopenia</td>
<td>M.-C. Gonthier, D. Faille, M. Alhenc-Gelas, C. Pouplard, N. Hezard, M.-G. Huisse, M.-C. Bourrienne, N. Ajzenberg (France)</td>
</tr>
<tr>
<td>PB 2374</td>
<td>Regulation of FcyRIIA-mediated Platelet Activation by a Cytochalasin-sensitive Cytoskeletal Rearrangement: its Clinical Application to the Detection of Functional HIT Antibody</td>
<td>A. Yasumoto, Y. Yatomi (Japan)</td>
</tr>
<tr>
<td>PB 2375</td>
<td>Vitamin D Receptor Gene Polymorphisms in Adult Primary Immune Thrombocytopenia</td>
<td>M. Sakr (Egypt)</td>
</tr>
<tr>
<td>PB 2376</td>
<td>Anti-PF4/Heparin Antibodies and Platelet Derived PF4 Bearing Microparticles in Acute Sepsis</td>
<td>M.T. Sartori, C. Zurlo, E. Campello, M. Bon, E. Duner, C.M. Radu, R. Bendo, P. Simioni, F. Fabris (Italy)</td>
</tr>
</tbody>
</table>
PB 2377  Monocyte Subsets and Platelet Apoptosis in Patients with Primary Immune Thrombocytopenia  

PB 2378  BAFF-TACI Signaling Promotes the Differentiation of Terminal Effector T Cells in Primary Immune Thrombocytopenia (ITP)  
Y. Min1, X. Li1, M. Nie1, C. Wang1, P. Jun1, M. Hou1, N. Li2, Y. Shi1 (1China, 2Sweden)

PB 2379  Delayed Clearance of Argatroban in Patients with Heparin Induced Thrombocytopenia  
E. Groarke, A.M. Sweeney, N. O'Connell (Ireland)

PB 2380  Sleep Quality in Chinese Patients with Primary Immune Thrombocytopenia: Contributing Factors and Effects on Health-related Quality of Life  
Y. Li, B. Sun, Y. Hao, M. Lyu, H. Li, R. Yang (China)

PB 2381  Immune Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection and Non-alcoholic Fatty Liver Disease  
T. Saralidze, F. Gabunia, N. Gogokhia, T. Svanidze, T. Saralidze (Georgia)

PB 2382  Epidemiology and Management of Immune Thrombocytopenia: A Nationwide Population-based Study in Korea  

PB 2383  Laboratory Identification of Heparin Induced Thrombocytopenia: A Re-evaluation  
E.J. Favaloro, G. McCaughan, K.K.E. Lau, S. Mohammed, L. Pasalic (Australia)

PB 2384  Experience in Diagnostic Assays for Heparin-induced Thrombocytopenia  
A. Keren Politansky, R. Hoffman, Y. Nadir, B. Brenner, G. Sarig (Israel)

PB 2385  Prevalence of Heparin Induced Thrombocytopenia among Iranian Patients with Cardiac Surgery  
M. Shahbazi, M. Ahmadinejad, A. Chegini, R. Shamriz, Z. Ahmadinejad (Iran, Islamic Republic of)

PB 2386  HIT or Miss: Improving the Quality of Diagnosing Heparin-induced Thrombocytopenia at an Academic Medical Center  
M. Schaffner, I. Bogdanich, M. Zimmerman, J. Smelser, R. Hobbs, U. Pererepu (United States)
### POSTER SESSIONS

| PB 2399 | Neuropilin-1 Expression on Regulatory T Cell Can Affect its Immunosuppressive Function in ITP  
H. Zhou, L. Su, L. Liu, Y. Song (China) |
|-----------------|------------------------------------------------------------------------------------------|
| PB 2400 | Thrombotic Events in Patients Treated with Eltrombog  
| PB 2401 | Familial Thrombocytopenia - Course of 3 Subsequent Pregnancies in an Idiopathic Thrombocytopenic Purpura (ITP) Patient; Case Report  
J.M. Teliga-Czajkowska, A. Sikorska, B. Ceglarek, K. Bykowska, E. Dmoch-Gazierska, K. Czajkowski (Poland) |
| PB 2402 | Treatment Options and their Outcomes in Pediatric Immune Thrombocytopenic Purpura Patients  
K. Perveen, S. Ansari, S. Parveen, S. Munzir, T. Shamsi (Pakistan) |
| PB 2404 | Childhood Immune Thrombocytopenic Purpura (ITP) in Gorgan Taleghani Hospital  
N. Mirbehbahani, Z. Payab (Iran, Islamic Republic of) |
| PB 2405 | Pharmacokinetic Variations, Fc Receptor Polymorphisms and their Impact on Response to IVIG in Pediatric Immune Thrombocytopenia  
| PB 2406 | Fetal/Neonatal Alloimmune Thrombocytopenia - An Underestimated Life-threatening Clinical Condition  
L. Bonstein, R. Lauterbach, N. Atweh, A. Abu-rumi, N. Haddad (Israel) |
| PB 2407 | Variable Impairment of Platelet Function in Patients with Severe, Genetically Linked Immune Deficiencies  
M. Napy, T.G. Mastenbroek, N.I.A. Mattheij, S. de Witt, K.J. Clemetson, J.M.E.M. Cosemans, B. Zieger, J.W.M. Heemskerk (The Netherlands, Switzerland, Germany) |
| PB 2408 | Whole Blood Aggregometry to Assess Platelet Function in Children on Cardiopulmonary Bypass  
R. Bercovitz, C. Drew, S. Jobe, D. Newman (United States) |
| PB 2409 | Platelet PAC1 expression and dense granules function reflects bleeding severity in children  
P. Zharkov, I. Demina, D. Fedorova, M. Panteeleev (Russian Federation) |

### POSTER SESSIONS

| PB 2411 | Utility of Small Volume Whole Blood Platelet Function Assays in Adolescent Women with Heavy Menstrual Bleeding  
A. Rocheleau, A. Khader, A. Ngo, M. Recht, O. McCarty, K. Haley (United States) |
|-----------------|------------------------------------------------------------------------------------------|
| PB 2412 | Novel Mutations in Thai Patients with Glanzmann Thrombasthenia  
D. Sosothikul, P. Suchartlikitwong, K. Kittikalayawong, R. Hirunsatit, C. Ittiwut, V. Shotelersuk, K. Suphapeetiporn (Thailand) |
| PB 2413 | Chemotherapy Induced Thrombocytopenia and Bleeding in Children and Young Adults with Cancer  
| PB 2414 | Pregnancy Management of Fetal Alloimmune Thrombocytopenia (NAIT): A Case Report  

### Vascular Biology & Angiogenesis

| PB 2415 | Thioredoxin Interacting Protein Endothelial Deletion Protects from Alterations of Angiogenic Process in Adult Mice Submitted to Vascular Accelerated Aging  
A. Domingues, D. Dizier, P. Gaussem, C. Boisson-Vidal, N. Nivet-Antoine (France) |
|-----------------|------------------------------------------------------------------------------------------|
| PB 2416 | FHL2 is Important for Angiogenesis and Regulates TF Expression in Normal Vasculartone  
C. Kroone, H.H. Versteeg (The Netherlands) |
| PB 2417 | MiRNA-21 Mediates the Antiangiogenic Activity of Metformin through Targeting PTEN and SMAD7 Expression and PI3K/AKT Pathway  
M. Luo, X. Tan, J. Wu (China) |
| PB 2418 | Role of SerpinE2 (PN-1) in Diabetic Microangiopathy  
L. Idir, A. Aymonnier, Y. Boulaftali, M. Jandrot-Perrus, M.-C. Bouton, V. Arrocas (France) |
| PB 2419 | Human Aortic Valvular Interstitial Cells: Evidence of Vasculogenic Potential during Aortic Valve Stenosis  
**POSTER SESSIONS**

**PB 2420**  
Nestin Is an Endothelial Enriched Protein in the Nonproliferative Vasculature with Potential Role in Endothelial Apoptosis  
P.Dusart¹, L. Fagerberg¹, B. Hallström¹, M. Uhlén¹, M. Civelek², M. Germain³, P. Morange¹, D.-A. Tregouet¹, T. Renné¹, J. Odeberg¹, L. Butler¹  
¹(Sweden, ²United States, ³France)

**PB 2421**  
Shiga Toxin Type 2, a Causal Agent of Hemolytic Uremic Syndrome, Improved Angiogenic and Repair Abilities of Late Outgrowth Endothelial Progenitor Cells  

**PB 2422**  
Osteoprotegerin Promotes Tumour Development by Increasing Neovascularization  
C. Boisson-Vidal¹, Z. Benslimane-Ahmim¹, A. Lokajczyk¹, B. Dizier¹, D. Heymann²  
¹(France, ²United Kingdom)

**PB 2423**  
Platelet Endothelial Aggregation Receptor-1 (PEAR1) Modulates Neovascularisation Via the Notch Pathway  
M. Criel, K. Cludts, L. Marleen, C. Vandenbriele, L. Liesenborghs, P. Verhamme, M. Hoylaerts (Belgium)

**PB 2424**  
Angiostatin Demonstrates Differential Hypoxic-dependent Anti-angiogenic Effects on Cardiac Endothelial Cells Derived from Non-vs Type 2 Diabetics  
G. Govindasamy, N. Lifeso, P. Jurasz (Canada)

**PB 2425**  
Structural and Functional Study of Hypochlorous Acid Modified Human Antithrombin: Possible Role in Cancer  
P. Ahmad, M.A. Jairajpuri (India)

**PB 2426**  
Frequency of Post Thrombotic Syndrome (PTS) in Patients with Proximal Deep Venous Thrombosis (DVT) - A Prospective Observational Study from a Tertiary Care Hospital in North India  

**PB 2428**  
Intracellular von Willebrand Factor Prominently Influences Angiogenesis  
S. Selvam, M. Bowman, C. Pruss, P. James (Canada)

**PB 2429**  
Low Grade Inflammation Inhibits VEGF Induced HUVECs Migration in p53 Dependent Manner  
M. Yamakuchi, S. Panta, T. Hashiguchi (Japan)

**PB 2430**  
Oroxin A Effectively Inhibits Breast Cancer Cell-mediated Tumor Vasculogenic Mimicry  
J. He¹, J. Wang, X. Yang, H. Qian, L. Qin (China)

**POSTER SESSIONS**

**PB 2431**  
Acidic preconditioning improves endothelial progenitor cell survival and angiogenesis under proinflammatory conditions and post-ischemic tissue regeneration in a murine model of type II diabetes  
S. Negrotto¹, H.A. Menà³, C. Boisson-Vidal², M. Schattner¹  
¹(Argentina, ³France)

**PB 2432**  
Angiopoietin-2 Reduces Arteriogenesis Associated with the Suppression of the Infiltration of Macrophages in Mouse Ischemia Hindlimb Model  
J. Wu¹, X. Tan, K. Yan (China)

**PB 2433**  
Role of Circulating Endothelial Progenitor Cells at the Early-stage of Neovascularization in Post-menopausal Luminal-A-Type Breast-cancer Patients  
B. Ruszkowska-Ciastek, P. Rhone, R. Wieczór, D. Roś (Poland)

**PB 2434**  
Pro-Angiogenic Biomarkers are Upregulated in Patients with Advanced Osteoarthritis Undergoing Orthopedic Surgery  
L. Shih, M. Rondina, N. Guler, D. Syed, A. Walborn, D. Hoppensteadt, J. Fareed (United States)

**PB 2435**  
VEGF-induced Angiogenesis Requires Autophagy  
K. Spengler, N. Kryeziu, S. Lindenmüller, L.-O. Klodz, A.S. Mosig, R. Heller (Germany)

**PB 2436**  
G-protein Coupled Receptor 15 Mediates Angiogenesis and Cytoprotective Function of Thrombomodulin  
B. Pan¹, X. Wang², C. Nishioka¹, G. Honda¹, L. Zeng³, K. Xu¹, T. Ikezoe¹  
¹(Japan, ²China)

**PB 2437**  
CCL5 and CXCL4 Are Rapidly Internalized in Endothelial Cells  
T.M. Hackeng, R.R. Koenen (The Netherlands)

**PB 2438**  
Biased Activation of PAR1: Dissecting Signal Transduction Networks that Regulate the Endothelial Barrier Function  
B.L. van den Eshof, A.J. Hoogendijk, P.J. Simpson, F.P.J. van Alphen, K. Mertens, A.B. Meijer, M. van den Biggelaar (The Netherlands)

**PB 2441**  
Free Heme Triggers the Disruption of the Endothelial Barrier  
M.M.L. Fiusa¹, D. Garcia-Weber², M. Lazarini³, J.M. Annichino-Bizzacchi³, F. Ferreira Costa¹, J. Millà³, E.V. de Paula¹  
¹(Brazil, ²Spain)
**POSTER SESSIONS**

PB 2442  
The Relevance Study of between miRNA Machinery Gene Polymorphisms (DICER rs3742330A>G, DROSHA rs10719T>C, RAN rs14035C>T, XPO5 rs11077A>C, DGCR8 rs417309G>A) and the Risk of Recurrent Implantation Failure (RIF) in Korean Women  

PB 2443  
Plasma microRNA (miRNA) Profiling in Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin Receptor Agonists (TPO-RA)  
I. Garabet	extsuperscript{1}, W. Ghanima	extsuperscript{1}, A. Rangberg	extsuperscript{1}, R. Teruel-Montoya	extsuperscript{1}, C. Martinez	extsuperscript{2}, J.B. Busset	extsuperscript{1}, P.M. Sandset	extsuperscript{1}, C. Monceyron Jonassen	extsuperscript{1} (1Norway, 2Spain, 3United States)

PB 2444  
The Role of miR-143 in Collateral Vessel Growth  
T. Hammerschick, K. Troidl, K.T. Preissner, S. Fischer (Germany)

PB 2445  
Circulating miRNA-24 as a Potential Biomarker for Coronary Heart Disease in Type 2 Diabetes Mellitus Patients  
X. Deng, M. Luo, J. Wu (China)

PB 2446  
Circulating Extracellular Vesicles microRNA Profile in Transfusion Dependent β-Thalassemia  
C. Levin, A. Rebibo-Sabbah, A. Koren, B. Brenner, A. Aharon (Israel)

PB 2447  
Plasma miR-103b as a Novel Biomarker for Screening Pre-diabetes and Newly Diagnosis of Type 2 Diabetes  
M. Luo, Y. Luo, J. Wu (China)

PB 2448  
Overexpression of p21Cip1 and p27Kip1 Regulates the Proliferation of Endothelial Colony Forming Cells from Patients with Deep Venous Thrombosis  
J.A. Alvarado Moreno, D. Moreno Lorenzana, J.R. Hernández López, J. Ramirez-Chan, I. Isordia Salas, M.A. Chávez Gonzalez, A. Majul Cruz (Mexico)

Publication Only

PO 01  
New Potential Marker for Analysis of the Organism State Under the Cardiovascular Disorders  
Y. Tyravska, V. Lizogub, T. Katri, O. Savchuk (Ukraine)

PO 02  
Apolipoproteins and Serum Inflammatory Markers in Young Patients with Myocardial Infarction  

PO 03  
Particularities of Superficial Venous Thrombosis  

PO 04  
Venous Thrombosis in Systemic Lupus Erythematosus  

PO 05  
Clinical Profile of Digestive Thrombosis Patients  

PO 06  
Prevalence of Resistance to Anti-platelet Therapy among Patients with Ischemic Stroke - Preliminary Results  
A. Pathare, O. Al Awidi, A. Alfayybi, A. Gujjar (Oman)

PO 07  
Intracerebral Hemorrhage under Antithrombotic Medication in a Recent Year  
T. Nakase, J. Moroi, T. Ishikawa (Japan)

PO 08  
Methylenetetrahydrofolate Reductasa (MTHFR) C 677 Mutation-risk Factor for Ischemic Stroke or Not - Case Report  
D. Stambolieva, M. Sorova (Macedonia, the Former Yugoslav Republic of)

PO 09  
Role Glycin-containing Olygopeptides in Platelet Aggregation  
M. Golubeva (Russian Federation)

PO 10  
Bleeding Disorders in Ashkenazi Jews  
H.D. Solomons (South Africa)

PO 11  
Management of a Severe Congenital Protein C Deficiency Case  
N. Ozdemir, H. Kızılocak, G. Dikme, T. Celkan (Turkey)

PO 12  
Laboratory Detection of Thrombophilic Markers Frequency  
V. Necseva (Macedonia, the Former Yugoslav Republic of)
POSTER SESSIONS

XXVI ISTH Congress and 63rd Annual SSC Meeting

PO 13
Red Blood Cells Distribution Width to Estimate Lupus Activity
S. Shoeib, M. Abdelhafez, A. Hassan, H. Sherif (Egypt)

PO 14
Levels of von Willebrand Factor Antigens in Apheresis Donors and in Mild Bleeders with Near Normal Screening Coagulogram: A Study from a Tertiary Care Teaching Hospital, South India
R. Kar, P.L. Ambika, R. Kulkarni, D. Basu, S.S. Kar (India)

PO 15
Screening Test for Leiden Mutation Relevance
N. Lazic, Z. Pastar, D. Mandic (Bosnia and Herzegovina)

PO 16
Simultaneously Label-free Measurement of Hemoglobin Concentration and Erythrocyte Shape by Scanning Flow Cytometry
E. Iastrebova, K. Gilev, A. Chernyshev (Russian Federation)

PO 17
Interaction of Antithrombotic Preparation Pijavit with Proteinase Complex Longolytin and its Producer Imperfect Fungi Arthrobortys Longa
L. Podorolskaya, T. Sharkova, I. Pavlova (Russian Federation)

PO 18
Immune Tolerance Induction in an Adult Haemophilia A Patient with a Long-standing Inhibitor
C. Feistritzer, D. Nachbaur, M. Steurer (Austria)

PO 19
Evaluation of the Quality and Safety of Care in Hemophilia Self-treatment

PO 20
Participation of a Group of Healthcare Professionals in the Improvement of Hemophilia Treatment in Latin America

PO 21
Successful Non-operative Management of Intra-abdominal Hemorrhage in Patient with Hemophilia
H.S. Yoon, M.J. Kim (Republic of Korea)

PO 22
Inhibitor Screening of Children with Hemophilia in the Diyarbakir - A Single Centre Study
M. Söker, H. Uzel, K. Öncel, S. Söker (Turkey)

PO 23
Liver Transplantation in Hemophilia Patients
A. Aires, M.J. Diniz, M. Antunes, A. Santos, T. Araújo, A. Mascarenhas, M. Rameiras, M. Campos, A. Ribeiro, S. Gouveia, E. Barroso, R. Perdigoto, A. Ferreira (Portugal)

PO 24
Chronic Osteolytic Lesions Secondary to Gigantic Pseudotumor of the Thigh in a Young Adult with Hemophilia B: Poor Prognosis and Outcome
R. Silva, J. Marun, D. Perez (Colombia)

PO 25
Pseudotumor ans Succeful Conservative Management in Hemophilia Patient with Inhibitors
R. Silva, J. Marun, D. C (Colombia)

PO 27
Unexpected Incidence of Inhibitor Development in a Hemophilic Population from the North of Spain
L.F. Avila Idrovo, A. Bernardo Gutierrez, D. Martinez Carballeira, I. Soto Ortega (Spain)

PO 28
Hereditary Hypofibrinogenemia - Rare Familial Disease with Tendency to Increased Bleeding
J. Prochazkova, L. Slavik, J. Ulehlova, V. Krcova, A. Hlusi (Czech Republic)

PO 29
A Case with Factor X Deficiency and Malignant Melanoma
B. Koc, S. Buyukkapu Bay, B. Zulfikar, F. Taq, R. Kebudi (Turkey)

PO 30
Inherited Thrombocytopenia - Impact on Patient's QOL
J.M. Teliga-Czajkowska, A. Sikorska, B. Ceglarek, K. Bykowska, A. Buđko, E. Dmoch-Gajzlerska, K. Czajkowski (Poland)

PO 31
Duodenal Dieulafoy’s Lesion in a Patient with Type 2 von Willebrand Disease: Case Report from Colombia
J. Restrepo-Avenia, J. Duque-Gil, J. Ramirez-Varela (Colombia)

PO 32
Von Willebrand Disease Diagnosis in Algeria: A Monocentric Study
H. Boukerb (Algeria)

PO 33
The Relevance of Personalized Therapy by New Oral Anticoagulants. Current Possibilities of Laboratory Monitoring and Control in Difficult Patients
S. Safiullina, T. Vuimo, I. Tyutlina, L. Feiskhanova (Russian Federation)

PO 34
Long-term Anticoagulation with Direct Oral Anticoagulants (DOACs) for the Prevention of Recurrent Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE)
R. Santoro, P. Iannaccaro, S. Morgione, M.T. Paparo (Italy)

PO 35
Laboratory Tests for Management in Patient with Direct Oral Anticoagulants
L.F. Avila Idrovo, A. Bernardo Gutierrez, A. Caro Gomez, A. Fonseca Mourele, L. Rodriguez Lorenzo, A.P. Rodriguez Gonzalez, I. Soto Ortega (Spain)
POSTER SESSIONS

PO 36  Effective reversal of High Dose Dabigatran Intoxication by Idarucizumab in a Bleeding Polytrauma Patient  
S. Ohlenforst, V. Ivaskevicius, C. Deborre, N. Theuerkauf, C. Putensen, J. Oldenburg, H.-J. Hertfelder (Germany)

PO 37  Does Intra-venous Unfractionated Heparin (UFH) Have a Role In the Management of Acute Peripheral Vascular Ischaemia and Surgery In 2017?  
M. Creagh, S. Matthews, V. Sathish, X. Taylor (United Kingdom)

PO 38  Oral Anticoagulants in Patients with Hereditary Protein Z Deficiency - A Case Report  
J.C. Groß, B. Hummel, H. Lauer, B. Stephan, J. Schenk, H. Eichler (Germany)

PO 39  Prevalence of Laboratory Markers of Thrombophilia in Pregnant Women with Normal Obstetric Outcomes  
E. Ferreira Filho, V. Barros, F. Baptista, R. Francisco, M. Zugaib (Brazil)

PO 40  Variation of Clotting Factor Levels of Pregnant Women Attending Antenatal Clinics in Irrua Specialist Teaching Hospital (ISTH), Irrua, Edo State, Nigeria  
R.A. Anyanwu, K.C. Lele (Nigeria)

PO 41  Catastrophic Antiphospholipid Syndrome in Obstetrics Practice (Clinical case)  
A. Makatsariya, V. Bitsadze, D. Khizroeva (Russian Federation)

PO 42  Personalized Antithrombotic Prophylaxis in Patients with Multigenie and Combined Forms of Thrombophilia and APS  
V. Bitsadze, D. Khizroeva, A. Makatsariya, D. Kapanadze (Russian Federation)

PO 43  Thrombophilia and IVF  

PO 44  Risk Factors and Outcome of Thromboembolism in Pregnancy and Postpartum Period: A Two Years Retrospective Analysis in a Tertiary Care Hospital of Pakistan  
A. Rashid, B. Moiz (Pakistan)

PO 45  The Clinical Significance of Determining Homocysteine Levels and Functions of the Natural Anticoagulants in Women Taking Combined Oral Contraceptives and Planning Pregnancy  
V. Bitsadze, N. Khamani, O. Kaplina (Russian Federation)

PO 46  Case Reports of Successful Management of Pregnancy Complications and VTE in Women with Inherited Thrombophilia  
L. Makhaldiani, N. Pirtskhelani, N. Kochiashvili, K. Kartvelishvili (Georgia)

PO 47  Control of the Anticoagulants and Antiplatelets during the Pregnancy in Women with Complicated Obstetric Medical History with Routines and Global Tests for Assessment of Hemostasis  
S. Safiullina, T. Vuimo, L. Feiskhanova, N. Ilizarova (Russian Federation)

PO 49  β2GPI Titer and its Clinical Correlation with Laboratory Antiphospholipid Antibodies Syndrome Presented by Fetal Loss  
N. Kassim, M. Ismail, D. Khattab, A. Atta, A. Salama, R. Mohie Eldine (Egypt)

PO 50  Antiphospholipid Syndrome in Pregnancy: A Case Report  
F. Raka (Macedonia, the Former Yugoslav Republic of)

PO 51  One Hundred Days of Repetitive Thrombosis - Diagnostic and Therapeutic Challenge  
N. Diaconu, Doina Bejenari (Moldova, Republic of)

PO 52  Pulmonary Thromboembolism: A Rare Cause of Respiratory Distress in Infants with Neuroblastoma  
T. Patiroglu, S. Kose, A. Ozcan, E. Unal, M. Karakukcu, A. Coskun (Turkey)

PO 53  A Challenging Deep Venous Thrombosis in a Child  
A. Unuvar, S. Karaman, Z. Karakas, B. Bilgic, M. Aksoy (Turkey)

PO 54  Use of Direct Oral Anticoagulants in Multiple Myeloma Patient with Atrial Fibrillation  

PO 55  Clinical Analysis of 399 Cases of Malignant Tumor Complicated with Venous Thrombosis in the Uygur and Han nationality in Xinjiang  
Q. Luo (China)

PO 56  Circulating Neutrophil-extracellular Traps (NETs) Are Elevated in Patients with Endometriosis  
D. Tàssies, J. Munrós, A. Perez, F. Carmona, J.C. Reverter, M.A. Martinez-Zamora (Spain)

PO 57  Thrombophilia Associated with an Unusual Presentation of Liver Fibrosis/ Cirrhosis and Splanchnic Vein Thrombosis  

PO 58  Antithrombin Activity in Newly Diagnosed Diabetis Mellitus Patient seen at the University of Benin Teaching Hospital, Benin City, Nigeria  
B. Nwogoh, K. Akaba (Nigeria)
POSTER SESSIONS

PO 59  Portal, Mesenteric and Splenic Vein Thrombosis in a Patient with Homozygous Factor V Leiden Mutation (A1691G) Receiving Oral Contraception
A. Sikorska, B. Ceglarek, K. Bykowska, A. Bucko, A. Gwozdzowska, J.M. Teliga-Czajkowska, J. Windyga (Poland)

PO 60  Deep Vein Thrombosis in a Family with Leiden Mutation (FVL, G1691A), Antithrombin Deficiency (AT) and ARhD (+) Blood Type
A. Sikorska, B. Ceglarek, K. Bykowska, E. Odnoczko, B. Baran, J.M. Teliga-Czajkowska, J. Windyga (Poland)

PO 61  Prothrombotic Mutations, Protein C Deficiency and Hyperhomocysteinemia in a Patient Presenting Recurrent Venous Thrombosis
A. Sikorska, B. Ceglarek, K. Bykowska, B. Baran, E. Odnoczko, E. Pleban, P. Szopiński (Poland)

PO 62  Rise and Fall of Thrombophilia Law in Argentina
B. Grand, A. Rossi (Argentina)

PO 63  Hypofibrinogenemia and Thrombosis
Y. Ouarhlent, H. Laiaidhi., F. Mezhoud, R. Chafai (Algeria)

PO 64  Role of Thrombophilia Testing in Retinal Vein Occlusion: Single Center Experience from Oman
K. Al Hashmi, F. Al-Ghafri, A. Pathare (Oman)

PO 65  Acute Severe Thrombocytopenia Induced by Abciximab: A Case Report
L. Gonçalves, S. Afonso, H. Nascimento, A. Leite, C. Koch (Portugal)

PO 66  Prolactin Level in Patients’ Sera with Hepatitis C Virus Related Thrombocytopenia
A. Hassan, S. Shoeib, M. Abdelhafiez, W. Algheriany (Egypt)

PO 67  Study of Serum Prolactin in Primary Immune Thrombocytopenic Patients
M. Abdelhafiez, S. Shoeib, S. Gazareen, H. Elkholy (Egypt)

PO 68  Immune Thrombocytopenic Purpura in a Patient with History of Non-Hodgkin Lymphoma and Common Variable Immune Deficiency
F.N. Kalkan, Ş. Ünal, F. Gümruk, M. Çetin (Turkey)

NOTES

PO 59  Portal, Mesenteric and Splenic Vein Thrombosis in a Patient with Homozygous Factor V Leiden Mutation (A1691G) Receiving Oral Contraception
A. Sikorska, B. Ceglarek, K. Bykowska, A. Bucko, A. Gwozdzowska, J.M. Teliga-Czajkowska, J. Windyga (Poland)

PO 60  Deep Vein Thrombosis in a Family with Leiden Mutation (FVL, G1691A), Antithrombin Deficiency (AT) and ARhD (+) Blood Type
A. Sikorska, B. Ceglarek, K. Bykowska, E. Odnoczko, B. Baran, J.M. Teliga-Czajkowska, J. Windyga (Poland)

PO 61  Prothrombotic Mutations, Protein C Deficiency and Hyperhomocysteinemia in a Patient Presenting Recurrent Venous Thrombosis
A. Sikorska, B. Ceglarek, K. Bykowska, B. Baran, E. Odnoczko, E. Pleban, P. Szopiński (Poland)

PO 62  Rise and Fall of Thrombophilia Law in Argentina
B. Grand, A. Rossi (Argentina)

PO 63  Hypofibrinogenemia and Thrombosis
Y. Ouarhlent, H. Laiaidhi., F. Mezhoud, R. Chafai (Algeria)

PO 64  Role of Thrombophilia Testing in Retinal Vein Occlusion: Single Center Experience from Oman
K. Al Hashmi, F. Al-Ghafri, A. Pathare (Oman)

PO 65  Acute Severe Thrombocytopenia Induced by Abciximab: A Case Report
L. Gonçalves, S. Afonso, H. Nascimento, A. Leite, C. Koch (Portugal)

PO 66  Prolactin Level in Patients’ Sera with Hepatitis C Virus Related Thrombocytopenia
A. Hassan, S. Shoeib, M. Abdelhafiez, W. Algheriany (Egypt)

PO 67  Study of Serum Prolactin in Primary Immune Thrombocytopenic Patients
M. Abdelhafiez, S. Shoeib, S. Gazareen, H. Elkholy (Egypt)

PO 68  Immune Thrombocytopenic Purpura in a Patient with History of Non-Hodgkin Lymphoma and Common Variable Immune Deficiency
F.N. Kalkan, Ş. Ünal, F. Gümruk, M. Çetin (Turkey)
Participate in the ISTH Academy!
Your Personal Resource for Education

academy.isth.org

- 2017 Webinar Series, Plus Archived 2014-2016 Webinars Covering Laboratory and Clinical Science
- New! Integration with JTH Articles and Research
- Webcasts, Posters and Abstracts from Congresses and SSC Meetings
- Education Courses – Access the ISTH Course on Venous Thrombosis
- CME Opportunities

The ISTH Academy includes a comprehensive webinar series, educational webcasts and online webinar series, educational webcasts and online course modules for scientists, physicians and allied health professionals with notable speakers and health professionals with notable speakers and presenters on a variety of topics related to bleeding and clotting. All accessible from a computer and location of your choice, let the ISTH Academy provide you with the knowledge needed to advance science and patient care to improve the health outcomes for patients around the world.

Join Us! For more information on upcoming programming, visit academy.isth.org.

New Educational Opportunity: ISTH Training Fellowship Program
Attention early career professionals! The ISTH Training Fellowships are an excellent opportunity to study at prestigious host institutes with expert clinicians and researchers. Training Fellowship grants provide financial support for a period of up to two months for clinicians and scientists within 10 years of completion of a Ph.D. or clinical subspecialty training.

Learn more at isth.org/fellowships

Congress Information
Venue and Contacts
Venue Floor Plans
ISTH 2017 Attendee Services and Innovations
Congress Information
ISTH 2017 Networking Events
ISTH 2017 5K Charity Run/Walk
Local Information
Transportation
VENUE AND CONTACTS

Venue
Messe Berlin
Messedamm 26
14055 Berlin, Germany
T: +49 30-3038-3000
E: guestevents@messe-berlin.de
W: www.messe-berlin.de

Contacts
ISTH Headquarters:
International Society on Thrombosis and Haemostasis (ISTH)
610 Jones Ferry Road
Suite 205
Carrboro, NC 27510
USA
T: +1 919-929-3807
F: +1 919-929-3935
E: headquarters@isth.org
W: www.isth.org

Executive Meeting Matters:
Lisa Astorga
ISTH Director of Meetings
E: lisa_astorga@isth.org

Sponsorship and Exhibition:
Thomas Reiser
Executive Director
T: +1 919-929-3807
E: tom_reiser@isth.org

Marketing and Media:
Louise M. St. Germain
Director of Marketing and Membership
T: +1 919-929-3807
E: louise_stgermain@isth.org

Membership Questions or General ISTH Inquiries:
ISTH Membership Staff
T: +1 919-929-3807
E: membership@isth.org

ISTH 2017 Organizing Secretariat:
(Registration, Logistics, Exhibition, Hotel Accommodations)
c/o K.I.T. Group GmbH
Kurfuerstendamm 71
10709 Berlin
Germany
T: +49 30-24603-0
E: isth2017@kit-group.org
isth2017-registration@kit-group.org
isth2017-industry@kit-group.org

Abstract Questions:
E: abstracts@isth.org

Unmet needs require unmatched commitment.

Our purpose is clear: to make a difference in the lives of those living with and affected by rare diseases and highly specialized conditions.

For more information, please visit shire.com
VENUE FLOOR PLANS

CityCube Level 1 – Lower Level

On this Level:
Session Rooms: A1-A8
Speaker Ready Room
Partner Resource Center

*Only Saturday, Sunday, Thursday

VENUE FLOOR PLANS

CityCube Level ZE1 – Main Entrance/Registration Level

On this Level:
Registration Area
Congress Materials Pick Up
Industry Welcome Desks
Self Printing Terminals
Business Center
Cloakroom
Prayer Room

*Only Saturday, Sunday, Thursday
ANCILLARY MEETING ROOMS

Ancillary Meeting Rooms are pre-arranged by related organizations or partners for internal meetings on the occasion of the ISTH 2017 Congress. The locations of these meeting rooms are primarily in the CityCube Building of the congress center. Please check with the organizers of your meetings for the exact location.

BUSINESS CENTER

The convention center has its own Business Center that provides the following services:

- Printing (including business cards)
- Copying
- Faxing
- Scanning
- Use of laptop
- Internet
- Phone

The Business Center is located on the main entrance level of the CityCube Berlin.

BUSINESS CENTER HOURS:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, July 7</td>
<td>12:00–18:00</td>
</tr>
<tr>
<td>Saturday, July 8 –</td>
<td>08:00–18:00</td>
</tr>
<tr>
<td>Wednesday, July 12</td>
<td>08:00–18:00</td>
</tr>
<tr>
<td>Thursday, July 13</td>
<td>08:00–13:00</td>
</tr>
</tbody>
</table>

CERTIFICATES OF ATTENDANCE

Certificates of Attendance will be available for printing on Wednesday, July 12, and Thursday, July 13, at the REACT Fast terminals located in the Registration Area on the main entrance level of the CityCube Berlin. Attendees will need to scan their name badge to print a certificate.

CLOAKROOM AND LUGGAGE

The cloakroom (free of charge) is located on the main entrance level of the CityCube Berlin near the Registration Area. It is open at the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, July 8</td>
<td>08:00–18:00</td>
</tr>
<tr>
<td>Sunday, July 9 –</td>
<td>06:30–19:00</td>
</tr>
<tr>
<td>Wednesday, July 12</td>
<td>07:30–15:00</td>
</tr>
<tr>
<td>Thursday, July 13</td>
<td>08:00–18:00</td>
</tr>
</tbody>
</table>

COLLABORATIVE MEETING ROOMS

Located in Hall 6.2.b, the congress will feature Attendee Collaborative Meeting Rooms accommodating up to 10 persons and can be booked by congress attendees to meet and collaborate in private, formal meeting spaces. Collaborative Meeting Rooms are free to reserve for up to 45 minutes beginning at the top of each hour and are each equipped with a meeting table, seating, flat screen monitor, and cable to connect a personal laptop. Each congress attendee may reserve one 45-minute time slot per day. No catering will be provided.

To reserve a Collaborative Meeting Room, visit www2.kit.de/profileportal/login/ISTH/en or see the service desk in Hall 6.2b onsite.

CONFERENCE CAPTURES

Plenary and State-of-the-Art lectures of ISTH 2017 will be recorded and available online 24 hours after the presentation to both meeting attendees and ISTH members. These lectures can be accessed on the ISTH Academy at academy.isth.org or by downloading the ISTH Academy Mobile App (search Apple Store or Google Play for ISTH Congress). ISTH full members must use their ISTH login credentials for full access to the Academy. Non-member congress attendees must use their email address and password “isth2017” to access the meeting content. Contact headquarters@isth.org for any login issues. Conference captures, e-posters and Academy content may also be viewed in the ISTH 2017 Academy e-Education Zone located in Hall 6.2.a.

INTERNET STATIONS

The ISTH 2017 Internet Stations are located in three locations (one in each of the Exhibit Halls 2.2, 4.2 and 6.2.a), as well as in front of Hall B on Level 2 of the CityCube Berlin and allow participants to stay connected while attending the congress. Attendees can use the Internet Stations to check email, print airline boarding passes and search the internet. Each station features eight (8) computer terminals as well as one (1) printer for the exclusive use of meeting attendees.

The ISTH 2017 Internet Stations are located in Hall 6.2b onsite.

CONGRESS CAPTURES

Plenary and State-of-the-Art lectures of ISTH 2017 will be recorded and available online 24 hours after the presentation to both meeting attendees and ISTH members. These lectures can be accessed on the ISTH Academy at academy.isth.org or by downloading the ISTH Academy Mobile App (search Apple Store or Google Play for ISTH Congress). ISTH full members must use their ISTH login credentials for full access to the Academy. Non-member congress attendees must use their email address and password “isth2017” to access the meeting content. Contact headquarters@isth.org for any login issues. Conference captures, e-posters and Academy content may also be viewed in the ISTH 2017 Academy e-Education Zone located in Hall 6.2.a.

The ISTH 2017 Congress publishes its official daily news online and via email during the meeting, as well as a post-congress issue two weeks following the meeting. The ISTH Congress Daily can be accessed via the Congress Mobile App and is also sent via email to all congress registrants and ISTH members. It can also be accessed directly at: www.isthcongressdaily.org.

INSTH TV

The ISTH is proud to present ISTH Congress TV, featuring 30 minutes of video programming Monday, Tuesday and Wednesday during the meeting. ISTH Congress TV focuses on the scientific content of the congress, such as reviewing top abstracts, interviews with authors, expert interviews and discussions on the impact of presented data on patient care and much more. Programming will be featured on the ISTH Congress Daily website and archived on the ISTH Academy.

ISTH CONGRESS VIRTUAL EVENT

Although the conference in Berlin will bring together the leaders in our field, we know there are many medical professionals that can’t be there face-to-face and would still benefit from the ISTH educational content. As the Society looks to the future and in an effort to engage a wider audience, an online component of the meeting is being offered at no charge. Select Plenary and State-of-the-Art sessions will be streamed around the world for those that are unable to attend. Sessions will be available each day to better accommodate international time zones. Live scientific moderators will be available online to answer virtual attendee questions. The content will be accessible July 12-13 from 15:30 to 18:30 UTC for those who register for the online meeting. Archives of the sessions will be available the following day on the ISTH Academy for ISTH members and congress participants. Please visit academy.isth.org for a schedule of the sessions and when they will be available for viewing.

Use your mobile device to navigate the ISTH 2017 Congress by downloading the free Congress Mobile App (Apple Store or Google Play)! It conveniently provides iPhone/iPad, Windows and Android smartphone and tablet users with on-the-go access to the ISTH 2017’s most important informational and interactive features, such as program overviews, speaker and abstract information, general meeting and exhibitor information, venue and city maps and tips.

Use your mobile device to navigate the ISTH 2017 Congress by downloading the free Congress Mobile App (search Apple Store or Google Play for ISTH Congress). ISTH full members must use their ISTH login credentials for full access to the Academy. Non-member congress attendees must use their email address and password “isth2017” to access the meeting content. Contact headquarters@isth.org for any login issues. Conference captures, e-posters and Academy content may also be viewed in the ISTH 2017 Academy e-Education Zone located in Hall 6.2.a.

The ISTH Congress Daily mobile app is available for viewing.
Congress attendees and ISTH members will receive wider access to recorded content and will be able to access all recorded sessions on the ISTH Academy website and Academy Mobile App 24 hours after the session.

**Job Board**

ISTH 2017 Congress participants may share open position announcements via a job board located in the Foyer to Building 7. Simply bring your printed job announcement(s) and use the provided board to display your announcements. ISTH members and congress participants are also encouraged to announce open positions via the ISTH Online Career Center at jobs.isth.org.

**Partner Resource Centers**

Partner organizations and congress organizers who would like to announce upcoming meetings may do so by displaying materials at the official Partner Resource Centers. Likewise, participants are encouraged to visit these Resource Centers to learn about upcoming scientific events in the field. Partner Resource Centers are located in the Foyer to Hall 7, in the Foyer to Hall A on Level 1 of the CityCube Berlin and in Hall 6.2.b.

**Passport Program**

Participate in the ISTH 2017 Passport Program by visiting exhibitors or other participating destinations, asking questions and learning about products and services of industry partners and/or Society and the congress. Gain new insights, earn points, compete with your fellow attendees and be eligible to win exciting prizes that the ISTH will raffle off among the highest ranked Passport Program participants. Conveniently access the Passport Program through the Congress Mobile App.

Download the ISTH app and scan this code to get started

![QR Code](image)

**Product Theaters**

New this year, ISTH 2017 features Product Theaters that allow companies and organizations to present new research findings on products, provide product details, and/or give demonstrations to a small group of interested participants. Product Theaters are located in each of the Exhibition Halls (2.2, 4.2 and 6.2.a) and their programs can be found in the dedicated section in this program, as well as in the official ISTH 2017 Show Guide publication. Product Theater presentations take place daily (Monday-Wednesday) between 12:15 and 13:00.

**Relax and Recharge Areas**

Relax and unwind in five (5) dedicated “Relax and Recharge” areas at the congress. Busy participants can sit, continue their conversations with colleagues or get some work done. These areas offer outlets to recharge computers/mobile devices either on site or to leave them in the provided charging stations. Relax and Recharge areas are located in the Exhibition Halls (three areas in Hall 2.2; two areas in Hall 4.2). Additional seating can be found in Hall 6.2.b.

**Show Guide to the Exhibition, Supported Symposia and Product Theaters**

For a detailed program of the Industry Symposia and Product Theater Sessions, as well as a full profile of the ISTH 2017 exhibitors (including floor plans), please consult the ISTH Show Guide. The Show Guide can be collected from distribution boxes around the congress center. Please return your Show Guide publication after use.

**Transit (Local)**

Participants have a logo on their name badge indicating that they have free access to all public transportation in Zone AB in Berlin. The closest station to the venue is The Messe Süd Station and is located across the street. Please note: Exhibitors do not have the logo on their badge.

Please visit the Berlin Public Transportation website at www.bvg.de for more information.

**Virtual Delegate Bag**

Consult the ISTH 2017 Virtual Delegate Bag to take advantage of a new and innovative service. Receive exclusive and valuable information from the ISTH and its partner organizations, as well as supporters and exhibitors. Conveniently accessible via the Congress Mobile App or via: goveb.co/ml/13ad97. The Virtual Delegate Bag is always with you without having to carry it around.
CONGRESS INFORMATION

Abstracts
ISTH 2017 abstracts are available online for easy viewing and download from the journal website of ISTH’s new open-access journal, Research and Practice in Thrombosis and Haemostasis (RPTH). Access them via the Congress Mobile App, the ISTH 2017 website at isth2017.org and/or the RPTH website at www.isth.org/rpth.

Accommodations
Participants who have booked their accommodations in advance can visit the Registration Help Desk counter located in the Registration Area on the main entrance level of the CityCube Berlin for any questions related to their hotel booking. The staff at this counter can also help you to find and book rooms if required and share pending availability.

ATM/Cash Machines
ATMs are widespread and found in most banks, hotels and shopping centers in Berlin. In the convention center, an ATM machine is located in the main entrance of the CityCube Berlin.

Badges
Participants receive their name badges when collecting their meeting documents onsite. Participants are required to wear a name badge during all meeting events, including the Networking Reception. Participants are required to wear a name badge during all meeting events, including the Networking Reception. For city information, please visit the Berlin Information Desk located near the Registration Area on the main entrance level of the CityCube Berlin.

Please note:
- Exhibitors are not admitted to the scientific sessions.
- The charge for the replacement of a lost badge is EUR 10.

Berlin Information Desk
For city information, please visit the Berlin Information Desk located near the Registration Area on Level 2 next to the escalators in the CityCube Berlin.

Date Price
Saturday, July 8 10:00–17:00
Sunday, July 9 09:30–18:00
Monday, July 10 09:00–16:00
Tuesday, July 11 09:00–16:00
Wednesday, July 12 09:00–16:00
Thursday, July 13 09:00–15:00

CME/Accreditation
The XXVI Congress of the ISTH and 63rd Annual Scientific and Standardization Committee (SSC) Meeting, Berlin, Germany, 08/07/2017-13/07/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 28 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Congress Bag
The congress bag, including all delegate materials, is distributed to registered participants at the congress bag desk in the Registration Area. Please note that there are no replacements for lost bags.

Duplicating/Recording
Any form of duplication (recording, audio taping, photography and/or video) of sessions is prohibited without expressed written consent of the author and congress organizer. Please do not use your mobile device to duplicate or record any sessions.

We kindly ask that attendees DO NOT photograph, record, film, or use a cellphone to capture images of presentations at any time during the meeting, as well as on the poster and exhibition floors.

Please note that you may be photographed, videotaped and/or recorded during your visit by the official ISTH 2017 photography/video team. By entering the ISTH 2017 Congress, you agree to each of the following: 1) You consent to be photographed, filmed and/or otherwise recorded in connection with, or as part of ISTH 2017 journalistic, advertising, marketing, promotional, archival and/or security activities; 2) You consent to such photography, filming and/or recording and to any use, in any and all media throughout the world in perpetuity, without compensation to you, of your appearance, voice and/or name for the above noted purposes; 3) You understand that all photography, filming and/or recording will be done in reliance on these consents given by you by entering the congress; 4) To protect, among other things, the personal information of our attendees, you agree not to reproduce, perform, display or upload any photographs of sessions/presentations.

Any form of duplication (recording, audio taping, photography and/or video) of sessions is prohibited without expressed written consent of the author and congress organizer. Please do not use your mobile device to duplicate or record any sessions.

Insurance and Liability
It is recommended that participants obtain adequate insurance coverage for travel, health and accidents before they depart from their countries of residence. ISTH and K.I.T. Group as organizers cannot accept responsibility for personal injuries, or loss of, or damage to private property belonging to the conference participants and accompanying persons.

ISTH Secretariat
The ISTH secretariat is located in Room M4 on Level 3 of the CityCube Berlin.

Language
The official language of the meeting is English. There is no simultaneous translation service provided.

Lost and Found
Found articles may be brought to the Registration Area on the main entrance level of the CityCube Berlin.

Lunches and Coffee Breaks
Lunch is provided as part of the registration fee on each of the congress days. Lunch vouchers are provided as part of the registration package. The vouchers are valid from Saturday, July 8, to Wednesday, July 12.

From Monday, July 10, to Wednesday, July 12, lunch and coffee breaks will be available in the catering areas of Exhibition Halls 2.2, 4.2 and 6.2. On Thursday, July 13, coffee and a lunch...

Exhibition Hours
The ISTH 2017 Industry Exhibition is located in Halls 2.2, 4.2 and 6.2.

Date Hours
Sunday, July 9 18:30–21:00 (Welcome Reception in the Exhibition Halls)
Monday, July 10 10:30–17:00
Tuesday, July 11 10:30–17:00
Wednesday, July 12 10:30–17:00

Lost and Found
Found articles may be brought to the Registration Area on the main entrance level of the CityCube Berlin.

Lunches and Coffee Breaks
Lunch is provided as part of the registration fee on each of the congress days. Lunch vouchers are provided as part of the registration package. The vouchers are valid from Saturday, July 8, to Wednesday, July 12.

From Monday, July 10, to Wednesday, July 12, lunch and coffee breaks will be available in the catering areas of Exhibition Halls 2.2, 4.2 and 6.2. On Thursday, July 13, coffee and a lunch...

Emergency Phone Numbers
Dial 110 or 112 for all emergencies (police, fire, medical). Callers will then be placed through to the appropriate emergency service.

Emergencies
The emergency numbers for the congress include the following:

- Police: 110
- Fire: 112
- Medical: 110

In case of emergency, attendees should contact the congress secretariat immediately.
CONGRESS INFORMATION

snack will be available in the Foyers of the CityCube Berlin.

On Saturday and Sunday, July 8-9, lunch and coffee will be available in the Foyers of the CityCube Berlin.

Mobile Telephones
As a courtesy to speakers and other participants, all mobile phones and pagers must be turned off when attending sessions or symposia.

Notepads and Pens
A notepad and pen are included in the congress bag.

Hours

<table>
<thead>
<tr>
<th></th>
<th>Friday</th>
<th>Saturday</th>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration Area</td>
<td>12:00-</td>
<td>08:00-</td>
<td>06:30-</td>
<td>06:30-</td>
<td>06:30-</td>
<td>06:30-</td>
<td>07:30-</td>
</tr>
<tr>
<td></td>
<td>18:00</td>
<td>18:00</td>
<td>20:00</td>
<td>19:00</td>
<td>19:00</td>
<td>19:00</td>
<td>15:00</td>
</tr>
<tr>
<td>Speaker Ready Room</td>
<td>12:30-</td>
<td>07:30-</td>
<td>07:30-</td>
<td>07:30-</td>
<td>07:30-</td>
<td>07:30-</td>
<td>07:30-</td>
</tr>
<tr>
<td></td>
<td>20:00</td>
<td>18:00</td>
<td>18:00</td>
<td>18:00</td>
<td>18:00</td>
<td>18:00</td>
<td>13:00</td>
</tr>
<tr>
<td>Exhibition Area</td>
<td>18:30-</td>
<td>10:30-</td>
<td>10:30-</td>
<td>10:30-</td>
<td>10:30-</td>
<td>10:30-</td>
<td>13:00</td>
</tr>
<tr>
<td></td>
<td>20:30</td>
<td>17:00</td>
<td>17:00</td>
<td>17:00</td>
<td>17:00</td>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>Poster Pick-Up Booth</td>
<td>18:30-</td>
<td>7:30-</td>
<td>7:30-</td>
<td>7:30-</td>
<td>7:30-</td>
<td>7:30-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>21:00</td>
<td>18:00</td>
<td>18:00</td>
<td>18:00</td>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Press Room</td>
<td>10:00-</td>
<td>8:30-</td>
<td>8:30-</td>
<td>8:30-</td>
<td>8:30-</td>
<td>8:30-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17:00</td>
<td>17:00</td>
<td>17:00</td>
<td>17:00</td>
<td>17:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Online Disclosures
As part of the CME accreditation procedures, all speakers are obliged to provide disclosure of potential conflicts of interest. On the first slide of every presentation, these disclosures must be presented. The Speaker Ready Room can assist you with drafting this slide.

Overflow
Please be advised that overflow rooms are available in Room A4 on Level 1 of the CityCube Berlin and in Room Paris on Level 1 of Hall 7.1c. Should any session be full, the Overflow will be activated and a hostess will direct you to the Overflow room.

Pocket Program
A pocket program is provided to participants upon registration. It is a handy reference and contains a program-at-a-glance, venue and congress information and map, information about Berlin and other useful tips.

Poster Sessions
Posters will be presented on different days during the congress and are accessible at the same times as the exhibition opening hours. The official poster sessions will take place as follows:

Date                  | Hours
----------------------|-------
Monday, July 10       | 12:00–13:15
Tuesday, July 11      | 12:00–13:15
Wednesday, July 12    | 12:00–13:15

Poster Areas are located in Halls 2.2, 4.2 and 6.2.

Posters can be hung beginning at 07:30 and should be dismantled by 17:00 each day. Posters not taken down after the dismantling time will be discarded.

Poster strips are available for hanging posters and can be found at the Poster Help Desk located next to the Poster Area.

Prayer Room
An all-denomination prayer room is located in Room O13 on the main entrance level of the CityCube Berlin.

Press Room
ISTH 2017 features a press room (Room S1) available for journalists attending the congress, as well as a press briefing room (Room S2). Both rooms will be open Sunday, July 9, from 10:00-17:00, and Monday to Wednesday from 8:30-17:00 and are located on Level 3 of the CityCube Berlin.

All journalists are asked to register first. To use the press room, media credentials must be presented. Public relations and company representatives may enter the room to drop off materials to share with the media; however, we kindly ask that they do not stay. All media are asked to follow the media policy in its entirety.

For a full schedule of media briefings, see the board in front of the press briefing room or stop by the press lounge for the schedule.

Poster Pick-Up Booth
Accepted poster presenters were offered the opportunity to have their posters professionally printed and delivered to the congress at no cost. If you have opted to take advantage of this service, kindly note that you can pick up your poster(s) at the Poster Pick-Up Booth located in
CONGRESS INFORMATION

Hall 6.2.b during the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, July 9</td>
<td>18:30–21:00</td>
</tr>
<tr>
<td>Monday, July 10</td>
<td>07:30–18:00</td>
</tr>
<tr>
<td>Tuesday, July 11</td>
<td>07:30–18:00</td>
</tr>
<tr>
<td>Wednesday, July 12</td>
<td>07:30–12:00</td>
</tr>
</tbody>
</table>

Program Changes
Program changes will be made public via the official ISTH 2017 Congress Mobile App and the website.

Registration Location and Hours
Registration starts on Friday, July 7, in the afternoon. The Registration Area is located on the main entrance level of the CityCube Berlin and is open during the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, July 7</td>
<td>12:00–18:00</td>
</tr>
<tr>
<td>Saturday, July 8</td>
<td>08:00–18:00</td>
</tr>
<tr>
<td>Sunday, July 9</td>
<td>06:30–20:00</td>
</tr>
<tr>
<td>Monday, July 10</td>
<td>06:30–19:00</td>
</tr>
<tr>
<td>Tuesday, July 11</td>
<td>06:30–19:00</td>
</tr>
<tr>
<td>Wednesday, July 12</td>
<td>06:30–19:00</td>
</tr>
<tr>
<td>Thursday, July 13</td>
<td>07:30–15:00</td>
</tr>
</tbody>
</table>

Smoking
Please note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the exhibition area.

Social Media
ISTH 2017 encourages the use of social media, such as Twitter, Facebook, LinkedIn, Instagram and other social media platforms at the conference as a way to summarize, highlight, excerpt, review or promote the presented materials of the congress in general, provided that:

Copyright law is observed;
Verbatim information is limited to a few quotes. The author or speaker is referenced and cited appropriately.

Congress hashtag: #ISTH2017

To get the latest updates throughout the congress, follow ISTH online via the following links:

Facebook: www.facebook.com/internationalsocietythrombosisandhaemostasis

Twitter: www.twitter.com/isth

LinkedIn: www.linkedin.com/company/2253026/

Instagram: www.instagram.com/isthofficeteam

Water Stations
Staying hydrated is always important, particularly during a busy day at ISTH 2017. Water stations are located throughout the convention center for the convenience of our attendees.

Website
Up-to-date information regarding the congress program, including all abstracts, is available at www.isth2017.org.

WIFI
WIFI is available throughout the entire convention center.

Travel Awards
Travel Award recipients can go to the specific “Travel Award” desk in the Registration Area on the main entrance level of the CityCube Berlin to receive their grant. Grants can be collected between 08:00 on Saturday, July 8, through 12:00 on Tuesday, July 11. See page 24 for more information about travel grants.

Useful Telephone Numbers
Registration Help Desk:
+49 30 30 38 81600

Hotel Information Desk:
+49 30 30 38 81605

ISTH Executive Office:
+49 30 30 38 81601
CELEBRATING 60 YEARS
Thrombosis and Haemostasis (1957 – 2017)

Celebrate with us the 60th Anniversary of our journal Thrombosis and Haemostasis!
Visit us at our booth 638 in Hall 6.2a and get your free sample copy!
Sign up for our free eTOC service: www.schattauer.de/eTOC-EN.html

XXVI ISTH Congress and 63rd Annual SSC Meeting

ISTH 2017 NETWORKING EVENTS

Opening Ceremony and Welcome Reception
Sunday, July 9, 2017
Time: 18:00–21:00
Venue: Messe Berlin
Price: Included in registration fee

The Opening Ceremony takes place in the Plenary Hall (Hall B) on Level 2 of the CityCube Berlin from 18:15–19:15. Under the theme “River of Knowledge,” participants are invited to enjoy a journey through the host countries Germany, Austria and Switzerland.

The Welcome Reception will take place in the adjacent Exhibition Halls 2.2, 4.2 and 6.2 from 19:15–21:00.

ISTH 2017 Congress Networking Evening
Wednesday, July 12, 2017
Time: 18:30–1:00
Venue: Tempodrom, Möckernstraße 10, 10963 Berlin
Price: 120,00 € (inclusive of VAT)

Join us for this exciting event at the visionary and unique Tempodrom where participants will have the opportunity to network with friends and colleagues. The evening will feature musical performances from local artists, local cuisine combined with inspirations from other countries, and a great selection of drinks.

Tickets can be purchased in the Registration Area on the main entrance level of the CityCube Berlin at the Congress Networking Event Counter or via your online ISTH Congress Profile at www2.kit.de/profileportal/login-7479.
ISTH 2017 5K CHARITY RUN/WALK

Keep Life Flowing – Benefiting World Thrombosis Day
Tuesday, July 11, 2017
Time: 20:00 - 21:30
Venue: Grunewald, Berlin
Buses will leave in front of the CityCube Berlin between 19:15-19:30 at the latest.
Registration: Fee €10

Join us for the ISTH 2017 5K Charity Run to stay fit, help raise awareness and support ISTH’s World Thrombosis Day awareness campaign.

All congress attendees are invited to participate in a beautiful evening run (or walk) nearby in Berlin’s famous Grunewald forest while positively impacting their health and contributing to a good cause. For more information and to register, please visit my2.raceresult.com/67475/ or visit the Charity Run Information Desk in the Registration Area on the main entrance level of the CityCube Berlin.

ISLH 2018
Brussels, Belgium

Conference Dates: May 10-12
Educational Workshop: May 9

Abstract Submission Deadline: February 1
Early Registration Deadline: April 10

WWW.ISLH.ORG
LOCAL INFORMATION

Currency, Banks and Foreign Exchange Offices
The Euro (EUR) is the unit of currency in Germany, which comes in bills and coins. Only major banks exchange foreign currency. Banking hours are Monday to Friday, 09:00 to 17:00. Currency exchange is also available at the airport.

Climate
Berlin has a humid continental climate. Summers are usually warm and humid with moderate rainfall. The average temperature in July is 18 degrees C (64 degrees F), with a high around 23 degrees C (73 degrees F) and 13 degrees C (55 degrees F) for a low.

Credit Cards
Credit cards are accepted at most (but not all) major retailers, in hotels and shop but it is advisable to still carry cash for some transactions.

Electricity
Electrical sockets in Germany usually supply electricity between 220 – 240 volts. Germany uses two of the European standard electrical socket types: The “Type C” Europlug and the “Type E” and “Type F” Schuko. An adapter is necessary if your appliances do not already have these types of shapes to match the socket.

Restaurants
Berlin is an international metropolis and has a variety of cuisines to choose from when dining out. Berlin is home to a variety of shopping options. From traditional and new department stores, modern shopping malls, luxury designer shops to small handicraft manufactures, flea and antique markets and bargain stores - you’ll find it all. Please note that shops are usually closed on Sunday. Visit www.berlin.de/en/shopping/ for more information.

Tipping
Tips and value added tax (VAT) are officially included in all prices. For exceptional service, an extra tip is recommended. When tipping at a restaurant, tips should be handed to the waiter/waitress and not left on the table.

Taxis
In Germany, the standard Value Added Tax (VAT) rate is 19% of the net price. All beverages, except milk and bottled water, are also taxed at the standard VAT rate. Products used on a daily basis such as books, newspapers, and food, as well as art, are taxed at the reduced rate of 7%.

Non-EU residents may qualify for a refund of some of the VAT they have paid during their visit in Germany. Please visit the Berlin.de website for more information: www.berlin.de/en/tourism/travel-information/1741381-2862820-value-added-tax-vat-refund.en.html.

The Euro (EUR) is the unit of currency in Germany. Please visit the Berlin.de website for more information: www.berlin.de/en/tourism/travel-information/1741381-2862820-value-added-tax-vat-refund.en.html.

Time Zone
Standard time zone: UTC/GMT +1 hour
Daylight Savings Time: +1 hour Berlin is on CET (Central European Time)

Taxis
The standard color for taxis is beige. Taxis can be hailed by raising your hand. The light on the roof is switched on, the taxi is available and can be hailed by raising your hand. For easy access, download MyTaxi via its app to order a taxi with ease.

By car:
From Tegel Airport: take the A100 and exit at Messedamm/Messe Gelände/ICC then follow the signs on Messedamm to the CityCube Berlin.

By car:
From Schönefeld Airport: take the A113 to the A100. Exit at Messedamm/Messe Gelände/ICC then follow the signs on Messedamm to the CityCube Berlin.

By taxi:
The transfer by taxi takes approximately 20 (Tegel) to 30-40 minutes (Schönefeld) according to the traffic and costs around €18 (Tegel) or €35 (Schönefeld). Taxis are always available in front of the airport building.

Berlin's City Transit
Berlin’s public transit system will take you almost anywhere you want to go. Participants will have a logo on their name badge indicating that they have free access to all public transportation in Zone AB (exhibitors do not receive this benefit).

How to get to the Messe Berlin convention center:
From the airport:
Two airports can be found in Berlin – Tegel Airport and Schönefeld Airport. However, Tegel Airport (TXL) is located 8 km north-west outside the city center and Schönefeld Airport is situated 18 km south-east from the city center.

By public transportation:
From Tegel Airport: take the bus lines X9 or 109 direction Zoologischer Garten. At Zoologischer Garten take the S-Bahn line 5 direction Spandau and get off at Messe Süd.

By car:
From Schönefeld Airport: take the regional express train RB19 direction Gesundbrunnen and stop at Hauptbahnhof. From there take the S-Bahn line 5 direction Spandau and get off at Messe Süd.

Price for one journey: Single Ticket Berlin Zone AB: 2.70€

Public transport in the city
The public transportation system in Berlin is very well organized. Detailed information regarding public transportation is available at www.bvg.de.

Messe Berlin public transport connection
S-Bahn 5: From the city center take the direction Spandau and stop at Messe Süd Station. Entrance to the CityCube Berlin is across the street.

Shopping in Berlin
Berlin has a wide variety of shopping options. From traditional and new department stores, modern shopping malls, luxury designer shops to small handicraft manufactures, flea and antique markets and bargain stores - you’ll find it all. Please note that shops are usually closed on Sunday. Visit www.berlin.de/en/shopping/ for more information.

By public transportation:
From Tegel Airport: take the bus lines X9 or 109 direction Zoologischer Garten. At Zoologischer Garten take the S-Bahn line 5 direction Spandau and get off at Messe Süd.

Price for one journey: Single Ticket Berlin Zone AB: 2.70€

From Schönefeld Airport: take the regional express train RB19 direction Gesundbrunnen and stop at Hauptbahnhof. From there take the S-Bahn line 5 direction Spandau and get off at Messe Süd.

Price for one journey: Single Ticket Berlin Zone ABC: 3.30€

How to get to the Messe Berlin convention center:
From the airport:
Two airports can be found in Berlin – Tegel Airport and Schönefeld Airport. However, Tegel Airport (TXL) is located 8 km north-west outside the city center and Schönefeld Airport is situated 18 km south-east from the city center.

From both airports, you can reach the city center either by taxi, car or public transportation.

By car:
From Tegel Airport: take the A100 and exit at Messedamm/Messe Gelände/ICC then follow the signs on Messedamm to the CityCube Berlin.

By car:
From Schönefeld Airport: take the A113 to the A100. Exit at Messedamm/Messe Gelände/ICC then follow the signs on Messedamm to the CityCube Berlin.

By taxi:
The transfer by taxi takes approximately 20 (Tegel) to 30-40 minutes (Schönefeld) according to the traffic and costs around €18 (Tegel) or €35 (Schönefeld). Taxis are always available in front of the airport building.
Management of bleeding in anticoagulated patients

Co-chairs: Jerrold Levy (USA), Walter Ageno (Italy)

16:15 – Chairs’ welcome

The safety profile of PCC in warfarin reversal trials
Truman J Milling Jr (USA)

Warfarin reversal treatment: PCC versus FFP
Mark Crowther (Canada)

Treatment of rivaroxaban-associated bleeding emergencies: a single-centre pilot study
Bettina Schenk (Austria)

The clinical reality of bleeding complications during anticoagulant therapy: the RADOA registry
Edelgard Lindhoff-Last (Germany)

17:45 – Close of symposium

Sunday 9 July 2017, 16:15–17:45
Room A3, CityCube Berlin, Berlin, Germany

A CSL Behring-sponsored satellite symposium at the XXVI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

The licensing status of the products mentioned herewith differs between countries. Please contact your local medical representative for information. PCCs are not approved for the treatment of major bleeding associated with factor IIa or Xa inhibitor therapy.
## EXHIBITION AND CONGRESS SUPPORT

ISTH wishes to recognize the following companies and organizations for their support of ISTH 2017.

### Platinum

<table>
<thead>
<tr>
<th>Company</th>
<th>Logo</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSL Behring</td>
<td><img src="CSL_Behring.png" alt="Logo" /></td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td><img src="Novo_Nordisk.png" alt="Logo" /></td>
</tr>
<tr>
<td>Octapharma</td>
<td><img src="Octapharma.png" alt="Logo" /></td>
</tr>
</tbody>
</table>

### Gold

<table>
<thead>
<tr>
<th>Company</th>
<th>Logo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td><img src="Pfizer.png" alt="Logo" /></td>
</tr>
<tr>
<td>Roche</td>
<td><img src="Roche.png" alt="Logo" /></td>
</tr>
<tr>
<td>Shire</td>
<td><img src="Shire.png" alt="Logo" /></td>
</tr>
</tbody>
</table>

### Silver

<table>
<thead>
<tr>
<th>Company</th>
<th>Logo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioverativ</td>
<td><img src="Bioverativ.png" alt="Logo" /></td>
</tr>
<tr>
<td>Grifols</td>
<td><img src="Grifols.png" alt="Logo" /></td>
</tr>
<tr>
<td>Portola</td>
<td><img src="Portola.png" alt="Logo" /></td>
</tr>
</tbody>
</table>

### Bronze

<table>
<thead>
<tr>
<th>Company</th>
<th>Logo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexion</td>
<td><img src="Alexion.png" alt="Logo" /></td>
</tr>
<tr>
<td>Biomarin</td>
<td><img src="Biomarin.png" alt="Logo" /></td>
</tr>
<tr>
<td>Daiichi-Sankyo</td>
<td><img src="Daiichi-Sankyo.png" alt="Logo" /></td>
</tr>
</tbody>
</table>

### Other Supporters

- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)
- ![Logo](Bioverativ.png)

---

**Science matters. Because patients matter.**

It’s because of this belief that we:

**Brought the leading extended half-life therapies to people with hemophilia** — innovation that has changed the way hemophilia can be managed.

**Opened the world’s largest genetic hemophilia repository to scientists** through *My Life, Our Future*, together with program co-founders the American Thrombosis and Hemostasis Network, Bloodworks Northwest, and the National Hemophilia Foundation.

**Transformed humanitarian aid in hemophilia**, with Sobi, by committing to donate up to one billion IUs of factor therapy over 10 years to help close the treatment gap in the developing world. More than 12,300 people have been treated through the WFH Humanitarian Aid Program, which is receiving 500 million IUs over five years.

We not only believe great science can conquer the toughest medical challenges, we live it every single day.

Bioverativ.com
Towards Life Without Limitation
Growing Experience with Nuwiq® in Patients with Haemophilia A

Sunday 9 July, 2017. 16:15–17:45, Room A8
Pier M. Mannucci (Chair), Ellis J. Neufeld, Natascha Marquardt, John Pasi, Massimo Morfini

wilate® for a Lifetime of Care
Bleeding Management Across High-Risk Patient Populations

Monday 10 July, 2017. 13:15–14:30, Room Paris
Ute Scholz (Chair), Stacy Croteau, Jill Johnsen, John Pasi, Robert Klaassen
Supported Symposia

For more details and the program of each of these symposia and sessions, please refer to the ISTH Show Guide. It is distributed at the entrances of the Exhibition Halls.

14:15 – 15:45  
Engaging in New Options for Anticoagulation Therapy  
ITREAS (supported by an unrestricted grant from Daiichi-Sankyo Europe GmbH).

14:15 – 15:45  
Thrombotic Microangiopathies: Challenging Diseases, Challenging Stories  
Alexion Pharmaceuticals, Inc.

14:15 – 15:45  
DOACs and Reversal Agents: Take the Next Step in Anticoagulation Care  
Boehringer Ingelheim

14:15 – 15:45  
Venous Thromboembolism (VTE): Pervasive, Persistent, Preventable  
The Unmet Need in Acutely Ill Medical Patients After Hospital Discharge  
Portola Pharmaceuticals

14:15 – 15:45  
Innovating for Improved Outcomes: Driving the Evolution of Hemophilia A Management  
Bayer

14:15 – 15:30  
SIPPET Study: One Year Later. New Insights to Help Manage "my Next Patient"  
Grifols

16:15 – 17:45  
Haemostatic Control of aPCC: Update on the MOA, Efficacy, and Safety  
Shire Pharmaceuticals Inc.

16:15 – 17:45  
Controversies in Cancer and Thrombosis: Management of High-Risk Patients  
Pfizer

16:15 – 17:45  
Management of Bleeding in Anticoagulated Patients  
CSL Behring
**SUPPORTED SYMPOSIA**

**16:15 – 17:45**  
**A5**  
**Stopping the VTE Epidemic in Hospitalized Medically ill Patients: An Innovative, Cutting Edge and State-Of-The-Art Action Plan**  
MEDSCAPE EDUCATION & NATF

**16:15 – 17:45**  
**A6**  
**Breaking Scientific Walls in the Treatment of Haemophilia and Rare Bleeding Disorders: From Laboratory Assays to Patient Outcomes**  
Novo Nordisk Health Care AG

**16:15 – 17:45**  
**A7**  
**The Challenge of Cancer Associated Thrombosis (CAT): Are NOACs an Option?**  
Bayer

**16:15 – 17:45**  
**A8**  
**Towards Life Without Limitation: Growing Experience with Nuwiq® in Patients with Hemophilia A**  
Octapharma

---

**Supported Symposia**

**Monday, July 10, 2017**

**13:15 – 14:30**  
**New York**  
**Managing Extended Anticoagulation Therapy in Venous Thromboembolism. What Have We Learned From EINSTEIN CHOICE?**  
Bayer

**13:15 – 14:30**  
**London**  
**Fc Extended Half-Life Recombinant Factor Concentrates: Recent Updates on Haemophilia Management and Treatment Goals**  
Sobi Bioverativ

**13:15 – 14:30**  
**Paris**  
**wilate® for a Lifetime of Care: Bleeding Management Across High-Risk Patient Populations**  
Octapharma

**13:15 – 14:30**  
**Helsinki 1**  
**Haemostasis in Critical Care Medicine**  
Stago
### SUPPORTED SYMPOSIA

**Tuesday, July 11, 2017**

**Supported Symposia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Organiser</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Budapest</td>
<td>Individualising Treatment and Redefining Physical Activity to Optimise Joint Health</td>
<td>Pfizer</td>
</tr>
<tr>
<td></td>
<td>Berlin</td>
<td>Beyond Factor: Potential New Approaches to Hemophilia</td>
<td>Alnylam Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>London</td>
<td>Venous Thromboembolism - Improving Patient Care With non VKA Oral Anticoagulants</td>
<td>Bristol-Myers Squibb and Pfizer</td>
</tr>
<tr>
<td></td>
<td>Paris</td>
<td>Treating Thrombosis Today: From Latest Data to Clinical Application</td>
<td>Medscape Education</td>
</tr>
<tr>
<td></td>
<td>Helsinki 1</td>
<td>Anticoagulation and Reversal: Clinical Cases to Test your Knowledge</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td></td>
<td>Helsinki 2</td>
<td>Immune Tolerance Induction (ITI): What Have We Learned in the Past 40 Years?</td>
<td>Grifols</td>
</tr>
</tbody>
</table>
SUPPORTED SYMPOSIA

**XXVI ISTH Congress and 63rd Annual SSC Meeting**

**Supported Symposia**

Wednesday, July 12, 2017

13:15 – 14:30

**New York**

**Living With Haemophilia A: Raising the Bar for New Treatments**

Roche/Chugai

13:15 – 14:30

**Paris**

**IDELVION: A Gold Standard in the Treatment of Haemophilia B?**

CSL Behring

13:15 – 14:30

**Helsinki 1**

**Management of Direct Oral Anticoagulants—Challenges and Perspectives**

DOASENSE GmbH

13:15 – 14:30

**Helsinki 2**

**The Continuing Challenge of Venous Thromboembolism: Insights From the GARFIELD-VTE Registry**

The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

13:15 – 14:30

**Budapest**

**Towards a New Era in Haemophilia Care**

Pfizer

---

**Supported Symposia**

13:15 – 14:30

**Budapest**

**Reach High in Haemophilia A: Treatment With AFSTYLA**

CSL Behring

13:15 – 14:30

**Berlin**

**Extended Half-Life rFVIII: Advanced Therapeutic Options Providing Benefits in Clinical Practice**

Shire Pharmaceuticals Inc.
PRODUCT THEATER PRESENTATIONS

Monday, July 10, 2017

12:15 – 13:00

**Kovaltry in Practice: Insights From Real-World Experience**
Bayer

**The Patient Experience in Haemophilia A: Half-Life Is Not Even Half the Story**
CSL Behring

12:15 – 13:00

**4 Patients - 4 Solutions**
SVT - HIT - GFR - CAT
Aspen Parenteral Anticoagulants

---

**AGENDA**

**TIME** | **TOPIC** | **SPEAKER** | **LOCATION**
--- | --- | --- | ---
13:15 | Welcome and introduction | Robert Klamroth (Germany) | Exhibition Hall 2.2
13:25 | Individualised approaches to treatment: the role of pharmacokinetics in supporting patient lifestyles | Gerry Dolan (UK) | Exhibition Hall 4.2
13:45 | The secret life of FIX: where are we now? | Andreas Tiede (Germany) | Exhibition Hall 6.2
14:00 | Towards endogenous prophylaxis: gene therapy | Thierry VandenDriessche (Belgium) | Exhibition Hall 4.2
14:20 | Panel discussion | John Pasi (UK) | Exhibition Hall 4.2
14:30 | Meeting close | | }

---

**AGENDA**

**TIME** | **TOPIC** | **SPEAKER** | **LOCATION**
--- | --- | --- | ---
13:15 | Welcome and introduction | John Pasi (UK) | Exhibition Hall 4.2
13:25 | The secret life of FIX: where are we now? | Gerry Dolan (UK) | Exhibition Hall 6.2
13:45 | Thinking outside the factor: the future of non-factor based haemophilia therapy | Andreas Tiede (Germany) | Exhibition Hall 6.2
14:00 | Towards endogenous prophylaxis: gene therapy | Thierry VandenDriessche (Belgium) | Exhibition Hall 4.2
14:20 | Panel discussion | John Pasi (UK) | Exhibition Hall 4.2
14:30 | Meeting close | | }
PRODUCT THEATER PRESENTATIONS

Tuesday, July 11, 2017
Product Theaters

12:15 – 13:00
Exhibition Hall 2.2
NOACs in Venous Thromboembolism: Learnings From the Real World
Bayer

12:15 – 13:00
Exhibition Hall 6.2
ST Genesia®: Thrombin Generation Entering the Clinical Lab
Stago

Wednesday, July 12, 2017
Product Theater

12:15 – 13:00
Exhibition Hall 2.2
Integrating the Only Specific Replacement Therapy for Factor X Deficiency Into Clinical Practice
Bio Products Laboratory Ltd.

12:15 – 13:00
Exhibition Hall 4.2
Tough Decisions in the Treatment of VTE A Multidisciplinary Case-Based Discussion
Bristol-Myers Squibb and Pfizer

12:15 – 13:00
Exhibition Hall 6.2
Haemophilia Academy at 10 Years: A Platform for Career Development and Global Networking
Haemophilia Academy
Please join us at the Shire satellite symposium to learn more about:

**Extended half-life rFVIII: Advanced therapeutic options providing benefits in clinical practice**

Monday July 10th | 13:15 – 14:30
Hall 7.3 | 3rd Floor | Room: Berlin
City Cube & Messe Berlin Exhibition Grounds, Berlin, Germany

**Chair:** Dr. Robert Klamroth, Germany
### EXHIBITOR & SUPPORTER LIST / BOOTH NUMBER

<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Hall Number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>Hall 2.2</td>
<td>International Society on Thrombosis and Haemostasis (ISTH)</td>
</tr>
<tr>
<td>200</td>
<td>Hall 2.2</td>
<td>ISTH 2019 – Melbourne</td>
</tr>
<tr>
<td>200</td>
<td>Hall 2.2</td>
<td>ISTH SSC 2018</td>
</tr>
<tr>
<td>200</td>
<td>Hall 2.2</td>
<td>Journal of Thrombosis and Haemostasis</td>
</tr>
<tr>
<td>200</td>
<td>Hall 2.2</td>
<td>Research and Practice in Thrombosis and Haemostasis</td>
</tr>
<tr>
<td>211</td>
<td>Hall 2.2</td>
<td>GRIFOLS</td>
</tr>
<tr>
<td>212</td>
<td>Hall 2.2</td>
<td>Alexion Pharmad</td>
</tr>
<tr>
<td>213</td>
<td>Hall 2.2</td>
<td>Kedrion Biopharma</td>
</tr>
<tr>
<td>214</td>
<td>Hall 2.2</td>
<td>Bio Products Laboratory</td>
</tr>
<tr>
<td>215</td>
<td>Hall 2.2</td>
<td>SEBIA</td>
</tr>
<tr>
<td>216</td>
<td>Hall 2.2</td>
<td>Alnylam Pharmaceuticals</td>
</tr>
<tr>
<td>220</td>
<td>Hall 2.2</td>
<td>Bayer</td>
</tr>
<tr>
<td>221</td>
<td>Hall 2.2</td>
<td>Shire</td>
</tr>
<tr>
<td>222</td>
<td>Hall 2.2</td>
<td>Novo Nordisk Healthcare</td>
</tr>
<tr>
<td>231</td>
<td>Hall 2.2</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>232</td>
<td>Hall 2.2</td>
<td>HYPHEN BioMed</td>
</tr>
<tr>
<td>233</td>
<td>Hall 2.2</td>
<td>5-Diagnostics</td>
</tr>
<tr>
<td>234</td>
<td>Hall 2.2</td>
<td>Affinity Biologicals</td>
</tr>
<tr>
<td>235</td>
<td>Hall 2.2</td>
<td>Novo Nordisk Haemophilia Foundation</td>
</tr>
<tr>
<td>241</td>
<td>Hall 2.2</td>
<td>Stago</td>
</tr>
<tr>
<td>242</td>
<td>Hall 2.2</td>
<td>Thrombosis Research Institute</td>
</tr>
<tr>
<td>400</td>
<td>Hall 4.2</td>
<td>Haemochrom Diagnostica</td>
</tr>
<tr>
<td>401</td>
<td>Hall 4.2</td>
<td>HemoSonics</td>
</tr>
<tr>
<td>402</td>
<td>Hall 4.2</td>
<td>Aspen Europe</td>
</tr>
<tr>
<td>403</td>
<td>Hall 4.2</td>
<td>LFB BIOMEDICAMENTS</td>
</tr>
<tr>
<td>404</td>
<td>Hall 4.2</td>
<td>Roche</td>
</tr>
<tr>
<td>405</td>
<td>Hall 4.2</td>
<td>Instrumentation Laboratory</td>
</tr>
<tr>
<td>410</td>
<td>Hall 4.2</td>
<td>Bioverativ</td>
</tr>
<tr>
<td>410</td>
<td>Hall 4.2</td>
<td>Sobi</td>
</tr>
<tr>
<td>411</td>
<td>Hall 4.2</td>
<td>Octapharma</td>
</tr>
<tr>
<td>412</td>
<td>Hall 4.2</td>
<td>Roche Diagnostics International</td>
</tr>
<tr>
<td>413</td>
<td>Hall 4.2</td>
<td>Technoclone</td>
</tr>
<tr>
<td>414</td>
<td>Hall 4.2</td>
<td>3i - Intelligent Imaging Innovations</td>
</tr>
<tr>
<td>415</td>
<td>Hall 4.2</td>
<td>LABITEC LABOR BIOMEDICAL TECHNOLOGIES</td>
</tr>
<tr>
<td>416</td>
<td>Hall 4.2</td>
<td>Chrono-log Corp.</td>
</tr>
<tr>
<td>417</td>
<td>Hall 4.2</td>
<td>DOASENSE</td>
</tr>
<tr>
<td>420</td>
<td>Hall 4.2</td>
<td>CSL Behring</td>
</tr>
<tr>
<td>430</td>
<td>Hall 4.2</td>
<td>BMS Pfizer Alliance</td>
</tr>
<tr>
<td>431</td>
<td>Hall 4.2</td>
<td>Pfizer</td>
</tr>
<tr>
<td>432</td>
<td>Hall 4.2</td>
<td>BioMarin Pharmaceutical</td>
</tr>
<tr>
<td>433</td>
<td>Hall 4.2</td>
<td>Haemoscan</td>
</tr>
<tr>
<td>434</td>
<td>Hall 4.2</td>
<td>uniQure</td>
</tr>
<tr>
<td>440</td>
<td>Hall 4.2</td>
<td>Portola Pharmaceuticals</td>
</tr>
<tr>
<td>441</td>
<td>Hall 4.2</td>
<td>Daiichi Sankyo</td>
</tr>
<tr>
<td>442</td>
<td>Hall 4.2</td>
<td>Biotest</td>
</tr>
<tr>
<td>443</td>
<td>Hall 4.2</td>
<td>Siemens Healthineers</td>
</tr>
<tr>
<td>443</td>
<td>Hall 4.2</td>
<td>Sysmex</td>
</tr>
<tr>
<td>444</td>
<td>Hall 4.2</td>
<td>Abbott</td>
</tr>
<tr>
<td>600</td>
<td>Hall 6.2</td>
<td>Diagon</td>
</tr>
<tr>
<td>601</td>
<td>Hall 6.2</td>
<td>Emosis Diagnostics</td>
</tr>
<tr>
<td>602</td>
<td>Hall 6.2</td>
<td>HRA Healthcare Research &amp; Analytics</td>
</tr>
<tr>
<td>603</td>
<td>Hall 6.2</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>604</td>
<td>Hall 6.2</td>
<td>European Haemophilia Consortium</td>
</tr>
<tr>
<td>605</td>
<td>Hall 6.2</td>
<td>EU Horizon 2020 MSCA ITN &quot;PROFILE&quot;</td>
</tr>
<tr>
<td>606</td>
<td>Hall 6.2</td>
<td>European and Mediterranean League Against Thrombotic Diseases</td>
</tr>
<tr>
<td>607</td>
<td>Hall 6.2</td>
<td>Deutsche Gesellschaft für Angiologie</td>
</tr>
<tr>
<td>608</td>
<td>Hall 6.2</td>
<td>APSTH</td>
</tr>
<tr>
<td>614</td>
<td>Hall 6.2</td>
<td>Precision Biologic</td>
</tr>
</tbody>
</table>
## EXHIBITOR & SUPPORTER LIST / BOOTH NUMBER

<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Hall Number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>615</td>
<td>Hall 6.2</td>
<td>ACON Laboratories</td>
</tr>
<tr>
<td>616</td>
<td>Hall 6.2</td>
<td>Haematologic Technologies</td>
</tr>
<tr>
<td>617</td>
<td>Hall 6.2</td>
<td>World Federation of Hemophilia</td>
</tr>
<tr>
<td>618</td>
<td>Hall 6.2</td>
<td>Comite de Trombosis y Hemostasia AMEH-CLAHT AC</td>
</tr>
<tr>
<td>619</td>
<td>Hall 6.2</td>
<td>International Network of Venous Thromboembolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Research Networks</td>
</tr>
<tr>
<td>624</td>
<td>Hall 6.2</td>
<td>Mitsubishi Tanabe Pharma</td>
</tr>
<tr>
<td>626</td>
<td>Hall 6.2</td>
<td>Medtronic</td>
</tr>
<tr>
<td>627</td>
<td>Hall 6.2</td>
<td>Wiley</td>
</tr>
<tr>
<td>628</td>
<td>Hall 6.2</td>
<td>Wisepress</td>
</tr>
<tr>
<td>629</td>
<td>Hall 6.2</td>
<td>GTH</td>
</tr>
<tr>
<td>633</td>
<td>Hall 6.2</td>
<td>Haemonetics</td>
</tr>
<tr>
<td>634</td>
<td>Hall 6.2</td>
<td>British Society of Hematology/National Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of Health Research</td>
</tr>
<tr>
<td>635</td>
<td>Hall 6.2</td>
<td>DSM Pentapharm</td>
</tr>
<tr>
<td>636</td>
<td>Hall 6.2</td>
<td>International Initiative on Thrombosis and Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(ITAC-CME)</td>
</tr>
<tr>
<td>637</td>
<td>Hall 6.2</td>
<td>Hematological Journal</td>
</tr>
<tr>
<td>638</td>
<td>Hall 6.2</td>
<td>Thrombosis and Haemostasis</td>
</tr>
<tr>
<td>639</td>
<td>Hall 6.2</td>
<td>European Hematology Association</td>
</tr>
<tr>
<td>643</td>
<td>Hall 6.2</td>
<td>Enzyme Research Laboratories / R2 Diagnostics</td>
</tr>
<tr>
<td>645</td>
<td>Hall 6.2</td>
<td>Sekisui Diagnostics</td>
</tr>
<tr>
<td>646</td>
<td>Hall 6.2</td>
<td>Karger Publishers</td>
</tr>
<tr>
<td>647</td>
<td>Hall 6.2</td>
<td>The Lancet</td>
</tr>
<tr>
<td>648</td>
<td>Hall 6.2</td>
<td>Thrombosis.TV</td>
</tr>
<tr>
<td>651</td>
<td>Hall 6.2</td>
<td>International Self-Monitoring Association of Oral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anticoagulated Patients (ISMAAP)</td>
</tr>
<tr>
<td>652</td>
<td>Hall 6.2</td>
<td>phamx</td>
</tr>
<tr>
<td>653</td>
<td>Hall 6.2</td>
<td>ORGENTEC - Corgenix</td>
</tr>
<tr>
<td>654</td>
<td>Hall 6.2</td>
<td>Phenom-World</td>
</tr>
<tr>
<td>655</td>
<td>Hall 6.2</td>
<td>BioMedica Diagnostics</td>
</tr>
<tr>
<td>656</td>
<td>Hall 6.2</td>
<td>Helena Biosciences</td>
</tr>
</tbody>
</table>

## EXHIBITOR & SUPPORTER LIST / ALPHABETICAL

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
<th>Hall Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>3i - Intelligent Imaging Innovations</td>
<td>414</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>5-Diagnostics</td>
<td>233</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Abbott</td>
<td>444</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>ACON Laboratories</td>
<td>615</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Affinity Biologicals - Hemostasis Reference Lab</td>
<td>234</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Alexion Pharma</td>
<td>212</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>216</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>American Heart Association</td>
<td>603</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>APSTH</td>
<td>608</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Aspen Europe</td>
<td>402</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Bayer</td>
<td>210, 220, 230, 240</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Bio Products Laboratory</td>
<td>214</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>432</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>BioMedica Diagnostics</td>
<td>655</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Biotest</td>
<td>442</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Bioverativ</td>
<td>410</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>BMS Pfizer Alliance</td>
<td>430</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>231</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>British Society of Hematology/National Institute of Health Research</td>
<td>634</td>
<td>Hall 6.2.</td>
</tr>
<tr>
<td>Chrono-log Corp.</td>
<td>416</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Comite de Trombosis y Hemostasia AMEH-CLAHT</td>
<td>618</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>420</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>441</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Deutsche Gesellschaft für Angiologie</td>
<td>607</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Diagon</td>
<td>600</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>DOASENSE</td>
<td>417</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>DSM Pentapharm</td>
<td>635</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Emosis Diagnostics</td>
<td>601</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Enzyme Research Laboratories / R2 Diagnostics</td>
<td>643</td>
<td>Hall 6.2</td>
</tr>
</tbody>
</table>
## EXHIBITOR & SUPPORTER LIST / ALPHABETICAL

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
<th>Hall Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU Horizon 2020 MSCA ITN &quot;PROFILE&quot;</td>
<td>605</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>European and Mediterranean League Against Thrombotic Diseases</td>
<td>606</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>European Haemophilia Consortium</td>
<td>604</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>European Hematology Association</td>
<td>639</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>GRIFOLS</td>
<td>211</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>GTH</td>
<td>629</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Haematologic Technologies</td>
<td>616</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Haemochrom Diagnostica</td>
<td>400</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Haemonetix</td>
<td>633</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>HaemoScan</td>
<td>433</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Helena Biosciences</td>
<td>656</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Hematologica Journal</td>
<td>637</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>HemoSonics</td>
<td>401</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>HRA Healthcare Research &amp; Analytics</td>
<td>602</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>HYPHEN BioMed</td>
<td>232</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>I&amp;L Biosystems</td>
<td>625</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Instrumentation Laboratory</td>
<td>405</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>International Initiative on Thrombosis and Cancer (ITAC-CME)</td>
<td>636</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>International Network of Venous Thromboembolism Clinical Research Networks</td>
<td>619</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>International Society on Thrombosis and Haemostasis (ISTH)</td>
<td>200</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>ISTH 2019 – Melbourne</td>
<td>200</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>ISTH SSC 2018</td>
<td>200</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Journal of Thrombosis and Haemostasis</td>
<td>200</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)</td>
<td>651</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Karger Publishers</td>
<td>646</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Kedrion Biopharma</td>
<td>213</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>LABITEC LABOR BIOMEDICAL TECHNOLOGIES</td>
<td>415</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>LFB BIOMEDICAMENTS</td>
<td>403</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Medtronic</td>
<td>626</td>
<td>Hall 6.2</td>
</tr>
</tbody>
</table>

## EXHIBITOR & SUPPORTER LIST / ALPHABETICAL

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
<th>Hall Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitsubishi Tanabe Pharma</td>
<td>624</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Novo Nordisk Healthcare</td>
<td>222</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Novo Nordisk Haemophilia Foundation</td>
<td>235</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Octapharma</td>
<td>411, 421</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>ORGENTEC - Corgenix</td>
<td>653</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Pfizer</td>
<td>431</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>phammax</td>
<td>652</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Phenom-World</td>
<td>654</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Portola Pharmaceuticals</td>
<td>440</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Precision Biologic</td>
<td>614</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Research and Practice in Thrombosis and Haemostasis</td>
<td>200</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Roche</td>
<td>404</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Roche Diagnostics International</td>
<td>412</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>SEBIA</td>
<td>215</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Sekisui Diagnostics</td>
<td>645</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Shire</td>
<td>221</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>443</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Sobi</td>
<td>410</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Stago</td>
<td>241</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Sysmex Corporation</td>
<td>443</td>
<td>Hall 4.2,</td>
</tr>
<tr>
<td>Technoclone</td>
<td>413</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>The Lancet</td>
<td>647</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Thrombosis and Haemostasis</td>
<td>638</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Thrombosis Research Institute</td>
<td>242</td>
<td>Hall 2.2</td>
</tr>
<tr>
<td>Thrombosis.TV</td>
<td>648</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>uniQure</td>
<td>434</td>
<td>Hall 4.2</td>
</tr>
<tr>
<td>Wiley</td>
<td>627</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>Wisepress</td>
<td>628</td>
<td>Hall 6.2</td>
</tr>
<tr>
<td>World Federation of Hemophilia</td>
<td>617</td>
<td>Hall 6.2</td>
</tr>
</tbody>
</table>
COMPANY PROFILES

Booth 414  Hall 4.2
3i - Intelligent Imaging Innovations
Königsallee 9-21
D-37081
Göttingen
Germany
+49 0 551 508 39 266
+49 0 551 508 39 268
www.intelligent-imaging.com
3i designs and manufactures technologies for live-cell and intravital fluorescence microscopy including digital holography, spinning disk confocal, multi-photon and lightsheet. SlideBook software manages everything from instrument control to image capture, processing and data analysis.

Booth 444  Hall 4.2
Abbott
100 Abbott Park Road
60064
Abbott Park, IL
United States
+1 224 6676100
www.abbottdiagnostics.com
Abbott is a global leader in in vitro diagnostics offering a broad portfolio spanning immunoassay, clinical chemistry, hematology, blood screening, molecular, bio-identification, point of care, and informatics. Our diagnostics solutions are more than just a test or data point, they are designed to anticipate, leverage and improve decision-making and patient care across the entire health care system.

Booth 233  Hall 2.2
5-Diagnostics
Heuberg 7
4051
Basel
Switzerland
+41 61 588 07 84
+41 61 588 07 86
www.5-diagnostics.com
5-Diagnostics offers innovative IVD systems, ready to use assays and biochemicals to the research and diagnostic market. Recently launched assays are heparin QC bioreagents and buffers in compliance with EP and USP and the NAPPT reagent for the detection of activated coagulation factors in therapeutic products or for detecting contact activation and hyper coagulability.

Booth 615  Hall 6.2
ACON Laboratories
10125 Mesa Rim Road
92121
San Diego, CA
United States
+1 858 875 8000
+1 858 875 8098
www.aconlabs.com
ACON Laboratories is leading the way to make high quality point-of-care diagnostics and medical devices more affordable to people around the world for over 21 years.

COMPANY PROFILES

ACON offers Mission® brand and OEM/private label products for both PT/INR and Cholesterol Monitoring Systems, in addition to several other point-of-care meters and test strips. ACON is committed to continuously monitoring our quality systems to ensure their effectiveness and compliance to all applicable regulatory and quality requirements. Exceeding customer expectations and maintaining customer loyalty are our top priorities.

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and haemostasis research and medical diagnostics. Products include an extensive line of antibodies, ELISA kits, and human plasma products.

Hemostasis Reference Laboratory offers a complete range of testing for clinical trials, sample analysis, research projects, product evaluation, value assignments, instrument validation, and more servicing pharmaceutical companies, diagnostic manufacturers, veterinarians, and researchers.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors.
COMPANY PROFILES

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases.

Booth 603  Hall 6.2
American Heart Association

7272 Greenville Avenue
75231
Dallas, TX
United States
+1 214 570 5978
www.heart.org

American Heart Association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. Founded by six cardiologists in 1924, our organization now includes more than 30 million volunteers and supporters. We have invested more than $4 billion in research. American Stroke Association is a division that brings together the organization’s stroke-related activities.

Booth 608  Hall 6.2
APSTH

Asahikawa Medical University
Midorigaoka Higashi 2-1-1-1
078-8510
Asahikawa
Japan
www.apsth.org

The Asian-Pacific Society of Thrombosis and Hemostasis, hereafter referred to as “APSTH”, is a non-profit-making organization, which shall be open to any interested workers in the field of thrombosis and hemostasis in the Asian and Pacific regions. The objectives of APSTH are to foster and advance clinical and scientific knowledge in the field of thrombosis, hemostasis and vascular biology in the Asian and Pacific regions, and to promote scientific exchange and cooperation through scientific meetings and publications.

Booth 402  Hall 4.2
Aspen Europe

Montgelaspark, Montgelasstr. 14
81679
München
Germany
+49 99 93083800
+49 89 95993517
www.aspenpharma.com

Aspen is a global pharmaceutical company with an extensive portfolio in speciality, branded and generic and healthcare products with particular focus on therapeutic areas that include thrombosis, anesthesia, high potency & cytotoxics and infant nutritionals. Aspen product range provides treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life. Aspen has been offering the market a portfolio of quality injectable antithrombotics since 2014, with these product manufactured at Aspen sites in Europe.
COMPANY PROFILES

Approved products include the first and only medications for PKU and LEMS, and the first and only enzyme replacement therapies for MPS I, MPS VI and Morquio A syndrome. Visit www.biocarin.com to learn more.

**Booth 655 Hall 6.2**

**BioMedica Diagnostics**

PO Box 1030
BON 2T0
Windsor, ON
Canada
+1 902 798 5105
+1 902 7981025
www.biomedicadiagnostics.com

BioMedica focuses on thrombosis & haemostasis diagnostic solutions for human and animal health. BioMedica offers a complete line of diagnostic and research products, recently strengthened by an acquisition of specialty coagulation products and technologies.

The BioMedica line-up includes high quality kits, controls, reagents and calibrators that are designed for use in routine and specialty coagulation and are also widely used in research and industry spaces. Many products are Health Canada Registered, FDA 510(k) cleared and/or CE marked.

**Booth 442 Hall 4.2**

**Biotest**

Landsteinerstr. 5
63303 Dreieich
Germany
+49 6103 8010
+49 6103 801150
www.biotest.com

Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indication cancer of plasma cells and systemic lupus erythematosus (SLE), which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

**Booth 410 Hall 4.2**

**Bioverativ**

225 Second Avenue
02451
Waltham, MA
United States
+1 781-663-4400
www.bioverativ.com

Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ’s mission is to create progress for patients where they need it most, and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com.

**Booth 231 Hall 2.2**

**Boehringer Ingelheim**

Bingerstrasse 173
55216 Ingelheim
Germany
+49 6132 77 181805
www.boehringer-ingelheim.com

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 50 000 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

**Booth 634 Hall 6.2**

**British Society of Haematology / National Institute of Health Research**

100 White Lion Street
N1 9PF
London
United Kingdom
+44 20 7713 0990

The British Society for Haematology is the haematology hub for all health care professionals and the voice for the specialty in the UK. The NIHR Clinical Research Network (CRN) provides the infrastructure that allows high-quality clinical research to take place in the NHS in England.
COMPANY PROFILES

This includes assisting researchers, the life sciences industry and funders to deliver their studies in the NHS, and supporting the research community to maximize the value of leading-edge approaches and techniques, so that patients can benefit from new and better treatments.

2 West Park Road
19083
Havertown, PA
United States
+1 610 853 1130
+1 610 853 3972
www.chronolog.com

Hemostasis defects may be due to Platelet abnormalities such as VWD, Glanzmann’s, Secretion Defects, and anti-platelet drugs such as Aspirin and Plavix. In addition to LTA with PRP, Chrono-log also offers Whole Blood Impedance Aggregation/WBA and ATP Release with Luminiscence. The Model 700’s provide all of these testing capabilities while the NEW Model 490-4+4 provide LTA testing in 4 or 8 test channels. To discuss your platelet testing needs, please visit with us at Booth No. 416.

2do Retorno de Pablo de la Llave 35-4
4730
Mexico City
Mexico
+52 55 54367350
www.cth.org.mx

To promote the increase of clinical knowledge, research, and rise awareness within the general population. Organize and sponsor congresses, seminars, conferences, courses and meetings between health professionals interested in our fields of study. To fosters the bond of union and collaboration with affiliated and international grupos while generating an inclusive environment among all actors to achieve excellence in our purposes.

Emil-von-Behring-Straße 76
35041
Marburg
Germany
+49 6421 39 12
www.CSLBehring.com

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, delivering its life-saving therapies to people in more than 60 countries.

Zielstattstrasse 48
81379
Munich
Germany
+49 89 78080
www.dsi.com

At Daiichi Sankyo, we are dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise, we draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, our research and development is focused on bringing forth novel therapies in oncology, including immuno-oncology. For more information, please visit: www.daiichi-sankyo.eu.

Baross street 48-52
1047
Budapest
Hungary
+36 1 3696500
+36 1 3696301
www.diagon.com
At Diagon Ltd. we strive to bring laboratory professionals unique solutions for their testing needs. As market leader in diagnostic systems for hematology and hemostasis our success comes from proven record of high performance and reliable solutions, resulting from our commitment to and understanding of our customers and our dedication to innovation and quality. Founded in 1989 Diagon’s success builds on more than 25 years experience in R&D and world class manufacturing in vitro diagnostic products and analysers.

DOASENSE presents a new generation of devices for point-of-care testing for Direct Oral Anticoagulants (DOACs):
- DOAC testing – now fast and easy as with creatinine.
- When every minute counts ... fast DOAC testing really matters.

DSM Pentapharm is focused on development and production of diagnostic reagents for coagulation disorders and has been in operation since 1948. We are a high-quality manufacturer of diagnostic kits. We also offer various reagents (from research to bulk quantities) including custom/OEM manufacturing as well as synthesis of peptides and small organic molecules. Besides Diagnostic, we produce active pharmaceutical ingredients.

Enzyme Research Laboratories provides purified coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. Additionally, we offer monoclonal and polyclonal antibodies, immunodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.

Enzyme Research Laboratories provides purified coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. Additionally, we offer monoclonal and polyclonal antibodies, immunodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.

Enzyme Research Laboratories focuses on the production of high quality, innovative products for the hemostasis diagnostic market. Our products are designed to detect thrombophilia, including kits for PC, PS and lupus anticoagulants.

The “PROFILE” Innovative Training Network within the EU Horizon 2020 MSCA program aims at stratifying patients with acquired thrombotic purpura (TTP) by extending disease pathology using new types of biomarkers and predicting risk for relapse. The outcomes of this project will guide development of personalised medicine for TTP patients. We group top academic experts and frontline innovators from industry in the EU. The project is coordinated by prof. Karen Vanhoorelbeke from KU Leuven, Belgium.

Since its inception in 2015, EMOSIS is committed to innovative platelet- or microparticle-based diagnostics kits used on off-the-shelf benchtop flow cytometers. Routinely diagnosing and differentiating among various bleeding and thrombotic disorders will enable faster monitoring and cost-effective therapeutic decisions. We will support several clinical applications such as confirming the diagnosis of HIT (first test in 2017), assessing various platelet functions or testing hypercoagulable states. See more on www.emosis-diagnostics.com
COMPANY PROFILES

EMLTD is a non-profit Society created with the aim to promote the scientific advance and dissemination of knowledge in the diagnosis, prophylaxis and treatment of Thrombosis and Haemostasis.

It aims to create bridges between the clinical practice and the basic science, bringing together research scientists on vascular and molecular biology and clinicians of many different specialties related to thrombosis. We contributes to the translation of scientific advances to the clinical practice with a multidisciplinary and international approach organizing international Congresses oriented to the advance in the fight against thrombosis.

Booth 604  Hall 6.2
European Haemophilia Consortium

Koninginnegracht 12b
2814 AA
Den Haag
Netherlands
+31 70 3020099
www.ehc.eu

The European Haemophilia Consortium (EHC) is an umbrella organisation that represents 45 national patients’ groups, active in the area of rare bleeding disorders such as haemophilia and von Willebrand Disease. Through advocacy, project developments and work with stakeholders, the EHC aims to improve the quality of life of the 90 000 people in Europe affected by these disorders. It is a member of the European Organisation for Rare Diseases and the European Patients’ Forum, and has a close collaboration with the World Federation of Hemophilia.

Booth 616  Hall 6.2
Haematologic Technologies

57 River Road
05452
Essex Junction, VT
United States
+1 802 878 1777
+1 802 878 1776
www.haemtech.com

Haematologic Technologies, Inc. (HTI) is a primary manufacturer of research reagents, specializing in the isolation and characterization of plasma proteins involved in the regulation of blood coagulation and fibrinolysis. Our product line of highly purified proteins includes zymogens, enzymes, cofactors, and inhibitors as well as monoclonal and polyclonal antibodies. Services available by contract include: cGMP stability, release and other QC testing, ADA and TGA assay development and custom blood collection tube manufacturing.

Booth 629  Hall 6.2
GTH

Feodor-Lynen Str. 5
30625
Hannover
Germany
+49 511 5328488
+49 511 5324146
www.gth-online.org

GTH is the scientific society on Thrombosis & Hemostasis in Germany, Austria, and Switzerland. It is ISTH’s partner society in this geographic region. GTH offers an annual meeting that takes place at the end of February each year. Forthcoming GTH meetings will be in Vienna (2018) and Berlin (2019). GTH is the partnering society of two scientific journals, Hämostaseologie (Editor-in-Chief Rüdiger Scharf) and Thrombosis & Hemostasis (Editors-in-Chief Christian Weber and Gregory Lip).

Booth 637  Hall 6.2
Haematologica Journal

via G. Belli, 4
27100
Pavia
Italy
+39 0 38227129
www.haematologica.org

Grifols is a global healthcare company with more than 75-year legacy focused on improving people’s health and well-being by offering high-quality plasma-derived protein therapies, innovative diagnostic tools and essential hospital services.

In the field of hemostasis we are committed to offering complete disease management comprising a clear and precise diagnosis and plasma-derived therapies with outstanding records of efficacy and safety, to treat patients with coagulation disorders and improve life expectancy.
COMPANY PROFILES

Haematologica

The official journal of the European Hematology Association. Founded in 1920 and published by the Ferrata Storti Foundation (Pavia, Italy). Haematologica publishes articles in the broad field of hematology, reporting on novel findings in basic, clinical and translational research. Haematologica ranks 4th out of all hematology related journals. Print Circulation: 4000

2015 ISI Impact Factor: 6.671

2014 Citations: 14.110

Booth 400
Hall 4.2
Haemochrom Diagnostica

Renteilichtung 1
45134
Essen
Germany
+49 201 843770
+49 201 536456
www.haemochrom.de

For more than 25 years, Haemochrom Diagnostica has been playing an important role in supplying the pharmaceutical industries, university research and routine diagnostic laboratories with reagents within haemostasis diagnostics and endotoxin analytics in central and northern Europe. In cooperation with well-known manufacturers, Haemochrom Diagnostica offers a wide range of products for all current instrumentation systems based on certified and validated methods as well as an innovative reagent within endotoxin analytics.

Company Profiles

Haemonetics

400 Wood Road
02184
Braintree, MA
United States
+1 781 848 7100
+1 781 394 0538
www.haemonetics.com

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers. We offer the TEG® 5000 Hemostasis Analyzer System which has been shown to reduce unnecessary blood component administration to help reduce the risks, complications, and costs of allogeneic transfusions. TEG provides a unique and more complete picture of hemostasis to facilitate a better understanding of each patient’s risk of hemorrhage or thrombosis. http://www.haemonetics.com.

Booth 633
Hall 6.2
Haemonetics

Supporter
Haemophilia Academy

160 Blackfriars Road
7th Floor
SE1 8EZ
London
United Kingdom
www.haemophiliaacademy.com

The Haemophilia Academy is an annual, haemophilia-focused educational training course run by international experts in haematology. Its aim is to provide specific education and support for haemophilia treaters at an early stage in their career. The interactive programme is designed to equip participants with the knowledge and skills that they need to develop their career in haemophilia and to work together to discuss how to apply this information in a way that will help to improve patient care.

The Haemophilia Academy is supported by an unrestricted educational grant from Novo Nordisk Health Care AG.

Booth 433
Hall 4.2
Haemoscan

Stavangerweg 23-23
9723JC
Groningen
Netherlands
+31 50 7370187
www.haemoscan.com

HaemoScan is a leading company in haemocompatibility research and development of circulating-blood test models. We have experience in testing medical devices with blood according to ISO 10993-4 in order to obtain CE and FDA certification. HaemoScan is innovative in the field of biomarker analysis and has developed many assays to measure organ damage. HaemoScan tests human or animal coagulation, inflammation, organ, tissue, and other blood responses and has developed several haemocompatibility test kits.

Booth 656
Hall 6.2
Helena Biosciences

Queenway South
NE11 0SD
Gateshead
United Kingdom
+44 0191 4828440
www.helena-biosciences.com

Helena Biosciences is a world-leading Coagulation manufacturer specialising in the design and development of advanced laboratory analysers, interpretation software and reagents, selling to end-users, distributors and OEM clients. We offer an extensive portfolio of reagents for the testing of various disorders, with validated support for a wide range of industry-standard and Helena-branded analysers:
- Routine (PT, APTT, Fibrinogen, TT)
- Factor Deficient Plasmas
- D-Dimer
- Anti-thrombin, Protein C, Protein S, Lupus Anticoagulant
- Controls/Calibrators

Booth 401
Hall 4.2
HemoSonics

400 Preston Ave, Suite 250
22903
Charlottesville, VA
United States
+1 434 2021032
www.hemosonics.com

HemoSonics is a global leader in the development of hemostasis, coagulation, and inflammation measurement solutions.

Booth 401
Hall 4.2
HemoSonics
COMPANY PROFILES

HemoSonics, an innovative diagnostic company, is bringing to market the Quantra™ Hemostasis Analyzer, a next-generation platform that provides rapid, near-patient measurement of key hemostasis parameters to guide treatment in critical bleeding situations. The Quantra uses SEER, a proprietary ultrasound-based technology, to rapidly measure the clot time and stiffness of whole blood during coagulation. Fast, easy-to-interpret results enable clinicians to make rapid transfusion decisions. Visit our booth to see the Quantra live.

Hemostasis Analyzer
SEER technology
Fast, easy-to-interpret results

HYPHEN BioMed

HYPHEN BioMed is highly specialized for developing, manufacturing and distributing in-vitro diagnostic and research reagents in thrombosis and hemostasis. Being expert in this field, the company provides innovative and value-adding solutions to hospital laboratories (e.g., DOACs, HIT, Hemophilia), research institutions and pharmaceutical industry (customized solutions). Our unique offer of high quality reagents is available worldwide through an extensive distributor network in all major markets: Find your local distributor on our web site.

HYPHEN BioMed
155 rue d’Eragny
95000
Neuville-sur-Oise
France
+33 1 34406510
+33 1 34487184
www.hyphen-biomed.com

I&L Biosystems

I&L Biosystems is a leading provider of high-quality laboratory equipment and supplies for microbiology, cell biology and biotechnology markets in Western Europe, UK and Scandinavia. The company offers a wide range of products and services, including automated systems, microfluidics, cell imaging and more. They also provide comprehensive support and training to their customers.

I&L Biosystems
Königswinter Str. 409a
53639
Königswinter
Germany
+49 2223 91920
www.il-group.eu

COMPANY PROFILES

The company was founded in 1991. Focus of I&L is on sales and distribution of high quality laboratory equipment to customers and researchers in microbiology, cell biology and biotechnology markets in Western Europe, UK and Scandinavia. Excellent products, competent advice and fast service are basis for long-lasting relationships with our customers in industry, research and development. We present you at booth 626 - Multi-Well Microfluidics as well as Live Cell-Imaging Systems for your incubator.

Instrumentation Laboratory

Instrumentation Laboratory is passionate about delivering innovative IVD solutions for a range of Hemostasis testing needs. The IL booth features: ACL TOP® Family 50 Series Systems, new HemoCell® Specialized Lab Automation and new HemoHub® Intelligent Data Management, ACL AcuStar® System, and HemosIL® assays. With the recent acquisition of Tem and Accriva, IL has expanded its leadership into Hemostasis point-of-care testing, with ROTEM® Patient Blood Management, Hemochron® and VerifyNow® systems. IL is a Werfen Company.

ITAC-CME

ITAC-CME is the education section of the nonprofit physician organization Groupe Franco-Phone Thrombose et Cancer, a multidisciplinary group of healthcare providers globally. ITAC-CME published the 2016 International Clinical Practice Guidelines including Guidance for Direct Oral Anticoagulants in the Treatment and Prophylaxis of Venous Thromboembolism in Patients with Cancer (The Lancet Oncology, Volume 17, No. 10, October 2016), endorsed by ISTH. ITAC-CME is implementing and measuring the clinical adoption of the guidelines in clinical practice to prevent and manage VTE in cancer patients.
ISMAAP (International Self-Monitoring Association of oral anticoagulated Patients). More than 4,000,000 patients in Europe are living on long-term oral VKA anticoagulants. But only 3000.000 of these patients manage the INR self-monitoring on their own and take control of their anticoagulation therapy. International scientific studies and experience of these anticoagulated patients have shown a better quality of compliance. ISMAAP activities are focussed on these patients to offer them information around the life with VKA anticoagulants.

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

The ISTH is proud to present the next Scientiﬁc and Standardization Committee (SSC) meeting in Dublin, Ireland on 18-21 July 2018. Both engaging and insightful, ISTH SSC 2018 is unlike any other meeting. It is an excellently designed and affordable scientiﬁc event in the ﬁeld of thrombosis and hemostasis that brings together the world’s leading experts. Through the efforts of thousands of specialists, SSC meetings are a vivid platform for scientiﬁc and clinical working groups that lay the foundation for future breakthroughs. SSC 2018 will facilitate an exciting discourse about current diagnostic and therapeutic challenges, discussing novel approaches and standards that allow the ﬁeld to work together toward real-time and patient-centric solutions. Learn more at SSC2018.org.
S. Karger Medical Publishers present their journals 'Acta Haematologica' and 'Transfusion Medicine and Hemotherapy', as well as the new book 'SickKids Handbook of Pediatric Thrombosis and Hemostasis'. Publications are accessible online, with full-text search of articles, pay-per-view options and many other services. Founded 127 years ago, this Swiss-based family-owned publishing house combines highly sophisticated production technology with customized services for its authors, editors and readers.

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from hemophilia, immune deficiencies and other serious illnesses. Headquartered in Italy, the company has a market presence in approximately 100 countries. Kedrion acts as a bridge between donors and the people who need treatments, and works on a global scale to expand the patients’ access to available treatments.

LABiTec GmbH offers a full range of high quality coagulation and platelet aggregation semi and fully automated analysers, consumables and reagents. As a competent partner in customized developments of system concepts, components and disposable solutions we guarantee unique and market oriented products and instrumentation to clients all over the world.

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products indicated for the treatment of serious and often rare diseases in major therapeutic areas: hemostasis, immunology, intensive care and perinatal care. LFB Group is one of the leading European players specialized in biological medicinal products, and for the development and production of proteins and innovative treatments derived from biotechnologies. With 2,111 employees, the LFB group currently markets medicinal products in 40 countries throughout the world. http://www.groupe-lfb.com

Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME. Medscape offers specialists, primary care physicians and other health care professionals the most robust and integrated medical information and educational tools across more than 33 medical specialties. Given its strong editorial credibility, Medscape is the preferred source of information for physicians worldwide.
**COMPANY PROFILES**

**Booth 624  Hall 6.2**  
Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma GmbH, headquartered in Düsseldorf, Germany, was founded in 2003 under the name Mitsubishi Pharma Deutschland GmbH as a subsidiary of Mitsubishi Pharma Europe Ltd. (London / UK). It was the first country’s representative agency to bring products from its own research to the market outside Asia. 

The main focus of business activity in Germany, Austria and Switzerland is the marketing of the thrombin inhibitor Argatro® (Argatroban monohydrate).

**Booth 222  Hall 2.2**  
Novo Nordisk Healthcare

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. 

For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

**Booth 235  Hall 2.2**  
Novo Nordisk Haemophilia Foundation

Novo Nordisk Haemophilia Foundation

Thurgauerstrasse 36/38
8050 Zurich, Switzerland
www.nnhf.org

Founded in 2005 and situated in Zurich, Switzerland, Novo Nordisk Haemophilia Foundation (NNHF) is a non-profit organisation dedicated to defining and funding sustainable programmes which improve access to quality care benefitting people with haemophilia and allied bleeding disorders in developing and emerging countries. With local partners and renowned experts, we address three focus areas: capacity building; diagnosis and registry; education and empowerment.

**Booth 411, 421  Hall 4.2**  
Octapharma

Octapharma develops and produces human proteins from human plasma and human cell lines for the treatment of patients in the areas:  
- Haematology  
- Critical Care  
- Immunotherapy

The Swiss-based family-owned company is one of the world’s largest manufacturers of human proteins. Employing over 7000 people in 113 countries Octapharma has been advancing human life since 1983. www.octapharma.com

**Booth 653  Hall 6.2**  
ORGENTEC - Corgenix

ORGENTEC-Corgenix will highlight the AspirinWorks® Test. An ELISA test to determine levels of 11-dehydro thromboxane B2 (11 dhTxB2) in human urine, which aids in the qualitative de-

**Booth 431  Hall 4.2**  
Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
phamax
Baarerstrasse 82
6300 Zug
Switzerland
+41 61 8215687
+41 61 8215836
www.phamax.ch

phamax is a specialized scientific and analytical healthcare market access firm headquartered in Zug, Switzerland with offices in Bangalore, India and Singapore. We bring forth credible scientific evidence and unbiased recommendations globally, and formulate robust health plans and collaborate with health ministries, physician associations, patient groups and the healthcare industry to aid access to care for patients. Our scientific initiatives range from real world studies, stakeholder engagements, policy shaping, health economics outcomes research and scientific publications to patient access programs.

Portola Pharmaceuticals
270 East Grand Ave
94080
South San Francisco, CA
+1 650 246 7000
+1 650 246 7376
www.portola.com

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers.

Phenom-world is globally the yearly number 1 manufacturer of desktop scanning electron microscopes and imaging & analysis packages for sub-micron-scale applications. Delphi is the world’s first fully integrated solution that enables fast correlative microscopy with unique overlay precision. The Delphi is easy to use for both light- and electron microscopy users. It opens the door to these techniques for all laboratories through a cost-efficient package.

Twenty-five years ago we launched our first cryo-check™ product—a normal control for PTs and APTTs that could also be used as an alternative to in-house collected pools of normal plasma. The benefits of frozen quickly caught on and cryocheck grew from a single product to an integrated line of frozen diagnostic products that are synonymous with quality in labs around the globe. With our lab, biotech and pharma partners, we’re now developing new products to address current and future challenges in the diagnosis and therapeutic monitoring of disease.

The ISTH is excited to announce the launch of its new open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH). As an open access and online-only publication, RPTH will serve as a catalyst for global discussion and connect scientists and clinicians with the non-scientist public to discuss the latest findings and research in the field. Visit rpth.isth.org to get started.

Roche
Konzern-Hauptsitz
Grenzacherstrasse 124
CH-4070 Basel
Switzerland
+41 61 688 1111
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front-runner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
Roche Diagnostics International
Forrenstrasse 2
6343 Rotkreuz
Switzerland
+41 41 799 2244
+41 79 5398222
www.roche-rotkreuz.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Sekisui Diagnostics
4 Hartwell Place
02421 Lexington, MA
United States
+1 781 652 7800
www.sekisuidiagnostics.com

Sekisui Diagnostics is committed to improving patient’s lives by providing innovative medical diagnostics to physicians and laboratories. We develop, manufacture, and supply over one billion tests each year through our global commercial network. Our range of coagulation products include the high throughput CP3000 instrument system with dedicated barcoded reagents, as well as specialty and research use coagulation reagents. Our other product lines include clinical chemistry, diabetes, infectious disease rapid tests and novel markers. In addition, we offer enzymes and specialist biochemicals to the global healthcare market.

Sobi
Tomtebodavägen 23A
112 76 Stockholm
Sweden
+46 8 697 20 00
www.sobi.com

Sobi is a pioneer in rare diseases. Our history of innovation in haemophilia treatments stretches over 50 years. We have the simple goal to provide people with haemophilia treatment choices that will help them live the lives they want. Please visit: www.sobihaemophilia.com.

Siemens Healthineers
Emil-von-Behring Str. 76
35041 Marburg
Germany
+49 6421 390
www.siemens.com/healthcare

Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Driven by our long legacy of engineering excellence and our pioneering approach to developing the latest advancements, we are a global leader in medical imaging, laboratory diagnostics, clinical IT, and services. We are dedicated to helping our partners be successful—clinically, operationally and financially—from prevention through diagnosis and treatment.

Spark Therapeutics
3737 Market Street, Suite 1300
19104 Philadelphia, PA
United States
+1 215 220 9300
www.sparktx.com

Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal
COMPANY PROFILES

Stago

3 allée Thérésa
92600
Asnières-sur-Seine
France
+33 1 46882020
+33 1 47910891
www.stago.com

Stago, created in 1945, is an IVD Company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Its products are also available in more than 110 countries throughout the world through a network of 15 affiliates and 95 distributors. In 2016, Stago has more than 2,200 employees worldwide.

Sysmex Corporation

4-4-4 Takatsukadai, Nishi-ku
651-2271 Kobe
Japan
+81 78 265 0500
+81 78 265 0524
www.sysmex.co.jp/en

Sysmex Corporation is an integrated supplier of the instruments, reagents and software that are essential to testing processes performed during health checkups, treatment and ongoing disease management. Sysmex products are used by medical institutions in more than 170 of the world’s countries and Sysmex holds the top share of the global market in the field of hematology. We are expanding our operations, augmenting our traditional strength in hematology with non-hematology fields such as immunochemistry and hemostasis, as well as the life science field. Sysmex is leveraging its proprietary technologies to create new testing and diagnostic technologies that aim to ensure optimal healthcare for all.

Technoclone

Brunner Str. 67
1230
Vienna
Austria
+43 1 863730
+43 1 8637344
www.technoclone.com

Technoclone offers both global as well as specialty coagulation tests, a fully automated coagulation analyzer the Ceveron® alpha and the new semi-automated analyzers the Ceveron® one, four and ten. Ceveron® alpha TGA offers the unique feature of a fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin. Furthermore it provides a complete range of ADAMTS-13 ELISAs, as well a complete portfolio for the new anticoagulants such as for Xa inhibitors and direct thrombin inhibitors.

The Lancet

125 London Wall
EC2Y 5AS
London
United Kingdom
+44 207 424 4950
www.thelancet.com

The Lancet is a family of world-class journals committed to improving lives through medical research. With offices in London, New York, and Beijing, the Lancet publishes a weekly journal and monthly specialty journals, including The Lancet Haematology.

Thrombosis and Haemostasis

Hölderlinstraße 3
70174
Stuttgart
Germany
+49 711 2298763
www.thrombosis-online.com

Thrombosis and Haemostasis publishes reports on basic, translational and clinical research dedicated to novel results and highest quality in any area of thrombosis and haemostasis, vascular biology and medicine, inflammation and infection, platelet and leukocyte biology. Thrombosis and Haemostasis provides position and guideline papers, state-of-the-art papers, expert analysis and commentaries, and dedicated Theme issues covering recent developments and key topics in the field.

Thrombosis Research Institute

Emmanuel Kaye Building
SW3 6LR
London
United Kingdom
+44 207 351 8300
www.tri-london.ac.uk

Internationally renowned for pioneering, multi-disciplinary research, the Thrombosis Research Institutes are dedicated to the study of thrombosis and related disorders. Two research establishments in London and Bangalore are
united by their shared mission: To provide excellence in thrombosis research, education and patient care and to develop new strategies to prevent and treat thrombosis, thereby reducing healthcare costs and saving millions of lives.

Thrombosis.TV
6707 113th Place SE
Bellevue, WA
United States
+1 267 3950001
www.totalcme.com

Thrombosis.tv is a leading online destination for high quality venous and arterial thrombosis education, news and expert opinion. We offer health care professionals the timeliest comprehensive and relevant clinical information to improve patient care.

uniQure
Paasheuvelweg 25a
1105 BA
Amsterdam
Netherlands
+31 20 240 6000
www.uniqure.com

uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We are advancing a focused pipeline of innovative adeno-associated virus (AAV)-based gene therapies, and have established clinical proof-of-concept in our lead indication, hemophilia B.

Our vision is to build an industry-leading, fully integrated global company that leverages its validated technology and manufacturing platform to deliver transformative gene therapy products to patients with serious unmet medical needs.

Wiley
The Atrium PO19 8SQ
Chichester, West Sussex
United Kingdom
+44 1243 779777
+44 1243 775878
www.wiley.com

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.

Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

For 50 years, the World Federation of Hemophilia (WFH) has provided global leadership to improve and sustain care for people with inherited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders. Come visit our booth and enter a draw for a trip to the WFH 2018 World Congress in Glasgow, Scotland, May 20-24, 2018. The WFH World Congress is the largest international meeting for the global bleeding disorders community.
### CORPORATE MEETING SUITES

<table>
<thead>
<tr>
<th>Company</th>
<th>Room</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Lindau 5</td>
<td>Hall 7, Meeting Bridge A, Mezzanine Level 1</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Lindau 6</td>
<td>Hall 7, Meeting Bridge A, Mezzanine Level 1</td>
</tr>
<tr>
<td>Bayer</td>
<td>Ulm</td>
<td>Entrance Foyer to Hall 2.2, Level 2</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Dessau 1</td>
<td>Hall 7, Meeting Bridge C, Mezzanine Level 1</td>
</tr>
<tr>
<td>BioMarin Pharmaceuticals</td>
<td>Lindau 4</td>
<td>Hall 7, Meeting Bridge A, Mezzanine Level 1</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Dessau 6</td>
<td>Hall 7, Meeting Bridge C, Mezzanine Level 1</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>Dessau 3</td>
<td>Hall 7, Meeting Bridge C, Mezzanine Level 1</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche</td>
<td>Lindau 2</td>
<td>Hall 7, Meeting Bridge A, Mezzanine Level 1</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche</td>
<td>Dessau 4</td>
<td>Hall 7, Meeting Bridge C, Mezzanine Level 1</td>
</tr>
<tr>
<td>Grifols</td>
<td>S3</td>
<td>CityCube Berlin, West Lobby 3, Level 3</td>
</tr>
<tr>
<td>Novo Nordisk Healthcare</td>
<td>Lindau 1</td>
<td>Hall 7, Meeting Bridge A, Mezzanine Level 1</td>
</tr>
<tr>
<td>Octapharma</td>
<td>Weimar 1</td>
<td>Hall 7, Meeting Bridge B, Mezzanine Level 1</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Weimar 2</td>
<td>Hall 7, Meeting Bridge B, Mezzanine Level 1</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Weimar 4</td>
<td>Hall 7, Meeting Bridge B, Mezzanine Level 1</td>
</tr>
<tr>
<td>Portola Pharmaceuticals</td>
<td>Dessau 2</td>
<td>Hall 7, Meeting Bridge C, Mezzanine Level 1</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>Frankfurt 2</td>
<td>Back Foyer of Hall 4.2, Level 2</td>
</tr>
<tr>
<td>Shire</td>
<td>Lindau 3</td>
<td>Hall 7, Meeting Bridge A, Mezzanine Level 1</td>
</tr>
<tr>
<td>Shire</td>
<td>Dessau 5</td>
<td>Hall 7, Meeting Bridge C, Mezzanine Level 1</td>
</tr>
<tr>
<td>Sobi/Bioverativ</td>
<td>Weimar 3</td>
<td>Hall 7, Meeting Bridge B, Mezzanine Level 1</td>
</tr>
<tr>
<td>Sobi/Bioverativ</td>
<td>Weimar 5</td>
<td>Hall 7, Meeting Bridge B, Mezzanine Level 1</td>
</tr>
<tr>
<td>Sobi/Bioverativ</td>
<td>Gera</td>
<td>Hall 7, Foyer of Meeting Bridge C (7b), Mezzanine Level 1</td>
</tr>
</tbody>
</table>

*Weimar 1 is assigned to Octapharma from July 8 until July 10 at 13:00. Weimar 1 is assigned to World Federation of Hemophilia from July 10 at 14:00. Regensburg is assigned to Octapharma from Monday 10 at 14:00.*
**CONFLICT OF INTEREST DISCLOSURE INFORMATION**

**Local Organizing Committee**

Anne Angelillo-Scherrer

Andreas Greinacher
Receipt of grants/research supports: Deutsches Rotes Kreuz Blutspendedienst NSTOB; Rovi, Sagent, Biomarin/Prosensa Aspen, Boehringer Ingelheim, Merck Sharp and Dome, Bayer Healthcare, Gore Inc. Receipt of honoraria or consultation fees: Aspen, Boehringer Ingelheim, MSD, Macopharma, Bristol Myers Squibb, Chromatec, Instrumentation Laboratory

Bettina Kemkes-Matthes
Receipt of honoraria or consultation fees: (travel grants) Bayer Healthcare, Stemens, Boehringer Ingelheim, Biotest, CSL, Daiichi Sankyo, Novo Nordisk, Pfizer, Sobi, Shire, Baxalta

Christoph Male
Receipt of grants/research supports: Bayer, Baxter/Shire, Biotest, Bristol-Myers Squibb, Boehringer Ingelheim, CSL Behring, Novo Nordisk
Receipt of honoraria or consultation fees: Bayer, Bristol-Myers Squibb, CSL Behring Participation in a company sponsored speaker’s bureau: Baxter/Shire, Biotest, Boehringer Ingelheim, Novo Nordisk

Christine Mannhalter
Receipt of honoraria or consultation fees: Bayer Austria, Qiagen Spouse/partner: Stocks – Baxter, Novartis, Bayer, Pfizer, Novo Nordisk

**Johannes Oldenburg**
Receipt of grants/research supports: Baxter, Bayer, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, and Pfizer
Receipt of honoraria or consultation fees: Baxter, Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, and Swedish Orphan Biovitrum Participation in a company sponsored speaker’s bureau: Baxter, Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche and Swedish Orphan Biovitrum

**Ingrid Pabinger-Fasching**
Receipt of grants/research supports: CSL Behring
Receipt of honoraria or consultation fees: Bayer, CSL Behring, Boehringer Ingelheim, Pfizer, Daiichi Sankyo, Baxter/Shire, Biotest, Amgen, Novartis

**Klaus T. Preisnner**
No potential conflict of interest to report

**Wolfram Ruf**
Receipt of grants/research supports: Novo Nordisk
Receipt of honoraria or consultation fees: ICONIC Therapeutics

**Christian Weber**
No potential conflict of interest to report

**Andreas Tiede**
Receipt of grants/research supports: Bayer, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Shire
Receipt of honoraria or consultation fees: Bayer, Biogen Idec, Biotest, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, Pfizer, Shire, and SOBI

**Johann Wojta**
No potential conflict of interest to report

**Scientific Program Committee**

**Topic Chairs**

Hellmut G. Augustin
No potential conflict of interest to report

Christoph J. Binder
Receipt of honoraria or consultation fees: Sanofi Other Support: Board Member, Technoclone GmbH

Sabine Eichinger
Receipt of honoraria or consultation fees: Bayer, Boehringer-Ingelheim, Pfizer, Daiichi-Sankyo

Bernd Engelmann
No potential conflict of interest to report

Meinrad Gawaz
No potential conflict of interest to report

Berend Isermann
No potential conflict of interest to report

Stavros Konstantinides
Receipt of grants/research supports to my institution: Bayer HealthCare, Boehringer Ingelheim, Actelion, Daiichi Sankyo
Receipt of honoraria or consultation fees: Bayer HealthCare, Pfizer – Bristol-Myers Squibb, Servier, Actelion

**Karl Lackner**
Receipt of grants/research supports: Abbott Diagnostics, Roche Diagnostics, Thermo Fisher, Siemens Healthcare

Bernhard Nieswandt
No potential conflict of interest to report

Erhard Seifried
No potential conflict of interest to report
TAKE CONTROL OF HAEMOSTASIS

Enjoy a UNIQUE experience!

Discover the new episode about primary haemostasis and coagulation cascade update

Developed in collaboration with Pr C. NEGRIER and Dr L. RUGERI, Lyon HTC, France

COMING TO HALL 4.2 NR. 403

Authors Index
AUTHORS INDEX

XXVI ISTH Congress and 63rd Annual SSC Meeting

[Authors listed]
AUTHORS INDEX

Guerrero J., OC 53.5
Guiglielmini G., PB 369, PB 1565
Guiglielmo H.A., PB 094, PB 2030, PB 2038
Guillemin C., PB 1544
Guilen A.J.W., PB 1219
Gümüslük F., PB 1768
Gupta N., PB 087
Gupta S., OC 66.2, PB 1305
Guria K.G., PB 2114
Gurney M., OC 48.3
Guthold M., PB 175
Guy A., ASY 18.3, OC 67.1
Gwozdowska A., PB 1521

H

Haas S., PB 1188
Hackeng T., PB 838
Hagan K., OC 12.2
Hagen M., PB 1632
Hald E.M., PB 1651, PB 1670
Hall A., PB 1140
Hamaia S., PB 575
Hamid C., PB 353
Hamilton J., OC 45.3
Hammelburger J., PB 132
Hammerschick T., PB 2444
Hampshire D.J., OC 22.5
Han Y., OC 74.1
Handtke S., PB 563
Hansen A.T., ASY 36.3
Hansen J.-B., PB 1414
Hartmann R., PB 2363, PB 2366
Hardy L., PB 820
Harenberg J., PB 454
Harper A., PB 2205
Harrison P., PB 1568
Harsfali J., PB 1444
Hart G., PB 112, PB 824, PB 832, PB 856
Hartmann R., OC 47.2, PB 1079
Hashimoto E., PB 755
Hasaan A., PO 66
Hastings S.M., PB 930
Hasumi K., PB 2350
Haugard S., PB 586
Hauschner H., PB 1594
Hawks K., PB 1405
Hay C.R., ASY 01.4
Hayashi H., PB 1379
Hayashi T., PB 883
Hayman M.A., PB 2218
Haynes L.M., OC 72.3
Hayward C.P.M., PB 2736
He J., PB 2430
He Y., PB 1591
Hebsgaard J.B., PB 1069
Heestermans M., PB 878, PB 1683
Heijdra J.M., PB 2053
Heftmeier S., PB 2138, PB 2140
Hell L., ASY 06.2
Heller C., OC 24.2
Hellfritzsch M., PB 493
Helten C., PB 426
Hemker H.C., PB 1235
Hendelmeier M., PB 2073
Henriksen C.E., PB 679
Henskens Y., ASY 04.2, PB 2113
Heplinstill S., PB 1423, PB 1673
Heremans J., ASY 20.4
Hermit M.B., OC 10.2
Herrera L., PB 1172
Herrera M.D.L., PB 1218
Hers I., OC 06.5
Hertfelder H.-J., PB 1527
Herzog E., PB 340
Herzog R.W., OC 75.3
Hew-Girard J.D., PB 1913, NUR 0.2
Higuera D., PB 1643
Himoroja J., PB 1000
Hisada Y., ASY 29.2, PB 682
Hoellriegel W., PB 1094, PB 1099, PB 1101, PB 1118
Hoelsel B., PB 907
Hofer S., PB 371
Hoffman M., PB 1630, PB 2059
Hoffmann M., PB 812
Hoffmann T., PB 1032
Hofmann Z.L.M., OC 40.1
Hofmann M., PB 1121
Hogg P., OC 08.5
Hohenhinner P., PB 2275
Hohmann J.D., ASY 31.4
Holand I., PB 582
Holand I.I., PB 1707
Hofsten A.A., NUR 05.8
Holbrook L.M., PB 1261, PB 1319, PB 2196
Holmestad M., PB 1313
Hollerbach A., ASY 06.3
Holme P.A., PB 1780
Holz M.K., PB 1104
Holzhauser S., PB 529
Honickel M., PB 469, PB 1212
Hop H., PB 199
Hoppenstead D., OC 36.5, PB 330, PB 797, PB 804, PB 1876, PB 2144
Horie S., PB 1661
Horing F., OC 62.2
Horvei L.D., PB 1394, PB 1496
Ho-Tin-Noé B., PB 1656
Hou Y., PB 2372
Hounkpe B.W., PB 1723
Howard T., OC 61.2
Howman S., PB 047
Hrudinova J., OC 09.5
Hu L., PB 2215
Hu Y., PB 1330
Hua B., PB 973
Huffman J.E., OC 68.2
Hughes A., PB 413, PB 1145
Huynh K., ASY 37.4
Hul S.-K., PB 396
Huisman M., PB 465
Hunter R., NUR 05.11
Huntington J., OC 10.1
Hur W., OC 19.2
Hussain S., PB 2042
Husseinazedeh H., PB 957
Huyuk K., PB 2228
Hwang B.-F., PB 679
Hydema G., PB 1354
Iftikhar T., PB 1354
Iglesiass Varela M.L., PB 450
Ignowski J., PB 2256
Ikezaki R., PB 2303
Ikezoe T., PB 2436
Ilich A., PB 171, PB 1167
Imhof D., PB 1725
Induruwa L., OC 66.1
Iqbal A., OC 14.1
Isaksen T., PB 776
Israelis S.J., PB 1150
Itô T., PB 1237
Ivaniciu L., PB 148
Ivanov I., OC 15.1
Ivaskevicius V., PB 2020
Iversen N., PB 2026
Izzi B., PB 554

J

Jaffer I., PB 497
Jalal M.M., PB 1264
Jamal M.A., OC 16.1, PB 1757
Jämsä A., OC 72.5
Janaki Krishnamoorthi A., PB 1419
Janbain M., OC 37.5
Janke U., PB 576
Janse van Rensburg W., PB 1087
Jansen A.J.G., ASY 19.2, PB 1340
Jansen M., PB 238
Jansen S.B.G., OC 66.3
Jaukonysyte J., PB 509
Jaramillo Zepa A., PB 535
Jara-Palomares L., PB 2114, PB 2157
Jary K., PB 361, PB 740
Jayme P., PB 1637
Jia S., PB 2132

K

Kizlovec H., PB 869
Kaatz S., ASY 14.2, ASY 36.2, PB 486
Kabbel H., PB 613, PB 935, PB 1397, LB 02
Kahn S.R., OC 52.1, PB 1003
Kahr W., PB 1078
Kalabushova S., OC 26.5
Kalaska B., PB 2153
Kalish Y., PB 1862, PB 1870, PB 1907
Kamal F., PB 1698
Kampouraki E., PB 260
Kanematsu T., PB 976
Kaneva N.V., PB 2231
Kang K.-Y., PB 1128
Kanse S., PB 118, PB 1400
Kappelmayer J., PB 1589
Kaptijn M.Y., PB 922
Kar R., PO 14
Karampin E., ASY 12.3
Karbach S.H., PB 2277
Karim M., PB 685, PB 2037
Karpha I., PB 691
Kartsios C., PB 485
Karumori T., PB 979
Kask L., PB 1386
Kaspékl D., PB 718
Kassim N., PO 49
Katayama H., PB 1822
Kato H., PB 574, PB 733
Katona C., PB 178
Katren T., PB 1441
Kattula S., ASY 07.3, PB 1497
Kauf C., PB 1084
Kaur D., PB 1253
Kaur H., PB 502
Kautbally S., PB 014
Kavakli K., PB 829
Kawecik C., OC 38.4
Kurov S., PB 2034
Kazanecka B., PB 2333
Kearney K., PB 161
Keenan C., PB 1972
Kehrel B.E., PB 1363
Kespert C., PB 1976
Kielchertmans H., PB 1434
Keltar A., PB 439
Kempten C., PB 206
Kennet G., PB 1982
Kenny D., PB 1558
Keren Politsansky A., PB 2384
Kerényi A., PB 2084
XXVI ISTH Congress and 63rd Annual SSC Meeting

AUTHORS INDEX

AUTHORS INDEX

Ow K.W., PB 1569
Owaidah T., PB 2075
Owens P., ASY 16.4, PB 1606
Owens W.E., PB 221, PB 232
Oymak Y., PB 313
Özdemir N., PB 2039, PO 11

P
Paauwe M., PB 923
Pabinger I., OC 21.1, PB 213,
PB 1903
Padro T., PB 010
Pagel O., OC 68.3
Pailleret Ringuier C., PB 1231
Paiva J., PB 696, PB 710, PB
2079
Pakdeeto S., OC 24.4
Palankar R., OC 58.1
Palla R., ASY 12.2
Palma-Barqueros V., OC 59.1, OC
69.4, PB 572
Palmer O.R., PB 089
Palomo M., PB 585
Panchenko E., PB 262, PB 796
Pandey D., OC 42.1
Panes O., PB 816
Panova-Noeva M., OC 28.5, PB
637, PB 1389
Paoletti O., PB 1965, PB 2414
Pap Á.F., PB 1217
Papadakis E., PB 507, PB 1437
Papageorgiou L., PB 2326
Papayan L., PB 1534, PB 1993,
PB 2190
Paredes A.C., PB 220
Paris C., PB 388
Park Y.S., PB 240
Parry B.A., PB 2093
Pasalic L., PB 1374, PB 1559,
PB 2383
Pasca S., PB 2180
Pasi K.J., ASY 01.2, PB 212, LB
01.1
Paskaleva I., PB 2147
Pasquier E., PB 2349

598

Passam F., OC 57.3
Patel V., OC 72.2
Patel-Hett S., PB 1124
Pathare A., PO 06
Patiroglu T., PB 1031, PO 52
Paul D.S., PB 1303
Paulsen B., PB 634, PB 643
Pavlova A., PB 2003
Pavlova I., PB 942
Pawlinski R., PB 2286
Payne A.B., LB 08
Paz L., PB 806
Pechlivani N., PB 108
Pedersen O.H., PB 2234
Pelland-Marcotte M.-C., ASY 26.1
Pelzing M., PB 121
Penaloza A., PB 1134
Pequeriaux N., PB 1466
Peraramelli S., OC 28.2
Pereira J., PB 024
Pereira M., PB 1243
Pereira M.S., PB 1856
Pereira Gonçalves M.L., PB 1175
Perés S., PB 595
Pérez L., PB 1433
Persson E., PB 1120
Perveen K., PB 2402
Pesavento R., OC 25.1, OC 25.2
Pestel S., PB 1126
Petermann V., OC 30.4
Petersen M., PB 1082
Petito E., PB 1372
Petkovikj E., PB 1547
Petri A., OC 09.3
Petrillo T., PB 099
Petzold T., PB 133
Peyron I., OC 61.4
Peyvandi F., OC 61.1, PB 363, PB
389, PB 1776
Pezeshkpoor B., PB 151, PB 152,
PB 2090
Phatale R., PB 430
Phusanti S., PB 628
Pierce G.F., PB 1808
Pignani S., OC 38.3
Pilch J., OC 50.5, PB 911

Pino M., PB 1270
Pipe S., LB 04
Piran S., PB 489
Pitkänen H., PB 2002
Pizzini A.M., PB 532, PB 1681,
PB 1829
Planquette B., PB 1393
Plantier J.-L., PB 130, PB 1111,
PB 2265
Plantureux L., PB 2308
Platton S., PB 403
Pleines I., ASY 20.1, OC 44.3
Plug T., PB 1755
Podda G.M., PB 771, PB 1596,
PB 1601, PB 2232
Podoplelova N., PB 1281
Podorolskaya L., PO 17
Pohlreichova V., PB 706
Poletaev A., PB 2126
Poli D., PB 257, PB 281, PB
1842
Pollack C., LB 01.4
Pollard D., PB 1961
Pongtanakul B., PB 2162
Ponnusamy T., PB 022, PB 025
Pons Vila Z., ASY 25.3
Pontarollo G., PB 1706
Poon M.-C., PB 204
Portier I., PB 357
Posch F., ASY 06.1, PB 648, PB
1443, PB 1446
Posma J.J.N., PB 1642
Posthuma J.J., PB 004, PB 867,
PB 1713, PB 1730
Potylitsina V., PB 138
Pourtau L., PB 1587
Powell Gray B., OC 35.4
Prabhudesai A., PB 180
Pradella P., PB 1960
Praefcke G.J.K., PB 2108
Prandoni P., OC 25.4, PB 777
Preijers T., PB 158
Preisler B., PB 408
Prévost N., OC 70.1
Prezoto B., PB 090, PB 876
Prezotti A.N., PB 969

Prince R., OC 76.1, PB 1526
Prins M.H., OC 39.1
Prior S., PB 345, PB 831, PB
1701
Privitera V., PB 1850
Prochaska J., OC 20.2, PB 1402
Prochazkova J., PO 28
Protopopova A.D., OC 72.1
Proulle V., PB 364
Provaznikova D., PB 1511
Prüller F., PB 837
Przeradzka M., OC 08.4
Pshenichnikova T., PB 1905
Puetz J., PB 2179, PB 2181, PB
2183
Pugh N., PB 1327, PB 1336
Puy C., OC 40.3, PB 1686

Q
Qaddoori Y., PB 583
Qiao J., PB 2237
Qu C., PB 1582
Quach M., ASY 05.3
Qvigstad C., PB 1792

R
Rabinovich A., OC 60.4
Rabizadeh E., PB 2216
Rabouel Y., PB 2248
Radic C.P., PB 1975
Radu C., PB 550, PB 1747
Raka F., PO 50
Rakhimov R., PB 660
Rakic L., PB 1061
Raksha N., PB 1577
Rand M., PB 966, PB 1269
Rao A.K., LB 06
Raquet E., PB 1129, PB 1130
Rashid A., PB 1880, PB 2032,
PO 44
Rastogi P., PB 1518
Rattanawan C., PB 192
Rauch A., PB 373, PB 1940
Rauova L., ASY 39.2

Ravanat C., PB 1048
Rawley O., OC 22.3
Rayes J., ASY 32.1, OC 29.2
Reddel C.J., PB 681
Reed G., ASY 31.1
Rees S., PB 1209
Reinhardt C., PB 009
Reipert B.M., PB 110
Reitsma S.E., PB 1695
Rejtö J., PB 1809
Remijn J.A., PB 1357
Remiker A.S., OC 28.4
Remotti L., PB 2106
Ren L., PB 019
Reny J.-L., PB 556
Reshetnyak T., PB 1471
Restrepo-Avenia J., PO 31
Reusswig F., PB 074
Reverter J.C., PB 1470
Reyes M., PB 1038
Reyes Gil M., ASY 17.2
Rezende D.C., PB 1152
Rezende S.M., PB 2076
Rhodes S., PB 629, PB 1059
Ribeiro D.D., PB 394
Riedl J., PB 2304, PB 2317
Riera-Mestre A., PB 1022
Rigg R., PB 1687
Rigg R.A., PB 2290
Rijken D.C., PB 1760
Rijkers M., PB 1262
Riley P., PB 1171
Rimsans J., PB 2396
Rinde L.B., PB 1490, PB 1491
Riva S., PB 251
Rivera J., OC 69.2
Rivera S., PB 1052
Rivera Rivas J.J., PB 599
Rivera-Caravaca J.M., OC 33.1,
PB 787, PB 1660
Rość D., PB 027, PB 814, PB
899
Robert-Ebadi H., PB 407
Robinson M., PB 111
Rocheleau A., PB 2411
Rockwood K., PB 203

Rode F., PB 1974
Rodriguez Moreno S.J., PB 764
Rohmann J.L., PB 1694
Rojas-Hernandez C.M., PB 2298
Roka-Moiia Y., PB 2223
Romano A.V.C., PB 1506
Roncal C., PB 046
Rondina M., PB 541, PB 2434
Roose E., ASY 19.4, OC 09.1,
PB 690
Rosas M., PB 902
Rosenberg N., PB 739, PB 2390
Rosendaal F.R., PB 943
Rosovsky R., PB 934
Rossetti L., PB 2214
Rossi E., ASY 17.3, OC 29.3
Rottensteiner H., OC 13.6, PB
1097
Roweth H.G., OC 45.5, PB 2200
Rowswell H., PB 1435, NUR 05.2
Ruchutrakool T., PB 1600, PB
1669
Rühl H., PB 386, PB 1404
Rühle F., PB 1659
Rupa-Matysek J., PB 631
Rupon J., PB 231
Russick J., PB 1113
Ruszkowska-Ciastek B., PB 2433
Rutgers J., OC 11.3, PB 1251,
LB 11
Ryu C.S., PB 1667, PB 2442

S
Saad A., PB 1515
Sabater-Lleal M., OC 55.1
Sabban A., PB 1759
Sabio F., PB 2330
Sabor L., PB 2151
Sacco M., PB 500, PB 1074
Saes J.L., PB 2025
Saez R.C., PB 2226
Safiullina S., PO 33, PO 47
Saharov G., NUR 05.9
Sahli K.A., PB 1274
Saïd F., PB 066, PB 067, PB

599

Authors Index

XXVI ISTH Congress and 63rd Annual SSC Meeting


AUTHORS INDEX

AUTHORS INDEX
AUTHORS INDEX

Yuan Y., ASY 03.1
Yunliang C., PB 916, PB 917, PB 927
Yushi C., PB 1823

Z
Zabczyk M., PB 912
Zadro R., PB 1666
Zaid Y., PB 1700
Zaldivia M.T.K., PB 1345
Zamalek N., PB 1185
Zanon E., OC 36.1, OC 36.2, PB 1788, PB 1936
Zapponi K.C.S., PB 1624
Zara C., PB 555
Zawilska K., PB 1815
Żekanowska E., PB 1430
Zelaya M., ASY 34.2
Zelinskiy V., PB 062
Zhang D., PB 741, PB 1979
Zhang L., PB 273, PB 439, PB 1156
Zhang X., PB 2362
Zhao X., OC 06.1, PB 1358
Zhao Y., PB 037
Zharkov P., PB 526, PB 1254, PB 2409
Zheng G., PB 2088
Zheng Z., OC 01.4
Zhu M., PB 2007
Zibrova D., ASY 30.2
Ziegler M., ASY 24.4
Zilberman-Rudenko J., PB 310, PB 1631, PB 1689
Zintner S.M., OC 26.3
Zipperle J., PB 1932
Zivelin A., PB 2116
Zlot R.B., PB 1499, PB 1883
Zou Y., PB 1460
Zuo Y., PB 235

FUTURE ISTH MEETINGS AND CONGRESSES

64TH ANNUAL SSC MEETING
President: Dermot Cox
Date: July 17–21, 2018
Location: Dublin, Ireland
www.ssc2018.org

XXVII ISTH CONGRESS AND 65TH ANNUAL SSC MEETING
President: Robert Medcalf
Date: July 6–10, 2019
Location: Melbourne, Australia
www.isth2019.org
The evolution of an unmodified, full-length recombinant FVIII molecule, developed through innovative manufacturing.1-5

Demonstrated efficacy and safety in prophylaxis across all age groups with as few as 2 infusions per week.2,3
Breaking scientific walls in the treatment of haemophilia and rare bleeding disorders: from laboratory assays to patient outcomes

9th July 2017
16:15 - 17:45, Room A6
novonordiskisth2017.com

16:15 – 16:20  Welcome and introduction  
Chairman Robert Klamroth, Germany

16:20 – 16:35  Bridging the gap between the laboratory and the patient  
David Lillicrap, Canada

16:35 – 16:50  Prolonging coagulation factor IX activity: a win-win situation  
Guy Young, USA

16:50 – 17:05  Congenital haemophilia with inhibitors and acquired haemophilia: how to treat and how to evaluate  
Andreas Tiede, Germany

17:05 – 17:25  Treating haemophilia A for life  
Elena Santagostino, Italy

17:25 – 17:40  Panel discussion  
Faculty

17:40 – 17:45  Final remarks  
Chairman Robert Klamroth, Germany

Refreshments available

Come and visit us at booth 222 to find out more about our commitment to science